Gene	O
expression	O
studies	O
in	O
isolated	O
mitochondria	O
:	O
Solanum	B-LIVB
tuberosum	I-LIVB
rps10	O
is	O
recognized	O
by	O
cognate	O
potato	B-LIVB
but	O
not	O
by	O
the	O
transcription	O
,	O
splicing	O
and	O
editing	O
machinery	O
of	O
wheat	B-LIVB
mitochondria	O

Abstract	O

The	O
complex	O
gene	O
expression	O
mechanisms	O
that	O
occur	O
in	O
plant	O
mitochondria	O
,	O
such	O
as	O
RNA	O
editing	O
and	O
splicing	O
,	O
are	O
not	O
yet	O
well	O
understood	O
.	O

RNA	O
editing	O
in	O
higher	O
plant	O
mitochondria	O
is	O
a	O
highly	O
specific	O
process	O
which	O
modifies	O
mRNA	O
sequences	O
by	O
C	O
-	O
to	O
-	O
U	O
conversions	O
.	O

It	O
has	O
been	O
suggested	O
that	O
in	O
some	O
cases	O
this	O
process	O
is	O
required	O
for	O
splicing	O
.	O

Here	O
,	O
we	O
use	O
an	O
experimental	O
model	O
based	O
on	O
the	O
introduction	O
of	O
DNA	O
into	O
isolated	O
mitochondria	O
by	O
electroporation	O
to	O
study	O
organellar	O
gene	O
expression	O
events	O
.	O

Our	O
aim	O
was	O
to	O
compare	O
processing	O
and	O
editing	O
of	O
potato	B-LIVB
small	O
ribosomal	O
protein	O
10	O
gene	O
(	O
rps10	O
)	O
transcripts	O
in	O
heterologous	O
(	O
wheat	B-LIVB
mitochondria	O
)	O
and	O
homologous	O
(	O
potato	B-LIVB
mitochondria	O
)	O
contexts	O
.	O

rps10	O
is	O
a	O
suitable	O
model	O
because	O
it	O
contains	O
a	O
group	O
II	O
intron	O
,	O
is	O
absent	O
in	O
wheat	B-LIVB
mitochondria	O
but	O
is	O
actively	O
expressed	O
in	O
potato	B-LIVB
mitochondria	O
,	O
where	O
transcripts	O
are	O
spliced	O
and	O
undergo	O
five	O
C	O
-	O
to	O
-	O
U	O
editing	O
events	O
.	O

For	O
this	O
purpose	O
,	O
conditions	O
for	O
electroporating	O
isolated	O
potato	B-LIVB
mitochondria	O
were	O
established	O
.	O

rps10	O
was	O
placed	O
under	O
the	O
control	O
of	O
either	O
potato	B-LIVB
or	O
wheat	B-LIVB
cox2	O
promoters	O
.	O

We	O
found	O
that	O
rps10	O
was	O
only	O
transcribed	O
under	O
the	O
control	O
of	O
a	O
cognate	O
promoter	O
.	O

In	O
wheat	B-LIVB
mitochondria	O
,	O
rps10	O
transcripts	O
were	O
neither	O
spliced	O
nor	O
edited	O
while	O
they	O
are	O
correctly	O
processed	O
in	O
potato	B-LIVB
mitochondria	O
.	O

Interestingly	O
,	O
a	O
wheat	B-LIVB
editing	O
site	O
grafted	O
into	O
rps10	O
was	O
not	O
recognized	O
by	O
wheat	B-LIVB
mitochondria	O
but	O
was	O
correctly	O
edited	O
in	O
potato	B-LIVB
mitochondria	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
editing	O
might	O
occur	O
only	O
when	O
the	O
transcripts	O
are	O
engaged	O
in	O
processing	O
and	O
that	O
they	O
would	O
not	O
be	O
available	O
to	O
editing	O
factors	O
outside	O
of	O
a	O
putative	O
RNA	O
maturation	O
machinery	O
complex	O
.	O

INTRODUCTION	O

Gene	O
expression	O
in	O
plant	O
mitochondria	O
is	O
a	O
complex	O
process	O
involving	O
multiple	O
steps	O
such	O
as	O
transcription	O
,	O
cis	O
-	O
and	O
trans	O
-	O
splicing	O
,	O
RNA	O
trimming	O
and	O
RNA	O
editing	O
on	O
the	O
way	O
to	O
translation	O
(	O
1	O
)	O
.	O

RNA	O
editing	O
has	O
been	O
found	O
in	O
a	O
variety	O
of	O
organisms	O
and	O
occurs	O
through	O
different	O
mechanisms	O
such	O
as	O
insertion	O
or	O
deletion	O
of	O
nucleotides	O
,	O
or	O
base	O
conversions	O
[	O
for	O
details	O
see	O
reference	O
(	O
2	O
)	O
]	O
.	O

In	O
higher	O
plant	O
organelles	O
,	O
RNA	O
editing	O
is	O
an	O
important	O
post	O
-	O
transcriptional	O
event	O
characterized	O
by	O
C	O
-	O
to	O
-	O
U	O
changes	O
via	O
a	O
deamination	O
mechanism	O
(	O
3	O
-	O
5	O
)	O
.	O

In	O
Arabidopsis	B-LIVB
thaliana	I-LIVB
456	O
C	O
-	O
to	O
-	O
U	O
editing	O
events	O
have	O
been	O
described	O
(	O
6	O
)	O
.	O

RNA	O
editing	O
occurs	O
mostly	O
in	O
the	O
coding	O
regions	O
which	O
alter	O
the	O
identity	O
of	O
the	O
encoded	O
amino	O
acid	O
,	O
but	O
some	O
editing	O
events	O
occur	O
in	O
highly	O
structured	O
regions	O
of	O
introns	O
(	O
7	O
,	O
8	O
)	O
.	O

Like	O
other	O
maturation	O
processes	O
,	O
RNA	O
editing	O
is	O
an	O
essential	O
post	O
-	O
transcriptional	O
event	O
in	O
plant	O
mitochondrial	O
gene	O
expression	O
(	O
9	O
-	O
11	O
)	O
required	O
for	O
the	O
synthesis	O
of	O
functional	O
proteins	O
(	O
12	O
,	O
13	O
)	O
.	O

The	O
introduction	O
of	O
foreign	O
DNA	O
into	O
isolated	O
mitochondria	O
is	O
a	O
novel	O
experimental	O
model	O
which	O
has	O
provided	O
important	O
information	O
on	O
RNA	O
editing	O
and	O
RNA	O
splicing	O
enabling	O
the	O
use	O
of	O
a	O
site	O
-	O
directed	O
mutagenesis	O
approach	O
(	O
14	O
,	O
15	O
)	O
.	O

Using	O
a	O
cognate	O
cox2	O
chimeric	O
gene	O
construct	O
,	O
the	O
cis	O
-	O
recognition	O
elements	O
required	O
for	O
plant	O
mitochondria	O
RNA	O
editing	O
have	O
been	O
determined	O
(	O
16	O
,	O
17	O
)	O
.	O

Using	O
the	O
same	O
approach	O
,	O
Staudinger	O
and	O
Kempken	O
(	O
18	O
)	O
have	O
reported	O
that	O
transcripts	O
from	O
A	B-LIVB
.	I-LIVB
thaliana	I-LIVB
cox2	O
,	O
but	O
not	O
Sorghum	B-LIVB
bicolor	I-LIVB
atp6	O
,	O
are	O
edited	O
when	O
the	O
genes	O
are	O
introduced	O
into	O
maize	B-LIVB
mitochondria	O
.	O

Interestingly	O
,	O
higher	O
plant	O
mitochondrial	O
genomes	O
differ	O
in	O
their	O
gene	O
contents	O
due	O
to	O
an	O
evolutionary	O
information	O
transfer	O
from	O
the	O
organelle	O
to	O
the	O
nucleus	O
(	O
19	O
)	O
.	O

Of	O
particular	O
interest	O
is	O
the	O
situation	O
of	O
the	O
small	O
ribosomal	O
protein	O
10	O
gene	O
(	O
rps10	O
)	O
,	O
a	O
group	O
II	O
intron	O
-	O
bearing	O
gene	O
which	O
is	O
encoded	O
in	O
Solanum	B-LIVB
tuberosum	I-LIVB
mitochondrial	O
DNA	O
but	O
is	O
absent	O
from	O
the	O
wheat	B-LIVB
mitochondrial	O
genome	O
(	O
20	O
)	O
.	O

Higher	O
plant	O
mitochondria	O
contain	O
group	O
II	O
introns	O
either	O
in	O
cis	O
-	O
or	O
trans	O
-	O
configuration	O
(	O
1	O
)	O
which	O
can	O
be	O
folded	O
in	O
a	O
characteristic	O
secondary	O
structure	O
(	O
21	O
)	O
.	O

Intron	O
removal	O
in	O
plant	O
mitochondrial	O
mRNAs	O
is	O
not	O
well	O
documented	O
because	O
such	O
introns	O
are	O
unable	O
to	O
self	O
-	O
splice	O
.	O

Previously	O
,	O
we	O
described	O
that	O
electroporated	O
cox2	O
constructs	O
were	O
a	O
good	O
model	O
for	O
the	O
study	O
of	O
the	O
splicing	O
process	O
.	O

Using	O
this	O
model	O
,	O
we	O
found	O
that	O
editing	O
and	O
splicing	O
of	O
cox2	O
transcripts	O
were	O
not	O
linked	O
in	O
wheat	B-LIVB
mitochondria	O
(	O
15	O
)	O
.	O

To	O
challenge	O
the	O
ability	O
of	O
mitochondrial	O
gene	O
expression	O
machinery	O
to	O
recognize	O
genetic	O
information	O
which	O
has	O
been	O
lost	O
during	O
evolution	O
,	O
we	O
decided	O
to	O
introduce	O
the	O
S	B-LIVB
.	I-LIVB
tuberosum	I-LIVB
non	O
-	O
cognate	O
rps10	O
gene	O
into	O
wheat	B-LIVB
mitochondria	O
.	O

Five	O
C	O
residues	O
are	O
changed	O
to	O
U	O
in	O
potato	B-LIVB
mitochondria	O
rps10	O
transcripts	O
by	O
editing	O
.	O

Two	O
of	O
them	O
have	O
been	O
postulated	O
as	O
being	O
necessary	O
for	O
acquisition	O
of	O
a	O
proper	O
secondary	O
and	O
/	O
or	O
tertiary	O
structure	O
for	O
splicing	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
it	O
was	O
necessary	O
to	O
set	O
up	O
the	O
conditions	O
for	O
electroporation	O
of	O
foreign	O
DNA	O
into	O
S	B-LIVB
.	I-LIVB
tuberosum	I-LIVB
mitochondria	O
.	O

Here	O
,	O
we	O
show	O
that	O
a	O
potato	B-LIVB
rps10	O
construct	O
is	O
transcribed	O
when	O
introduced	O
into	O
wheat	B-LIVB
mitochondria	O
,	O
but	O
transcripts	O
are	O
not	O
recognized	O
by	O
the	O
post	O
-	O
transcriptional	O
processing	O
machinery	O
.	O

In	O
contrast	O
,	O
a	O
rps10	O
construct	O
is	O
correctly	O
expressed	O
and	O
processed	O
in	O
cognate	O
potato	B-LIVB
mitochondria	O
.	O

Moreover	O
,	O
we	O
present	O
evidence	O
that	O
transcript	O
editing	O
might	O
be	O
linked	O
to	O
overall	O
RNA	O
processing	O
.	O

This	O
is	O
the	O
first	O
report	O
on	O
DNA	O
electroporation	O
into	O
potato	B-LIVB
mitochondria	O
.	O

MATERIALS	O
AND	O
METHODS	O

Plasmids	O

All	O
plasmids	O
used	O
in	O
this	O
study	O
are	O
based	O
on	O
the	O
previously	O
described	O
pCOXII	O
vector	O
(	O
14	O
)	O
.	O

An	O
NsiI	O
restriction	O
site	O
was	O
introduced	O
at	O
the	O
initiation	O
codon	O
of	O
the	O
wheat	B-LIVB
cox2	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
.	O

Then	O
,	O
NsiI	O
was	O
used	O
in	O
combination	O
with	O
a	O
SpeI	O
restriction	O
site	O
present	O
in	O
the	O
original	O
vector	O
after	O
the	O
stop	O
codon	O
,	O
to	O
produce	O
the	O
chimeric	O
vectors	O
.	O

S	B-LIVB
.	I-LIVB
tuberosum	I-LIVB
cox2	O
gene	O
,	O
including	O
a	O
727	O
bp	O
non	O
-	O
coding	O
upstream	O
region	O
,	O
was	O
isolated	O
by	O
PCR	O
from	O
total	O
DNA	O
using	O
the	O
primer	O
A	O
designed	O
from	O
partial	O
sequences	O
reported	O
by	O
L	O
o	O
essl	O
et	O
al	O
.	O

(	O
22	O
)	O
,	O
accession	O
no	O
.	O

AF096321	O
,	O
containing	O
the	O
KpnI	O
restriction	O
sequence	O
,	O
and	O
primer	O
B	O
derived	O
from	O
Triticum	B-LIVB
timopheevi	I-LIVB
cox2	O
(	O
AF336134	O
)	O
.	O

A	O
fragment	O
of	O
2888	O
bp	O
was	O
obtained	O
and	O
cloned	O
on	O
pGEM	O
-	O
T	O
vector	O
.	O

The	O
complete	O
sequence	O
of	O
the	O
S	B-LIVB
.	I-LIVB
tuberosum	I-LIVB
cox2	O
was	O
determined	O
(	O
accession	O
no	O
.	O
DQ18064	O
)	O
.	O

To	O
generate	O
the	O
plasmid	O
pCOXIISt	O
containing	O
the	O
S	B-LIVB
.	I-LIVB
tuberosum	I-LIVB
cox2	O
gene	O
,	O
a	O
KpnI	O
/	O
SpeI	O
fragment	O
containing	O
the	O
727	O
bp	O
upstream	O
region	O
and	O
the	O
complete	O
coding	O
region	O
was	O
used	O
to	O
replace	O
the	O
wheat	B-LIVB
gene	O
from	O
pCOXII	O
.	O

As	O
for	O
pCOXII	O
,	O
a	O
NsiI	O
site	O
was	O
inserted	O
at	O
the	O
ATG	O
start	O
codon	O
and	O
a	O
23	O
bp	O
fragment	O
was	O
inserted	O
at	O
position	O
-	O
20	O
.	O

This	O
23	O
bp	O
insertion	O
provides	O
a	O
specific	O
sequence	O
allowing	O
isolation	O
of	O
potato	B-LIVB
cox2	O
transcripts	O
originating	O
from	O
the	O
introduced	O
DNA	O
by	O
RT	O
-	O
PCR	O
.	O

The	O
chimeric	O
wheat	B-LIVB
/	O
potato	B-LIVB
cox2	O
gene	O
was	O
constructed	O
by	O
replacing	O
727	O
bp	O
KpnI	O
/	O
NsiI	O
promoter	O
sequence	O
from	O
pCOXIISt	O
with	O
the	O
880	O
bp	O
wheat	B-LIVB
upstream	O
region	O
from	O
pCOXII	O
.	O

The	O
vectors	O
pRPS10W	O
and	O
the	O
pRPS10St	O
derivative	O
,	O
containing	O
wheat	B-LIVB
and	O
potato	B-LIVB
cox2	O
promoters	O
,	O
respectively	O
,	O
were	O
constructed	O
by	O
inserting	O
the	O
1178	O
bp	O
rps10	O
sequence	O
containing	O
two	O
exons	O
separated	O
by	O
a	O
777	O
bp	O
intronic	O
sequence	O
[	O
(	O
23	O
)	O
,	O
accession	O
no	O
.	O
X74826	O
]	O
.	O

The	O
coding	O
region	O
was	O
isolated	O
from	O
total	O
S	B-LIVB
.	I-LIVB
tuberosum	I-LIVB
DNA	O
by	O
PCR	O
using	O
primers	O
D1	O
and	O
D2	O
containing	O
the	O
restriction	O
sites	O
NsiI	O
and	O
SpeI	O
,	O
respectively	O
.	O

The	O
fragment	O
NsiI	O
/	O
SpeI	O
was	O
purified	O
and	O
cloned	O
into	O
pCOXII	O
and	O
pCOXIISt	O
,	O
replacing	O
the	O
respective	O
cox2	O
coding	O
regions	O
.	O

Since	O
all	O
vectors	O
used	O
here	O
were	O
based	O
on	O
pCOXII	O
,	O
they	O
contain	O
the	O
downstream	O
region	O
from	O
the	O
wheat	B-LIVB
cob	O
gene	O
(	O
Ir	O
-	O
cob	O
)	O
(	O
accession	O
no	O
.	O
AF337547	O
)	O
(	O
14	O
)	O
.	O

This	O
sequence	O
,	O
combined	O
with	O
the	O
23	O
bp	O
upstream	O
insert	O
sequence	O
served	O
to	O
distinguish	O
,	O
using	O
primers	O
1a	O
and	O
1b	O
,	O
foreign	O
from	O
endogenous	O
transcripts	O
.	O

All	O
mutants	O
were	O
obtained	O
using	O
QuickChange	O
(R)	O
Site	O
-	O
Directed	O
Mutagenesis	O
kit	O
(	O
Stratagene	O
)	O
.	O

PCR	O
product	O
purifications	O
were	O
carried	O
out	O
with	O
the	O
Wizard	O
(R)	O
Clean	O
-	O
Up	O
System	O
(	O
Promega	O
)	O
.	O

PCR	O
primers	O
used	O

Oligonucleotides	O
sequences	O
are	O
in	O
5	O
'	O
to	O
3	O
'	O
orientation	O
.	O

(	O
1a	O
)	O
,	O
GCGGTGCAGTCATACAGATCTGC	O
;	O
(	O
1b	O
)	O
,	O
TATCCAGATTTGGTACCAAAC	O
;	O
(	O
2a	O
)	O
,	O
GCAGTCATACAGATCTGCCAAAG	O
;	O
(	O
2b	O
)	O
,	O
AGATTTGGTACCAAACCCGGG	O
;	O
(	O
A	O
)	O
,	O
TATAGGTACCTCTCAGGTGTCAAAGTGTGGATTT	O
;	O
(	O
B	O
)	O
,	O
TATAACTAGTTTAAGCTTCCCCG	O
;	O
(	O
D1	O
)	O
,	O
TATAATGCATAGACAAAGGAGAGCACTTA	O
;	O
(	O
D2	O
)	O
,	O
TATAACTAGTTCAGGAAAGGGTCAACGCAA	O
.	O

Restriction	O
sites	O
are	O
underlined	O
.	O

Mutagenesis	O
primers	O
(	O
only	O
sense	O
primers	O
in	O
5	O
'	O
-	O
3	O
'	O
orientation	O
are	O
indicated	O
)	O

Single	O
C2	O
,	O
C3	O
and	O
C2	O
+	O
C3	O
double	O
mutant	O
plasmids	O
were	O
constructed	O
with	O
primers	O
(	O
C2	O
)	O
AAGAAGTTCTTTTGGTTAAAACGCC	O
and	O
(	O
C3	O
)	O
CGCCGTGCGACTTGGAGGACATAAG	O
.	O

NsiI	O
-	O
pCOXII	O
:	O
GGAAATCCAATGCATCTTCGTTCATT	O
and	O
NsiI	O
-	O
pCOXIISt	O
:	O
CCAAACCAAATGCATGTTCTAGAATG	O
.	O

Construct	O
pCOXIISt	O
containing	O
a	O
23	O
nt	O
insertion	O
in	O
the	O
promoter	O
region	O
,	O
was	O
carried	O
out	O
into	O
two	O
consecutive	O
insertions	O
using	O
primers	O
:	O
TGGGGGGAGCAGAGCAGTGCGGTGCAGTCACAAAGAATGAACCAAACC	O
and	O
GCAGTGCGGTGCAGTCATACAGATCTGCCAAAGAATGAACCAAACC	O
.	O

For	O
constructs	O
MA	O
and	O
MAB	O
containing	O
the	O
wheat	B-LIVB
cox2	O
C259	O
editing	O
site	O
,	O
two	O
consecutive	O
insertions	O
were	O
carried	O
out	O
using	O
primers	O
:	O
GGAAGATTGGATTACTATCGAAATTGCCCTGAATCA	O
and	O
TACTATCGAAATTATTCGGACCATGCCCTGAATCA	O
.	O

For	O
ME6	O
and	O
ME6b	O
constructs	O
,	O
primers	O
CCGCGAGGAATCAACTACTATCGAAATTATTGCCGGTGCTGAC	O
and	O
CAACTACTATCGAAATTATTCGGACCATATTGCCGGTGCTGAC	O
were	O
used	O
.	O

Inserted	O
nucleotides	O
are	O
underlined	O
and	O
the	O
modified	O
residues	O
are	O
indicated	O
in	O
bold	O
.	O

Mitochondria	O
purification	O

S	B-LIVB
.	I-LIVB
tuberosum	I-LIVB
cv	O
.	O

Rosevalt	O
tubers	O
and	O
T	B-LIVB
.	I-LIVB
aestivum	I-LIVB
var	I-LIVB
Fortal	I-LIVB
seeds	O
were	O
used	O
.	O

Potato	B-LIVB
mitochondria	O
were	O
prepared	O
from	O
2	O
kg	O
of	O
tubers	O
in	O
batches	O
of	O
200	O
g	O
with	O
200	O
ml	O
of	O
a	O
homogenization	O
buffer	O
containing	O
0	O
.	O
4	O
M	O
mannitol	O
,	O
25	O
mM	O
MOPS	O
(	O
pH	O
7	O
.	O
8	O
)	O
,	O
1	O
mM	O
EGTA	O
,	O
8	O
mM	O
cysteine	O
and	O
1	O
mg	O
/	O
ml	O
fatty	O
acid	O
-	O
free	O
BSA	O
.	O

Homogenization	O
was	O
carried	O
out	O
for	O
15	O
s	O
in	O
a	O
Waring	O
blendor	O
at	O
full	O
speed	O
.	O

Homogenate	O
was	O
centrifuged	O
in	O
a	O
Sorvall	O
GSA	O
rotor	O
at	O
1500	O
g	O
for	O
10	O
min	O
at	O
4	O
degrees	O
C	O
.	O

Supernatant	O
was	O
centrifuged	O
in	O
a	O
GSA	O
rotor	O
at	O
12	O
000	O
g	O
for	O
15	O
min	O
.	O

The	O
mitochondrial	O
pellet	O
was	O
resuspended	O
in	O
50	O
ml	O
of	O
homogenization	O
buffer	O
and	O
centrifuged	O
at	O
1500	O
g	O
.	O

The	O
supernatant	O
was	O
centrifuged	O
in	O
a	O
Sorvall	O
SS	O
-	O
34	O
rotor	O
at	O
15	O
000	O
g	O
for	O
10	O
min	O
,	O
the	O
pellet	O
was	O
resuspended	O
in	O
12	O
ml	O
of	O
homogenization	O
buffer	O
and	O
mitochondria	O
were	O
purified	O
by	O
centrifugation	O
on	O
a	O
sucrose	O
gradient	O
essentially	O
as	O
described	O
for	O
wheat	B-LIVB
embryo	O
mitochondria	O
(	O
14	O
)	O
.	O

Electroporation	O

Electrotransfer	O
experiments	O
were	O
carried	O
out	O
with	O
1	O
mg	O
of	O
purified	O
wheat	B-LIVB
embryo	O
or	O
potato	B-LIVB
tuber	O
mitochondria	O
in	O
50	O
micro	O
l	O
of	O
0	O
.	O
33	O
M	O
sucrose	O
and	O
1	O
micro	O
g	O
of	O
recombinant	O
plasmid	O
as	O
described	O
(	O
14	O
)	O
.	O

The	O
electroporated	O
mitochondria	O
were	O
incubated	O
for	O
18	O
h	O
at	O
25	O
degrees	O
C	O
,	O
then	O
recovered	O
by	O
centrifugation	O
in	O
a	O
Sigma	O
N	O
degrees	O
12024	O
rotor	O
(	O
Sigma	O
1K15	O
refrigerated	O
centrifuge	O
)	O
at	O
15	O
000	O
g	O
for	O
15	O
min	O
at	O
4	O
degrees	O
C	O
.	O

In	O
the	O
case	O
of	O
potato	B-LIVB
mitochondria	O
the	O
incubation	O
mixture	O
was	O
supplemented	O
with	O
1	O
mg	O
/	O
ml	O
of	O
fatty	O
acid	O
-	O
free	O
BSA	O
.	O

RNA	O
was	O
purified	O
with	O
200	O
micro	O
l	O
of	O
TRIzol	O
(TM)	O
reagent	O
(	O
Gibco	O
-	O
BRL	O
)	O
according	O
to	O
the	O
supplier	O
'	O
s	O
protocol	O
.	O

DNAse	O
I	O
protection	O
assay	O
and	O
DNA	O
purification	O

After	O
electroporation	O
and	O
centrifugation	O
,	O
the	O
mitochondrial	O
pellet	O
was	O
resuspended	O
in	O
100	O
micro	O
l	O
of	O
buffer	O
[	O
10	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
7	O
.	O
5	O
)	O
,	O
2	O
mM	O
magnesium	O
acetate	O
and	O
0	O
.	O
33	O
M	O
sucrose	O
]	O
containing	O
60	O
U	O
of	O
DNase	O
I	O
(	O
Gibco	O
-	O
BRL	O
)	O
and	O
incubated	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

The	O
DNase	O
reaction	O
was	O
stopped	O
by	O
adding	O
4	O
micro	O
l	O
of	O
0	O
.	O
5	O
M	O
EDTA	O
and	O
then	O
heating	O
for	O
10	O
min	O
at	O
65	O
degrees	O
C	O
.	O

Mitochondria	O
were	O
incubated	O
with	O
100	O
micro	O
g	O
of	O
Proteinase	O
K	O
(	O
Merck	O
)	O
for	O
4	O
h	O
at	O
37	O
degrees	O
C	O
.	O

One	O
microliter	O
of	O
20	O
%	O
SDS	O
was	O
added	O
to	O
achieve	O
mitochondrial	O
lysis	O
and	O
the	O
DNA	O
was	O
extracted	O
with	O
phenol	O
/	O
chloroform	O
,	O
precipitated	O
with	O
0	O
.	O
1	O
vol	O
of	O
3	O
M	O
Sodium	O
Acetate	O
(	O
pH	O
5	O
.	O
2	O
)	O
,	O
3	O
vol	O
of	O
100	O
%	O
ethanol	O
and	O
100	O
ng	O
of	O
carrier	O
yeast	B-LIVB
tRNA	O
and	O
left	O
overnight	O
at	O
-	O
20	O
degrees	O
C	O
.	O

After	O
centrifugation	O
,	O
the	O
DNA	O
pellet	O
was	O
resuspended	O
in	O
TE	O
buffer	O
[	O
10	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
8	O
)	O
and	O
1	O
mM	O
EDTA	O
]	O
.	O

RT	O
-	O
PCR	O

RNA	O
(	O
1	O
micro	O
g	O
)	O
was	O
treated	O
with	O
2	O
U	O
of	O
Amplification	O
grade	O
DNase	O
I	O
(	O
Promega	O
)	O
.	O

cDNA	O
synthesis	O
was	O
performed	O
with	O
200	O
U	O
of	O
Superscript	O
II	O
RT	O
using	O
100	O
ng	O
of	O
random	O
hexamers	O
.	O

The	O
PCR	O
were	O
performed	O
with	O
primers	O
1a	O
and	O
1b	O
using	O
Advantage	O
(R)	O
2	O
Polymerase	O
Mix	O
(	O
Clontech	O
)	O
as	O
follows	O
:	O
95	O
degrees	O
C	O
,	O
1	O
min	O
;	O
5	O
cycles	O
at	O
95	O
degrees	O
C	O
for	O
30	O
s	O
and	O
68	O
degrees	O
C	O
for	O
1	O
min	O
;	O
30	O
cycles	O
at	O
95	O
degrees	O
C	O
for	O
30	O
s	O
,	O
58	O
degrees	O
C	O
for	O
30	O
s	O
and	O
68	O
degrees	O
C	O
for	O
30	O
s	O
,	O
and	O
finally	O
68	O
degrees	O
C	O
for	O
1	O
min	O
.	O

Primers	O
2a	O
and	O
2b	O
were	O
used	O
for	O
nested	O
PCR	O
from	O
1	O
micro	O
l	O
of	O
the	O
first	O
PCR	O
.	O

No	O
RT	O
-	O
PCR	O
amplification	O
products	O
were	O
obtained	O
with	O
RNA	O
from	O
non	O
-	O
electroporated	O
mitochondria	O
.	O

DNA	O
sequencing	O

Sequence	O
analyses	O
were	O
performed	O
directly	O
on	O
the	O
RT	O
-	O
PCR	O
product	O
using	O
an	O
automatic	O
DNA	O
sequencing	O
equipment	O
with	O
the	O
BigDye	O
(R)	O
Terminator	O
Cycle	O
Sequencing	O
Kit	O
(	O
Applied	O
Biosystem	O
)	O
.	O

RESULTS	O

S	B-LIVB
.	I-LIVB
tuberosum	I-LIVB
rps10	O
transcripts	O
are	O
not	O
processed	O
in	O
wheat	B-LIVB
mitochondria	O

The	O
S	B-LIVB
.	I-LIVB
tuberosum	I-LIVB
rps10	O
construct	O
under	O
control	O
of	O
a	O
wheat	B-LIVB
cox2	O
promoter	O
(	O
Figure	O
1A	O
)	O
was	O
incorporated	O
into	O
purified	O
wheat	B-LIVB
mitochondria	O
by	O
electroporation	O
as	O
indicated	O
in	O
Materials	O
and	O
Methods	O
.	O

After	O
electroporation	O
and	O
incubation	O
in	O
expression	O
medium	O
,	O
mitochondrial	O
RNA	O
was	O
extracted	O
and	O
analysed	O
by	O
RT	O
-	O
PCR	O
.	O

The	O
primers	O
used	O
allowed	O
detection	O
of	O
the	O
transcripts	O
generated	O
by	O
the	O
constructs	O
introduced	O
and	O
excluded	O
any	O
product	O
from	O
endogenous	O
cox2	O
(	O
or	O
rps10	O
in	O
the	O
potato	B-LIVB
system	O
)	O
.	O

Two	O
bands	O
of	O
1204	O
and	O
427	O
bp	O
were	O
expected	O
from	O
precursor	O
and	O
mature	O
rps10	O
mRNAs	O
,	O
respectively	O
.	O

Only	O
precursor	O
rps10	O
molecules	O
were	O
detected	O
(	O
Figure	O
1B	O
)	O
.	O

As	O
a	O
control	O
,	O
a	O
cognate	O
cox2	O
construct	O
(	O
16	O
)	O
was	O
used	O
.	O

In	O
this	O
case	O
,	O
the	O
2048	O
and	O
827	O
bp	O
RT	O
-	O
PCR	O
bands	O
representing	O
the	O
precursor	O
and	O
spliced	O
cox2	O
products	O
,	O
respectively	O
were	O
observed	O
(	O
Figure	O
1B	O
)	O
.	O

In	O
all	O
cases	O
,	O
the	O
PCR	O
bands	O
actually	O
represent	O
transcription	O
products	O
since	O
when	O
PCR	O
was	O
performed	O
without	O
the	O
RT	O
step	O
we	O
observed	O
no	O
amplification	O
products	O
.	O

Previously	O
,	O
five	O
C	O
residues	O
,	O
two	O
in	O
exon	O
1	O
,	O
one	O
in	O
the	O
intron	O
and	O
two	O
in	O
exon	O
2	O
have	O
been	O
reported	O
to	O
be	O
changed	O
to	O
U	O
by	O
editing	O
in	O
potato	B-LIVB
mitochondria	O
(	O
23	O
)	O
.	O

To	O
determine	O
if	O
the	O
non	O
-	O
cognate	O
transcript	O
could	O
be	O
recognized	O
by	O
the	O
wheat	B-LIVB
RNA	O
editing	O
machinery	O
,	O
the	O
1204	O
bp	O
RT	O
-	O
PCR	O
product	O
was	O
sequenced	O
.	O

While	O
wheat	B-LIVB
cox2	O
editing	O
sites	O
were	O
correctly	O
edited	O
in	O
control	O
as	O
expected	O
(	O
Figure	O
1C	O
,	O
only	O
site	O
C77	O
is	O
shown	O
)	O
,	O
all	O
five	O
editable	O
residues	O
in	O
potato	B-LIVB
rps10	O
transcript	O
remain	O
unchanged	O
.	O

cox2	O
C77	O
editing	O
sites	O
are	O
identical	O
in	O
potato	B-LIVB
and	O
wheat	B-LIVB
.	O

Failure	O
of	O
rps10	O
transcript	O
splicing	O
in	O
wheat	B-LIVB
mitochondria	O
is	O
not	O
linked	O
to	O
the	O
absence	O
of	O
editing	O

It	O
has	O
been	O
suggested	O
that	O
residues	O
C2	O
and	O
C3	O
participate	O
in	O
the	O
secondary	O
structure	O
of	O
the	O
intron	O
necessary	O
for	O
splicing	O
(	O
23	O
)	O
.	O

A	O
possible	O
explanation	O
to	O
the	O
failure	O
observed	O
in	O
precursor	O
rps10	O
splicing	O
could	O
be	O
that	O
the	O
absence	O
of	O
edition	O
of	O
C2	O
and	O
C3	O
prevent	O
the	O
intron	O
from	O
organizing	O
itself	O
in	O
a	O
catalytically	O
competent	O
conformation	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
single	O
C2	O
and	O
C3	O
mutants	O
and	O
a	O
C2	O
+	O
C3	O
double	O
mutant	O
were	O
constructed	O
by	O
changing	O
the	O
C	O
residues	O
to	O
T	O
.	O

Neither	O
single	O
nor	O
double	O
mutants	O
were	O
able	O
to	O
undergo	O
splicing	O
(	O
Figure	O
2	O
)	O
.	O

Electroporation	O
of	O
S	B-LIVB
.	I-LIVB
tuberosum	I-LIVB
mitochondria	O

Since	O
two	O
important	O
post	O
-	O
transcriptional	O
processes	O
,	O
RNA	O
editing	O
and	O
splicing	O
,	O
were	O
inoperative	O
when	O
S	B-LIVB
.	I-LIVB
tuberosum	I-LIVB
rps10	O
was	O
expressed	O
in	O
wheat	B-LIVB
mitochondria	O
,	O
we	O
decided	O
to	O
verify	O
whether	O
the	O
negative	O
results	O
were	O
inherent	O
to	O
the	O
rps10	O
chimeric	O
constructs	O
or	O
due	O
to	O
the	O
lack	O
of	O
trans	O
-	O
recognition	O
elements	O
in	O
wheat	B-LIVB
mitochondria	O
.	O

For	O
this	O
purpose	O
,	O
it	O
was	O
necessary	O
to	O
set	O
up	O
an	O
electroporation	O
protocol	O
adapted	O
to	O
S	B-LIVB
.	I-LIVB
tuberosum	I-LIVB
mitochondria	O
.	O

Purified	O
organelles	O
were	O
prepared	O
from	O
potato	B-LIVB
tubers	O
as	O
indicated	O
in	O
Materials	O
and	O
Methods	O
.	O

Electric	O
pulses	O
in	O
the	O
range	O
between	O
8	O
and	O
20	O
kV	O
were	O
performed	O
.	O

Internalization	O
of	O
exogenous	O
DNA	O
was	O
measured	O
by	O
DNAse	O
protection	O
assays	O
(	O
14	O
)	O
.	O

Potato	B-LIVB
mitochondria	O
show	O
a	O
broad	O
range	O
response	O
with	O
a	O
maximum	O
around	O
13	O
kV	O
(	O
Figure	O
3	O
)	O
.	O

This	O
voltage	O
setting	O
was	O
therefore	O
used	O
for	O
further	O
experiments	O
.	O

S	B-LIVB
.	I-LIVB
tuberosum	I-LIVB
mitochondria	O
does	O
not	O
recognize	O
the	O
wheat	B-LIVB
cox2	O
promoter	O

To	O
ascertain	O
the	O
ability	O
of	O
electroporated	O
mitochondria	O
to	O
perform	O
expression	O
of	O
the	O
exogenous	O
gene	O
construct	O
,	O
we	O
used	O
a	O
plasmid	O
containing	O
the	O
potato	B-LIVB
cox2	O
gene	O
controlled	O
either	O
by	O
T	B-LIVB
.	I-LIVB
aestivum	I-LIVB
or	O
S	B-LIVB
.	I-LIVB
tuberosum	I-LIVB
promoters	O
.	O

As	O
shown	O
in	O
Figure	O
4	O
,	O
the	O
construct	O
containing	O
the	O
wheat	B-LIVB
or	O
potato	B-LIVB
promoters	O
was	O
transcribed	O
only	O
in	O
cognate	O
mitochondria	O
.	O

In	O
potato	B-LIVB
,	O
the	O
mature	O
product	O
is	O
barely	O
detectable	O
.	O

In	O
contrast	O
to	O
wheat	B-LIVB
mitochondria	O
,	O
the	O
821	O
nt	O
mature	O
transcript	O
was	O
only	O
detected	O
when	O
the	O
electroporated	O
potato	B-LIVB
mitochondria	O
were	O
incubated	O
in	O
the	O
presence	O
of	O
fatty	O
acid	O
-	O
free	O
BSA	O
.	O

A	O
cognate	O
rps10	O
construct	O
is	O
correctly	O
expressed	O
,	O
edited	O
and	O
processed	O
in	O
potato	B-LIVB
mitochondria	O

The	O
construct	O
expressing	O
potato	B-LIVB
rps10	O
under	O
the	O
control	O
of	O
potato	B-LIVB
cox2	O
promoter	O
was	O
introduced	O
into	O
S	B-LIVB
.	I-LIVB
tuberosum	I-LIVB
isolated	O
mitochondria	O
.	O

After	O
incubation	O
,	O
the	O
precursor	O
and	O
mature	O
transcripts	O
were	O
amplified	O
by	O
RT	O
-	O
PCR	O
(	O
Figure	O
5A	O
)	O
and	O
sequenced	O
.	O

As	O
shown	O
in	O
Figure	O
5B	O
,	O
the	O
four	O
editing	O
sites	O
C1	O
,	O
C2	O
,	O
C4	O
and	O
C5	O
,	O
described	O
previously	O
in	O
endogenous	O
transcripts	O
,	O
were	O
found	O
edited	O
in	O
mature	O
mRNA	O
.	O

The	O
presence	O
of	O
spliced	O
molecules	O
containing	O
unedited	O
residues	O
(	O
Figure	O
5B	O
)	O
indicates	O
that	O
rps10	O
transcripts	O
could	O
be	O
spliced	O
before	O
editing	O
.	O

To	O
confirm	O
this	O
observation	O
,	O
the	O
PCR	O
product	O
was	O
cloned	O
and	O
sequenced	O
.	O

One	O
half	O
of	O
the	O
individual	O
clones	O
were	O
found	O
edited	O
at	O
sites	O
C1	O
and	O
C2	O
;	O
65	O
%	O
were	O
edited	O
at	O
site	O
C4	O
and	O
25	O
%	O
were	O
edited	O
at	O
site	O
C5	O
.	O

A	O
cognate	O
editing	O
site	O
in	O
a	O
non	O
-	O
native	O
context	O
is	O
not	O
recognized	O
by	O
wheat	B-LIVB
mitochondria	O
but	O
is	O
recognized	O
in	O
heterologous	O
mitochondria	O

To	O
test	O
whether	O
wheat	B-LIVB
mitochondria	O
are	O
able	O
to	O
edit	O
a	O
cognate	O
site	O
when	O
placed	O
in	O
the	O
context	O
of	O
a	O
potato	B-LIVB
transcript	O
,	O
we	O
introduced	O
the	O
C259	O
-	O
16	O
/	O
+	O
6	O
region	O
from	O
wheat	B-LIVB
cox2	O
into	O
potato	B-LIVB
rps10	O
exon	O
1	O
or	O
intron	O
(	O
Figure	O
6A	O
,	O
construct	O
MA	O
and	O
ME6	O
,	O
respectively	O
)	O
.	O

As	O
reported	O
previously	O
,	O
the	O
23	O
nt	O
region	O
forming	O
the	O
C259	O
editing	O
site	O
from	O
wheat	B-LIVB
cox2	O
was	O
efficiently	O
edited	O
when	O
grafted	O
into	O
a	O
different	O
context	O
in	O
a	O
wheat	B-LIVB
transcript	O
(	O
17	O
)	O
.	O

Wild	O
-	O
type	O
rps10	O
(	O
pRPS10W	O
)	O
and	O
the	O
MA	O
and	O
ME6	O
mutants	O
were	O
expressed	O
in	O
wheat	B-LIVB
mitochondria	O
but	O
no	O
splicing	O
was	O
observed	O
(	O
Figure	O
6B	O
)	O
.	O

Unexpectedly	O
,	O
wheat	B-LIVB
mitochondria	O
appear	O
to	O
be	O
unable	O
to	O
edit	O
the	O
cognate	O
C259	O
site	O
when	O
the	O
-	O
16	O
/	O
+	O
6	O
region	O
is	O
located	O
on	O
a	O
potato	B-LIVB
rps10	O
precursor	O
.	O

The	O
control	O
CM	O
construct	O
,	O
containing	O
the	O
C259	O
site	O
grafted	O
in	O
a	O
different	O
context	O
but	O
in	O
its	O
own	O
cox2	O
gene	O
,	O
was	O
expressed	O
,	O
spliced	O
and	O
edited	O
as	O
expected	O
[	O
(	O
17	O
)	O
,	O
Figure	O
6B	O
and	O
D	O
]	O
.	O

To	O
compare	O
the	O
editing	O
status	O
of	O
RNAs	O
at	O
the	O
same	O
stage	O
of	O
processing	O
,	O
the	O
editing	O
status	O
of	O
the	O
inserted	O
C259	O
site	O
in	O
precursor	O
cox2	O
transcripts	O
is	O
shown	O
(	O
Figure	O
6D	O
)	O
.	O

The	O
analogous	O
MAb	O
and	O
ME6b	O
constructs	O
,	O
containing	O
the	O
S	B-LIVB
.	I-LIVB
tuberosum	I-LIVB
cox2	O
promoter	O
and	O
the	O
C259	O
region	O
inserted	O
into	O
rps10	O
exon	O
1	O
and	O
intron	O
were	O
used	O
to	O
electroporate	O
potato	B-LIVB
mitochondria	O
.	O

As	O
shown	O
in	O
Figure	O
6C	O
,	O
MAb	O
and	O
ME6b	O
were	O
expressed	O
and	O
spliced	O
at	O
the	O
same	O
level	O
as	O
the	O
control	O
in	O
the	O
homologous	O
context	O
,	O
indicating	O
that	O
insertion	O
does	O
not	O
affect	O
the	O
splicing	O
process	O
.	O

Interestingly	O
,	O
while	O
C259	O
insertion	O
was	O
not	O
recognized	O
in	O
wheat	B-LIVB
mitochondria	O
(	O
Figure	O
6D	O
)	O
,	O
the	O
potato	B-LIVB
RNA	O
editing	O
machinery	O
edited	O
the	O
inserted	O
C259	O
region	O
(	O
Figure	O
6E	O
)	O
.	O

The	O
C259	O
region	O
inserted	O
in	O
the	O
rps10	O
intron	O
(	O
construct	O
ME6b	O
)	O
was	O
also	O
edited	O
,	O
although	O
at	O
a	O
very	O
low	O
level	O
,	O
showing	O
that	O
editing	O
may	O
precede	O
intron	O
removal	O
(	O
not	O
shown	O
)	O
.	O

DISCUSSION	O

Plant	O
mitochondria	O
undergo	O
complex	O
expression	O
mechanisms	O
which	O
are	O
poorly	O
understood	O
.	O

Most	O
studies	O
are	O
based	O
on	O
analysis	O
of	O
in	O
vivo	O
mature	O
or	O
intermediate	O
gene	O
products	O
giving	O
clues	O
on	O
possible	O
mechanisms	O
and	O
suggesting	O
pathways	O
operating	O
in	O
gene	O
expression	O
.	O

Direct	O
tests	O
using	O
in	O
vitro	O
approaches	O
have	O
been	O
fruitful	O
(	O
4	O
,	O
5	O
,	O
24	O
)	O
,	O
but	O
are	O
hampered	O
by	O
the	O
difficulty	O
of	O
obtaining	O
active	O
mitochondrial	O
extracts	O
.	O

Previously	O
,	O
we	O
devised	O
an	O
experimental	O
model	O
based	O
on	O
electroporation	O
of	O
isolated	O
mitochondria	O
that	O
allows	O
us	O
to	O
test	O
gene	O
expression	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
genes	O
.	O

This	O
approach	O
has	O
been	O
very	O
useful	O
in	O
elucidating	O
the	O
process	O
of	O
RNA	O
maturation	O
in	O
plant	O
mitochondria	O
,	O
in	O
particular	O
splicing	O
and	O
editing	O
(	O
14	O
,	O
15	O
)	O
.	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
analyse	O
different	O
gene	O
expression	O
events	O
when	O
a	O
foreign	O
gene	O
was	O
expressed	O
in	O
a	O
heterologous	O
context	O
.	O

rps10	O
was	O
chosen	O
precisely	O
because	O
this	O
genetic	O
information	O
is	O
lacking	O
in	O
wheat	B-LIVB
mitochondria	O
but	O
is	O
active	O
in	O
potato	B-LIVB
mitochondria	O
(	O
20	O
,	O
23	O
,	O
25	O
)	O
.	O

Moreover	O
,	O
rps10	O
transcripts	O
undergo	O
five	O
C	O
-	O
to	O
-	O
U	O
editing	O
events	O
in	O
potato	B-LIVB
mitochondria	O
and	O
rps10	O
contains	O
an	O
intron	O
,	O
thus	O
facilitating	O
the	O
analysis	O
of	O
post	O
-	O
transcriptional	O
processing	O
.	O

To	O
best	O
evaluate	O
the	O
expression	O
of	O
rps10	O
in	O
the	O
non	O
-	O
cognate	O
mitochondria	O
,	O
it	O
was	O
necessary	O
to	O
set	O
up	O
electroporation	O
conditions	O
for	O
introducing	O
foreign	O
DNA	O
into	O
S	B-LIVB
.	I-LIVB
tuberosum	I-LIVB
mitochondria	O
.	O

Potato	B-LIVB
tuber	O
mitochondria	O
were	O
able	O
to	O
incorporate	O
DNA	O
essentially	O
under	O
the	O
same	O
conditions	O
described	O
for	O
wheat	B-LIVB
embryo	O
organelles	O
(	O
14	O
)	O
,	O
except	O
that	O
the	O
optimal	O
voltage	O
range	O
was	O
larger	O
.	O

A	O
major	O
difference	O
to	O
wheat	B-LIVB
was	O
that	O
isolated	O
potato	B-LIVB
mitochondria	O
were	O
viable	O
for	O
3	O
-	O
4	O
h	O
as	O
measured	O
by	O
oxygen	O
consumption	O
(	O
data	O
not	O
shown	O
)	O
.	O

Thus	O
,	O
to	O
observe	O
transcript	O
maturation	O
after	O
electroporation	O
the	O
incubation	O
mixture	O
needed	O
to	O
be	O
supplemented	O
with	O
fatty	O
acid	O
-	O
free	O
BSA	O
(	O
see	O
Figure	O
4	O
)	O
.	O

This	O
behaviour	O
probably	O
reflects	O
the	O
uncoupling	O
of	O
oxidative	O
phosphorylation	O
by	O
fatty	O
acids	O
during	O
incubation	O
of	O
potato	B-LIVB
mitochondria	O
(	O
26	O
)	O
.	O

In	O
fact	O
,	O
previously	O
we	O
found	O
that	O
proper	O
gene	O
expression	O
in	O
isolated	O
mitochondria	O
requires	O
a	O
functional	O
organelle	O
able	O
to	O
generate	O
ATP	O
from	O
ADP	O
and	O
succinate	O
(	O
14	O
)	O
.	O

An	O
interesting	O
observation	O
was	O
that	O
neither	O
the	O
wheat	B-LIVB
nor	O
the	O
potato	B-LIVB
cox2	O
promoters	O
were	O
recognized	O
in	O
a	O
heterologous	O
context	O
(	O
Figure	O
4A	O
and	O
B	O
)	O
.	O

This	O
situation	O
might	O
by	O
explained	O
by	O
the	O
fact	O
that	O
potato	B-LIVB
and	O
wheat	B-LIVB
promoter	O
sequences	O
have	O
no	O
recognizable	O
homologous	O
motifs	O
.	O

Plant	O
mitochondria	O
promoters	O
are	O
characterized	O
by	O
a	O
conserved	O
core	O
CRTA	O
sequence	O
with	O
differences	O
in	O
the	O
extent	O
and	O
the	O
composition	O
of	O
sequences	O
around	O
the	O
consensus	O
motif	O
(	O
27	O
,	O
28	O
)	O
.	O

While	O
the	O
transcription	O
initiation	O
site	O
in	O
wheat	B-LIVB
mitochondria	O
is	O
located	O
at	O
position	O
-	O
170	O
(	O
29	O
)	O
,	O
the	O
potato	B-LIVB
promoter	O
has	O
not	O
yet	O
been	O
described	O
.	O

Transcription	O
may	O
be	O
initiated	O
at	O
numerous	O
sites	O
suggesting	O
a	O
relaxed	O
promoter	O
recognition	O
by	O
the	O
transcription	O
machinery	O
(	O
28	O
)	O
.	O

However	O
,	O
the	O
lack	O
of	O
crossed	O
recognition	O
of	O
cox2	O
promoters	O
in	O
wheat	B-LIVB
and	O
potato	B-LIVB
is	O
not	O
a	O
general	O
situation	O
since	O
the	O
A	B-LIVB
.	I-LIVB
thaliana	I-LIVB
cox2	O
gene	O
is	O
expressed	O
and	O
spliced	O
when	O
introduced	O
into	O
maize	B-LIVB
mitochondria	O
,	O
indicating	O
that	O
the	O
Arabidopsis	B-LIVB
gene	O
shares	O
some	O
signals	O
with	O
maize	B-LIVB
cox2	O
promoter	O
that	O
are	O
sufficient	O
for	O
transcription	O
(	O
18	O
)	O
.	O

The	O
sites	O
required	O
for	O
transcript	O
initiation	O
have	O
been	O
recently	O
described	O
in	O
A	B-LIVB
.	I-LIVB
thaliana	I-LIVB
mitochondrial	O
genes	O
(	O
28	O
)	O
.	O

Three	O
regions	O
were	O
described	O
as	O
important	O
for	O
transcription	O
initiation	O
.	O

We	O
found	O
no	O
such	O
homologous	O
sequences	O
in	O
the	O
potato	B-LIVB
cox2	O
upstream	O
region	O
indicating	O
that	O
the	O
two	O
dicot	O
promoters	O
do	O
not	O
have	O
the	O
same	O
origin	O
.	O

This	O
in	O
turn	O
may	O
reflect	O
the	O
natural	O
history	O
of	O
this	O
particular	O
mitochondrial	O
gene	O
evolving	O
in	O
its	O
own	O
context	O
.	O

It	O
should	O
be	O
mentioned	O
that	O
the	O
presence	O
of	O
a	O
conserved	O
sequence	O
is	O
not	O
sufficient	O
for	O
expression	O
since	O
a	O
region	O
that	O
acts	O
as	O
promoter	O
in	O
Arabidopsis	B-LIVB
,	O
potato	B-LIVB
and	O
Oenothera	O
is	O
inactive	O
in	O
vivo	O
in	O
pea	B-LIVB
(	O
30	O
)	O
.	O

Further	O
studies	O
will	O
be	O
required	O
to	O
understand	O
the	O
transcriptional	O
events	O
in	O
plant	O
mitochondria	O
.	O

Electroporation	O
of	O
foreign	O
DNA	O
into	O
isolated	O
mitochondria	O
provides	O
an	O
interesting	O
functional	O
model	O
,	O
complementary	O
to	O
in	O
vitro	O
transcription	O
assay	O
,	O
for	O
answering	O
these	O
questions	O
.	O

The	O
potato	B-LIVB
rps10	O
gene	O
controlled	O
by	O
a	O
T	B-LIVB
.	I-LIVB
aestivum	I-LIVB
promoter	O
(	O
Figure	O
1A	O
)	O
was	O
transcribed	O
as	O
a	O
1204	O
nt	O
precursor	O
in	O
wheat	B-LIVB
mitochondria	O
,	O
but	O
no	O
traces	O
of	O
mature	O
RNA	O
were	O
observed	O
.	O

Moreover	O
,	O
the	O
five	O
C	O
residues	O
reported	O
as	O
RNA	O
editing	O
targets	O
in	O
vivo	O
(	O
23	O
)	O
remain	O
unchanged	O
,	O
indicating	O
that	O
rps10	O
transcript	O
was	O
not	O
recognized	O
by	O
the	O
wheat	B-LIVB
splicing	O
and	O
editing	O
machinery	O
.	O

A	O
control	O
using	O
the	O
cognate	O
cox2	O
construct	O
demonstrates	O
that	O
electroporated	O
organelles	O
were	O
competent	O
for	O
splicing	O
and	O
editing	O
(	O
Figure	O
1B	O
and	O
C	O
)	O
.	O

Some	O
editing	O
events	O
occur	O
in	O
highly	O
structured	O
domains	O
of	O
introns	O
.	O

Because	O
in	O
some	O
cases	O
,	O
editing	O
corrects	O
A	O
-	O
C	O
mispairing	O
improving	O
conformation	O
of	O
the	O
intron	O
,	O
it	O
has	O
been	O
proposed	O
that	O
the	O
C	O
-	O
to	O
-	O
U	O
change	O
might	O
be	O
necessary	O
for	O
efficient	O
splicing	O
(	O
8	O
,	O
9	O
,	O
23	O
,	O
31	O
)	O
.	O

Based	O
on	O
the	O
canonical	O
structure	O
of	O
group	O
II	O
mitochondrial	O
introns	O
(	O
21	O
)	O
,	O
two	O
editing	O
sites	O
,	O
C2	O
located	O
at	O
the	O
Intron	O
Binding	O
Site	O
2	O
(	O
IBS2	O
)	O
and	O
C3	O
located	O
in	O
the	O
intron	O
,	O
nine	O
residues	O
downstream	O
from	O
the	O
end	O
of	O
exon	O
1	O
in	O
S	B-LIVB
.	I-LIVB
tuberosum	I-LIVB
rps10	O
are	O
of	O
particular	O
interest	O
.	O

It	O
has	O
been	O
predicted	O
that	O
both	O
edited	O
residues	O
participate	O
in	O
base	O
-	O
pair	O
interactions	O
in	O
the	O
putative	O
secondary	O
structure	O
.	O

Of	O
particular	O
interest	O
is	O
the	O
site	O
C3	O
located	O
in	O
intron	O
domain	O
I	O
(	O
23	O
)	O
.	O

This	O
position	O
may	O
be	O
crucial	O
for	O
splicing	O
as	O
inferred	O
from	O
mutants	O
of	O
a	O
yeast	B-LIVB
mitochondrial	O
intron	O
(	O
32	O
)	O
.	O

We	O
addressed	O
this	O
question	O
by	O
introducing	O
rps10	O
mutant	O
genes	O
presenting	O
C2	O
,	O
C3	O
or	O
both	O
positions	O
in	O
the	O
edited	O
form	O
into	O
mitochondria	O
.	O

As	O
shown	O
in	O
Figure	O
2	O
,	O
transcription	O
was	O
as	O
efficient	O
as	O
for	O
the	O
cognate	O
cox2	O
construct	O
but	O
neither	O
wild	O
-	O
type	O
rps10	O
nor	O
the	O
C	O
-	O
U	O
mutants	O
underwent	O
splicing	O
.	O

These	O
results	O
clearly	O
demonstrate	O
that	O
C2	O
and	O
C3	O
editing	O
is	O
not	O
sufficient	O
for	O
splicing	O
of	O
rps10	O
precursor	O
in	O
wheat	B-LIVB
mitochondria	O
and	O
lead	O
us	O
to	O
conclude	O
that	O
splicing	O
failure	O
is	O
probably	O
linked	O
to	O
the	O
lack	O
of	O
trans	O
-	O
recognition	O
elements	O
.	O

One	O
may	O
speculate	O
that	O
these	O
trans	O
-	O
acting	O
factors	O
,	O
for	O
instance	O
nuclear	O
-	O
encoded	O
maturases	O
,	O
were	O
lost	O
after	O
rps10	O
was	O
transferred	O
to	O
the	O
nucleus	O
in	O
monocots	O
(	O
20	O
,	O
25	O
)	O
.	O

The	O
C	O
-	O
to	O
-	O
U	O
mutants	O
were	O
also	O
tested	O
in	O
potato	B-LIVB
mitochondria	O
;	O
no	O
significant	O
differences	O
were	O
detected	O
in	O
splicing	O
efficiency	O
when	O
compared	O
to	O
the	O
unedited	O
construct	O
(	O
D	O
.	O
Choury	O
,	O
unpublished	O
data	O
)	O
.	O

It	O
should	O
be	O
noted	O
that	O
the	O
lack	O
of	O
splicing	O
in	O
wheat	B-LIVB
mitochondria	O
is	O
not	O
a	O
general	O
feature	O
of	O
potato	B-LIVB
introns	O
,	O
since	O
the	O
potato	B-LIVB
cox2	O
intron	O
is	O
removed	O
efficiently	O
(	O
Figure	O
4B	O
)	O
.	O

This	O
is	O
consistent	O
with	O
the	O
hypothesis	O
that	O
potato	B-LIVB
and	O
wheat	B-LIVB
mitochondria	O
have	O
similar	O
trans	O
-	O
acting	O
factors	O
for	O
cox2	O
intron	O
removal	O
.	O

A	O
possible	O
link	O
between	O
intron	O
removal	O
and	O
editing	O
has	O
been	O
proposed	O
for	O
splicing	O
of	O
nad1e	O
and	O
nad5III	O
trans	O
-	O
introns	O
where	O
domain	O
six	O
may	O
require	O
editing	O
to	O
be	O
structured	O
in	O
a	O
catalytic	O
competent	O
secondary	O
conformation	O
(	O
8	O
)	O
.	O

In	O
rice	B-LIVB
,	O
failure	O
of	O
RNA	O
maturation	O
and	O
editing	O
has	O
been	O
correlated	O
with	O
cytoplasmic	O
male	O
sterile	O
phenotype	O
.	O

In	O
this	O
model	O
,	O
the	O
absence	O
of	O
the	O
nuclear	O
gene	O
Rf	O
-	O
1	O
affects	O
B	O
-	O
atp6	O
RNA	O
cleavage	O
and	O
editing	O
(	O
33	O
)	O
.	O

In	O
organello	O
studies	O
have	O
shown	O
that	O
S	B-LIVB
.	I-LIVB
bicolor	I-LIVB
atp6	O
-	O
1	O
gene	O
was	O
transcribed	O
but	O
not	O
edited	O
when	O
introduced	O
into	O
maize	B-LIVB
mitochondria	O
(	O
18	O
)	O
.	O

However	O
,	O
partially	O
edited	O
molecules	O
were	O
detected	O
in	O
sorghum	B-LIVB
-	O
maize	B-LIVB
atp6	O
chimeric	O
transcripts	O
when	O
they	O
included	O
the	O
maize	B-LIVB
atp6	O
5	O
'	O
-	O
untranslated	O
sequence	O
,	O
suggesting	O
that	O
the	O
5	O
'	O
non	O
-	O
coding	O
region	O
provides	O
a	O
structural	O
motif	O
or	O
binding	O
site	O
for	O
a	O
transcript	O
-	O
specific	O
editing	O
factor	O
(	O
34	O
)	O
.	O

Unfortunately	O
,	O
no	O
data	O
on	O
atp6	O
processing	O
was	O
reported	O
to	O
determine	O
whether	O
this	O
region	O
is	O
directly	O
involved	O
in	O
editing	O
or	O
some	O
other	O
maturation	O
event	O
.	O

Since	O
wheat	B-LIVB
mitochondria	O
do	O
not	O
have	O
rps10	O
encoded	O
in	O
the	O
mitochondrial	O
genome	O
(	O
20	O
)	O
,	O
it	O
was	O
interesting	O
to	O
test	O
whether	O
wheat	B-LIVB
mitochondria	O
were	O
able	O
to	O
recognize	O
editing	O
sites	O
which	O
had	O
been	O
lost	O
during	O
evolution	O
.	O

In	O
other	O
words	O
,	O
whether	O
the	O
mitochondrial	O
trans	O
-	O
recognition	O
elements	O
are	O
specific	O
for	O
each	O
site	O
or	O
whether	O
they	O
are	O
operating	O
on	O
a	O
subset	O
of	O
editing	O
sites	O
.	O

This	O
question	O
is	O
important	O
since	O
to	O
date	O
the	O
factors	O
responsible	O
for	O
RNA	O
editing	O
in	O
plant	O
mitochondria	O
remain	O
unknown	O
.	O

Solving	O
this	O
issue	O
may	O
provide	O
clues	O
to	O
uncover	O
such	O
factors	O
.	O

As	O
described	O
above	O
,	O
the	O
rps10	O
transcript	O
was	O
not	O
processed	O
in	O
wheat	B-LIVB
but	O
it	O
was	O
correctly	O
spliced	O
in	O
cognate	O
mitochondria	O
(	O
Figure	O
5A	O
)	O
.	O

Indeed	O
,	O
the	O
mature	O
transcript	O
had	O
identical	O
exon1	O
and	O
exon2	O
junction	O
as	O
found	O
in	O
endogenous	O
rps10	O
mRNA	O
(	O
data	O
not	O
shown	O
)	O
.	O

More	O
importantly	O
,	O
all	O
editing	O
sites	O
,	O
C1	O
,	O
C2	O
,	O
C4	O
and	O
C5	O
were	O
significantly	O
converted	O
to	O
Us	O
(	O
Figure	O
5B	O
)	O
.	O

The	O
fact	O
that	O
the	O
four	O
editing	O
sites	O
were	O
found	O
either	O
edited	O
or	O
unedited	O
in	O
spliced	O
rps10	O
mRNA	O
is	O
an	O
indication	O
that	O
editing	O
does	O
not	O
precede	O
splicing	O
as	O
was	O
previously	O
found	O
for	O
cox2	O
in	O
wheat	B-LIVB
(	O
15	O
)	O
.	O

It	O
may	O
be	O
argued	O
that	O
the	O
absence	O
of	O
splicing	O
precluded	O
editing	O
.	O

This	O
possibility	O
can	O
be	O
discarded	O
since	O
potato	B-LIVB
rps10	O
precursor	O
mRNA	O
was	O
found	O
to	O
be	O
edited	O
in	O
vivo	O
(	O
23	O
)	O
.	O

These	O
data	O
clearly	O
show	O
that	O
splicing	O
is	O
not	O
required	O
for	O
rps10	O
editing	O
,	O
similar	O
to	O
previous	O
findings	O
for	O
cox2	O
mRNA	O
and	O
also	O
in	O
cox2	O
mutant	O
derivatives	O
unable	O
to	O
remove	O
the	O
intron	O
(	O
15	O
)	O
.	O

This	O
led	O
us	O
to	O
postulate	O
that	O
the	O
inability	O
of	O
wheat	B-LIVB
mitochondria	O
to	O
recognize	O
rps10	O
editing	O
sites	O
is	O
likely	O
due	O
to	O
the	O
fact	O
that	O
wheat	B-LIVB
mitochondria	O
have	O
lost	O
the	O
editing	O
trans	O
-	O
recognition	O
elements	O
which	O
become	O
dispensable	O
after	O
transfer	O
of	O
rps10	O
to	O
the	O
nucleus	O
.	O

To	O
test	O
this	O
possibility	O
,	O
rps10	O
chimeric	O
plasmids	O
containing	O
editing	O
site	O
C259	O
from	O
wheat	B-LIVB
cox2	O
inserted	O
either	O
in	O
exon1	O
or	O
the	O
intron	O
were	O
constructed	O
.	O

Site	O
C259	O
is	O
formed	O
by	O
23	O
nt	O
corresponding	O
to	O
the	O
-	O
16	O
/	O
+	O
6	O
sequence	O
embedding	O
the	O
target	O
C	O
.	O

Previously	O
we	O
found	O
that	O
this	O
small	O
region	O
could	O
be	O
recognized	O
by	O
the	O
RNA	O
editing	O
machinery	O
when	O
placed	O
outside	O
of	O
its	O
natural	O
context	O
(	O
16	O
,	O
17	O
)	O
.	O

The	O
wheat	B-LIVB
C259	O
editing	O
site	O
in	O
the	O
chimeric	O
construct	O
was	O
correctly	O
edited	O
by	O
potato	B-LIVB
mitochondria	O
.	O

This	O
result	O
is	O
not	O
unexpected	O
since	O
the	O
corresponding	O
region	O
in	O
endogenous	O
potato	B-LIVB
cox2	O
mRNA	O
,	O
which	O
presents	O
two	O
differences	O
at	O
positions	O
-	O
3	O
(	O
C	O
instead	O
of	O
A	O
)	O
and	O
-	O
7	O
(	O
G	O
instead	O
of	O
A	O
)	O
,	O
is	O
edited	O
.	O

Furthermore	O
,	O
these	O
positions	O
were	O
not	O
crucial	O
for	O
editing	O
of	O
C259	O
(	O
17	O
)	O
.	O

Surprisingly	O
,	O
the	O
C259	O
editing	O
site	O
grafted	O
in	O
rps10	O
was	O
not	O
recognized	O
by	O
the	O
wheat	B-LIVB
editing	O
machinery	O
.	O

We	O
cannot	O
exclude	O
the	O
possibility	O
that	O
editing	O
efficiency	O
in	O
precursor	O
molecules	O
is	O
very	O
low	O
and	O
so	O
is	O
undetectable	O
when	O
sequencing	O
RT	O
-	O
PCR	O
products	O
representing	O
a	O
pool	O
of	O
transcripts	O
.	O

However	O
,	O
analysis	O
of	O
the	O
same	O
region	O
in	O
cox2	O
precursors	O
indicates	O
that	O
this	O
was	O
not	O
the	O
case	O
since	O
significant	O
C	O
-	O
to	O
-	O
U	O
conversion	O
was	O
observed	O
(	O
Figure	O
6D	O
)	O
.	O

These	O
observations	O
lead	O
us	O
to	O
postulate	O
that	O
editing	O
is	O
occurring	O
only	O
when	O
the	O
transcript	O
is	O
engaged	O
in	O
post	O
-	O
transcriptional	O
processing	O
,	O
suggesting	O
that	O
rps10	O
transcripts	O
are	O
not	O
available	O
to	O
editing	O
factors	O
independently	O
of	O
the	O
RNA	O
maturation	O
machinery	O
.	O

The	O
fact	O
that	O
the	O
wheat	B-LIVB
editing	O
site	O
C259	O
inserted	O
in	O
chimeric	O
rps10	O
transcripts	O
was	O
not	O
recognized	O
by	O
wheat	B-LIVB
mitochondria	O
is	O
a	O
strong	O
argument	O
for	O
this	O
hypothesis	O
.	O

One	O
might	O
speculate	O
that	O
in	O
plant	O
mitochondria	O
,	O
transcripts	O
have	O
to	O
be	O
engaged	O
in	O
a	O
kind	O
of	O
multiprotein	O
processing	O
complex	O
.	O

A	O
failure	O
to	O
be	O
recognized	O
at	O
some	O
early	O
stage	O
will	O
lead	O
to	O
their	O
accumulation	O
as	O
unmodified	O
precursors	O
.	O

Rap1p	O
and	O
other	O
transcriptional	O
regulators	O
can	O
function	O
in	O
defining	O
distinct	O
domains	O
of	O
gene	O
expression	O

Abstract	O

Barrier	O
elements	O
that	O
are	O
able	O
to	O
block	O
the	O
propagation	O
of	O
transcriptional	O
silencing	O
in	O
yeast	B-LIVB
are	O
functionally	O
similar	O
to	O
chromatin	O
boundary	O
/	O
insulator	O
elements	O
in	O
metazoans	O
that	O
delimit	O
functional	O
chromosomal	O
domains	O
.	O

We	O
show	O
that	O
the	O
upstream	O
activating	O
sequences	O
of	O
many	O
highly	O
expressed	O
ribosome	O
protein	O
genes	O
and	O
glycolytic	O
genes	O
exhibit	O
barrier	O
activity	O
.	O

Analyses	O
of	O
these	O
barriers	O
indicate	O
that	O
binding	O
sites	O
for	O
transcriptional	O
regulators	O
Rap1p	O
,	O
Abf1p	O
,	O
Reb1p	O
,	O
Adr1p	O
and	O
Gcn4p	O
may	O
participate	O
in	O
barrier	O
function	O
.	O

We	O
also	O
present	O
evidence	O
suggesting	O
that	O
Rap1p	O
is	O
directly	O
involved	O
in	O
barrier	O
activity	O
,	O
and	O
its	O
barrier	O
function	O
correlates	O
with	O
local	O
changes	O
in	O
chromatin	O
structure	O
.	O

We	O
further	O
demonstrate	O
that	O
tethering	O
the	O
transcriptional	O
activation	O
domain	O
of	O
Rap1p	O
to	O
DNA	O
is	O
sufficient	O
to	O
recapitulate	O
barrier	O
activity	O
.	O

Moreover	O
,	O
targeting	O
the	O
activation	O
domain	O
of	O
Adr1p	O
or	O
Gcn4p	O
also	O
establishes	O
a	O
barrier	O
to	O
silencing	O
.	O

These	O
results	O
support	O
the	O
notion	O
that	O
transcriptional	O
regulators	O
could	O
also	O
participate	O
in	O
delimiting	O
functional	O
domains	O
in	O
the	O
genome	O
.	O

INTRODUCTION	O

The	O
eukaryotic	O
genome	O
is	O
organized	O
into	O
discrete	O
functional	O
domains	O
in	O
which	O
gene	O
expression	O
is	O
either	O
permitted	O
or	O
repressed	O
.	O

Domains	O
permissive	O
for	O
gene	O
expression	O
are	O
usually	O
defined	O
as	O
euchromatin	O
or	O
active	O
chromatin	O
,	O
and	O
domains	O
that	O
repress	O
gene	O
expression	O
heterochromatin	O
or	O
silent	O
chromatin	O
.	O

The	O
HML	O
and	O
HMR	O
loci	O
in	O
Saccharomyces	B-LIVB
cerevisiae	I-LIVB
are	O
silent	O
chromatin	O
domains	O
(	O
1	O
)	O
.	O

Compared	O
to	O
active	O
chromatin	O
,	O
silent	O
chromatin	O
is	O
more	O
compact	O
and	O
its	O
histone	O
components	O
are	O
hypoacetylated	O
(	O
2	O
)	O
.	O

The	O
SIR	O
complex	O
consisting	O
of	O
Sir2p	O
through	O
Sir4p	O
is	O
an	O
integral	O
part	O
of	O
yeast	B-LIVB
silent	O
chromatin	O
.	O

Sir3p	O
and	O
Sir4p	O
interact	O
with	O
the	O
N	O
-	O
terminal	O
tails	O
of	O
histones	O
H3	O
and	O
H4	O
providing	O
the	O
structural	O
basis	O
of	O
silent	O
chromatin	O
(	O
1	O
)	O
.	O

Sir2p	O
was	O
recently	O
found	O
to	O
be	O
an	O
NAD	O
-	O
dependent	O
histone	O
deacetylase	O
and	O
was	O
suggested	O
to	O
be	O
responsible	O
for	O
histone	O
hypoacetylation	O
in	O
silent	O
chromatin	O
(	O
3	O
)	O
.	O

Silent	O
chromatin	O
is	O
initiated	O
at	O
small	O
cis	O
-	O
acting	O
DNA	O
elements	O
known	O
as	O
the	O
E	O
and	O
I	O
silencers	O
flanking	O
each	O
of	O
the	O
HM	O
loci	O
(	O
4	O
)	O
.	O

Increasing	O
evidence	O
indicates	O
that	O
histone	O
deacetylation	O
is	O
key	O
to	O
the	O
propagation	O
of	O
silent	O
chromatin	O
(	O
4	O
)	O
.	O

In	O
vertebrates	O
and	O
fission	O
yeast	B-LIVB
,	O
spread	O
of	O
silent	O
chromatin	O
involves	O
a	O
chain	O
of	O
events	O
of	O
histone	O
H3	O
deacetylation	O
-->	O
H3	O
methylation	O
-->	O
binding	O
of	O
methylated	O
H3	O
by	O
HP1	O
(	O
heterochromatin	O
protein	O
1	O
)	O
or	O
swi6	O
(	O
4	O
)	O
.	O

In	O
S	B-LIVB
.	I-LIVB
cerevisiae	I-LIVB
,	O
there	O
is	O
evidence	O
that	O
Sir3p	O
(	O
hence	O
the	O
SIR	O
complex	O
)	O
has	O
much	O
higher	O
affinity	O
to	O
unacetylated	O
histone	O
H4	O
than	O
acetylated	O
H4	O
(	O
5	O
)	O
.	O

Based	O
on	O
this	O
and	O
the	O
fact	O
that	O
Sir2p	O
is	O
a	O
histone	O
deacetylase	O
,	O
a	O
refined	O
model	O
for	O
the	O
propagation	O
of	O
silent	O
chromatin	O
can	O
be	O
proposed	O
.	O

In	O
this	O
model	O
,	O
Sir2p	O
recruited	O
to	O
the	O
silencer	O
deacetylates	O
histones	O
in	O
an	O
adjacent	O
nucleosome	O
enabling	O
it	O
to	O
bind	O
another	O
SIR	O
complex	O
with	O
high	O
affinity	O
.	O

The	O
nucleosome	O
-	O
bound	O
SIR	O
complex	O
in	O
turn	O
deacetylates	O
the	O
neighboring	O
nucleosome	O
allowing	O
it	O
to	O
recruit	O
a	O
new	O
SIR	O
complex	O
.	O

In	O
this	O
manner	O
,	O
the	O
SIR	O
complex	O
promotes	O
its	O
own	O
propagation	O
along	O
an	O
array	O
of	O
nucleosomes	O
(	O
4	O
)	O
.	O

The	O
fact	O
that	O
transcriptionally	O
silent	O
chromatin	O
can	O
encroach	O
upon	O
active	O
chromatin	O
poses	O
the	O
question	O
of	O
how	O
interspersed	O
domains	O
of	O
silent	O
and	O
active	O
chromatin	O
are	O
demarcated	O
.	O

Studies	O
of	O
the	O
Drosophila	O
and	O
vertebrate	O
genomes	O
demonstrated	O
that	O
some	O
domains	O
are	O
delimited	O
by	O
boundary	O
or	O
insulator	O
elements	O
(	O
6	O
)	O
.	O

These	O
elements	O
are	O
specialized	O
DNA	O
sequences	O
that	O
act	O
as	O
barriers	O
to	O
enhancers	O
and	O
/	O
or	O
silent	O
chromatin	O
.	O

One	O
of	O
the	O
best	O
characterized	O
insulators	O
is	O
the	O
chicken	B-LIVB
HS4	O
insulator	O
at	O
the	O
beta	O
-	O
globin	O
locus	O
.	O

Histones	O
surrounding	O
this	O
insulator	O
are	O
hyperacetylated	O
indicating	O
the	O
presence	O
of	O
histone	O
acetyltransferase	O
(	O
HAT	O
)	O
activity	O
at	O
the	O
insulator	O
(	O
6	O
)	O
.	O

Recently	O
,	O
sequences	O
that	O
could	O
block	O
the	O
spread	O
of	O
silent	O
chromatin	O
have	O
been	O
discovered	O
in	O
S	B-LIVB
.	I-LIVB
cerevisiae	I-LIVB
(	O
7	O
,	O
8	O
)	O
.	O

These	O
sequences	O
(	O
referred	O
to	O
as	O
silent	O
chromatin	O
barriers	O
)	O
include	O
sub	O
-	O
telomeric	O
anti	O
-	O
silencing	O
regions	O
(	O
STARs	O
)	O
,	O
the	O
right	O
boundary	O
of	O
HMR	O
,	O
and	O
the	O
upstream	O
activating	O
sequence	O
(	O
UAS	O
)	O
of	O
the	O
highly	O
expressed	O
TEF2	O
gene	O
(	O
9	O
-	O
11	O
)	O
.	O

The	O
mechanisms	O
underlying	O
barrier	O
functions	O
in	O
yeast	B-LIVB
are	O
not	O
known	O
.	O

TEF2	O
-	O
UAS	O
contains	O
three	O
tandem	O
repressor	O
activator	O
protein	O
1	O
(	O
Rap1p	O
)	O
-	O
binding	O
sites	O
that	O
are	O
necessary	O
and	O
sufficient	O
for	O
its	O
barrier	O
function	O
(	O
11	O
)	O
.	O

Rap1p	O
is	O
an	O
abundant	O
sequence	O
-	O
specific	O
DNA	O
-	O
binding	O
protein	O
(	O
12	O
)	O
.	O

Variants	O
of	O
the	O
13	O
bp	O
consensus	O
sequence	O
for	O
Rap1p	O
binding	O
(	O
ACACC	O
CRYACAYM	O
)	O
(	O
13	O
)	O
lie	O
not	O
only	O
in	O
the	O
UASs	O
of	O
numerous	O
genes	O
but	O
also	O
in	O
the	O
silencers	O
of	O
the	O
HM	O
loci	O
and	O
in	O
telomeric	O
C1	O
-	O
3A	O
repeats	O
.	O

Accordingly	O
,	O
Rap1p	O
functions	O
as	O
a	O
global	O
regulator	O
of	O
transcriptional	O
activation	O
and	O
repression	O
,	O
silencing	O
,	O
as	O
well	O
as	O
telomere	O
length	O
(	O
12	O
)	O
.	O

Rap1p	O
performs	O
these	O
diverse	O
functions	O
by	O
interacting	O
with	O
different	O
factors	O
in	O
respective	O
contexts	O
.	O

As	O
an	O
activator	O
,	O
Rap1p	O
binds	O
to	O
the	O
promoters	O
of	O
362	O
ORFs	O
(	O
13	O
)	O
and	O
can	O
function	O
via	O
at	O
least	O
three	O
mechanisms	O
.	O

First	O
,	O
Rap1p	O
binding	O
can	O
'	O
open	O
up	O
'	O
local	O
chromatin	O
structure	O
at	O
a	O
promoter	O
to	O
help	O
another	O
activator	O
to	O
bind	O
(	O
14	O
)	O
.	O

Secondly	O
,	O
Rap1p	O
bound	O
to	O
DNA	O
can	O
help	O
Gcr1p	O
bind	O
to	O
an	O
adjacent	O
site	O
in	O
the	O
promoter	O
through	O
physical	O
interaction	O
(	O
15	O
)	O
.	O

Thirdly	O
,	O
Rap1p	O
is	O
involved	O
in	O
the	O
recruitment	O
of	O
the	O
NuA4	O
HAT	O
complex	O
and	O
TFIID	O
to	O
ribosome	O
protein	O
genes	O
(	O
RPGs	O
)	O
(	O
16	O
,	O
17	O
)	O
.	O

As	O
a	O
silencing	O
factor	O
,	O
Rap1p	O
binds	O
to	O
silencers	O
or	O
telomeric	O
repeats	O
and	O
recruits	O
Sir3p	O
/	O
Sir4p	O
through	O
direct	O
interactions	O
(	O
18	O
)	O
.	O

Rap1p	O
also	O
interacts	O
with	O
telomere	O
-	O
specific	O
proteins	O
in	O
executing	O
its	O
role	O
in	O
regulating	O
telomere	O
length	O
(	O
19	O
)	O
.	O

It	O
is	O
puzzling	O
that	O
a	O
protein	O
that	O
helps	O
establish	O
silent	O
chromatin	O
could	O
also	O
act	O
as	O
a	O
barrier	O
to	O
its	O
propagation	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
in	O
addition	O
to	O
TEF2	O
-	O
UAS	O
,	O
UASs	O
of	O
many	O
yeast	B-LIVB
genes	O
exhibit	O
barrier	O
activity	O
.	O

Analyses	O
of	O
these	O
UASs	O
indicate	O
that	O
binding	O
sites	O
for	O
transcriptional	O
regulators	O
Abf1p	O
,	O
Reb1p	O
,	O
Adr1p	O
,	O
Gcn4p	O
,	O
as	O
well	O
as	O
Rap1p	O
,	O
may	O
participate	O
in	O
barrier	O
function	O
.	O

These	O
UASs	O
are	O
dispersed	O
across	O
the	O
genome	O
and	O
might	O
play	O
a	O
role	O
in	O
defining	O
functional	O
chromosomal	O
domains	O
.	O

Moreover	O
,	O
we	O
demonstrated	O
that	O
targeting	O
the	O
activation	O
domain	O
of	O
Rap1p	O
,	O
Adr1p	O
or	O
Gcn4p	O
alone	O
,	O
led	O
to	O
barrier	O
function	O
.	O

Since	O
the	O
activation	O
domain	O
of	O
an	O
activator	O
was	O
usually	O
involved	O
in	O
interacting	O
with	O
co	O
-	O
activators	O
and	O
/	O
or	O
components	O
of	O
the	O
transcriptional	O
machinery	O
,	O
these	O
data	O
indicated	O
that	O
other	O
factors	O
might	O
also	O
be	O
involved	O
in	O
barrier	O
function	O
.	O

MATERIALS	O
AND	O
METHODS	O

Plasmids	O
and	O
strains	O

Plasmids	O
1	O
-	O
53	O
were	O
used	O
to	O
make	O
strains	O
1	O
-	O
53	O
,	O
respectively	O
(	O
see	O
Figs	O
1	O
-	O
6	O
)	O
.	O

Plasmid	O
1	O
was	O
previously	O
named	O
pMB22	O
-	O
a	O
that	O
contained	O
a	O
HindIII	O
-	O
BamHI	O
fragment	O
of	O
chromosome	O
III	O
(	O
coordinates	O
14838	O
-	O
16263	O
)	O
with	O
a	O
URA3	O
gene	O
inserted	O
at	O
its	O
EcoRV	O
site	O
(	O
20	O
)	O
.	O

Plasmid	O
2	O
was	O
derived	O
from	O
1	O
by	O
inserting	O
TEF2	O
-	O
UAS	O
(	O
-	O
511	O
to	O
-	O
407	O
bp	O
relative	O
to	O
the	O
translation	O
start	O
codon	O
)	O
at	O
the	O
SnaBI	O
site	O
.	O

Plasmids	O
3	O
-	O
38	O
were	O
identical	O
to	O
2	O
except	O
that	O
different	O
fragments	O
from	O
various	O
promoters	O
(	O
see	O
Figs	O
1	O
and	O
2	O
)	O
were	O
inserted	O
at	O
the	O
SnaBI	O
site	O
.	O

Plasmid	O
29	O
had	O
a	O
sequence	O
of	O
chromosome	O
III	O
(	O
295327	O
-	O
295713	O
)	O
containing	O
the	O
HMR	O
-	O
tRNA	O
gene	O
(	O
21	O
)	O
inserted	O
at	O
the	O
SnaBI	O
site	O
of	O
plasmid	O
1	O
.	O

Plasmids	O
39	O
and	O
40	O
were	O
previously	O
named	O
pYXB26	O
and	O
pYXB59	O
,	O
respectively	O
(	O
11	O
)	O
.	O

Plasmid	O
41	O
was	O
identical	O
to	O
pYXB59	O
except	O
bearing	O
mutations	O
illustrated	O
in	O
Figure	O
3A	O
.	O

Plasmids	O
42	O
-	O
48	O
were	O
previously	O
described	O
as	O
pYXB29	O
,	O
48	O
,	O
28	O
,	O
27	O
,	O
59	O
,	O
31	O
and	O
37	O
,	O
respectively	O
(	O
11	O
)	O
.	O

Plasmid	O
50	O
was	O
derived	O
from	O
plasmid	O
1	O
by	O
inserting	O
two	O
copies	O
of	O
a	O
sequence	O
bearing	O
the	O
consensus	O
binding	O
sequence	O
of	O
LexA	O
(	O
bold	O
)	O
(	O
22	O
)	O
,	O
GGGGTACGTACTGTATGTACATACAGGATATCGGGG	O
,	O
at	O
the	O
SnaBI	O
site	O
.	O

Plasmid	O
51	O
was	O
identical	O
to	O
50	O
except	O
having	O
only	O
one	O
copy	O
of	O
the	O
LexA	O
-	O
binding	O
sequence	O
.	O

Plasmid	O
52	O
was	O
derived	O
from	O
pYXB26	O
(	O
11	O
)	O
by	O
inserting	O
a	O
SpeI	O
-	O
ADE2	O
-	O
AvrII	O
sequence	O
at	O
the	O
SpeI	O
site	O
.	O

Plasmid	O
53	O
was	O
derived	O
from	O
plasmid	O
52	O
by	O
inserting	O
TEF2	O
-	O
UAS	O
(	O
-	O
511	O
to	O
-	O
407	O
bp	O
relative	O
to	O
the	O
translation	O
start	O
codon	O
)	O
at	O
the	O
SpeI	O
site	O
.	O

Plasmid	O
L1	O
(	O
see	O
Fig	O
.	O
5A	O
)	O
was	O
made	O
by	O
inserting	O
LEU2	O
into	O
pBTM116	O
(	O
23	O
)	O
carrying	O
the	O
LexA	O
gene	O
flanked	O
by	O
the	O
promoter	O
and	O
terminator	O
of	O
ADH1	O
.	O

L2	O
through	O
L8	O
were	O
derived	O
from	O
L1	O
by	O
fusing	O
various	O
sequences	O
to	O
LexA	O
(	O
see	O
Fig	O
.	O
5A	O
and	O
B	O
)	O
.	O

Plasmid	O
pRS425	O
(	O
24	O
)	O
carried	O
the	O
2	O
micro	O
m	O
origin	O
and	O
LEU2	O
.	O

Strain	O
YXB76	O
was	O
MATa	O
ura3	O
-	O
52	O
leu2	O
-	O
3	O
,	O
112	O
ade2	O
-	O
1	O
lys1	O
-	O
1	O
his5	O
-	O
2	O
can1	O
-	O
100	O
,	O
E	O
-	O
HML	O
alpha	O
-	O
Iinverted	O
(	O
20	O
)	O
.	O

Y2047b	O
was	O
MATa	O
HMRa	O
HML	O
alpha	O
E	O
Delta	O
79	O
-	O
113	O
:	O
:	O
SUP4	O
-	O
o	O
I	O
Delta	O
242	O
LEU2	O
-	O
GAL10	O
-	O
FLP1	O
ura3	O
-	O
52	O
ade2	O
-	O
1	O
lys1	O
-	O
1	O
his5	O
-	O
1	O
can1	O
-	O
100	O
[	O
cir0	O
]	O
(	O
25	O
)	O
.	O

Strain	O
1	O
was	O
made	O
by	O
transforming	O
YXB76	O
to	O
Ura	O
+	O
with	O
HindIII	O
+	O
BamHI	O
digested	O
plasmid	O
1	O
.	O

Strains	O
2	O
-	O
38	O
,	O
50	O
and	O
51	O
were	O
similarly	O
made	O
with	O
corresponding	O
plasmids	O
,	O
respectively	O
(	O
e	O
.	O
g	O
.	O
strain	O
2	O
was	O
made	O
with	O
plasmid	O
2	O
)	O
.	O

Strains	O
39	O
,	O
40	O
and	O
42	O
-	O
48	O
were	O
previously	O
described	O
as	O
YXB26	O
,	O
48	O
,	O
29	O
,	O
48	O
,	O
28	O
,	O
27	O
,	O
59	O
,	O
31	O
and	O
37	O
,	O
respectively	O
(	O
11	O
)	O
.	O

Strains	O
41	O
,	O
52	O
and	O
53	O
(	O
see	O
Figs	O
3C	O
and	O
6	O
)	O
were	O
made	O
by	O
transforming	O
Y2047b	O
to	O
canavanine	O
-	O
resistant	O
by	O
BamHI	O
-	O
digested	O
plasmids	O
41	O
,	O
52	O
and	O
53	O
,	O
respectively	O
.	O

Strains	O
40	O
'	O
-	O
48	O
'	O
were	O
sir3	O
:	O
:	O
URA3	O
derivatives	O
of	O
strains	O
40	O
-	O
48	O
,	O
respectively	O
.	O

The	O
relevant	O
genotypes	O
of	O
all	O
the	O
strains	O
were	O
confirmed	O
by	O
Southern	O
blotting	O
.	O

Quantitative	O
mating	O
assay	O

Quantitative	O
mating	O
was	O
performed	O
as	O
described	O
(	O
11	O
)	O
.	O

Electrophoresis	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O

Rap1p	O
was	O
expressed	O
in	O
Escherichia	B-LIVB
coli	I-LIVB
BL21	I-LIVB
(	I-LIVB
DE3	I-LIVB
)	I-LIVB
from	O
pL3S5	O
,	O
a	O
pET	O
vector	O
carrying	O
the	O
RAP1	O
gene	O
downstream	O
of	O
a	O
T7	O
promoter	O
(	O
26	O
)	O
.	O

Crude	O
protein	O
extracts	O
were	O
prepared	O
from	O
40	O
ml	O
cultures	O
harvested	O
after	O
3	O
h	O
of	O
IPTG	O
induction	O
and	O
resuspended	O
in	O
1	O
ml	O
of	O
lysis	O
buffer	O
(	O
50	O
mM	O
NaH2PO4	O
,	O
300	O
mM	O
NaCl	O
,	O
pH	O
8	O
.	O
0	O
)	O
.	O

A	O
control	O
extract	O
was	O
prepared	O
from	O
a	O
culture	O
without	O
IPTG	O
induction	O
.	O

Western	O
blotting	O
revealed	O
that	O
Rap1p	O
protein	O
was	O
present	O
in	O
the	O
induced	O
extract	O
but	O
not	O
the	O
uninduced	O
one	O
(	O
data	O
not	O
shown	O
)	O
.	O

DNA	O
fragments	O
of	O
26	O
bp	O
in	O
length	O
(	O
see	O
Fig	O
.	O
3A	O
)	O
were	O
end	O
-	O
labeled	O
with	O
32P	O
-	O
phosphate	O
.	O

Fifteen	O
microliter	O
binding	O
reactions	O
were	O
prepared	O
,	O
each	O
consisting	O
of	O
20	O
000	O
c	O
.	O
p	O
.	O
m	O
.	O
radiolabeled	O
DNA	O
probe	O
,	O
5	O
micro	O
g	O
of	O
crude	O
protein	O
extract	O
,	O
non	O
-	O
specific	O
competitor	O
DNAs	O
(	O
0	O
.	O
3	O
micro	O
g	O
of	O
yeast	B-LIVB
tRNA	O
,	O
0	O
.	O
3	O
micro	O
g	O
of	O
salmon	B-LIVB
sperm	O
DNA	O
and	O
0	O
.	O
5	O
micro	O
g	O
of	O
E	B-LIVB
.	I-LIVB
coli	I-LIVB
DNA	O
)	O
,	O
10	O
micro	O
g	O
of	O
BSA	O
,	O
10	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
8	O
.	O
0	O
)	O
,	O
10	O
mM	O
MgCl2	O
and	O
8	O
%	O
glycerol	O
.	O

The	O
reactions	O
were	O
incubated	O
at	O
25	O
degrees	O
C	O
for	O
20	O
min	O
and	O
loaded	O
onto	O
non	O
-	O
denaturing	O
polyacrylamide	O
gels	O
(	O
4	O
-	O
5	O
%	O
)	O
.	O

Gels	O
were	O
run	O
at	O
40	O
mA	O
for	O
1	O
h	O
in	O
0	O
.	O
5	O
x	O
TBE	O
buffer	O
.	O

Analysis	O
of	O
the	O
supercoiling	O
of	O
DNA	O
circles	O

Cells	O
were	O
grown	O
in	O
YPR	O
(	O
yeast	B-LIVB
extract	O
+	O
bacto	O
peptone	O
+	O
2	O
%	O
raffinose	O
)	O
to	O
early	O
log	O
phase	O
.	O

Galactose	O
(	O
2	O
%	O
)	O
was	O
then	O
added	O
to	O
the	O
culture	O
to	O
induce	O
the	O
expression	O
of	O
FLP1	O
.	O

After	O
2	O
.	O
5	O
h	O
of	O
incubation	O
,	O
nucleic	O
acid	O
was	O
isolated	O
using	O
the	O
glass	O
bead	O
method	O
and	O
fractionated	O
on	O
agarose	O
gels	O
with	O
30	O
micro	O
g	O
/	O
ml	O
chloroquine	O
.	O

DNA	O
circles	O
were	O
detected	O
by	O
Southern	O
blotting	O
.	O

RESULTS	O

UASs	O
of	O
many	O
highly	O
expressed	O
genes	O
can	O
function	O
as	O
barriers	O
to	O
the	O
spread	O
of	O
silencing	O

We	O
have	O
previously	O
shown	O
that	O
TEF2	O
-	O
UAS	O
was	O
able	O
to	O
block	O
the	O
spread	O
of	O
silencing	O
in	O
a	O
silencer	O
-	O
blocking	O
assay	O
(	O
11	O
)	O
.	O

Such	O
an	O
assay	O
tested	O
if	O
a	O
sequence	O
had	O
the	O
ability	O
to	O
prevent	O
a	O
silencer	O
from	O
silencing	O
a	O
reporter	O
gene	O
when	O
it	O
was	O
positioned	O
between	O
the	O
silencer	O
and	O
the	O
reporter	O
.	O

In	O
this	O
report	O
we	O
used	O
a	O
new	O
silencer	O
-	O
blocking	O
assay	O
to	O
identify	O
more	O
barrier	O
elements	O
.	O

This	O
assay	O
employed	O
the	O
URA3	O
gene	O
and	O
an	O
inverted	O
HML	O
-	O
I	O
that	O
could	O
silence	O
sequences	O
to	O
the	O
right	O
of	O
HML	O
(	O
20	O
)	O
(	O
Fig	O
.	O
1	O
,	O
strain	O
1	O
)	O
.	O

URA3	O
expression	O
makes	O
cells	O
sensitive	O
to	O
5	O
-	O
fluoroorotic	O
acid	O
(	O
FOA	O
)	O
thus	O
URA3	O
silencing	O
could	O
be	O
measured	O
by	O
cell	O
growth	O
on	O
FOA	O
medium	O
(	O
Fig	O
.	O
1	O
,	O
strain	O
1	O
)	O
.	O

As	O
expected	O
,	O
TEF2	O
-	O
UAS	O
and	O
another	O
known	O
barrier	O
element	O
,	O
HMR	O
-	O
tRNA	O
gene	O
(	O
21	O
)	O
exhibited	O
barrier	O
activity	O
in	O
this	O
assay	O
as	O
indicated	O
by	O
the	O
lack	O
of	O
silencing	O
of	O
URA3	O
in	O
strains	O
2	O
and	O
29	O
(	O
Fig	O
.	O
1	O
)	O
.	O

TEF2	O
encoding	O
translation	O
elongation	O
factor	O
1	O
alpha	O
is	O
one	O
of	O
the	O
most	O
highly	O
expressed	O
genes	O
in	O
yeast	B-LIVB
(	O
27	O
)	O
.	O

Other	O
highly	O
expressed	O
genes	O
include	O
ribosome	O
protein	O
genes	O
(	O
RPGs	O
)	O
and	O
genes	O
coding	O
for	O
glycolytic	O
enzymes	O
(	O
27	O
)	O
.	O

The	O
coordinated	O
regulation	O
of	O
most	O
of	O
these	O
genes	O
requires	O
the	O
so	O
-	O
called	O
general	O
regulatory	O
factors	O
Rap1p	O
,	O
Abf1p	O
and	O
Reb1p	O
(	O
28	O
,	O
29	O
)	O
.	O

Using	O
the	O
above	O
silencer	O
-	O
blocking	O
assay	O
,	O
we	O
tested	O
if	O
the	O
UASs	O
of	O
other	O
highly	O
expressed	O
genes	O
could	O
also	O
block	O
URA3	O
silencing	O
(	O
Fig	O
.	O
1	O
)	O
.	O

Seventeen	O
new	O
barrier	O
elements	O
were	O
identified	O
from	O
a	O
total	O
of	O
26	O
UASs	O
tested	O
.	O

These	O
17	O
elements	O
were	O
UASs	O
of	O
eight	O
RPGs	O
(	O
see	O
Fig	O
.	O
1	O
,	O
strains	O
3	O
-	O
10	O
)	O
,	O
eight	O
glycolytic	O
genes	O
(	O
strains	O
18	O
-	O
25	O
)	O
and	O
the	O
HIS3	O
gene	O
(	O
strain	O
26	O
)	O
.	O

All	O
17	O
elements	O
except	O
ADH2	O
-	O
UAS	O
and	O
HIS3	O
-	O
UAS	O
exhibited	O
very	O
strong	O
barrier	O
activity	O
as	O
evidenced	O
by	O
the	O
absence	O
of	O
URA3	O
-	O
silencing	O
in	O
strains	O
3	O
-	O
10	O
and	O
18	O
-	O
24	O
(	O
Fig	O
.	O
1	O
)	O
.	O

Seven	O
of	O
the	O
eight	O
RPG	O
-	O
UASs	O
that	O
had	O
barrier	O
activity	O
,	O
contained	O
a	O
single	O
or	O
a	O
pair	O
of	O
tandem	O
Rap1p	O
-	O
binding	O
sites	O
(	O
Fig	O
.	O
1	O
,	O
strains	O
3	O
-	O
9	O
)	O
.	O

Three	O
of	O
them	O
also	O
contained	O
an	O
Abf1p	O
or	O
Reb1p	O
site	O
(	O
strains	O
6	O
,	O
8	O
and	O
9	O
)	O
.	O

One	O
barrier	O
RPG	O
-	O
UAS	O
(	O
strain	O
10	O
)	O
had	O
only	O
a	O
predicted	O
Abf1p	O
site	O
.	O

Of	O
the	O
seven	O
RPG	O
-	O
UASs	O
that	O
had	O
no	O
barrier	O
activity	O
(	O
Fig	O
.	O
1	O
,	O
11	O
-	O
17	O
)	O
,	O
only	O
two	O
bore	O
no	O
site	O
for	O
Rap1p	O
,	O
Abf1p	O
or	O
Reb1p	O
(	O
11	O
and	O
12	O
)	O
.	O

The	O
remaining	O
five	O
each	O
contained	O
one	O
to	O
three	O
Rap1p	O
sites	O
(	O
strains	O
13	O
-	O
17	O
)	O
.	O

RPL15A	O
-	O
UAS	O
(	O
17	O
)	O
also	O
contained	O
an	O
Abf1p	O
site	O
.	O

For	O
most	O
of	O
the	O
15	O
RPG	O
-	O
UASs	O
tested	O
(	O
3	O
-	O
17	O
)	O
,	O
the	O
presence	O
or	O
absence	O
of	O
predicted	O
Rap1p	O
sites	O
correlated	O
with	O
the	O
presence	O
or	O
absence	O
of	O
Rap1p	O
association	O
in	O
vivo	O
as	O
previously	O
examined	O
by	O
chromatin	O
immunoprecipitation	O
assays	O
(	O
13	O
)	O
.	O

Exceptions	O
were	O
the	O
UASs	O
of	O
RPS24B	O
,	O
RPS28A	O
and	O
RPL15A	O
(	O
13	O
)	O
.	O

Of	O
the	O
eight	O
UASs	O
of	O
glycolytic	O
genes	O
tested	O
(	O
Fig	O
.	O
1	O
,	O
strains	O
18	O
-	O
25	O
)	O
,	O
seven	O
exhibited	O
strong	O
barrier	O
activity	O
(	O
18	O
-	O
24	O
)	O
and	O
one	O
had	O
weaker	O
but	O
detectable	O
barrier	O
activity	O
(	O
strain	O
25	O
)	O
.	O

Glycolytic	O
genes	O
are	O
among	O
the	O
most	O
highly	O
expressed	O
genes	O
and	O
their	O
high	O
expression	O
depends	O
on	O
the	O
functions	O
of	O
Rap1p	O
,	O
Abf1p	O
or	O
Reb1p	O
as	O
well	O
as	O
Gcr1p	O
(	O
29	O
,	O
30	O
)	O
.	O

The	O
seven	O
strong	O
glycolytic	O
barriers	O
all	O
consist	O
of	O
one	O
or	O
two	O
Rap1p	O
sites	O
plus	O
one	O
or	O
two	O
Reb1p	O
or	O
Abf1p	O
sites	O
(	O
Fig	O
.	O
1	O
,	O
strains	O
18	O
-	O
24	O
)	O
.	O

In	O
addition	O
,	O
one	O
or	O
more	O
Gcr1p	O
-	O
binding	O
sites	O
are	O
found	O
adjacent	O
to	O
each	O
Rap1p	O
site	O
.	O

It	O
was	O
proposed	O
that	O
the	O
function	O
of	O
Rap1p	O
was	O
to	O
facilitate	O
the	O
binding	O
of	O
Gcr1p	O
to	O
the	O
UAS	O
(	O
15	O
)	O
.	O

Abf1p	O
or	O
Reb1p	O
was	O
shown	O
to	O
play	O
a	O
role	O
similar	O
to	O
that	O
of	O
Rap1p	O
in	O
activating	O
glycolytic	O
genes	O
(	O
31	O
-	O
33	O
)	O
.	O

Although	O
the	O
above	O
data	O
reinforced	O
the	O
notion	O
that	O
certain	O
Rap1p	O
-	O
binding	O
UASs	O
could	O
serve	O
as	O
barriers	O
to	O
silencing	O
,	O
they	O
raised	O
new	O
questions	O
about	O
the	O
essential	O
components	O
of	O
a	O
barrier	O
element	O
.	O

For	O
example	O
,	O
some	O
of	O
the	O
UASs	O
that	O
contained	O
only	O
a	O
single	O
Rap1p	O
site	O
had	O
barrier	O
activity	O
(	O
e	O
.	O
g	O
.	O
RPL19B	O
-	O
UAS	O
,	O
strain	O
3	O
)	O
whereas	O
others	O
that	O
contained	O
two	O
or	O
three	O
sites	O
had	O
no	O
activity	O
(	O
e	O
.	O
g	O
.	O
RPL39	O
,	O
strain	O
16	O
)	O
.	O

One	O
explanation	O
was	O
that	O
sequences	O
flanking	O
the	O
Rap1p	O
site	O
(	O
s	O
)	O
in	O
a	O
particular	O
UAS	O
could	O
positively	O
or	O
negatively	O
influence	O
barrier	O
function	O
.	O

Moreover	O
,	O
the	O
presence	O
of	O
Abf1p	O
or	O
Reb1p	O
sites	O
in	O
11	O
of	O
the	O
17	O
new	O
barriers	O
made	O
us	O
wonder	O
if	O
they	O
also	O
participated	O
in	O
barrier	O
function	O
.	O

We	O
began	O
to	O
address	O
these	O
issues	O
by	O
analyzing	O
three	O
new	O
barrier	O
elements	O
(	O
Fig	O
.	O
2	O
)	O
.	O

RPS10A	O
-	O
UAS	O
containing	O
an	O
Abf1p	O
-	O
binding	O
site	O
and	O
a	O
pair	O
of	O
Rap1p	O
sites	O
was	O
divided	O
into	O
three	O
fragments	O
that	O
were	O
tested	O
in	O
a	O
silencer	O
-	O
blocking	O
assay	O
(	O
Fig	O
.	O
2	O
,	O
strains	O
30	O
-	O
32	O
)	O
.	O

It	O
was	O
clear	O
that	O
only	O
the	O
fragment	O
containing	O
Rap1p	O
sites	O
functioned	O
as	O
a	O
barrier	O
(	O
strain	O
31	O
)	O
.	O

TPI1	O
-	O
UAS	O
bearing	O
a	O
Reb1p	O
site	O
and	O
a	O
Rap1p	O
site	O
was	O
divided	O
into	O
two	O
parts	O
with	O
one	O
containing	O
the	O
Rap1p	O
site	O
(	O
Fig	O
.	O
2	O
,	O
strain	O
34	O
)	O
and	O
the	O
other	O
Reb1p	O
site	O
(	O
strain	O
33	O
)	O
.	O

Neither	O
of	O
these	O
fragments	O
alone	O
retained	O
barrier	O
activity	O
indicating	O
that	O
concerted	O
action	O
of	O
Reb1p	O
and	O
Rap1p	O
was	O
required	O
for	O
barrier	O
activity	O
.	O

Duplicating	O
the	O
Reb1p	O
-	O
bearing	O
part	O
of	O
TPI1	O
-	O
UAS	O
didn	O
'	O
t	O
restore	O
barrier	O
activity	O
(	O
strain	O
35	O
)	O
.	O

However	O
,	O
triplicating	O
the	O
Rap1p	O
-	O
containing	O
part	O
did	O
re	O
-	O
create	O
barrier	O
function	O
(	O
strain	O
36	O
)	O
.	O

RPS28A	O
-	O
UAS	O
bore	O
,	O
in	O
addition	O
to	O
a	O
Rap1p	O
site	O
,	O
an	O
Abf1p	O
site	O
and	O
an	O
adjacent	O
T	O
-	O
rich	O
region	O
that	O
are	O
required	O
for	O
efficient	O
transcription	O
of	O
RPS28A	O
(	O
34	O
)	O
.	O

A	O
sequence	O
of	O
RPS28A	O
-	O
UAS	O
deleted	O
for	O
a	O
fragment	O
bearing	O
the	O
Rap1p	O
site	O
lost	O
the	O
barrier	O
activity	O
(	O
Fig	O
.	O
2	O
,	O
strain	O
37	O
)	O
.	O

However	O
,	O
duplicating	O
this	O
sequence	O
restored	O
barrier	O
activity	O
(	O
strain	O
38	O
)	O
.	O

The	O
above	O
results	O
indicated	O
again	O
that	O
Rap1p	O
sites	O
could	O
form	O
barriers	O
(	O
strains	O
31	O
and	O
36	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
they	O
also	O
suggested	O
that	O
synergistic	O
actions	O
of	O
Abf1p	O
sites	O
(	O
strain	O
38	O
)	O
,	O
Reb1p	O
site	O
+	O
Rap1p	O
site	O
(	O
strain	O
18	O
)	O
,	O
or	O
Abf1p	O
site	O
+	O
Rap1p	O
site	O
(	O
strain	O
16	O
)	O
could	O
all	O
lead	O
to	O
barrier	O
function	O
.	O

This	O
was	O
not	O
very	O
surprising	O
since	O
Rap1p	O
,	O
Abf1p	O
and	O
Reb1p	O
could	O
perform	O
similar	O
and	O
sometimes	O
interchangeable	O
functions	O
in	O
gene	O
regulation	O
(	O
16	O
,	O
35	O
,	O
36	O
)	O
.	O

Note	O
,	O
however	O
,	O
we	O
haven	O
'	O
t	O
ruled	O
out	O
the	O
possibility	O
that	O
other	O
factors	O
(	O
e	O
.	O
g	O
.	O
Gcr1p	O
)	O
or	O
structure	O
features	O
of	O
DNA	O
(	O
e	O
.	O
g	O
.	O
T	O
-	O
tracks	O
)	O
were	O
also	O
involved	O
in	O
barrier	O
function	O
.	O

It	O
was	O
interesting	O
that	O
ADH2	O
-	O
UAS	O
and	O
HIS3	O
-	O
UAS	O
bearing	O
no	O
site	O
for	O
Rap1p	O
,	O
Abf1p	O
or	O
Reb1p	O
exhibited	O
detectable	O
barrier	O
activity	O
(	O
Fig	O
.	O
1	O
,	O
strains	O
25	O
and	O
26	O
)	O
.	O

However	O
,	O
binding	O
sites	O
for	O
other	O
transcriptional	O
activators	O
existed	O
in	O
these	O
UASs	O
.	O

The	O
major	O
regulator	O
that	O
binds	O
to	O
ADH2	O
-	O
UAS	O
is	O
Adr1p	O
(	O
37	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
Gcn4p	O
binds	O
to	O
multiple	O
sites	O
in	O
HIS3	O
-	O
UAS	O
and	O
activates	O
HIS3	O
transcription	O
(	O
38	O
)	O
.	O

The	O
possible	O
involvement	O
of	O
Adr1p	O
or	O
Gcn4p	O
in	O
barrier	O
function	O
was	O
examined	O
below	O
.	O

Note	O
Adr1p	O
function	O
was	O
subject	O
to	O
glucose	O
repression	O
(	O
37	O
)	O
,	O
which	O
might	O
explain	O
why	O
ADH2	O
-	O
UAS	O
only	O
exhibited	O
limited	O
barrier	O
activity	O
since	O
glucose	O
was	O
used	O
in	O
the	O
media	O
used	O
in	O
our	O
assay	O
.	O

Effect	O
of	O
mutating	O
Rap1p	O
-	O
binding	O
sites	O
in	O
TEF2	O
-	O
UAS	O
on	O
barrier	O
function	O

Although	O
we	O
had	O
shown	O
that	O
the	O
three	O
Rap1p	O
-	O
binding	O
sites	O
in	O
TEF2	O
-	O
UAS	O
were	O
necessary	O
and	O
sufficient	O
for	O
its	O
barrier	O
activity	O
(	O
11	O
)	O
,	O
we	O
had	O
not	O
shown	O
if	O
binding	O
of	O
Rap1p	O
to	O
these	O
sites	O
was	O
required	O
.	O

To	O
address	O
this	O
we	O
performed	O
mutational	O
analysis	O
of	O
TEF2	O
-	O
UAS	O
.	O

As	O
shown	O
in	O
Figure	O
3A	O
and	O
B	O
,	O
the	O
three	O
Rap1p	O
-	O
binding	O
sites	O
in	O
TEF2	O
-	O
UAS	O
(	O
designated	O
as	O
R1	O
,	O
R2	O
and	O
R3	O
)	O
were	O
all	O
able	O
to	O
bind	O
Rap1p	O
in	O
an	O
EMSA	O
(	O
Fig	O
.	O
3B	O
)	O
.	O

Single	O
or	O
double	O
C	O
-->	O
A	O
mutations	O
were	O
introduced	O
into	O
R1	O
,	O
R2	O
and	O
R3	O
resulting	O
in	O
m1	O
,	O
m2	O
and	O
m3	O
,	O
respectively	O
(	O
Fig	O
.	O
3A	O
)	O
.	O

The	O
m2	O
and	O
m3	O
sites	O
had	O
both	O
lost	O
the	O
ability	O
to	O
bind	O
Rap1p	O
,	O
whereas	O
m1	O
still	O
bound	O
Rap1p	O
(	O
Fig	O
.	O
3B	O
)	O
,	O
which	O
could	O
be	O
predicted	O
from	O
the	O
specific	O
mutations	O
in	O
each	O
site	O
(	O
Fig	O
.	O
3A	O
,	O
compare	O
m1	O
,	O
m2	O
and	O
m3	O
to	O
the	O
consensus	O
sequence	O
)	O
.	O

We	O
then	O
tested	O
a	O
mutated	O
TEF2	O
-	O
UAS	O
containing	O
m1	O
,	O
m2	O
and	O
m3	O
in	O
a	O
silencer	O
-	O
blocking	O
assay	O
using	O
the	O
HML	O
-	O
E	O
silencer	O
and	O
the	O
HML	O
alpha	O
genes	O
(	O
Fig	O
.	O
3C	O
)	O
.	O

In	O
this	O
assay	O
,	O
the	O
HML	O
-	O
I	O
silencer	O
was	O
deleted	O
but	O
the	O
HML	O
-	O
E	O
silencer	O
was	O
sufficient	O
to	O
silence	O
the	O
HML	O
alpha	O
genes	O
(	O
Fig	O
.	O
3C	O
,	O
strain	O
39	O
)	O
(	O
11	O
)	O
.	O

Silencing	O
in	O
strain	O
39	O
(	O
a	O
-	O
type	O
)	O
was	O
measured	O
by	O
its	O
ability	O
to	O
mate	O
with	O
an	O
alpha	O
-	O
type	O
strain	O
(	O
Fig	O
.	O
3C	O
)	O
.	O

As	O
predicted	O
,	O
the	O
wild	O
-	O
type	O
TEF2	O
-	O
UAS	O
blocked	O
HML	O
alpha	O
silencing	O
(	O
11	O
)	O
(	O
Fig	O
.	O
3C	O
,	O
strain	O
40	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
mutated	O
TEF2	O
-	O
UAS	O
containing	O
m1	O
,	O
m2	O
and	O
m3	O
had	O
lost	O
barrier	O
activity	O
(	O
Fig	O
.	O
3C	O
,	O
compare	O
the	O
mating	O
efficiencies	O
of	O
strains	O
41	O
and	O
40	O
)	O
.	O

Therefore	O
,	O
mutations	O
that	O
prevented	O
Rap1p	O
from	O
binding	O
two	O
of	O
the	O
three	O
sites	O
in	O
TEF2	O
-	O
UAS	O
abolished	O
its	O
barrier	O
activity	O
,	O
indicating	O
that	O
association	O
of	O
Rap1p	O
with	O
TEF2	O
-	O
UAS	O
at	O
more	O
than	O
one	O
site	O
was	O
required	O
for	O
barrier	O
function	O
.	O

The	O
barrier	O
TEF2	O
-	O
UAS	O
alters	O
local	O
chromatin	O
structure	O

In	O
eukaryotic	O
cells	O
,	O
the	O
topology	O
of	O
local	O
DNA	O
reflects	O
the	O
chromatin	O
structure	O
in	O
which	O
it	O
resides	O
.	O

We	O
had	O
previously	O
developed	O
a	O
DNA	O
topology	O
-	O
based	O
assay	O
to	O
examine	O
chromatin	O
structure	O
in	O
vivo	O
,	O
which	O
involved	O
excising	O
a	O
chromosomal	O
region	O
of	O
interest	O
from	O
its	O
genomic	O
location	O
as	O
a	O
circle	O
using	O
site	O
-	O
specific	O
recombination	O
(	O
39	O
)	O
.	O

Using	O
this	O
strategy	O
,	O
we	O
demonstrated	O
that	O
DNA	O
in	O
silenced	O
chromatin	O
was	O
more	O
negatively	O
supercoiled	O
than	O
that	O
in	O
active	O
chromatin	O
(	O
39	O
)	O
.	O

In	O
this	O
report	O
we	O
used	O
the	O
topology	O
assay	O
to	O
address	O
if	O
barrier	O
elements	O
altered	O
local	O
chromatin	O
structure	O
as	O
Drosophila	B-LIVB
or	O
chicken	B-LIVB
insulators	O
did	O
(	O
40	O
,	O
41	O
)	O
.	O

Various	O
sequences	O
(	O
designated	O
X	O
)	O
from	O
UASs	O
of	O
TEF2	O
,	O
AgTEF	O
(	O
TEF	O
gene	O
from	O
Ashbya	B-LIVB
gossypii	I-LIVB
)	O
and	O
ADE2	O
were	O
inserted	O
between	O
HML	O
-	O
E	O
and	O
HML	O
alpha	O
at	O
HML	O
Delta	O
I	O
(	O
HML	O
locus	O
deleted	O
for	O
the	O
I	O
silencer	O
)	O
flanked	O
by	O
the	O
FRT	O
sites	O
for	O
the	O
Flp1p	O
site	O
-	O
specific	O
recombinase	O
(	O
Fig	O
.	O
4A	O
and	O
B	O
)	O
.	O

The	O
FLP1	O
gene	O
was	O
under	O
the	O
control	O
of	O
the	O
inducible	O
GAL10	O
promoter	O
(	O
39	O
)	O
.	O

The	O
mating	O
efficiency	O
of	O
each	O
strain	O
measured	O
silencing	O
of	O
HML	O
alpha	O
(	O
Fig	O
.	O
4C	O
)	O
.	O

In	O
strains	O
40	O
,	O
42	O
,	O
44	O
and	O
47	O
,	O
silencing	O
was	O
restricted	O
to	O
the	O
left	O
of	O
the	O
X	O
insertions	O
and	O
HML	O
alpha	O
was	O
derepressed	O
(	O
Fig	O
.	O
4C	O
)	O
.	O

Consistently	O
,	O
the	O
proportion	O
of	O
silent	O
chromatin	O
in	O
the	O
region	O
flanked	O
by	O
the	O
FRT	O
sites	O
in	O
each	O
of	O
these	O
strains	O
was	O
decreased	O
,	O
as	O
indicated	O
by	O
the	O
reduced	O
negative	O
supercoiling	O
of	O
the	O
excised	O
circle	O
(	O
11	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

Note	O
that	O
the	O
above	O
effect	O
of	O
a	O
barrier	O
on	O
HML	O
chromatin	O
reflected	O
both	O
change	O
in	O
the	O
scope	O
of	O
silencing	O
caused	O
by	O
the	O
barrier	O
activity	O
and	O
alteration	O
(	O
if	O
any	O
)	O
in	O
chromatin	O
structure	O
at	O
the	O
barrier	O
independent	O
of	O
the	O
silencing	O
state	O
of	O
the	O
locus	O
.	O

To	O
exclusively	O
examine	O
the	O
latter	O
,	O
we	O
analyzed	O
the	O
topology	O
of	O
HML	O
DNA	O
in	O
a	O
silencing	O
-	O
deficient	O
background	O
.	O

The	O
SIR3	O
gene	O
in	O
strains	O
described	O
in	O
Figure	O
4B	O
was	O
disrupted	O
rendering	O
them	O
defective	O
in	O
silencing	O
(	O
strains	O
40	O
'	O
-	O
48	O
'	O
in	O
Fig	O
.	O
4D	O
)	O
.	O

Recombination	O
mediated	O
by	O
Flp1p	O
in	O
these	O
strains	O
led	O
to	O
the	O
excision	O
of	O
a	O
group	O
of	O
chromosomal	O
circles	O
that	O
differed	O
only	O
in	O
the	O
X	O
insertion	O
.	O

The	O
supercoiling	O
of	O
these	O
circles	O
was	O
analyzed	O
as	O
a	O
function	O
of	O
the	O
length	O
of	O
the	O
insertion	O
(	O
Fig	O
.	O
4D	O
)	O
.	O

If	O
an	O
insertion	O
simply	O
lengthened	O
a	O
circle	O
without	O
causing	O
abnormal	O
changes	O
in	O
nucleosomal	O
structure	O
and	O
/	O
or	O
density	O
,	O
the	O
topoisomers	O
of	O
this	O
circle	O
would	O
migrate	O
slower	O
relative	O
to	O
those	O
of	O
a	O
similar	O
circle	O
with	O
a	O
smaller	O
size	O
.	O

Otherwise	O
,	O
migration	O
of	O
the	O
topoisomers	O
would	O
deviate	O
from	O
that	O
predicted	O
based	O
on	O
the	O
size	O
of	O
the	O
circle	O
.	O

As	O
shown	O
in	O
Figure	O
4D	O
,	O
the	O
circle	O
from	O
strain	O
40	O
'	O
bearing	O
a	O
104	O
bp	O
barrier	O
element	O
migrated	O
faster	O
rather	O
than	O
slower	O
than	O
the	O
circle	O
from	O
strain	O
46	O
'	O
bearing	O
a	O
91	O
bp	O
non	O
-	O
barrier	O
element	O
.	O

Circles	O
bearing	O
other	O
barrier	O
elements	O
also	O
exhibited	O
unexpected	O
faster	O
migration	O
(	O
compare	O
strains	O
44	O
'	O
to	O
45	O
'	O
,	O
47	O
'	O
to	O
43	O
'	O
,	O
42	O
'	O
to	O
48	O
'	O
,	O
respectively	O
)	O
.	O

Therefore	O
,	O
these	O
data	O
indicated	O
that	O
barrier	O
function	O
correlated	O
with	O
altered	O
topology	O
of	O
local	O
DNA	O
.	O

This	O
was	O
further	O
demonstrated	O
by	O
that	O
mutations	O
in	O
TEF2	O
-	O
UAS	O
that	O
abolished	O
its	O
barrier	O
activity	O
also	O
abolished	O
its	O
effect	O
on	O
DNA	O
topology	O
(	O
Fig	O
.	O
4D	O
,	O
compare	O
41	O
'	O
to	O
40	O
'	O
;	O
note	O
that	O
circles	O
from	O
both	O
strains	O
had	O
the	O
same	O
size	O
)	O
.	O

Since	O
in	O
our	O
gel	O
assay	O
more	O
negatively	O
supercoiled	O
DNA	O
migrate	O
slower	O
,	O
we	O
concluded	O
that	O
every	O
fragment	O
with	O
barrier	O
activity	O
caused	O
a	O
reduction	O
in	O
negative	O
supercoiling	O
of	O
approximately	O
one	O
to	O
two	O
turns	O
in	O
HML	O
Delta	O
I	O
DNA	O
(	O
Fig	O
.	O
4D	O
,	O
compare	O
the	O
centers	O
of	O
distributions	O
of	O
topoisomers	O
in	O
pairs	O
of	O
lanes	O
,	O
e	O
.	O
g	O
.	O
40	O
'	O
and	O
41	O
'	O
)	O
.	O

The	O
topology	O
of	O
eukaryotic	O
DNA	O
reflects	O
mainly	O
the	O
wrapping	O
of	O
DNA	O
into	O
nucleosomes	O
(	O
approximately	O
one	O
negative	O
superhelical	O
turn	O
is	O
associated	O
with	O
each	O
nucleosome	O
)	O
(	O
42	O
)	O
.	O

Therefore	O
,	O
removal	O
of	O
one	O
nucleosome	O
would	O
eliminate	O
approximately	O
one	O
turn	O
.	O

On	O
the	O
other	O
hand	O
,	O
histone	O
acetylation	O
can	O
reduce	O
negative	O
supercoiling	O
associated	O
with	O
a	O
nucleosome	O
by	O
approximately	O
0	O
.	O
2	O
turns	O
(	O
43	O
)	O
.	O

Therefore	O
,	O
acetylating	O
five	O
nucleosomes	O
would	O
reduce	O
negative	O
supercoiling	O
by	O
approximately	O
one	O
turn	O
.	O

Consequently	O
,	O
the	O
linking	O
number	O
change	O
of	O
one	O
to	O
two	O
brought	O
about	O
by	O
TEF2	O
-	O
UAS	O
can	O
be	O
accounted	O
for	O
by	O
either	O
the	O
loss	O
of	O
one	O
to	O
two	O
nucleosomes	O
or	O
acetylation	O
of	O
five	O
to	O
10	O
nucleosomes	O
.	O

Further	O
experiments	O
are	O
under	O
way	O
to	O
clarify	O
the	O
nature	O
of	O
change	O
in	O
chromatin	O
induced	O
by	O
a	O
barrier	O
.	O

Targeting	O
the	O
transcription	O
activation	O
domain	O
of	O
Rap1p	O
recapitulates	O
its	O
barrier	O
activity	O

The	O
multifunctional	O
Rap1p	O
can	O
be	O
divided	O
into	O
at	O
least	O
four	O
functional	O
domains	O
(	O
Fig	O
.	O
5A	O
)	O
(	O
12	O
)	O
.	O

We	O
were	O
interested	O
in	O
defining	O
which	O
of	O
these	O
domains	O
might	O
be	O
involved	O
in	O
the	O
barrier	O
activity	O
of	O
Rap1p	O
.	O

To	O
this	O
end	O
,	O
we	O
fused	O
various	O
parts	O
of	O
Rap1p	O
to	O
the	O
bacterial	O
LexA	O
protein	O
and	O
tested	O
if	O
targeting	O
any	O
of	O
the	O
fusion	O
proteins	O
to	O
LexA	O
-	O
binding	O
sites	O
could	O
re	O
-	O
create	O
a	O
barrier	O
to	O
silencing	O
(	O
Fig	O
.	O
5A	O
)	O
.	O

The	O
LexA	O
-	O
RAP1	O
fusion	O
genes	O
were	O
carried	O
on	O
2	O
micro	O
m	O
based	O
plasmids	O
marked	O
by	O
LEU2	O
(	O
designated	O
L1	O
-	O
L6	O
,	O
Fig	O
.	O
5A	O
)	O
.	O

When	O
introduced	O
into	O
strain	O
50	O
in	O
which	O
two	O
LexA	O
-	O
binding	O
sites	O
had	O
been	O
inserted	O
between	O
the	O
inverted	O
HML	O
-	O
I	O
and	O
URA3	O
,	O
LexA	O
alone	O
had	O
no	O
effect	O
on	O
URA3	O
silencing	O
(	O
Fig	O
.	O
5A	O
,	O
plasmid	O
L1	O
)	O
.	O

Targeting	O
the	O
DNA	O
binding	O
domain	O
,	O
DNA	O
bending	O
domain	O
,	O
silencing	O
domain	O
,	O
or	O
the	O
activating	O
+	O
silencing	O
domain	O
of	O
Rap1p	O
also	O
did	O
not	O
affect	O
URA3	O
silencing	O
(	O
L2	O
-	O
L5	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
targeting	O
the	O
activation	O
domain	O
alone	O
recapitulated	O
the	O
barrier	O
activity	O
of	O
Rap1p	O
(	O
L6	O
)	O
.	O

These	O
results	O
indicated	O
that	O
the	O
activation	O
domain	O
of	O
Rap1p	O
was	O
involved	O
in	O
barrier	O
activity	O
.	O

The	O
inability	O
of	O
the	O
Rap1p	O
-	O
silencing	O
domain	O
to	O
block	O
URA3	O
silencing	O
in	O
our	O
assay	O
did	O
not	O
necessarily	O
mean	O
that	O
this	O
domain	O
had	O
no	O
barrier	O
function	O
,	O
since	O
such	O
a	O
function	O
might	O
be	O
suppressed	O
by	O
much	O
stronger	O
silencing	O
activity	O
associated	O
with	O
the	O
silencing	O
domain	O
.	O

Was	O
the	O
lack	O
of	O
barrier	O
function	O
of	O
fusion	O
constructs	O
L2	O
-	O
L5	O
due	O
to	O
a	O
lack	O
of	O
expression	O
of	O
these	O
proteins	O
?	O

To	O
address	O
this	O
possibility	O
,	O
we	O
examined	O
the	O
levels	O
of	O
L1	O
-	O
L6	O
proteins	O
as	O
well	O
as	O
L7	O
and	O
L8	O
proteins	O
described	O
in	O
Figure	O
5B	O
by	O
western	O
blotting	O
using	O
an	O
antibody	O
against	O
LexA	O
.	O

As	O
shown	O
in	O
Figure	O
5C	O
,	O
L5	O
was	O
expressed	O
at	O
a	O
level	O
comparable	O
to	O
L6	O
,	O
and	O
L4	O
was	O
expressed	O
at	O
a	O
higher	O
level	O
than	O
L6	O
.	O

Therefore	O
,	O
the	O
lack	O
of	O
barrier	O
function	O
of	O
L4	O
and	O
L6	O
was	O
not	O
the	O
result	O
of	O
their	O
lack	O
of	O
expression	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
level	O
of	O
L2	O
or	O
L3	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
L6	O
,	O
hence	O
the	O
lack	O
of	O
barrier	O
function	O
of	O
L2	O
and	O
L3	O
might	O
be	O
due	O
to	O
their	O
insufficient	O
expression	O
.	O

As	O
an	O
important	O
control	O
for	O
the	O
above	O
targeting	O
experiments	O
,	O
we	O
showed	O
that	O
plasmids	O
L1	O
-	O
L6	O
(	O
Fig	O
.	O
5A	O
)	O
as	O
well	O
as	O
L7	O
and	O
L8	O
(	O
Fig	O
.	O
5B	O
)	O
bearing	O
LexA	O
-	O
fusion	O
genes	O
had	O
no	O
effect	O
on	O
URA3	O
silencing	O
in	O
strain	O
1	O
(	O
Fig	O
.	O
1	O
)	O
in	O
which	O
there	O
was	O
no	O
binding	O
site	O
for	O
LexA	O
present	O
between	O
HML	O
-	O
I	O
and	O
URA3	O
(	O
data	O
not	O
shown	O
)	O
.	O

Hence	O
,	O
the	O
effect	O
of	O
the	O
fusion	O
proteins	O
on	O
URA3	O
silencing	O
was	O
the	O
result	O
of	O
their	O
targeting	O
to	O
specific	O
loci	O
,	O
not	O
the	O
consequence	O
of	O
non	O
-	O
specific	O
,	O
indirect	O
functions	O
(	O
if	O
any	O
)	O
of	O
these	O
proteins	O
.	O

Targeted	O
activation	O
domain	O
of	O
Adr1p	O
or	O
Gcn4p	O
can	O
also	O
act	O
as	O
a	O
barrier	O
factor	O

We	O
have	O
shown	O
above	O
that	O
ADH2	O
-	O
UAS	O
bearing	O
Adr1p	O
-	O
binding	O
sites	O
and	O
HIS3	O
-	O
UAS	O
bearing	O
Gcn4p	O
sites	O
both	O
had	O
detectable	O
barrier	O
activity	O
(	O
Fig	O
.	O
1	O
,	O
strains	O
25	O
and	O
26	O
)	O
.	O

Given	O
that	O
tethering	O
the	O
activation	O
domain	O
of	O
Rap1p	O
is	O
sufficient	O
for	O
barrier	O
function	O
,	O
we	O
tested	O
if	O
targeting	O
the	O
activation	O
domain	O
of	O
Adr1p	O
or	O
Gcn4p	O
could	O
also	O
establish	O
a	O
barrier	O
.	O

Adr1p	O
contains	O
four	O
separate	O
activation	O
domains	O
(	O
TADI	O
-	O
TADIV	O
)	O
that	O
can	O
contact	O
Ada2p	O
,	O
Gcn5p	O
and	O
/	O
or	O
TFIIB	O
(	O
45	O
)	O
.	O

TAD	O
III	O
(	O
415	O
-	O
467	O
)	O
interacts	O
with	O
only	O
Gcn5p	O
but	O
not	O
Ada2p	O
or	O
TFIIB	O
.	O

We	O
fused	O
this	O
domain	O
of	O
Adr1p	O
and	O
the	O
activation	O
domain	O
of	O
Gcn4p	O
(	O
102	O
-	O
149	O
)	O
to	O
LexA	O
,	O
respectively	O
(	O
Fig	O
.	O
5B	O
,	O
L7	O
and	O
L8	O
)	O
.	O

Targeting	O
these	O
fusion	O
proteins	O
to	O
two	O
LexA	O
-	O
binding	O
sites	O
between	O
HML	O
-	O
I	O
and	O
URA3	O
in	O
strain	O
50	O
dramatically	O
reduced	O
URA3	O
silencing	O
(	O
Fig	O
.	O
5B	O
,	O
compare	O
L7	O
and	O
L8	O
to	O
L1	O
)	O
.	O

Therefore	O
,	O
like	O
LexA	O
-	O
Rap1p	O
(	O
627	O
-	O
695	O
)	O
,	O
both	O
LexA	O
-	O
Adr1p	O
(	O
415	O
-	O
467	O
)	O
and	O
LexA	O
-	O
Gcn4p	O
(	O
102	O
-	O
149	O
)	O
also	O
had	O
barrier	O
activity	O
.	O

Barrier	O
function	O
of	O
these	O
fusion	O
proteins	O
was	O
significantly	O
decreased	O
in	O
strain	O
51	O
in	O
which	O
only	O
one	O
LexA	O
site	O
was	O
inserted	O
between	O
HML	O
-	O
I	O
and	O
URA3	O
(	O
compare	O
strains	O
50	O
and	O
51	O
carrying	O
plasmid	O
L7	O
)	O
,	O
indicating	O
that	O
the	O
potency	O
of	O
such	O
barriers	O
was	O
dependent	O
on	O
the	O
amount	O
of	O
tethered	O
fusion	O
proteins	O
.	O

DISCUSSION	O

We	O
have	O
shown	O
in	O
this	O
report	O
that	O
UASs	O
of	O
many	O
highly	O
expressed	O
genes	O
could	O
function	O
as	O
barriers	O
to	O
the	O
spread	O
of	O
transcriptional	O
silencing	O
.	O

These	O
newly	O
identified	O
barrier	O
elements	O
together	O
with	O
previously	O
described	O
barrier	O
elements	O
(	O
STARs	O
,	O
HMR	O
-	O
tRNA	O
gene	O
,	O
TEF2	O
-	O
UAS	O
and	O
CHA1	O
-	O
UAS	O
)	O
(	O
9	O
-	O
11	O
,	O
21	O
)	O
are	O
scattered	O
across	O
the	O
yeast	B-LIVB
genome	O
and	O
may	O
play	O
a	O
role	O
in	O
dividing	O
the	O
genome	O
into	O
functional	O
domains	O
.	O

Analyses	O
of	O
the	O
barrier	O
UASs	O
suggest	O
that	O
binding	O
sites	O
for	O
transcriptional	O
regulators	O
Rap1p	O
,	O
Abf1p	O
,	O
Reb1p	O
,	O
Adr1p	O
and	O
Gcn4p	O
can	O
participate	O
in	O
barrier	O
function	O
.	O

Barrier	O
activity	O
often	O
requires	O
concerted	O
actions	O
of	O
more	O
than	O
one	O
factor	O
-	O
binding	O
site	O
.	O

Our	O
mutational	O
analysis	O
of	O
TEF2	O
-	O
UAS	O
suggests	O
a	O
direct	O
involvement	O
of	O
Rap1p	O
in	O
its	O
barrier	O
function	O
.	O

It	O
is	O
noteworthy	O
that	O
not	O
all	O
UASs	O
of	O
highly	O
expressed	O
genes	O
have	O
barrier	O
activity	O
.	O

Many	O
non	O
-	O
barrier	O
UASs	O
also	O
consist	O
of	O
multiple	O
regulator	O
binding	O
sites	O
,	O
therefore	O
other	O
unknown	O
factors	O
might	O
determine	O
whether	O
a	O
UAS	O
could	O
act	O
as	O
a	O
barrier	O
.	O

How	O
Rap1p	O
and	O
the	O
other	O
transcriptional	O
regulators	O
act	O
to	O
block	O
silencing	O
is	O
not	O
clear	O
.	O

Since	O
they	O
can	O
all	O
act	O
as	O
transcriptional	O
activators	O
,	O
one	O
natural	O
explanation	O
is	O
that	O
they	O
may	O
overcome	O
the	O
silencing	O
effect	O
of	O
a	O
silencer	O
and	O
directly	O
activate	O
the	O
reporter	O
gene	O
.	O

However	O
,	O
it	O
has	O
been	O
well	O
documented	O
that	O
Rap1p	O
and	O
the	O
other	O
transcriptional	O
regulators	O
usually	O
act	O
at	O
relatively	O
short	O
distances	O
(	O
less	O
than	O
~	O
600	O
bp	O
upstream	O
of	O
the	O
translation	O
start	O
codon	O
)	O
(	O
28	O
,	O
29	O
,	O
46	O
)	O
,	O
but	O
the	O
binding	O
sites	O
for	O
these	O
regulators	O
were	O
>	O
800	O
bp	O
from	O
the	O
translation	O
start	O
codon	O
in	O
most	O
of	O
the	O
silencing	O
-	O
blocking	O
tests	O
in	O
this	O
report	O
(	O
Figs	O
1	O
and	O
2	O
)	O
.	O

In	O
the	O
test	O
shown	O
in	O
Figure	O
6	O
,	O
TEF2	O
-	O
UAS	O
blocked	O
ADE2	O
silencing	O
when	O
it	O
was	O
~	O
2	O
kb	O
downstream	O
from	O
the	O
translation	O
start	O
codon	O
of	O
the	O
gene	O
.	O

Moreover	O
,	O
Fourel	O
et	O
al	O
.	O

(	O
44	O
)	O
demonstrated	O
that	O
the	O
barrier	O
function	O
(	O
or	O
anti	O
-	O
silencing	O
function	O
)	O
of	O
an	O
activator	O
was	O
independent	O
of	O
its	O
role	O
in	O
activating	O
transcription	O
.	O

Therefore	O
,	O
it	O
is	O
unlikely	O
that	O
the	O
ability	O
of	O
a	O
UAS	O
to	O
prevent	O
gene	O
silencing	O
is	O
due	O
to	O
its	O
direct	O
activation	O
of	O
the	O
gene	O
.	O

In	O
light	O
of	O
this	O
,	O
our	O
results	O
are	O
in	O
agreement	O
with	O
the	O
notion	O
that	O
transcriptional	O
regulators	O
can	O
also	O
participate	O
in	O
defining	O
the	O
boundaries	O
of	O
functional	O
chromosomal	O
domains	O
.	O

A	O
few	O
models	O
have	O
been	O
proposed	O
for	O
the	O
barrier	O
functions	O
of	O
transcriptional	O
regulators	O
.	O

One	O
model	O
proposed	O
that	O
binding	O
of	O
a	O
regulator	O
to	O
a	O
barrier	O
led	O
to	O
the	O
formation	O
of	O
a	O
nucleosome	O
-	O
free	O
region	O
thereby	O
disrupting	O
a	O
continuous	O
nucleosome	O
array	O
(	O
11	O
)	O
.	O

Since	O
the	O
SIR	O
complexes	O
spread	O
by	O
self	O
-	O
interaction	O
and	O
interacting	O
with	O
adjacent	O
nucleosmes	O
in	O
a	O
stepwise	O
fashion	O
(	O
4	O
)	O
,	O
a	O
nucleosome	O
-	O
free	O
gap	O
could	O
present	O
a	O
barrier	O
to	O
the	O
spreading	O
SIR	O
complex	O
.	O

This	O
'	O
nucleosome	O
gap	O
'	O
hypothesis	O
is	O
consistent	O
with	O
that	O
certain	O
barrier	O
factors	O
such	O
as	O
Rap1p	O
and	O
Reb1p	O
could	O
indeed	O
prevent	O
nucleosome	O
formation	O
around	O
their	O
binding	O
sites	O
(	O
14	O
)	O
and	O
the	O
barrier	O
function	O
of	O
TEF2	O
-	O
UAS	O
correlated	O
with	O
its	O
ability	O
to	O
alter	O
local	O
chromatin	O
structure	O
(	O
this	O
report	O
)	O
.	O

In	O
fact	O
,	O
many	O
insulator	O
/	O
boundary	O
elements	O
in	O
higher	O
organisms	O
have	O
also	O
been	O
shown	O
to	O
alter	O
local	O
chromatin	O
structure	O
.	O

For	O
instance	O
,	O
the	O
chicken	B-LIVB
beta	O
-	O
globin	O
insulator	O
was	O
linked	O
to	O
changes	O
in	O
nucleosome	O
positioning	O
,	O
and	O
the	O
Drosophila	B-LIVB
scs	O
and	O
scs	O
'	O
boundary	O
elements	O
are	O
associated	O
with	O
unusual	O
chromatin	O
structures	O
that	O
are	O
hypersensitive	O
to	O
nucleases	O
(	O
40	O
,	O
41	O
)	O
.	O

However	O
,	O
it	O
is	O
not	O
clear	O
whether	O
any	O
chromatin	O
change	O
associated	O
with	O
barrier	O
function	O
in	O
yeast	B-LIVB
or	O
insulator	O
function	O
in	O
higher	O
cells	O
is	O
the	O
cause	O
or	O
effect	O
of	O
the	O
function	O
.	O

Another	O
model	O
for	O
barrier	O
action	O
proposed	O
by	O
R	O
.	O

Kamakaka	O
and	O
colleagues	O
(	O
21	O
)	O
proposed	O
that	O
barrier	O
factors	O
recruit	O
chromatin	O
modifying	O
and	O
/	O
or	O
remodeling	O
complexes	O
to	O
counteract	O
the	O
more	O
compact	O
,	O
hypoacetylated	O
silent	O
chromatin	O
.	O

In	O
agreement	O
with	O
this	O
hypothesis	O
,	O
targeted	O
HATs	O
SAS2	O
,	O
GCN5	O
and	O
ESA1	O
all	O
had	O
barrier	O
activity	O
(	O
21	O
;	O
Y	O
.	O
-	O
H	O
.	O
Chiu	O
,	O
Q	O
.	O
Yu	O
and	O
X	O
.	O
Bi	O
,	O
unpublished	O
results	O
)	O
.	O

Interestingly	O
,	O
Rap1p	O
,	O
Adr1p	O
,	O
Gcn4p	O
and	O
Abf1p	O
share	O
the	O
ability	O
to	O
recruit	O
HAT	O
complexes	O
NuA4	O
and	O
/	O
or	O
SAGA	O
to	O
target	O
genes	O
(	O
16	O
,	O
45	O
,	O
47	O
-	O
49	O
)	O
.	O

Therefore	O
,	O
these	O
factors	O
that	O
are	O
capable	O
of	O
binding	O
to	O
the	O
newly	O
identified	O
barriers	O
may	O
function	O
as	O
barrier	O
factors	O
by	O
recruiting	O
HAT	O
complexes	O
.	O

In	O
fact	O
,	O
recruitment	O
of	O
HAT	O
activity	O
has	O
also	O
been	O
suggested	O
to	O
be	O
the	O
mechanism	O
underlying	O
the	O
function	O
of	O
the	O
chicken	B-LIVB
beta	O
-	O
globin	O
insulator	O
(	O
6	O
)	O
,	O
although	O
it	O
was	O
not	O
known	O
what	O
HAT	O
might	O
be	O
involved	O
.	O

Our	O
demonstration	O
that	O
tethering	O
the	O
activation	O
domain	O
of	O
Rap1p	O
,	O
Adr1p	O
or	O
Gcn4p	O
alone	O
recapitulates	O
barrier	O
activity	O
is	O
consistent	O
with	O
the	O
above	O
HAT	O
model	O
for	O
barrier	O
function	O
,	O
since	O
at	O
least	O
the	O
activation	O
domain	O
of	O
Adr1p	O
has	O
been	O
shown	O
to	O
directly	O
interact	O
with	O
HAT	O
complexes	O
(	O
45	O
)	O
.	O

However	O
,	O
we	O
haven	O
'	O
t	O
ruled	O
out	O
the	O
possibility	O
that	O
the	O
barrier	O
function	O
of	O
the	O
targeted	O
activation	O
domain	O
of	O
Rap1p	O
,	O
Adr1p	O
or	O
Gcn4p	O
is	O
not	O
related	O
to	O
the	O
barrier	O
function	O
of	O
the	O
native	O
protein	O
.	O

Note	O
that	O
the	O
'	O
nucleosome	O
gap	O
'	O
model	O
and	O
the	O
HAT	O
model	O
are	O
not	O
mutually	O
exclusive	O
since	O
the	O
nucleosome	O
gap	O
could	O
result	O
from	O
destabilization	O
of	O
nucelosomes	O
caused	O
by	O
HAT	O
function	O
.	O

A	O
recent	O
intriguing	O
study	O
showed	O
that	O
targeting	O
proteins	O
of	O
the	O
nuclear	O
pore	O
complex	O
(	O
NPC	O
)	O
could	O
also	O
establish	O
a	O
boundary	O
for	O
silent	O
chromatin	O
,	O
and	O
that	O
tethering	O
to	O
NPC	O
was	O
required	O
for	O
boundary	O
activity	O
(	O
50	O
)	O
.	O

This	O
led	O
to	O
a	O
revisit	O
to	O
the	O
looping	O
model	O
for	O
the	O
function	O
of	O
boundary	O
/	O
insulator	O
elements	O
(	O
51	O
)	O
.	O

However	O
,	O
an	O
alternative	O
explanation	O
was	O
that	O
the	O
NPC	O
compartment	O
could	O
simply	O
be	O
rich	O
in	O
transcriptional	O
activating	O
factors	O
or	O
poor	O
in	O
silencing	O
factors	O
like	O
the	O
SIR	O
proteins	O
(	O
50	O
)	O
.	O

In	O
summary	O
,	O
results	O
from	O
this	O
and	O
other	O
studies	O
indicate	O
that	O
factors	O
previously	O
identified	O
as	O
positive	O
and	O
/	O
or	O
negative	O
regulators	O
of	O
gene	O
activation	O
could	O
also	O
function	O
in	O
demarcating	O
distinct	O
domains	O
of	O
gene	O
activity	O
.	O

How	O
these	O
factors	O
carry	O
out	O
their	O
boundary	O
function	O
is	O
not	O
resolved	O
but	O
recruitment	O
of	O
other	O
factors	O
(	O
e	O
.	O
g	O
.	O
chromatin	O
modifying	O
complexes	O
)	O
is	O
likely	O
to	O
be	O
involved	O
.	O

NOTE	O
ADDED	O
IN	O
PROOF	O

After	O
this	O
work	O
was	O
completed	O
and	O
submitted	O
for	O
publication	O
the	O
first	O
time	O
,	O
Fourel	O
et	O
al	O
.	O

(	O
52	O
)	O
reported	O
that	O
targeted	O
activation	O
domains	O
of	O
Rap1p	O
and	O
Abf1p	O
had	O
insulating	O
capacity	O
.	O

Comparison	O
of	O
age	O
-	O
specific	O
cataract	O
prevalence	O
in	O
two	O
population	O
-	O
based	O
surveys	O
6	O
years	O
apart	O

Abstract	O

Background	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
compare	O
age	O
-	O
specific	O
cortical	O
,	O
nuclear	O
and	O
posterior	O
subcapsular	O
(	O
PSC	O
)	O
cataract	O
prevalence	O
in	O
two	O
surveys	O
6	O
years	O
apart	O
.	O

Methods	O

The	O
Blue	O
Mountains	O
Eye	O
Study	O
examined	O
3654	O
participants	B-LIVB
(	O
82	O
.	O
4	O
%	O
of	O
those	O
eligible	O
)	O
in	O
cross	O
-	O
section	O
I	O
(	O
1992	O
-	O
4	O
)	O
and	O
3509	O
participants	B-LIVB
(	O
75	O
.	O
1	O
%	O
of	O
survivors	O
and	O
85	O
.	O
2	O
%	O
of	O
newly	O
eligible	O
)	O
in	O
cross	O
-	O
section	O
II	O
(	O
1997	O
-	O
2000	O
,	O
66	O
.	O
5	O
%	O
overlap	O
with	O
cross	O
-	O
section	O
I	O
)	O
.	O

Cataract	O
was	O
assessed	O
from	O
lens	O
photographs	O
following	O
the	O
Wisconsin	O
Cataract	O
Grading	O
System	O
.	O

Cortical	O
cataract	O
was	O
defined	O
if	O
cortical	O
opacity	O
comprised	O
>=	O
5	O
%	O
of	O
lens	O
area	O
.	O

Nuclear	O
cataract	O
was	O
defined	O
if	O
nuclear	O
opacity	O
>=	O
Wisconsin	O
standard	O
4	O
.	O

PSC	O
was	O
defined	O
if	O
any	O
present	O
.	O

Any	O
cataract	O
was	O
defined	O
to	O
include	O
persons	B-LIVB
who	O
had	O
previous	O
cataract	O
surgery	O
.	O

Weighted	O
kappa	O
for	O
inter	O
-	O
grader	O
reliability	O
was	O
0	O
.	O
82	O
,	O
0	O
.	O
55	O
and	O
0	O
.	O
82	O
for	O
cortical	O
,	O
nuclear	O
and	O
PSC	O
cataract	O
,	O
respectively	O
.	O

We	O
assessed	O
age	O
-	O
specific	O
prevalence	O
using	O
an	O
interval	O
of	O
5	O
years	O
,	O
so	O
that	O
participants	B-LIVB
within	O
each	O
age	O
group	O
were	O
independent	O
between	O
the	O
two	O
surveys	O
.	O

Results	O

Age	O
and	O
gender	O
distributions	O
were	O
similar	O
between	O
the	O
two	O
populations	O
.	O

The	O
age	O
-	O
specific	O
prevalence	O
of	O
cortical	O
(	O
23	O
.	O
8	O
%	O
in	O
1st	O
,	O
23	O
.	O
7	O
%	O
in	O
2nd	O
)	O
and	O
PSC	O
cataract	O
(	O
6	O
.	O
3	O
%	O
,	O
6	O
.	O
0	O
%	O
)	O
was	O
similar	O
.	O

The	O
prevalence	O
of	O
nuclear	O
cataract	O
increased	O
slightly	O
from	O
18	O
.	O
7	O
%	O
to	O
23	O
.	O
9	O
%	O
.	O

After	O
age	O
standardization	O
,	O
the	O
similar	O
prevalence	O
of	O
cortical	O
(	O
23	O
.	O
8	O
%	O
,	O
23	O
.	O
5	O
%	O
)	O
and	O
PSC	O
cataract	O
(	O
6	O
.	O
3	O
%	O
,	O
5	O
.	O
9	O
%	O
)	O
,	O
and	O
the	O
increased	O
prevalence	O
of	O
nuclear	O
cataract	O
(	O
18	O
.	O
7	O
%	O
,	O
24	O
.	O
2	O
%	O
)	O
remained	O
.	O

Conclusion	O

In	O
two	O
surveys	O
of	O
two	O
population	O
-	O
based	O
samples	O
with	O
similar	O
age	O
and	O
gender	O
distributions	O
,	O
we	O
found	O
a	O
relatively	O
stable	O
cortical	O
and	O
PSC	O
cataract	O
prevalence	O
over	O
a	O
6	O
-	O
year	O
period	O
.	O

The	O
increased	O
prevalence	O
of	O
nuclear	O
cataract	O
deserves	O
further	O
study	O
.	O

Background	O

Age	O
-	O
related	O
cataract	O
is	O
the	O
leading	O
cause	O
of	O
reversible	O
visual	O
impairment	O
in	O
older	O
persons	B-LIVB
[	O
1	O
-	O
6	O
]	O
.	O

In	O
Australia	O
,	O
it	O
is	O
estimated	O
that	O
by	O
the	O
year	O
2021	O
,	O
the	O
number	O
of	O
people	B-LIVB
affected	O
by	O
cataract	O
will	O
increase	O
by	O
63	O
%	O
,	O
due	O
to	O
population	O
aging	O
[	O
7	O
]	O
.	O

Surgical	O
intervention	O
is	O
an	O
effective	O
treatment	O
for	O
cataract	O
and	O
normal	O
vision	O
(	O
>	O
20	O
/	O
40	O
)	O
can	O
usually	O
be	O
restored	O
with	O
intraocular	O
lens	O
(	O
IOL	O
)	O
implantation	O
.	O

Cataract	O
surgery	O
with	O
IOL	O
implantation	O
is	O
currently	O
the	O
most	O
commonly	O
performed	O
,	O
and	O
is	O
,	O
arguably	O
,	O
the	O
most	O
cost	O
effective	O
surgical	O
procedure	O
worldwide	O
.	O

Performance	O
of	O
this	O
surgical	O
procedure	O
has	O
been	O
continuously	O
increasing	O
in	O
the	O
last	O
two	O
decades	O
.	O

Data	O
from	O
the	O
Australian	O
Health	O
Insurance	O
Commission	O
has	O
shown	O
a	O
steady	O
increase	O
in	O
Medicare	O
claims	O
for	O
cataract	O
surgery	O
[	O
8	O
]	O
.	O

A	O
2	O
.	O
6	O
-	O
fold	O
increase	O
in	O
the	O
total	O
number	O
of	O
cataract	O
procedures	O
from	O
1985	O
to	O
1994	O
has	O
been	O
documented	O
in	O
Australia	O
[	O
9	O
]	O
.	O

The	O
rate	O
of	O
cataract	O
surgery	O
per	O
thousand	O
persons	B-LIVB
aged	O
65	O
years	O
or	O
older	O
has	O
doubled	O
in	O
the	O
last	O
20	O
years	O
[	O
8	O
,	O
9	O
]	O
.	O

In	O
the	O
Blue	O
Mountains	O
Eye	O
Study	O
population	O
,	O
we	O
observed	O
a	O
one	O
-	O
third	O
increase	O
in	O
cataract	O
surgery	O
prevalence	O
over	O
a	O
mean	O
6	O
-	O
year	O
interval	O
,	O
from	O
6	O
%	O
to	O
nearly	O
8	O
%	O
in	O
two	O
cross	O
-	O
sectional	O
population	O
-	O
based	O
samples	O
with	O
a	O
similar	O
age	O
range	O
[	O
10	O
]	O
.	O

Further	O
increases	O
in	O
cataract	O
surgery	O
performance	O
would	O
be	O
expected	O
as	O
a	O
result	O
of	O
improved	O
surgical	O
skills	O
and	O
technique	O
,	O
together	O
with	O
extending	O
cataract	O
surgical	O
benefits	O
to	O
a	O
greater	O
number	O
of	O
older	O
people	B-LIVB
and	O
an	O
increased	O
number	O
of	O
persons	B-LIVB
with	O
surgery	O
performed	O
on	O
both	O
eyes	O
.	O

Both	O
the	O
prevalence	O
and	O
incidence	O
of	O
age	O
-	O
related	O
cataract	O
link	O
directly	O
to	O
the	O
demand	O
for	O
,	O
and	O
the	O
outcome	O
of	O
,	O
cataract	O
surgery	O
and	O
eye	O
health	O
care	O
provision	O
.	O

This	O
report	O
aimed	O
to	O
assess	O
temporal	O
changes	O
in	O
the	O
prevalence	O
of	O
cortical	O
and	O
nuclear	O
cataract	O
and	O
posterior	O
subcapsular	O
cataract	O
(	O
PSC	O
)	O
in	O
two	O
cross	O
-	O
sectional	O
population	O
-	O
based	O
surveys	O
6	O
years	O
apart	O
.	O

Methods	O

The	O
Blue	O
Mountains	O
Eye	O
Study	O
(	O
BMES	O
)	O
is	O
a	O
population	O
-	O
based	O
cohort	O
study	O
of	O
common	O
eye	O
diseases	O
and	O
other	O
health	O
outcomes	O
.	O

The	O
study	O
involved	O
eligible	O
permanent	O
residents	O
aged	O
49	O
years	O
and	O
older	O
,	O
living	O
in	O
two	O
postcode	O
areas	O
in	O
the	O
Blue	O
Mountains	O
,	O
west	O
of	O
Sydney	O
,	O
Australia	O
.	O

Participants	B-LIVB
were	O
identified	O
through	O
a	O
census	O
and	O
were	O
invited	O
to	O
participate	O
.	O

The	O
study	O
was	O
approved	O
at	O
each	O
stage	O
of	O
the	O
data	O
collection	O
by	O
the	O
Human	B-LIVB
Ethics	O
Committees	O
of	O
the	O
University	O
of	O
Sydney	O
and	O
the	O
Western	O
Sydney	O
Area	O
Health	O
Service	O
and	O
adhered	O
to	O
the	O
recommendations	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
each	O
participant	B-LIVB
.	O

Details	O
of	O
the	O
methods	O
used	O
in	O
this	O
study	O
have	O
been	O
described	O
previously	O
[	O
11	O
]	O
.	O

The	O
baseline	O
examinations	O
(	O
BMES	O
cross	O
-	O
section	O
I	O
)	O
were	O
conducted	O
during	O
1992	O
-	O
1994	O
and	O
included	O
3654	O
(	O
82	O
.	O
4	O
%	O
)	O
of	O
4433	O
eligible	O
residents	O
.	O

Follow	O
-	O
up	O
examinations	O
(	O
BMES	O
IIA	O
)	O
were	O
conducted	O
during	O
1997	O
-	O
1999	O
,	O
with	O
2335	O
(	O
75	O
.	O
0	O
%	O
of	O
BMES	O
cross	O
section	O
I	O
survivors	O
)	O
participating	O
.	O

A	O
repeat	O
census	O
of	O
the	O
same	O
area	O
was	O
performed	O
in	O
1999	O
and	O
identified	O
1378	O
newly	O
eligible	O
residents	O
who	O
moved	O
into	O
the	O
area	O
or	O
the	O
eligible	O
age	O
group	O
.	O

During	O
1999	O
-	O
2000	O
,	O
1174	O
(	O
85	O
.	O
2	O
%	O
)	O
of	O
this	O
group	O
participated	O
in	O
an	O
extension	O
study	O
(	O
BMES	O
IIB	O
)	O
.	O

BMES	O
cross	O
-	O
section	O
II	O
thus	O
includes	O
BMES	O
IIA	O
(	O
66	O
.	O
5	O
%	O
)	O
and	O
BMES	O
IIB	O
(	O
33	O
.	O
5	O
%	O
)	O
participants	B-LIVB
(	O
n	O
=	O
3509	O
)	O
.	O

Similar	O
procedures	O
were	O
used	O
for	O
all	O
stages	O
of	O
data	O
collection	O
at	O
both	O
surveys	O
.	O

A	O
questionnaire	O
was	O
administered	O
including	O
demographic	O
,	O
family	O
and	O
medical	O
history	O
.	O

A	O
detailed	O
eye	O
examination	O
included	O
subjective	O
refraction	O
,	O
slit	O
-	O
lamp	O
(	O
Topcon	O
SL	O
-	O
7e	O
camera	O
,	O
Topcon	O
Optical	O
Co	O
,	O
Tokyo	O
,	O
Japan	O
)	O
and	O
retroillumination	O
(	O
Neitz	O
CT	O
-	O
R	O
camera	O
,	O
Neitz	O
Instrument	O
Co	O
,	O
Tokyo	O
,	O
Japan	O
)	O
photography	O
of	O
the	O
lens	O
.	O

Grading	O
of	O
lens	O
photographs	O
in	O
the	O
BMES	O
has	O
been	O
previously	O
described	O
[	O
12	O
]	O
.	O

Briefly	O
,	O
masked	O
grading	O
was	O
performed	O
on	O
the	O
lens	O
photographs	O
using	O
the	O
Wisconsin	O
Cataract	O
Grading	O
System	O
[	O
13	O
]	O
.	O

Cortical	O
cataract	O
and	O
PSC	O
were	O
assessed	O
from	O
the	O
retroillumination	O
photographs	O
by	O
estimating	O
the	O
percentage	O
of	O
the	O
circular	O
grid	O
involved	O
.	O

Cortical	O
cataract	O
was	O
defined	O
when	O
cortical	O
opacity	O
involved	O
at	O
least	O
5	O
%	O
of	O
the	O
total	O
lens	O
area	O
.	O

PSC	O
was	O
defined	O
when	O
opacity	O
comprised	O
at	O
least	O
1	O
%	O
of	O
the	O
total	O
lens	O
area	O
.	O

Slit	O
-	O
lamp	O
photographs	O
were	O
used	O
to	O
assess	O
nuclear	O
cataract	O
using	O
the	O
Wisconsin	O
standard	O
set	O
of	O
four	O
lens	O
photographs	O
[	O
13	O
]	O
.	O

Nuclear	O
cataract	O
was	O
defined	O
when	O
nuclear	O
opacity	O
was	O
at	O
least	O
as	O
great	O
as	O
the	O
standard	O
4	O
photograph	O
.	O

Any	O
cataract	O
was	O
defined	O
to	O
include	O
persons	B-LIVB
who	O
had	O
previous	O
cataract	O
surgery	O
as	O
well	O
as	O
those	O
with	O
any	O
of	O
three	O
cataract	O
types	O
.	O

Inter	O
-	O
grader	O
reliability	O
was	O
high	O
,	O
with	O
weighted	O
kappa	O
0	O
.	O
82	O
for	O
cortical	O
cataract	O
,	O
0	O
.	O
55	O
(	O
simple	O
kappa	O
0	O
.	O
75	O
)	O
for	O
nuclear	O
cataract	O
and	O
0	O
.	O
82	O
for	O
PSC	O
grading	O
.	O

The	O
intra	O
-	O
grader	O
reliability	O
for	O
nuclear	O
cataract	O
was	O
assessed	O
with	O
simple	O
kappa	O
0	O
.	O
83	O
for	O
the	O
senior	O
grader	O
who	O
graded	O
nuclear	O
cataract	O
at	O
both	O
surveys	O
.	O

All	O
PSC	O
cases	O
were	O
confirmed	O
by	O
an	O
ophthalmologist	O
(	O
PM	O
)	O
.	O

In	O
cross	O
-	O
section	O
I	O
,	O
219	O
persons	B-LIVB
(	O
6	O
.	O
0	O
%	O
)	O
had	O
missing	O
or	O
ungradable	O
Neitz	O
photographs	O
,	O
leaving	O
3435	O
with	O
photographs	O
available	O
for	O
cortical	O
cataract	O
and	O
PSC	O
assessment	O
,	O
while	O
1153	O
(	O
31	O
.	O
6	O
%	O
)	O
had	O
randomly	O
missing	O
or	O
ungradable	O
Topcon	O
photographs	O
due	O
to	O
a	O
camera	O
malfunction	O
,	O
leaving	O
2501	O
with	O
photographs	O
available	O
for	O
nuclear	O
cataract	O
assessment	O
.	O

Comparison	O
of	O
characteristics	O
between	O
participants	B-LIVB
with	O
and	O
without	O
Neitz	O
or	O
Topcon	O
photographs	O
in	O
cross	O
-	O
section	O
I	O
showed	O
no	O
statistically	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
,	O
as	O
reported	O
previously	O
[	O
12	O
]	O
.	O

In	O
cross	O
-	O
section	O
II	O
,	O
441	O
persons	B-LIVB
(	O
12	O
.	O
5	O
%	O
)	O
had	O
missing	O
or	O
ungradable	O
Neitz	O
photographs	O
,	O
leaving	O
3068	O
for	O
cortical	O
cataract	O
and	O
PSC	O
assessment	O
,	O
and	O
648	O
(	O
18	O
.	O
5	O
%	O
)	O
had	O
missing	O
or	O
ungradable	O
Topcon	O
photographs	O
,	O
leaving	O
2860	O
for	O
nuclear	O
cataract	O
assessment	O
.	O

Data	O
analysis	O
was	O
performed	O
using	O
the	O
Statistical	O
Analysis	O
System	O
(	O
SAS	O
,	O
SAS	O
Institute	O
,	O
Cary	O
,	O
NC	O
,	O
USA	O
)	O
.	O

Age	O
-	O
adjusted	O
prevalence	O
was	O
calculated	O
using	O
direct	O
standardization	O
of	O
the	O
cross	O
-	O
section	O
II	O
population	O
to	O
the	O
cross	O
-	O
section	O
I	O
population	O
.	O

We	O
assessed	O
age	O
-	O
specific	O
prevalence	O
using	O
an	O
interval	O
of	O
5	O
years	O
,	O
so	O
that	O
participants	B-LIVB
within	O
each	O
age	O
group	O
were	O
independent	O
between	O
the	O
two	O
cross	O
-	O
sectional	O
surveys	O
.	O

Results	O

Characteristics	O
of	O
the	O
two	O
survey	O
populations	O
have	O
been	O
previously	O
compared	O
[	O
14	O
]	O
and	O
showed	O
that	O
age	O
and	O
sex	O
distributions	O
were	O
similar	O
.	O

Table	O
1	O
compares	O
participant	B-LIVB
characteristics	O
between	O
the	O
two	O
cross	O
-	O
sections	O
.	O

Cross	O
-	O
section	O
II	O
participants	B-LIVB
generally	O
had	O
higher	O
rates	O
of	O
diabetes	O
,	O
hypertension	O
,	O
myopia	O
and	O
more	O
users	O
of	O
inhaled	O
steroids	O
.	O

Cataract	O
prevalence	O
rates	O
in	O
cross	O
-	O
sections	O
I	O
and	O
II	O
are	O
shown	O
in	O
Figure	O
1	O
.	O

The	O
overall	O
prevalence	O
of	O
cortical	O
cataract	O
was	O
23	O
.	O
8	O
%	O
and	O
23	O
.	O
7	O
%	O
in	O
cross	O
-	O
sections	O
I	O
and	O
II	O
,	O
respectively	O
(	O
age	O
-	O
sex	O
adjusted	O
P	O
=	O
0	O
.	O
81	O
)	O
.	O

Corresponding	O
prevalence	O
of	O
PSC	O
was	O
6	O
.	O
3	O
%	O
and	O
6	O
.	O
0	O
%	O
for	O
the	O
two	O
cross	O
-	O
sections	O
(	O
age	O
-	O
sex	O
adjusted	O
P	O
=	O
0	O
.	O
60	O
)	O
.	O

There	O
was	O
an	O
increased	O
prevalence	O
of	O
nuclear	O
cataract	O
,	O
from	O
18	O
.	O
7	O
%	O
in	O
cross	O
-	O
section	O
I	O
to	O
23	O
.	O
9	O
%	O
in	O
cross	O
-	O
section	O
II	O
over	O
the	O
6	O
-	O
year	O
period	O
(	O
age	O
-	O
sex	O
adjusted	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Prevalence	O
of	O
any	O
cataract	O
(	O
including	O
persons	B-LIVB
who	O
had	O
cataract	O
surgery	O
)	O
,	O
however	O
,	O
was	O
relatively	O
stable	O
(	O
46	O
.	O
9	O
%	O
and	O
46	O
.	O
8	O
%	O
in	O
cross	O
-	O
sections	O
I	O
and	O
II	O
,	O
respectively	O
)	O
.	O

After	O
age	O
-	O
standardization	O
,	O
these	O
prevalence	O
rates	O
remained	O
stable	O
for	O
cortical	O
cataract	O
(	O
23	O
.	O
8	O
%	O
and	O
23	O
.	O
5	O
%	O
in	O
the	O
two	O
surveys	O
)	O
and	O
PSC	O
(	O
6	O
.	O
3	O
%	O
and	O
5	O
.	O
9	O
%	O
)	O
.	O

The	O
slightly	O
increased	O
prevalence	O
of	O
nuclear	O
cataract	O
(	O
from	O
18	O
.	O
7	O
%	O
to	O
24	O
.	O
2	O
%	O
)	O
was	O
not	O
altered	O
.	O

Table	O
2	O
shows	O
the	O
age	O
-	O
specific	O
prevalence	O
rates	O
for	O
cortical	O
cataract	O
,	O
PSC	O
and	O
nuclear	O
cataract	O
in	O
cross	O
-	O
sections	O
I	O
and	O
II	O
.	O

A	O
similar	O
trend	O
of	O
increasing	O
cataract	O
prevalence	O
with	O
increasing	O
age	O
was	O
evident	O
for	O
all	O
three	O
types	O
of	O
cataract	O
in	O
both	O
surveys	O
.	O

Comparing	O
the	O
age	O
-	O
specific	O
prevalence	O
between	O
the	O
two	O
surveys	O
,	O
a	O
reduction	O
in	O
PSC	O
prevalence	O
in	O
cross	O
-	O
section	O
II	O
was	O
observed	O
in	O
the	O
older	O
age	O
groups	O
(	O
>=	O
75	O
years	O
)	O
.	O

In	O
contrast	O
,	O
increased	O
nuclear	O
cataract	O
prevalence	O
in	O
cross	O
-	O
section	O
II	O
was	O
observed	O
in	O
the	O
older	O
age	O
groups	O
(	O
>=	O
70	O
years	O
)	O
.	O

Age	O
-	O
specific	O
cortical	O
cataract	O
prevalence	O
was	O
relatively	O
consistent	O
between	O
the	O
two	O
surveys	O
,	O
except	O
for	O
a	O
reduction	O
in	O
prevalence	O
observed	O
in	O
the	O
80	O
-	O
84	O
age	O
group	O
and	O
an	O
increasing	O
prevalence	O
in	O
the	O
older	O
age	O
groups	O
(	O
>=	O
85	O
years	O
)	O
.	O

Similar	O
gender	O
differences	O
in	O
cataract	O
prevalence	O
were	O
observed	O
in	O
both	O
surveys	O
(	O
Table	O
3	O
)	O
.	O

Higher	O
prevalence	O
of	O
cortical	O
and	O
nuclear	O
cataract	O
in	O
women	B-LIVB
than	O
men	B-LIVB
was	O
evident	O
but	O
the	O
difference	O
was	O
only	O
significant	O
for	O
cortical	O
cataract	O
(	O
age	O
-	O
adjusted	O
odds	O
ratio	O
,	O
OR	O
,	O
for	O
women	B-LIVB
1	O
.	O
3	O
,	O
95	O
%	O
confidence	O
intervals	O
,	O
CI	O
,	O
1	O
.	O
1	O
-	O
1	O
.	O
5	O
in	O
cross	O
-	O
section	O
I	O
and	O
OR	O
1	O
.	O
4	O
,	O
95	O
%	O
CI	O
1	O
.	O
1	O
-	O
1	O
.	O
6	O
in	O
cross	O
-	O
section	O
II	O
)	O
.	O

In	O
contrast	O
,	O
men	B-LIVB
had	O
slightly	O
higher	O
PSC	O
prevalence	O
than	O
women	B-LIVB
in	O
both	O
cross	O
-	O
sections	O
but	O
the	O
difference	O
was	O
not	O
significant	O
(	O
OR	O
1	O
.	O
1	O
,	O
95	O
%	O
CI	O
0	O
.	O
8	O
-	O
1	O
.	O
4	O
for	O
men	B-LIVB
in	O
cross	O
-	O
section	O
I	O
and	O
OR	O
1	O
.	O
2	O
,	O
95	O
%	O
0	O
.	O
9	O
-	O
1	O
.	O
6	O
in	O
cross	O
-	O
section	O
II	O
)	O
.	O

Discussion	O

Findings	O
from	O
two	O
surveys	O
of	O
BMES	O
cross	O
-	O
sectional	O
populations	O
with	O
similar	O
age	O
and	O
gender	O
distribution	O
showed	O
that	O
the	O
prevalence	O
of	O
cortical	O
cataract	O
and	O
PSC	O
remained	O
stable	O
,	O
while	O
the	O
prevalence	O
of	O
nuclear	O
cataract	O
appeared	O
to	O
have	O
increased	O
.	O

Comparison	O
of	O
age	O
-	O
specific	O
prevalence	O
,	O
with	O
totally	O
independent	O
samples	O
within	O
each	O
age	O
group	O
,	O
confirmed	O
the	O
robustness	O
of	O
our	O
findings	O
from	O
the	O
two	O
survey	O
samples	O
.	O

Although	O
lens	O
photographs	O
taken	O
from	O
the	O
two	O
surveys	O
were	O
graded	O
for	O
nuclear	O
cataract	O
by	O
the	O
same	O
graders	O
,	O
who	O
documented	O
a	O
high	O
inter	O
-	O
and	O
intra	O
-	O
grader	O
reliability	O
,	O
we	O
cannot	O
exclude	O
the	O
possibility	O
that	O
variations	O
in	O
photography	O
,	O
performed	O
by	O
different	O
photographers	O
,	O
may	O
have	O
contributed	O
to	O
the	O
observed	O
difference	O
in	O
nuclear	O
cataract	O
prevalence	O
.	O

However	O
,	O
the	O
overall	O
prevalence	O
of	O
any	O
cataract	O
(	O
including	O
cataract	O
surgery	O
)	O
was	O
relatively	O
stable	O
over	O
the	O
6	O
-	O
year	O
period	O
.	O

Although	O
different	O
population	O
-	O
based	O
studies	O
used	O
different	O
grading	O
systems	O
to	O
assess	O
cataract	O
[	O
15	O
]	O
,	O
the	O
overall	O
prevalence	O
of	O
the	O
three	O
cataract	O
types	O
were	O
similar	O
across	O
different	O
study	O
populations	O
[	O
12	O
,	O
16	O
-	O
23	O
]	O
.	O

Most	O
studies	O
have	O
suggested	O
that	O
nuclear	O
cataract	O
is	O
the	O
most	O
prevalent	O
type	O
of	O
cataract	O
,	O
followed	O
by	O
cortical	O
cataract	O
[	O
16	O
-	O
20	O
]	O
.	O

Ours	O
and	O
other	O
studies	O
reported	O
that	O
cortical	O
cataract	O
was	O
the	O
most	O
prevalent	O
type	O
[	O
12	O
,	O
21	O
-	O
23	O
]	O
.	O

Our	O
age	O
-	O
specific	O
prevalence	O
data	O
show	O
a	O
reduction	O
of	O
15	O
.	O
9	O
%	O
in	O
cortical	O
cataract	O
prevalence	O
for	O
the	O
80	O
-	O
84	O
year	O
age	O
group	O
,	O
concordant	O
with	O
an	O
increase	O
in	O
cataract	O
surgery	O
prevalence	O
by	O
9	O
%	O
in	O
those	O
aged	O
80	O
+	O
years	O
observed	O
in	O
the	O
same	O
study	O
population	O
[	O
10	O
]	O
.	O

Although	O
cortical	O
cataract	O
is	O
thought	O
to	O
be	O
the	O
least	O
likely	O
cataract	O
type	O
leading	O
to	O
a	O
cataract	O
surgery	O
,	O
this	O
may	O
not	O
be	O
the	O
case	O
in	O
all	O
older	O
persons	B-LIVB
.	O

A	O
relatively	O
stable	O
cortical	O
cataract	O
and	O
PSC	O
prevalence	O
over	O
the	O
6	O
-	O
year	O
period	O
is	O
expected	O
.	O

We	O
cannot	O
offer	O
a	O
definitive	O
explanation	O
for	O
the	O
increase	O
in	O
nuclear	O
cataract	O
prevalence	O
.	O

A	O
possible	O
explanation	O
could	O
be	O
that	O
a	O
moderate	O
level	O
of	O
nuclear	O
cataract	O
causes	O
less	O
visual	O
disturbance	O
than	O
the	O
other	O
two	O
types	O
of	O
cataract	O
,	O
thus	O
for	O
the	O
oldest	O
age	O
groups	O
,	O
persons	B-LIVB
with	O
nuclear	O
cataract	O
could	O
have	O
been	O
less	O
likely	O
to	O
have	O
surgery	O
unless	O
it	O
is	O
very	O
dense	O
or	O
co	O
-	O
existing	O
with	O
cortical	O
cataract	O
or	O
PSC	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
functional	O
vision	O
and	O
reading	O
performance	O
were	O
high	O
in	O
patients	B-LIVB
undergoing	O
cataract	O
surgery	O
who	O
had	O
nuclear	O
cataract	O
only	O
compared	O
to	O
those	O
with	O
mixed	O
type	O
of	O
cataract	O
(	O
nuclear	O
and	O
cortical	O
)	O
or	O
PSC	O
[	O
24	O
,	O
25	O
]	O
.	O

In	O
addition	O
,	O
the	O
overall	O
prevalence	O
of	O
any	O
cataract	O
(	O
including	O
cataract	O
surgery	O
)	O
was	O
similar	O
in	O
the	O
two	O
cross	O
-	O
sections	O
,	O
which	O
appears	O
to	O
support	O
our	O
speculation	O
that	O
in	O
the	O
oldest	O
age	O
group	O
,	O
nuclear	O
cataract	O
may	O
have	O
been	O
less	O
likely	O
to	O
be	O
operated	O
than	O
the	O
other	O
two	O
types	O
of	O
cataract	O
.	O

This	O
could	O
have	O
resulted	O
in	O
an	O
increased	O
nuclear	O
cataract	O
prevalence	O
(	O
due	O
to	O
less	O
being	O
operated	O
)	O
,	O
compensated	O
by	O
the	O
decreased	O
prevalence	O
of	O
cortical	O
cataract	O
and	O
PSC	O
(	O
due	O
to	O
these	O
being	O
more	O
likely	O
to	O
be	O
operated	O
)	O
,	O
leading	O
to	O
stable	O
overall	O
prevalence	O
of	O
any	O
cataract	O
.	O

Possible	O
selection	O
bias	O
arising	O
from	O
selective	O
survival	O
among	O
persons	B-LIVB
without	O
cataract	O
could	O
have	O
led	O
to	O
underestimation	O
of	O
cataract	O
prevalence	O
in	O
both	O
surveys	O
.	O

We	O
assume	O
that	O
such	O
an	O
underestimation	O
occurred	O
equally	O
in	O
both	O
surveys	O
,	O
and	O
thus	O
should	O
not	O
have	O
influenced	O
our	O
assessment	O
of	O
temporal	O
changes	O
.	O

Measurement	O
error	O
could	O
also	O
have	O
partially	O
contributed	O
to	O
the	O
observed	O
difference	O
in	O
nuclear	O
cataract	O
prevalence	O
.	O

Assessment	O
of	O
nuclear	O
cataract	O
from	O
photographs	O
is	O
a	O
potentially	O
subjective	O
process	O
that	O
can	O
be	O
influenced	O
by	O
variations	O
in	O
photography	O
(	O
light	O
exposure	O
,	O
focus	O
and	O
the	O
slit	O
-	O
lamp	O
angle	O
when	O
the	O
photograph	O
was	O
taken	O
)	O
and	O
grading	O
.	O

Although	O
we	O
used	O
the	O
same	O
Topcon	O
slit	O
-	O
lamp	O
camera	O
and	O
the	O
same	O
two	O
graders	O
who	O
graded	O
photos	O
from	O
both	O
surveys	O
,	O
we	O
are	O
still	O
not	O
able	O
to	O
exclude	O
the	O
possibility	O
of	O
a	O
partial	O
influence	O
from	O
photographic	O
variation	O
on	O
this	O
result	O
.	O

A	O
similar	O
gender	O
difference	O
(	O
women	B-LIVB
having	O
a	O
higher	O
rate	O
than	O
men	B-LIVB
)	O
in	O
cortical	O
cataract	O
prevalence	O
was	O
observed	O
in	O
both	O
surveys	O
.	O

Our	O
findings	O
are	O
in	O
keeping	O
with	O
observations	O
from	O
the	O
Beaver	O
Dam	O
Eye	O
Study	O
[	O
18	O
]	O
,	O
the	O
Barbados	O
Eye	O
Study	O
[	O
22	O
]	O
and	O
the	O
Lens	O
Opacities	O
Case	O
-	O
Control	O
Group	O
[	O
26	O
]	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
difference	O
could	O
be	O
related	O
to	O
hormonal	O
factors	O
[	O
18	O
,	O
22	O
]	O
.	O

A	O
previous	O
study	O
on	O
biochemical	O
factors	O
and	O
cataract	O
showed	O
that	O
a	O
lower	O
level	O
of	O
iron	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
cortical	O
cataract	O
[	O
27	O
]	O
.	O

No	O
interaction	O
between	O
sex	O
and	O
biochemical	O
factors	O
were	O
detected	O
and	O
no	O
gender	O
difference	O
was	O
assessed	O
in	O
this	O
study	O
[	O
27	O
]	O
.	O

The	O
gender	O
difference	O
seen	O
in	O
cortical	O
cataract	O
could	O
be	O
related	O
to	O
relatively	O
low	O
iron	O
levels	O
and	O
low	O
hemoglobin	O
concentration	O
usually	O
seen	O
in	O
women	B-LIVB
[	O
28	O
]	O
.	O

Diabetes	O
is	O
a	O
known	O
risk	O
factor	O
for	O
cortical	O
cataract	O
but	O
in	O
this	O
particular	O
population	O
diabetes	O
is	O
more	O
prevalent	O
in	O
men	B-LIVB
than	O
women	B-LIVB
in	O
all	O
age	O
groups	O
[	O
29	O
]	O
.	O

Differential	O
exposures	O
to	O
cataract	O
risk	O
factors	O
or	O
different	O
dietary	O
or	O
lifestyle	O
patterns	O
between	O
men	B-LIVB
and	O
women	B-LIVB
may	O
also	O
be	O
related	O
to	O
these	O
observations	O
and	O
warrant	O
further	O
study	O
.	O

Conclusion	O

In	O
summary	O
,	O
in	O
two	O
population	O
-	O
based	O
surveys	O
6	O
years	O
apart	O
,	O
we	O
have	O
documented	O
a	O
relatively	O
stable	O
prevalence	O
of	O
cortical	O
cataract	O
and	O
PSC	O
over	O
the	O
period	O
.	O

The	O
observed	O
overall	O
increased	O
nuclear	O
cataract	O
prevalence	O
by	O
5	O
%	O
over	O
a	O
6	O
-	O
year	O
period	O
needs	O
confirmation	O
by	O
future	O
studies	O
,	O
and	O
reasons	O
for	O
such	O
an	O
increase	O
deserve	O
further	O
study	O
.	O

Competing	O
interests	O

The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O

AGT	O
graded	O
the	O
photographs	O
,	O
performed	O
literature	O
search	O
and	O
wrote	O
the	O
first	O
draft	O
of	O
the	O
manuscript	O
.	O

JJW	O
graded	O
the	O
photographs	O
,	O
critically	O
reviewed	O
and	O
modified	O
the	O
manuscript	O
.	O

ER	O
performed	O
the	O
statistical	O
analysis	O
and	O
critically	O
reviewed	O
the	O
manuscript	O
.	O

PM	O
designed	O
and	O
directed	O
the	O
study	O
,	O
adjudicated	O
cataract	O
cases	O
and	O
critically	O
reviewed	O
and	O
modified	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Pre	O
-	O
publication	O
history	O

The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

QGRS	O
Mapper	O
:	O
a	O
web	O
-	O
based	O
server	O
for	O
predicting	O
G	O
-	O
quadruplexes	O
in	O
nucleotide	O
sequences	O

Abstract	O

The	O
quadruplex	O
structures	O
formed	O
by	O
guanine	O
-	O
rich	O
nucleic	O
acid	O
sequences	O
have	O
received	O
significant	O
attention	O
recently	O
because	O
of	O
growing	O
evidence	O
for	O
their	O
role	O
in	O
important	O
biological	O
processes	O
and	O
as	O
therapeutic	O
targets	O
.	O

G	O
-	O
quadruplex	O
DNA	O
has	O
been	O
suggested	O
to	O
regulate	O
DNA	O
replication	O
and	O
may	O
control	O
cellular	O
proliferation	O
.	O

Sequences	O
capable	O
of	O
forming	O
G	O
-	O
quadruplexes	O
in	O
the	O
RNA	O
have	O
been	O
shown	O
to	O
play	O
significant	O
roles	O
in	O
regulation	O
of	O
polyadenylation	O
and	O
splicing	O
events	O
in	O
mammalian	O
transcripts	O
.	O

Whether	O
quadruplex	O
structure	O
directly	O
plays	O
a	O
role	O
in	O
regulating	O
RNA	O
processing	O
requires	O
investigation	O
.	O

Computational	O
approaches	O
to	O
study	O
G	O
-	O
quadruplexes	O
allow	O
detailed	O
analysis	O
of	O
mammalian	O
genomes	O
.	O

There	O
are	O
no	O
known	O
easily	O
accessible	O
user	O
-	O
friendly	O
tools	O
that	O
can	O
compute	O
G	O
-	O
quadruplexes	O
in	O
the	O
nucleotide	O
sequences	O
.	O

We	O
have	O
developed	O
a	O
web	O
-	O
based	O
server	O
,	O
QGRS	O
Mapper	O
,	O
that	O
predicts	O
quadruplex	O
forming	O
G	O
-	O
rich	O
sequences	O
(	O
QGRS	O
)	O
in	O
nucleotide	O
sequences	O
.	O

It	O
is	O
a	O
user	O
-	O
friendly	O
application	O
that	O
provides	O
many	O
options	O
for	O
defining	O
and	O
studying	O
G	O
-	O
quadruplexes	O
.	O

It	O
performs	O
analysis	O
of	O
the	O
user	O
provided	O
genomic	O
sequences	O
,	O
e	O
.	O
g	O
.	O
promoter	O
and	O
telomeric	O
regions	O
,	O
as	O
well	O
as	O
RNA	O
sequences	O
.	O

It	O
is	O
also	O
useful	O
for	O
predicting	O
G	O
-	O
quadruplex	O
structures	O
in	O
oligonucleotides	O
.	O

The	O
program	O
provides	O
options	O
to	O
search	O
and	O
retrieve	O
desired	O
gene	O
/	O
nucleotide	O
sequence	O
entries	O
from	O
NCBI	O
databases	O
for	O
mapping	O
G	O
-	O
quadruplexes	O
in	O
the	O
context	O
of	O
RNA	O
processing	O
sites	O
.	O

This	O
feature	O
is	O
very	O
useful	O
for	O
investigating	O
the	O
functional	O
relevance	O
of	O
G	O
-	O
quadruplex	O
structure	O
,	O
in	O
particular	O
its	O
role	O
in	O
regulating	O
the	O
gene	O
expression	O
by	O
alternative	O
processing	O
.	O

In	O
addition	O
to	O
providing	O
data	O
on	O
composition	O
and	O
locations	O
of	O
QGRS	O
relative	O
to	O
the	O
processing	O
sites	O
in	O
the	O
pre	O
-	O
mRNA	O
sequence	O
,	O
QGRS	O
Mapper	O
features	O
interactive	O
graphic	O
representation	O
of	O
the	O
data	O
.	O

The	O
user	O
can	O
also	O
use	O
the	O
graphics	O
module	O
to	O
visualize	O
QGRS	O
distribution	O
patterns	O
among	O
all	O
the	O
alternative	O
RNA	O
products	O
of	O
a	O
gene	O
simultaneously	O
on	O
a	O
single	O
screen	O
.	O

QGRS	O
Mapper	O
can	O
be	O
accessed	O
at	O
.	O

INTRODUCTION	O

The	O
quadruplex	O
structures	O
formed	O
by	O
guanine	O
-	O
rich	O
nucleic	O
acid	O
sequences	O
have	O
received	O
significant	O
attention	O
recently	O
because	O
of	O
increasing	O
evidence	O
for	O
their	O
role	O
in	O
important	O
biological	O
processes	O
and	O
as	O
therapeutic	O
targets	O
(	O
1	O
-	O
5	O
)	O
.	O

The	O
G	O
-	O
quadruplex	O
structure	O
,	O
also	O
known	O
as	O
a	O
G	O
-	O
quartet	O
,	O
is	O
formed	O
by	O
repeated	O
folding	O
of	O
either	O
the	O
single	O
polynucleotide	O
molecule	O
or	O
by	O
association	O
of	O
two	O
or	O
four	O
molecules	O
.	O

The	O
structure	O
consists	O
of	O
stacked	O
G	O
-	O
tetrads	O
,	O
which	O
are	O
square	O
co	O
-	O
planar	O
arrays	O
of	O
four	O
guanine	O
bases	O
each	O
(	O
6	O
)	O
.	O

G	O
-	O
quadruplex	O
is	O
stabilized	O
with	O
cyclic	O
Hoogsteen	O
hydrogen	O
bonding	O
between	O
the	O
four	O
guanines	O
within	O
each	O
tetrad	O
.	O

The	O
present	O
work	O
focuses	O
only	O
on	O
the	O
unimolecular	O
quadruplexes	O
,	O
since	O
it	O
is	O
more	O
likely	O
to	O
be	O
encountered	O
in	O
physiological	O
conditions	O
(	O
7	O
,	O
8	O
)	O
.	O

Guanine	O
-	O
rich	O
sequences	O
capable	O
of	O
forming	O
G	O
-	O
quadruplexes	O
are	O
found	O
in	O
telomeres	O
,	O
promoter	O
regions	O
,	O
transcribed	O
and	O
other	O
biologically	O
important	O
regions	O
of	O
the	O
mammalian	O
genomes	O
.	O

G	O
-	O
quadruplex	O
DNA	O
has	O
been	O
suggested	O
to	O
regulate	O
DNA	O
replication	O
in	O
retinoblastoma	O
susceptibility	O
gene	O
(	O
Rb	O
)	O
region	O
(	O
9	O
)	O
.	O

This	O
structure	O
may	O
control	O
cellular	O
proliferation	O
at	O
telomeric	O
level	O
and	O
by	O
transcriptional	O
regulation	O
of	O
oncogenes	O
like	O
c	O
-	O
myc	O
(	O
2	O
,	O
10	O
,	O
11	O
)	O
and	O
c	O
-	O
kit	O
(	O
12	O
)	O
.	O

Formation	O
of	O
G	O
-	O
quadruplex	O
seems	O
to	O
be	O
regulated	O
through	O
interactions	O
with	O
cellular	O
proteins	O
.	O

While	O
some	O
proteins	O
help	O
stabilize	O
the	O
structure	O
(	O
13	O
)	O
,	O
others	O
are	O
known	O
to	O
resolve	O
it	O
(	O
1	O
,	O
4	O
,	O
14	O
,	O
15	O
)	O
.	O

Proteins	O
and	O
chemicals	O
that	O
stabilize	O
the	O
G	O
-	O
quadruplex	O
structure	O
can	O
inhibit	O
telomerase	O
action	O
and	O
,	O
therefore	O
,	O
are	O
being	O
evaluated	O
as	O
anticancer	O
therapeutic	O
agents	O
(	O
16	O
-	O
20	O
)	O
.	O

Chemical	O
compounds	O
that	O
inhibit	O
G	O
-	O
quadruplex	O
helicase	O
activity	O
may	O
also	O
be	O
capable	O
of	O
regulating	O
cellular	O
proliferation	O
(	O
4	O
)	O
.	O

G	O
-	O
quadruplexes	O
are	O
also	O
being	O
eyed	O
as	O
potential	O
antimicrobial	O
agents	O
due	O
to	O
their	O
ability	O
to	O
transport	O
monovalent	O
anions	O
(	O
21	O
)	O
.	O

G	O
-	O
quadruplex	O
motifs	O
in	O
the	O
RNA	O
have	O
been	O
shown	O
to	O
play	O
significant	O
roles	O
in	O
mRNA	O
turnover	O
(	O
1	O
)	O
,	O
FMRP	O
binding	O
(	O
22	O
)	O
,	O
translation	O
initiation	O
(	O
23	O
)	O
as	O
well	O
as	O
repression	O
(	O
24	O
)	O
.	O

We	O
have	O
shown	O
previously	O
that	O
a	O
G	O
-	O
rich	O
sequence	O
(	O
GRS	O
)	O
can	O
mediate	O
3	O
'	O
end	O
processing	O
of	O
mammalian	O
pre	O
-	O
mRNAs	O
by	O
interacting	O
with	O
DSEF	O
-	O
1	O
/	O
hnRNPH	O
/	O
H	O
'	O
protein	O
(	O
25	O
-	O
27	O
)	O
.	O

Members	O
of	O
the	O
hnRNP	O
H	O
protein	O
family	O
recognize	O
G	O
-	O
rich	O
motifs	O
capable	O
of	O
forming	O
G	O
-	O
quadruplexes	O
and	O
are	O
known	O
to	O
regulate	O
polyadenylation	O
and	O
splicing	O
events	O
in	O
mammalian	O
transcripts	O
(	O
28	O
-	O
30	O
)	O
.	O

Regulated	O
RNA	O
processing	O
is	O
an	O
essential	O
component	O
of	O
differential	O
gene	O
expression	O
which	O
is	O
central	O
to	O
many	O
important	O
biologically	O
processes	O
.	O

More	O
than	O
half	O
of	O
human	B-LIVB
genes	O
are	O
known	O
to	O
have	O
alternative	O
polyadenylation	O
(	O
31	O
)	O
.	O

Over	O
two	O
-	O
thirds	O
of	O
human	B-LIVB
genes	O
are	O
thought	O
to	O
undergo	O
alternative	O
splicing	O
(	O
32	O
)	O
.	O

Sequences	O
capable	O
of	O
forming	O
G	O
-	O
quadruplexes	O
found	O
in	O
the	O
vicinity	O
of	O
polyadenylation	O
and	O
splice	O
sites	O
act	O
as	O
regulators	O
by	O
interacting	O
with	O
hnRNP	O
F	O
and	O
H	O
proteins	O
(	O
25	O
-	O
27	O
,	O
30	O
,	O
33	O
)	O
.	O

Whether	O
quadruplex	O
structure	O
directly	O
plays	O
a	O
role	O
in	O
regulating	O
RNA	O
processing	O
events	O
requires	O
investigation	O
.	O

Computational	O
approaches	O
to	O
study	O
G	O
-	O
quadruplexes	O
in	O
the	O
mammalian	O
genomes	O
allow	O
large	O
-	O
scale	O
and	O
detailed	O
analysis	O
of	O
mammalian	O
genes	O
.	O

Although	O
,	O
G	O
-	O
quadruplexes	O
have	O
been	O
surveyed	O
in	O
the	O
human	B-LIVB
genome	O
with	O
such	O
techniques	O
(	O
34	O
,	O
35	O
)	O
,	O
there	O
are	O
no	O
known	O
user	O
-	O
friendly	O
computational	O
tools	O
easily	O
accessible	O
to	O
the	O
public	O
.	O

We	O
had	O
previously	O
built	O
a	O
database	O
of	O
mapped	O
G	O
-	O
quadruplex	O
sequences	O
in	O
selected	O
alternatively	O
processed	O
human	B-LIVB
and	O
mouse	B-LIVB
genes	O
(	O
36	O
)	O
.	O

Our	O
preliminary	O
analysis	O
of	O
the	O
database	O
suggests	O
prevalence	O
of	O
such	O
motifs	O
near	O
alternative	O
splice	O
and	O
poly	O
(	O
A	O
)	O
sites	O
.	O

We	O
have	O
now	O
developed	O
a	O
web	O
-	O
based	O
server	O
,	O
QGRS	O
Mapper	O
,	O
that	O
generates	O
detailed	O
information	O
on	O
composition	O
and	O
distribution	O
of	O
putative	O
quadruplex	O
forming	O
G	O
-	O
rich	O
sequences	O
(	O
QGRS	O
)	O
in	O
any	O
NCBI	O
nucleotide	O
sequence	O
identified	O
or	O
provided	O
by	O
the	O
user	O
.	O

The	O
program	O
is	O
also	O
designed	O
to	O
handle	O
the	O
analysis	O
of	O
mammalian	O
pre	O
-	O
mRNA	O
sequences	O
,	O
including	O
those	O
that	O
are	O
alternatively	O
processed	O
(	O
alternatively	O
spliced	O
or	O
alternatively	O
polyadenylated	O
)	O
.	O

Researchers	O
interested	O
in	O
predicting	O
the	O
ability	O
of	O
a	O
nucleotide	O
sequence	O
to	O
form	O
G	O
-	O
quadruplex	O
structure	O
will	O
find	O
QGRS	O
Mapper	O
to	O
be	O
a	O
user	O
-	O
friendly	O
application	O
that	O
provides	O
many	O
options	O
for	O
analysis	O
.	O

The	O
user	O
can	O
define	O
the	O
minimum	O
number	O
of	O
tetrads	O
,	O
maximum	O
length	O
of	O
the	O
G	O
-	O
quadruplex	O
motif	O
,	O
and	O
size	O
as	O
well	O
as	O
composition	O
of	O
the	O
loops	O
.	O

The	O
program	O
can	O
map	O
unimolecular	O
QGRS	O
in	O
the	O
entire	O
nucleotide	O
sequence	O
provided	O
in	O
the	O
raw	O
or	O
FASTA	O
format	O
by	O
the	O
user	O
.	O

This	O
method	O
can	O
be	O
used	O
for	O
the	O
analysis	O
of	O
genomic	O
sequences	O
,	O
e	O
.	O
g	O
.	O
promoter	O
and	O
telomeric	O
regions	O
,	O
as	O
well	O
as	O
RNA	O
sequences	O
.	O

It	O
is	O
also	O
useful	O
for	O
predicting	O
G	O
-	O
quadruplex	O
structures	O
in	O
oligonucleotides	O
.	O

Alternatively	O
,	O
the	O
program	O
provides	O
options	O
to	O
search	O
the	O
entire	O
NCBI	O
Gene	O
Entrez	O
,	O
RefSeq	O
and	O
GenBank	O
databases	O
in	O
order	O
to	O
retrieve	O
the	O
desired	O
gene	O
/	O
nucleotide	O
sequence	O
entries	O
for	O
analysis	O
of	O
their	O
transcribed	O
regions	O
.	O

Furthermore	O
,	O
QGRS	O
Mapper	O
is	O
a	O
unique	O
tool	O
for	O
mapping	O
G	O
-	O
quadruplex	O
forming	O
sequences	O
in	O
the	O
context	O
of	O
RNA	O
processing	O
sites	O
.	O

This	O
feature	O
is	O
very	O
useful	O
for	O
investigating	O
the	O
functional	O
relevance	O
of	O
G	O
-	O
quadruplex	O
structure	O
,	O
in	O
particular	O
its	O
role	O
in	O
regulating	O
the	O
gene	O
expression	O
by	O
alternative	O
processing	O
.	O

In	O
addition	O
to	O
providing	O
data	O
on	O
composition	O
and	O
locations	O
of	O
QGRS	O
relative	O
to	O
the	O
processing	O
sites	O
in	O
the	O
pre	O
-	O
mRNA	O
sequence	O
,	O
QGRS	O
Mapper	O
offers	O
interactive	O
graphic	O
representation	O
of	O
the	O
data	O
.	O

The	O
user	O
can	O
also	O
use	O
a	O
graphics	O
module	O
to	O
visualize	O
QGRS	O
distribution	O
patterns	O
among	O
all	O
the	O
alternative	O
RNA	O
products	O
of	O
a	O
gene	O
simultaneously	O
on	O
a	O
single	O
screen	O
.	O

METHODS	O

QGRS	O
definition	O

The	O
main	O
goal	O
of	O
the	O
QGRS	O
Mapper	O
program	O
is	O
to	O
predict	O
the	O
presence	O
of	O
QGRS	O
in	O
nucleotide	O
entries	O
.	O

These	O
putative	O
G	O
-	O
quadruplexes	O
are	O
identified	O
using	O
the	O
following	O
motif	O
.	O

GxNy1GxNy2GxNy3Gx	O

Here	O
x	O
=	O
number	O
of	O
guanine	O
tetrads	O
in	O
the	O
G	O
-	O
quadruplex	O
and	O
y1	O
,	O
y2	O
,	O
y3	O
=	O
length	O
of	O
gaps	O
(	O
i	O
.	O
e	O
.	O
the	O
length	O
of	O
the	O
loops	O
connecting	O
the	O
guanine	O
tetrads	O
)	O
.	O

The	O
motif	O
consists	O
of	O
four	O
equal	O
length	O
sets	O
of	O
guanines	O
(	O
which	O
we	O
call	O
G	O
-	O
groups	O
)	O
,	O
separated	O
by	O
arbitrary	O
nucleotide	O
sequences	O
,	O
with	O
the	O
following	O
restrictions	O
.	O

The	O
sequence	O
must	O
contain	O
at	O
least	O
two	O
tetrads	O
(	O
i	O
.	O
e	O
.	O
x	O
>=	O
2	O
)	O
.	O

Although	O
structures	O
with	O
three	O
or	O
more	O
G	O
-	O
tetrads	O
are	O
considered	O
to	O
be	O
more	O
stable	O
,	O
many	O
nucleotide	O
sequences	O
are	O
known	O
to	O
form	O
quadruplexes	O
with	O
two	O
G	O
-	O
tetrads	O
(	O
37	O
,	O
38	O
)	O
.	O

QGRS	O
Mapper	O
is	O
meant	O
to	O
be	O
a	O
flexible	O
and	O
comprehensive	O
tool	O
for	O
investigating	O
G	O
-	O
quadruplexes	O
;	O
hence	O
it	O
considers	O
sequences	O
with	O
two	O
tetrads	O
.	O
By	O
default	O
,	O
only	O
QGRS	O
of	O
maximum	O
length	O
of	O
30	O
bases	O
are	O
considered	O
.	O

However	O
,	O
the	O
program	O
gives	O
the	O
user	O
the	O
option	O
to	O
search	O
for	O
sequences	O
up	O
to	O
45	O
bases	O
.	O

This	O
restriction	O
on	O
the	O
length	O
of	O
the	O
sequences	O
being	O
considered	O
is	O
in	O
agreement	O
with	O
recent	O
literature	O
(	O
34	O
,	O
35	O
)	O
.	O

The	O
maximum	O
length	O
of	O
30	O
bases	O
restricts	O
G	O
-	O
groups	O
to	O
a	O
maximum	O
size	O
of	O
6	O
.	O
The	O
gaps	O
or	O
loops	O
between	O
the	O
G	O
-	O
groups	O
may	O
be	O
arbitrary	O
in	O
composition	O
or	O
length	O
(	O
within	O
the	O
overall	O
restrictions	O
on	O
the	O
length	O
of	O
QGRS	O
)	O
.	O

The	O
program	O
gives	O
the	O
user	O
the	O
option	O
to	O
search	O
for	O
QGRS	O
having	O
loops	O
with	O
a	O
specified	O
length	O
range	O
(	O
e	O
.	O
g	O
.	O
the	O
user	O
can	O
search	O
for	O
QGRS	O
with	O
loops	O
of	O
lengths	O
between	O
1	O
and	O
4	O
)	O
.	O

The	O
user	O
can	O
also	O
specify	O
a	O
string	O
that	O
one	O
or	O
more	O
loops	O
of	O
each	O
QGRS	O
must	O
contain	O
.	O

This	O
string	O
can	O
be	O
given	O
as	O
a	O
regular	O
expression	O
.	O

For	O
example	O
,	O
entering	O
the	O
regular	O
expression	O
'	O
T	O
{	O
3	O
,	O
5	O
}	O
'	O
will	O
search	O
for	O
QGRS	O
having	O
one	O
or	O
more	O
loops	O
that	O
contain	O
three	O
to	O
five	O
consecutive	O
T	O
'	O
s	O
.	O
Also	O
,	O
at	O
most	O
one	O
of	O
the	O
gaps	O
is	O
allowed	O
to	O
be	O
of	O
zero	O
length	O

Table	O
1	O
shows	O
some	O
examples	O
of	O
valid	O
QGRS	O
.	O

The	O
guanine	O
groups	O
which	O
form	O
the	O
tetrads	O
are	O
underlined	O
.	O

The	O
first	O
sequence	O
has	O
four	O
tetrads	O
and	O
equal	O
length	O
gaps	O
.	O

This	O
would	O
seem	O
to	O
provide	O
a	O
G	O
-	O
quadruplex	O
that	O
is	O
the	O
most	O
stable	O
of	O
the	O
three	O
sequences	O
.	O

The	O
second	O
sequence	O
is	O
notable	O
for	O
the	O
significant	O
differences	O
in	O
the	O
size	O
of	O
its	O
loops	O
.	O

The	O
third	O
sequence	O
has	O
two	O
tetrads	O
,	O
even	O
though	O
three	O
of	O
the	O
G	O
-	O
groups	O
could	O
have	O
included	O
another	O
G	O
(	O
since	O
all	O
G	O
-	O
groups	O
must	O
be	O
equal	O
in	O
size	O
)	O
.	O

G	O
-	O
scores	O

We	O
have	O
devised	O
a	O
scoring	O
system	O
that	O
evaluates	O
a	O
QGRS	O
for	O
its	O
likelihood	O
to	O
form	O
a	O
stable	O
G	O
-	O
quadruplex	O
.	O

Higher	O
scoring	O
sequences	O
will	O
make	O
better	O
candidates	O
for	O
G	O
-	O
quadruplexes	O
.	O

The	O
scoring	O
method	O
uses	O
the	O
following	O
principles	O
which	O
are	O
based	O
on	O
previous	O
studies	O
(	O
34	O
,	O
35	O
,	O
39	O
-	O
42	O
)	O
.	O

Shorter	O
loops	O
are	O
more	O
common	O
than	O
longer	O
loops	O
.	O
G	O
-	O
quadruplexes	O
tend	O
to	O
have	O
loops	O
roughly	O
equal	O
in	O
size	O
.	O
The	O
greater	O
the	O
number	O
of	O
guanine	O
tetrads	O
,	O
the	O
more	O
stable	O
the	O
quadruplex	O
.	O

The	O
computed	O
G	O
-	O
scores	O
are	O
dependent	O
on	O
the	O
user	O
selected	O
maximum	O
QGRS	O
length	O
.	O

The	O
highest	O
possible	O
G	O
-	O
score	O
,	O
using	O
the	O
default	O
maximum	O
QGRS	O
length	O
of	O
30	O
,	O
is	O
105	O
.	O

Here	O
is	O
a	O
sequence	O
attaining	O
that	O
score	O
:	O

GGGGGGTGGGGGGTGGGGGGTGGGGGG	O
.	O

Eliminating	O
QGRS	O
overlaps	O

Two	O
QGRS	O
are	O
said	O
to	O
overlap	O
if	O
their	O
positions	O
in	O
the	O
nucleotide	O
sequence	O
overlap	O
.	O

QGRS	O
Mapper	O
will	O
start	O
with	O
a	O
nucleotide	O
sequence	O
,	O
find	O
all	O
QGRS	O
occurring	O
in	O
the	O
sequence	O
and	O
then	O
produce	O
a	O
non	O
-	O
overlapping	O
set	O
of	O
QGRS	O
.	O

Overlaps	O
are	O
eliminated	O
by	O
selecting	O
the	O
higher	O
scoring	O
QGRS	O
.	O

In	O
the	O
non	O
-	O
overlapping	O
view	O
,	O
only	O
this	O
sequence	O
will	O
be	O
displayed	O
,	O
although	O
the	O
user	O
can	O
request	O
that	O
all	O
overlapping	O
sequences	O
be	O
displayed	O
.	O

Please	O
see	O
supplementary	O
materials	O
at	O
NAR	O
online	O
for	O
more	O
details	O
on	O
the	O
elimination	O
of	O
overlapping	O
QGRS	O
.	O

FEATURES	O

Design	O
and	O
implementation	O

QGRS	O
Mapper	O
is	O
a	O
web	O
-	O
based	O
program	O
,	O
written	O
in	O
PHP	O
,	O
with	O
Java	O
being	O
used	O
for	O
some	O
of	O
its	O
graphics	O
.	O

The	O
program	O
takes	O
a	O
nucleotide	O
sequence	O
from	O
NCBI	O
(	O
or	O
as	O
provided	O
by	O
the	O
user	O
)	O
and	O
analyzes	O
it	O
for	O
the	O
presence	O
of	O
putative	O
G	O
-	O
quadruplexes	O
.	O

The	O
structure	O
of	O
QGRS	O
Mapper	O
is	O
summarized	O
in	O
Table	O
2	O
.	O

Search	O
and	O
analysis	O

QGRS	O
Mapper	O
allows	O
the	O
user	O
to	O
search	O
for	O
putative	O
G	O
-	O
quadruplexes	O
in	O
a	O
variety	O
of	O
ways	O
.	O

It	O
is	O
possible	O
to	O
enter	O
a	O
nucleotide	O
sequence	O
in	O
raw	O
or	O
FASTA	O
format	O
for	O
analysis	O
.	O

One	O
can	O
search	O
and	O
analyze	O
gene	O
sequences	O
by	O
Gene	O
ID	O
,	O
Gene	O
name	O
or	O
symbol	O
,	O
accession	O
number	O
or	O
GI	O
number	O
for	O
an	O
NCBI	O
nucleotide	O
sequence	O
entry	O
.	O

The	O
user	O
can	O
opt	O
to	O
change	O
the	O
maximum	O
length	O
of	O
QGRS	O
that	O
will	O
be	O
searched	O
for	O
(	O
the	O
default	O
maximum	O
length	O
being	O
30	O
)	O
and	O
change	O
the	O
minimum	O
sized	O
G	O
-	O
group	O
(	O
which	O
is	O
two	O
by	O
default	O
)	O
.	O

Also	O
,	O
the	O
user	O
can	O
specify	O
that	O
the	O
loops	O
in	O
the	O
QGRS	O
fall	O
within	O
a	O
given	O
size	O
range	O
and	O
that	O
one	O
or	O
more	O
loops	O
of	O
the	O
QGRS	O
contain	O
a	O
given	O
string	O
(	O
for	O
which	O
the	O
user	O
may	O
enter	O
a	O
regular	O
expression	O
)	O
.	O

The	O
web	O
page	O
for	O
QGRS	O
analysis	O
can	O
be	O
seen	O
in	O
Figure	O
1	O
.	O

After	O
entering	O
a	O
sequence	O
in	O
raw	O
or	O
FASTA	O
format	O
,	O
QGRS	O
Mapper	O
will	O
search	O
the	O
sequence	O
for	O
occurrences	O
of	O
QGRS	O
.	O

The	O
user	O
may	O
enter	O
any	O
combination	O
of	O
the	O
letters	O
A	O
,	O
C	O
,	O
T	O
,	O
G	O
,	O
U	O
,	O
N	O
.	O

The	O
Gene	O
ID	O
field	O
allows	O
the	O
user	O
to	O
search	O
the	O
NCBI	O
Entrez	O
Gene	O
database	O
.	O

QGRS	O
Mapper	O
will	O
connect	O
to	O
NCBI	O
,	O
download	O
and	O
parse	O
the	O
gene	O
entry	O
,	O
and	O
then	O
analyze	O
the	O
transcribed	O
region	O
of	O
its	O
nucleotide	O
sequence	O
for	O
the	O
presence	O
of	O
QGRS	O
.	O

For	O
example	O
,	O
entering	O
the	O
gene	O
ID	O
403437	O
results	O
in	O
downloading	O
the	O
Brca1	O
gene	O
sequence	O
for	O
Canis	B-LIVB
familiaris	I-LIVB
.	O

Using	O
the	O
default	O
QGRS	O
search	O
parameters	O
,	O
QGRS	O
Mapper	O
finds	O
156	O
non	O
-	O
overlapping	O
QGRS	O
and	O
3394	O
overlapping	O
QGRS	O
in	O
the	O
transcribed	O
region	O
of	O
this	O
gene	O
.	O

The	O
Gene	O
Name	O
or	O
Gene	O
Symbol	O
field	O
also	O
allows	O
the	O
user	O
to	O
search	O
the	O
NCBI	O
databases	O
for	O
all	O
such	O
genes	O
.	O

Entering	O
the	O
gene	O
name	O
Bcl2	O
results	O
in	O
nine	O
different	O
hits	O
which	O
are	O
displayed	O
in	O
Table	O
3	O
.	O

All	O
nine	O
of	O
these	O
entries	O
can	O
be	O
analyzed	O
for	O
the	O
occurrence	O
of	O
QGRS	O
.	O

Clicking	O
on	O
the	O
Gene	O
ID	O
takes	O
the	O
user	O
to	O
the	O
respective	O
Entrez	O
Gene	O
entry	O
.	O

Clicking	O
on	O
the	O
last	O
column	O
initiates	O
analysis	O
of	O
the	O
selection	O
by	O
QGRS	O
Mapper	O
.	O

Similarly	O
,	O
the	O
user	O
can	O
also	O
enter	O
an	O
NCBI	O
accession	O
number	O
to	O
search	O
for	O
gene	O
sequences	O
.	O

For	O
example	O
,	O
searching	O
the	O
accession	O
number	O
AF312033	O
results	O
in	O
12	O
hits	O
being	O
displayed	O
for	O
this	O
GenBank	O
nucleotide	O
sequence	O
entry	O
.	O

The	O
search	O
phase	O
of	O
the	O
program	O
is	O
followed	O
by	O
an	O
analysis	O
of	O
the	O
QGRS	O
contained	O
in	O
the	O
query	O
sequence	O
.	O

In	O
this	O
phase	O
of	O
QGRS	O
Mapper	O
,	O
the	O
sequence	O
data	O
downloaded	O
previously	O
is	O
analyzed	O
to	O
identify	O
and	O
map	O
all	O
QGRS	O
relative	O
to	O
locations	O
such	O
as	O
splice	O
sites	O
in	O
exons	O
/	O
introns	O
,	O
and	O
poly	O
(	O
A	O
)	O
site	O
(	O
if	O
these	O
locations	O
are	O
known	O
)	O
.	O

Furthermore	O
the	O
QGRS	O
are	O
scored	O
by	O
the	O
method	O
described	O
above	O
.	O

The	O
computed	O
G	O
-	O
score	O
is	O
used	O
to	O
eliminate	O
overlapping	O
QGRS	O
.	O

At	O
times	O
,	O
QGRS	O
Mapper	O
must	O
analyze	O
a	O
considerable	O
amount	O
of	O
data	O
.	O

For	O
example	O
,	O
the	O
mouse	B-LIVB
version	O
of	O
the	O
gene	O
PTPRU	O
,	O
which	O
is	O
69822	O
bases	O
long	O
,	O
contains	O
94681	O
QGRS	O
of	O
length	O
up	O
to	O
45	O
bases	O
.	O

QGRS	O
Mapper	O
will	O
find	O
,	O
analyze	O
and	O
map	O
all	O
of	O
these	O
sequences	O
.	O

During	O
this	O
analysis	O
a	O
message	O
is	O
displayed	O
indicating	O
the	O
estimated	O
time	O
left	O
to	O
completion	O
.	O

QGRS	O
Mapper	O
output	O

After	O
the	O
analysis	O
of	O
overlaps	O
is	O
completed	O
,	O
QGRS	O
Mapper	O
displays	O
a	O
summary	O
of	O
its	O
findings	O
,	O
in	O
the	O
Gene	O
View	O
.	O

This	O
summary	O
includes	O
basic	O
gene	O
information	O
such	O
as	O
the	O
gene	O
ID	O
,	O
gene	O
symbol	O
,	O
gene	O
name	O
,	O
a	O
link	O
to	O
the	O
NCBI	O
entry	O
,	O
organism	O
name	O
,	O
chromosome	O
number	O
and	O
number	O
of	O
products	O
and	O
poly	O
(	O
A	O
)	O
signals	O
.	O

Information	O
is	O
also	O
given	O
for	O
each	O
product	O
,	O
such	O
as	O
the	O
number	O
of	O
exons	O
and	O
introns	O
,	O
number	O
of	O
QGRS	O
(	O
non	O
-	O
overlapping	O
and	O
overlapping	O
)	O
,	O
number	O
of	O
QGRS	O
found	O
near	O
RNA	O
processing	O
sites	O
,	O
and	O
a	O
visual	O
map	O
of	O
the	O
product	O
.	O

As	O
an	O
example	O
,	O
the	O
Gene	O
View	O
for	O
the	O
human	B-LIVB
GREB1	O
is	O
displayed	O
in	O
Figure	O
2	O
,	O
showing	O
the	O
table	O
of	O
gene	O
information	O
and	O
product	O
information	O
for	O
the	O
first	O
product	O
(	O
the	O
output	O
for	O
all	O
products	O
may	O
be	O
seen	O
in	O
the	O
supplementary	O
material	O
)	O
.	O

At	O
this	O
stage	O
in	O
the	O
analysis	O
the	O
user	O
can	O
choose	O
among	O
three	O
further	O
displays	O
:	O
'	O
Data	O
View	O
'	O
,	O
'	O
Data	O
View	O
(	O
with	O
overlaps	O
)	O
'	O
and	O
'	O
Graphics	O
View	O
'	O
.	O

This	O
can	O
be	O
done	O
for	O
the	O
entire	O
gene	O
or	O
for	O
any	O
particular	O
product	O
.	O

In	O
the	O
Data	O
View	O
,	O
a	O
table	O
is	O
displayed	O
showing	O
information	O
for	O
each	O
of	O
the	O
set	O
of	O
non	O
-	O
overlapping	O
QGRS	O
.	O

This	O
table	O
displays	O
the	O
position	O
of	O
the	O
QGRS	O
,	O
which	O
exon	O
/	O
intron	O
it	O
appears	O
in	O
,	O
its	O
distance	O
from	O
3	O
'	O
and	O
5	O
'	O
splice	O
sites	O
,	O
the	O
QGRS	O
sequence	O
(	O
with	O
each	O
G	O
-	O
group	O
underlined	O
)	O
and	O
the	O
corresponding	O
G	O
-	O
score	O
.	O

Similar	O
display	O
is	O
also	O
shown	O
for	O
each	O
QGRS	O
mapped	O
to	O
poly	O
(	O
A	O
)	O
region	O
in	O
the	O
product	O
.	O

If	O
the	O
user	O
requests	O
the	O
Data	O
View	O
for	O
the	O
entire	O
gene	O
,	O
then	O
the	O
QGRS	O
information	O
is	O
shown	O
for	O
each	O
product	O
.	O

The	O
'	O
Data	O
View	O
(	O
with	O
overlaps	O
)	O
'	O
gives	O
the	O
same	O
information	O
but	O
shows	O
the	O
locations	O
of	O
all	O
QGRS	O
.	O

Figure	O
3	O
shows	O
the	O
Data	O
View	O
for	O
product	O
1	O
of	O
the	O
GREB1	O
gene	O
.	O

The	O
user	O
can	O
also	O
choose	O
the	O
Graphics	O
View	O
to	O
give	O
a	O
visual	O
display	O
of	O
the	O
location	O
of	O
QGRS	O
.	O

This	O
allows	O
the	O
user	O
to	O
see	O
the	O
location	O
of	O
QGRS	O
relative	O
to	O
exons	O
and	O
introns	O
(	O
if	O
that	O
information	O
is	O
available	O
)	O
.	O

The	O
Graphics	O
View	O
has	O
the	O
following	O
components	O
.	O

A	O
graphic	O
display	O
of	O
the	O
entire	O
gene	O
(	O
showing	O
the	O
location	O
of	O
the	O
exons	O
)	O
.	O

This	O
display	O
includes	O
a	O
sliding	O
window	O
that	O
can	O
be	O
used	O
to	O
focus	O
on	O
any	O
particular	O
segment	O
of	O
the	O
gene	O
.	O

This	O
window	O
may	O
be	O
dragged	O
to	O
the	O
left	O
or	O
right	O
to	O
change	O
position	O
within	O
the	O
gene	O
.	O
A	O
magnified	O
view	O
of	O
the	O
fragment	O
of	O
the	O
gene	O
within	O
the	O
sliding	O
window	O
.	O
A	O
graph	O
showing	O
the	O
location	O
of	O
QGRS	O
within	O
the	O
fragment	O
,	O
with	O
each	O
QGRS	O
being	O
displayed	O
by	O
a	O
bar	O
whose	O
height	O
represents	O
its	O
G	O
-	O
score	O
.	O
A	O
vertical	O
slider	O
that	O
allows	O
the	O
user	O
to	O
change	O
the	O
size	O
of	O
the	O
window	O
.	O

This	O
allows	O
the	O
user	O
to	O
zoom	O
in	O
or	O
out	O
on	O
any	O
part	O
of	O
the	O
gene	O
.	O

The	O
sliding	O
window	O
on	O
the	O
gene	O
expands	O
or	O
contracts	O
as	O
one	O
zooms	O
in	O
or	O
out	O
.	O

It	O
is	O
possible	O
to	O
see	O
the	O
nucleotide	O
sequence	O
of	O
the	O
product	O
at	O
maximum	O
zoom	O
levels	O
.	O

The	O
Graphics	O
View	O
for	O
the	O
entire	O
gene	O
shows	O
the	O
G	O
-	O
score	O
graph	O
together	O
with	O
an	O
exon	O
/	O
intron	O
map	O
for	O
each	O
product	O
.	O

This	O
allows	O
the	O
user	O
to	O
visually	O
compare	O
the	O
location	O
of	O
QGRS	O
for	O
each	O
product	O
relative	O
to	O
that	O
of	O
splice	O
sites	O
.	O

The	O
Graphics	O
View	O
for	O
the	O
first	O
product	O
of	O
the	O
GREB1	O
gene	O
is	O
represented	O
in	O
Figure	O
4	O
.	O

The	O
Graphics	O
View	O
for	O
the	O
entire	O
GREB1	O
gene	O
may	O
be	O
seen	O
in	O
the	O
Supplementary	O
Data	O
.	O

CONCLUSIONS	O

QGRS	O
Mapper	O
is	O
a	O
user	O
-	O
friendly	O
web	O
-	O
based	O
server	O
that	O
provides	O
computational	O
tools	O
for	O
prediction	O
of	O
Quadruplex	O
forming	O
G	O
-	O
rich	O
sequences	O
in	O
the	O
nucleotide	O
sequences	O
identified	O
or	O
provided	O
by	O
the	O
user	O
.	O

The	O
program	O
offers	O
many	O
options	O
,	O
including	O
user	O
-	O
defined	O
composition	O
of	O
the	O
quadruplex	O
.	O

It	O
can	O
analyze	O
DNA	O
or	O
RNA	O
sequence	O
provided	O
by	O
the	O
user	O
in	O
the	O
raw	O
or	O
FASTA	O
format	O
.	O

The	O
application	O
also	O
provides	O
tools	O
for	O
searching	O
and	O
retrieving	O
gene	O
/	O
nucleotide	O
entries	O
from	O
a	O
variety	O
of	O
NCBI	O
databases	O
.	O

There	O
are	O
several	O
options	O
for	O
data	O
output	O
format	O
,	O
including	O
an	O
interactive	O
graphic	O
module	O
.	O

Researchers	O
interested	O
in	O
evaluating	O
the	O
ability	O
of	O
nucleotide	O
sequences	O
to	O
form	O
unimolecular	O
G	O
-	O
quadruplexes	O
will	O
find	O
QGRS	O
Mapper	O
to	O
be	O
very	O
useful	O
.	O

Owing	O
to	O
the	O
flexible	O
and	O
comprehensive	O
nature	O
of	O
the	O
design	O
,	O
it	O
is	O
expected	O
to	O
serve	O
a	O
variety	O
of	O
scientists	O
.	O

The	O
application	O
will	O
be	O
especially	O
attractive	O
to	O
individuals	O
interested	O
in	O
exploring	O
the	O
role	O
of	O
G	O
-	O
quadruplexes	O
in	O
regulated	O
RNA	O
processing	O
.	O

We	O
are	O
using	O
the	O
server	O
to	O
perform	O
a	O
large	O
-	O
scale	O
analysis	O
of	O
alternatively	O
processed	O
mammalian	O
transcripts	O
.	O

We	O
are	O
particularly	O
interested	O
in	O
studying	O
the	O
composition	O
and	O
distribution	O
patterns	O
of	O
G	O
-	O
quadruplexes	O
in	O
the	O
transcribed	O
regions	O
of	O
mammalian	O
genes	O
.	O

SUPPLEMENTARY	O
DATA	O

Supplementary	O
Data	O
are	O
available	O
at	O
NAR	O
online	O
.	O

Drug	O
information	O
resources	O
used	O
by	O
nurse	O
practitioners	O
and	O
collaborating	O
physicians	O
at	O
the	O
point	O
of	O
care	O
in	O
Nova	O
Scotia	O
,	O
Canada	O
:	O
a	O
survey	O
and	O
review	O
of	O
the	O
literature	O

Abstract	O

Background	O

Keeping	O
current	O
with	O
drug	O
therapy	O
information	O
is	O
challenging	O
for	O
health	O
care	O
practitioners	O
.	O

Technologies	O
are	O
often	O
implemented	O
to	O
facilitate	O
access	O
to	O
current	O
and	O
credible	O
drug	O
information	O
sources	O
.	O

In	O
the	O
Canadian	O
province	O
of	O
Nova	O
Scotia	O
,	O
legislation	O
was	O
passed	O
in	O
2002	O
to	O
allow	O
nurse	O
practitioners	O
(	O
NPs	O
)	O
to	O
practice	O
collaboratively	O
with	O
physician	O
partners	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
current	O
utilization	O
patterns	O
of	O
information	O
technologies	O
by	O
these	O
groups	O
of	O
practitioners	O
.	O

Methods	O

Nurse	O
practitioners	O
and	O
their	O
collaborating	O
physician	O
partners	O
in	O
Nova	O
Scotia	O
were	O
sent	O
a	O
survey	O
in	O
February	O
2005	O
to	O
determine	O
the	O
frequency	O
of	O
use	O
,	O
usefulness	O
,	O
accessibility	O
,	O
credibility	O
,	O
and	O
current	O
/	O
timeliness	O
of	O
personal	O
digital	O
assistant	O
(	O
PDA	O
)	O
,	O
computer	O
,	O
and	O
print	O
drug	O
information	O
resources	O
.	O

Two	O
surveys	O
were	O
developed	O
(	O
one	O
for	O
PDA	O
users	O
and	O
one	O
for	O
computer	O
users	O
)	O
and	O
revised	O
based	O
on	O
a	O
literature	O
search	O
,	O
stakeholder	O
consultation	O
,	O
and	O
pilot	O
-	O
testing	O
results	O
.	O

A	O
second	O
distribution	O
to	O
nonresponders	O
occurred	O
two	O
weeks	O
following	O
the	O
first	O
.	O

Data	O
were	O
entered	O
and	O
analysed	O
with	O
SPSS	O
.	O

Results	O

Twenty	O
-	O
seven	O
(	O
14	O
NPs	O
and	O
13	O
physicians	O
)	O
of	O
36	O
(	O
75	O
%	O
)	O
recipients	O
responded	O
.	O

22	O
%	O
(	O
6	O
)	O
returned	O
personal	O
digital	O
assistant	O
(	O
PDA	O
)	O
surveys	O
.	O

Respondents	O
reported	O
print	O
,	O
health	O
professionals	O
,	O
and	O
online	O
/	O
electronic	O
resources	O
as	O
the	O
most	O
to	O
least	O
preferred	O
means	O
to	O
access	O
drug	O
information	O
,	O
respectively	O
.	O

37	O
%	O
and	O
35	O
%	O
of	O
respondents	O
reported	O
using	O
"	O
both	O
print	O
and	O
electronic	O
but	O
print	O
more	O
than	O
electronic	O
"	O
and	O
"	O
print	O
only	O
"	O
,	O
respectively	O
,	O
to	O
search	O
monograph	O
-	O
related	O
drug	O
information	O
queries	O
whereas	O
4	O
%	O
reported	O
using	O
"	O
PDA	O
only	O
"	O
.	O

Analysis	O
of	O
respondent	O
ratings	O
for	O
all	O
resources	O
in	O
the	O
categories	O
print	O
,	O
health	O
professionals	O
and	O
other	O
,	O
and	O
online	O
/	O
electronic	O
resources	O
,	O
indicated	O
that	O
the	O
Compendium	O
of	O
Pharmaceuticals	O
and	O
Specialties	O
and	O
pharmacists	O
ranked	O
highly	O
for	O
frequency	O
of	O
use	O
,	O
usefulness	O
,	O
accessibility	O
,	O
credibility	O
,	O
and	O
current	O
/	O
timeliness	O
by	O
both	O
groups	O
of	O
practitioners	O
.	O

Respondents	O
'	O
preferences	O
and	O
resource	O
ratings	O
were	O
consistent	O
with	O
self	O
-	O
reported	O
methods	O
for	O
conducting	O
drug	O
information	O
queries	O
.	O

Few	O
differences	O
existed	O
between	O
NP	O
and	O
physician	O
rankings	O
of	O
resources	O
.	O

Conclusion	O

The	O
use	O
of	O
computers	O
and	O
PDAs	O
remains	O
limited	O
,	O
which	O
is	O
also	O
consistent	O
with	O
preferred	O
and	O
frequent	O
use	O
of	O
print	O
resources	O
.	O

Education	O
for	O
these	O
practitioners	O
regarding	O
available	O
electronic	O
drug	O
information	O
resources	O
may	O
facilitate	O
future	O
computer	O
and	O
PDA	O
use	O
.	O

Further	O
research	O
is	O
needed	O
to	O
determine	O
methods	O
to	O
increase	O
computer	O
and	O
PDA	O
use	O
and	O
whether	O
these	O
technologies	O
affect	O
prescribing	O
and	O
patient	B-LIVB
outcomes	O
.	O

Background	O

Challenges	O
with	O
knowledge	O
management	O
for	O
health	O
care	O
professionals	O

In	O
1986	O
,	O
Haynes	O
et	O
al	O
.	O
published	O
a	O
series	O
of	O
6	O
articles	O
entitled	O
"	O
how	O
to	O
keep	O
up	O
with	O
the	O
medical	O
literature	O
"	O
in	O
an	O
effort	O
to	O
help	O
clinicians	O
with	O
information	O
management	O
,	O
but	O
this	O
challenge	O
has	O
not	O
decreased	O
in	O
last	O
two	O
decades	O
[	O
1	O
-	O
6	O
]	O
.	O

Alper	O
et	O
al	O
.	O
suggest	O
that	O
maintaining	O
currency	O
with	O
relevant	O
literature	O
in	O
primary	O
care	O
would	O
"	O
require	O
627	O
.	O
5	O
hours	O
per	O
month	O
,	O
or	O
about	O
29	O
hours	O
per	O
weekday	O
,	O
or	O
3	O
.	O
6	O
full	O
-	O
time	O
equivalents	O
of	O
physician	O
effort	O
"	O
[	O
7	O
]	O
.	O

The	O
volume	O
of	O
information	O
associated	O
with	O
keeping	O
up	O
to	O
date	O
is	O
frequently	O
cited	O
as	O
a	O
barrier	O
[	O
8	O
]	O
.	O

It	O
is	O
estimated	O
that	O
annually	O
there	O
are	O
approximately	O
10	O
,	O
000	O
new	O
randomized	O
trials	O
in	O
MEDLINE	O
and	O
over	O
450	O
,	O
000	O
clinical	O
trials	O
identified	O
by	O
the	O
Cochrane	O
Collaboration	O
[	O
9	O
,	O
10	O
]	O
.	O

Keeping	O
up	O
to	O
date	O
has	O
been	O
described	O
with	O
several	O
analogies	O
including	O
clinicians	O
attempting	O
to	O
drink	O
water	O
from	O
a	O
fire	O
hose	O
and	O
swimming	O
in	O
rivers	O
of	O
clinical	O
research	O
with	O
unprecedented	O
depth	O
,	O
velocity	O
,	O
and	O
turbulence	O
[	O
11	O
,	O
12	O
]	O
.	O

Difficulties	O
with	O
dissemination	O
of	O
research	O
evidence	O
and	O
keeping	O
up	O
to	O
date	O
on	O
pharmacotherapeutic	O
interventions	O
are	O
reported	O
despite	O
the	O
development	O
of	O
tools	O
such	O
as	O
clinical	O
practice	O
guidelines	O
and	O
systematic	O
reviews	O
that	O
are	O
intended	O
to	O
reduce	O
the	O
need	O
for	O
practitioners	O
to	O
evaluate	O
original	O
research	O
[	O
13	O
]	O
.	O

To	O
complicate	O
matters	O
further	O
,	O
there	O
are	O
often	O
issues	O
of	O
credibility	O
,	O
timeliness	O
,	O
and	O
volume	O
of	O
clinical	O
practice	O
guidelines	O
and	O
reviews	O
.	O

Many	O
guidelines	O
are	O
criticized	O
for	O
their	O
methodological	O
development	O
.	O

Shaneyfelt	O
et	O
al	O
.	O
reviewed	O
279	O
guidelines	O
for	O
methodological	O
standards	O
from	O
peer	O
reviewed	O
medical	O
literature	O
[	O
14	O
]	O
.	O

These	O
authors	O
found	O
that	O
only	O
51	O
%	O
,	O
33	O
.	O
6	O
%	O
,	O
and	O
46	O
%	O
adhered	O
to	O
standards	O
on	O
guideline	O
development	O
and	O
format	O
,	O
evidence	O
identification	O
and	O
summary	O
,	O
and	O
formulation	O
of	O
recommendations	O
,	O
respectively	O
[	O
14	O
]	O
.	O

A	O
Canadian	O
review	O
on	O
drug	O
therapy	O
guidelines	O
found	O
significant	O
variation	O
in	O
quality	O
depending	O
on	O
the	O
developer	O
[	O
13	O
]	O
.	O

Approximately	O
25	O
%	O
of	O
guidelines	O
were	O
not	O
recommended	O
for	O
use	O
in	O
practice	O
by	O
the	O
appraisers	O
'	O
criteria	O
[	O
13	O
]	O
.	O

As	O
an	O
example	O
of	O
the	O
volume	O
of	O
clinical	O
practice	O
guidelines	O
available	O
,	O
eleven	O
recent	O
guidelines	O
on	O
community	O
acquired	O
pneumonia	O
exist	O
[	O
15	O
]	O
.	O

To	O
add	O
to	O
the	O
complexities	O
involved	O
with	O
keeping	O
current	O
with	O
pharmacotherapeutic	O
management	O
strategies	O
,	O
as	O
of	O
2000	O
,	O
there	O
were	O
over	O
22	O
,	O
000	O
drug	O
products	O
approved	O
for	O
sale	O
in	O
Canada	O
for	O
human	B-LIVB
use	O
[	O
16	O
]	O
.	O

There	O
is	O
also	O
considerable	O
debate	O
regarding	O
what	O
constitutes	O
"	O
evidence	O
"	O
in	O
practice	O
,	O
which	O
contributes	O
to	O
confusion	O
for	O
clinicians	O
[	O
17	O
,	O
18	O
]	O
.	O

Sim	O
et	O
al	O
.	O
succinctly	O
describe	O
the	O
gap	O
between	O
evidence	O
and	O
action	O
as	O
difficulties	O
with	O
obtaining	O
,	O
systematically	O
reviewing	O
,	O
applying	O
in	O
context	O
,	O
and	O
measuring	O
the	O
outcome	O
following	O
application	O
of	O
evidence	O
[	O
19	O
]	O
.	O

Maintaining	O
competence	O
-	O
nurse	O
practitioners	O
as	O
a	O
new	O
group	O
of	O
prescribers	O

Competencies	O
for	O
nurse	O
practitioners	O
(	O
NPs	O
)	O
on	O
a	O
local	O
and	O
international	O
level	O
include	O
critically	O
appraising	O
and	O
applying	O
literature	O
and	O
research	O
findings	O
in	O
practice	O
[	O
20	O
-	O
23	O
]	O
.	O

The	O
Canadian	O
Nurses	O
Association	O
(	O
CNA	O
)	O
has	O
developed	O
the	O
Canadian	O
Nurse	O
Practitioner	O
Core	O
Competency	O
Framework	O
that	O
describes	O
the	O
knowledge	O
,	O
skills	O
,	O
judgment	O
,	O
and	O
attributes	O
required	O
for	O
practice	O
.	O

Evidence	O
based	O
practice	O
is	O
integral	O
to	O
pharmacotherapeutic	O
interventions	O
and	O
prescribing	O
competencies	O
[	O
23	O
]	O
.	O

The	O
National	O
Prescribing	O
Centre	O
,	O
an	O
organization	O
of	O
the	O
National	O
Health	O
Service	O
in	O
the	O
UK	O
,	O
describes	O
several	O
competencies	O
around	O
information	O
needs	O
relevant	O
to	O
prescribing	O
and	O
emphasis	O
is	O
placed	O
on	O
using	O
relevant	O
and	O
up	O
to	O
date	O
information	O
in	O
various	O
formats	O
(	O
e	O
.	O
g	O
.	O
print	O
,	O
electronic	O
,	O
verbal	O
)	O
.	O

Several	O
related	O
competencies	O
include	O
understanding	O
advantages	O
and	O
disadvantages	O
of	O
information	O
sources	O
and	O
the	O
currency	O
of	O
resources	O
[	O
21	O
]	O
.	O

Researchers	O
in	O
the	O
US	O
developed	O
NP	O
informatics	O
competencies	O
for	O
integration	O
into	O
advanced	O
nursing	O
practice	O
curricula	O
[	O
24	O
]	O
.	O

Competencies	O
related	O
to	O
informatics	O
knowledge	O
include	O
critical	O
analysis	O
of	O
data	O
and	O
information	O
for	O
use	O
in	O
evidence	O
based	O
practice	O
,	O
evaluating	O
and	O
applying	O
relevant	O
information	O
,	O
synthesizing	O
best	O
evidence	O
,	O
and	O
using	O
optimal	O
search	O
strategies	O
to	O
locate	O
clinically	O
sound	O
and	O
useful	O
studies	O
from	O
information	O
resources	O
[	O
24	O
]	O
.	O

Achieving	O
and	O
maintaining	O
competence	O
in	O
these	O
domains	O
as	O
well	O
as	O
a	O
solid	O
foundation	O
in	O
pharmacology	O
is	O
necessary	O
to	O
support	O
NPs	O
in	O
their	O
relatively	O
new	O
role	O
as	O
a	O
prescriber	O
[	O
25	O
-	O
27	O
]	O
.	O

Knowledge	O
management	O
and	O
information	O
seeking	O
behaviours	O
among	O
nurse	O
practitioners	O
and	O
physicians	O

Information	O
seeking	O
behaviours	O
of	O
physicians	O
are	O
better	O
documented	O
than	O
NPs	O
[	O
11	O
]	O
.	O

Information	O
related	O
to	O
diagnosis	O
is	O
important	O
to	O
both	O
groups	O
but	O
drug	O
therapy	O
queries	O
may	O
occur	O
more	O
frequently	O
with	O
NPs	O
[	O
28	O
-	O
33	O
]	O
.	O

Research	O
on	O
nurses	O
'	O
behaviours	O
related	O
to	O
information	O
seeking	O
is	O
available	O
from	O
the	O
hospital	O
setting	O
[	O
33	O
-	O
35	O
]	O
but	O
the	O
generalizability	O
of	O
these	O
behaviours	O
to	O
NPs	O
with	O
a	O
prescribing	O
role	O
is	O
unclear	O
.	O

Differences	O
in	O
nursing	O
roles	O
,	O
responsibilities	O
,	O
and	O
legislation	O
,	O
including	O
prescriptive	O
authority	O
,	O
exist	O
depending	O
on	O
the	O
country	O
of	O
practice	O
.	O

Nurse	O
practitioners	O
and	O
their	O
collaborating	O
physician	O
partners	O
in	O
Nova	O
Scotia	O

Nova	O
Scotia	O
is	O
a	O
Canadian	O
province	O
with	O
a	O
population	O
of	O
approximately	O
942	O
,	O
000	O
[	O
36	O
]	O
.	O

The	O
province	O
is	O
divided	O
into	O
six	O
health	O
zones	O
that	O
include	O
nine	O
district	O
health	O
authorities	O
,	O
one	O
of	O
which	O
includes	O
the	O
provincial	O
capital	O
and	O
is	O
considered	O
to	O
be	O
urban	O
[	O
37	O
,	O
38	O
]	O
.	O

Health	O
care	O
service	O
delivery	O
is	O
challenging	O
due	O
to	O
many	O
factors	O
including	O
the	O
rural	O
nature	O
of	O
the	O
province	O
,	O
which	O
is	O
estimated	O
to	O
be	O
60	O
%	O
of	O
population	O
[	O
37	O
,	O
39	O
]	O
.	O

Starting	O
in	O
1998	O
,	O
the	O
Nova	O
Scotia	O
Department	O
of	O
Health	O
led	O
an	O
initiative	O
to	O
explore	O
different	O
methods	O
of	O
delivering	O
,	O
managing	O
,	O
and	O
funding	O
primary	O
care	O
services	O
.	O

The	O
Strengthening	O
Primary	O
Care	O
in	O
Nova	O
Scotia	O
Communities	O
Initiative	O
(	O
SPCI	O
)	O
was	O
established	O
with	O
the	O
selection	O
of	O
four	O
primary	O
care	O
demonstration	O
sites	O
where	O
a	O
primary	O
health	O
care	O
NP	O
was	O
hired	O
to	O
practice	O
collaboratively	O
with	O
one	O
or	O
more	O
family	O
/	O
general	O
physicians	O
and	O
other	O
members	O
of	O
an	O
interdisciplinary	O
team	O
.	O

Each	O
demonstration	O
site	O
adopted	O
alternative	O
(	O
non	O
fee	O
-	O
for	O
-	O
service	O
)	O
physician	O
payment	O
mechanisms	O
and	O
used	O
electronic	O
patient	B-LIVB
records	O
(	O
EPRs	O
)	O
to	O
support	O
service	O
delivery	O
[	O
41	O
]	O
.	O

Demonstration	O
sites	O
participated	O
in	O
project	O
evaluation	O
components	O
that	O
included	O
,	O
but	O
were	O
not	O
limited	O
to	O
,	O
NP	O
roles	O
,	O
alternative	O
fee	O
structures	O
,	O
consumer	O
satisfaction	O
,	O
and	O
implementation	O
and	O
integration	O
of	O
EPRs	O
[	O
41	O
,	O
42	O
]	O
.	O

Legislation	O
to	O
allow	O
NPs	O
to	O
practice	O
collaboratively	O
with	O
physicians	O
in	O
Nova	O
Scotia	O
was	O
passed	O
in	O
2002	O
,	O
part	O
way	O
through	O
the	O
SPCI	O
project	O
[	O
39	O
]	O
.	O

Prescriptive	O
authority	O
granted	O
through	O
legislation	O
authorizes	O
NPs	O
to	O
prescribe	O
from	O
a	O
schedule	O
of	O
drugs	O
[	O
43	O
,	O
44	O
]	O
.	O

At	O
the	O
time	O
of	O
conducting	O
this	O
research	O
project	O
,	O
16	O
primary	O
health	O
care	O
NPs	O
were	O
in	O
active	O
practice	O
[	O
43	O
]	O
.	O

The	O
EPR	O
component	O
of	O
the	O
SPCI	O
project	O
evaluation	O
provided	O
information	O
on	O
the	O
use	O
of	O
technologies	O
in	O
the	O
community	O
context	O
.	O

Results	O
from	O
the	O
implementation	O
process	O
indicated	O
that	O
considerable	O
attention	O
is	O
required	O
for	O
technology	O
literacy	O
,	O
time	O
for	O
training	O
,	O
and	O
selection	O
of	O
software	O
for	O
EPRs	O
[	O
41	O
]	O
.	O

Although	O
the	O
majority	O
of	O
community	O
-	O
based	O
,	O
non	O
-	O
institutional	O
clinical	O
practice	O
settings	O
in	O
Nova	O
Scotia	O
primarily	O
operate	O
with	O
paper	O
-	O
based	O
charting	O
systems	O
,	O
there	O
is	O
a	O
movement	O
toward	O
integrating	O
electronic	O
technologies	O
,	O
including	O
the	O
EPR	O
,	O
in	O
practice	O
among	O
health	O
care	O
providers	O
,	O
administrators	O
,	O
and	O
the	O
provincial	O
government	O
.	O

In	O
addition	O
to	O
recording	O
patient	B-LIVB
visit	O
information	O
,	O
a	O
component	O
of	O
the	O
EPR	O
package	O
serves	O
to	O
provide	O
drug	O
information	O
resources	O
.	O

Drug	O
therapy	O
information	O
resources	O
for	O
NPs	O
and	O
nurse	O
prescribers	O
have	O
frequently	O
been	O
described	O
as	O
essential	O
in	O
supporting	O
practice	O
[	O
25	O
,	O
28	O
,	O
29	O
]	O
.	O

The	O
role	O
of	O
NPs	O
is	O
relatively	O
new	O
in	O
Canada	O
[	O
39	O
]	O
and	O
there	O
is	O
limited	O
information	O
available	O
to	O
indicate	O
the	O
type	O
of	O
resources	O
(	O
e	O
.	O
g	O
.	O
print	O
,	O
electronic	O
,	O
EPR	O
based	O
)	O
these	O
prescribers	O
use	O
for	O
drug	O
and	O
therapeutic	O
information	O
queries	O
at	O
the	O
point	O
of	O
care	O
.	O

It	O
is	O
unknown	O
as	O
to	O
whether	O
differences	O
exist	O
regarding	O
types	O
of	O
resources	O
used	O
,	O
drug	O
information	O
needs	O
,	O
and	O
utilization	O
patterns	O
among	O
NPs	O
and	O
collaborating	O
physician	O
partners	O
.	O

Some	O
research	O
has	O
suggested	O
that	O
the	O
degree	O
of	O
multidisciplinary	O
team	O
functioning	O
relates	O
to	O
the	O
adoption	O
of	O
technology	O
or	O
innovations	O
in	O
practice	O
but	O
more	O
research	O
is	O
required	O
to	O
determine	O
the	O
extent	O
of	O
these	O
relationships	O
[	O
45	O
,	O
46	O
]	O
.	O

The	O
use	O
of	O
EPR	O
technology	O
is	O
increasing	O
in	O
Nova	O
Scotia	O
but	O
little	O
information	O
is	O
available	O
regarding	O
the	O
readiness	O
of	O
practitioners	O
for	O
use	O
of	O
specific	O
features	O
such	O
as	O
drug	O
information	O
resources	O
.	O

Based	O
on	O
the	O
EPR	O
related	O
results	O
of	O
the	O
SPCI	O
evaluation	O
,	O
use	O
of	O
these	O
functions	O
could	O
be	O
challenging	O
without	O
proper	O
facilitation	O
.	O

The	O
purpose	O
of	O
the	O
survey	O
for	O
this	O
research	O
was	O
to	O
describe	O
drug	O
information	O
resources	O
used	O
by	O
NPs	O
and	O
their	O
collaborating	O
physician	O
partners	O
at	O
the	O
point	O
of	O
care	O
.	O

The	O
results	O
of	O
the	O
survey	O
will	O
be	O
used	O
to	O
guide	O
further	O
technology	O
implementation	O
strategies	O
and	O
stimulate	O
further	O
discussion	O
around	O
drug	O
information	O
resource	O
usage	O
at	O
the	O
point	O
of	O
care	O
.	O

Methods	O

Survey	O
development	O

Survey	O
development	O
involved	O
three	O
stages	O
including	O
identification	O
of	O
important	O
content	O
areas	O
,	O
development	O
of	O
draft	O
questions	O
,	O
and	O
survey	O
refinement	O
.	O

Identifying	O
important	O
content	O
areas	O
for	O
inclusion	O
in	O
the	O
survey	O
involved	O
conducting	O
a	O
comprehensive	O
English	O
language	O
literature	O
search	O
,	O
consultation	O
with	O
relevant	O
stakeholders	O
(	O
e	O
.	O
g	O
.	O
members	O
of	O
the	O
Nova	O
Scotia	O
Department	O
of	O
Health	O
)	O
,	O
and	O
input	O
from	O
subject	O
matter	O
experts	O
at	O
Dalhousie	O
University	O
.	O

The	O
literature	O
review	O
was	O
conducted	O
using	O
the	O
following	O
bibliographic	O
databases	O
:	O
PubMed	O
,	O
Cumulative	O
Index	O
to	O
Nursing	O
and	O
Allied	O
Health	O
Literature	O
(	O
CINAHL	O
)	O
,	O
International	O
Pharmaceutical	O
Abstracts	O
(	O
IPA	O
)	O
,	O
and	O
Web	O
of	O
Science	O
Citation	O
Databases	O
.	O

Hand	O
and	O
electronic	O
searching	O
of	O
relevant	O
journals	O
was	O
also	O
conducted	O
.	O

Broad	O
search	O
terms	O
were	O
used	O
without	O
limits	O
on	O
publication	O
date	O
or	O
place	O
as	O
nurse	O
practitioner	O
titles	O
,	O
roles	O
and	O
scopes	O
of	O
practice	O
,	O
and	O
terminology	O
regarding	O
technology	O
vary	O
nationally	O
and	O
internationally	O
.	O

Some	O
examples	O
of	O
terms	O
used	O
included	O
nurse	O
practitioner	O
,	O
nurse	O
prescriber	O
,	O
nurse	O
clinicians	O
,	O
district	O
nurse	O
,	O
health	O
visitor	O
,	O
drug	O
information	O
resources	O
,	O
drug	O
information	O
services	O
,	O
information	O
needs	O
,	O
and	O
information	O
technology	O
.	O

The	O
draft	O
survey	O
was	O
reviewed	O
by	O
the	O
research	O
team	O
to	O
reduce	O
the	O
number	O
of	O
items	O
and	O
improve	O
clarity	O
.	O

The	O
layout	O
of	O
the	O
questionnaire	O
was	O
carefully	O
examined	O
to	O
ensure	O
that	O
it	O
was	O
easy	O
to	O
follow	O
and	O
complete	O
.	O

Research	O
results	O
from	O
a	O
previous	O
investigation	O
of	O
Nova	O
Scotian	O
physicians	O
'	O
behaviours	O
regarding	O
drug	O
information	O
were	O
also	O
used	O
to	O
further	O
revise	O
the	O
survey	O
[	O
47	O
]	O
.	O

This	O
draft	O
questionnaire	O
was	O
pilot	O
tested	O
by	O
two	O
out	O
of	O
province	O
NPs	O
and	O
one	O
physician	O
.	O

The	O
results	O
of	O
the	O
pilot	O
were	O
used	O
to	O
make	O
final	O
revisions	O
to	O
the	O
survey	O
.	O

Based	O
on	O
pilot	O
-	O
testing	O
feedback	O
and	O
investigator	O
consensus	O
,	O
the	O
final	O
survey	O
was	O
divided	O
into	O
2	O
versions	O
,	O
one	O
for	O
personal	O
digital	O
assistant	O
(	O
PDA	O
)	O
users	O
and	O
one	O
for	O
computer	O
users	O
.	O

The	O
10	O
page	O
surveys	O
for	O
PDA	O
and	O
computer	O
users	O
had	O
5	O
or	O
6	O
sections	O
,	O
respectively	O
,	O
and	O
37	O
questions	O
,	O
many	O
with	O
multiple	O
parts	O
.	O

The	O
survey	O
content	O
included	O
demographics	O
,	O
computer	O
or	O
PDA	O
use	O
and	O
experience	O
,	O
drug	O
and	O
therapeutic	O
resource	O
use	O
and	O
preferences	O
,	O
PDA	O
future	O
use	O
,	O
perceived	O
barriers	O
and	O
facilitators	O
to	O
PDA	O
use	O
,	O
and	O
technology	O
training	O
preferences	O
.	O

Section	O
one	O
contained	O
demographic	O
questions	O
such	O
as	O
gender	O
,	O
age	O
,	O
job	O
title	O
,	O
volume	O
of	O
patients	B-LIVB
,	O
and	O
EPR	O
availability	O
in	O
the	O
practice	O
setting	O
.	O

Section	O
two	O
was	O
designed	O
to	O
determine	O
PDA	O
or	O
computer	O
use	O
and	O
experience	O
in	O
the	O
practice	O
setting	O
with	O
questions	O
regarding	O
length	O
of	O
use	O
,	O
costs	O
,	O
and	O
work	O
versus	O
home	O
usage	O
.	O

This	O
section	O
also	O
addressed	O
usage	O
and	O
rating	O
of	O
different	O
drug	O
information	O
resources	O
.	O

Resource	O
ratings	O
were	O
based	O
on	O
the	O
frequency	O
of	O
usage	O
,	O
usefulness	O
,	O
accessibility	O
,	O
credibility	O
,	O
and	O
current	O
/	O
timeliness	O
.	O

Resources	O
were	O
grouped	O
as	O
print	O
(	O
i	O
.	O
e	O
.	O
books	O
,	O
journals	O
,	O
and	O
clinical	O
practice	O
guidelines	O
)	O
,	O
online	O
/	O
electronic	O
resources	O
,	O
and	O
health	O
professionals	O
and	O
other	O
.	O

Respondents	O
used	O
5	O
-	O
point	O
Likert	O
scales	O
(	O
strongly	O
agree	O
to	O
strongly	O
disagree	O
)	O
for	O
rating	O
opinions	O
related	O
to	O
resources	O
.	O

A	O
rating	O
of	O
6	O
(	O
not	O
applicable	O
,	O
I	O
do	O
not	O
use	O
this	O
resource	O
)	O
was	O
also	O
included	O
for	O
respondents	O
who	O
did	O
not	O
use	O
a	O
particular	O
resource	O
.	O

Frequency	O
of	O
searching	O
for	O
specific	O
information	O
was	O
rated	O
on	O
a	O
3	O
-	O
point	O
Likert	O
scale	O
(	O
frequently	O
to	O
never	O
)	O
.	O

The	O
final	O
sections	O
of	O
the	O
survey	O
included	O
categorical	O
,	O
open	O
-	O
ended	O
,	O
and	O
Likert	O
scale	O
questions	O
regarding	O
preferred	O
resources	O
,	O
technology	O
barriers	O
,	O
PDA	O
future	O
use	O
,	O
and	O
technology	O
training	O
preferences	O
.	O

Copies	O
of	O
the	O
surveys	O
are	O
attached	O
as	O
an	O
appendix	O
in	O
PDF	O
format	O
[	O
see	O
additional	O
file	O
1	O
and	O
2	O
]	O
or	O
can	O
also	O
be	O
accessed	O
from	O
the	O
Initiative	O
for	O
Medication	O
Management	O
,	O
Policy	O
Analysis	O
,	O
Research	O
&	O
Training	O
(	O
IMPART	O
)	O
website	O
[	O
48	O
]	O
.	O

Ethics	O
approval	O
for	O
the	O
survey	O
was	O
granted	O
through	O
Dalhousie	O
University	O
Research	O
Ethics	O
Board	O
on	O
February	O
3	O
,	O
2005	O
.	O

Survey	O
population	O

Licensed	O
,	O
actively	O
practicing	O
,	O
primary	O
health	O
care	O
NPs	O
(	O
n	O
=	O
16	O
)	O
and	O
their	O
collaborating	O
physician	O
partners	O
(	O
n	O
=	O
21	O
)	O
were	O
eligible	O
to	O
participate	O
.	O

Survey	O
procedures	O

The	O
survey	O
recruitment	O
procedures	O
were	O
based	O
on	O
the	O
methods	O
of	O
Dillman	O
[	O
49	O
]	O
and	O
Salant	O
and	O
Dillman	O
[	O
50	O
]	O
.	O

Survey	O
packages	O
contained	O
a	O
cover	O
letter	O
,	O
separate	O
surveys	O
for	O
PDA	O
and	O
computer	O
users	O
,	O
and	O
a	O
return	O
self	O
-	O
addressed	O
stamped	O
envelope	O
.	O

The	O
covering	O
letter	O
instructed	O
respondents	O
to	O
self	O
-	O
select	O
the	O
appropriate	O
survey	O
(	O
either	O
PDA	O
or	O
computer	O
)	O
based	O
on	O
their	O
drug	O
information	O
seeking	O
behaviours	O
.	O

Participants	B-LIVB
who	O
had	O
used	O
a	O
PDA	O
at	O
any	O
time	O
were	O
instructed	O
to	O
complete	O
the	O
PDA	O
version	O
of	O
the	O
survey	O
.	O

Those	O
who	O
had	O
never	O
used	O
a	O
PDA	O
for	O
drug	O
information	O
were	O
instructed	O
to	O
complete	O
the	O
computer	O
version	O
of	O
the	O
survey	O
.	O

Several	O
strategies	O
were	O
used	O
to	O
optimize	O
response	O
rate	O
and	O
included	O
:	O
personalized	O
cover	O
letters	O
,	O
coloured	O
paper	O
for	O
surveys	O
,	O
stamped	O
return	O
envelopes	O
,	O
follow	O
-	O
up	O
mailing	O
,	O
and	O
a	O
priority	O
post	O
mailing	O
[	O
51	O
]	O
.	O

The	O
covering	O
letter	O
included	O
coloured	O
logos	O
of	O
Dalhousie	O
University	O
and	O
the	O
Nova	O
Scotia	O
Department	O
of	O
Health	O
representing	O
the	O
investigator	O
affiliations	O
and	O
endorsement	O
of	O
the	O
project	O
.	O

A	O
master	O
mailing	O
list	O
with	O
names	O
and	O
addresses	O
of	O
NPs	O
and	O
their	O
collaborating	O
physician	O
partners	O
was	O
created	O
.	O

To	O
maintain	O
confidentiality	O
of	O
respondents	O
,	O
a	O
number	O
placed	O
on	O
the	O
bottom	O
right	O
corner	O
of	O
each	O
survey	O
corresponded	O
to	O
a	O
name	O
on	O
the	O
confidential	O
master	O
mailing	O
sheet	O
.	O

The	O
postage	O
paid	O
return	O
envelopes	O
were	O
addressed	O
to	O
the	O
research	O
coordinator	O
at	O
the	O
School	O
of	O
Nursing	O
,	O
Dalhousie	O
University	O
,	O
who	O
matched	O
respondents	O
to	O
the	O
mailing	O
list	O
from	O
the	O
first	O
distribution	O
.	O

The	O
cross	O
-	O
referenced	O
mailing	O
list	O
was	O
not	O
accessible	O
to	O
those	O
entering	O
or	O
analysing	O
data	O
.	O

The	O
research	O
coordinator	O
sent	O
the	O
second	O
distribution	O
to	O
those	O
who	O
had	O
not	O
initially	O
responded	O
.	O

A	O
fluorescent	O
coloured	O
page	O
was	O
included	O
in	O
the	O
second	O
mailing	O
to	O
notify	O
recipients	O
of	O
the	O
second	O
and	O
final	O
mailing	O
status	O
.	O

The	O
second	O
mailing	O
followed	O
2	O
weeks	O
after	O
the	O
initial	O
mailing	O
(	O
February	O
2005	O
)	O
.	O

The	O
surveys	O
were	O
sent	O
via	O
Xpresspost	O
(TM)	O
through	O
Canada	O
Post	O
.	O

Data	O
analyses	O

Quantitative	O

Data	O
were	O
entered	O
and	O
analysed	O
in	O
Statistical	O
Package	O
for	O
Social	O
Sciences	O
(	O
SPSS	O
)	O
(	O
version	O
11	O
.	O
5	O
for	O
Windows	O
)	O
.	O

Five	O
surveys	O
were	O
randomly	O
selected	O
as	O
a	O
check	O
for	O
accuracy	O
of	O
data	O
entry	O
.	O

Descriptive	O
statistics	O
were	O
used	O
to	O
describe	O
resource	O
usage	O
by	O
practitioners	O
.	O

Chi	O
Square	O
(	O
Fisher	O
'	O
s	O
Exact	O
when	O
cell	O
count	O
less	O
than	O
5	O
)	O
analyses	O
were	O
used	O
to	O
determine	O
differences	O
in	O
computer	O
or	O
PDA	O
use	O
based	O
on	O
predetermined	O
variables	O
(	O
e	O
.	O
g	O
.	O
high	O
speed	O
Internet	O
connection	O
,	O
number	O
of	O
patients	B-LIVB
per	O
day	O
)	O
.	O

Mann	O
Whitney	O
U	O
tests	O
were	O
used	O
to	O
compare	O
physician	O
and	O
NPs	O
Likert	O
scale	O
ratings	O
(	O
1	O
=	O
strongly	O
agree	O
to	O
5	O
=	O
strongly	O
disagree	O
)	O
of	O
resource	O
use	O
.	O

Physician	O
and	O
NP	O
rankings	O
of	O
all	O
resources	O
(	O
print	O
,	O
online	O
/	O
electronic	O
,	O
and	O
health	O
professionals	O
and	O
other	O
)	O
were	O
determined	O
from	O
means	O
of	O
Likert	O
scale	O
ratings	O
(	O
1	O
=	O
strongly	O
agree	O
,	O
5	O
=	O
strongly	O
disagree	O
)	O
for	O
each	O
of	O
the	O
pre	O
-	O
specified	O
characteristics	O
(	O
e	O
.	O
g	O
.	O
frequency	O
of	O
use	O
,	O
accessibility	O
,	O
etc	O
.	O
)	O
and	O
the	O
frequency	O
of	O
use	O
of	O
the	O
resources	O
.	O

The	O
best	O
rankings	O
were	O
assigned	O
for	O
the	O
lowest	O
mean	O
scores	O
and	O
the	O
largest	O
number	O
of	O
the	O
sample	O
using	O
a	O
resource	O
.	O

These	O
rankings	O
(	O
ranks	O
based	O
on	O
mean	O
and	O
ranks	O
based	O
on	O
sample	O
)	O
were	O
then	O
entered	O
into	O
a	O
formula	O
to	O
calculate	O
an	O
overall	O
rank	O
.	O

The	O
formula	O
includes	O
:	O
rank	O
=	O
[	O
(	O
rank	O
according	O
to	O
%	O
of	O
sample	O
using	O
the	O
resource	O
+	O
rank	O
based	O
on	O
mean	O
score	O
)	O
/	O
2	O
]	O
.	O

This	O
formula	O
was	O
used	O
to	O
account	O
for	O
mean	O
scores	O
based	O
on	O
small	O
samples	O
as	O
these	O
numbers	O
could	O
potentially	O
over	O
or	O
underestimate	O
the	O
value	O
of	O
a	O
resource	O
.	O

Ratings	O
of	O
6	O
(	O
i	O
.	O
e	O
.	O
not	O
applicable	O
,	O
I	O
do	O
not	O
use	O
this	O
resource	O
)	O
were	O
excluded	O
from	O
the	O
analyses	O
.	O

Qualitative	O

Comments	O
were	O
entered	O
in	O
a	O
word	O
-	O
processing	O
program	O
and	O
organized	O
by	O
type	O
of	O
respondent	O
(	O
PDA	O
versus	O
computer	O
)	O
and	O
question	O
number	O
.	O

The	O
coded	O
survey	O
number	O
and	O
respondent	O
type	O
(	O
NP	O
or	O
physician	O
)	O
were	O
also	O
included	O
next	O
to	O
comments	O
.	O

Investigators	O
determined	O
themes	O
and	O
categorized	O
comments	O
based	O
on	O
previous	O
experience	O
,	O
knowledge	O
,	O
and	O
familiarity	O
with	O
the	O
topic	O
.	O

Results	O

Surveys	O
were	O
completed	O
and	O
returned	O
by	O
75	O
%	O
of	O
eligible	O
participants	B-LIVB
(	O
27	O
of	O
36	O
)	O
.	O

One	O
physician	O
survey	O
was	O
undeliverable	O
.	O

The	O
response	O
rates	O
from	O
within	O
the	O
NP	O
and	O
physician	O
samples	O
were	O
88	O
%	O
and	O
65	O
%	O
,	O
respectively	O
.	O

Complete	O
demographic	O
information	O
is	O
available	O
in	O
Table	O
1	O
.	O

Methods	O
for	O
accessing	O
resources	O
and	O
self	O
-	O
reported	O
resource	O
use	O

Resource	O
use	O
was	O
similar	O
amongst	O
practitioners	O
.	O

Respondents	O
indicated	O
that	O
print	O
resources	O
(	O
mean	O
4	O
.	O
56	O
,	O
SD	O
0	O
.	O
80	O
)	O
,	O
health	O
professionals	O
(	O
mean	O
3	O
.	O
26	O
,	O
SD	O
0	O
.	O
90	O
)	O
,	O
and	O
online	O
/	O
electronic	O
resources	O
(	O
mean	O
2	O
.	O
70	O
,	O
SD	O
1	O
.	O
20	O
)	O
were	O
the	O
preferred	O
method	O
(	O
1	O
=	O
least	O
preferred	O
to	O
5	O
=	O
most	O
preferred	O
)	O
for	O
accessing	O
drug	O
information	O
.	O

Thirty	O
-	O
seven	O
percent	O
of	O
respondents	O
reported	O
that	O
searching	O
for	O
specific	O
questions	O
related	O
to	O
drug	O
information	O
(	O
e	O
.	O
g	O
.	O
usual	O
dosage	O
,	O
duration	O
of	O
therapy	O
)	O
was	O
conducted	O
using	O
both	O
print	O
and	O
electronic	O
resources	O
(	O
but	O
print	O
use	O
greater	O
than	O
electronic	O
)	O
(	O
Table	O
2	O
)	O
.	O

The	O
preferred	O
means	O
(	O
i	O
.	O
e	O
.	O
print	O
)	O
to	O
access	O
resources	O
was	O
consistent	O
with	O
the	O
most	O
common	O
means	O
of	O
conducting	O
searches	O
for	O
specific	O
drug	O
information	O
queries	O
.	O

Respondents	O
'	O
ratings	O
for	O
pre	O
-	O
specified	O
print	O
,	O
online	O
/	O
electronic	O
,	O
and	O
professional	O
resources	O
and	O
other	O
,	O
based	O
on	O
means	O
from	O
Likert	O
scales	O
and	O
number	O
of	O
respondents	O
using	O
the	O
resources	O
,	O
are	O
presented	O
in	O
Tables	O
3	O
,	O
4	O
,	O
and	O
5	O
.	O

Of	O
all	O
resources	O
within	O
the	O
print	O
,	O
online	O
/	O
electronic	O
,	O
and	O
health	O
professionals	O
or	O
other	O
categories	O
,	O
NPs	O
and	O
physicians	O
rated	O
the	O
Compendium	O
of	O
Pharmaceuticals	O
and	O
Specialties	O
(	O
CPS	O
)	O
[	O
52	O
]	O
and	O
pharmacists	O
as	O
the	O
top	O
two	O
most	O
frequently	O
used	O
resources	O
for	O
providing	O
drug	O
and	O
therapeutic	O
information	O
.	O

Physicians	O
rated	O
other	O
physicians	O
as	O
the	O
third	O
most	O
frequently	O
used	O
resource	O
.	O

The	O
book	O
Therapeutic	O
Choices	O
[	O
53	O
]	O
ranked	O
third	O
for	O
NPs	O
.	O

Based	O
on	O
written	O
feedback	O
,	O
physicians	O
and	O
NPs	O
consulted	O
pharmacists	O
and	O
other	O
physicians	O
most	O
frequently	O
.	O

The	O
CPS	O
and	O
pharmacists	O
were	O
also	O
ranked	O
as	O
the	O
top	O
two	O
resources	O
overall	O
in	O
terms	O
of	O
usefulness	O
,	O
accessibility	O
,	O
credibility	O
,	O
and	O
current	O
/	O
timeliness	O
for	O
physicians	O
.	O

Rankings	O
by	O
NPs	O
were	O
similar	O
for	O
usefulness	O
,	O
accessibility	O
,	O
and	O
credibility	O
.	O

NPs	O
ranked	O
pharmacists	O
,	O
Therapeutic	O
Choices	O
,	O
and	O
academic	O
detailing	O
first	O
and	O
the	O
CPS	O
as	O
second	O
for	O
current	O
/	O
timeliness	O
.	O

Within	O
the	O
online	O
/	O
electronic	O
category	O
,	O
electronic	O
clinical	O
practice	O
guidelines	O
(	O
eCPGs	O
)	O
were	O
rated	O
the	O
highest	O
for	O
all	O
characteristics	O
(	O
e	O
.	O
g	O
.	O
usefulness	O
,	O
credibility	O
)	O
.	O

Although	O
eCPGs	O
were	O
highly	O
ranked	O
,	O
approximately	O
30	O
%	O
of	O
the	O
sample	O
reported	O
not	O
using	O
this	O
resource	O
.	O

Other	O
resources	O
in	O
this	O
category	O
were	O
infrequently	O
used	O
based	O
on	O
respondents	O
'	O
self	O
-	O
reports	O
.	O

Pharmaceutical	O
industry	O
representatives	O
were	O
used	O
as	O
a	O
source	O
of	O
drug	O
information	O
by	O
85	O
%	O
and	O
86	O
%	O
of	O
physicians	O
and	O
NPs	O
,	O
respectively	O
(	O
Table	O
5	O
)	O
.	O

This	O
was	O
higher	O
than	O
regional	O
drug	O
information	O
services	O
(	O
used	O
by	O
23	O
%	O
of	O
physicians	O
and	O
50	O
%	O
of	O
NPs	O
)	O
.	O

After	O
exclusion	O
of	O
traditional	O
health	O
professionals	O
(	O
i	O
.	O
e	O
.	O
physicians	O
,	O
nurses	O
,	O
pharmacists	O
,	O
allied	O
health	O
)	O
in	O
the	O
health	O
professionals	O
and	O
other	O
category	O
,	O
pharmaceutical	O
industry	O
representatives	O
received	O
rankings	O
for	O
second	O
or	O
third	O
for	O
frequency	O
of	O
use	O
,	O
usefulness	O
,	O
accessibility	O
,	O
credibility	O
,	O
and	O
current	O
/	O
timeliness	O
,	O
based	O
on	O
means	O
and	O
number	O
of	O
respondents	O
using	O
this	O
resource	O
(	O
data	O
not	O
shown	O
)	O
.	O

Differences	O
between	O
nurse	O
practitioners	O
and	O
physicians	O

A	O
series	O
of	O
Mann	O
Whitney	O
U	O
tests	O
were	O
used	O
to	O
compare	O
the	O
responses	O
of	O
NPs	O
and	O
physicians	O
on	O
their	O
use	O
of	O
print	O
,	O
online	O
/	O
electronic	O
,	O
and	O
health	O
professional	O
resources	O
.	O

In	O
total	O
95	O
statistical	O
tests	O
were	O
conducted	O
.	O

The	O
large	O
number	O
of	O
tests	O
increases	O
the	O
likelihood	O
of	O
a	O
type	O
I	O
error	O
as	O
five	O
significant	O
differences	O
would	O
be	O
expected	O
by	O
chance	O
alone	O
at	O
an	O
alpha	O
threshold	O
of	O
0	O
.	O
05	O
.	O

It	O
is	O
therefore	O
important	O
to	O
treat	O
these	O
results	O
with	O
caution	O
.	O

A	O
limited	O
number	O
of	O
statistically	O
significant	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
differences	O
were	O
identified	O
between	O
physicians	O
and	O
NPs	O
and	O
are	O
reported	O
in	O
Table	O
6	O
.	O

Therapeutic	O
Choices	O
differed	O
significantly	O
for	O
frequency	O
of	O
use	O
with	O
more	O
NPs	O
making	O
use	O
of	O
this	O
resource	O
.	O

Allied	O
health	O
professionals	O
significantly	O
differed	O
between	O
NPs	O
and	O
physicians	O
for	O
accessibility	O
and	O
current	O
/	O
timeliness	O
while	O
NPs	O
were	O
more	O
in	O
agreement	O
with	O
these	O
characteristics	O
of	O
the	O
resource	O
.	O

Nurse	O
colleague	O
credibility	O
and	O
current	O
/	O
timeliness	O
was	O
rated	O
significantly	O
higher	O
by	O
NPs	O
versus	O
physicians	O
.	O

Factors	O
influencing	O
electronic	O
technology	O
use	O
at	O
the	O
point	O
of	O
care	O

Factors	O
such	O
as	O
gender	O
,	O
age	O
,	O
practitioner	O
type	O
(	O
NP	O
vs	O
physician	O
)	O
,	O
accessibility	O
,	O
technical	O
support	O
,	O
Internet	O
connection	O
speed	O
,	O
patient	B-LIVB
volume	O
,	O
presence	O
of	O
an	O
EPR	O
,	O
and	O
home	O
computer	O
use	O
were	O
examined	O
to	O
determine	O
if	O
they	O
were	O
associated	O
with	O
the	O
use	O
of	O
a	O
work	O
computer	O
to	O
search	O
for	O
drug	O
information	O
at	O
the	O
point	O
of	O
care	O
.	O

No	O
statistically	O
significant	O
associations	O
were	O
found	O
(	O
Fisher	O
'	O
s	O
Exact	O
)	O
.	O

Additional	O
resources	O
from	O
respondent	O
comments	O

Respondents	O
indicated	O
other	O
resources	O
and	O
programs	O
,	O
such	O
as	O
clinical	O
calculators	O
,	O
that	O
they	O
would	O
like	O
to	O
access	O
from	O
their	O
computer	O
or	O
PDA	O
.	O

The	O
top	O
three	O
resources	O
that	O
were	O
desired	O
included	O
Canadian	O
clinical	O
practice	O
guidelines	O
,	O
patient	B-LIVB
education	O
information	O
,	O
and	O
ability	O
to	O
track	O
clinical	O
activities	O
/	O
statistics	O
.	O

Further	O
comments	O
from	O
two	O
NP	O
computer	O
survey	O
respondents	O
revealed	O
that	O
a	O
resource	O
on	O
drug	O
interactions	O
and	O
dosages	O
would	O
be	O
desired	O
.	O

One	O
other	O
NP	O
also	O
indicated	O
"	O
up	O
to	O
date	O
info	O
[	O
sic	O
]	O
on	O
drugs	O
to	O
treat	O
various	O
illnesses	O
ie	O
doseage	O
[	O
sic	O
]	O
,	O
length	O
of	O
use	O
etc	O
.	O
"	O

Computer	O
or	O
personal	O
digital	O
assistant	O
use	O
in	O
practice	O

Approximately	O
50	O
%	O
of	O
computer	O
survey	O
respondents	O
reported	O
using	O
their	O
work	O
computers	O
for	O
searching	O
drug	O
or	O
therapeutic	O
information	O
related	O
to	O
patient	B-LIVB
care	O
.	O

Of	O
those	O
respondents	O
,	O
just	O
over	O
half	O
(	O
54	O
%	O
)	O
also	O
reported	O
using	O
their	O
home	O
computer	O
for	O
this	O
purpose	O
.	O

Sixty	O
-	O
seven	O
and	O
17	O
%	O
of	O
PDA	O
survey	O
respondents	O
reported	O
using	O
their	O
PDA	O
for	O
searching	O
drug	O
or	O
therapeutic	O
information	O
related	O
to	O
patient	B-LIVB
care	O
at	O
work	O
and	O
home	O
,	O
respectively	O
.	O

Searching	O
on	O
a	O
weekly	O
basis	O
for	O
specific	O
information	O
related	O
to	O
drugs	O

Of	O
the	O
24	O
specified	O
categories	O
of	O
drug	O
information	O
included	O
in	O
the	O
survey	O
,	O
the	O
majority	O
were	O
reported	O
as	O
infrequently	O
searched	O
and	O
a	O
smaller	O
percentage	O
as	O
never	O
searched	O
by	O
respondents	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
top	O
three	O
categories	O
rated	O
as	O
frequently	O
searched	O
were	O
side	O
effects	O
,	O
adult	O
or	O
usual	O
drug	O
dosage	O
,	O
and	O
most	O
appropriate	O
drug	O
for	O
an	O
indication	O
.	O

(	O
Table	O
7	O
)	O

Issues	O
related	O
to	O
personal	O
digital	O
assistants	O

Respondents	O
reported	O
their	O
level	O
of	O
agreement	O
with	O
statements	O
related	O
to	O
how	O
PDAs	O
may	O
influence	O
their	O
practice	O
.	O

The	O
statements	O
included	O
aspects	O
of	O
workload	O
(	O
organization	O
and	O
paper	O
work	O
)	O
,	O
convenience	O
,	O
and	O
improving	O
quality	O
of	O
care	O
and	O
patient	B-LIVB
outcomes	O
.	O

(	O
Table	O
8	O
)	O
Respondents	O
agreed	O
that	O
PDAs	O
are	O
a	O
convenient	O
resource	O
but	O
indicated	O
that	O
PDAs	O
would	O
not	O
decrease	O
paperwork	O
or	O
improve	O
patient	B-LIVB
health	O
outcomes	O
.	O

Barriers	O
and	O
facilitators	O
to	O
personal	O
digital	O
assistants	O
:	O
themes	O
from	O
written	O
comments	O

Peer	O
support	O
from	O
colleagues	O
,	O
convenience	O
,	O
standardized	O
usage	O
,	O
and	O
financial	O
and	O
technical	O
support	O
were	O
the	O
main	O
perceived	O
facilitators	O
to	O
PDA	O
use	O
reported	O
by	O
respondents	O
.	O

The	O
main	O
perceived	O
barrier	O
to	O
PDA	O
use	O
reported	O
by	O
respondents	O
(	O
n	O
=	O
10	O
)	O
included	O
cost	O
.	O

Other	O
factors	O
such	O
as	O
technology	O
literacy	O
,	O
time	O
,	O
lack	O
of	O
peer	O
support	O
,	O
no	O
high	O
speed	O
internet	O
for	O
downloads	O
,	O
lack	O
of	O
needed	O
resources	O
,	O
keeping	O
up	O
to	O
date	O
on	O
resources	O
,	O
and	O
searching	O
speed	O
were	O
also	O
reported	O
.	O

Future	O
use	O
of	O
personal	O
digital	O
assistants	O

Fifty	O
-	O
two	O
percent	O
,	O
including	O
current	O
PDA	O
users	O
,	O
reported	O
that	O
they	O
would	O
use	O
a	O
PDA	O
in	O
the	O
future	O
.	O

Twenty	O
two	O
percent	O
were	O
uncertain	O
and	O
19	O
%	O
reported	O
that	O
they	O
would	O
not	O
use	O
a	O
PDA	O
in	O
the	O
future	O
.	O

Two	O
people	B-LIVB
did	O
not	O
respond	O
.	O

Confidentiality	O

Fifty	O
two	O
percent	O
of	O
respondents	O
indicated	O
that	O
patient	B-LIVB
confidentiality	O
with	O
PDAs	O
was	O
no	O
more	O
concerning	O
compared	O
to	O
use	O
of	O
other	O
technologies	O
.	O

Forty	O
-	O
four	O
percent	O
did	O
not	O
know	O
if	O
they	O
had	O
a	O
policy	O
on	O
patient	B-LIVB
confidentiality	O
with	O
regard	O
to	O
technologies	O
.	O

Technology	O
training	O
and	O
reimbursement	O

Respondents	O
rated	O
(	O
1	O
=	O
least	O
preferred	O
to	O
5	O
=	O
most	O
preferred	O
)	O
one	O
on	O
one	O
instruction	O
and	O
group	O
learning	O
led	O
by	O
an	O
expert	O
facilitator	O
as	O
the	O
most	O
preferred	O
(	O
mean	O
4	O
.	O
32	O
,	O
SD	O
0	O
.	O
99	O
)	O
means	O
by	O
which	O
to	O
receive	O
instruction	O
on	O
a	O
new	O
technology	O
.	O

Least	O
preferred	O
methods	O
included	O
online	O
discussions	O
/	O
chatrooms	O
(	O
mean	O
1	O
.	O
52	O
,	O
SD	O
1	O
.	O
04	O
)	O
,	O
internet	O
videos	O
(	O
live	O
:	O
mean	O
1	O
.	O
70	O
,	O
SD	O
1	O
.	O
10	O
,	O
or	O
static	O
:	O
mean	O
1	O
.	O
87	O
,	O
SD	O
1	O
.	O
14	O
)	O
,	O
video	O
cassettes	O
(	O
mean	O
2	O
.	O
30	O
,	O
SD	O
1	O
.	O
55	O
)	O
,	O
trial	O
and	O
error	O
learning	O
(	O
mean	O
2	O
.	O
32	O
,	O
SD	O
1	O
.	O
28	O
)	O
,	O
and	O
written	O
manuals	O
(	O
mean	O
2	O
.	O
92	O
,	O
SD	O
1	O
.	O
44	O
)	O
.	O

Paid	O
leave	O
for	O
attendance	O
at	O
technology	O
training	O
sessions	O
was	O
the	O
preferred	O
means	O
(	O
mean	O
1	O
.	O
77	O
,	O
SD	O
0	O
.	O
86	O
;	O
1	O
=	O
strongly	O
agree	O
to	O
5	O
=	O
strongly	O
disagree	O
)	O
of	O
remuneration	O
for	O
respondents	O
.	O

Respondents	O
also	O
indicated	O
that	O
if	O
financial	O
remuneration	O
was	O
to	O
occur	O
,	O
it	O
should	O
correspond	O
to	O
the	O
amount	O
of	O
time	O
for	O
training	O
that	O
is	O
required	O
(	O
versus	O
a	O
flat	O
rate	O
)	O
(	O
mean	O
1	O
.	O
96	O
,	O
SD	O
1	O
.	O
08	O
)	O
.	O

Continuing	O
education	O
credits	O
were	O
not	O
viewed	O
as	O
an	O
incentive	O
(	O
mean	O
2	O
.	O
69	O
,	O
SD	O
1	O
.	O
44	O
)	O
.	O

Discussion	O

Preferred	O
resources	O

In	O
our	O
study	O
,	O
printed	O
materials	O
(	O
e	O
.	O
g	O
.	O
compendia	O
,	O
journals	O
,	O
textbook	O
resources	O
)	O
and	O
professionals	O
(	O
e	O
.	O
g	O
.	O
pharmacists	O
)	O
were	O
the	O
most	O
preferred	O
and	O
frequently	O
used	O
means	O
to	O
access	O
information	O
.	O

Physician	O
reliance	O
on	O
text	O
and	O
compendia	O
relative	O
to	O
online	O
/	O
electronic	O
resources	O
has	O
been	O
frequently	O
reported	O
[	O
11	O
]	O
.	O

In	O
a	O
study	O
examining	O
family	O
doctors	O
'	O
use	O
of	O
information	O
sources	O
to	O
answer	O
clinical	O
questions	O
,	O
human	B-LIVB
resources	O
(	O
e	O
.	O
g	O
.	O
doctor	O
,	O
pharmacist	O
)	O
,	O
non	O
-	O
prescribing	O
print	O
information	O
(	O
e	O
.	O
g	O
.	O
textbooks	O
and	O
journal	O
articles	O
)	O
,	O
and	O
prescribing	O
texts	O
were	O
used	O
36	O
%	O
,	O
32	O
%	O
,	O
and	O
25	O
%	O
of	O
the	O
time	O
,	O
respectively	O
[	O
54	O
]	O
.	O

Books	O
from	O
the	O
workplace	O
were	O
reported	O
by	O
approximately	O
79	O
%	O
of	O
UK	O
primary	O
care	O
nurses	O
as	O
a	O
commonly	O
used	O
source	O
of	O
knowledge	O
and	O
information	O
used	O
to	O
support	O
practice	O
[	O
55	O
]	O
.	O

Fewer	O
than	O
one	O
-	O
third	O
(	O
31	O
%	O
)	O
reported	O
using	O
electronic	O
resources	O
(	O
e	O
.	O
g	O
.	O
Internet	O
,	O
electronic	O
journals	O
)	O
for	O
this	O
purpose	O
[	O
55	O
]	O
.	O

Results	O
of	O
a	O
postal	O
questionnaire	O
to	O
NPs	O
demonstrated	O
that	O
61	O
%	O
and	O
51	O
%	O
of	O
respondents	O
reported	O
using	O
drug	O
reference	O
manuals	O
and	O
textbooks	O
,	O
respectively	O
,	O
a	O
few	O
times	O
a	O
week	O
or	O
more	O
[	O
29	O
]	O
.	O

These	O
frequencies	O
were	O
second	O
and	O
third	O
only	O
to	O
consulting	O
with	O
their	O
physician	O
supervisor	O
(	O
63	O
%	O
)	O
.	O

Data	O
from	O
structured	O
interviews	O
of	O
a	O
sample	O
of	O
22	O
community	O
nurse	O
prescribers	O
reported	O
by	O
Hall	O
et	O
al	O
.	O
revealed	O
that	O
the	O
majority	O
relied	O
on	O
print	O
materials	O
to	O
access	O
information	O
,	O
namely	O
the	O
British	O
National	O
Formulary	O
[	O
32	O
]	O
.	O

A	O
survey	O
of	O
a	O
primary	O
care	O
practice	O
-	O
based	O
research	O
network	O
in	O
the	O
US	O
that	O
included	O
physicians	O
,	O
physician	O
assistants	O
,	O
and	O
nurse	O
practitioners	O
,	O
revealed	O
that	O
interpersonal	O
and	O
rapidly	O
accessed	O
print	O
resources	O
were	O
preferred	O
.	O

Sixty	O
-	O
one	O
and	O
58	O
%	O
of	O
respondents	O
reported	O
using	O
drug	O
reference	O
sources	O
such	O
as	O
the	O
Physician	O
'	O
s	O
Desk	O
Reference	O
(	O
PDR	O
)	O
and	O
medical	O
textbooks	O
,	O
respectively	O
,	O
a	O
few	O
times	O
a	O
day	O
or	O
daily	O
[	O
56	O
]	O
.	O

The	O
clinicians	O
in	O
our	O
sample	O
perceived	O
the	O
Canadian	O
compendium	O
,	O
the	O
CPS	O
,	O
to	O
be	O
useful	O
,	O
accessible	O
,	O
credible	O
,	O
and	O
current	O
/	O
timely	O
.	O

The	O
CPS	O
,	O
is	O
described	O
as	O
"	O
the	O
Canadian	O
drug	O
reference	O
for	O
health	O
professionals	O
"	O
and	O
is	O
intended	O
to	O
provide	O
a	O
central	O
source	O
of	O
drug	O
information	O
on	O
drug	O
products	O
available	O
in	O
Canada	O
[	O
52	O
]	O
.	O

It	O
is	O
available	O
in	O
print	O
(	O
English	O
and	O
French	O
)	O
and	O
became	O
available	O
online	O
in	O
June	O
2004	O
.	O

The	O
CPS	O
includes	O
drug	O
monographs	O
for	O
commonly	O
used	O
products	O
approved	O
for	O
use	O
in	O
Canada	O
,	O
but	O
it	O
does	O
not	O
include	O
all	O
drugs	O
available	O
on	O
the	O
Canadian	O
market	O
[	O
57	O
]	O
.	O

The	O
majority	O
of	O
these	O
product	O
monographs	O
are	O
based	O
on	O
monographs	O
submitted	O
by	O
pharmaceutical	O
manufacturers	O
and	O
approved	O
by	O
Health	O
Canada	O
.	O

Some	O
of	O
the	O
monographs	O
are	O
written	O
by	O
the	O
Canadian	O
Pharmacists	O
Association	O
and	O
are	O
described	O
as	O
being	O
evidence	O
-	O
based	O
[	O
52	O
]	O
.	O

The	O
CPS	O
also	O
includes	O
more	O
than	O
100	O
pages	O
of	O
clinical	O
tools	O
[	O
52	O
]	O
.	O

The	O
CPS	O
has	O
been	O
criticized	O
for	O
including	O
pharmaceutical	O
company	O
advertising	O
and	O
requiring	O
manufacturer	O
payment	O
for	O
inclusion	O
of	O
product	O
monographs	O
[	O
58	O
]	O
.	O

The	O
accuracy	O
of	O
particular	O
components	O
of	O
CPS	O
monographs	O
has	O
also	O
been	O
investigated	O
.	O

A	O
review	O
of	O
overdose	O
management	O
in	O
119	O
monographs	O
from	O
the	O
2001	O
CPS	O
revealed	O
considerable	O
variability	O
in	O
the	O
utility	O
of	O
information	O
with	O
50	O
%	O
of	O
the	O
monographs	O
containing	O
misleading	O
or	O
dangerous	O
advice	O
[	O
59	O
]	O
.	O

Since	O
2004	O
,	O
the	O
CPS	O
has	O
included	O
an	O
alert	O
box	O
in	O
the	O
overdose	O
section	O
of	O
monographs	O
notifying	O
users	O
to	O
contact	O
Poison	O
Control	O
Centres	O
for	O
overdose	O
management	O
information	O
.	O

Some	O
authors	O
have	O
criticized	O
references	O
that	O
are	O
similar	O
to	O
the	O
CPS	O
as	O
being	O
inadequate	O
with	O
regard	O
to	O
inclusion	O
of	O
evidence	O
based	O
information	O
[	O
60	O
]	O
.	O

The	O
NPs	O
in	O
our	O
sample	O
also	O
rated	O
Therapeutic	O
Choices	O
highly	O
for	O
all	O
characteristics	O
.	O

This	O
finding	O
is	O
most	O
likely	O
attributable	O
to	O
the	O
fact	O
that	O
it	O
is	O
a	O
recommended	O
resource	O
for	O
coursework	O
associated	O
with	O
the	O
Dalhousie	O
NP	O
university	O
program	O
curriculum	O
.	O

Therapeutic	O
Choices	O
is	O
a	O
concise	O
therapeutics	O
reference	O
text	O
published	O
by	O
the	O
Canadian	O
Pharmacists	O
Association	O
.	O

The	O
text	O
contains	O
approximately	O
120	O
extensively	O
referenced	O
chapters	O
with	O
a	O
disease	O
management	O
approach	O
including	O
easy	O
to	O
use	O
algorithms	O
and	O
tables	O
.	O

An	O
editorial	O
board	O
is	O
responsible	O
for	O
extensively	O
reviewing	O
the	O
content	O
to	O
ensure	O
unbiased	O
and	O
objective	O
information	O
is	O
presented	O
[	O
53	O
]	O
.	O

Health	O
professionals	O

Reliance	O
on	O
other	O
health	O
professionals	O
,	O
especially	O
pharmacists	O
and	O
physicians	O
,	O
as	O
a	O
resource	O
for	O
information	O
was	O
evident	O
from	O
our	O
study	O
and	O
concurs	O
with	O
the	O
findings	O
of	O
others	O
[	O
28	O
,	O
32	O
,	O
55	O
,	O
61	O
]	O
.	O

Nurse	O
practitioners	O
have	O
reported	O
that	O
collaborative	O
relationships	O
with	O
pharmacists	O
increase	O
NP	O
role	O
satisfaction	O
[	O
61	O
]	O
.	O

NPs	O
frequently	O
consult	O
with	O
allied	O
health	O
care	O
professionals	O
in	O
their	O
primary	O
health	O
care	O
provider	O
role	O
and	O
this	O
is	O
supported	O
by	O
written	O
feedback	O
from	O
our	O
sample	O
regarding	O
frequently	O
consulted	O
health	O
professionals	O
.	O

Nursing	O
colleagues	O
are	O
also	O
likely	O
to	O
be	O
rated	O
highly	O
by	O
NPs	O
due	O
to	O
their	O
affiliation	O
with	O
peers	O
from	O
the	O
same	O
profession	O
.	O

Some	O
investigators	O
have	O
shown	O
that	O
non	O
-	O
human	B-LIVB
references	O
(	O
e	O
.	O
g	O
.	O
textbook	O
)	O
are	O
sought	O
for	O
more	O
technical	O
aspects	O
of	O
prescribing	O
(	O
e	O
.	O
g	O
.	O
dose	O
)	O
,	O
whereas	O
guidance	O
regarding	O
selection	O
of	O
agents	O
(	O
i	O
.	O
e	O
.	O
right	O
drug	O
for	O
an	O
indication	O
)	O
is	O
sought	O
from	O
human	B-LIVB
resources	O
(	O
e	O
.	O
g	O
.	O
pharmacists	O
or	O
physicians	O
)	O
[	O
62	O
]	O
.	O

We	O
were	O
unable	O
to	O
determine	O
what	O
kinds	O
of	O
resources	O
were	O
used	O
for	O
specific	O
purposes	O
from	O
our	O
study	O
.	O

Online	O
and	O
electronic	O
resources	O
,	O
computers	O
,	O
and	O
personal	O
digital	O
assistants	O

From	O
our	O
study	O
,	O
computer	O
survey	O
respondents	O
ranked	O
online	O
/	O
electronic	O
resources	O
third	O
in	O
preference	O
following	O
print	O
and	O
health	O
professionals	O
.	O

Various	O
barriers	O
and	O
facilitators	O
to	O
accessing	O
information	O
online	O
/	O
electronically	O
or	O
via	O
the	O
Internet	O
have	O
been	O
described	O
in	O
the	O
literature	O
[	O
55	O
,	O
63	O
-	O
66	O
]	O
.	O

Variables	O
that	O
have	O
been	O
described	O
by	O
others	O
as	O
barriers	O
such	O
as	O
accessibility	O
,	O
high	O
speed	O
internet	O
access	O
,	O
patient	B-LIVB
volume	O
,	O
age	O
,	O
practitioner	O
type	O
,	O
and	O
technology	O
support	O
did	O
not	O
appear	O
to	O
influence	O
computer	O
searching	O
for	O
information	O
on	O
drugs	O
or	O
therapeutics	O
related	O
to	O
patient	B-LIVB
care	O
in	O
our	O
results	O
.	O

Some	O
qualitative	O
feedback	O
does	O
however	O
support	O
this	O
notion	O
.	O

As	O
an	O
example	O
,	O
in	O
response	O
to	O
a	O
request	O
for	O
a	O
rationale	O
for	O
not	O
using	O
computers	O
one	O
physician	O
commented	O
:	O
"	O
Retro	O
tech	O
[	O
sic	O
]	O
/	O
old	O
fashion	O
.	O

I	O
still	O
like	O
to	O
use	O
my	O
mind	O
and	O
have	O
always	O
been	O
a	O
fan	O
of	O
pen	O
and	O
paper	O
"	O
.	O

Barriers	O
that	O
were	O
identified	O
with	O
our	O
sample	O
regarding	O
the	O
use	O
of	O
handheld	O
technologies	O
such	O
as	O
PDAs	O
included	O
cost	O
,	O
time	O
,	O
and	O
issues	O
related	O
to	O
technology	O
literacy	O
.	O

Several	O
people	B-LIVB
questioned	O
the	O
value	O
of	O
PDAs	O
.	O

One	O
GP	O
stated	O
when	O
referring	O
to	O
a	O
PDA	O
:	O
"	O
So	O
far	O
I	O
have	O
not	O
discovered	O
a	O
use	O
for	O
one	O
"	O
.	O

Other	O
respondents	O
reinforced	O
their	O
preferences	O
for	O
other	O
resources	O
(	O
e	O
.	O
g	O
.	O
books	O
)	O
and	O
resistance	O
to	O
technology	O
.	O

When	O
responding	O
to	O
barriers	O
for	O
the	O
use	O
of	O
PDAs	O
,	O
one	O
NP	O
commented	O
,	O
"	O
My	O
huge	O
dislike	O
for	O
machinery	O
that	O
frequently	O
requires	O
updating	O
and	O
patience	O
"	O
.	O

A	O
physician	O
responded	O
,	O
"	O
as	O
stated	O
,	O
I	O
like	O
to	O
use	O
my	O
own	O
mind	O
,	O
and	O
can	O
get	O
all	O
the	O
info	O
I	O
need	O
from	O
books	O
relatively	O
quickly	O
"	O
.	O

Facilitators	O
to	O
the	O
use	O
of	O
PDAs	O
mainly	O
included	O
convenience	O
factors	O
such	O
as	O
having	O
resources	O
all	O
in	O
one	O
place	O
,	O
faster	O
means	O
to	O
get	O
information	O
,	O
and	O
portability	O
.	O

Our	O
sample	O
was	O
not	O
in	O
agreement	O
with	O
some	O
convenience	O
factors	O
in	O
that	O
they	O
did	O
not	O
feel	O
that	O
PDAs	O
would	O
decrease	O
paperwork	O
.	O

Practitioners	O
from	O
our	O
sample	O
felt	O
relatively	O
neutral	O
about	O
PDAs	O
improving	O
patient	B-LIVB
'	O
s	O
health	O
outcomes	O
with	O
41	O
%	O
responding	O
in	O
this	O
manner	O
.	O

Results	O
from	O
a	O
sample	O
of	O
primary	O
care	O
practitioners	O
in	O
the	O
US	O
revealed	O
that	O
76	O
%	O
agreed	O
that	O
the	O
use	O
of	O
handheld	O
devices	O
for	O
electronic	O
prescribing	O
would	O
substantially	O
reduce	O
medical	O
errors	O
and	O
improve	O
the	O
quality	O
of	O
health	O
care	O
[	O
67	O
]	O
.	O

Our	O
study	O
also	O
suggests	O
that	O
resources	O
such	O
as	O
the	O
Cochrane	O
Library	O
and	O
its	O
Database	O
of	O
Systematic	O
Reviews	O
were	O
not	O
frequently	O
used	O
.	O

This	O
finding	O
is	O
similar	O
to	O
that	O
of	O
other	O
investigators	O
[	O
30	O
,	O
35	O
,	O
64	O
]	O
.	O

Despite	O
the	O
desire	O
of	O
some	O
clinicians	O
to	O
use	O
these	O
resources	O
,	O
lack	O
of	O
confidence	O
and	O
ability	O
to	O
use	O
them	O
appropriately	O
has	O
been	O
found	O
[	O
30	O
,	O
64	O
,	O
68	O
,	O
69	O
]	O
.	O

Our	O
study	O
suggests	O
that	O
although	O
this	O
resource	O
is	O
perceived	O
as	O
credible	O
,	O
current	O
/	O
timely	O
,	O
and	O
useful	O
,	O
it	O
is	O
also	O
perceived	O
to	O
be	O
somewhat	O
inaccessible	O
.	O

The	O
Cochrane	O
Library	O
is	O
available	O
to	O
the	O
health	O
professionals	O
(	O
e	O
.	O
g	O
.	O
nurses	O
,	O
physicians	O
,	O
pharmacists	O
,	O
occupational	O
therapists	O
,	O
physiotherapists	O
,	O
etc	O
.	O
)	O
in	O
our	O
sample	O
through	O
professional	O
bodies	O
via	O
the	O
Atlantic	O
Health	O
Knowledge	O
Partnership	O
[	O
70	O
]	O
.	O

Technology	O
training	O
:	O
preferences	O
and	O
incentives	O

With	O
regard	O
to	O
receiving	O
training	O
for	O
a	O
new	O
technology	O
,	O
our	O
study	O
demonstrates	O
that	O
in	O
person	B-LIVB
conferences	O
or	O
one	O
on	O
one	O
training	O
sessions	O
are	O
the	O
preferred	O
means	O
to	O
receive	O
continuing	O
education	O
.	O

Person	B-LIVB
to	O
person	B-LIVB
interaction	O
has	O
been	O
reported	O
as	O
the	O
preferred	O
and	O
most	O
frequently	O
used	O
means	O
to	O
access	O
continuing	O
education	O
or	O
training	O
by	O
other	O
investigators	O
[	O
55	O
,	O
71	O
]	O
.	O

Our	O
study	O
also	O
indicates	O
that	O
this	O
group	O
of	O
practitioners	O
may	O
benefit	O
from	O
accessing	O
resources	O
[	O
72	O
-	O
80	O
]	O
that	O
provide	O
guidance	O
on	O
useful	O
drug	O
information	O
resources	O
available	O
for	O
devices	O
such	O
as	O
PDAs	O
.	O

This	O
is	O
exemplified	O
by	O
one	O
respondent	O
'	O
s	O
statement	O
"	O
knowledge	O
regarding	O
good	O
software	O
programs	O
"	O
as	O
a	O
barrier	O
to	O
the	O
use	O
of	O
PDAs	O
.	O

Pharmaceutical	O
industry	O

The	O
influence	O
of	O
the	O
pharmaceutical	O
industry	O
on	O
physician	O
prescribing	O
and	O
research	O
outcomes	O
has	O
been	O
documented	O
[	O
81	O
,	O
82	O
]	O
.	O

Although	O
NP	O
use	O
of	O
industry	O
representatives	O
as	O
a	O
source	O
of	O
pharmacological	O
information	O
has	O
been	O
documented	O
,	O
the	O
influence	O
on	O
prescribing	O
is	O
largely	O
uninvestigated	O
[	O
32	O
,	O
61	O
,	O
83	O
-	O
85	O
]	O
.	O

The	O
CNA	O
competency	O
framework	O
includes	O
a	O
statement	O
regarding	O
prescribing	O
and	O
industry	O
relations	O
[	O
23	O
]	O
.	O

In	O
our	O
study	O
,	O
the	O
physician	O
and	O
NP	O
rankings	O
of	O
industry	O
representatives	O
were	O
similar	O
.	O

Within	O
the	O
health	O
professionals	O
and	O
other	O
category	O
,	O
pharmaceutical	O
representatives	O
were	O
used	O
as	O
a	O
resource	O
by	O
more	O
of	O
the	O
sample	O
than	O
regional	O
drug	O
information	O
services	O
and	O
comparably	O
to	O
academic	O
detailing	O
services	O
.	O

Academic	O
detailing	O
is	O
a	O
form	O
of	O
continuing	O
medical	O
education	O
where	O
a	O
trained	O
health	O
professional	O
visits	O
prescribers	O
for	O
a	O
fifteen	O
to	O
twenty	O
minute	O
session	O
to	O
provide	O
objective	O
information	O
regarding	O
a	O
therapeutic	O
topic	O
based	O
on	O
best	O
available	O
evidence	O
[	O
86	O
,	O
87	O
]	O
.	O

Following	O
academic	O
detailing	O
,	O
physician	O
and	O
NP	O
rankings	O
of	O
pharmaceutical	O
industry	O
representatives	O
were	O
second	O
or	O
third	O
for	O
frequency	O
of	O
use	O
,	O
usefulness	O
,	O
accessibility	O
,	O
credibility	O
,	O
and	O
current	O
/	O
timeliness	O
.	O

Limitations	O

We	O
do	O
not	O
have	O
demographics	O
or	O
information	O
regarding	O
the	O
reasons	O
why	O
survey	O
recipients	O
did	O
not	O
respond	O
.	O

As	O
per	O
ethical	O
requirements	O
to	O
maintain	O
confidentiality	O
of	O
respondents	O
,	O
we	O
were	O
not	O
able	O
to	O
match	O
respondents	O
from	O
their	O
respective	O
place	O
of	O
practice	O
and	O
therefore	O
cannot	O
conclude	O
whether	O
the	O
practitioners	O
within	O
a	O
practice	O
setting	O
influenced	O
the	O
others	O
'	O
responses	O
.	O

The	O
sample	O
size	O
of	O
the	O
survey	O
is	O
small	O
although	O
it	O
includes	O
88	O
%	O
response	O
from	O
community	O
based	O
NPs	O
in	O
Nova	O
Scotia	O
.	O

The	O
generalizability	O
of	O
the	O
results	O
is	O
limited	O
due	O
to	O
the	O
variations	O
in	O
NP	O
scopes	O
of	O
practice	O
nationally	O
and	O
internationally	O
.	O

It	O
is	O
unknown	O
whether	O
the	O
findings	O
are	O
generalizable	O
to	O
nonresponding	O
physicians	O
within	O
Nova	O
Scotia	O
collaborating	O
with	O
NPs	O
or	O
to	O
physicians	O
not	O
in	O
collaborative	O
practices	O
with	O
NPs	O
as	O
they	O
were	O
not	O
included	O
as	O
a	O
part	O
of	O
the	O
sample	O
.	O

Due	O
to	O
multiple	O
statistical	O
comparisons	O
(	O
Mann	O
Whitney	O
U	O
)	O
,	O
the	O
results	O
comparing	O
NP	O
and	O
physician	O
ratings	O
of	O
results	O
should	O
be	O
interpreted	O
with	O
caution	O
.	O

Conclusion	O

Respondent	O
ratings	O
of	O
resources	O
and	O
preferences	O
for	O
resource	O
use	O
were	O
consistent	O
with	O
self	O
-	O
reported	O
means	O
of	O
conducting	O
searches	O
for	O
specific	O
drug	O
information	O
queries	O
.	O

The	O
use	O
of	O
computers	O
and	O
PDAs	O
remains	O
limited	O
and	O
also	O
matches	O
preferences	O
and	O
resource	O
ratings	O
.	O

Education	O
to	O
this	O
group	O
of	O
practitioners	O
regarding	O
available	O
drug	O
information	O
resources	O
may	O
facilitate	O
use	O
of	O
computer	O
and	O
PDA	O
resources	O
.	O

Further	O
research	O
is	O
needed	O
to	O
determine	O
methods	O
to	O
increase	O
the	O
use	O
of	O
computers	O
and	O
PDAs	O
and	O
if	O
use	O
of	O
these	O
technologies	O
affects	O
prescribing	O
and	O
patient	B-LIVB
outcomes	O
.	O

Competing	O
interests	O

Ingrid	O
Sketris	O
holds	O
a	O
Chair	O
from	O
Canadian	O
Institutes	O
of	O
Health	O
Research	O
(	O
CIHR	O
)	O
,	O
Canadian	O
Health	O
Services	O
Research	O
Foundation	O
(	O
CHSRF	O
)	O
co	O
-	O
sponsored	O
by	O
the	O
Nova	O
Scotia	O
Health	O
Research	O
Foundation	O
(	O
NSHRF	O
)	O
.	O

Andrea	O
Murphy	O
received	O
salary	O
support	O
through	O
this	O
Chair	O
as	O
a	O
research	O
fellow	O
at	O
the	O
time	O
of	O
conducting	O
this	O
research	O
.	O

The	O
survey	O
was	O
performed	O
in	O
fulfillment	O
of	O
the	O
requirements	O
for	O
the	O
Drug	O
Use	O
Management	O
and	O
Policy	O
Residency	O
that	O
Murphy	O
participated	O
in	O
as	O
a	O
part	O
of	O
her	O
fellowship	O
.	O

The	O
residency	O
was	O
conducted	O
with	O
a	O
decision	O
making	O
partner	O
from	O
the	O
Nova	O
Scotia	O
Department	O
of	O
Health	O
.	O

The	O
opinions	O
expressed	O
in	O
this	O
paper	O
are	O
those	O
of	O
the	O
authors	O
and	O
do	O
not	O
represent	O
the	O
opinions	O
of	O
the	O
Nova	O
Scotia	O
Department	O
of	O
Health	O
,	O
CIHR	O
/	O
CHSRF	O
or	O
NSHRF	O
.	O

MF	O
,	O
MM	O
,	O
RMM	O
,	O
and	O
DG	O
have	O
no	O
competing	O
interests	O
to	O
declare	O
.	O

Authors	O
'	O
contributions	O

AM	O
conceptualized	O
the	O
design	O
and	O
composed	O
the	O
survey	O
instruments	O
,	O
carried	O
out	O
the	O
study	O
,	O
entered	O
and	O
analyzed	O
the	O
data	O
,	O
drafted	O
the	O
original	O
manuscript	O
,	O
and	O
modified	O
subsequent	O
drafts	O
based	O
on	O
authors	O
'	O
and	O
reviewers	O
'	O
feedback	O
.	O

MF	O
,	O
RMM	O
,	O
IS	O
,	O
MM	O
,	O
and	O
DG	O
reviewed	O
and	O
suggested	O
revisions	O
to	O
the	O
survey	O
tools	O
,	O
covering	O
letters	O
,	O
overall	O
study	O
design	O
,	O
and	O
contributed	O
to	O
feedback	O
on	O
the	O
analysis	O
and	O
manuscript	O
revisions	O
.	O

Pre	O
-	O
publication	O
history	O

The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

Supplementary	O
Material	O

Expression	O
of	O
C	O
-	O
terminal	O
deleted	O
p53	O
isoforms	O
in	O
neuroblastoma	O

Abstract	O

The	O
tumor	O
suppressor	O
gene	O
,	O
p53	O
,	O
is	O
rarely	O
mutated	O
in	O
neuroblastomas	O
(	O
NB	O
)	O
at	O
the	O
time	O
of	O
diagnosis	O
,	O
but	O
its	O
dysfunction	O
could	O
result	O
from	O
a	O
nonfunctional	O
conformation	O
or	O
cytoplasmic	O
sequestration	O
of	O
the	O
wild	O
-	O
type	O
p53	O
protein	O
.	O

However	O
,	O
p53	O
mutation	O
,	O
when	O
it	O
occurs	O
,	O
is	O
found	O
in	O
NB	O
tumors	O
with	O
drug	O
resistance	O
acquired	O
over	O
the	O
course	O
of	O
chemotherapy	O
.	O

As	O
yet	O
,	O
no	O
study	O
has	O
been	O
devoted	O
to	O
the	O
function	O
of	O
the	O
specific	O
p53	O
mutants	O
identified	O
in	O
NB	O
cells	O
.	O

This	O
study	O
includes	O
characterization	O
and	O
functional	O
analysis	O
of	O
p53	O
expressed	O
in	O
eight	O
cell	O
lines	O
:	O
three	O
wild	O
-	O
type	O
cell	O
lines	O
and	O
five	O
cell	O
lines	O
harboring	O
mutations	O
.	O

We	O
identified	O
two	O
transcription	O
-	O
inactive	O
p53	O
variants	O
truncated	O
in	O
the	O
C	O
-	O
terminus	O
,	O
one	O
of	O
which	O
corresponded	O
to	O
the	O
p53	O
beta	O
isoform	O
recently	O
identified	O
in	O
normal	O
tissue	O
by	O
Bourdon	O
et	O
al	O
.	O

[	O
J	O
.	O
C	O
.	O
Bourdon	O
,	O
K	O
.	O
Fernandes	O
,	O
F	O
.	O
Murray	O
-	O
Zmijewski	O
,	O
G	O
.	O
Liu	O
,	O
A	O
.	O
Diot	O
,	O
D	O
.	O
P	O
.	O
Xirodimas	O
,	O
M	O
.	O
K	O
.	O
Saville	O
and	O
D	O
.	O
P	O
.	O
Lane	O
(	O
2005	O
)	O
Genes	O
Dev	O
.	O
,	O
19	O
,	O
2122	O
-	O
2137	O
]	O
.	O

Our	O
results	O
show	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
the	O
p53	O
beta	O
isoform	O
is	O
the	O
only	O
p53	O
species	O
to	O
be	O
endogenously	O
expressed	O
in	O
the	O
human	B-LIVB
NB	O
cell	O
line	O
SK	O
-	O
N	O
-	O
AS	O
,	O
suggesting	O
that	O
the	O
C	O
-	O
terminus	O
truncated	O
p53	O
isoforms	O
may	O
play	O
an	O
important	O
role	O
in	O
NB	O
tumor	O
development	O
.	O

INTRODUCTION	O

The	O
p53	O
tumor	O
suppressor	O
gene	O
remains	O
the	O
most	O
frequently	O
altered	O
gene	O
in	O
human	B-LIVB
tumors	O
.	O

Several	O
p53	O
mutation	O
databases	O
have	O
been	O
reported	O
previously	O
(	O
1	O
-	O
3	O
)	O
,	O
and	O
to	O
date	O
,	O
more	O
than	O
1500	O
different	O
p53	O
mutants	O
have	O
been	O
described	O
(	O
4	O
)	O
.	O

Functional	O
inactivation	O
of	O
p53	O
is	O
usually	O
due	O
to	O
gene	O
mutation	O
,	O
deletion	O
or	O
protein	O
degradation	O
.	O

In	O
general	O
,	O
the	O
majority	O
of	O
p53	O
mutations	O
in	O
human	B-LIVB
neoplasia	O
are	O
missense	O
mutations	O
affecting	O
the	O
DNA	O
-	O
binding	O
domain	O
(	O
DBD	O
)	O
.	O

Unlike	O
other	O
human	B-LIVB
cancers	O
,	O
p53	O
in	O
neuroblastoma	O
(	O
NB	O
)	O
is	O
rarely	O
mutated	O
in	O
the	O
primary	O
tumor	O
at	O
diagnosis	O
but	O
high	O
levels	O
of	O
wild	O
-	O
type	O
p53	O
(	O
wt	O
p53	O
)	O
protein	O
expression	O
have	O
been	O
found	O
in	O
the	O
cytoplasm	O
of	O
undifferentiated	O
tumors	O
(	O
5	O
,	O
6	O
)	O
.	O

More	O
recently	O
,	O
in	O
normal	O
unstressed	O
cells	O
,	O
wt	O
p53	O
protein	O
was	O
found	O
to	O
be	O
retained	O
in	O
the	O
cytoplasm	O
as	O
a	O
latent	O
form	O
,	O
in	O
huge	O
,	O
p53	O
-	O
associated	O
protein	O
complexes	O
known	O
as	O
'	O
Parc	O
'	O
(	O
7	O
)	O
.	O

The	O
steady	O
-	O
state	O
concentration	O
of	O
p53	O
in	O
normal	O
unstressed	O
cells	O
is	O
usually	O
very	O
low	O
because	O
of	O
the	O
short	O
half	O
-	O
life	O
of	O
the	O
wild	O
-	O
type	O
(	O
wt	O
)	O
protein	O
.	O

Overexpression	O
of	O
p53	O
in	O
most	O
of	O
the	O
transformed	O
cells	O
containing	O
a	O
missense	O
mutation	O
within	O
the	O
p53	O
gene	O
appears	O
to	O
be	O
due	O
to	O
the	O
increased	O
stability	O
of	O
mutated	O
p53	O
(	O
8	O
)	O
.	O

In	O
unstressed	O
NB	O
cells	O
,	O
high	O
wt	O
p53	O
expression	O
may	O
reflect	O
the	O
embryonic	O
origin	O
of	O
NBs	O
,	O
in	O
which	O
precursor	O
cells	O
fail	O
to	O
mature	O
(	O
9	O
)	O
.	O

p53	O
mutations	O
are	O
unusual	O
in	O
human	B-LIVB
NB	O
but	O
,	O
when	O
they	O
do	O
occur	O
,	O
are	O
found	O
in	O
post	O
-	O
chemotherapy	O
tumors	O
.	O

In	O
this	O
respect	O
,	O
Tweddle	O
et	O
al	O
.	O

(	O
10	O
)	O
described	O
how	O
two	O
NB	O
cell	O
lines	O
derived	O
from	O
the	O
same	O
patient	B-LIVB
can	O
elicit	O
a	O
different	O
p53	O
status	O
:	O
wt	O
p53	O
for	O
SK	O
-	O
N	O
-	O
BE	O
(	O
1a	O
)	O
established	O
before	O
treatment	O
,	O
and	O
mutated	O
p53	O
for	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2c	O
)	O
established	O
after	O
relapse	O
of	O
the	O
patient	B-LIVB
under	O
treatment	O
with	O
cytotoxic	O
agents	O
such	O
as	O
cyclophosphamide	O
,	O
doxorubicin	O
,	O
vincristine	O
and	O
radiotherapy	O
.	O

In	O
NB	O
cell	O
lines	O
,	O
p53	O
mutation	O
has	O
been	O
found	O
in	O
multidrug	O
-	O
resistant	O
cells	O
(	O
11	O
)	O
.	O

Various	O
types	O
of	O
p53	O
mutation	O
have	O
been	O
detected	O
in	O
NB	O
cells	O
and	O
can	O
lead	O
to	O
inactivation	O
either	O
by	O
shut	O
-	O
down	O
of	O
protein	O
expression	O
or	O
production	O
of	O
aberrant	O
p53	O
products	O
.	O

Indeed	O
,	O
in	O
LAN	O
-	O
1	O
cells	O
,	O
p53	O
nonsense	O
mutation	O
at	O
cysteine	O
182	O
in	O
exon	O
5	O
leads	O
to	O
the	O
absence	O
of	O
protein	O
(	O
9	O
)	O
,	O
whereas	O
in	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
cells	O
,	O
missense	O
mutation	O
at	O
codon	O
135	O
(	O
C135F	O
)	O
leads	O
to	O
stable	O
overexpressed	O
protein	O
(	O
11	O
)	O
.	O

By	O
analyzing	O
IGR	O
-	O
N	O
-	O
91	O
,	O
a	O
cell	O
line	O
established	O
in	O
our	O
laboratory	O
from	O
the	O
bone	O
marrow	O
of	O
a	O
patient	B-LIVB
with	O
metastatic	O
NB	O
after	O
unsuccessful	O
Adriamycin	O
-	O
vincristine	O
chemotherapy	O
(	O
12	O
)	O
,	O
we	O
identified	O
another	O
type	O
of	O
aberrant	O
protein	O
that	O
arises	O
from	O
the	O
duplication	O
of	O
exons	O
7	O
-	O
8	O
-	O
9	O
.	O

This	O
duplication	O
spans	O
from	O
amino	O
acids	O
225	O
to	O
331	O
,	O
which	O
represent	O
part	O
of	O
the	O
DBD	O
and	O
part	O
of	O
the	O
oligomerization	O
domain	O
(	O
13	O
)	O
.	O

However	O
,	O
each	O
p53	O
mutant	O
has	O
been	O
described	O
in	O
the	O
literature	O
as	O
a	O
case	O
report	O
,	O
and	O
so	O
far	O
,	O
no	O
comparative	O
study	O
has	O
been	O
undertaken	O
to	O
link	O
their	O
biochemical	O
features	O
with	O
functional	O
properties	O
.	O

In	O
the	O
present	O
study	O
we	O
report	O
two	O
novel	O
p53	O
C	O
-	O
terminus	O
mutants	O
identified	O
in	O
SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
human	B-LIVB
NB	O
cell	O
lines	O
.	O

The	O
biological	O
properties	O
of	O
these	O
two	O
new	O
variants	O
were	O
analyzed	O
in	O
comparison	O
with	O
p53	O
isolated	O
from	O
six	O
other	O
human	B-LIVB
NB	O
lines	O
:	O
three	O
[	O
LAN	O
-	O
1	O
,	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
and	O
IGR	O
-	O
N	O
-	O
91	O
]	O
expressing	O
mutant	O
p53	O
and	O
three	O
(	O
SH	O
-	O
SY5Y	O
,	O
LAN	O
-	O
5	O
and	O
IMR	O
-	O
32	O
)	O
expressing	O
the	O
wt	O
protein	O
.	O

This	O
characterization	O
was	O
done	O
by	O
using	O
a	O
range	O
of	O
functional	O
assays	O
:	O
(	O
i	O
)	O
the	O
ability	O
of	O
the	O
protein	O
to	O
bind	O
with	O
p53	O
consensus	O
sequence	O
using	O
the	O
functional	O
analysis	O
of	O
separated	O
allele	O
in	O
yeast	B-LIVB
(	O
FASAY	O
)	O
;	O
(	O
ii	O
)	O
the	O
ability	O
of	O
the	O
protein	O
to	O
transactivate	O
the	O
p53	O
-	O
responsive	O
element	O
(	O
RE	O
)	O
identified	O
either	O
in	O
the	O
promoter	O
of	O
p21	O
/	O
WAF1	O
or	O
in	O
the	O
first	O
intron	O
of	O
BAX	O
,	O
using	O
luciferase	O
reporter	O
assay	O
;	O
(	O
iii	O
)	O
the	O
induction	O
of	O
endogenous	O
p21	O
/	O
WAF1	O
gene	O
expression	O
under	O
stress	O
conditions	O
.	O

MATERIALS	O
AND	O
METHODS	O

Neuroblastoma	O
cell	O
lines	O
,	O
culture	O
and	O
drug	O
treatments	O

The	O
parental	O
human	B-LIVB
NB	O
SH	O
-	O
SY5Y	O
,	O
SK	O
-	O
N	O
-	O
AS	O
,	O
IMR	O
-	O
32	O
and	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
cell	O
lines	O
were	O
purchased	O
from	O
the	O
European	O
Collection	O
of	O
Cell	O
Cultures	O
(	O
ECACC	O
,	O
Wiltshire	O
,	O
UK	O
)	O
.	O

The	O
human	B-LIVB
IGR	O
-	O
NB8	O
cells	O
(	O
a	O
gift	O
of	O
Prof	O
.	O
Gilles	O
Vassal	O
,	O
UPRES	O
EA	O
3535	O
,	O
Institut	O
Gustave	O
Roussy	O
,	O
Villejuif	O
)	O
were	O
derived	O
from	O
a	O
previously	O
untreated	O
localized	O
NB	O
(	O
14	O
)	O
.	O

The	O
LAN	O
-	O
1	O
and	O
LAN	O
-	O
5	O
cell	O
lines	O
were	O
provided	O
by	O
Dr	O
Nicole	O
Gross	O
(	O
Pediatric	O
Oncology	O
Research	O
,	O
Lausanne	O
,	O
Switzerland	O
)	O
.	O

The	O
human	B-LIVB
IGR	O
-	O
N	O
-	O
91	O
cell	O
line	O
was	O
established	O
in	O
our	O
laboratory	O
from	O
the	O
bone	O
marrow	O
of	O
a	O
patient	B-LIVB
with	O
metastatic	O
NB	O
after	O
unsuccessful	O
adriamycin	O
-	O
vincristin	O
chemotherapy	O
(	O
12	O
)	O
.	O

LAN	O
-	O
1	O
,	O
LAN	O
-	O
5	O
and	O
IMR	O
-	O
32	O
were	O
grown	O
in	O
RPMI	O
medium	O
supplemented	O
with	O
2	O
mM	O
l	O
-	O
glutamine	O
and	O
10	O
%	O
fetal	O
calf	O
serum	O
and	O
gentamicine	O
10	O
mu	O
g	O
/	O
ml	O
.	O

Others	O
cell	O
lines	O
were	O
cultured	O
in	O
DMEM	O
.	O

For	O
activation	O
of	O
endogenous	O
p53	O
,	O
cells	O
were	O
treated	O
with	O
cis	O
-	O
platinum	O
(	O
Sigma	O
)	O
(	O
10	O
mu	O
g	O
/	O
ml	O
)	O
for	O
24	O
h	O
then	O
lysed	O
for	O
western	O
blot	O
analysis	O
.	O

Western	O
blot	O
analysis	O

This	O
procedure	O
was	O
carried	O
out	O
as	O
described	O
previously	O
(	O
13	O
)	O
.	O

Protein	O
lysates	O
(	O
50	O
mu	O
g	O
)	O
were	O
submitted	O
to	O
10	O
%	O
SDS	O
-	O
PAGE	O
,	O
and	O
then	O
transferred	O
onto	O
nitrocellulose	O
filters	O
.	O

After	O
saturation	O
,	O
the	O
membranes	O
were	O
incubated	O
with	O
primary	O
antibody	O
diluted	O
in	O
0	O
.	O
1	O
%	O
phosphate	O
-	O
buffered	O
saline	O
,	O
Tween	O
-	O
20	O
and	O
3	O
%	O
skim	O
milk	O
.	O

The	O
primary	O
antibodies	O
used	O
were	O
anti	O
-	O
p53	O
monoclonal	O
antibody	O
(	O
clone	O
DO	O
-	O
7	O
,	O
1	O
/	O
1000	O
,	O
DAKO	O
)	O
,	O
anti	O
-	O
p21	O
/	O
WAF1	O
monoclonal	O
antibody	O
(	O
Ab	O
-	O
1	O
,	O
1	O
/	O
200	O
,	O
Oncogene	O
Research	O
)	O
and	O
anti	O
-	O
beta	O
-	O
actin	O
monoclonal	O
antibody	O
(	O
1	O
/	O
1000	O
;	O
Chemicon	O
)	O
as	O
internal	O
control	O
.	O

Protein	O
bands	O
were	O
detected	O
by	O
ECL	O
system	O
(	O
Amersham	O
)	O
.	O

PCR	O
,	O
plasmids	O
cloning	O

Genomic	O
DNA	O
was	O
extracted	O
using	O
lysis	O
buffer	O
containing	O
20	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
7	O
.	O
5	O
;	O
0	O
.	O
4	O
M	O
NaCl	O
;	O
0	O
.	O
5	O
%	O
SDS	O
;	O
10	O
mM	O
EDTA	O
,	O
treated	O
with	O
proteinase	O
K	O
(	O
200	O
mu	O
g	O
/	O
mu	O
l	O
)	O
,	O
purified	O
with	O
phenol	O
/	O
chloroform	O
,	O
precipitated	O
with	O
ethanol	O
and	O
dissolved	O
in	O
DNase	O
free	O
water	O
.	O

Total	O
RNA	O
were	O
purified	O
using	O
RNAble	O
reagent	O
(	O
Eurobio	O
)	O
,	O
precipitated	O
with	O
isopropanol	O
and	O
dissolved	O
in	O
RNase	O
free	O
water	O
.	O

cDNA	O
was	O
obtained	O
by	O
reverse	O
transcription	O
of	O
1	O
mu	O
g	O
of	O
total	O
RNA	O
using	O
Superscript	O
II	O
(TM)	O
RNase	O
H	O
-	O
Reverse	O
transcriptase	O
(	O
Invitrogen	O
)	O
and	O
Oligo	O
-	O
d	O
(	O
T	O
)	O
16	O
in	O
conditions	O
specified	O
by	O
the	O
manufacturer	O
.	O

Amplification	O
of	O
full	O
-	O
length	O
p53	O
coding	O
region	O
from	O
SH	O
-	O
SY5Y	O
,	O
IGR	O
-	O
N	O
-	O
91	O
,	O
IGR	O
-	O
NB8	O
and	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
cell	O
lines	O
was	O
performed	O
using	O
forward	O
primer	O
at	O
position	O
152	O
and	O
reverse	O
primer	O
at	O
position	O
1583	O
(	O
F1	O
and	O
R7	O
,	O
respectively	O
,	O
Table	O
1	O
;	O
GenBank	O
accession	O
no	O
.	O
K03199	O
)	O
.	O

p53	O
cDNA	O
from	O
SK	O
-	O
N	O
-	O
AS	O
cells	O
for	O
cloning	O
was	O
obtained	O
from	O
RT	O
-	O
PCR	O
using	O
F1	O
and	O
reverse	O
primer	O
i9	O
+	O
:	O
5	O
'	O
-	O
GCAAAGTCATAGAACCATTTTCAT	O
-	O
3	O
'	O
(	O
nucleotide	O
position	O
14989	O
,	O
GenBank	O
accession	O
no	O
.	O
X54156	O
)	O
primers	O
which	O
encompass	O
from	O
exon	O
1	O
to	O
exon	O
i9	O
+	O
first	O
identified	O
by	O
Flaman	O
et	O
al	O
.	O

(	O
15	O
)	O
included	O
.	O

The	O
PCR	O
was	O
done	O
in	O
the	O
presence	O
of	O
pfu	O
Hotstart	O
DNA	O
polymerase	O
(	O
Stratagene	O
)	O
for	O
30	O
cycles	O
of	O
1	O
min	O
at	O
90	O
degrees	O
C	O
,	O
1	O
min	O
at	O
65	O
degrees	O
C	O
and	O
2	O
min	O
30	O
s	O
at	O
72	O
degrees	O
C	O
using	O
PTC	O
-	O
100	O
thermocycler	O
(	O
MJ	O
-	O
Research	O
)	O
.	O

The	O
p53	O
cDNA	O
from	O
SH	O
-	O
SY5Y	O
,	O
SK	O
-	O
N	O
-	O
AS	O
,	O
IGR	O
-	O
N	O
-	O
91	O
,	O
IGR	O
-	O
NB8	O
and	O
SK	O
-	O
N	O
-	O
AS	O
cells	O
were	O
then	O
cloned	O
into	O
pcDNA3	O
.	O
1	O
/	O
V5	O
-	O
His	O
-	O
Topo	O
vector	O
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instruction	O
.	O

The	O
p53	O
sequence	O
of	O
each	O
cell	O
line	O
was	O
investigated	O
by	O
sequencing	O
of	O
plasmids	O
after	O
cloning	O
.	O

Sequencing	O
was	O
performed	O
by	O
Genome	O
Express	O
(	O
Meylan	O
,	O
France	O
)	O
.	O

The	O
pDDm	O
-	O
TO	O
harboring	O
p53	O
dominant	O
negative	O
form	O
(	O
p53DD	O
)	O
pGL3	O
-	O
E1bTATA	O
and	O
the	O
pE1B	O
-	O
hWAF1	O
firefly	O
luciferase	O
reporter	O
containing	O
the	O
p53	O
-	O
responsive	O
element	O
of	O
the	O
p21	O
/	O
WAF1	O
promoter	O
were	O
described	O
previously	O
(	O
16	O
,	O
17	O
)	O
pE1B	O
-	O
BAXi	O
contains	O
the	O
p53RE	O
identified	O
in	O
the	O
intron	O
1	O
of	O
the	O
BAX	O
gene	O
[	O
(	O
18	O
)	O
and	O
D	O
.	O
Munsch	O
,	O
personal	O
communication	O
]	O
.	O

Oligonucleotides	O
TCGAGGGCAGGCCCGGGCTTGTCG	O
and	O
CTAGCGACAAGCCCGGGCCTGCCC	O
were	O
annealed	O
and	O
cloned	O
into	O
pGL3	O
-	O
E1bTATA	O
digested	O
with	O
NheI	O
and	O
XhoI	O
to	O
obtain	O
pE1B	O
-	O
BAXi	O
.	O

The	O
pcDNA3	O
-	O
Delta	O
Np73	O
alpha	O
expression	O
plasmid	O
was	O
a	O
gift	O
of	O
Dr	O
Daniel	O
Caput	O
(	O
SANOFI	O
,	O
Lab	O
e	O
ges	O
,	O
France	O
)	O
.	O

Fluorescent	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O

Cytogenetic	O
preparations	O

Metaphase	O
spreads	O
from	O
healthy	O
human	B-LIVB
male	O
lymphocytes	O
and	O
tumor	O
cell	O
lines	O
were	O
prepared	O
as	O
described	O
previously	O
(	O
19	O
)	O
.	O

BAC	O
probe	O
RP11	O
-	O
199F11	O
,	O
containing	O
a	O
167	O
kb	O
region	O
spanning	O
TP53	O
gene	O
,	O
was	O
labeled	O
by	O
random	O
priming	O
in	O
the	O
presence	O
of	O
Alexa	O
594	O
-	O
dUTP	O
(	O
Molecular	O
Probes	O
)	O
.	O

A	O
commercial	O
probe	O
specific	O
for	O
chromosome	O
17	O
centromere	O
,	O
and	O
labeled	O
with	O
spectrum	O
green	O
,	O
was	O
obtained	O
from	O
Vysis	O
.	O

After	O
over	O
-	O
night	O
cohybridization	O
of	O
the	O
probes	O
in	O
the	O
presence	O
of	O
Cot	O
-	O
1	O
DNA	O
,	O
the	O
slides	O
were	O
washed	O
and	O
DNA	O
counterstained	O
with	O
DAPI	O
.	O

The	O
preparations	O
were	O
observed	O
with	O
an	O
epifluorescence	O
microscope	O
and	O
images	O
captured	O
with	O
a	O
Vysis	O
imaging	O
station	O
.	O

Between	O
3	O
and	O
14	O
metaphases	O
spreads	O
and	O
30	O
-	O
200	O
nuclei	O
were	O
examined	O
for	O
each	O
cell	O
line	O
.	O

Luciferase	O
reporter	O
assays	O

LAN	O
-	O
1	O
or	O
SH	O
-	O
SY5Y	O
cells	O
were	O
seeded	O
in	O
duplicates	O
onto	O
6	O
-	O
well	O
plates	O
at	O
a	O
density	O
of	O
2	O
x	O
104	O
cells	O
per	O
cm2	O
and	O
cotransfected	O
24	O
h	O
later	O
with	O
0	O
.	O
5	O
mu	O
g	O
(	O
2	O
.	O
5	O
mu	O
g	O
/	O
ml	O
)	O
of	O
pGL3	O
firefly	O
luciferase	O
reporter	O
gene	O
plasmid	O
under	O
the	O
control	O
of	O
either	O
pE1B	O
-	O
hWAF1	O
or	O
pE1B	O
-	O
BAX	O
using	O
lipofectamine	O
2000	O
and	O
1	O
mu	O
g	O
of	O
either	O
a	O
p53	O
expressing	O
plasmid	O
or	O
an	O
empty	O
vector	O
.	O

At	O
24	O
h	O
after	O
transfection	O
,	O
cells	O
were	O
lysed	O
with	O
200	O
mu	O
l	O
/	O
well	O
of	O
passive	O
lysis	O
buffer	O
provided	O
with	O
the	O
'	O
Luciferase	O
assay	O
kit	O
'	O
(	O
Promega	O
)	O
.	O

Luciferase	O
activity	O
was	O
measured	O
using	O
Microlumat	O
LB96P	O
luminometer	O
(	O
EG	O
&	O
G	O
Berthold	O
Instrument	O
)	O
.	O

Functional	O
assay	O
in	O
yeast	B-LIVB

cDNA	O
was	O
obtained	O
by	O
RT	O
of	O
1	O
mu	O
g	O
of	O
total	O
RNA	O
using	O
Superscript	O
II	O
(TM)	O
RNase	O
H	O
-	O
Reverse	O
transcriptase	O
(	O
Invitrogen	O
)	O
and	O
random	O
hexamers	O
to	O
prime	O
the	O
synthesis	O
in	O
conditions	O
specified	O
by	O
the	O
manufacturer	O
.	O

p53	O
cDNA	O
was	O
amplified	O
by	O
PCR	O
and	O
cotransformed	O
into	O
yeast	B-LIVB
,	O
IG397	O
Ade2	O
strain	O
,	O
together	O
with	O
either	O
pRDI	O
-	O
22	O
vector	O
for	O
p53	O
-	O
standard	O
assay	O
or	O
pFW35	O
and	O
pFW34	O
plasmid	O
for	O
5	O
'	O
or	O
3	O
'	O
split	O
assay	O
,	O
respectively	O
,	O
carrying	O
the	O
ADE2	O
open	O
reading	O
frame	O
under	O
the	O
control	O
of	O
a	O
p53	O
-	O
responsive	O
promoter	O
(	O
20	O
)	O
.	O

In	O
a	O
selective	O
medium	O
lacking	O
leucine	O
,	O
wt	O
-	O
p53	O
activates	O
transcription	O
of	O
ADE2	O
gene	O
that	O
encodes	O
enzyme	O
--	O
phosphoribosylimidazole	O
carboxylase	O
--	O
implicated	O
in	O
adenine	O
biosynthesis	O
.	O

Therefore	O
,	O
a	O
colony	O
of	O
cells	O
that	O
expresses	O
ADE2	O
gene	O
is	O
white	O
whereas	O
the	O
one	O
composed	O
of	O
cells	O
where	O
ADE2	O
gene	O
is	O
not	O
expressed	O
owing	O
p53	O
mutation	O
is	O
red	O
.	O

RESULTS	O

P53	O
status	O
in	O
SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
cells	O

We	O
first	O
compared	O
the	O
migration	O
profiles	O
of	O
p53	O
expressed	O
in	O
SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
with	O
those	O
expressed	O
in	O
the	O
other	O
six	O
NB	O
cells	O
,	O
SH	O
-	O
SY5Y	O
,	O
LAN	O
-	O
5	O
,	O
LAN	O
-	O
1	O
,	O
IMR	O
-	O
32	O
,	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
and	O
IGR	O
-	O
N	O
-	O
91	O
.	O

Western	O
blots	O
from	O
50	O
mu	O
g	O
of	O
total	O
protein	O
extracts	O
were	O
revealed	O
with	O
p53	O
monoclonal	O
antibody	O
(	O
DO	O
-	O
7	O
)	O
.	O

A	O
range	O
of	O
profiles	O
was	O
identified	O
as	O
shown	O
in	O
Figure	O
1A	O
.	O

As	O
expected	O
,	O
p53	O
extracted	O
from	O
the	O
three	O
cell	O
lines	O
,	O
SH	O
-	O
SY5Y	O
,	O
LAN	O
-	O
5	O
and	O
IMR	O
-	O
32	O
,	O
expressing	O
wt	O
protein	O
(	O
13	O
,	O
21	O
)	O
migrated	O
at	O
the	O
wt	O
position	O
.	O

Of	O
particular	O
note	O
in	O
these	O
three	O
wt	O
p53	O
cell	O
lines	O
was	O
an	O
additional	O
faint	O
band	O
that	O
migrated	O
faster	O
than	O
the	O
full	O
-	O
length	O
protein	O
.	O

The	O
LAN	O
-	O
1	O
cells	O
were	O
found	O
to	O
be	O
p53	O
deficient	O
(	O
9	O
)	O
.	O

The	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
cell	O
line	O
showed	O
an	O
intense	O
band	O
reflecting	O
p53	O
stability	O
due	O
to	O
a	O
missense	O
mutation	O
at	O
codon	O
135	O
(	O
11	O
)	O
.	O

As	O
expected	O
,	O
due	O
to	O
the	O
previously	O
identified	O
duplication	O
of	O
exons	O
7	O
-	O
8	O
-	O
9	O
(	O
13	O
)	O
,	O
p53	O
protein	O
migration	O
was	O
delayed	O
in	O
the	O
IGR	O
-	O
N	O
-	O
91	O
cells	O
.	O

In	O
contrast	O
,	O
the	O
p53	O
protein	O
in	O
the	O
SK	O
-	O
N	O
-	O
AS	O
cell	O
line	O
migrated	O
noticeably	O
faster	O
than	O
the	O
wt	O
protein	O
,	O
indicating	O
that	O
it	O
was	O
smaller	O
in	O
size	O
.	O

The	O
p53	O
protein	O
in	O
the	O
IGR	O
-	O
NB8	O
cell	O
line	O
was	O
even	O
smaller	O
than	O
that	O
in	O
SK	O
-	O
N	O
-	O
AS	O
.	O

To	O
analyze	O
the	O
coding	O
region	O
of	O
each	O
of	O
the	O
p53	O
variants	O
,	O
RT	O
-	O
PCR	O
was	O
performed	O
using	O
p53	O
-	O
specific	O
F1	O
-	O
R7	O
primers	O
(	O
Table	O
1	O
and	O
Figure	O
1B	O
)	O
.	O

The	O
expected	O
1430	O
bp	O
for	O
full	O
-	O
length	O
p53	O
was	O
amplified	O
from	O
wt	O
p53	O
-	O
expressing	O
SH	O
-	O
SY5Y	O
,	O
LAN	O
-	O
5	O
and	O
IMR	O
-	O
32	O
cell	O
lines	O
.	O

As	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
harbors	O
a	O
single	O
point	O
mutation	O
at	O
codon	O
135	O
(	O
C135F	O
)	O
,	O
the	O
amplified	O
fragment	O
analyzed	O
by	O
electrophoresis	O
migrated	O
as	O
wt	O
p53	O
(	O
Figure	O
1B	O
)	O
.	O

The	O
longer	O
RT	O
-	O
PCR	O
fragment	O
from	O
the	O
mutated	O
IGR	O
-	O
N	O
-	O
91	O
cell	O
line	O
resulted	O
from	O
the	O
duplication	O
of	O
exons	O
7	O
-	O
8	O
-	O
9	O
,	O
as	O
shown	O
in	O
our	O
previous	O
data	O
(	O
13	O
)	O
,	O
which	O
corresponds	O
to	O
extra	O
nucleic	O
material	O
of	O
321	O
nt	O
.	O

For	O
the	O
LAN	O
-	O
1	O
cells	O
,	O
no	O
amplified	O
fragment	O
was	O
observed	O
in	O
accordance	O
with	O
published	O
data	O
,	O
which	O
demonstrates	O
the	O
extremely	O
low	O
levels	O
of	O
p53	O
mRNA	O
and	O
the	O
undetectable	O
level	O
of	O
protein	O
(	O
9	O
)	O
.	O

An	O
amplified	O
fragment	O
of	O
the	O
same	O
length	O
as	O
the	O
wt	O
protein	O
was	O
observed	O
in	O
the	O
IGR	O
-	O
NB8	O
cell	O
line	O
(	O
Figure	O
1B	O
)	O
.	O

Indeed	O
,	O
complete	O
gene	O
sequencing	O
revealed	O
a	O
point	O
mutation	O
E326STOP	O
leading	O
to	O
a	O
truncated	O
protein	O
at	O
C	O
-	O
terminus	O
.	O

No	O
fragment	O
,	O
however	O
,	O
was	O
amplified	O
from	O
SK	O
-	O
N	O
-	O
AS	O
with	O
F1	O
-	O
R7	O
primers	O
.	O

To	O
further	O
map	O
the	O
p53	O
mRNA	O
transcribed	O
in	O
these	O
cells	O
,	O
series	O
of	O
RT	O
-	O
PCR	O
tests	O
were	O
performed	O
using	O
the	O
forward	O
primer	O
,	O
F2	O
(	O
exon	O
8	O
position	O
1008th	O
according	O
to	O
GenBank	O
accession	O
no	O
.	O
K03199	O
)	O
,	O
matched	O
with	O
different	O
reverse	O
primers	O
,	O
R3	O
(	O
at	O
the	O
junction	O
of	O
exon	O
8	O
/	O
9	O
,	O
nt	O
position	O
1124	O
)	O
,	O
R4	O
,	O
R5	O
(	O
in	O
exon	O
9	O
at	O
positions	O
1154	O
and	O
1184	O
,	O
respectively	O
)	O
,	O
and	O
R6	O
(	O
in	O
exon	O
10	O
,	O
at	O
position	O
1230	O
)	O
.	O

The	O
sequences	O
of	O
these	O
primers	O
are	O
given	O
in	O
Table	O
1	O
and	O
the	O
results	O
are	O
presented	O
in	O
Figure	O
2A	O
.	O

SK	O
-	O
N	O
-	O
AS	O
cDNA	O
gave	O
an	O
amplified	O
fragment	O
of	O
the	O
same	O
size	O
as	O
SH	O
-	O
SY5Y	O
cDNA	O
with	O
the	O
three	O
primer	O
pairs	O
,	O
F2	O
/	O
R3	O
,	O
F2	O
/	O
R4	O
and	O
F3	O
/	O
R5	O
.	O

However	O
,	O
in	O
contrast	O
to	O
SH	O
-	O
SY5Y	O
,	O
no	O
fragment	O
was	O
obtained	O
with	O
SK	O
-	O
N	O
-	O
AS	O
cDNA	O
using	O
the	O
F2	O
/	O
R6	O
primer	O
pair	O
,	O
which	O
suggests	O
the	O
absence	O
of	O
exon	O
10	O
in	O
SK	O
-	O
N	O
-	O
AS	O
mRNA	O
.	O

The	O
p53	O
protein	O
expressed	O
in	O
SK	O
-	O
N	O
-	O
AS	O
is	O
the	O
p53	O
beta	O
isoform	O

An	O
alternatively	O
spliced	O
form	O
of	O
human	B-LIVB
p53	O
mRNA	O
with	O
an	O
additional	O
133	O
bp	O
exon	O
derived	O
from	O
intron	O
9	O
has	O
been	O
detected	O
in	O
normal	O
human	B-LIVB
lymphocytes	O
(	O
15	O
)	O
.	O

This	O
spliced	O
variant	O
named	O
'	O
i9	O
+	O
'	O
encodes	O
a	O
truncated	O
protein	O
of	O
341	O
amino	O
acids	O
including	O
10	O
new	O
amino	O
acids	O
derived	O
from	O
the	O
novel	O
exon	O
,	O
the	O
p53	O
beta	O
isoform	O
according	O
to	O
Bourdon	O
et	O
al	O
.	O
nomenclature	O
(	O
22	O
)	O
.	O

This	O
led	O
us	O
to	O
hypothesize	O
that	O
the	O
shorter	O
protein	O
expressed	O
by	O
the	O
SK	O
-	O
N	O
-	O
AS	O
cell	O
line	O
could	O
be	O
the	O
p53	O
beta	O
isoform	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
RT	O
-	O
PCRs	O
were	O
performed	O
using	O
primer	O
sets	O
designed	O
to	O
amplify	O
the	O
3	O
'	O
region	O
of	O
p53	O
mRNA	O
encoding	O
either	O
the	O
specific	O
C	O
-	O
terminal	O
part	O
of	O
the	O
wt	O
protein	O
(	O
wt	O
C	O
-	O
ter	O
)	O
or	O
the	O
specific	O
C	O
-	O
terminal	O
part	O
of	O
the	O
beta	O
isoform	O
(	O
beta	O
C	O
-	O
ter	O
)	O
.	O

In	O
parallel	O
amplification	O
with	O
a	O
primer	O
pair	O
amplifying	O
the	O
DBD	O
was	O
used	O
as	O
control	O
.	O

The	O
sequences	O
of	O
these	O
oligonucleotides	O
are	O
given	O
in	O
Table	O
1	O
.	O

The	O
results	O
presented	O
in	O
Figure	O
2B	O
are	O
consistent	O
with	O
the	O
only	O
expression	O
of	O
the	O
p53	O
beta	O
isoform	O
in	O
SK	O
-	O
N	O
-	O
AS	O
as	O
no	O
band	O
was	O
observed	O
in	O
lane	O
using	O
specific	O
C	O
-	O
ter	O
primer	O
located	O
in	O
exon	O
10	O
.	O

Interestingly	O
,	O
RT	O
-	O
PCR	O
using	O
SH	O
-	O
SY5Y	O
(	O
SH	O
)	O
gave	O
an	O
amplified	O
fragment	O
not	O
only	O
with	O
the	O
primer	O
pair	O
specific	O
to	O
the	O
C	O
-	O
ter	O
domain	O
of	O
wt	O
p53	O
but	O
also	O
with	O
the	O
primer	O
pair	O
specific	O
to	O
the	O
p53	O
beta	O
isoform	O
.	O

This	O
result	O
,	O
combined	O
with	O
the	O
presence	O
of	O
an	O
additional	O
faint	O
band	O
migrating	O
faster	O
than	O
wt	O
p53	O
in	O
denaturing	O
polyacrylamide	O
gel	O
(	O
Figure	O
1A	O
)	O
,	O
strongly	O
suggests	O
that	O
both	O
the	O
p53	O
full	O
-	O
length	O
protein	O
and	O
the	O
beta	O
isoform	O
were	O
expressed	O
in	O
the	O
SH	O
-	O
SY5Y	O
cells	O
.	O

The	O
full	O
-	O
length	O
SK	O
-	O
N	O
-	O
AS	O
p53	O
cDNA	O
was	O
then	O
amplified	O
with	O
the	O
forward	O
primer	O
F1	O
and	O
a	O
reverse	O
primer	O
located	O
within	O
the	O
novel	O
exon	O
i9	O
+	O
(	O
Table	O
1	O
)	O
.	O

This	O
amplified	O
fragment	O
was	O
cloned	O
in	O
pcDNA3	O
/	O
V5	O
-	O
His	O
-	O
Topo	O
,	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O

Its	O
sequence	O
analysis	O
confirmed	O
that	O
the	O
truncated	O
p53	O
expressed	O
in	O
SK	O
-	O
N	O
-	O
AS	O
was	O
encoded	O
by	O
the	O
i9	O
+	O
splice	O
variant	O
described	O
previously	O
by	O
Flaman	O
et	O
al	O
.	O

(	O
15	O
)	O
that	O
encodes	O
the	O
p53	O
beta	O
isoform	O
characterized	O
by	O
Bourdon	O
et	O
al	O
.	O

(	O
22	O
)	O
.	O

A	O
series	O
of	O
genomic	O
amplifications	O
were	O
performed	O
to	O
identify	O
a	O
possible	O
deletion	O
within	O
the	O
intron	O
9	O
that	O
could	O
account	O
for	O
the	O
absence	O
of	O
normal	O
size	O
p53	O
in	O
SK	O
-	O
N	O
-	O
AS	O
cells	O
.	O

The	O
primer	O
sequences	O
are	O
given	O
in	O
Table	O
1	O
.	O

Amplifications	O
were	O
performed	O
in	O
parallel	O
with	O
total	O
DNA	O
extracted	O
from	O
SH	O
-	O
SY5Y	O
and	O
SK	O
-	O
N	O
-	O
AS	O
cells	O
.	O

Results	O
are	O
presented	O
in	O
Figure	O
3	O
.	O

Normal	O
size	O
fragments	O
that	O
encompass	O
the	O
acceptor	O
site	O
of	O
intron	O
9	O
were	O
amplified	O
with	O
SH	O
-	O
SY5Y	O
as	O
well	O
as	O
with	O
SK	O
-	O
N	O
-	O
AS	O
DNA	O
.	O

On	O
the	O
contrary	O
amplification	O
fragments	O
that	O
encompass	O
the	O
intron	O
9	O
donor	O
site	O
were	O
obtained	O
only	O
with	O
SH	O
-	O
SY5Y	O
but	O
not	O
with	O
SK	O
-	O
N	O
-	O
AS	O
DNA	O
.	O

These	O
results	O
identify	O
a	O
deletion	O
of	O
the	O
intron	O
9	O
/	O
exon	O
10	O
junction	O
within	O
the	O
SK	O
-	O
N	O
-	O
AS	O
p53	O
gene	O
.	O

A	O
yeast	B-LIVB
functional	O
assay	O
confirmed	O
the	O
absence	O
of	O
p53	O
full	O
-	O
length	O
expression	O
in	O
SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O

It	O
is	O
possible	O
to	O
detect	O
p53	O
mutation	O
using	O
a	O
simple	O
yeast	B-LIVB
colony	O
color	O
assay	O
as	O
described	O
by	O
Flaman	O
et	O
al	O
.	O

(	O
23	O
)	O
.	O

When	O
the	O
strain	O
is	O
transformed	O
with	O
a	O
plasmid	O
-	O
encoding	O
wt	O
p53	O
,	O
the	O
cells	O
express	O
the	O
ADE2	O
gene	O
and	O
produce	O
white	O
colonies	O
(	O
Figure	O
4A	O
,	O
a	O
,	O
b2	O
and	O
c1	O
,	O
and	O
Figure	O
4B	O
,	O
dish	O
a	O
)	O
.	O

Cells	O
containing	O
mutant	O
p53	O
fail	O
to	O
express	O
ADE2	O
and	O
form	O
small	O
red	O
colonies	O
(	O
Figure	O
4A	O
,	O
b	O
and	O
b1	O
,	O
and	O
Figure	O
4B	O
,	O
dish	O
c	O
)	O
.	O

When	O
the	O
p53	O
cDNA	O
fragment	O
is	O
deleted	O
,	O
cells	O
are	O
unable	O
to	O
form	O
a	O
colony	O
(	O
Figure	O
4A	O
,	O
c	O
and	O
c2	O
)	O
.	O

As	O
shown	O
in	O
Table	O
2	O
,	O
FASAY	O
was	O
performed	O
as	O
a	O
p53	O
-	O
standard	O
test	O
with	O
full	O
-	O
length	O
cDNA	O
or	O
with	O
the	O
split	O
version	O
at	O
the	O
5	O
'	O
and	O
3	O
'	O
end	O
(	O
15	O
)	O
.	O

The	O
background	O
of	O
FASAY	O
experiments	O
is	O
around	O
10	O
%	O
.	O

p53	O
wt	O
expressing	O
SH	O
-	O
SY5Y	O
and	O
LAN	O
-	O
5	O
,	O
2	O
wt	O
cell	O
lines	O
,	O
yielded	O
~	O
92	O
-	O
97	O
%	O
of	O
white	O
colonies	O
(	O
Table	O
2	O
)	O
.	O

One	O
hundred	O
percent	O
of	O
the	O
colonies	O
carrying	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
p53	O
,	O
which	O
is	O
homozygous	O
for	O
the	O
C135F	O
mutation	O
,	O
turned	O
red	O
with	O
the	O
standard	O
or	O
5	O
'	O
split	O
assay	O
,	O
whereas	O
94	O
%	O
of	O
the	O
colonies	O
turned	O
white	O
with	O
the	O
3	O
'	O
split	O
assay	O
since	O
the	O
missense	O
mutation	O
does	O
not	O
extend	O
to	O
the	O
C	O
'	O
-	O
terminus	O
of	O
the	O
gene	O
(	O
Table	O
2	O
and	O
Figure	O
4B	O
,	O
dish	O
c	O
)	O
.	O

No	O
colonies	O
were	O
observed	O
with	O
p53	O
-	O
deficient	O
LAN	O
-	O
1	O
cells	O
,	O
(	O
see	O
also	O
Figure	O
4A	O
,	O
c	O
and	O
c2	O
)	O
.	O

With	O
SK	O
-	O
N	O
-	O
AS	O
cells	O
,	O
the	O
split	O
5	O
'	O
assay	O
gave	O
96	O
%	O
white	O
colonies	O
,	O
while	O
the	O
p53	O
-	O
standard	O
and	O
split	O
3	O
'	O
assay	O
did	O
not	O
produce	O
any	O
colonies	O
(	O
Table	O
2	O
)	O
.	O

This	O
means	O
that	O
the	O
5	O
'	O
terminus	O
was	O
intact	O
whereas	O
the	O
3	O
'	O
terminus	O
had	O
been	O
deleted	O
,	O
as	O
was	O
confirmed	O
by	O
nucleotide	O
sequence	O
analysis	O
.	O

The	O
IGR	O
-	O
NB8	O
colonies	O
,	O
however	O
,	O
were	O
red	O
both	O
with	O
the	O
p53	O
-	O
standard	O
assay	O
and	O
the	O
split	O
3	O
'	O
assay	O
.	O

In	O
the	O
IGR	O
-	O
N	O
-	O
91	O
cell	O
line	O
,	O
where	O
p53	O
harbors	O
two	O
contiguous	O
sets	O
of	O
exons	O
7	O
-	O
9	O
,	O
spanning	O
the	O
DBD	O
and	O
oligomerization	O
domain	O
,	O
it	O
is	O
interesting	O
to	O
note	O
that	O
the	O
yeast	B-LIVB
colonies	O
were	O
predominantly	O
white	O
(	O
Figure	O
4B	O
,	O
dish	O
b	O
)	O
with	O
the	O
split	O
5	O
'	O
and	O
the	O
split	O
3	O
'	O
assay	O
(	O
96	O
and	O
87	O
%	O
of	O
white	O
colonies	O
,	O
respectively	O
)	O
This	O
suggests	O
that	O
the	O
cells	O
express	O
a	O
binding	O
ability	O
that	O
is	O
specific	O
to	O
wild	O
-	O
type	O
p53	O
rather	O
than	O
mutated	O
p53	O
(	O
Table	O
2	O
)	O
.	O

Transcription	O
activity	O
of	O
SH	O
-	O
SY5Y	O
,	O
IGR	O
-	O
N	O
-	O
91	O
,	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
,	O
SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
p53	O
variants	O
in	O
mammalian	O
cells	O

To	O
determine	O
the	O
transactivation	O
ability	O
of	O
p53	O
variants	O
in	O
mammalian	O
cells	O
,	O
we	O
used	O
a	O
reporter	O
gene	O
strategy	O
.	O

The	O
p53RE	O
located	O
within	O
either	O
the	O
human	B-LIVB
p21	O
/	O
WAF1	O
promoter	O
or	O
the	O
intron	O
1	O
of	O
the	O
mouse	B-LIVB
and	O
human	B-LIVB
BAX	O
gene	O
[	O
(	O
18	O
)	O
and	O
D	O
.	O

Munsch	O
,	O
personnal	O
communication	O
)	O
were	O
cloned	O
in	O
a	O
luciferase	O
reporter	O
gene	O
plasmid	O
upstream	O
of	O
the	O
E1B	O
minimal	O
promoter	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O

The	O
p53	O
-	O
negative	O
LAN	O
-	O
1	O
cells	O
were	O
cotransfected	O
with	O
the	O
p53	O
vectors	O
expressing	O
the	O
p53	O
cloned	O
from	O
either	O
SH	O
-	O
SY5Y	O
,	O
IGR	O
-	O
N	O
-	O
91	O
,	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
,	O
SK	O
-	O
N	O
-	O
AS	O
or	O
IGR	O
-	O
NB8	O
and	O
the	O
luciferase	O
reporter	O
plasmids	O
.	O

Both	O
p53RE	O
were	O
strongly	O
stimulated	O
in	O
cells	O
cotransfected	O
with	O
wt	O
p53	O
cloned	O
from	O
SH	O
-	O
SY5Y	O
,	O
as	O
compared	O
to	O
cells	O
cotransfected	O
with	O
an	O
empty	O
plasmid	O
.	O

In	O
contrast	O
,	O
none	O
of	O
the	O
p53	O
variants	O
was	O
able	O
to	O
transactivate	O
the	O
expression	O
of	O
luciferase	O
driven	O
by	O
either	O
p21	O
/	O
WAF1	O
or	O
BAX	O
p53RE	O
(	O
Figure	O
5	O
)	O
.	O

To	O
test	O
transactivation	O
capability	O
at	O
the	O
protein	O
level	O
,	O
each	O
variant	O
was	O
transfected	O
into	O
p53	O
-	O
negative	O
LAN	O
-	O
1	O
cells	O
and	O
the	O
stimulation	O
of	O
endogenous	O
p21	O
/	O
Waf1	O
gene	O
expression	O
was	O
analyzed	O
by	O
western	O
blotting	O
.	O

As	O
shown	O
in	O
Figure	O
6	O
,	O
in	O
contrast	O
to	O
wt	O
p53	O
,	O
none	O
of	O
the	O
p53	O
variants	O
was	O
able	O
to	O
induce	O
p21	O
protein	O
accumulation	O
.	O

We	O
then	O
tested	O
for	O
a	O
possible	O
dominant	O
negative	O
effect	O
of	O
these	O
various	O
mutants	O
on	O
wt	O
p53	O
-	O
dependent	O
transcriptional	O
activity	O
.	O

To	O
this	O
end	O
,	O
SH	O
-	O
SY5Y	O
cells	O
were	O
cotransfected	O
with	O
constructs	O
encoding	O
the	O
luciferase	O
gene	O
driven	O
by	O
either	O
the	O
p21	O
/	O
Waf1	O
or	O
BAX	O
p53RE	O
and	O
the	O
constructs	O
expressing	O
the	O
various	O
p53s	O
cloned	O
from	O
IGR	O
-	O
NB8	O
,	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
,	O
IGR	O
-	O
N	O
-	O
91	O
,	O
SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
NB	O
cells	O
or	O
p53DD	O
,	O
a	O
dominant	O
negative	O
mutant	O
of	O
wt	O
p53	O
(	O
24	O
)	O
.	O

The	O
stress	O
induced	O
by	O
transfection	O
activated	O
the	O
transcriptional	O
activity	O
of	O
the	O
wt	O
p53	O
expressed	O
in	O
SH	O
-	O
SY5Y	O
,	O
leading	O
to	O
a	O
p53	O
-	O
dependent	O
expression	O
of	O
luciferase	O
as	O
illustrated	O
by	O
the	O
fact	O
that	O
coexpression	O
of	O
p53DD	O
led	O
to	O
a	O
substantial	O
decrease	O
in	O
luciferase	O
activity	O
when	O
compared	O
to	O
the	O
luciferase	O
activity	O
of	O
cells	O
cotransfected	O
with	O
an	O
empty	O
plasmid	O
(	O
Figure	O
5	O
)	O
.	O

Compared	O
to	O
p53DD	O
,	O
mutants	O
within	O
the	O
DBD	O
isolated	O
from	O
IGR	O
-	O
N	O
-	O
91	O
or	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
had	O
only	O
a	O
moderate	O
dominant	O
negative	O
effect	O
on	O
endogenous	O
wt	O
p53	O
transcriptional	O
activity	O
.	O

More	O
surprisingly	O
,	O
the	O
transfection	O
of	O
the	O
C	O
-	O
terminal	O
truncated	O
variant	O
IGR	O
-	O
NB8	O
enhanced	O
both	O
BAX	O
and	O
p21	O
/	O
WAF1	O
p53RE	O
activity	O
.	O

The	O
coexpression	O
of	O
p53	O
beta	O
cloned	O
from	O
SK	O
-	O
N	O
-	O
AS	O
also	O
enhanced	O
BAX	O
p53RE	O
activity	O
.	O

A	O
similar	O
effect	O
has	O
been	O
reported	O
already	O
for	O
p53	O
beta	O
by	O
Bourdon	O
et	O
al	O
.	O

(	O
22	O
)	O
.	O

When	O
combined	O
,	O
these	O
results	O
show	O
that	O
all	O
the	O
p53	O
variants	O
isolated	O
from	O
the	O
NB	O
cells	O
had	O
lost	O
the	O
ability	O
to	O
specifically	O
transactivate	O
the	O
p53	O
target	O
genes	O
.	O

Their	O
effect	O
on	O
the	O
transcriptional	O
activity	O
of	O
endogenous	O
wt	O
p53	O
expressed	O
in	O
SH	O
-	O
SY5Y	O
cells	O
,	O
however	O
,	O
largely	O
depended	O
on	O
the	O
p53	O
domain	O
affected	O
by	O
the	O
modification	O
.	O

All	O
the	O
identified	O
p53	O
variants	O
inhibited	O
the	O
induction	O
of	O
endogenous	O
p21	O
/	O
WAF1	O
gene	O
expression	O
under	O
stress	O
conditions	O

We	O
further	O
examined	O
whether	O
the	O
four	O
p53	O
variants	O
,	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
,	O
IGR	O
-	O
N	O
-	O
91	O
,	O
SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
,	O
had	O
loss	O
their	O
ability	O
to	O
stimulate	O
the	O
endogenous	O
expression	O
of	O
the	O
p21	O
/	O
WAF1	O
gene	O
,	O
the	O
archetypical	O
cell	O
cycle	O
inhibitor	O
and	O
the	O
true	O
target	O
of	O
p53	O
.	O

To	O
this	O
end	O
,	O
cellular	O
response	O
to	O
genotoxic	O
stress	O
was	O
analyzed	O
by	O
western	O
blot	O
following	O
treatment	O
of	O
the	O
various	O
cell	O
lines	O
with	O
cisplatin	O
,	O
one	O
of	O
the	O
most	O
potent	O
antitumor	O
agents	O
used	O
in	O
neuroblastoma	O
.	O

Results	O
are	O
presented	O
in	O
Figure	O
7	O
.	O

None	O
of	O
the	O
mutant	O
cells	O
,	O
regardless	O
of	O
the	O
type	O
of	O
mutation	O
,	O
was	O
able	O
to	O
induce	O
p21	O
/	O
WAF1	O
protein	O
accumulation	O
,	O
unlike	O
the	O
3	O
p53	O
wild	O
-	O
type	O
cells	O
(	O
SH	O
-	O
SY5Y	O
,	O
IMR	O
-	O
32	O
and	O
LAN	O
-	O
5	O
)	O
.	O

Genomic	O
status	O
of	O
TP53	O
region	O
in	O
the	O
various	O
cell	O
lines	O

According	O
to	O
Knudson	O
'	O
s	O
'	O
two	O
hit	O
'	O
model	O
of	O
tumor	O
suppressor	O
gene	O
functional	O
inactivation	O
,	O
the	O
mutation	O
of	O
one	O
allele	O
is	O
supposed	O
to	O
be	O
associated	O
with	O
a	O
deletion	O
of	O
the	O
second	O
allele	O
.	O

To	O
assess	O
this	O
genetic	O
mechanism	O
,	O
we	O
performed	O
FISH	O
experiments	O
to	O
search	O
for	O
deletions	O
of	O
one	O
copy	O
of	O
the	O
TP53	O
region	O
,	O
especially	O
in	O
cell	O
lines	O
with	O
a	O
mutated	O
TP53	O
gene	O
.	O

For	O
this	O
purpose	O
,	O
metaphase	O
preparations	O
of	O
the	O
studied	O
cell	O
lines	O
were	O
cohybridized	O
with	O
a	O
p53	O
DNA	O
probe	O
labeled	O
in	O
red	O
(	O
BAC	O
clone	O
RP11	O
-	O
199F11	O
)	O
as	O
described	O
previously	O
(	O
25	O
)	O
and	O
a	O
chromosome	O
17	O
-	O
specific	O
centromeric	O
probe	O
labeled	O
in	O
green	O
.	O

The	O
three	O
cell	O
lines	O
shown	O
previously	O
to	O
express	O
a	O
wt	O
p53	O
protein	O
(	O
LAN5	O
,	O
IMR32	O
and	O
SH	O
-	O
SY5Y	O
)	O
,	O
displayed	O
as	O
expected	O
two	O
signals	O
with	O
each	O
probe	O
,	O
confirming	O
the	O
presence	O
of	O
both	O
TP53	O
alleles	O
in	O
these	O
cells	O
(	O
Figure	O
8	O
and	O
Table	O
3	O
)	O
.	O

Conversely	O
,	O
IGR	O
-	O
N	O
-	O
91	O
and	O
SK	O
-	O
N	O
-	O
AS	O
cell	O
lines	O
displayed	O
only	O
one	O
fluorescent	O
signal	O
for	O
each	O
probe	O
,	O
suggesting	O
a	O
whole	O
chromosome	O
17	O
lost	O
,	O
or	O
at	O
least	O
losses	O
of	O
the	O
17p	O
arm	O
and	O
the	O
centromeric	O
region	O
.	O

The	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
cell	O
line	O
has	O
been	O
described	O
as	O
containing	O
only	O
one	O
chromosome	O
17	O
and	O
one	O
TP53	O
signal	O
(	O
10	O
)	O
.	O

In	O
our	O
analysis	O
,	O
only	O
10	O
%	O
of	O
the	O
cells	O
displayed	O
this	O
characteristic	O
,	O
whilst	O
most	O
of	O
the	O
cells	O
had	O
two	O
copies	O
of	O
both	O
(	O
Figure	O
8	O
and	O
Table	O
3	O
)	O
.	O

p53	O
sequencing	O
,	O
however	O
,	O
confirmed	O
the	O
previously	O
described	O
mutation	O
,	O
and	O
the	O
absence	O
of	O
a	O
normal	O
allele	O
,	O
suggesting	O
that	O
the	O
cells	O
used	O
in	O
our	O
study	O
had	O
acquired	O
,	O
during	O
culture	O
,	O
an	O
uniparental	O
disomy	O
for	O
the	O
TP53	O
-	O
mutated	O
chromosome	O
17	O
.	O

Finally	O
,	O
the	O
other	O
two	O
cell	O
lines	O
(	O
LAN	O
-	O
1	O
and	O
IGR	O
-	O
NB8	O
)	O
displayed	O
highly	O
variable	O
genetic	O
heterogeneity	O
from	O
one	O
cell	O
to	O
the	O
next	O
(	O
Table	O
3	O
)	O
.	O

Surprisingly	O
,	O
although	O
p53	O
transcripts	O
are	O
extremely	O
faintly	O
expressed	O
in	O
LAN	O
-	O
1	O
cell	O
line	O
,	O
all	O
cells	O
showed	O
several	O
FISH	O
signals	O
with	O
the	O
167	O
kb	O
BAC	O
probe	O
used	O
here	O
.	O

To	O
understand	O
this	O
apparent	O
contradiction	O
,	O
an	O
array	O
-	O
CGH	O
experiment	O
was	O
performed	O
on	O
an	O
oligo	O
-	O
array	O
Agilent	O
,	O
which	O
indicated	O
a	O
133	O
kb	O
interstitial	O
deletion	O
corresponding	O
to	O
the	O
p53	O
coding	O
region	O
and	O
the	O
97	O
kb	O
upstream	O
region	O
.	O

Accordingly	O
,	O
the	O
fluorescent	O
spots	O
observed	O
in	O
FISH	O
experiments	O
on	O
LAN	O
-	O
1	O
cells	O
should	O
be	O
related	O
to	O
the	O
hybridization	O
of	O
the	O
57	O
kb	O
region	O
downstream	O
of	O
p53	O
gene	O
present	O
in	O
the	O
BAC	O
probe	O
.	O

IGRN	O
-	O
B8	O
cell	O
line	O
displayed	O
a	O
number	O
of	O
signals	O
of	O
both	O
colors	O
ranging	O
from	O
0	O
to	O
4	O
,	O
with	O
87	O
%	O
of	O
cells	O
displaying	O
a	O
loss	O
for	O
one	O
TP53	O
allele	O
.	O

Despite	O
this	O
genomic	O
variability	O
,	O
analysis	O
of	O
the	O
p53	O
protein	O
showed	O
a	O
single	O
shortened	O
form	O
in	O
IGR	O
-	O
N	O
-	O
B8	O
cell	O
line	O
(	O
Figure	O
1	O
)	O
.	O

Consequently	O
,	O
and	O
as	O
suggested	O
for	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
cell	O
line	O
,	O
IGR	O
-	O
N	O
-	O
B8	O
cell	O
line	O
should	O
contain	O
a	O
variable	O
number	O
of	O
copies	O
of	O
chromosome	O
17	O
with	O
mutated	O
p53	O
.	O

DISCUSSION	O

The	O
p53	O
gene	O
,	O
the	O
'	O
genome	O
guardian	O
'	O
,	O
is	O
mutated	O
in	O
over	O
50	O
%	O
of	O
human	B-LIVB
cancers	O
,	O
with	O
the	O
most	O
common	O
mutations	O
being	O
missense	O
mutations	O
(	O
>	O
2	O
/	O
3	O
of	O
mutations	O
)	O
(	O
26	O
)	O
.	O

In	O
human	B-LIVB
neuroblastoma	O
tumors	O
,	O
p53	O
mutations	O
are	O
rarely	O
present	O
at	O
the	O
time	O
of	O
diagnosis	O
(	O
5	O
,	O
27	O
)	O
;	O
however	O
,	O
oncogenic	O
p53	O
mutations	O
can	O
be	O
found	O
in	O
advanced	O
neuroblastomas	O
that	O
often	O
relapse	O
following	O
high	O
-	O
dose	O
chemotherapy	O
(	O
10	O
)	O
.	O

In	O
contrast	O
,	O
in	O
breast	O
cancers	O
,	O
it	O
has	O
been	O
reported	O
that	O
p53	O
mutations	O
might	O
improve	O
response	O
to	O
high	O
-	O
dose	O
chemotherapy	O
including	O
therapy	O
with	O
epirubicin	O
and	O
cyclophosphamide	O
(	O
28	O
)	O
.	O

An	O
investigation	O
into	O
the	O
p53	O
genomic	O
status	O
and	O
functions	O
of	O
eight	O
human	B-LIVB
NB	O
lines	O
revealed	O
that	O
all	O
five	O
of	O
the	O
mutated	O
cell	O
lines	O
had	O
distinct	O
genetic	O
characteristics	O
as	O
is	O
schematically	O
represented	O
in	O
Figure	O
9	O
:	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
with	O
a	O
single	O
missense	O
mutation	O
in	O
the	O
p53	O
gene	O
,	O
encoding	O
a	O
highly	O
stable	O
full	O
-	O
length	O
protein	O
.	O

SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
proteins	O
,	O
although	O
they	O
have	O
intact	O
transactivation	O
and	O
DBDs	O
,	O
were	O
truncated	O
at	O
the	O
C	O
-	O
terminus	O
generating	O
341	O
and	O
326	O
amino	O
acids	O
respectively	O
;	O
they	O
therefore	O
lack	O
the	O
tetramerization	O
domain	O
that	O
is	O
essential	O
for	O
an	O
active	O
conformation	O
.	O

Very	O
recently	O
,	O
Bourdon	O
et	O
al	O
.	O

(	O
22	O
)	O
reported	O
the	O
putative	O
occurrence	O
of	O
beta	O
and	O
gamma	O
isoforms	O
from	O
different	O
tissues	O
due	O
to	O
alternate	O
splicing	O
that	O
indicates	O
the	O
similarity	O
to	O
those	O
of	O
p73	O
and	O
p63	O
as	O
identified	O
previously	O
by	O
Daniel	O
Caput	O
and	O
co	O
-	O
workers	O
(	O
29	O
)	O
.	O

In	O
the	O
p53	O
isoforms	O
scheme	O
proposed	O
by	O
Bourdon	O
et	O
al	O
.	O

(	O
22	O
)	O
,	O
the	O
SK	O
-	O
N	O
-	O
AS	O
cell	O
line	O
that	O
elicits	O
p53i9	O
protein	O
expression	O
is	O
consistent	O
with	O
the	O
p53	O
beta	O
isoform	O
.	O

Genomic	O
analysis	O
reveals	O
that	O
the	O
only	O
occurrence	O
of	O
the	O
p53	O
beta	O
isoform	O
in	O
SK	O
-	O
N	O
-	O
AS	O
results	O
from	O
a	O
deletion	O
spanning	O
the	O
intron	O
9	O
/	O
exon	O
10	O
junction	O
.	O

Similar	O
to	O
the	O
p53	O
beta	O
isoform	O
in	O
SK	O
-	O
N	O
-	O
AS	O
,	O
the	O
p53	O
in	O
IGR	O
-	O
NB8	O
that	O
lacks	O
67	O
amino	O
acids	O
at	O
C	O
-	O
terminus	O
was	O
,	O
alone	O
,	O
unable	O
to	O
induce	O
p21	O
/	O
WAF1	O
promoter	O
activation	O
except	O
with	O
endogenous	O
wt	O
-	O
p53	O
on	O
SH	O
-	O
SY5Y	O
cells	O
where	O
transfection	O
with	O
IGR	O
-	O
NB8	O
significantly	O
augmented	O
the	O
transcriptional	O
activation	O
of	O
the	O
p21	O
/	O
Waf	O
-	O
1	O
promoter	O
(	O
Figure	O
5A	O
)	O
.	O

Studies	O
by	O
other	O
authors	O
have	O
reported	O
the	O
interaction	O
between	O
the	O
C	O
-	O
terminal	O
domain	O
and	O
another	O
region	O
that	O
impedes	O
the	O
active	O
conformation	O
of	O
p53	O
,	O
suggesting	O
an	O
allosteric	O
model	O
for	O
p53	O
activity	O
regulation	O
(	O
30	O
)	O
.	O

Such	O
events	O
have	O
been	O
demonstrated	O
for	O
the	O
342	O
-	O
stop	O
mutant	O
,	O
generated	O
by	O
mutagenesis	O
,	O
which	O
can	O
modulate	O
transactivation	O
,	O
growth	O
and	O
apoptosis	O
(	O
31	O
)	O
.	O

Moreover	O
,	O
Harms	O
and	O
Chen	O
(	O
32	O
)	O
reported	O
that	O
the	O
C	O
-	O
terminal	O
basic	O
domain	O
inhibits	O
induction	O
of	O
the	O
proapoptotic	O
target	O
gene	O
insulin	O
-	O
like	O
growth	O
factor	O
binding	O
protein	O
3	O
,	O
suggesting	O
that	O
IGR	O
-	O
NB8	O
might	O
induce	O
this	O
gene	O
.	O

IGR	O
-	O
N	O
-	O
91	O
had	O
an	O
abnormally	O
high	O
molecular	O
weight	O
protein	O
due	O
to	O
the	O
duplication	O
of	O
wild	O
-	O
type	O
exons	O
7	O
-	O
8	O
-	O
9	O
,	O
thus	O
affecting	O
the	O
DBD	O
and	O
OD	O
;	O
and	O
LAN	O
-	O
1	O
,	O
with	O
a	O
mutation	O
at	O
codon	O
182	O
(	O
Cys	O
-->	O
stop	O
)	O
concurred	O
with	O
an	O
earlier	O
report	O
showing	O
extremely	O
low	O
levels	O
of	O
mRNA	O
and	O
undetectable	O
protein	O
expression	O
(	O
9	O
)	O
.	O

Notably	O
,	O
all	O
the	O
p53	O
variants	O
,	O
including	O
SK	O
-	O
N	O
-	O
AS	O
(	O
beta	O
isoform	O
)	O
and	O
IGR	O
-	O
NB8	O
(	O
C	O
-	O
terminal	O
truncated	O
p53	O
)	O
,	O
elicited	O
a	O
total	O
lack	O
of	O
p21	O
promoter	O
activation	O
.	O

In	O
particular	O
,	O
the	O
p53	O
beta	O
isoform	O
was	O
unable	O
to	O
induce	O
endogenous	O
p21	O
expression	O
in	O
SK	O
-	O
N	O
-	O
AS	O
(	O
Figure	O
6	O
)	O
,	O
concurring	O
with	O
data	O
obtained	O
from	O
in	O
vitro	O
transfection	O
experiments	O
in	O
H1299	O
cells	O
by	O
Bourdon	O
et	O
al	O
.	O

(	O
22	O
)	O
.	O

For	O
the	O
IGR	O
-	O
N	O
-	O
91	O
cells	O
,	O
although	O
p53	O
was	O
mutated	O
and	O
unable	O
to	O
transactivate	O
the	O
p21	O
/	O
WAF1	O
promoter	O
,	O
the	O
FASAY	O
global	O
test	O
was	O
not	O
conclusive	O
since	O
~	O
80	O
%	O
of	O
colonies	O
were	O
white	O
and	O
nearly	O
20	O
%	O
(	O
see	O
also	O
Table	O
2	O
)	O
,	O
though	O
not	O
enough	O
,	O
were	O
red	O
.	O

Moreover	O
,	O
in	O
this	O
particular	O
line	O
,	O
standard	O
sequencing	O
on	O
cDNA	O
using	O
primers	O
located	O
within	O
each	O
exon	O
as	O
used	O
for	O
routine	O
tumor	O
analysis	O
was	O
unable	O
to	O
detect	O
any	O
anomalies	O
in	O
p53	O
genetic	O
status	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
results	O
enlighten	O
the	O
limit	O
of	O
the	O
conventional	O
tests	O
to	O
detect	O
a	O
transcription	O
inactivation	O
of	O
p53	O
brought	O
by	O
duplication	O
within	O
the	O
DBD	O
.	O

Analysis	O
of	O
p53	O
genomic	O
status	O
was	O
explored	O
by	O
FISH	O
experiments	O
,	O
in	O
search	O
for	O
a	O
potential	O
biallelic	O
inactivation	O
of	O
p53	O
,	O
with	O
a	O
mutation	O
of	O
one	O
allele	O
and	O
a	O
deletion	O
of	O
the	O
second	O
one	O
.	O

This	O
situation	O
was	O
indeed	O
clearly	O
observed	O
in	O
IGR	O
-	O
N	O
-	O
91	O
and	O
SK	O
-	O
N	O
-	O
AS	O
cell	O
lines	O
,	O
with	O
an	O
unambiguous	O
loss	O
of	O
one	O
chromosome	O
17p	O
arm	O
in	O
all	O
cells	O
of	O
both	O
.	O

SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
,	O
LAN	O
-	O
1	O
and	O
IGR	O
-	O
NB	O
-	O
8	O
cell	O
lines	O
showed	O
a	O
more	O
complex	O
genomic	O
situation	O
which	O
should	O
be	O
relevant	O
of	O
variable	O
copy	O
numbers	O
of	O
chromosome	O
17	O
bearing	O
in	O
most	O
cases	O
(	O
LAN	O
-	O
1	O
)	O
or	O
in	O
all	O
cases	O
[	O
SKN	O
-	O
BE	O
(	O
2	O
)	O
,	O
IGR	O
-	O
NB8	O
]	O
the	O
mutated	O
characteristic	O
p53	O
allele	O
.	O

Our	O
data	O
therefore	O
clearly	O
demonstrate	O
that	O
each	O
technique	O
has	O
a	O
role	O
and	O
a	O
combination	O
of	O
techniques	O
is	O
required	O
in	O
order	O
to	O
correctly	O
define	O
the	O
p53	O
phenotype	O
and	O
genotype	O
in	O
tumor	O
and	O
particularly	O
in	O
NB	O
cells	O
.	O

Our	O
data	O
enlighten	O
a	O
high	O
frequency	O
of	O
the	O
C	O
-	O
terminal	O
abnormalities	O
(	O
3	O
/	O
5	O
mutated	O
)	O
in	O
NB	O
cell	O
lines	O
.	O

For	O
SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
,	O
a	O
part	O
of	O
the	O
oligomerization	O
domain	O
was	O
lost	O
and	O
IGR	O
-	O
N	O
-	O
91	O
gained	O
an	O
extra	O
oligomerization	O
domain	O
.	O

According	O
to	O
FASAY	O
assay	O
the	O
p53	O
expressed	O
in	O
IGR	O
-	O
N	O
-	O
91	O
still	O
specifically	O
bind	O
DNA	O
but	O
not	O
the	O
p53	O
expressed	O
in	O
SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
in	O
agreement	O
with	O
previous	O
published	O
data	O
obtained	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
33	O
)	O
.	O

With	O
regards	O
to	O
biological	O
relevance	O
,	O
different	O
mutants	O
within	O
the	O
DBD	O
vary	O
in	O
their	O
oncogenicity	O
.	O

They	O
are	O
classified	O
into	O
two	O
types	O
depending	O
of	O
the	O
location	O
of	O
the	O
mutation	O
,	O
mutations	O
of	O
class	O
I	O
occur	O
in	O
the	O
DNA	O
contact	O
areas	O
,	O
while	O
class	O
II	O
mutations	O
occur	O
in	O
areas	O
important	O
for	O
the	O
conformational	O
stability	O
of	O
p53	O
protein	O
(	O
30	O
)	O
.	O

Although	O
both	O
class	O
I	O
and	O
class	O
II	O
mutants	O
have	O
loss	O
its	O
ability	O
to	O
specifically	O
bind	O
DNA	O
,	O
class	O
II	O
mutations	O
have	O
been	O
shown	O
to	O
be	O
more	O
oncogenic	O
than	O
class	O
I	O
.	O

However	O
,	O
to	O
our	O
knowledge	O
the	O
oncogenicity	O
of	O
mutant	O
affecting	O
the	O
C	O
-	O
terminal	O
domain	O
have	O
not	O
been	O
studied	O
.	O

The	O
biological	O
role	O
of	O
the	O
C	O
-	O
terminal	O
mutants	O
needs	O
now	O
to	O
be	O
thoroughly	O
investigated	O
in	O
NB	O
tumors	O
.	O

MUC1	O
alters	O
oncogenic	O
events	O
and	O
transcription	O
in	O
human	B-LIVB
breast	O
cancer	O
cells	O

Abstract	O

Introduction	O

MUC1	O
is	O
an	O
oncoprotein	O
whose	O
overexpression	O
correlates	O
with	O
aggressiveness	O
of	O
tumors	O
and	O
poor	O
survival	O
of	O
cancer	O
patients	B-LIVB
.	O

Many	O
of	O
the	O
oncogenic	O
effects	O
of	O
MUC1	O
are	O
believed	O
to	O
occur	O
through	O
interaction	O
of	O
its	O
cytoplasmic	O
tail	O
with	O
signaling	O
molecules	O
.	O

As	O
expected	O
for	O
a	O
protein	O
with	O
oncogenic	O
functions	O
,	O
MUC1	O
is	O
linked	O
to	O
regulation	O
of	O
proliferation	O
,	O
apoptosis	O
,	O
invasion	O
,	O
and	O
transcription	O
.	O

Methods	O

To	O
clarify	O
the	O
role	O
of	O
MUC1	O
in	O
cancer	O
,	O
we	O
transfected	O
two	O
breast	O
cancer	O
cell	O
lines	O
(	O
MDA	O
-	O
MB	O
-	O
468	O
and	O
BT	O
-	O
20	O
)	O
with	O
small	O
interfering	O
(	O
si	O
)	O
RNA	O
directed	O
against	O
MUC1	O
and	O
analyzed	O
transcriptional	O
responses	O
and	O
oncogenic	O
events	O
(	O
proliferation	O
,	O
apoptosis	O
and	O
invasion	O
)	O
.	O

Results	O

Transcription	O
of	O
several	O
genes	O
was	O
altered	O
after	O
transfection	O
of	O
MUC1	O
siRNA	O
,	O
including	O
decreased	O
MAP2K1	O
(	O
MEK1	O
)	O
,	O
JUN	O
,	O
PDGFA	O
,	O
CDC25A	O
,	O
VEGF	O
and	O
ITGAV	O
(	O
integrin	O
alpha	O
v	O
)	O
,	O
and	O
increased	O
TNF	O
,	O
RAF1	O
,	O
and	O
MMP2	O
.	O

Additional	O
changes	O
were	O
seen	O
at	O
the	O
protein	O
level	O
,	O
such	O
as	O
increased	O
expression	O
of	O
c	O
-	O
Myc	O
,	O
heightened	O
phosphorylation	O
of	O
AKT	O
,	O
and	O
decreased	O
activation	O
of	O
MEK1	O
/	O
2	O
and	O
ERK1	O
/	O
2	O
.	O

These	O
were	O
correlated	O
with	O
cellular	O
events	O
,	O
as	O
MUC1	O
siRNA	O
in	O
the	O
MDA	O
-	O
MB	O
-	O
468	O
line	O
decreased	O
proliferation	O
and	O
invasion	O
,	O
and	O
increased	O
stress	O
-	O
induced	O
apoptosis	O
.	O

Intriguingly	O
,	O
BT	O
-	O
20	O
cells	O
displayed	O
similar	O
levels	O
of	O
apoptosis	O
regardless	O
of	O
siRNA	O
,	O
and	O
actually	O
increased	O
proliferation	O
after	O
MUC1	O
siRNA	O
.	O

Conclusion	O

These	O
results	O
further	O
the	O
growing	O
knowledge	O
of	O
the	O
role	O
of	O
MUC1	O
in	O
transcription	O
,	O
and	O
suggest	O
that	O
the	O
regulation	O
of	O
MUC1	O
in	O
breast	O
cancer	O
may	O
be	O
more	O
complex	O
than	O
previously	O
appreciated	O
.	O

The	O
differences	O
between	O
these	O
two	O
cell	O
lines	O
emphasize	O
the	O
importance	O
of	O
understanding	O
the	O
context	O
of	O
cell	O
-	O
specific	O
signaling	O
events	O
when	O
analyzing	O
the	O
oncogenic	O
functions	O
of	O
MUC1	O
,	O
and	O
caution	O
against	O
generalizing	O
the	O
results	O
of	O
individual	O
cell	O
lines	O
without	O
adequate	O
confirmation	O
in	O
intact	O
biological	O
systems	O
.	O

Introduction	O

MUC1	O
is	O
the	O
founding	O
member	O
of	O
the	O
mucin	O
family	O
:	O
proteins	O
characterized	O
by	O
heavy	O
O	O
-	O
glycosylation	O
centering	O
around	O
a	O
variable	O
number	O
of	O
tandem	O
repeats	O
that	O
are	O
rich	O
in	O
serine	O
and	O
threonine	O
residues	O
[	O
1	O
,	O
2	O
]	O
.	O

MUC1	O
is	O
a	O
transmembrane	O
heterodimer	O
with	O
one	O
subunit	O
solely	O
extracellular	O
(	O
MUC1	O
-	O
EX	O
)	O
,	O
and	O
the	O
other	O
subunit	O
composed	O
of	O
a	O
short	O
extracellular	O
stem	O
,	O
a	O
single	O
transmembrane	O
domain	O
,	O
and	O
the	O
cytoplasmic	O
tail	O
(	O
together	O
called	O
the	O
MUC1	O
-	O
CT	O
)	O
.	O

MUC1	O
possesses	O
both	O
pro	O
-	O
and	O
anti	O
-	O
adhesive	O
capacities	O
,	O
as	O
the	O
MUC1	O
-	O
EX	O
provides	O
binding	O
sites	O
for	O
a	O
variety	O
of	O
adhesion	O
proteins	O
,	O
while	O
its	O
large	O
size	O
and	O
extended	O
structure	O
prevents	O
cell	O
-	O
cell	O
contact	O
[	O
3	O
-	O
5	O
]	O
.	O

Initially	O
described	O
as	O
a	O
tumor	O
antigen	O
overexpressed	O
in	O
>	O
90	O
%	O
of	O
breast	O
cancers	O
,	O
MUC1	O
is	O
now	O
known	O
to	O
be	O
an	O
oncogene	O
with	O
roles	O
in	O
both	O
tumor	O
formation	O
and	O
progression	O
[	O
1	O
,	O
6	O
]	O
.	O

Mouse	B-LIVB
studies	O
have	O
been	O
integral	O
to	O
the	O
current	O
understanding	O
of	O
MUC1	O
in	O
cancer	O
.	O

Muc1	O
knockout	O
mice	B-LIVB
(	O
Muc1	O
-	O
/	O
-	O
;	O
MUC1	O
is	O
human	B-LIVB
;	O
Muc1	O
is	O
mouse	B-LIVB
)	O
show	O
a	O
reduction	O
in	O
tumorigenic	O
phenotype	O
when	O
crossed	O
onto	O
mice	B-LIVB
overexpressing	O
the	O
Wnt	O
-	O
1	O
[	O
7	O
]	O
or	O
polyomavirus	O
middle	O
T	O
antigen	O
[	O
8	O
]	O
oncogenes	O
in	O
the	O
mammary	O
gland	O
.	O

In	O
contrast	O
,	O
MUC1	O
overexpression	O
in	O
the	O
mammary	O
gland	O
drives	O
tumor	O
formation	O
[	O
9	O
]	O
,	O
indicating	O
that	O
MUC1	O
is	O
a	O
true	O
oncogene	O
.	O

Many	O
of	O
the	O
oncogenic	O
effects	O
of	O
MUC1	O
stem	O
from	O
its	O
cytoplasmic	O
tail	O
,	O
which	O
binds	O
to	O
several	O
proteins	O
implicated	O
in	O
cancer	O
,	O
including	O
c	O
-	O
Src	O
[	O
10	O
,	O
11	O
]	O
and	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
family	O
[	O
12	O
,	O
13	O
]	O
.	O

MUC1	O
stimulates	O
mitogen	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
signaling	O
through	O
the	O
extracellular	O
signal	O
regulated	O
kinases	O
(	O
ERK1	O
/	O
2	O
)	O
[	O
12	O
,	O
14	O
]	O
;	O
this	O
can	O
occur	O
through	O
MUC1	O
association	O
with	O
Grb2	O
and	O
son	O
of	O
sevenless	O
to	O
activate	O
Ras	O
[	O
15	O
]	O
.	O

ERK1	O
/	O
2	O
signaling	O
is	O
commonly	O
stimulated	O
by	O
the	O
Ras	O
-	O
Raf	O
-	O
MEK	O
(	O
MAPK	O
and	O
ERK	O
kinase	O
)	O
cascade	O
downstream	O
of	O
mitogens	O
such	O
as	O
EGFR	O
[	O
16	O
]	O
,	O
and	O
regulates	O
transcription	O
via	O
factors	O
like	O
the	O
activator	O
protein	O
-	O
1	O
complex	O
.	O

Loss	O
of	O
MUC1	O
can	O
reduce	O
EGFR	O
expression	O
[	O
17	O
]	O
,	O
providing	O
another	O
means	O
of	O
affecting	O
MAPK	O
signaling	O
.	O

Our	O
results	O
describe	O
a	O
novel	O
mechanism	O
by	O
which	O
MUC1	O
regulates	O
the	O
ERK1	O
/	O
2	O
pathway	O
,	O
through	O
modulating	O
transcription	O
of	O
the	O
genes	O
encoding	O
MEK1	O
,	O
Raf	O
-	O
1	O
,	O
and	O
c	O
-	O
Jun	O
.	O

MUC1	O
expression	O
correlates	O
with	O
increased	O
survival	O
in	O
response	O
to	O
cytotoxic	O
or	O
oxidative	O
agents	O
[	O
18	O
-	O
21	O
]	O
,	O
and	O
can	O
activate	O
the	O
phosphoinositol	O
-	O
3	O
kinase	O
-	O
AKT	O
pathway	O
as	O
part	O
of	O
an	O
anti	O
-	O
apoptotic	O
response	O
[	O
18	O
]	O
.	O

MUC1	O
has	O
also	O
recently	O
been	O
linked	O
to	O
transcription	O
,	O
as	O
the	O
MUC1	O
-	O
CT	O
localizes	O
to	O
the	O
nucleus	O
[	O
22	O
]	O
and	O
affects	O
transcription	O
by	O
beta	O
-	O
catenin	O
[	O
22	O
,	O
23	O
]	O
,	O
FOXO3a	O
[	O
21	O
]	O
,	O
p53	O
[	O
24	O
]	O
,	O
and	O
estrogen	O
receptor	O
alpha	O
[	O
25	O
]	O
.	O

However	O
,	O
there	O
are	O
indications	O
that	O
the	O
role	O
of	O
MUC1	O
in	O
oncogenesis	O
is	O
regulated	O
by	O
cell	O
type	O
and	O
signaling	O
context	O
.	O

For	O
example	O
,	O
MUC1	O
can	O
stimulate	O
Fas	O
-	O
mediated	O
apoptosis	O
[	O
26	O
]	O
,	O
while	O
Muc1	O
is	O
specifically	O
down	O
-	O
regulated	O
in	O
c	O
-	O
neu	O
-	O
induced	O
mammary	O
tumors	O
[	O
27	O
]	O
.	O

This	O
report	O
emphasizes	O
the	O
complexity	O
of	O
MUC1	O
signaling	O
in	O
breast	O
cancer	O
by	O
contrasting	O
results	O
from	O
two	O
established	O
breast	O
cancer	O
cell	O
lines	O
.	O

To	O
understand	O
MUC1	O
function	O
in	O
cells	O
with	O
high	O
endogenous	O
expression	O
,	O
that	O
is	O
,	O
cells	O
likely	O
to	O
have	O
evolved	O
with	O
active	O
MUC1	O
signaling	O
,	O
we	O
used	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
to	O
knock	O
down	O
MUC1	O
in	O
MDA	O
-	O
MB	O
-	O
468	O
and	O
BT	O
-	O
20	O
cells	O
.	O

We	O
then	O
analyzed	O
transcription	O
of	O
84	O
genes	O
involved	O
in	O
cancer	O
,	O
as	O
well	O
as	O
the	O
effects	O
upon	O
cellular	O
events	O
linked	O
to	O
oncogenesis	O
,	O
such	O
as	O
apoptosis	O
and	O
proliferation	O
.	O

Though	O
the	O
cell	O
lines	O
show	O
some	O
similarity	O
in	O
transcriptional	O
alterations	O
after	O
transfection	O
with	O
MUC1	O
siRNA	O
,	O
their	O
phenotypes	O
are	O
quite	O
dissimilar	O
:	O
MDA	O
-	O
MB	O
-	O
468	O
increases	O
apoptosis	O
and	O
reduces	O
proliferation	O
and	O
invasion	O
,	O
while	O
BT	O
-	O
20	O
proliferates	O
more	O
rapidly	O
after	O
loss	O
of	O
MUC1	O
.	O

This	O
last	O
may	O
reflect	O
the	O
striking	O
amount	O
of	O
active	O
AKT	O
in	O
BT	O
-	O
20	O
;	O
AKT	O
activity	O
is	O
increased	O
in	O
both	O
cell	O
lines	O
after	O
MUC1	O
siRNA	O
,	O
which	O
agrees	O
with	O
a	O
previous	O
study	O
of	O
MUC1	O
siRNA	O
[	O
21	O
]	O
,	O
but	O
disagrees	O
with	O
results	O
from	O
3Y1	O
fibroblasts	O
[	O
18	O
]	O
.	O

Recent	O
studies	O
have	O
emphasized	O
the	O
complex	O
and	O
context	O
-	O
specific	O
regulation	O
of	O
even	O
such	O
classic	O
oncogenes	O
as	O
AKT	O
[	O
28	O
]	O
.	O

The	O
differences	O
between	O
the	O
two	O
breast	O
cancer	O
cell	O
lines	O
in	O
this	O
study	O
suggest	O
that	O
MUC1	O
oncogenic	O
functions	O
are	O
also	O
subject	O
to	O
cell	O
-	O
specific	O
regulation	O
,	O
and	O
stress	O
the	O
need	O
for	O
understanding	O
the	O
cellular	O
signaling	O
context	O
when	O
interpreting	O
results	O
.	O

Materials	O
and	O
methods	O

Cell	O
culture	O
and	O
siRNA	O
transfection	O

MDA	O
-	O
MB	O
-	O
468	O
and	O
BT	O
-	O
20	O
cells	O
(	O
American	O
Type	O
Culture	O
Collection	O
)	O
were	O
cultured	O
in	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
'	O
s	O
medium	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
plus	O
10	O
%	O
fetal	O
calf	B-LIVB
serum	O
,	O
1	O
%	O
Glutamax	O
(	O
Invitrogen	O
)	O
and	O
1	O
%	O
penicillin	O
/	O
streptomycin	O
.	O

Stable	O
cell	O
lines	O
(	O
468	O
.	O
Neo	O
and	O
468	O
.	O
MUC1	O
Delta	O
8	O
)	O
were	O
selected	O
with	O
0	O
.	O
5	O
mg	O
/	O
ml	O
G418	O
.	O

For	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
stimulation	O
,	O
MDA	O
-	O
MB	O
-	O
468	O
cells	O
were	O
serum	O
-	O
starved	O
overnight	O
and	O
treated	O
for	O
10	O
minutes	O
at	O
37	O
degrees	O
C	O
with	O
100	O
ng	O
/	O
ml	O
EGF	O
.	O

Transient	O
siRNA	O
transfection	O
was	O
performed	O
with	O
Lipofectamine2000	O
(	O
Invitrogen	O
)	O
and	O
100	O
nM	O
siRNA	O
oligonucleotides	O
.	O

The	O
commercially	O
available	O
siRNA	O
constructs	O
(	O
all	O
from	O
Dharmacon	O
,	O
Lafayette	O
,	O
CO	O
,	O
USA	O
)	O
were	O
scrambled	O
(	O
siCONTROL	O
non	O
-	O
targeting	O
siRNA	O
#	O
1	O
)	O
,	O
or	O
directed	O
against	O
firefly	O
luciferase	O
(	O
siCONTROL	O
non	O
-	O
targeting	O
siRNA	O
#	O
2	O
)	O
or	O
MUC1	O
(	O
siGENOME	O
smartpool	O
)	O
.	O

The	O
independent	O
oligonucleotides	O
designed	O
in	O
our	O
laboratory	O
target	O
sequences	O
beginning	O
at	O
MUC1	O
codons	O
882	O
and	O
956	O
,	O
and	O
have	O
been	O
described	O
previously	O
[	O
29	O
]	O
.	O

The	O
scrambled	O
siRNA	O
construct	O
was	O
used	O
only	O
in	O
BT	O
-	O
20	O
cells	O
as	O
it	O
causes	O
a	O
non	O
-	O
specific	O
knockdown	O
of	O
MUC1	O
in	O
the	O
MDA	O
-	O
MB	O
-	O
468	O
line	O
.	O

Cloning	O
of	O
MUC1	O
WT	O
vector	O
and	O
stable	O
transfection	O

Two	O
silent	O
mutations	O
(	O
G891A	O
and	O
T894C	O
)	O
were	O
introduced	O
into	O
the	O
MUC1	O
cDNA	O
(	O
called	O
MUC1	O
Delta	O
8	O
)	O
to	O
make	O
it	O
resistant	O
to	O
the	O
882	O
siRNA	O
that	O
targets	O
that	O
region	O
of	O
the	O
mRNA	O
.	O

The	O
mutant	O
cDNA	O
was	O
cloned	O
into	O
the	O
pLNCX	O
.	O
1	O
vector	O
with	O
neomycin	O
resistance	O
(	O
gift	O
of	O
Joseph	O
Loftus	O
,	O
Mayo	O
Clinic	O
,	O
Arizona	O
,	O
USA	O
)	O
.	O

Stable	O
transfection	O
was	O
performed	O
with	O
Lipofectamine2000	O
;	O
cells	O
were	O
selected	O
beginning	O
24	O
hours	O
post	O
-	O
transfection	O
and	O
maintained	O
as	O
a	O
polyclonal	O
population	O
.	O

Western	O
blots	O
and	O
antibodies	O

Cells	O
were	O
lysed	O
in	O
buffer	O
(	O
20	O
mM	O
HEPES	O
pH	O
8	O
.	O
0	O
,	O
150	O
mM	O
sodium	O
chloride	O
,	O
1	O
%	O
Triton	O
X	O
-	O
100	O
,	O
2	O
mM	O
EDTA	O
)	O
with	O
commercial	O
protease	O
(	O
Complete	O
inhibitor	O
cocktail	O
,	O
Roche	O
,	O
Pleasanton	O
,	O
CA	O
,	O
USA	O
)	O
and	O
phosphatase	O
inhibitors	O
(	O
10	O
mM	O
sodium	O
fluoride	O
,	O
2	O
mM	O
sodium	O
vanadate	O
,	O
50	O
mu	O
M	O
ammonium	O
molybdate	O
)	O
.	O

Protein	O
concentration	O
was	O
determined	O
by	O
BCA	O
(	O
Pierce	O
,	O
Rockford	O
,	O
IL	O
,	O
USA	O
)	O
;	O
50	O
mu	O
g	O
of	O
lysate	O
were	O
loaded	O
on	O
SDS	O
-	O
PAGE	O
gels	O
for	O
each	O
experiment	O
,	O
except	O
for	O
the	O
pMEK1	O
/	O
2	O
blot	O
in	O
MDA	O
-	O
MB	O
-	O
468	O
,	O
where	O
150	O
mu	O
g	O
were	O
used	O
.	O

Non	O
-	O
commercial	O
antibodies	O
used	O
were	O
:	O
BC2	O
,	O
a	O
mouse	B-LIVB
monoclonal	O
to	O
the	O
MUC1	O
-	O
EX	O
(	O
gift	O
of	O
Dr	O
McGuckin	O
,	O
Queensland	O
University	O
,	O
Queensland	O
,	O
Australia	O
)	O
,	O
and	O
CT2	O
,	O
an	O
Armenian	B-LIVB
hamster	I-LIVB
monoclonal	O
to	O
the	O
MUC1	O
-	O
CT	O
developed	O
in	O
our	O
lab	O
[	O
12	O
]	O
.	O

Antibodies	O
to	O
pMEK1	O
/	O
2	O
,	O
MEK1	O
/	O
2	O
,	O
ERK1	O
/	O
2	O
,	O
Myc	O
,	O
pAKT	O
,	O
AKT	O
,	O
beta	O
-	O
tubulin	O
(	O
all	O
Cell	O
Signaling	O
,	O
Danvers	O
,	O
MA	O
,	O
USA	O
)	O
,	O
beta	O
-	O
actin	O
and	O
dpERK1	O
/	O
2	O
(	O
both	O
Sigma	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
were	O
used	O
according	O
to	O
manufacturers	O
'	O
recommendations	O
.	O

All	O
antibodies	O
except	O
beta	O
-	O
actin	O
(	O
1	O
:	O
2	O
,	O
500	O
)	O
and	O
dpERK1	O
/	O
2	O
(	O
1	O
:	O
10	O
,	O
000	O
)	O
were	O
used	O
at	O
1	O
:	O
1	O
,	O
000	O
dilution	O
for	O
western	O
blots	O
.	O

Flow	O
cytometric	O
analysis	O
of	O
MUC1	O
was	O
done	O
with	O
HMPV	O
-	O
FITC	O
,	O
which	O
recognizes	O
the	O
core	O
peptide	O
of	O
the	O
MUC1	O
-	O
EX	O
tandem	O
repeats	O
(	O
Pharmingen	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Bromodeoxyuridine	O
(	O
BrdU	O
)	O
staining	O
was	O
performed	O
with	O
a	O
fluorescently	O
conjugated	O
antibody	O
to	O
BrdU	O
(	O
BrdU	O
-	O
PE	O
,	O
BD	O
Biosciences	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
as	O
described	O
below	O
.	O

Densitometry	O
was	O
performed	O
using	O
the	O
public	O
domain	O
ImageJ	O
program	O
(	O
developed	O
at	O
the	O
NIH	O
and	O
available	O
at	O
[	O
30	O
]	O
.	O

Each	O
band	O
was	O
measured	O
in	O
three	O
places	O
;	O
the	O
results	O
were	O
averaged	O
and	O
normalized	O
to	O
tubulin	O
to	O
control	O
for	O
loading	O
.	O

Transwell	O
invasion	O
assays	O

Cells	O
were	O
serum	O
-	O
starved	O
beginning	O
24	O
hours	O
post	O
-	O
siRNA	O
transfection	O
.	O

Cells	O
were	O
re	O
-	O
plated	O
in	O
serum	O
-	O
free	O
medium	O
48	O
hours	O
post	O
-	O
transfection	O
at	O
50	O
,	O
000	O
cells	O
per	O
insert	O
(	O
sized	O
for	O
24	O
-	O
well	O
plates	O
)	O
,	O
with	O
serum	O
-	O
containing	O
medium	O
in	O
the	O
bottom	O
of	O
the	O
growth	O
well	O
as	O
an	O
attractant	O
.	O

Transwell	O
inserts	O
(	O
BD	O
Biosciences	O
)	O
pre	O
-	O
coated	O
with	O
laminin	O
,	O
fibronectin	O
,	O
collagen	O
IV	O
,	O
or	O
control	O
(	O
no	O
matrix	O
)	O
were	O
used	O
,	O
and	O
cells	O
were	O
permitted	O
to	O
invade	O
for	O
48	O
hours	O
.	O

At	O
this	O
point	O
(	O
96	O
hours	O
post	O
-	O
transfection	O
)	O
,	O
visual	O
inspection	O
of	O
the	O
growth	O
wells	O
confirmed	O
that	O
negligible	O
numbers	O
of	O
cells	O
went	O
through	O
to	O
the	O
bottom	O
of	O
the	O
plate	O
.	O

Non	O
-	O
invaded	O
cells	O
were	O
swabbed	O
from	O
the	O
tops	O
of	O
half	O
of	O
the	O
inserts	O
(	O
'	O
samples	O
'	O
,	O
containing	O
only	O
invaded	O
cells	O
)	O
,	O
and	O
retained	O
in	O
the	O
others	O
(	O
'	O
controls	O
'	O
,	O
all	O
cells	O
)	O
.	O

Inserts	O
were	O
stained	O
for	O
10	O
minutes	O
with	O
crystal	O
violet	O
(	O
0	O
.	O
5	O
%	O
in	O
20	O
%	O
methanol	O
)	O
and	O
washed	O
with	O
water	O
.	O

Membranes	O
were	O
cut	O
out	O
and	O
destained	O
for	O
10	O
minutes	O
in	O
10	O
%	O
acetic	O
acid	O
in	O
a	O
96	O
-	O
well	O
plate	O
;	O
membranes	O
were	O
removed	O
and	O
absorbance	O
was	O
read	O
at	O
570	O
nm	O
.	O

Percent	O
invasion	O
is	O
defined	O
as	O
(	O
absorbance	O
of	O
samples	O
/	O
absorbance	O
of	O
controls	O
)	O
x	O
100	O
.	O

[	O
3H	O
]	O
Thymidine	O
incorporation	O
assays	O

Cells	O
were	O
re	O
-	O
plated	O
in	O
quadruplicate	O
24	O
hours	O
post	O
-	O
siRNA	O
transfection	O
at	O
15	O
,	O
000	O
cells	O
/	O
well	O
(	O
96	O
-	O
well	O
plate	O
)	O
with	O
[	O
3H	O
]	O
thymidine	O
(	O
1	O
mu	O
Ci	O
/	O
well	O
)	O
,	O
then	O
incubated	O
in	O
normal	O
conditions	O
for	O
24	O
hours	O
.	O

At	O
this	O
time	O
(	O
48	O
hours	O
post	O
-	O
siRNA	O
transfection	O
)	O
excess	O
radioactivity	O
was	O
washed	O
off	O
and	O
the	O
cells	O
were	O
harvested	O
and	O
read	O
on	O
a	O
TopCount	O
plate	O
reader	O
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
JMP	O
5	O
.	O
1	O
.	O
2	O
software	O
(	O
SAS	O
Institute	O
,	O
Inc	O
.	O
,	O
Cary	O
,	O
NC	O
,	O
USA	O
)	O
;	O
the	O
student	O
'	O
s	O
t	O
test	O
was	O
used	O
to	O
determine	O
p	O
values	O
and	O
significance	O
was	O
confirmed	O
with	O
Wilcoxon	O
rank	O
sum	O
and	O
Pearson	O
chi	O
squared	O
analyses	O
.	O

BrdU	O
incorporation	O

BrdU	O
(	O
50	O
mu	O
M	O
)	O
was	O
given	O
to	O
cells	O
48	O
hours	O
post	O
-	O
siRNA	O
transfection	O
and	O
permitted	O
to	O
incorporate	O
for	O
1	O
.	O
5	O
hours	O
.	O

Cells	O
were	O
then	O
washed	O
with	O
PBS	O
,	O
trypsinized	O
,	O
and	O
washed	O
again	O
.	O

BrdU	O
staining	O
was	O
performed	O
according	O
to	O
an	O
adaptation	O
of	O
the	O
manufacturer	O
'	O
s	O
protocol	O
:	O
cells	O
were	O
re	O
-	O
suspended	O
in	O
PBS	O
,	O
mixed	O
1	O
:	O
1	O
with	O
-	O
20	O
degrees	O
C	O
neat	O
ethanol	O
,	O
and	O
incubated	O
1	O
hour	O
at	O
-	O
20	O
degrees	O
C	O
to	O
fix	O
.	O

Fixed	O
cells	O
were	O
then	O
washed	O
gently	O
and	O
denatured	O
in	O
2	O
M	O
HCl	O
for	O
20	O
minutes	O
at	O
room	O
temperature	O
.	O

Following	O
washing	O
and	O
2	O
minute	O
'	O
s	O
incubation	O
with	O
0	O
.	O
1	O
M	O
Tris	O
to	O
neutralize	O
the	O
acid	O
,	O
cells	O
were	O
re	O
-	O
suspended	O
in	O
FACS	O
buffer	O
(	O
0	O
.	O
5	O
%	O
fetal	O
calf	B-LIVB
serum	O
in	O
PBS	O
)	O
and	O
stained	O
with	O
Phycoerythrin	O
(	O
PE	O
)	O
-	O
conjugated	O
anti	O
-	O
BrdU	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
for	O
flow	O
cytometry	O
analysis	O
on	O
a	O
FACScan	O
instrument	O
.	O

Apoptosis	O
and	O
trypan	O
blue	O
staining	O

Apoptosis	O
was	O
measured	O
using	O
a	O
kit	O
(	O
BD	O
Biosciences	O
)	O
containing	O
propidium	O
iodide	O
(	O
PI	O
)	O
and	O
FITC	O
-	O
conjugated	O
annexin	O
V	O
.	O

Cells	O
were	O
stained	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
and	O
the	O
level	O
of	O
apoptosis	O
determined	O
by	O
flow	O
cytometry	O
.	O

Quadrants	O
are	O
:	O
early	O
apoptosis	O
(	O
annexin	O
V	O
+	O
/	O
PI	O
-	O
,	O
lower	O
right	O
)	O
late	O
apoptosis	O
(	O
annexin	O
V	O
+	O
/	O
PI	O
+	O
,	O
upper	O
right	O
)	O
and	O
non	O
-	O
apoptotic	O
cell	O
death	O
(	O
annexin	O
V	O
-	O
/	O
PI	O
+	O
,	O
upper	O
left	O
)	O
.	O

Treatments	O
for	O
the	O
stress	O
panel	O
were	O
:	O
no	O
treatment	O
(	O
control	O
)	O
;	O
DMSO	O
as	O
a	O
control	O
for	O
celecoxib	O
;	O
20	O
mM	O
celecoxib	O
,	O
brand	O
name	O
Celebrex	O
(TM)	O
(	O
dissolved	O
in	O
DMSO	O
)	O
[	O
31	O
]	O
;	O
0	O
.	O
2	O
mM	O
H2O2	O
[	O
32	O
]	O
;	O
or	O
1	O
mg	O
/	O
mL	O
G418	O
(	O
Pfizer	O
,	O
New	O
York	O
,	O
NY	O
,	O
USA	O
)	O
.	O

Real	O
-	O
time	O
PCR	O
arrays	O

Transcriptional	O
analysis	O
using	O
Cancer	O
PathwayFinder	O
RT2	O
profiler	O
arrays	O
(	O
SuperArray	O
,	O
Frederick	O
,	O
MD	O
,	O
USA	O
)	O
was	O
performed	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Briefly	O
,	O
total	O
RNA	O
was	O
isolated	O
using	O
an	O
RNeasy	O
extraction	O
kit	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
CA	O
,	O
USA	O
)	O
;	O
1	O
mu	O
g	O
of	O
RNA	O
was	O
reverse	O
transcribed	O
with	O
the	O
cDNA	O
synthesis	O
kit	O
(	O
SuperArray	O
)	O
and	O
cDNA	O
was	O
subjected	O
to	O
real	O
-	O
time	O
PCR	O
using	O
SYBR	O
green	O
to	O
detect	O
product	O
.	O

Arrays	O
were	O
performed	O
independently	O
at	O
least	O
twice	O
for	O
each	O
cell	O
line	O
;	O
all	O
PCR	O
products	O
were	O
checked	O
on	O
agarose	O
gels	O
.	O

Values	O
were	O
obtained	O
for	O
the	O
threshold	O
cycle	O
(	O
Ct	O
)	O
for	O
each	O
gene	O
and	O
normalized	O
using	O
the	O
average	O
of	O
four	O
housekeeping	O
genes	O
on	O
the	O
same	O
array	O
(	O
HPRT1	O
,	O
RPL13A	O
,	O
GAPD	O
,	O
ACTB	O
)	O
.	O

Ct	O
values	O
for	O
housekeeping	O
genes	O
and	O
a	O
dilution	O
series	O
of	O
ACTB	O
were	O
monitored	O
for	O
consistency	O
between	O
arrays	O
.	O

Change	O
(	O
Delta	O
Ct	O
)	O
between	O
MUC1	O
siRNA	O
and	O
control	O
siRNA	O
was	O
found	O
by	O
:	O

Delta	O
Ct	O
=	O
Ct	O
(	O
MUC1	O
siRNA	O
)	O
-	O
Ct	O
(	O
control	O
siRNA	O
)	O

and	O
fold	O
change	O
by	O
:	O

Fold	O
change	O
=	O
2	O
(	O
-	O
Delta	O
Ct	O
)	O

Values	O
are	O
given	O
as	O
fold	O
change	O
;	O
only	O
genes	O
showing	O
two	O
-	O
fold	O
or	O
greater	O
change	O
were	O
considered	O
.	O

Both	O
luciferase	O
and	O
scrambled	O
siRNA	O
controls	O
were	O
used	O
in	O
BT	O
-	O
20	O
;	O
only	O
genes	O
showing	O
consistent	O
alteration	O
with	O
both	O
controls	O
were	O
included	O
in	O
the	O
results	O
reported	O
here	O
.	O

The	O
scrambled	O
siRNA	O
could	O
be	O
not	O
used	O
in	O
MDA	O
-	O
MB	O
-	O
468	O
as	O
these	O
cells	O
decrease	O
MUC1	O
expression	O
in	O
response	O
to	O
this	O
construct	O
.	O

Results	O

siRNA	O
transfection	O
decreases	O
MUC1	O
expression	O
in	O
breast	O
cancer	O
cell	O
lines	O

Two	O
human	B-LIVB
breast	O
cancer	O
cell	O
lines	O
,	O
MDA	O
-	O
MB	O
-	O
468	O
and	O
BT	O
-	O
20	O
,	O
were	O
transiently	O
transfected	O
with	O
a	O
pool	O
of	O
four	O
siRNA	O
oligonucleotides	O
directed	O
against	O
the	O
MUC1	O
mRNA	O
(	O
468	O
.	O
siMUC1	O
and	O
BT	O
.	O
siMUC1	O
)	O
,	O
or	O
a	O
control	O
oligonucleotide	O
directed	O
against	O
luciferase	O
(	O
468	O
.	O
siLuc	O
and	O
BT	O
.	O
siLuc	O
)	O
.	O

Both	O
cell	O
lines	O
express	O
high	O
levels	O
of	O
MUC1	O
,	O
making	O
them	O
promising	O
targets	O
for	O
this	O
analysis	O
.	O

Western	O
blots	O
(	O
Figure	O
1a	O
)	O
show	O
successful	O
knockdown	O
of	O
both	O
the	O
extracellular	O
domain	O
and	O
cytoplasmic	O
tail	O
fragments	O
of	O
MUC1	O
;	O
luciferase	O
siRNA	O
does	O
not	O
substantially	O
change	O
the	O
level	O
of	O
MUC1	O
compared	O
to	O
parental	O
cells	O
.	O

468	O
.	O
siMUC1	O
show	O
a	O
substantial	O
decrease	O
in	O
the	O
amount	O
of	O
MUC1	O
-	O
CT	O
,	O
while	O
BT	O
.	O
siMUC1	O
show	O
slightly	O
less	O
knockdown	O
of	O
MUC1	O
-	O
CT	O
.	O

Both	O
MDA	O
-	O
MB	O
-	O
468	O
and	O
BT	O
-	O
20	O
display	O
a	O
less	O
dramatic	O
decrease	O
of	O
MUC1	O
extracellular	O
domain	O
compared	O
to	O
MUC1	O
-	O
CT	O
(	O
Figure	O
1a	O
)	O
;	O
this	O
likely	O
represents	O
protein	O
synthesized	O
prior	O
to	O
transfection	O
,	O
and	O
may	O
reflect	O
differences	O
in	O
the	O
turnover	O
rates	O
of	O
the	O
two	O
subunits	O
.	O

Analysis	O
of	O
the	O
MUC1	O
extracellular	O
domain	O
by	O
flow	O
cytometry	O
confirms	O
that	O
both	O
cell	O
lines	O
substantially	O
decrease	O
MUC1	O
expression	O
after	O
siRNA	O
(	O
Figure	O
1b	O
)	O
.	O

By	O
flow	O
cytometry	O
,	O
468	O
.	O
siMUC1	O
averaged	O
75	O
%	O
knockdown	O
of	O
MUC1	O
compared	O
to	O
468	O
.	O
siLuc	O
;	O
and	O
BT	O
.	O
siMUC1	O
averaged	O
50	O
%	O
knockdown	O
relative	O
to	O
BT	O
.	O
siLuc	O
.	O

These	O
effects	O
could	O
be	O
titrated	O
with	O
the	O
concentration	O
of	O
siRNA	O
,	O
were	O
seen	O
as	O
early	O
as	O
24	O
hours	O
post	O
-	O
transfection	O
(	O
data	O
not	O
shown	O
)	O
and	O
lasted	O
to	O
at	O
least	O
96	O
h	O
post	O
-	O
transfection	O
(	O
Figure	O
1b	O
)	O
.	O

All	O
experiments	O
were	O
conducted	O
within	O
48	O
to	O
96	O
hours	O
after	O
siRNA	O
transfection	O
.	O

Similar	O
results	O
were	O
obtained	O
using	O
two	O
independent	O
oligonucleotides	O
designed	O
in	O
our	O
lab	O
(	O
data	O
not	O
shown	O
)	O
,	O
designated	O
'	O
882	O
'	O
and	O
'	O
956	O
'	O
for	O
the	O
initial	O
codon	O
recognized	O
by	O
each	O
.	O

Transcriptional	O
changes	O
are	O
seen	O
after	O
MUC1	O
siRNA	O

Recent	O
work	O
indicates	O
that	O
MUC1	O
may	O
affect	O
transcription	O
both	O
directly	O
via	O
interaction	O
with	O
transcription	O
factors	O
and	O
indirectly	O
(	O
for	O
example	O
,	O
through	O
modulating	O
signaling	O
)	O
.	O

To	O
study	O
the	O
effects	O
of	O
MUC1	O
knockdown	O
in	O
breast	O
cancer	O
cell	O
lines	O
,	O
real	O
-	O
time	O
PCR	O
arrays	O
were	O
used	O
to	O
analyze	O
transcription	O
of	O
84	O
genes	O
implicated	O
in	O
cancer	O
.	O

Only	O
genes	O
with	O
greater	O
than	O
two	O
-	O
fold	O
change	O
were	O
considered	O
.	O

Three	O
genes	O
(	O
MAP2K1	O
,	O
VEGF	O
,	O
PDGFA	O
)	O
were	O
altered	O
two	O
-	O
fold	O
or	O
more	O
after	O
MUC1	O
siRNA	O
in	O
both	O
MDA	O
-	O
MB	O
-	O
468	O
and	O
BT	O
-	O
20	O
cells	O
(	O
Figure	O
2	O
)	O
;	O
two	O
genes	O
(	O
ITGAV	O
,	O
MMP2	O
)	O
changed	O
only	O
in	O
468	O
.	O
siMUC1	O
;	O
and	O
five	O
genes	O
(	O
TIMP3	O
,	O
RAF1	O
,	O
JUN	O
,	O
TNF	O
,	O
CDC25A	O
)	O
only	O
in	O
BT	O
.	O
siMUC1	O
.	O

This	O
list	O
represents	O
all	O
genes	O
affected	O
greater	O
than	O
two	O
-	O
fold	O
after	O
MUC1	O
siRNA	O
,	O
rather	O
than	O
a	O
select	O
group	O
.	O

Three	O
genes	O
whose	O
transcription	O
was	O
changed	O
by	O
less	O
than	O
two	O
-	O
fold	O
are	O
shown	O
,	O
two	O
of	O
which	O
(	O
PDGFB	O
and	O
ITGB1	O
)	O
are	O
listed	O
because	O
they	O
relate	O
closely	O
to	O
genes	O
altered	O
by	O
two	O
-	O
fold	O
(	O
PDGFA	O
and	O
ITGAV	O
)	O
.	O

The	O
third	O
,	O
MYC	O
,	O
is	O
included	O
because	O
western	O
blots	O
confirmed	O
a	O
substantial	O
change	O
at	O
the	O
protein	O
level	O
(	O
Figure	O
3a	O
)	O
that	O
may	O
reflect	O
both	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
regulation	O
.	O

Interestingly	O
,	O
transcription	O
of	O
MAP2K1	O
was	O
decreased	O
in	O
both	O
cell	O
lines	O
after	O
MUC1	O
siRNA	O
.	O

This	O
gene	O
encodes	O
MEK1	O
,	O
one	O
of	O
the	O
primary	O
regulators	O
of	O
the	O
ERK1	O
/	O
2	O
MAPK	O
pathway	O
[	O
33	O
]	O
,	O
a	O
network	O
that	O
has	O
been	O
linked	O
several	O
times	O
to	O
MUC1	O
[	O
12	O
,	O
34	O
-	O
36	O
]	O
.	O

We	O
examined	O
MEK1	O
and	O
MEK2	O
levels	O
by	O
western	O
blot	O
to	O
confirm	O
decreased	O
protein	O
in	O
MUC1	O
siRNA	O
-	O
treated	O
cells	O
(	O
Figure	O
3a	O
)	O
,	O
and	O
found	O
that	O
not	O
only	O
were	O
total	O
MEK1	O
/	O
2	O
levels	O
lower	O
in	O
468	O
.	O
siMUC1	O
and	O
BT	O
.	O
siMUC1	O
compared	O
to	O
controls	O
(	O
0	O
.	O
48	O
and	O
0	O
.	O
68	O
relative	O
to	O
siLuc	O
,	O
respectively	O
)	O
,	O
but	O
so	O
were	O
the	O
basal	O
amounts	O
of	O
active	O
(	O
phosphorylated	O
)	O
MEK1	O
/	O
2	O
(	O
pMEK1	O
/	O
2	O
;	O
0	O
.	O
12	O
and	O
0	O
.	O
42	O
relative	O
to	O
siLuc	O
,	O
respectively	O
)	O
.	O

Both	O
468	O
.	O
siMUC1	O
and	O
BT	O
.	O
siMUC1	O
also	O
showed	O
reduced	O
activation	O
of	O
ERK1	O
/	O
2	O
(	O
dpERK1	O
/	O
2	O
;	O
0	O
.	O
21	O
and	O
0	O
.	O
27	O
relative	O
to	O
siLuc	O
,	O
respectively	O
)	O
,	O
as	O
would	O
be	O
expected	O
with	O
diminished	O
signaling	O
through	O
MEK1	O
/	O
2	O
;	O
total	O
ERK1	O
/	O
2	O
levels	O
remain	O
unchanged	O
.	O

As	O
both	O
lines	O
have	O
high	O
levels	O
of	O
EGFR	O
and	O
thus	O
activate	O
the	O
MEK	O
-	O
ERK	O
cascade	O
intensely	O
when	O
stimulated	O
with	O
EGF	O
[	O
37	O
]	O
,	O
siRNA	O
-	O
transfected	O
cells	O
were	O
treated	O
with	O
EGF	O
.	O

Notably	O
,	O
MUC1	O
siRNA	O
impairs	O
this	O
important	O
oncogenic	O
pathway	O
in	O
MDA	O
-	O
MB	O
-	O
468	O
cells	O
,	O
as	O
468	O
.	O
siMUC1	O
display	O
less	O
pMEK1	O
/	O
2	O
in	O
response	O
to	O
EGF	O
than	O
do	O
468	O
.	O
siLuc	O
(	O
Figure	O
3b	O
)	O
.	O

Interestingly	O
,	O
EGF	O
treatment	O
of	O
BT	O
-	O
20	O
cells	O
results	O
in	O
slightly	O
higher	O
pMEK1	O
/	O
2	O
levels	O
in	O
BT	O
.	O
siMUC1	O
compared	O
to	O
BT	O
.	O
siLuc	O
.	O

Though	O
this	O
result	O
seems	O
paradoxical	O
in	O
light	O
of	O
decreased	O
MAP2K1	O
transcription	O
in	O
BT	O
.	O
siMUC1	O
,	O
it	O
likely	O
results	O
from	O
differential	O
functions	O
of	O
Raf	O
isoforms	O
in	O
combination	O
with	O
the	O
increased	O
RAF1	O
transcription	O
(	O
Figure	O
2	O
)	O
and	O
protein	O
level	O
(	O
Figure	O
3a	O
)	O
in	O
these	O
cells	O
.	O

Specifically	O
,	O
B	O
-	O
Raf	O
is	O
thought	O
to	O
be	O
the	O
main	O
activator	O
of	O
MEK	O
under	O
normal	O
conditions	O
;	O
Raf	O
-	O
1	O
activates	O
MEK	O
in	O
response	O
to	O
stimulus	O
[	O
38	O
]	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
basal	O
pMEK1	O
/	O
2	O
levels	O
are	O
not	O
greatly	O
affected	O
by	O
Raf	O
-	O
1	O
overexpression	O
in	O
BT	O
.	O
siMUC1	O
cells	O
,	O
likely	O
because	O
MEK	O
is	O
regulated	O
primarily	O
by	O
B	O
-	O
Raf	O
under	O
normal	O
growth	O
conditions	O
.	O

In	O
contrast	O
,	O
when	O
the	O
cells	O
are	O
stimulated	O
(	O
EGF	O
)	O
,	O
increased	O
Raf	O
-	O
1	O
levels	O
in	O
BT	O
.	O
siMUC1	O
leads	O
to	O
heightened	O
pMEK1	O
/	O
2	O
(	O
Figure	O
3b	O
)	O
.	O

MUC1	O
siRNA	O
increases	O
apoptosis	O
in	O
MDA	O
-	O
MB	O
-	O
468	O
but	O
not	O
BT	O
-	O
20	O

We	O
next	O
examined	O
whether	O
MUC1	O
knockdown	O
and	O
its	O
associated	O
transcriptional	O
alterations	O
would	O
affect	O
overall	O
cellular	O
events	O
.	O

As	O
several	O
of	O
the	O
genes	O
shown	O
in	O
Figure	O
2	O
are	O
important	O
in	O
regulating	O
proliferation	O
and	O
survival	O
,	O
and	O
because	O
of	O
the	O
recently	O
described	O
role	O
of	O
MUC1	O
in	O
modulating	O
apoptosis	O
in	O
response	O
to	O
cellular	O
stresses	O
[	O
20	O
,	O
21	O
,	O
24	O
]	O
,	O
we	O
first	O
analyzed	O
whether	O
MUC1	O
siRNA	O
would	O
alter	O
apoptosis	O
in	O
these	O
lines	O
.	O

Although	O
there	O
was	O
no	O
change	O
in	O
basal	O
apoptosis	O
in	O
either	O
line	O
(	O
Figure	O
4a	O
)	O
,	O
we	O
observed	O
that	O
the	O
cell	O
lines	O
responded	O
differently	O
when	O
trypsinized	O
for	O
re	O
-	O
plating	O
24	O
hours	O
after	O
transfection	O
(	O
Figure	O
4b	O
)	O
.	O

Interestingly	O
,	O
468	O
.	O
siMUC1	O
cells	O
show	O
greater	O
apoptosis	O
after	O
trypsinization	O
than	O
do	O
468	O
.	O
siLuc	O
(	O
49	O
.	O
8	O
%	O
versus	O
34	O
.	O
0	O
%	O
,	O
respectively	O
)	O
,	O
while	O
BT	O
-	O
20	O
cells	O
from	O
both	O
siRNA	O
treatments	O
display	O
similar	O
levels	O
of	O
apoptosis	O
(	O
around	O
22	O
%	O
)	O
.	O

To	O
examine	O
whether	O
this	O
phenomenon	O
is	O
specific	O
to	O
trypsin	O
treatment	O
or	O
part	O
of	O
a	O
general	O
stress	O
response	O
involving	O
MUC1	O
,	O
we	O
subjected	O
cells	O
to	O
a	O
panel	O
of	O
stresses	O
and	O
measured	O
cell	O
death	O
.	O

In	O
agreement	O
with	O
the	O
patterns	O
seen	O
with	O
trypsinization	O
,	O
BT	O
.	O
siLuc	O
and	O
BT	O
.	O
siMUC1	O
respond	O
similarly	O
to	O
all	O
treatments	O
(	O
data	O
not	O
shown	O
)	O
,	O
while	O
468	O
.	O
siMUC1	O
die	O
more	O
readily	O
than	O
468	O
.	O
siLuc	O
in	O
response	O
to	O
trypsin	O
,	O
G418	O
,	O
hydrogen	O
peroxide	O
,	O
or	O
celecoxib	O
,	O
a	O
chemotherapeutic	O
that	O
targets	O
the	O
cyclooxygenase	O
-	O
2	O
(	O
COX	O
-	O
2	O
)	O
pathway	O
(	O
Figure	O
4c	O
)	O
;	O
these	O
data	O
were	O
confirmed	O
with	O
two	O
independent	O
siRNA	O
constructs	O
(	O
data	O
not	O
shown	O
)	O
.	O

Like	O
the	O
MAPK	O
pathway	O
,	O
AKT	O
signaling	O
has	O
been	O
linked	O
to	O
MUC1	O
in	O
cancer	O
.	O

Although	O
transcription	O
of	O
AKT	O
was	O
not	O
altered	O
in	O
MUC1	O
siRNA	O
-	O
treated	O
cells	O
,	O
the	O
results	O
of	O
our	O
apoptosis	O
studies	O
prompted	O
us	O
to	O
investigate	O
levels	O
of	O
AKT	O
further	O
.	O

As	O
expected	O
,	O
the	O
total	O
AKT	O
protein	O
level	O
is	O
not	O
greatly	O
changed	O
after	O
MUC1	O
siRNA	O
in	O
either	O
cell	O
line	O
,	O
though	O
the	O
active	O
form	O
(	O
pAKT	O
)	O
is	O
increased	O
in	O
both	O
468	O
.	O
siMUC1	O
and	O
BT	O
.	O
siMUC1	O
compared	O
to	O
controls	O
(	O
Figure	O
3a	O
)	O
.	O

This	O
result	O
disagrees	O
with	O
MUC1	O
activation	O
of	O
the	O
AKT	O
pathway	O
in	O
rat	B-LIVB
3Y1	O
cells	O
[	O
18	O
]	O
,	O
and	O
may	O
reflect	O
regulation	O
more	O
appropriate	O
to	O
breast	O
cancer	O
cells	O
;	O
this	O
is	O
supported	O
by	O
activation	O
of	O
AKT	O
in	O
response	O
to	O
MUC1	O
siRNA	O
in	O
other	O
lines	O
[	O
21	O
]	O
.	O

In	O
addition	O
,	O
there	O
is	O
a	O
striking	O
difference	O
in	O
the	O
relative	O
amounts	O
of	O
AKT	O
and	O
pAKT	O
in	O
the	O
two	O
cell	O
lines	O
(	O
Figure	O
4d	O
)	O
.	O

When	O
lysates	O
from	O
both	O
lines	O
are	O
exposed	O
to	O
film	O
for	O
the	O
same	O
length	O
of	O
time	O
(	O
overexposure	O
masks	O
the	O
differences	O
between	O
BT	O
.	O
siLuc	O
and	O
BT	O
.	O
siMUC1	O
that	O
are	O
apparent	O
in	O
Figure	O
3a	O
)	O
,	O
it	O
is	O
clear	O
that	O
pAKT	O
levels	O
are	O
much	O
higher	O
in	O
BT	O
-	O
20	O
than	O
in	O
MDA	O
-	O
MB	O
-	O
468	O
,	O
despite	O
lower	O
total	O
AKT	O
expression	O
.	O

This	O
difference	O
in	O
AKT	O
activation	O
between	O
MDA	O
-	O
MB	O
-	O
468	O
and	O
BT	O
-	O
20	O
likely	O
contributes	O
to	O
the	O
disparity	O
in	O
their	O
sensitivity	O
to	O
the	O
increased	O
apoptosis	O
expected	O
with	O
loss	O
of	O
MUC1	O
.	O

MUC1	O
siRNA	O
alters	O
proliferation	O
and	O
invasion	O

As	O
MUC1	O
is	O
involved	O
in	O
apoptosis	O
,	O
we	O
next	O
analyzed	O
its	O
effects	O
on	O
proliferation	O
.	O

BrdU	O
and	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
were	O
used	O
to	O
analyze	O
proliferation	O
after	O
MUC1	O
siRNA	O
.	O

468	O
.	O
siMUC1	O
cells	O
show	O
a	O
significant	O
decrease	O
in	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
compared	O
to	O
468	O
.	O
siLuc	O
,	O
while	O
intriguingly	O
,	O
BT	O
.	O
siMUC1	O
cells	O
show	O
a	O
significant	O
increase	O
in	O
proliferation	O
(	O
Figure	O
5a	O
)	O
.	O

Growth	O
curves	O
mirror	O
these	O
results	O
,	O
as	O
do	O
experiments	O
with	O
the	O
two	O
independent	O
MUC1	O
siRNA	O
oligonucleotides	O
(	O
data	O
not	O
shown	O
)	O
.	O

Note	O
that	O
these	O
assays	O
require	O
trypsinizing	O
cells	O
24	O
hours	O
post	O
-	O
transfection	O
;	O
therefore	O
,	O
the	O
results	O
in	O
the	O
MDA	O
-	O
MB	O
-	O
468	O
line	O
could	O
stem	O
from	O
the	O
changes	O
in	O
apoptosis	O
described	O
in	O
the	O
previous	O
section	O
,	O
rather	O
than	O
a	O
true	O
effect	O
on	O
proliferation	O
.	O

To	O
control	O
for	O
this	O
,	O
we	O
incubated	O
non	O
-	O
trypsinized	O
,	O
siRNA	O
-	O
transfected	O
cells	O
at	O
similar	O
confluence	O
with	O
BrdU	O
to	O
measure	O
incorporation	O
.	O

The	O
'	O
clumped	O
'	O
profile	O
of	O
cells	O
(	O
contrast	O
to	O
Figure	O
4b	O
)	O
is	O
likely	O
a	O
result	O
of	O
the	O
acid	O
denaturation	O
(	O
recommended	O
by	O
the	O
antibody	O
manufacturer	O
)	O
,	O
as	O
it	O
occurs	O
uniformly	O
in	O
these	O
experiments	O
.	O

BrdU	O
incorporation	O
(	O
Figure	O
5b	O
)	O
confirms	O
that	O
the	O
[	O
3H	O
]	O
thymidine	O
results	O
are	O
not	O
solely	O
due	O
to	O
alterations	O
in	O
apoptosis	O
,	O
as	O
468	O
.	O
siMUC1	O
cells	O
incorporate	O
less	O
BrdU	O
than	O
468	O
.	O
siLuc	O
;	O
once	O
again	O
,	O
BT	O
.	O
siMUC1	O
cells	O
show	O
increased	O
proliferation	O
over	O
BT	O
.	O
siLuc	O
.	O

Given	O
the	O
role	O
of	O
MUC1	O
in	O
adhesion	O
,	O
we	O
examined	O
whether	O
MUC1	O
siRNA	O
affects	O
cellular	O
invasion	O
.	O

In	O
transwell	O
assays	O
,	O
BT	O
-	O
20	O
cells	O
invaded	O
poorly	O
,	O
regardless	O
of	O
the	O
siRNA	O
used	O
(	O
data	O
not	O
shown	O
)	O
.	O

However	O
,	O
MDA	O
-	O
MB	O
-	O
468	O
cells	O
invade	O
more	O
readily	O
,	O
and	O
were	O
analyzed	O
on	O
a	O
panel	O
of	O
three	O
different	O
extracellular	O
matrix	O
proteins	O
.	O

Interestingly	O
,	O
468	O
.	O
siMUC1	O
cells	O
display	O
somewhat	O
decreased	O
invasion	O
on	O
collagen	O
IV	O
,	O
laminin	O
,	O
and	O
fibronectin	O
matrices	O
,	O
and	O
on	O
a	O
no	O
-	O
matrix	O
control	O
(	O
Figure	O
5c	O
)	O
,	O
which	O
is	O
in	O
agreement	O
with	O
the	O
trend	O
towards	O
decreased	O
metastasis	O
observed	O
in	O
Muc1	O
-	O
/	O
-	O
x	O
MMTV	B-LIVB
-	O
PyV	O
MT	O
mice	B-LIVB
[	O
8	O
]	O
.	O

Transfection	O
of	O
MUC1	O
rescues	O
the	O
468	O
.	O
siMUC1	O
phenotype	O

To	O
determine	O
if	O
the	O
above	O
effects	O
are	O
specific	O
to	O
MUC1	O
,	O
we	O
created	O
stable	O
transfectants	O
of	O
the	O
MDA	O
-	O
MB	O
-	O
468	O
line	O
using	O
empty	O
vector	O
(	O
468	O
.	O
Neo	O
)	O
or	O
a	O
full	O
-	O
length	O
MUC1	O
construct	O
(	O
468	O
.	O
MUC1	O
Delta	O
8	O
)	O
that	O
is	O
resistant	O
to	O
one	O
of	O
the	O
independent	O
MUC1	O
-	O
directed	O
oligonucleotides	O
(	O
'	O
882	O
'	O
)	O
.	O

These	O
cells	O
were	O
maintained	O
in	O
G418	O
-	O
containing	O
medium	O
to	O
retain	O
transgene	O
selection	O
.	O

As	O
expected	O
,	O
468	O
.	O
MUC1	O
Delta	O
8	O
cells	O
show	O
higher	O
levels	O
of	O
both	O
the	O
MUC1	O
extracellular	O
domain	O
and	O
the	O
MUC1	O
-	O
CT	O
than	O
do	O
468	O
.	O
Neo	O
(	O
Figure	O
6a	O
)	O
.	O

Note	O
that	O
468	O
.	O
Neo	O
have	O
MUC1	O
expression	O
comparable	O
to	O
parental	O
MDA	O
-	O
MB	O
-	O
468	O
;	O
the	O
exposures	O
in	O
Figure	O
6a	O
are	O
lighter	O
than	O
those	O
in	O
Figure	O
1a	O
,	O
in	O
order	O
to	O
clearly	O
show	O
the	O
relative	O
levels	O
of	O
MUC1	O
in	O
the	O
stable	O
transfectants	O
.	O

After	O
MUC1	O
siRNA	O
,	O
468	O
.	O
MUC1	O
Delta	O
8	O
lose	O
some	O
MUC1	O
(	O
likely	O
endogenous	O
protein	O
,	O
which	O
is	O
not	O
siRNA	O
-	O
resistant	O
)	O
but	O
retain	O
high	O
-	O
level	O
expression	O
,	O
while	O
468	O
.	O
Neo	O
show	O
a	O
decrease	O
in	O
MUC1	O
levels	O
similar	O
to	O
parental	O
468	O
.	O
siMUC1	O
cells	O
(	O
Figures	O
6a	O
,	O
b	O
)	O
.	O

The	O
difference	O
in	O
the	O
amount	O
of	O
MUC1	O
knockdown	O
between	O
468	O
.	O
Neo	O
and	O
468	O
.	O
MUC1	O
Delta	O
8	O
is	O
highlighted	O
by	O
the	O
purple	O
shading	O
in	O
Figure	O
6b	O
.	O

BrdU	O
incorporation	O
(	O
Figure	O
6c	O
)	O
indicates	O
that	O
468	O
.	O
Neo	O
show	O
decreased	O
nucleotide	O
incorporation	O
after	O
MUC1	O
siRNA	O
compared	O
to	O
control	O
(	O
3	O
.	O
3	O
%	O
versus	O
25	O
.	O
0	O
%	O
,	O
respectively	O
)	O
;	O
this	O
is	O
not	O
seen	O
in	O
468	O
.	O
MUC1	O
Delta	O
8	O
cells	O
,	O
which	O
show	O
similar	O
levels	O
of	O
BrdU	O
incorporation	O
regardless	O
of	O
the	O
siRNA	O
used	O
(	O
21	O
.	O
5	O
%	O
for	O
luciferase	O
,	O
23	O
.	O
9	O
%	O
for	O
MUC1	O
)	O
.	O

468	O
.	O
Neo	O
cells	O
display	O
a	O
more	O
dramatic	O
decrease	O
in	O
BrdU	O
incorporation	O
after	O
MUC1	O
siRNA	O
than	O
what	O
is	O
seen	O
in	O
parental	O
468	O
.	O
siMUC1	O
cells	O
,	O
which	O
may	O
reflect	O
the	O
additional	O
stress	O
of	O
being	O
maintained	O
in	O
G418	O
-	O
containing	O
medium	O
.	O

Similarly	O
,	O
analysis	O
of	O
apoptosis	O
in	O
trypsinized	O
cells	O
indicates	O
that	O
the	O
increased	O
apoptosis	O
seen	O
in	O
parental	O
468	O
.	O
siMUC1	O
cells	O
is	O
also	O
present	O
in	O
the	O
468	O
.	O
Neo	O
line	O
after	O
MUC1	O
siRNA	O
(	O
Figure	O
6d	O
;	O
43	O
.	O
6	O
%	O
in	O
control	O
versus	O
59	O
.	O
6	O
%	O
in	O
MUC1	O
siRNA	O
)	O
.	O

However	O
,	O
in	O
468	O
.	O
MUC1	O
Delta	O
8	O
cells	O
,	O
the	O
level	O
of	O
apoptosis	O
after	O
luciferase	O
siRNA	O
(	O
34	O
.	O
1	O
%	O
)	O
is	O
lower	O
than	O
that	O
in	O
468	O
.	O
Neo	O
cells	O
;	O
MUC1	O
siRNA	O
increases	O
the	O
amount	O
of	O
apoptosis	O
slightly	O
(	O
42	O
.	O
8	O
%	O
)	O
,	O
restoring	O
it	O
to	O
a	O
level	O
similar	O
to	O
that	O
seen	O
in	O
luciferase	O
siRNA	O
-	O
treated	O
468	O
.	O
Neo	O
cells	O
.	O

Together	O
,	O
these	O
studies	O
suggest	O
that	O
the	O
above	O
-	O
described	O
results	O
are	O
specific	O
to	O
MUC1	O
,	O
as	O
stable	O
transfection	O
of	O
an	O
siRNA	O
-	O
resistant	O
MUC1	O
rescues	O
the	O
phenotype	O
seen	O
in	O
468	O
.	O
siMUC1	O
cells	O
.	O

Discussion	O

This	O
report	O
describes	O
both	O
the	O
transcriptional	O
alterations	O
seen	O
after	O
transfection	O
with	O
MUC1	O
siRNA	O
in	O
human	B-LIVB
breast	O
cancer	O
cells	O
and	O
the	O
effects	O
on	O
events	O
such	O
as	O
apoptosis	O
and	O
proliferation	O
.	O

The	O
two	O
cell	O
lines	O
used	O
(	O
MDA	O
-	O
MB	O
-	O
468	O
and	O
BT	O
-	O
20	O
)	O
were	O
chosen	O
for	O
high	O
expression	O
of	O
MUC1	O
and	O
a	O
substantial	O
(	O
50	O
%	O
to	O
75	O
%	O
)	O
,	O
consistent	O
decrease	O
in	O
MUC1	O
expression	O
after	O
siRNA	O
.	O

Both	O
lines	O
have	O
epithelial	O
morphology	O
,	O
form	O
tumors	O
slowly	O
in	O
nude	B-LIVB
mice	I-LIVB
[	O
37	O
]	O
,	O
have	O
mutant	O
p53	O
[	O
39	O
,	O
40	O
]	O
,	O
express	O
EGFR	O
[	O
37	O
]	O
,	O
and	O
lack	O
estrogen	O
receptor	O
alpha	O
[	O
41	O
]	O
.	O

One	O
striking	O
difference	O
between	O
these	O
lines	O
,	O
however	O
,	O
is	O
their	O
response	O
to	O
MUC1	O
siRNA	O
.	O

MDA	O
-	O
MB	O
-	O
468	O
cells	O
behave	O
as	O
expected	O
for	O
loss	O
of	O
an	O
oncogene	O
:	O
MUC1	O
siRNA	O
correlates	O
with	O
increased	O
apoptosis	O
in	O
response	O
to	O
stress	O
,	O
decreased	O
proliferation	O
,	O
and	O
reduced	O
invasion	O
.	O

In	O
contrast	O
,	O
BT	O
.	O
siMUC1	O
cells	O
proliferate	O
more	O
rapidly	O
than	O
BT	O
.	O
siLuc	O
cells	O
with	O
little	O
effect	O
on	O
apoptosis	O
.	O

Much	O
of	O
the	O
phenotype	O
of	O
these	O
cells	O
can	O
be	O
understood	O
in	O
light	O
of	O
protein	O
levels	O
and	O
transcriptional	O
activity	O
after	O
MUC1	O
siRNA	O
.	O

As	O
mentioned	O
,	O
both	O
MDA	O
-	O
MB	O
-	O
468	O
and	O
BT	O
-	O
20	O
display	O
increased	O
pAKT	O
after	O
MUC1	O
siRNA	O
,	O
but	O
the	O
ratio	O
of	O
active	O
to	O
total	O
AKT	O
is	O
considerably	O
higher	O
in	O
the	O
BT	O
-	O
20	O
line	O
,	O
which	O
may	O
help	O
these	O
cells	O
resist	O
the	O
increased	O
apoptosis	O
expected	O
with	O
loss	O
of	O
MUC1	O
.	O

Myc	O
levels	O
are	O
also	O
higher	O
in	O
both	O
cell	O
lines	O
after	O
MUC1	O
siRNA	O
,	O
although	O
the	O
ability	O
of	O
Myc	O
to	O
promote	O
proliferation	O
and	O
apoptosis	O
in	O
different	O
cellular	O
contexts	O
[	O
42	O
]	O
complicates	O
the	O
interpretation	O
of	O
this	O
finding	O
.	O

Both	O
cell	O
lines	O
show	O
reduced	O
transcription	O
of	O
VEGF	O
,	O
PDGFA	O
,	O
PDGFB	O
,	O
and	O
MAP2K1	O
(	O
MEK1	O
)	O
after	O
MUC1	O
siRNA	O
.	O

The	O
genes	O
encoding	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
the	O
A	O
and	O
B	O
chains	O
of	O
platelet	O
-	O
derived	O
growth	O
factor	O
(	O
PDGF	O
-	O
A	O
and	O
PDGF	O
-	O
B	O
)	O
are	O
interesting	O
as	O
these	O
proteins	O
have	O
been	O
heavily	O
implicated	O
in	O
angiogenesis	O
,	O
suggesting	O
a	O
novel	O
function	O
for	O
MUC1	O
in	O
regulating	O
this	O
process	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
expression	O
in	O
cancer	O
is	O
linked	O
to	O
tumor	O
growth	O
and	O
metastasis	O
[	O
43	O
,	O
44	O
]	O
;	O
platelet	O
-	O
derived	O
growth	O
factor	O
is	O
also	O
angiogenic	O
,	O
but	O
has	O
an	O
additional	O
role	O
in	O
stimulating	O
desmoplasia	O
[	O
45	O
]	O
.	O

Reduced	O
transcription	O
of	O
these	O
genes	O
after	O
MUC1	O
siRNA	O
suggests	O
that	O
MUC1	O
may	O
foster	O
angiogenesis	O
and	O
stromal	O
proliferation	O
,	O
although	O
this	O
must	O
be	O
confirmed	O
in	O
a	O
more	O
appropriate	O
model	O
system	O
.	O

Decreased	O
MAP2K1	O
(	O
MEK1	O
)	O
transcription	O
after	O
MUC1	O
siRNA	O
provides	O
a	O
novel	O
mechanism	O
by	O
which	O
MUC1	O
can	O
affect	O
the	O
ERK1	O
/	O
2	O
MAPK	O
pathway	O
.	O

MUC1	O
has	O
often	O
been	O
linked	O
to	O
the	O
Ras	O
-	O
Raf	O
-	O
MEK	O
-	O
ERK	O
cascade	O
[	O
12	O
,	O
34	O
-	O
36	O
,	O
46	O
]	O
,	O
and	O
at	O
least	O
two	O
mechanisms	O
by	O
which	O
MUC1	O
can	O
alter	O
MAPK	O
signaling	O
have	O
been	O
described	O
:	O
MUC1	O
interaction	O
with	O
and	O
phosphorylation	O
by	O
the	O
EGFR	O
family	O
[	O
12	O
,	O
13	O
]	O
,	O
and	O
MUC1	O
binding	O
to	O
the	O
Grb2	O
/	O
Sos	O
complex	O
that	O
activates	O
Ras	O
[	O
46	O
]	O
.	O

Reduction	O
of	O
MEK1	O
levels	O
after	O
MUC1	O
siRNA	O
agrees	O
with	O
the	O
role	O
of	O
MUC1	O
in	O
strengthening	O
MAPK	O
signaling	O
,	O
and	O
indicates	O
that	O
MUC1	O
can	O
regulate	O
both	O
the	O
transcription	O
and	O
activity	O
of	O
members	O
of	O
this	O
pathway	O
.	O

Two	O
additional	O
MAPK	O
pathway	O
members	O
are	O
altered	O
specifically	O
in	O
BT	O
.	O
siMUC1	O
,	O
with	O
no	O
corresponding	O
change	O
in	O
468	O
.	O
siMUC1	O
cells	O
.	O

These	O
genes	O
are	O
RAF1	O
and	O
JUN	O
which	O
are	O
increased	O
and	O
decreased	O
,	O
respectively	O
,	O
after	O
MUC1	O
siRNA	O
.	O

Raf	O
-	O
1	O
and	O
c	O
-	O
Jun	O
both	O
function	O
outside	O
of	O
the	O
ERK1	O
/	O
2	O
MAPK	O
pathway	O
,	O
which	O
may	O
explain	O
the	O
seeming	O
paradox	O
of	O
increased	O
RAF1	O
transcription	O
with	O
simultaneous	O
decreases	O
in	O
MAP2K1	O
and	O
JUN	O
.	O

Specifically	O
,	O
Raf	O
-	O
1	O
can	O
inhibit	O
ASK1	O
(	O
apoptosis	O
signal	O
-	O
regulated	O
kinase	O
1	O
)	O
upstream	O
of	O
p38	O
and	O
JNK	O
(	O
Jun	O
N	O
-	O
terminal	O
kinase	O
)	O
[	O
38	O
]	O
.	O

ASK1	O
phosphorylates	O
JNK	O
in	O
response	O
to	O
stress	O
,	O
resulting	O
in	O
activation	O
of	O
c	O
-	O
Jun	O
and	O
stimulation	O
of	O
apoptosis	O
[	O
47	O
]	O
,	O
indicating	O
that	O
the	O
coordinate	O
up	O
-	O
regulation	O
of	O
RAF1	O
and	O
down	O
-	O
regulation	O
of	O
JUN	O
may	O
provide	O
a	O
potent	O
anti	O
-	O
apoptotic	O
effect	O
in	O
BT	O
.	O
siMUC1	O
.	O

Regulation	O
of	O
life	O
and	O
death	O
is	O
also	O
a	O
hallmark	O
of	O
the	O
CDC25A	O
and	O
TNF	O
gene	O
products	O
.	O

CDC25A	O
is	O
a	O
phosphatase	O
that	O
stimulates	O
cell	O
cycle	O
progression	O
[	O
48	O
]	O
,	O
thus	O
the	O
effects	O
of	O
its	O
decrease	O
in	O
BT	O
.	O
siMUC1	O
are	O
unclear	O
in	O
light	O
of	O
the	O
increased	O
proliferation	O
of	O
these	O
cells	O
.	O

However	O
,	O
the	O
CDC25	O
proteins	O
(	O
A	O
,	O
B	O
,	O
and	O
C	O
)	O
were	O
recently	O
shown	O
to	O
have	O
greater	O
functional	O
overlap	O
than	O
was	O
previously	O
thought	O
[	O
49	O
]	O
,	O
suggesting	O
that	O
the	O
other	O
two	O
isoforms	O
may	O
compensate	O
for	O
reduced	O
CDC25A	O
levels	O
.	O

TNF	O
encodes	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
alpha	O
,	O
known	O
for	O
its	O
potent	O
,	O
cell	O
type	O
-	O
specific	O
control	O
of	O
life	O
and	O
death	O
.	O

In	O
tumor	O
cells	O
,	O
TNF	O
alpha	O
expression	O
can	O
promote	O
proliferation	O
and	O
inhibit	O
apoptosis	O
[	O
50	O
]	O
,	O
suggesting	O
that	O
increased	O
TNF	O
transcription	O
in	O
BT	O
.	O
siMUC1	O
could	O
contribute	O
to	O
the	O
increased	O
proliferation	O
seen	O
in	O
these	O
cells	O
.	O

Interestingly	O
,	O
the	O
increase	O
in	O
TNF	O
is	O
accompanied	O
by	O
decreased	O
transcription	O
of	O
TIMP3	O
,	O
encoding	O
tissue	O
inhibitor	O
of	O
metalloproteinases	O
(	O
TIMP	O
)	O
3	O
.	O

The	O
TIMP	O
family	O
disrupts	O
the	O
function	O
of	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
,	O
generally	O
resulting	O
in	O
decreased	O
invasion	O
[	O
51	O
]	O
.	O

TIMP3	O
is	O
unique	O
in	O
that	O
it	O
can	O
also	O
inhibit	O
TNF	O
alpha	O
converting	O
enzyme	O
(	O
TACE	O
)	O
,	O
which	O
activates	O
TNF	O
alpha	O
by	O
cleaving	O
it	O
from	O
the	O
cell	O
surface	O
[	O
50	O
]	O
.	O

Reduced	O
expression	O
of	O
TIMP3	O
would	O
,	O
therefore	O
,	O
foster	O
signaling	O
through	O
TNF	O
alpha	O
by	O
releasing	O
inhibition	O
of	O
TNF	O
alpha	O
converting	O
enzyme	O
.	O

In	O
agreement	O
with	O
this	O
,	O
TIMP3	O
can	O
promote	O
apoptosis	O
[	O
52	O
]	O
;	O
thus	O
,	O
its	O
down	O
-	O
regulation	O
in	O
BT	O
.	O
siMUC1	O
provides	O
another	O
mechanism	O
by	O
which	O
these	O
cells	O
are	O
able	O
to	O
resist	O
the	O
increased	O
apoptosis	O
expected	O
with	O
loss	O
of	O
MUC1	O
.	O

Another	O
TIMP	O
target	O
responds	O
to	O
MUC1	O
siRNA	O
,	O
as	O
468	O
.	O
siMUC1	O
cells	O
show	O
significantly	O
increased	O
expression	O
of	O
MMP2	O
(	O
encoding	O
MMP	O
-	O
2	O
/	O
gelatinase	O
A	O
)	O
,	O
the	O
product	O
of	O
which	O
degrades	O
type	O
IV	O
collagen	O
[	O
52	O
]	O
.	O

In	O
breast	O
cancer	O
,	O
the	O
ratio	O
of	O
active	O
to	O
latent	O
MMP	O
-	O
2	O
increases	O
with	O
tumor	O
progression	O
;	O
MMP	O
-	O
2	O
may	O
facilitate	O
both	O
angiogenesis	O
and	O
metastasis	O
[	O
52	O
]	O
.	O

Its	O
increase	O
after	O
loss	O
of	O
MUC1	O
is	O
,	O
therefore	O
,	O
unexpected	O
,	O
but	O
at	O
least	O
two	O
factors	O
may	O
clarify	O
this	O
result	O
.	O

First	O
,	O
though	O
MMP	O
-	O
2	O
levels	O
are	O
increased	O
in	O
mouse	B-LIVB
mammary	O
tumors	O
,	O
its	O
expression	O
is	O
confined	O
to	O
the	O
stroma	O
[	O
53	O
]	O
,	O
suggesting	O
that	O
increased	O
MMP2	O
transcription	O
after	O
loss	O
of	O
the	O
epithelium	O
-	O
specific	O
MUC1	O
might	O
reflect	O
a	O
shift	O
towards	O
a	O
more	O
mesenchymal	O
phenotype	O
.	O

Second	O
,	O
MMP	O
-	O
2	O
levels	O
are	O
increased	O
by	O
overexpression	O
of	O
erbB2	O
[	O
52	O
]	O
;	O
previous	O
studies	O
have	O
shown	O
that	O
erbB2	O
and	O
Muc1	O
expression	O
are	O
mutually	O
exclusive	O
in	O
mammary	O
tumors	O
[	O
27	O
]	O
,	O
implying	O
that	O
MMP2	O
might	O
be	O
part	O
of	O
a	O
transcriptional	O
profile	O
linked	O
to	O
low	O
MUC1	O
levels	O
.	O

It	O
is	O
intriguing	O
that	O
,	O
despite	O
increased	O
MMP2	O
transcription	O
,	O
invasion	O
is	O
decreased	O
in	O
468	O
.	O
siMUC1	O
cells	O
,	O
even	O
on	O
collagen	O
IV	O
.	O

This	O
may	O
reflect	O
insufficient	O
activation	O
of	O
MMP	O
-	O
2	O
,	O
as	O
the	O
precursor	O
protein	O
must	O
be	O
cleaved	O
for	O
enzymatic	O
function	O
[	O
52	O
]	O
.	O

Alternatively	O
,	O
the	O
slowed	O
invasion	O
of	O
these	O
cells	O
may	O
relate	O
to	O
impaired	O
adhesion	O
resulting	O
from	O
decreased	O
transcription	O
of	O
ITGAV	O
and	O
ITGB1	O
(	O
alpha	O
v	O
and	O
beta	O
1	O
integrins	O
,	O
respectively	O
)	O
.	O

Integrin	O
signaling	O
is	O
tied	O
to	O
life	O
-	O
or	O
-	O
death	O
decisions	O
in	O
epithelial	O
cells	O
,	O
and	O
integrin	O
expression	O
is	O
vital	O
for	O
processes	O
from	O
wound	O
healing	O
to	O
metastasis	O
[	O
54	O
]	O
.	O

Integrin	O
alpha	O
v	O
beta	O
3	O
is	O
implicated	O
in	O
facilitating	O
metastasis	O
of	O
breast	O
cancer	O
cells	O
to	O
bone	O
[	O
55	O
]	O
;	O
decreased	O
transcription	O
of	O
ITGAV	O
after	O
MUC1	O
siRNA	O
may	O
,	O
therefore	O
,	O
suggest	O
that	O
MUC1	O
is	O
involved	O
in	O
this	O
lethal	O
process	O
as	O
well	O
.	O

The	O
MUC1	O
oncogene	O
has	O
been	O
linked	O
to	O
apoptosis	O
[	O
18	O
,	O
20	O
,	O
26	O
]	O
,	O
proliferation	O
[	O
17	O
]	O
,	O
and	O
transcription	O
[	O
21	O
,	O
23	O
-	O
25	O
]	O
in	O
cancer	O
.	O

However	O
,	O
the	O
two	O
cell	O
lines	O
chosen	O
for	O
our	O
study	O
display	O
very	O
different	O
responses	O
to	O
MUC1	O
siRNA	O
,	O
indicating	O
that	O
regulation	O
of	O
MUC1	O
in	O
breast	O
cancer	O
is	O
likely	O
quite	O
complex	O
and	O
cautioning	O
against	O
over	O
-	O
generalization	O
of	O
results	O
from	O
individual	O
cell	O
lines	O
.	O

Previous	O
reports	O
suggest	O
that	O
,	O
though	O
most	O
studies	O
outline	O
a	O
clearly	O
oncogenic	O
role	O
for	O
MUC1	O
in	O
breast	O
cancer	O
,	O
the	O
exact	O
details	O
may	O
vary	O
depending	O
on	O
factors	O
such	O
as	O
cell	O
type	O
and	O
signaling	O
context	O
.	O

For	O
example	O
,	O
MUC1	O
stimulates	O
Fas	O
-	O
mediated	O
apoptosis	O
in	O
CHO	O
cells	O
[	O
26	O
]	O
,	O
quite	O
unlike	O
the	O
inhibition	O
of	O
apoptosis	O
seen	O
in	O
other	O
cell	O
lines	O
.	O

Similarly	O
,	O
though	O
MUC1	O
drives	O
mammary	O
oncogenesis	O
in	O
its	O
own	O
right	O
[	O
9	O
]	O
and	O
facilitates	O
tumorigenesis	O
driven	O
by	O
other	O
oncogenes	O
[	O
7	O
,	O
8	O
]	O
,	O
Muc1	O
is	O
selectively	O
down	O
-	O
regulated	O
in	O
c	O
-	O
neu	O
-	O
induced	O
mouse	B-LIVB
mammary	O
tumors	O
[	O
27	O
]	O
,	O
indicating	O
that	O
the	O
context	O
of	O
oncogenic	O
signaling	O
is	O
vital	O
to	O
understanding	O
the	O
function	O
of	O
MUC1	O
.	O

Thus	O
,	O
it	O
is	O
important	O
to	O
consider	O
the	O
relative	O
levels	O
of	O
knockdown	O
of	O
MUC1	O
in	O
the	O
two	O
cell	O
lines	O
:	O
BT	O
-	O
20	O
cells	O
reduce	O
MUC1	O
expression	O
after	O
siRNA	O
less	O
strongly	O
than	O
do	O
MDA	O
-	O
MB	O
-	O
468	O
(	O
50	O
%	O
versus	O
75	O
%	O
knockdown	O
,	O
respectively	O
)	O
.	O

As	O
MUC1	O
serves	O
as	O
a	O
scaffold	O
[	O
11	O
]	O
,	O
overexpression	O
of	O
MUC1	O
relative	O
to	O
its	O
associated	O
signaling	O
proteins	O
might	O
create	O
a	O
dilution	O
effect	O
,	O
sequestering	O
signal	O
transducers	O
away	O
from	O
each	O
other	O
;	O
this	O
would	O
be	O
relieved	O
by	O
MUC1	O
siRNA	O
.	O

Thus	O
,	O
enough	O
MUC1	O
may	O
be	O
retained	O
in	O
BT	O
.	O
siMUC1	O
cells	O
for	O
its	O
oncogenic	O
effects	O
,	O
while	O
signaling	O
complex	O
formation	O
would	O
be	O
enhanced	O
by	O
lowering	O
the	O
amount	O
of	O
MUC1	O
relative	O
to	O
other	O
signaling	O
proteins	O
.	O

Conclusion	O

The	O
contrast	O
between	O
the	O
MDA	O
-	O
MB	O
-	O
468	O
and	O
BT	O
-	O
20	O
lines	O
in	O
response	O
to	O
MUC1	O
siRNA	O
serves	O
as	O
a	O
reminder	O
that	O
simplified	O
models	O
such	O
as	O
cell	O
lines	O
fail	O
to	O
encompass	O
the	O
complexity	O
of	O
intact	O
biological	O
systems	O
.	O

This	O
report	O
describes	O
transcriptional	O
alterations	O
seen	O
after	O
MUC1	O
knockdown	O
:	O
decreased	O
transcription	O
of	O
MAP2K1	O
,	O
VEGF	O
,	O
PDGFA	O
,	O
ITGAV	O
,	O
TIMP3	O
,	O
CDC25A	O
,	O
and	O
JUN	O
,	O
and	O
increased	O
transcription	O
of	O
MMP2	O
,	O
TNF	O
,	O
and	O
RAF1	O
.	O

The	O
alterations	O
in	O
MAP2K1	O
,	O
RAF1	O
,	O
and	O
JUN	O
represent	O
a	O
novel	O
means	O
by	O
which	O
MUC1	O
can	O
affect	O
ERK1	O
/	O
2	O
signaling	O
:	O
transcriptional	O
regulation	O
of	O
MAPK	O
pathway	O
members	O
.	O

Oncogenic	O
events	O
are	O
also	O
altered	O
in	O
both	O
cell	O
lines	O
after	O
MUC1	O
siRNA	O
.	O

These	O
results	O
strengthen	O
the	O
growing	O
ties	O
linking	O
MUC1	O
and	O
transcriptional	O
regulation	O
,	O
and	O
suggest	O
that	O
the	O
role	O
of	O
MUC1	O
in	O
breast	O
cancer	O
may	O
be	O
more	O
complex	O
than	O
a	O
direct	O
correlation	O
between	O
MUC1	O
level	O
and	O
oncogenic	O
function	O
.	O

Abbreviations	O

BrdU	O
=	O
bromodeoxyuridine	O
;	O
EGF	O
=	O
epidermal	O
growth	O
factor	O
;	O
EGFR	O
=	O
epidermal	O
growth	O
factor	O
receptor	O
;	O
ERK	O
=	O
extracellular	O
signal	O
regulated	O
kinase	O
;	O
MAPK	O
=	O
mitogen	O
activated	O
protein	O
kinase	O
;	O
MEK	O
=	O
MAPK	O
and	O
ERK	O
kinase	O
;	O
MMP	O
=	O
matrix	O
metalloproteinases	O
;	O
MUC1	O
-	O
CT	O
=	O
MUC1	O
cytoplasmic	O
tail	O
;	O
MUC1	O
-	O
EX	O
=	O
MUC1	O
extracellular	O
subunit	O
;	O
PBS	O
=	O
phosphate	O
-	O
buffered	O
saline	O
;	O
PI	O
=	O
propidium	O
iodide	O
;	O
siRNA	O
=	O
small	O
interfering	O
RNA	O
;	O
TIMP	O
=	O
tissue	O
inhibitor	O
of	O
metalloproteinases	O
;	O
TNF	O
=	O
tumor	O
necrosis	O
factor	O
.	O

Competing	O
interests	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O

CLH	O
performed	O
all	O
studies	O
and	O
composed	O
the	O
manuscript	O
.	O

SJG	O
participated	O
in	O
the	O
design	O
and	O
coordination	O
of	O
the	O
studies	O
and	O
contributed	O
strongly	O
to	O
the	O
revision	O
of	O
the	O
manuscript	O
.	O

Both	O
authors	O
have	O
read	O
and	O
approved	O
the	O
manuscript	O
.	O

The	O
recombination	O
-	O
associated	O
protein	O
RdgC	O
adopts	O
a	O
novel	O
toroidal	O
architecture	O
for	O
DNA	O
binding	O

Abstract	O

RecA	O
plays	O
a	O
central	O
role	O
in	O
the	O
nonmutagenic	O
repair	O
of	O
stalled	O
replication	O
forks	O
in	O
bacteria	O
.	O

RdgC	O
,	O
a	O
recombination	O
-	O
associated	O
DNA	O
-	O
binding	O
protein	O
,	O
is	O
a	O
potential	O
negative	O
regulator	O
of	O
RecA	O
function	O
.	O

Here	O
,	O
we	O
have	O
determined	O
the	O
crystal	O
structure	O
of	O
RdgC	O
from	O
Pseudomonas	B-LIVB
aeruginosa	I-LIVB
.	O

The	O
J	O
-	O
shaped	O
monomer	O
has	O
a	O
unique	O
fold	O
and	O
can	O
be	O
divided	O
into	O
three	O
structural	O
domains	O
:	O
tip	O
domain	O
,	O
center	O
domain	O
and	O
base	O
domain	O
.	O

Two	O
such	O
monomers	O
dimerize	O
to	O
form	O
a	O
ring	O
-	O
shaped	O
molecule	O
of	O
approximate	O
2	O
-	O
fold	O
symmetry	O
.	O

Of	O
the	O
two	O
inter	O
-	O
subunit	O
interfaces	O
within	O
the	O
dimer	O
,	O
one	O
interface	O
(	O
'	O
interface	O
A	O
'	O
)	O
between	O
tip	O
/	O
center	O
domains	O
is	O
more	O
nonpolar	O
than	O
the	O
other	O
(	O
'	O
interface	O
B	O
'	O
)	O
between	O
base	O
domains	O
.	O

The	O
structure	O
allows	O
us	O
to	O
propose	O
that	O
the	O
RdgC	O
dimer	O
binds	O
dsDNA	O
through	O
the	O
central	O
hole	O
of	O
~	O
30	O
A	O
diameter	O
.	O

The	O
proposed	O
model	O
is	O
supported	O
by	O
our	O
DNA	O
-	O
binding	O
assays	O
coupled	O
with	O
mutagenesis	O
,	O
which	O
indicate	O
that	O
the	O
conserved	O
positively	O
charged	O
residues	O
on	O
the	O
protein	O
surface	O
around	O
the	O
central	O
hole	O
play	O
important	O
roles	O
in	O
DNA	O
binding	O
.	O

The	O
novel	O
ring	O
-	O
shaped	O
architecture	O
of	O
the	O
RdgC	O
dimer	O
has	O
significant	O
implications	O
for	O
its	O
role	O
in	O
homologous	O
recombination	O
.	O

INTRODUCTION	O

Homologous	O
recombination	O
systems	O
contribute	O
to	O
the	O
maintenance	O
of	O
genome	O
integrity	O
and	O
are	O
essential	O
for	O
the	O
repair	O
of	O
stalled	O
replication	O
forks	O
(	O
1	O
)	O
.	O

Genetic	O
studies	O
of	O
the	O
recombination	O
-	O
dependent	O
growth	O
C	O
(	O
rdgC	O
)	O
gene	O
in	O
bacterial	O
systems	O
have	O
suggested	O
that	O
it	O
is	O
involved	O
in	O
DNA	O
replication	O
and	O
recombination	O
(	O
2	O
,	O
3	O
)	O
.	O

In	O
Neisseria	B-LIVB
gonorrhoeae	I-LIVB
(	O
the	O
gonococcus	O
)	O
,	O
RdgC	O
is	O
required	O
for	O
efficient	O
pilin	O
antigenic	O
variation	O
and	O
plays	O
some	O
role	O
in	O
cell	O
growth	O
(	O
4	O
,	O
5	O
)	O
.	O

The	O
Escherichia	B-LIVB
coli	I-LIVB
rdgC	O
gene	O
encodes	O
a	O
DNA	O
-	O
binding	O
protein	O
of	O
34	O
kDa	O
,	O
whose	O
expression	O
level	O
was	O
at	O
its	O
highest	O
during	O
exponential	O
phase	O
,	O
reaching	O
its	O
maximum	O
at	O
~	O
1000	O
dimers	O
per	O
cell	O
(	O
2	O
)	O
.	O

Its	O
level	O
decreased	O
sharply	O
to	O
~	O
50	O
dimers	O
per	O
cell	O
in	O
stationary	O
phase	O
.	O

This	O
profile	O
suggests	O
that	O
RdgC	O
might	O
function	O
during	O
the	O
period	O
of	O
DNA	O
replication	O
(	O
2	O
)	O
.	O

The	O
RecA	O
proteins	O
and	O
their	O
homologs	O
play	O
a	O
key	O
role	O
in	O
recombinational	O
DNA	O
repair	O
in	O
bacteria	O
and	O
eukaryotes	O
.	O

Their	O
aberrant	O
reactions	O
could	O
result	O
in	O
gross	O
chromosomal	O
rearrangements	O
that	O
lead	O
to	O
human	B-LIVB
diseases	O
,	O
including	O
cancer	O
.	O

Therefore	O
,	O
their	O
functions	O
must	O
be	O
tightly	O
regulated	O
,	O
and	O
understanding	O
how	O
the	O
RecA	O
family	O
of	O
recombinases	O
is	O
regulated	O
is	O
of	O
utmost	O
importance	O
(	O
1	O
)	O
.	O

The	O
E	B-LIVB
.	I-LIVB
coli	I-LIVB
RdgC	O
protein	O
is	O
a	O
potential	O
negative	O
regulator	O
of	O
the	O
function	O
of	O
RecA	O
(	O
1	O
)	O
.	O

It	O
inhibits	O
RecA	O
-	O
promoted	O
DNA	O
strand	O
exchange	O
,	O
RecA	O
-	O
mediated	O
ATPase	O
activity	O
and	O
RecA	O
-	O
dependent	O
LexA	O
cleavage	O
(	O
1	O
)	O
.	O

Sedimentation	O
equilibrium	O
data	O
indicated	O
that	O
E	B-LIVB
.	I-LIVB
coli	I-LIVB
RdgC	O
exists	O
in	O
solution	O
as	O
a	O
mixture	O
of	O
oligomeric	O
states	O
in	O
equilibrium	O
,	O
most	O
likely	O
monomers	O
,	O
dimers	O
and	O
tetramers	O
(	O
1	O
)	O
.	O

This	O
concentration	O
-	O
dependent	O
change	O
in	O
the	O
oligomeric	O
state	O
appears	O
to	O
affect	O
its	O
mode	O
of	O
binding	O
to	O
DNA	O
and	O
its	O
capacity	O
to	O
inhibit	O
RecA	O
(	O
1	O
)	O
.	O

The	O
primary	O
mechanism	O
of	O
RdgC	O
inhibition	O
appears	O
to	O
involve	O
a	O
simple	O
competition	O
for	O
DNA	O
-	O
binding	O
sites	O
,	O
especially	O
on	O
double	O
-	O
stranded	O
DNA	O
(	O
dsDNA	O
)	O
(	O
1	O
)	O
.	O

Deletion	O
of	O
the	O
E	B-LIVB
.	I-LIVB
coli	I-LIVB
rdgC	O
gene	O
alone	O
causes	O
no	O
obvious	O
phenotype	O
but	O
is	O
highly	O
deleterious	O
in	O
strains	O
lacking	O
certain	O
enzymes	O
involved	O
in	O
recombination	O
and	O
replication	O
restart	O
(	O
2	O
,	O
3	O
)	O
.	O

RdgC	O
is	O
essential	O
for	O
the	O
growth	O
of	O
an	O
E	B-LIVB
.	I-LIVB
coli	I-LIVB
strain	O
lacking	O
PriA	O
,	O
indicating	O
that	O
it	O
might	O
affect	O
replication	O
fork	O
progression	O
or	O
fork	O
rescue	O
(	O
2	O
)	O
.	O

PriA	O
provides	O
a	O
means	O
to	O
load	O
the	O
DnaB	O
replicative	O
helicase	O
at	O
DNA	O
replication	O
fork	O
and	O
D	O
loop	O
structures	O
(	O
2	O
)	O
.	O

RdgC	O
is	O
,	O
therefore	O
,	O
a	O
key	O
factor	O
in	O
the	O
rescue	O
of	O
stalled	O
or	O
broken	O
forks	O
and	O
subsequent	O
replication	O
restart	O
.	O

dnaC	O
suppressors	O
of	O
PriA	O
can	O
overcome	O
this	O
inviability	O
,	O
especially	O
when	O
RecF	O
,	O
RecO	O
or	O
RecR	O
is	O
inactivated	O
,	O
which	O
indicates	O
that	O
RdgC	O
avoids	O
or	O
counters	O
the	O
toxic	O
effect	O
of	O
these	O
proteins	O
by	O
limiting	O
inappropriate	O
RecA	O
loading	O
on	O
SSB	O
-	O
coated	O
ssDNA	O
(	O
2	O
)	O
.	O

The	O
DNA	O
-	O
binding	O
ability	O
of	O
the	O
RdgC	O
protein	O
has	O
been	O
demonstrated	O
clearly	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
2	O
)	O
.	O

Escherichia	B-LIVB
coli	I-LIVB
RdgC	O
binds	O
non	O
-	O
specifically	O
to	O
dsDNA	O
and	O
with	O
higher	O
affinity	O
than	O
ssDNA	O
(	O
2	O
)	O
.	O

RdgC	O
from	O
N	B-LIVB
.	I-LIVB
meningitidis	I-LIVB
also	O
binds	O
DNA	O
with	O
little	O
specificity	O
for	O
sequence	O
or	O
structure	O
,	O
like	O
the	O
E	B-LIVB
.	I-LIVB
coli	I-LIVB
protein	O
(	O
4	O
)	O
.	O

RdgC	O
exhibits	O
no	O
preference	O
for	O
DNA	O
replication	O
or	O
recombination	O
intermediates	O
(	O
2	O
)	O
.	O

However	O
,	O
no	O
detectable	O
domains	O
or	O
nuclease	O
activity	O
could	O
be	O
identified	O
for	O
the	O
E	B-LIVB
.	I-LIVB
coli	I-LIVB
RdgC	O
protein	O
(	O
2	O
,	O
6	O
)	O
.	O

The	O
complexes	O
of	O
E	B-LIVB
.	I-LIVB
coli	I-LIVB
RdgC	O
with	O
both	O
linear	O
and	O
supercoiled	O
circular	O
plasmid	O
DNA	O
were	O
imaged	O
using	O
atomic	O
force	O
microscopy	O
(	O
7	O
)	O
.	O

RdgC	O
was	O
found	O
to	O
have	O
an	O
increased	O
affinity	O
to	O
DNA	O
ends	O
and	O
to	O
promote	O
bending	O
of	O
DNA	O
(	O
7	O
)	O
.	O

RdgC	O
has	O
the	O
effect	O
on	O
DNA	O
superstructure	O
;	O
the	O
promotion	O
of	O
DNA	O
condensation	O
was	O
observed	O
at	O
high	O
protein	O
concentrations	O
(	O
7	O
)	O
.	O

Recombination	O
is	O
largely	O
enhanced	O
by	O
close	O
contacts	O
of	O
distant	O
regions	O
along	O
the	O
DNA	O
strands	O
through	O
condensation	O
(	O
7	O
)	O
.	O

Pseudomonas	B-LIVB
aeruginosa	I-LIVB
is	O
a	O
ubiquitous	O
environmental	O
Gram	O
-	O
negative	O
bacterium	O
that	O
belongs	O
to	O
the	O
gamma	O
subdivision	O
of	O
the	O
Proteobacteria	O
.	O

Orthologs	O
of	O
the	O
rdgC	O
gene	O
are	O
found	O
only	O
in	O
beta	O
and	O
gamma	O
subdivisions	O
of	O
the	O
Proteobacteria	O
(	O
2	O
)	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
P	B-LIVB
.	I-LIVB
aeruginosa	I-LIVB
RdgC	O
,	O
a	O
306	O
-	O
residue	O
protein	O
,	O
shows	O
46	O
and	O
36	O
%	O
identities	O
against	O
those	O
of	O
E	B-LIVB
.	I-LIVB
coli	I-LIVB
and	O
N	B-LIVB
.	I-LIVB
meningitidis	I-LIVB
,	O
respectively	O
.	O

Despite	O
the	O
importance	O
of	O
DNA	O
-	O
binding	O
ability	O
of	O
RdgC	O
in	O
its	O
biological	O
roles	O
,	O
the	O
structural	O
details	O
of	O
RdgC	O
and	O
the	O
mechanism	O
of	O
its	O
action	O
remain	O
unclear	O
.	O

Here	O
,	O
we	O
report	O
the	O
crystal	O
structure	O
of	O
P	B-LIVB
.	I-LIVB
aeruginosa	I-LIVB
RdgC	O
as	O
determined	O
by	O
the	O
multiwavelength	O
anomalous	O
diffraction	O
(	O
MAD	O
)	O
method	O
of	O
X	O
-	O
ray	O
crystallography	O
.	O

It	O
reveals	O
that	O
RdgC	O
dimer	O
is	O
ring	O
-	O
shaped	O
,	O
with	O
a	O
central	O
hole	O
of	O
~	O
30	O
A	O
diameter	O
.	O

The	O
inside	O
surface	O
around	O
the	O
central	O
hole	O
is	O
rich	O
in	O
conserved	O
,	O
positively	O
charged	O
residues	O
,	O
which	O
are	O
implicated	O
in	O
DNA	O
-	O
binding	O
by	O
mutagenesis	O
.	O

We	O
propose	O
that	O
dsDNA	O
binds	O
to	O
RdgC	O
through	O
this	O
central	O
hole	O
.	O

Our	O
structure	O
provides	O
a	O
solid	O
structural	O
framework	O
for	O
a	O
better	O
understanding	O
of	O
the	O
role	O
of	O
RdgC	O
in	O
homologous	O
recombination	O
.	O

MATERIALS	O
AND	O
METHODS	O

Protein	O
expression	O
and	O
purification	O

The	O
rdgC	O
gene	O
(	O
PA3263	O
)	O
was	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
using	O
the	O
genomic	O
DNA	O
of	O
P	B-LIVB
.	I-LIVB
aeruginosa	I-LIVB
strain	O
PAO1	O
as	O
a	O
template	O
.	O

The	O
oligonucleotide	O
primers	O
designed	O
using	O
the	O
published	O
genome	O
sequence	O
(	O
8	O
)	O
were	O
5	O
'	O
-	O
G	O
GAA	O
TTC	O
CAT	O
ATG	O
TGG	O
TTC	O
CGC	O
AAT	O
CTG	O
CTC	O
G	O
-	O
3	O
'	O
(	O
forward	O
)	O
and	O
5	O
'	O
-	O
CCG	O
CCG	O
CTC	O
GAG	O
GAC	O
GCC	O
CTG	O
GGG	O
GAT	O
TTC	O
TTC	O
-	O
3	O
'	O
(	O
reverse	O
)	O
.	O

The	O
bases	O
in	O
bold	O
denote	O
the	O
NdeI	O
and	O
XhoI	O
cleavage	O
sites	O
,	O
respectively	O
.	O

The	O
PCR	O
product	O
was	O
digested	O
with	O
NdeI	O
and	O
XhoI	O
,	O
and	O
was	O
then	O
inserted	O
into	O
the	O
NdeI	O
/	O
XhoI	O
-	O
digested	O
expression	O
vector	O
pET	O
-	O
21a	O
(	O
+	O
)	O
(	O
Novagen	O
)	O
.	O

This	O
vector	O
construction	O
adds	O
an	O
eight	O
-	O
residue	O
tag	O
(	O
LEHHHHHH	O
)	O
to	O
the	O
carboxyl	O
terminus	O
of	O
the	O
gene	O
product	O
to	O
facilitate	O
protein	O
purification	O
.	O

The	O
protein	O
was	O
expressed	O
in	O
E	B-LIVB
.	I-LIVB
coli	I-LIVB
C41	O
(	O
DE3	O
)	O
cells	O
(	O
9	O
)	O
.	O

The	O
cells	O
were	O
grown	O
at	O
37	O
degrees	O
C	O
up	O
to	O
OD600	O
of	O
0	O
.	O
6	O
in	O
Luria	O
-	O
Bertani	O
medium	O
that	O
contained	O
50	O
mu	O
g	O
ml	O
-	O
1	O
ampicillin	O
,	O
and	O
the	O
protein	O
expression	O
was	O
induced	O
by	O
0	O
.	O
5	O
mM	O
isopropyl	O
-	O
beta	O
-	O
d	O
-	O
thiogalactopyranoside	O
(	O
IPTG	O
)	O
.	O

The	O
cells	O
were	O
allowed	O
to	O
grow	O
at	O
20	O
degrees	O
C	O
for	O
22	O
h	O
after	O
IPTG	O
induction	O
and	O
were	O
harvested	O
by	O
centrifugation	O
at	O
4200	O
g	O
(	O
6000	O
rev	O
min	O
-	O
1	O
;	O
Sorvall	O
GSA	O
rotor	O
)	O
for	O
10	O
min	O
at	O
4	O
degrees	O
C	O
.	O

The	O
cell	O
pellet	O
was	O
resuspended	O
in	O
an	O
ice	O
-	O
cold	O
lysis	O
buffer	O
[	O
20	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
7	O
.	O
9	O
)	O
,	O
500	O
mM	O
sodium	O
chloride	O
,	O
5	O
mM	O
imidazole	O
]	O
and	O
was	O
then	O
homogenized	O
with	O
an	O
ultrasonic	O
processor	O
.	O

The	O
crude	O
cell	O
extract	O
was	O
centrifuged	O
at	O
36	O
000	O
g	O
(	O
18	O
000	O
rev	O
min	O
-	O
1	O
;	O
Hanil	O
Supra	O
21	O
K	O
rotor	O
)	O
for	O
60	O
min	O
at	O
4	O
degrees	O
C	O
,	O
and	O
the	O
recombinant	O
protein	O
in	O
the	O
supernatant	O
fraction	O
was	O
purified	O
in	O
three	O
chromatographic	O
steps	O
.	O

The	O
first	O
purification	O
step	O
utilized	O
the	O
C	O
-	O
terminal	O
hexahistidine	O
-	O
tag	O
by	O
Ni2	O
+	O
-	O
chelated	O
HiTrap	O
chelating	O
column	O
(	O
GE	O
Healthcare	O
)	O
.	O

The	O
eluent	O
was	O
diluted	O
3	O
-	O
fold	O
with	O
50	O
mM	O
Tris	O
-	O
HCl	O
at	O
pH	O
7	O
.	O
4	O
.	O

The	O
diluted	O
solution	O
was	O
applied	O
to	O
a	O
20	O
-	O
ml	O
heparin	O
-	O
Sepharose	O
column	O
(	O
GE	O
Healthcare	O
)	O
,	O
which	O
was	O
previously	O
equilibrated	O
with	O
a	O
buffer	O
of	O
50	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
1	O
mM	O
dithiothreitol	O
and	O
1	O
mM	O
EDTA	O
.	O

The	O
protein	O
was	O
eluted	O
with	O
a	O
linear	O
gradient	O
of	O
0	O
-	O
2	O
.	O
0	O
M	O
sodium	O
chloride	O
in	O
the	O
same	O
buffer	O
.	O

The	O
first	O
peak	O
corresponded	O
to	O
high	O
molecular	O
aggregates	O
of	O
RdgC	O
and	O
the	O
second	O
peak	O
to	O
RdgC	O
dimers	O
,	O
which	O
was	O
also	O
consistent	O
with	O
our	O
dynamic	O
light	O
scattering	O
measurements	O
.	O

When	O
the	O
aggregates	O
were	O
not	O
separated	O
from	O
the	O
dimers	O
,	O
the	O
protein	O
readily	O
aggregated	O
within	O
a	O
day	O
.	O

The	O
dimer	O
fractions	O
were	O
concentrated	O
to	O
~	O
6	O
mg	O
ml	O
-	O
1	O
concentration	O
using	O
an	O
YM10	O
ultrafiltration	O
membrane	O
(	O
Millipore	O
-	O
Amicon	O
)	O
and	O
further	O
purified	O
by	O
gel	O
filtration	O
on	O
a	O
HiLoad	O
XK	O
16	O
Superdex	O
200	O
prep	O
-	O
grade	O
column	O
(	O
GE	O
Healthcare	O
)	O
,	O
which	O
was	O
previously	O
equilibrated	O
with	O
a	O
buffer	O
of	O
50	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
200	O
mM	O
sodium	O
chloride	O
,	O
1	O
mM	O
dithiothreitol	O
and	O
1	O
mM	O
EDTA	O
.	O

The	O
first	O
peak	O
corresponding	O
to	O
the	O
high	O
molecular	O
aggregates	O
of	O
RdgC	O
was	O
only	O
a	O
minor	O
component	O
,	O
and	O
the	O
second	O
peak	O
corresponding	O
to	O
RdgC	O
dimers	O
was	O
stable	O
for	O
several	O
weeks	O
when	O
frozen	O
at	O
-	O
70	O
degrees	O
C	O
.	O

The	O
procedure	O
for	O
purifying	O
the	O
SeMet	O
-	O
substituted	O
protein	O
was	O
the	O
same	O
,	O
except	O
for	O
the	O
presence	O
of	O
10	O
mM	O
dithiothreitol	O
in	O
all	O
buffers	O
used	O
during	O
purification	O
steps	O
.	O

Dynamic	O
light	O
scattering	O
experiments	O
were	O
performed	O
at	O
24	O
degrees	O
C	O
,	O
with	O
the	O
protein	O
(	O
at	O
2	O
mg	O
ml	O
-	O
1	O
concentration	O
)	O
dissolved	O
in	O
a	O
buffer	O
consisting	O
of	O
50	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
1	O
mM	O
dithiothreitol	O
,	O
1	O
mM	O
EDTA	O
and	O
200	O
mM	O
sodium	O
chloride	O
on	O
a	O
Model	O
DynaPro	O
-	O
801	O
instrument	O
(	O
Wyatt	O
,	O
Santa	O
Barbara	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O
protein	O
concentration	O
was	O
estimated	O
by	O
measuring	O
the	O
absorbance	O
at	O
280	O
nm	O
,	O
employing	O
the	O
calculated	O
extinction	O
coefficient	O
of	O
20	O
910	O
M	O
-	O
1	O
cm	O
-	O
1	O
(	O
SWISS	O
-	O
PROT	O
;	O
http	O
:	O
/	O
/	O
www	O
.	O
expasy	O
.	O
ch	O
/	O
)	O
.	O

Mutagenesis	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O

Point	O
mutants	O
were	O
prepared	O
using	O
the	O
QuikChange	O
Site	O
-	O
Directed	O
Mutagenesis	O
kit	O
(	O
Stratagene	O
)	O
,	O
and	O
the	O
mutations	O
were	O
confirmed	O
by	O
DNA	O
sequencing	O
.	O

The	O
seven	O
mutants	O
R4A	O
,	O
F120A	O
,	O
K146A	O
,	O
R198A	O
,	O
R208A	O
,	O
Q212A	O
and	O
R252A	O
were	O
well	O
expressed	O
and	O
soluble	O
.	O

The	O
three	O
mutants	O
K70A	O
,	O
R81A	O
and	O
R211A	O
were	O
not	O
expressed	O
,	O
while	O
R122A	O
mutant	O
was	O
expressed	O
but	O
was	O
not	O
soluble	O
.	O

Therefore	O
,	O
we	O
mutated	O
Lys70	O
,	O
Arg81	O
,	O
Arg122	O
and	O
Arg211	O
into	O
aspartate	O
.	O

The	O
K70D	O
,	O
R81D	O
,	O
R122D	O
and	O
R211D	O
mutants	O
were	O
well	O
expressed	O
and	O
soluble	O
.	O

The	O
soluble	O
mutants	O
were	O
expressed	O
and	O
purified	O
under	O
the	O
conditions	O
identical	O
to	O
those	O
for	O
the	O
wild	O
type	O
,	O
except	O
that	O
the	O
heparin	O
-	O
Sepharose	O
column	O
step	O
was	O
omitted	O
.	O

All	O
of	O
the	O
soluble	O
mutants	O
had	O
similar	O
elution	O
profiles	O
as	O
the	O
wild	O
type	O
upon	O
gel	O
filtration	O
,	O
and	O
the	O
dimer	O
fractions	O
were	O
used	O
for	O
DNA	O
-	O
binding	O
assays	O
.	O

We	O
mixed	O
5	O
mu	O
l	O
of	O
RdgC	O
(	O
1	O
.	O
1	O
mu	O
g	O
mu	O
l	O
-	O
1	O
)	O
and	O
5	O
mu	O
l	O
of	O
a	O
linear	O
dsDNA	O
with	O
414	O
bp	O
(	O
63	O
ng	O
mu	O
l	O
-	O
1	O
)	O
,	O
corresponding	O
to	O
the	O
molar	O
ratio	O
of	O
64	O
:	O
1	O
for	O
RdgC	O
dimer	O
to	O
dsDNA	O
.	O

The	O
reaction	O
mixtures	O
were	O
incubated	O
for	O
10	O
min	O
at	O
room	O
temperature	O
.	O

RdgC	O
-	O
DNA	O
complexes	O
were	O
analyzed	O
by	O
1	O
.	O
5	O
%	O
(	O
w	O
/	O
v	O
)	O
agarose	O
gel	O
electrophoresis	O
in	O
1	O
x	O
TAE	O
buffer	O
(	O
45	O
mM	O
Tris	O
-	O
acetate	O
at	O
pH	O
8	O
.	O
3	O
,	O
1	O
mM	O
EDTA	O
)	O
.	O

DNA	O
bands	O
were	O
visualized	O
by	O
ethidium	O
bromide	O
staining	O
.	O

For	O
DNA	O
-	O
binding	O
assays	O
,	O
the	O
protein	O
concentration	O
was	O
measured	O
with	O
a	O
Bio	O
-	O
Rad	O
protein	O
assay	O
kit	O
.	O

Crystallization	O
and	O
X	O
-	O
ray	O
data	O
collection	O

Crystals	O
were	O
grown	O
by	O
the	O
hanging	O
-	O
drop	O
vapor	O
diffusion	O
method	O
at	O
24	O
degrees	O
C	O
by	O
mixing	O
equal	O
volumes	O
(	O
2	O
mu	O
l	O
each	O
)	O
of	O
the	O
protein	O
solution	O
(	O
at	O
19	O
mg	O
ml	O
-	O
1	O
concentration	O
in	O
a	O
buffer	O
consisting	O
of	O
50	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
1	O
mM	O
dithiothreitol	O
,	O
1	O
mM	O
EDTA	O
and	O
200	O
mM	O
sodium	O
chloride	O
)	O
and	O
the	O
reservoir	O
solution	O
.	O

To	O
grow	O
the	O
native	O
crystals	O
,	O
we	O
used	O
a	O
reservoir	O
solution	O
consisting	O
of	O
0	O
.	O
1	O
M	O
sodium	O
HEPES	O
(	O
pH	O
7	O
.	O
5	O
)	O
,	O
1	O
.	O
0	O
M	O
tri	O
-	O
sodium	O
citrate	O
and	O
1	O
%	O
(	O
w	O
/	O
v	O
)	O
Anapoe	O
(R)	O
35	O
as	O
the	O
detergent	O
.	O

Native	O
crystals	O
grew	O
to	O
approximate	O
dimensions	O
of	O
0	O
.	O
2	O
mm	O
x	O
0	O
.	O
1	O
mm	O
x	O
0	O
.	O
1	O
mm	O
within	O
a	O
few	O
days	O
.	O

The	O
SeMet	O
-	O
substituted	O
protein	O
was	O
crystallized	O
under	O
conditions	O
identical	O
to	O
those	O
for	O
the	O
native	O
crystals	O
except	O
for	O
the	O
presence	O
of	O
10	O
mM	O
dithiothreitol	O
in	O
the	O
protein	O
solution	O
.	O

A	O
crystal	O
of	O
the	O
SeMet	O
-	O
substituted	O
protein	O
was	O
dipped	O
into	O
a	O
cryoprotectant	O
solution	O
for	O
a	O
few	O
seconds	O
and	O
was	O
flash	O
-	O
cooled	O
in	O
the	O
cold	O
nitrogen	O
gas	O
stream	O
at	O
100	O
K	O
.	O

The	O
cryoprotectant	O
solution	O
consisted	O
of	O
0	O
.	O
1	O
M	O
sodium	O
HEPES	O
(	O
pH	O
7	O
.	O
5	O
)	O
,	O
1	O
.	O
0	O
M	O
tri	O
-	O
sodium	O
citrate	O
,	O
1	O
%	O
(	O
w	O
/	O
v	O
)	O
Anapoe	O
(R)	O
35	O
as	O
the	O
detergent	O
and	O
10	O
%	O
(	O
v	O
/	O
v	O
)	O
glycerol	O
.	O

A	O
set	O
of	O
Se	O
MAD	O
data	O
was	O
collected	O
at	O
100	O
K	O
at	O
three	O
different	O
wavelengths	O
using	O
an	O
Area	O
Detector	O
System	O
Corporation	O
Quantum	O
210	O
charge	O
-	O
coupled	O
device	O
detector	O
at	O
the	O
beamline	O
NW12A	O
of	O
Photon	O
Factory	O
,	O
Tsukuba	O
,	O
Japan	O
.	O

The	O
crystal	O
was	O
rotated	O
through	O
a	O
total	O
of	O
180	O
degrees	O
with	O
a	O
1	O
degrees	O
oscillation	O
range	O
per	O
frame	O
.	O

The	O
raw	O
data	O
were	O
processed	O
and	O
scaled	O
using	O
the	O
program	O
suit	O
HKL2000	O
(	O
10	O
)	O
.	O

The	O
SeMet	O
-	O
substituted	O
crystal	O
belongs	O
to	O
the	O
space	O
group	O
P21212	O
,	O
with	O
unit	O
cell	O
parameters	O
of	O
a	O
=	O
87	O
.	O
04	O
A	O
,	O
b	O
=	O
115	O
.	O
60	O
A	O
and	O
c	O
=	O
76	O
.	O
07	O
A	O
.	O

The	O
native	O
crystals	O
were	O
soaked	O
for	O
10	O
min	O
in	O
10	O
mM	O
ethyl	O
mercury	O
thiosalicylate	O
(	O
EMTS	O
)	O
to	O
collect	O
a	O
set	O
of	O
Hg	O
MAD	O
data	O
at	O
four	O
different	O
wavelengths	O
.	O

X	O
-	O
ray	O
diffraction	O
data	O
from	O
the	O
EMTS	O
-	O
derivatized	O
crystal	O
,	O
as	O
well	O
as	O
a	O
native	O
crystal	O
,	O
were	O
collected	O
on	O
a	O
Bruker	O
charge	O
-	O
coupled	O
device	O
detector	O
at	O
the	O
beamline	O
BL	O
-	O
6B	O
of	O
Pohang	O
Light	O
Source	O
,	O
Pohang	O
,	O
Korea	O
.	O

The	O
EMTS	O
-	O
soaked	O
crystal	O
belongs	O
to	O
the	O
space	O
group	O
P21212	O
,	O
with	O
unit	O
cell	O
parameters	O
of	O
a	O
=	O
87	O
.	O
16	O
A	O
,	O
b	O
=	O
116	O
.	O
02	O
A	O
and	O
c	O
=	O
74	O
.	O
97	O
A	O
.	O

The	O
native	O
crystal	O
belongs	O
to	O
the	O
space	O
group	O
P21212	O
,	O
with	O
unit	O
cell	O
parameters	O
of	O
a	O
=	O
87	O
.	O
49	O
A	O
,	O
b	O
=	O
116	O
.	O
04	O
A	O
and	O
c	O
=	O
76	O
.	O
03	O
A	O
.	O

If	O
the	O
presence	O
of	O
a	O
dimeric	O
molecule	O
in	O
the	O
asymmetric	O
unit	O
is	O
assumed	O
,	O
the	O
calculated	O
crystal	O
volume	O
per	O
protein	O
mass	O
(	O
VM	O
)	O
is	O
2	O
.	O
75	O
A	O
3	O
Da	O
-	O
1	O
and	O
the	O
solvent	O
content	O
is	O
55	O
.	O
3	O
%	O
.	O

Supplementary	O
Table	O
1	O
summarizes	O
the	O
statistics	O
of	O
X	O
-	O
ray	O
diffraction	O
data	O
collection	O
.	O

Structure	O
solution	O
and	O
refinement	O

Heavy	O
atom	O
sites	O
were	O
located	O
with	O
the	O
program	O
SOLVE	O
(	O
11	O
)	O
.	O

Four	O
Se	O
sites	O
from	O
the	O
SeMet	O
-	O
substituted	O
crystal	O
and	O
two	O
Hg	O
sites	O
from	O
the	O
EMTS	O
-	O
soaked	O
crystal	O
were	O
located	O
.	O

Two	O
sets	O
of	O
the	O
initial	O
Se	O
and	O
Hg	O
MAD	O
phases	O
were	O
separately	O
improved	O
using	O
the	O
program	O
RESOLVE	O
(	O
12	O
)	O
.	O

Two	O
electron	O
density	O
maps	O
were	O
independently	O
interpreted	O
,	O
and	O
the	O
fragments	O
of	O
the	O
two	O
models	O
were	O
combined	O
into	O
a	O
single	O
model	O
,	O
since	O
the	O
two	O
maps	O
were	O
complementary	O
to	O
each	O
other	O
.	O

Non	O
-	O
crystallographic	O
symmetry	O
(	O
NCS	O
)	O
matrices	O
were	O
found	O
from	O
a	O
partial	O
model	O
built	O
from	O
the	O
initial	O
electron	O
density	O
map	O
,	O
and	O
phases	O
were	O
further	O
improved	O
by	O
the	O
2	O
-	O
fold	O
NCS	O
averaging	O
,	O
solvent	O
flattening	O
and	O
histogram	O
matching	O
with	O
the	O
program	O
DM	O
(	O
13	O
)	O
.	O

The	O
model	O
was	O
built	O
with	O
O	O
(	O
14	O
)	O
.	O

The	O
model	O
was	O
refined	O
with	O
the	O
program	O
CNS	O
(	O
15	O
)	O
,	O
including	O
the	O
bulk	O
solvent	O
correction	O
.	O

10	O
%	O
of	O
the	O
data	O
were	O
randomly	O
set	O
aside	O
as	O
the	O
test	O
data	O
for	O
the	O
calculation	O
of	O
Rfree	O
(	O
16	O
)	O
.	O

Several	O
rounds	O
of	O
model	O
building	O
,	O
simulated	O
annealing	O
,	O
positional	O
refinement	O
and	O
individual	O
B	O
-	O
factor	O
refinement	O
were	O
performed	O
.	O

Subsequently	O
,	O
this	O
model	O
was	O
used	O
to	O
refine	O
the	O
structure	O
of	O
the	O
native	O
protein	O
.	O

The	O
model	O
has	O
excellent	O
stereochemistry	O
,	O
as	O
evaluated	O
by	O
the	O
program	O
PROCHECK	O
(	O
17	O
)	O
.	O

Refinement	O
statistics	O
are	O
summarized	O
in	O
Supplementary	O
Table	O
1	O
.	O

RESULTS	O
AND	O
DISCUSSION	O

Model	O
quality	O
and	O
monomer	O
structure	O

The	O
structure	O
of	O
P	B-LIVB
.	I-LIVB
aeruginosa	I-LIVB
RdgC	O
was	O
solved	O
using	O
two	O
sets	O
of	O
MAD	O
data	O
collected	O
from	O
a	O
crystal	O
of	O
the	O
selenomethionine	O
(	O
SeMet	O
)	O
-	O
substituted	O
protein	O
and	O
from	O
a	O
mercury	O
derivative	O
crystal	O
of	O
the	O
native	O
protein	O
(	O
Supplementary	O
Table	O
1	O
)	O
.	O

The	O
model	O
has	O
subsequently	O
been	O
refined	O
using	O
the	O
20	O
.	O
0	O
-	O
2	O
.	O
50	O
A	O
data	O
from	O
a	O
native	O
crystal	O
to	O
crystallographic	O
Rwork	O
and	O
Rfree	O
values	O
of	O
23	O
.	O
4	O
and	O
27	O
.	O
9	O
%	O
,	O
respectively	O
,	O
with	O
no	O
sigma	O
cut	O
-	O
off	O
.	O

The	O
refined	O
model	O
contains	O
612	O
residues	O
of	O
the	O
two	O
monomers	O
in	O
the	O
asymmetric	O
unit	O
of	O
the	O
crystal	O
(	O
residues	O
1	O
-	O
306	O
for	O
both	O
chains	O
A	O
and	O
B	O
)	O
and	O
87	O
water	O
molecules	O
.	O

The	O
C	O
-	O
terminal	O
eight	O
-	O
residue	O
fusion	O
tag	O
has	O
no	O
electron	O
density	O
in	O
both	O
subunits	O
and	O
has	O
not	O
been	O
modeled	O
.	O

Conformations	O
of	O
the	O
two	O
monomers	O
in	O
the	O
asymmetric	O
unit	O
are	O
similar	O
.	O

The	O
root	O
-	O
mean	O
-	O
square	O
(	O
r	O
.	O
m	O
.	O
s	O
.	O
)	O
difference	O
between	O
the	O
two	O
monomers	O
is	O
0	O
.	O
69	O
A	O
for	O
306	O
C	O
alpha	O
atom	O
pairs	O
,	O
with	O
a	O
maximum	O
deviation	O
of	O
8	O
.	O
8	O
A	O
for	O
the	O
C	O
alpha	O
atom	O
of	O
Gly305	O
.	O

The	O
residues	O
giving	O
r	O
.	O
m	O
.	O
s	O
.	O
differences	O
larger	O
than	O
2	O
.	O
0	O
A	O
are	O
14	O
-	O
16	O
,	O
94	O
-	O
96	O
,	O
201	O
-	O
202	O
and	O
303	O
-	O
306	O
,	O
which	O
correspond	O
to	O
loops	O
connecting	O
secondary	O
structure	O
elements	O
or	O
the	O
C	O
-	O
terminus	O
.	O

They	O
are	O
located	O
on	O
the	O
surface	O
of	O
the	O
dimer	O
.	O

Subunit	O
A	O
has	O
a	O
better	O
map	O
quality	O
than	O
subunit	O
B	O
,	O
and	O
thus	O
has	O
a	O
lower	O
mean	O
B	O
-	O
factor	O
than	O
subunit	O
B	O
(	O
40	O
.	O
3	O
A	O
2	O
versus	O
.	O
56	O
.	O
1	O
A	O
2	O
for	O
all	O
4788	O
atoms	O
)	O
(	O
Supplementary	O
Figure	O
1	O
)	O
.	O

Therefore	O
,	O
subunit	O
A	O
is	O
chosen	O
for	O
discussions	O
,	O
unless	O
otherwise	O
stated	O
.	O

The	O
P	B-LIVB
.	I-LIVB
aeruginosa	I-LIVB
RdgC	O
monomer	O
is	O
J	O
-	O
shaped	O
and	O
has	O
approximate	O
dimensions	O
of	O
72	O
A	O
x	O
60	O
A	O
x	O
40	O
A	O
(	O
Figure	O
1	O
)	O
.	O

It	O
can	O
be	O
divided	O
into	O
three	O
structural	O
domains	O
:	O
center	O
domain	O
,	O
tip	O
domain	O
and	O
base	O
domain	O
.	O

Center	O
domain	O
(	O
residues	O
1	O
-	O
73	O
and	O
121	O
-	O
167	O
)	O
includes	O
a	O
six	O
-	O
stranded	O
anti	O
-	O
parallel	O
beta	O
-	O
sheet	O
with	O
two	O
flanking	O
alpha	O
helices	O
(	O
alpha	O
1	O
and	O
alpha	O
4	O
)	O
.	O

The	O
helix	O
alpha	O
1	O
runs	O
nearly	O
parallel	O
to	O
the	O
two	O
outermost	O
strands	O
beta	O
2	O
and	O
beta	O
3	O
,	O
which	O
in	O
turn	O
lie	O
adjacent	O
to	O
beta	O
4	O
.	O

Strands	O
beta	O
2	O
and	O
beta	O
3	O
are	O
separated	O
by	O
a	O
loop	O
.	O

The	O
helix	O
alpha	O
4	O
is	O
nearly	O
orthogonal	O
to	O
the	O
beta	O
-	O
strands	O
.	O

Tip	O
domain	O
(	O
residues	O
74	O
-	O
120	O
)	O
contains	O
two	O
alpha	O
helices	O
(	O
alpha	O
2	O
and	O
alpha	O
3	O
)	O
and	O
is	O
inserted	O
between	O
strands	O
beta	O
4	O
and	O
beta	O
5	O
of	O
the	O
center	O
domain	O
.	O

It	O
sticks	O
out	O
from	O
the	O
center	O
domain	O
.	O

The	O
two	O
connections	O
between	O
the	O
center	O
domain	O
and	O
the	O
tip	O
domain	O
are	O
rich	O
in	O
conserved	O
residues	O
,	O
hinting	O
at	O
an	O
important	O
functional	O
role	O
of	O
these	O
joints	O
.	O

They	O
could	O
act	O
as	O
a	O
hinge	O
for	O
a	O
possible	O
conformational	O
change	O
.	O

The	O
C	O
-	O
terminal	O
region	O
of	O
the	O
polypeptide	O
chain	O
is	O
folded	O
into	O
the	O
base	O
domain	O
(	O
residues	O
168	O
-	O
306	O
)	O
,	O
which	O
consists	O
of	O
a	O
five	O
-	O
stranded	O
anti	O
-	O
parallel	O
beta	O
-	O
sheet	O
with	O
four	O
alpha	O
-	O
helices	O
,	O
three	O
of	O
which	O
(	O
alpha	O
5	O
,	O
alpha	O
6	O
and	O
alpha	O
8	O
)	O
cover	O
one	O
side	O
of	O
the	O
beta	O
-	O
sheet	O
.	O

The	O
long	O
helix	O
alpha	O
8	O
is	O
slightly	O
bent	O
.	O

Structural	O
similarity	O
searches	O

When	O
we	O
searched	O
for	O
structural	O
similarity	O
against	O
the	O
Protein	O
Data	O
Bank	O
database	O
using	O
the	O
program	O
DALI	O
(	O
18	O
)	O
,	O
the	O
P	B-LIVB
.	I-LIVB
aeruginosa	I-LIVB
RdgC	O
monomer	O
showed	O
no	O
significant	O
similarity	O
with	O
a	O
Z	O
score	O
above	O
5	O
.	O

Therefore	O
,	O
we	O
conclude	O
that	O
the	O
overall	O
fold	O
of	O
the	O
RdgC	O
polypeptide	O
chain	O
is	O
unique	O
.	O

When	O
we	O
elaborated	O
the	O
structural	O
comparisons	O
with	O
individual	O
domains	O
of	O
P	B-LIVB
.	I-LIVB
aeruginosa	I-LIVB
RdgC	O
,	O
only	O
the	O
center	O
domain	O
gave	O
a	O
Z	O
score	O
above	O
5	O
.	O

Using	O
the	O
center	O
domain	O
(	O
residues	O
1	O
-	O
73	O
and	O
121	O
-	O
167	O
)	O
alone	O
,	O
the	O
highest	O
structural	O
similarity	O
is	O
found	O
with	O
the	O
human	B-LIVB
beta	O
2	O
-	O
adaptin	O
appendage	O
domain	O
(	O
PDB	O
code	O
1E42	O
,	O
Z	O
score	O
=	O
7	O
.	O
1	O
,	O
r	O
.	O
m	O
.	O
s	O
.	O
deviation	O
=	O
2	O
.	O
5	O
A	O
for	O
85	O
structurally	O
aligned	O
residues	O
,	O
residues	O
1	O
-	O
12	O
,	O
14	O
-	O
30	O
,	O
44	O
-	O
47	O
,	O
58	O
-	O
72	O
,	O
122	O
-	O
133	O
and	O
135	O
-	O
160	O
of	O
P	B-LIVB
.	I-LIVB
aeruginosa	I-LIVB
RdgC	O
chain	O
A	O
and	O
residues	O
838	O
-	O
841	O
,	O
848	O
-	O
880	O
,	O
885	O
-	O
906	O
and	O
912	O
-	O
967	O
of	O
the	O
human	B-LIVB
beta	O
2	O
-	O
adaptin	O
appendage	O
domain	O
chain	O
A	O
)	O
(	O
19	O
)	O
.	O

There	O
does	O
not	O
appear	O
to	O
be	O
any	O
functional	O
relatedness	O
between	O
these	O
two	O
proteins	O
.	O

The	O
next	O
highest	O
similarity	O
is	O
found	O
with	O
the	O
yeast	B-LIVB
TATA	O
-	O
box	O
-	O
binding	O
protein	O
(	O
PDB	O
code	O
1YTB	O
,	O
Z	O
score	O
=	O
5	O
.	O
7	O
,	O
r	O
.	O
m	O
.	O
s	O
.	O
deviation	O
=	O
2	O
.	O
6	O
A	O
for	O
79	O
structurally	O
aligned	O
residues	O
,	O
residues	O
4	O
-	O
12	O
,	O
14	O
-	O
19	O
,	O
21	O
-	O
27	O
,	O
56	O
-	O
70	O
,	O
124	O
-	O
132	O
and	O
134	O
-	O
166	O
of	O
P	B-LIVB
.	I-LIVB
aeruginosa	I-LIVB
RdgC	O
chain	O
A	O
and	O
residues	O
69	O
-	O
96	O
,	O
100	O
-	O
126	O
and	O
132	O
-	O
155	O
of	O
TATA	O
-	O
box	O
-	O
binding	O
protein	O
,	O
N	O
-	O
terminal	O
half	O
of	O
chain	O
A	O
)	O
(	O
20	O
)	O
.	O

The	O
TATA	O
-	O
box	O
-	O
binding	O
protein	O
is	O
composed	O
of	O
a	O
ten	O
-	O
stranded	O
antiparallel	O
beta	O
-	O
sheet	O
with	O
four	O
flanking	O
alpha	O
-	O
helices	O
on	O
the	O
convex	O
side	O
of	O
the	O
beta	O
-	O
sheet	O
(	O
20	O
)	O
.	O

It	O
has	O
an	O
internal	O
quasi	O
2	O
-	O
fold	O
symmetry	O
,	O
and	O
its	O
beta	O
-	O
strands	O
are	O
involved	O
in	O
DNA	O
binding	O
.	O

There	O
is	O
,	O
however	O
,	O
no	O
structural	O
similarity	O
of	O
functional	O
significance	O
,	O
because	O
the	O
two	O
center	O
domains	O
of	O
the	O
RdgC	O
dimer	O
are	O
well	O
separated	O
and	O
do	O
not	O
associate	O
into	O
a	O
single	O
unit	O
(	O
Figure	O
1C	O
and	O
D	O
)	O
.	O

Using	O
the	O
tip	O
domain	O
(	O
residues	O
74	O
-	O
120	O
)	O
alone	O
,	O
the	O
ATPase	O
domain	O
of	O
bovine	B-LIVB
Hsc70	O
chaperone	O
shows	O
highest	O
structural	O
similarity	O
(	O
PDB	O
code	O
1BA1	O
,	O
Z	O
score	O
=	O
4	O
.	O
8	O
,	O
r	O
.	O
m	O
.	O
s	O
.	O
deviation	O
=	O
1	O
.	O
7	O
A	O
for	O
45	O
structurally	O
aligned	O
residues	O
,	O
residues	O
76	O
-	O
120	O
of	O
P	B-LIVB
.	I-LIVB
aeruginosa	I-LIVB
RdgC	O
chain	O
A	O
and	O
residues	O
230	O
-	O
253	O
and	O
256	O
-	O
276	O
of	O
the	O
Hsc70	O
ATPase	O
domain	O
)	O
(	O
21	O
)	O
.	O

There	O
does	O
not	O
seem	O
to	O
be	O
any	O
significant	O
functional	O
relationship	O
between	O
these	O
two	O
proteins	O
.	O

The	O
alpha	O
-	O
helix	O
-	O
loop	O
-	O
alpha	O
-	O
helix	O
structure	O
of	O
the	O
tip	O
domain	O
is	O
reminiscent	O
of	O
the	O
helix	O
-	O
hairpin	O
-	O
helix	O
(	O
HhH	O
)	O
DNA	O
-	O
binding	O
motif	O
that	O
is	O
present	O
in	O
a	O
number	O
of	O
DNA	O
repair	O
enzymes	O
(	O
22	O
-	O
25	O
)	O
.	O

The	O
HhH	O
motifs	O
are	O
characterized	O
by	O
the	O
conserved	O
sequence	O
motif	O
hxxhxGhGxxxAxxxhh	O
,	O
where	O
h	O
is	O
any	O
hydrophobic	O
residue	O
(	O
VILMWFYA	O
)	O
and	O
x	O
any	O
residue	O
(	O
23	O
)	O
.	O

Two	O
conserved	O
glycines	O
allow	O
a	O
tight	O
turn	O
between	O
two	O
alpha	O
-	O
helices	O
.	O

However	O
,	O
the	O
tip	O
domain	O
of	O
P	B-LIVB
.	I-LIVB
aeruginosa	I-LIVB
RdgC	O
protein	O
does	O
not	O
have	O
such	O
a	O
sequence	O
motif	O
,	O
and	O
the	O
loop	O
in	O
the	O
RdgC	O
tip	O
domain	O
is	O
much	O
more	O
extended	O
than	O
that	O
of	O
the	O
HhH	O
motifs	O
.	O

Therefore	O
,	O
the	O
RdgC	O
tip	O
domain	O
is	O
uniquely	O
folded	O
.	O

With	O
the	O
base	O
domain	O
(	O
residues	O
168	O
-	O
306	O
)	O
alone	O
,	O
the	O
highest	O
similarity	O
is	O
found	O
with	O
P	B-LIVB
.	I-LIVB
aeruginosa	I-LIVB
isochorismate	O
-	O
pyruvate	O
lyase	O
(	O
unpublished	O
deposition	O
;	O
PDB	O
code	O
2H9C	O
,	O
Z	O
score	O
=	O
4	O
.	O
0	O
,	O
r	O
.	O
m	O
.	O
s	O
.	O
deviation	O
=	O
4	O
.	O
8	O
A	O
for	O
51	O
structurally	O
aligned	O
residues	O
,	O
residues	O
186	O
-	O
191	O
,	O
237	O
-	O
240	O
,	O
257	O
-	O
272	O
and	O
274	O
-	O
298	O
of	O
P	B-LIVB
.	I-LIVB
aeruginosa	I-LIVB
RdgC	O
chain	O
A	O
and	O
residues	O
36	O
-	O
41	O
,	O
50	O
-	O
53	O
,	O
55	O
-	O
66	O
and	O
68	O
-	O
96	O
of	O
P	B-LIVB
.	I-LIVB
aeruginosa	I-LIVB
isochorismate	O
-	O
pyruvate	O
lyase	O
chain	O
A	O
)	O
.	O

There	O
does	O
not	O
appear	O
to	O
be	O
any	O
functional	O
relationship	O
between	O
the	O
two	O
proteins	O
,	O
and	O
the	O
base	O
domain	O
of	O
RdgC	O
is	O
uniquely	O
folded	O
.	O

The	O
101	O
-	O
residue	O
chain	O
of	O
P	B-LIVB
.	I-LIVB
aeruginosa	I-LIVB
isochorismate	O
-	O
pyruvate	O
lyase	O
is	O
folded	O
into	O
three	O
alpha	O
-	O
helices	O
,	O
two	O
of	O
which	O
overlap	O
with	O
two	O
alpha	O
-	O
helices	O
(	O
alpha	O
2	O
and	O
alpha	O
3	O
)	O
of	O
the	O
base	O
domain	O
of	O
RdgC	O
.	O

Ring	O
-	O
shaped	O
dimer	O
structure	O
and	O
inter	O
-	O
subunit	O
interface	O

Our	O
structure	O
reveals	O
that	O
P	B-LIVB
.	I-LIVB
aeruginosa	I-LIVB
RdgC	O
forms	O
a	O
ring	O
-	O
shaped	O
dimer	O
of	O
approximate	O
2	O
-	O
fold	O
symmetry	O
in	O
the	O
crystal	O
(	O
Figure	O
1	O
)	O
.	O

This	O
observation	O
is	O
consistent	O
with	O
the	O
results	O
of	O
previous	O
gel	O
filtration	O
and	O
sedimentation	O
equilibrium	O
experiments	O
,	O
which	O
suggested	O
the	O
presence	O
of	O
dimeric	O
species	O
of	O
E	B-LIVB
.	I-LIVB
coli	I-LIVB
RdgC	O
in	O
solution	O
(	O
1	O
,	O
2	O
)	O
.	O

Depending	O
on	O
the	O
concentration	O
,	O
RdgC	O
could	O
also	O
exist	O
in	O
solution	O
as	O
monomers	O
,	O
tetramers	O
and	O
higher	O
oligomers	O
(	O
1	O
)	O
.	O

In	O
the	O
crystal	O
lattice	O
,	O
no	O
monomeric	O
,	O
trimeric	O
or	O
tetrameric	O
species	O
exist	O
.	O

Our	O
structure	O
unequivocally	O
rules	O
out	O
the	O
monomer	O
-	O
trimer	O
model	O
,	O
which	O
fits	O
the	O
sedimentation	O
equilibrium	O
data	O
approximately	O
,	O
as	O
well	O
as	O
the	O
monomer	O
-	O
dimer	O
-	O
tetramer	O
model	O
(	O
1	O
)	O
.	O

The	O
RdgC	O
dimer	O
has	O
approximate	O
dimensions	O
of	O
80	O
A	O
x	O
60	O
A	O
x	O
40	O
A	O
,	O
with	O
a	O
central	O
hole	O
of	O
~	O
30	O
A	O
diameter	O
.	O

Only	O
a	O
moderate	O
amount	O
of	O
surface	O
area	O
is	O
buried	O
upon	O
the	O
formation	O
of	O
the	O
RdgC	O
dimer	O
.	O

The	O
monomer	O
-	O
monomer	O
interface	O
buries	O
a	O
solvent	O
-	O
accessible	O
surface	O
area	O
of	O
~	O
1360	O
A	O
2	O
per	O
monomer	O
,	O
corresponding	O
to	O
~	O
8	O
%	O
of	O
the	O
total	O
surface	O
area	O
of	O
the	O
monomer	O
(	O
Protein	O
-	O
Protein	O
Interaction	O
Server	O
at	O
http	O
:	O
/	O
/	O
www	O
.	O
biochem	O
.	O
ucl	O
.	O
ac	O
.	O
uk	O
/	O
bsm	O
/	O
PP	O
/	O
server	O
/	O
)	O
.	O

Polar	O
and	O
nonpolar	O
atoms	O
in	O
interface	O
are	O
44	O
and	O
56	O
%	O
,	O
respectively	O
.	O

The	O
interface	O
can	O
be	O
divided	O
into	O
two	O
kinds	O
:	O
'	O
interface	O
A	O
'	O
involving	O
both	O
the	O
tip	O
domains	O
and	O
center	O
domains	O
,	O
and	O
'	O
interface	O
B	O
'	O
involving	O
the	O
base	O
domains	O
(	O
Figure	O
2A	O
)	O
.	O

These	O
two	O
interfaces	O
have	O
significantly	O
different	O
characters	O
.	O

The	O
interface	O
A	O
is	O
formed	O
largely	O
by	O
the	O
crossing	O
over	O
of	O
the	O
two	O
tip	O
domains	O
in	O
the	O
dimer	O
(	O
Figure	O
1	O
)	O
.	O

This	O
interface	O
covers	O
a	O
surface	O
area	O
of	O
~	O
565	O
A	O
2	O
and	O
is	O
largely	O
nonpolar	O
,	O
with	O
the	O
polar	O
and	O
nonpolar	O
atoms	O
in	O
the	O
interface	O
being	O
37	O
.	O
5	O
and	O
2	O
.	O
5	O
%	O
,	O
respectively	O
.	O

Phe120	O
contributes	O
considerably	O
to	O
the	O
nonpolar	O
character	O
of	O
the	O
interface	O
between	O
the	O
tip	O
domains	O
,	O
accounting	O
for	O
~	O
150	O
A	O
2	O
of	O
the	O
interface	O
area	O
.	O

Phe120	O
is	O
part	O
of	O
a	O
highly	O
conserved	O
sequence	O
segment	O
and	O
lies	O
at	O
the	O
boundary	O
between	O
the	O
tip	O
domain	O
and	O
the	O
center	O
domain	O
.	O

The	O
aromatic	O
ring	O
of	O
Phe120	O
'	O
inserts	O
into	O
a	O
hydrophobic	O
pocket	O
,	O
which	O
is	O
formed	O
by	O
the	O
hydrophobic	O
residues	O
Ile74	O
,	O
Leu75	O
,	O
Pro76	O
,	O
Val79	O
,	O
Leu115	O
,	O
Ala119	O
and	O
Phe120	O
of	O
the	O
neighboring	O
monomer	O
(	O
Figure	O
2B	O
)	O
.	O

The	O
primed	O
residue	O
belongs	O
to	O
the	O
adjacent	O
subunit	O
.	O

These	O
residues	O
are	O
well	O
conserved	O
in	O
the	O
RdgC	O
family	O
(	O
indicated	O
by	O
green	O
triangles	O
below	O
the	O
aligned	O
sequences	O
in	O
Figure	O
3	O
)	O
.	O

As	O
these	O
hydrophobic	O
residues	O
are	O
located	O
near	O
the	O
molecular	O
2	O
-	O
fold	O
axis	O
,	O
the	O
two	O
clusters	O
of	O
hydrophobic	O
side	O
chains	O
are	O
merged	O
into	O
a	O
single	O
,	O
large	O
cluster	O
in	O
the	O
dimer	O
(	O
Figure	O
2B	O
)	O
.	O

Of	O
the	O
16	O
hydrogen	O
bonds	O
that	O
exist	O
between	O
the	O
two	O
subunits	O
,	O
only	O
one	O
is	O
made	O
in	O
this	O
interface	O
between	O
Arg118	O
and	O
Arg118	O
'	O
.	O

The	O
interface	O
B	O
is	O
contributed	O
to	O
exclusively	O
by	O
the	O
two	O
base	O
domains	O
.	O

This	O
interface	O
covers	O
a	O
surface	O
area	O
of	O
~	O
795	O
A	O
2	O
.	O

The	O
polar	O
and	O
nonpolar	O
atoms	O
in	O
this	O
interface	O
are	O
50	O
%	O
each	O
.	O

The	O
two	O
beta	O
-	O
sheets	O
of	O
the	O
two	O
base	O
domains	O
merge	O
into	O
a	O
single	O
ten	O
-	O
stranded	O
antiparallel	O
beta	O
-	O
sheet	O
in	O
this	O
interface	O
(	O
Figure	O
2A	O
)	O
.	O

Thus	O
,	O
15	O
of	O
16	O
inter	O
-	O
subunit	O
hydrogen	O
bonds	O
are	O
clustered	O
in	O
this	O
interface	O
.	O

The	O
hydrogen	O
bond	O
networks	O
can	O
be	O
divided	O
into	O
two	O
types	O
.	O

The	O
first	O
type	O
involves	O
the	O
main	O
chain	O
atoms	O
of	O
Val206	O
,	O
Arg208	O
and	O
Lys210	O
in	O
strand	O
beta	O
9	O
;	O
this	O
strand	O
associates	O
with	O
the	O
equivalent	O
strand	O
from	O
the	O
other	O
subunit	O
in	O
an	O
antiparallel	O
manner	O
(	O
Figure	O
2C	O
)	O
.	O

The	O
other	O
type	O
involves	O
both	O
the	O
side	O
chain	O
and	O
main	O
chain	O
atoms	O
.	O

The	O
side	O
chain	O
of	O
Arg211	O
'	O
interacts	O
with	O
the	O
backbone	O
of	O
Gly204	O
,	O
while	O
the	O
side	O
chain	O
of	O
Lys227	O
hydrogen	O
bonds	O
to	O
those	O
of	O
both	O
Gln212	O
'	O
and	O
Glu218	O
(	O
Figure	O
2D	O
)	O
.	O

In	O
addition	O
,	O
the	O
side	O
chain	O
of	O
Gln212	O
'	O
interacts	O
with	O
that	O
of	O
Asp199	O
and	O
the	O
backbone	O
of	O
Arg211	O
'	O
(	O
Figure	O
2D	O
)	O
.	O

Arg211	O
,	O
Gln212	O
,	O
Glu218	O
and	O
Lys227	O
are	O
highly	O
conserved	O
among	O
the	O
RdgC	O
family	O
members	O
.	O

The	O
residues	O
participating	O
in	O
the	O
hydrogen	O
bond	O
networks	O
are	O
indicated	O
by	O
red	O
circles	O
below	O
the	O
aligned	O
sequences	O
in	O
Figure	O
3	O
.	O

The	O
observation	O
that	O
conserved	O
residues	O
play	O
important	O
roles	O
in	O
forming	O
the	O
dimer	O
implies	O
that	O
dimerization	O
of	O
RdgC	O
is	O
critical	O
for	O
its	O
function	O
.	O

If	O
one	O
or	O
both	O
of	O
interfaces	O
A	O
and	O
B	O
are	O
to	O
be	O
broken	O
for	O
functional	O
reasons	O
such	O
as	O
for	O
allowing	O
dsDNA	O
to	O
enter	O
into	O
the	O
central	O
hole	O
of	O
the	O
RdgC	O
dimer	O
,	O
we	O
can	O
conceive	O
of	O
three	O
scenarios	O
.	O

The	O
first	O
possibility	O
would	O
be	O
a	O
simultaneous	O
breakage	O
of	O
the	O
two	O
interfaces	O
A	O
and	O
B	O
.	O

The	O
second	O
would	O
be	O
the	O
sequential	O
disruption	O
of	O
the	O
interfaces	O
A	O
and	O
B	O
.	O

The	O
third	O
would	O
be	O
the	O
disruption	O
of	O
only	O
one	O
of	O
the	O
two	O
interfaces	O
A	O
and	O
B	O
.	O

Sedimentation	O
equilibrium	O
indicated	O
the	O
presence	O
of	O
monomers	O
in	O
solution	O
(	O
1	O
)	O
,	O
which	O
is	O
consistent	O
with	O
the	O
first	O
two	O
scenarios	O
.	O

If	O
the	O
third	O
scenario	O
holds	O
,	O
RdgC	O
dimers	O
could	O
possibly	O
exist	O
in	O
two	O
conformations	O
in	O
solution	O
,	O
i	O
.	O
e	O
.	O
a	O
closed	O
form	O
as	O
observed	O
in	O
the	O
present	O
crystal	O
structure	O
,	O
and	O
an	O
open	O
form	O
,	O
in	O
which	O
one	O
of	O
the	O
two	O
interfaces	O
A	O
and	O
B	O
is	O
broken	O
.	O

A	O
model	O
for	O
DNA	O
binding	O
by	O
RdgC	O
and	O
DNA	O
-	O
binding	O
assay	O

The	O
net	O
charge	O
of	O
P	B-LIVB
.	I-LIVB
aeruginosa	I-LIVB
RdgC	O
is	O
highly	O
negative	O
,	O
since	O
each	O
monomer	O
contains	O
12	O
aspartate	O
,	O
13	O
glutamate	O
,	O
10	O
lysine	O
,	O
9	O
arginine	O
and	O
2	O
histidine	O
residues	O
.	O

The	O
net	O
charge	O
of	O
a	O
dimer	O
would	O
be	O
-	O
12	O
(	O
or	O
-	O
8	O
)	O
,	O
if	O
we	O
assume	O
none	O
(	O
or	O
all	O
)	O
of	O
histidines	O
to	O
be	O
positively	O
charged	O
.	O

The	O
electrostatic	O
potential	O
at	O
the	O
molecular	O
surface	O
of	O
RdgC	O
dimer	O
shows	O
that	O
the	O
charge	O
distribution	O
on	O
the	O
protein	O
surface	O
is	O
highly	O
nonuniform	O
(	O
Figure	O
4A	O
)	O
.	O

Since	O
the	O
inner	O
surface	O
of	O
the	O
RdgC	O
dimer	O
is	O
rich	O
in	O
conserved	O
,	O
positively	O
charged	O
residues	O
and	O
the	O
diameter	O
of	O
the	O
central	O
hole	O
(	O
~	O
30	O
A	O
)	O
is	O
approximately	O
similar	O
to	O
that	O
of	O
other	O
toroidal	O
DNA	O
-	O
binding	O
proteins	O
(	O
26	O
)	O
,	O
it	O
appears	O
likely	O
that	O
RdgC	O
dimers	O
bind	O
dsDNA	O
through	O
the	O
central	O
hole	O
.	O

Despite	O
extensive	O
co	O
-	O
crystallization	O
and	O
soaking	O
trials	O
with	O
linear	O
dsDNAs	O
of	O
different	O
lengths	O
(	O
14	O
-	O
mer	O
,	O
16	O
-	O
mer	O
and	O
18	O
-	O
mer	O
)	O
,	O
we	O
could	O
not	O
locate	O
the	O
bound	O
DNA	O
experimentally	O
.	O

We	O
attribute	O
this	O
difficulty	O
to	O
the	O
nature	O
of	O
sequence	O
-	O
nonspecific	O
DNA	O
binding	O
by	O
RdgC	O
.	O

Therefore	O
,	O
we	O
built	O
a	O
crude	O
model	O
of	O
a	O
DNA	O
complex	O
of	O
the	O
RdgC	O
dimer	O
by	O
fitting	O
dsDNA	O
into	O
the	O
central	O
hole	O
(	O
Figure	O
4B	O
)	O
.	O

This	O
model	O
is	O
supported	O
by	O
the	O
DNA	O
-	O
binding	O
assays	O
coupled	O
with	O
mutagenesis	O
,	O
as	O
described	O
below	O
.	O

It	O
is	O
also	O
consistent	O
with	O
the	O
suggested	O
binding	O
site	O
size	O
of	O
~	O
16	O
nt	O
for	O
the	O
E	B-LIVB
.	I-LIVB
coli	I-LIVB
RdgC	O
dimer	O
(	O
1	O
)	O
and	O
the	O
approximate	O
thickness	O
(	O
~	O
40	O
A	O
)	O
of	O
the	O
P	B-LIVB
.	I-LIVB
aeruginosa	I-LIVB
RdgC	O
dimer	O
.	O

When	O
we	O
performed	O
electrophoretic	O
mobility	O
shift	O
assay	O
for	O
dsDNA	O
binding	O
,	O
P	B-LIVB
.	I-LIVB
aeruginosa	I-LIVB
RdgC	O
did	O
not	O
require	O
Mg2	O
+	O
ions	O
(	O
Supplementary	O
Figure	O
2	O
)	O
,	O
unlike	O
Deinococcus	B-LIVB
radiodurans	I-LIVB
RecR	O
,	O
which	O
required	O
high	O
concentrations	O
of	O
Mg2	O
+	O
ions	O
(	O
27	O
)	O
.	O

ATP	O
was	O
not	O
required	O
for	O
dsDNA	O
binding	O
by	O
P	B-LIVB
.	I-LIVB
aeruginosa	I-LIVB
RdgC	O
,	O
either	O
(	O
Supplementary	O
Figure	O
2	O
)	O
.	O

This	O
is	O
consistent	O
with	O
an	O
apparent	O
lack	O
of	O
an	O
ATP	O
-	O
binding	O
pocket	O
in	O
the	O
RdgC	O
dimer	O
structure	O
.	O

In	O
order	O
to	O
identify	O
the	O
residues	O
that	O
are	O
important	O
for	O
dsDNA	O
binding	O
,	O
we	O
carried	O
out	O
mutational	O
analyses	O
.	O

The	O
residues	O
for	O
mutagenesis	O
were	O
selected	O
on	O
the	O
basis	O
of	O
the	O
modeled	O
complex	O
between	O
RdgC	O
dimer	O
and	O
dsDNA	O
,	O
together	O
with	O
sequence	O
conservation	O
(	O
Figure	O
4C	O
)	O
.	O

We	O
prepared	O
eleven	O
point	O
mutants	O
(	O
R4A	O
,	O
K70D	O
,	O
R81D	O
,	O
F120A	O
,	O
R122D	O
,	O
K146A	O
,	O
R198A	O
,	O
R208A	O
,	O
R211D	O
,	O
Q212A	O
and	O
R252A	O
)	O
.	O

These	O
eleven	O
mutated	O
residues	O
are	O
well	O
conserved	O
among	O
RdgC	O
proteins	O
.	O

Eight	O
mutants	O
(	O
R4A	O
,	O
K70D	O
,	O
R81D	O
,	O
R122D	O
,	O
K146A	O
,	O
R198A	O
,	O
R208A	O
and	O
R252A	O
)	O
had	O
a	O
lower	O
affinity	O
for	O
dsDNA	O
than	O
the	O
wild	O
-	O
type	O
RdgC	O
(	O
Figure	O
4D	O
)	O
.	O

These	O
eight	O
mutated	O
residues	O
are	O
indicated	O
by	O
blue	O
squares	O
below	O
the	O
aligned	O
sequences	O
in	O
Figure	O
3	O
.	O

This	O
result	O
indicates	O
that	O
dsDNA	O
binds	O
to	O
the	O
inside	O
surface	O
around	O
the	O
central	O
hole	O
of	O
the	O
RdgC	O
dimer	O
,	O
since	O
the	O
mutated	O
residues	O
are	O
located	O
on	O
the	O
inner	O
surface	O
of	O
the	O
RdgC	O
dimer	O
.	O

It	O
is	O
worth	O
mentioning	O
that	O
a	O
single	O
mutation	O
introduces	O
two	O
alterations	O
per	O
RdgC	O
dimer	O
.	O

The	O
three	O
mutants	O
(	O
F120A	O
,	O
R211D	O
and	O
Q212A	O
)	O
were	O
prepared	O
to	O
investigate	O
whether	O
dimerization	O
of	O
RdgC	O
is	O
crucial	O
for	O
dsDNA	O
binding	O
.	O

Phe120	O
is	O
a	O
key	O
residue	O
located	O
in	O
the	O
inter	O
-	O
subunit	O
interface	O
A	O
(	O
Figure	O
2B	O
)	O
,	O
while	O
Arg211	O
makes	O
hydrogen	O
bonds	O
in	O
the	O
interface	O
B	O
(	O
Figure	O
2D	O
)	O
and	O
Gln212	O
is	O
involved	O
in	O
both	O
intra	O
-	O
and	O
inter	O
-	O
subunit	O
interactions	O
(	O
Figure	O
2D	O
)	O
.	O

dsDNA	O
binding	O
by	O
the	O
F120A	O
mutant	O
is	O
considerably	O
weakened	O
,	O
compared	O
to	O
either	O
the	O
R211D	O
or	O
Q212A	O
mutant	O
(	O
Figure	O
4D	O
)	O
.	O

This	O
result	O
suggests	O
that	O
destabilization	O
of	O
the	O
ring	O
-	O
shaped	O
architecture	O
of	O
the	O
RdgC	O
dimer	O
is	O
deleterious	O
for	O
tight	O
dsDNA	O
binding	O
and	O
that	O
interface	O
A	O
is	O
probably	O
more	O
important	O
than	O
interface	O
B	O
for	O
dsDNA	O
binding	O
.	O

dsDNA	O
-	O
binding	O
affinity	O
of	O
the	O
Q212A	O
mutant	O
was	O
lower	O
than	O
the	O
wild	O
type	O
(	O
Figure	O
4D	O
)	O
,	O
whereas	O
that	O
of	O
the	O
R211D	O
mutant	O
was	O
comparable	O
to	O
the	O
wild	O
type	O
(	O
Figure	O
4D	O
)	O
.	O

This	O
result	O
suggests	O
that	O
disruption	O
of	O
the	O
inter	O
-	O
subunit	O
interface	O
B	O
is	O
also	O
detrimental	O
for	O
dsDNA	O
binding	O
but	O
to	O
a	O
smaller	O
extent	O
than	O
disruption	O
of	O
the	O
interface	O
A	O
.	O

It	O
further	O
suggests	O
that	O
the	O
side	O
chain	O
of	O
Arg211	O
is	O
not	O
involved	O
in	O
recognizing	O
dsDNA	O
.	O

It	O
is	O
interesting	O
that	O
the	O
DNA	O
complex	O
for	O
wild	O
type	O
forms	O
a	O
distinct	O
band	O
(	O
lane	O
3	O
in	O
Figure	O
4D	O
)	O
,	O
as	O
opposed	O
to	O
a	O
more	O
diffuse	O
band	O
as	O
one	O
would	O
expect	O
if	O
the	O
complexes	O
contained	O
different	O
numbers	O
of	O
RdgC	O
dimers	O
.	O

Assuming	O
a	O
binding	O
site	O
size	O
of	O
~	O
16	O
nt	O
(	O
1	O
)	O
,	O
the	O
414	O
-	O
bp	O
duplex	O
DNA	O
would	O
bind	O
~	O
25	O
RdgC	O
dimers	O
if	O
it	O
is	O
fully	O
saturated	O
.	O

RdgC	O
is	O
unique	O
among	O
ring	O
-	O
shaped	O
DNA	O
-	O
binding	O
proteins	O

Pseudomonas	B-LIVB
aeruginosa	I-LIVB
RdgC	O
adds	O
a	O
unique	O
member	O
to	O
the	O
repertoire	O
of	O
toroidal	O
DNA	O
-	O
binding	O
proteins	O
(	O
26	O
)	O
such	O
as	O
D	B-LIVB
.	I-LIVB
radiodurans	I-LIVB
RecR	O
(	O
27	O
)	O
and	O
DNA	O
polymerase	O
processivity	O
factors	O
,	O
including	O
the	O
beta	O
subunit	O
of	O
E	B-LIVB
.	I-LIVB
coli	I-LIVB
DNA	O
polymerase	O
III	O
(	O
28	O
)	O
,	O
gp45	O
of	O
T4	O
DNA	O
polymerase	O
(	O
29	O
)	O
and	O
PCNA	O
of	O
eukaryotic	O
DNA	O
polymerase	O
delta	O
(	O
30	O
,	O
31	O
)	O
(	O
Figure	O
5	O
)	O
.	O

These	O
proteins	O
do	O
not	O
have	O
an	O
overall	O
sequence	O
similarity	O
among	O
themselves	O
,	O
and	O
their	O
quaternary	O
structures	O
also	O
vary	O
.	O

P	B-LIVB
.	I-LIVB
aeruginosa	I-LIVB
RdgC	O
and	O
E	B-LIVB
.	I-LIVB
coli	I-LIVB
beta	O
clamp	O
are	O
homodimers	O
,	O
T4	O
gp45	O
and	O
eukaryotic	O
PCNAs	O
are	O
homotrimers	O
and	O
D	B-LIVB
.	I-LIVB
radiodurans	I-LIVB
RecR	O
is	O
a	O
homotetramer	O
.	O

In	O
P	B-LIVB
.	I-LIVB
aeruginosa	I-LIVB
RdgC	O
,	O
the	O
inner	O
surface	O
of	O
the	O
ring	O
-	O
shaped	O
dimer	O
is	O
largely	O
formed	O
by	O
beta	O
-	O
strands	O
,	O
while	O
the	O
outer	O
surface	O
of	O
the	O
ring	O
is	O
mostly	O
formed	O
by	O
alpha	O
-	O
helices	O
(	O
Figure	O
5	O
)	O
.	O

The	O
predicted	O
DNA	O
-	O
binding	O
site	O
of	O
P	B-LIVB
.	I-LIVB
aeruginosa	I-LIVB
RdgC	O
dimer	O
is	O
primarily	O
formed	O
by	O
beta	O
-	O
strands	O
and	O
loops	O
.	O

In	O
contrast	O
,	O
in	O
other	O
ring	O
-	O
shaped	O
DNA	O
-	O
binding	O
proteins	O
such	O
as	O
the	O
beta	O
subunit	O
of	O
E	B-LIVB
.	I-LIVB
coli	I-LIVB
DNA	O
polymerase	O
III	O
(	O
28	O
)	O
,	O
gp45	O
of	O
T4	O
DNA	O
polymerase	O
(	O
29	O
)	O
,	O
PCNA	O
of	O
eukaryotic	O
DNA	O
polymerases	O
delta	O
(	O
30	O
,	O
31	O
)	O
and	O
D	B-LIVB
.	I-LIVB
radiodurans	I-LIVB
RecR	O
(	O
27	O
)	O
,	O
alpha	O
-	O
helices	O
are	O
located	O
toward	O
the	O
center	O
of	O
the	O
ring	O
and	O
are	O
surrounded	O
by	O
beta	O
-	O
strands	O
in	O
the	O
outermost	O
side	O
of	O
the	O
ring	O
(	O
Figure	O
5	O
)	O
.	O

Despite	O
a	O
superficial	O
resemblance	O
of	O
the	O
overall	O
ring	O
-	O
shaped	O
architecture	O
of	O
the	O
RdgC	O
dimer	O
with	O
those	O
of	O
other	O
toroidal	O
DNA	O
-	O
binding	O
proteins	O
,	O
the	O
internal	O
arrangement	O
of	O
the	O
secondary	O
structure	O
elements	O
in	O
the	O
RdgC	O
dimer	O
is	O
strikingly	O
different	O
from	O
those	O
of	O
other	O
toroidal	O
DNA	O
-	O
binding	O
proteins	O
.	O

Thus	O
,	O
RdgC	O
is	O
unique	O
among	O
ring	O
-	O
shaped	O
DNA	O
-	O
binding	O
proteins	O
.	O

A	O
number	O
of	O
other	O
proteins	O
involved	O
in	O
DNA	O
metabolism	O
also	O
adopt	O
a	O
ring	O
-	O
shaped	O
structure	O
despite	O
diversity	O
in	O
the	O
molecular	O
functions	O
(	O
26	O
)	O
.	O

They	O
include	O
NAD	O
+	O
-	O
dependent	O
DNA	O
ligase	O
(	O
25	O
)	O
,	O
lambda	O
exonuclease	O
(	O
32	O
)	O
,	O
hexameric	O
helicases	O
,	O
topoisomerases	O
,	O
the	O
trp	O
RNA	O
-	O
binding	O
attenuation	O
protein	O
,	O
the	O
bacteriophage	O
head	O
-	O
to	O
-	O
tail	O
connector	O
and	O
translin	O
(	O
26	O
)	O
.	O

There	O
are	O
also	O
many	O
examples	O
of	O
the	O
proteins	O
in	O
DNA	O
recombination	O
pathways	O
that	O
assemble	O
into	O
multi	O
-	O
subunit	O
toroids	O
containing	O
a	O
central	O
channel	O
(	O
26	O
)	O
.	O

Electron	O
microscopy	O
showed	O
that	O
the	O
E	B-LIVB
.	I-LIVB
coli	I-LIVB
RuvB	O
protein	O
,	O
in	O
the	O
presence	O
of	O
ATP	O
,	O
forms	O
a	O
dodecamer	O
on	O
double	O
-	O
stranded	O
DNA	O
in	O
which	O
two	O
stacked	O
hexameric	O
rings	O
encircle	O
the	O
DNA	O
and	O
are	O
oriented	O
in	O
opposite	O
directions	O
with	O
D6	O
symmetry	O
(	O
33	O
)	O
.	O

The	O
human	B-LIVB
RAD52	O
protein	O
was	O
found	O
to	O
assemble	O
into	O
heptameric	O
rings	O
with	O
a	O
large	O
funnel	O
-	O
shaped	O
channel	O
,	O
40	O
-	O
60	O
A	O
in	O
diameter	O
(	O
34	O
)	O
.	O

The	O
human	B-LIVB
DMC1	O
protein	O
has	O
so	O
far	O
been	O
detected	O
only	O
as	O
an	O
octameric	O
ring	O
(	O
35	O
)	O
.	O

Inhibition	O
mechanism	O
of	O
RecA	O
function	O
by	O
RdgC	O

RdgC	O
inhibits	O
RecA	O
-	O
promoted	O
DNA	O
strand	O
exchange	O
,	O
RecA	O
-	O
mediated	O
ATPase	O
activity	O
and	O
RecA	O
-	O
dependent	O
LexA	O
cleavage	O
(	O
1	O
)	O
.	O

It	O
was	O
observed	O
that	O
the	O
effects	O
of	O
RdgC	O
on	O
RecA	O
-	O
promoted	O
DNA	O
strand	O
exchange	O
were	O
much	O
more	O
pronounced	O
than	O
the	O
effects	O
of	O
RdgC	O
on	O
other	O
RecA	O
functions	O
,	O
when	O
RdgC	O
was	O
added	O
to	O
the	O
reaction	O
late	O
(	O
1	O
)	O
.	O

By	O
examining	O
the	O
effects	O
of	O
the	O
DinI	O
protein	O
on	O
RdgC	O
-	O
mediated	O
inhibition	O
of	O
RecA	O
activities	O
,	O
it	O
was	O
concluded	O
that	O
the	O
potent	O
effect	O
of	O
RdgC	O
in	O
the	O
inhibition	O
of	O
strand	O
exchange	O
did	O
not	O
primarily	O
reflect	O
a	O
displacement	O
of	O
RecA	O
in	O
the	O
nucleoprotein	O
filament	O
by	O
RdgC	O
,	O
but	O
instead	O
a	O
binding	O
of	O
RdgC	O
to	O
the	O
dsDNA	O
substrate	O
so	O
as	O
to	O
make	O
it	O
unavailable	O
to	O
the	O
filaments	O
for	O
strand	O
exchange	O
(	O
1	O
)	O
.	O

Our	O
work	O
contributes	O
to	O
a	O
better	O
understanding	O
of	O
the	O
inhibition	O
mechanism	O
of	O
RecA	O
function	O
by	O
RdgC	O
.	O

The	O
ring	O
-	O
shaped	O
architecture	O
with	O
a	O
central	O
hole	O
that	O
is	O
suitable	O
for	O
the	O
binding	O
of	O
dsDNA	O
lends	O
RdgC	O
with	O
a	O
capacity	O
to	O
hold	O
dsDNA	O
very	O
tightly	O
.	O

Therefore	O
,	O
we	O
suggest	O
that	O
RdgC	O
dimers	O
probably	O
function	O
as	O
a	O
tight	O
dsDNA	O
gripper	O
and	O
physically	O
block	O
access	O
to	O
the	O
target	O
dsDNA	O
by	O
RecA	O
filaments	O
,	O
because	O
tight	O
encircling	O
of	O
dsDNA	O
by	O
RdgC	O
dimers	O
,	O
possibly	O
as	O
a	O
linear	O
aggregate	O
,	O
would	O
prevent	O
the	O
two	O
strands	O
from	O
dissociating	O
.	O

However	O
,	O
it	O
remains	O
unclear	O
how	O
the	O
closed	O
-	O
ring	O
structure	O
of	O
the	O
RdgC	O
dimer	O
might	O
allow	O
binding	O
of	O
a	O
large	O
number	O
of	O
RdgC	O
dimers	O
on	O
the	O
duplex	O
DNA	O
.	O

It	O
may	O
be	O
conceivable	O
that	O
each	O
RdgC	O
dimer	O
can	O
open	O
temporarily	O
at	O
one	O
or	O
both	O
of	O
its	O
two	O
inter	O
-	O
subunit	O
interfaces	O
so	O
that	O
dsDNA	O
can	O
enter	O
the	O
central	O
hole	O
.	O

RdgC	O
was	O
at	O
its	O
highest	O
level	O
during	O
exponential	O
phase	O
,	O
reaching	O
its	O
maximum	O
of	O
~	O
1000	O
dimers	O
per	O
E	B-LIVB
.	I-LIVB
coli	I-LIVB
cell	O
.	O

Its	O
level	O
decreased	O
sharply	O
to	O
~	O
50	O
dimers	O
per	O
cell	O
in	O
stationary	O
phase	O
(	O
2	O
)	O
.	O

Under	O
normal	O
cellular	O
conditions	O
,	O
RecA	O
is	O
maintained	O
at	O
~	O
1000	O
molecules	O
per	O
cell	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
els	O
.	O
net	O
/	O
)	O
.	O

Following	O
LexA	O
repressor	O
cleavage	O
,	O
the	O
level	O
of	O
RecA	O
protein	O
in	O
the	O
cell	O
increases	O
by	O
as	O
much	O
as	O
20	O
-	O
fold	O
.	O

RdgC	O
inhibition	O
of	O
the	O
RecA	O
function	O
by	O
a	O
simple	O
competition	O
mechanism	O
at	O
the	O
cellular	O
concentration	O
of	O
RdgC	O
clearly	O
requires	O
a	O
much	O
higher	O
affinity	O
for	O
DNA	O
by	O
RdgC	O
than	O
RecA	O
.	O

Possible	O
protein	O
-	O
protein	O
interactions	O
between	O
RdgC	O
dimers	O
might	O
have	O
a	O
profound	O
effect	O
on	O
the	O
affinity	O
for	O
DNA	O
,	O
when	O
a	O
large	O
number	O
of	O
RdgC	O
dimers	O
are	O
bound	O
on	O
a	O
duplex	O
DNA	O
.	O

If	O
only	O
one	O
of	O
the	O
two	O
inter	O
-	O
subunit	O
interfaces	O
can	O
open	O
up	O
and	O
the	O
2	O
-	O
fold	O
symmetry	O
axes	O
of	O
the	O
RdgC	O
dimers	O
are	O
misaligned	O
sufficiently	O
,	O
the	O
escape	O
of	O
DNA	O
from	O
a	O
linear	O
array	O
of	O
interacting	O
RdgC	O
dimers	O
would	O
be	O
extremely	O
difficult	O
.	O

Alternatively	O
,	O
both	O
inter	O
-	O
subunit	O
interfaces	O
of	O
each	O
dimer	O
may	O
open	O
up	O
simultaneously	O
.	O

A	O
line	O
of	O
indirect	O
evidence	O
for	O
the	O
possible	O
protein	O
-	O
protein	O
interactions	O
between	O
RdgC	O
dimers	O
is	O
provided	O
by	O
the	O
cooperative	O
binding	O
of	O
RdgC	O
to	O
DNA	O
(	O
7	O
)	O
.	O

Cooperativity	O
of	O
RdgC	O
binding	O
may	O
be	O
caused	O
by	O
local	O
and	O
distant	O
protein	O
-	O
protein	O
interactions	O
(	O
7	O
)	O
.	O

A	O
kind	O
of	O
side	O
-	O
by	O
-	O
side	O
interaction	O
between	O
two	O
adjacent	O
molecules	O
of	O
RdgC	O
dimer	O
is	O
present	O
in	O
the	O
crystal	O
,	O
burying	O
an	O
accessible	O
surface	O
area	O
of	O
~	O
750	O
A	O
2	O
at	O
the	O
interface	O
.	O

The	O
interaction	O
involves	O
mostly	O
the	O
less	O
polar	O
side	O
surface	O
of	O
the	O
dimer	O
(	O
left	O
side	O
of	O
Figure	O
4A	O
)	O
,	O
with	O
2	O
-	O
fold	O
symmetry	O
axes	O
of	O
the	O
two	O
interacting	O
RdgC	O
molecules	O
making	O
an	O
angle	O
of	O
~	O
90	O
degrees	O
when	O
viewed	O
down	O
the	O
central	O
holes	O
and	O
~	O
15	O
degrees	O
when	O
viewed	O
perpendicular	O
to	O
the	O
holes	O
.	O

This	O
may	O
explain	O
the	O
observed	O
DNA	O
bending	O
by	O
RdgC	O
,	O
which	O
was	O
speculated	O
to	O
be	O
a	O
necessary	O
step	O
in	O
the	O
working	O
mechanism	O
of	O
RdgC	O
,	O
if	O
one	O
can	O
assume	O
that	O
the	O
strong	O
protein	O
-	O
protein	O
interactions	O
in	O
the	O
crystal	O
were	O
relevant	O
for	O
protein	O
-	O
protein	O
interactions	O
in	O
solution	O
(	O
7	O
)	O
.	O

RdgC	O
protein	O
was	O
shown	O
to	O
have	O
a	O
potent	O
effect	O
on	O
RecA	O
protein	O
-	O
promoted	O
DNA	O
strand	O
exchange	O
in	O
E	B-LIVB
.	I-LIVB
coli	I-LIVB
(	O
1	O
)	O
.	O

In	O
a	O
series	O
of	O
experiments	O
,	O
RdgC	O
was	O
added	O
after	O
RecA	O
filaments	O
had	O
formed	O
on	O
the	O
ssDNA	O
and	O
5	O
min	O
after	O
the	O
linear	O
dsDNA	O
was	O
added	O
.	O

With	O
3	O
mu	O
M	O
RecA	O
,	O
a	O
sharp	O
reduction	O
in	O
DNA	O
strand	O
exchange	O
products	O
was	O
seen	O
with	O
0	O
.	O
4	O
mu	O
M	O
RdgC	O
,	O
and	O
the	O
generation	O
of	O
products	O
was	O
abolished	O
at	O
0	O
.	O
8	O
mu	O
M	O
RdgC	O
(	O
1	O
)	O
.	O

This	O
suggests	O
that	O
the	O
binding	O
affinity	O
of	O
RdgC	O
to	O
dsDNA	O
is	O
considerably	O
higher	O
than	O
that	O
of	O
RecA	O
.	O

The	O
high	O
affinity	O
of	O
RdgC	O
could	O
be	O
explained	O
by	O
its	O
ring	O
shape	O
and	O
the	O
suggested	O
mode	O
of	O
DNA	O
binding	O
.	O

Tetrameric	O
species	O
of	O
E	B-LIVB
.	I-LIVB
coli	I-LIVB
RdgC	O
,	O
which	O
started	O
to	O
form	O
at	O
around	O
2	O
micro	O
M	O
concentrations	O
,	O
were	O
speculated	O
to	O
be	O
the	O
species	O
with	O
the	O
most	O
potent	O
inhibitory	O
effect	O
,	O
possibly	O
by	O
having	O
a	O
higher	O
affinity	O
for	O
DNA	O
(	O
1	O
)	O
.	O

Higher	O
affinity	O
for	O
DNA	O
of	O
the	O
tetrameric	O
species	O
could	O
be	O
understood	O
,	O
if	O
the	O
formation	O
of	O
a	O
tetramer	O
in	O
solution	O
involves	O
a	O
protein	O
-	O
protein	O
interaction	O
similar	O
to	O
the	O
side	O
-	O
by	O
-	O
side	O
interaction	O
between	O
two	O
adjacent	O
RdgC	O
dimers	O
in	O
the	O
crystal	O
,	O
although	O
there	O
is	O
no	O
experimental	O
evidence	O
.	O

Obviously	O
,	O
there	O
are	O
still	O
many	O
open	O
questions	O
that	O
need	O
to	O
be	O
addressed	O
in	O
future	O
biochemical	O
experiments	O
.	O

SUMMARY	O

The	O
crystal	O
structure	O
of	O
RdgC	O
,	O
a	O
recombination	O
-	O
associated	O
DNA	O
-	O
binding	O
protein	O
,	O
determined	O
in	O
this	O
study	O
reveals	O
that	O
the	O
polypeptide	O
chain	O
is	O
uniquely	O
folded	O
and	O
two	O
monomers	O
associate	O
to	O
form	O
a	O
ring	O
-	O
shaped	O
dimer	O
with	O
a	O
central	O
hole	O
of	O
~	O
30	O
A	O
diameter	O
.	O

The	O
inner	O
surface	O
around	O
the	O
central	O
hole	O
is	O
rich	O
in	O
positively	O
charged	O
residues	O
.	O

These	O
structural	O
features	O
suggest	O
that	O
dsDNA	O
runs	O
through	O
the	O
central	O
hole	O
when	O
it	O
binds	O
to	O
RdgC	O
dimers	O
.	O

This	O
idea	O
is	O
supported	O
by	O
our	O
mutational	O
studies	O
,	O
which	O
indicate	O
that	O
the	O
conserved	O
,	O
positively	O
charged	O
residues	O
around	O
the	O
central	O
hole	O
are	O
important	O
for	O
dsDNA	O
binding	O
.	O

The	O
toroidal	O
architecture	O
of	O
the	O
RdgC	O
dimer	O
provides	O
a	O
sound	O
framework	O
for	O
a	O
better	O
understanding	O
of	O
its	O
role	O
in	O
homologous	O
recombination	O
.	O

Coordinates	O

Atomic	O
coordinates	O
and	O
the	O
structure	O
factor	O
data	O
have	O
been	O
deposited	O
in	O
the	O
Protein	O
Data	O
Bank	O
(	O
accession	O
code	O
2OWY	O
)	O
.	O

SUPPLEMENTARY	O
DATA	O

Supplementary	O
Data	O
are	O
available	O
at	O
NAR	O
Online	O
.	O

Supplementary	O
Material	O

Port	O
site	O
herniation	O
of	O
the	O
small	O
bowel	O
following	O
laparoscopy	O
-	O
assisted	O
distal	O
gastrectomy	O
:	O
a	O
case	O
report	O

Abstract	O

Introduction	O

Port	O
-	O
site	O
herniation	O
is	O
a	O
rare	O
but	O
potentially	O
dangerous	O
complication	O
after	O
laparoscopic	O
surgery	O
.	O

Closure	O
of	O
port	O
sites	O
,	O
especially	O
those	O
measuring	O
10	O
mm	O
or	O
more	O
,	O
has	O
been	O
recommended	O
to	O
avoid	O
such	O
an	O
event	O
.	O

Case	O
presentation	O

We	O
herein	O
report	O
the	O
only	O
case	O
of	O
a	O
port	O
site	O
hernia	O
among	O
a	O
series	O
52	O
consecutive	O
cases	O
of	O
laparoscopy	O
-	O
assisted	O
distal	O
gastrectomy	O
(	O
LADG	O
)	O
carried	O
out	O
by	O
our	O
unit	O
between	O
July	O
2002	O
and	O
March	O
2007	O
.	O

In	O
this	O
case	O
the	O
small	O
bowel	O
herniated	O
and	O
incarcerated	O
through	O
the	O
port	O
site	O
on	O
day	O
4	O
after	O
LADG	O
despite	O
closure	O
of	O
the	O
fascia	O
.	O

Initial	O
manifestations	O
experienced	O
by	O
the	O
patient	B-LIVB
,	O
possibly	O
due	O
to	O
obstruction	O
,	O
and	O
including	O
mild	O
abdominal	O
pain	O
and	O
nausea	O
,	O
occurred	O
on	O
the	O
third	O
day	O
postoperatively	O
.	O

The	O
definitive	O
diagnosis	O
was	O
made	O
on	O
day	O
4	O
based	O
on	O
symptoms	O
related	O
to	O
leakage	O
from	O
the	O
duodenal	O
stump	O
,	O
which	O
was	O
considered	O
to	O
have	O
developed	O
after	O
severe	O
obstruction	O
of	O
the	O
bowel	O
.	O

Re	O
-	O
operation	O
for	O
reduction	O
of	O
the	O
incarcerated	O
bowel	O
and	O
tube	O
duodenostomy	O
with	O
peritoneal	O
drainage	O
were	O
required	O
to	O
manage	O
this	O
complication	O
.	O

Conclusion	O

We	O
present	O
this	O
case	O
report	O
and	O
review	O
of	O
literature	O
to	O
discuss	O
further	O
regarding	O
methods	O
of	O
fascial	O
closure	O
after	O
laparoscopic	O
surgery	O
.	O

Introduction	O

Bowel	O
herniation	O
through	O
the	O
fascial	O
defect	O
created	O
by	O
the	O
entry	O
of	O
trocars	O
is	O
now	O
recognized	O
as	O
a	O
rare	O
but	O
potentially	O
serious	O
complication	O
of	O
laparoscopic	O
surgery	O
[	O
1	O
]	O
.	O

Although	O
port	O
site	O
herniation	O
is	O
an	O
infrequent	O
complication	O
,	O
there	O
are	O
still	O
some	O
reports	O
of	O
port	O
site	O
herniation	O
after	O
these	O
procedures	O
,	O
even	O
with	O
closure	O
of	O
trocar	O
sites	O
[	O
1	O
,	O
2	O
]	O
.	O

The	O
following	O
report	O
describes	O
a	O
case	O
of	O
a	O
trocar	O
site	O
hernia	O
that	O
evolved	O
into	O
leakage	O
from	O
the	O
duodenal	O
stump	O
after	O
laparoscopy	O
-	O
assisted	O
distal	O
gastrectomy	O
(	O
LADG	O
)	O
.	O

Progression	O
occurred	O
because	O
of	O
complete	O
obstruction	O
of	O
the	O
incarcerated	O
bowel	O
after	O
a	O
Roux	O
-	O
en	O
-	O
Y	O
reconstruction	O
.	O

We	O
describe	O
the	O
significance	O
of	O
complete	O
closure	O
of	O
the	O
fascial	O
defect	O
at	O
the	O
trocar	O
site	O
including	O
the	O
peritoneum	O
in	O
the	O
prevention	O
of	O
this	O
condition	O
,	O
as	O
well	O
as	O
the	O
importance	O
of	O
early	O
diagnosis	O
to	O
avoid	O
serious	O
subsequent	O
events	O
.	O

Case	O
presentation	O

An	O
80	O
-	O
year	O
-	O
old	O
man	B-LIVB
was	O
found	O
to	O
have	O
early	O
gastric	O
cancer	O
during	O
his	O
yearly	O
check	O
-	O
up	O
by	O
gastrointestinal	O
endoscopy	O
.	O

He	O
was	O
158	O
cm	O
in	O
height	O
and	O
weighed	O
62	O
kg	O
.	O

Gastrointestinal	O
endoscopy	O
showed	O
a	O
depressed	O
lesion	O
that	O
was	O
diagnosed	O
as	O
early	O
gastric	O
cancer	O
by	O
pathological	O
examination	O
of	O
biopsy	O
specimens	O
.	O

He	O
underwent	O
LADG	O
with	O
regional	O
lymph	O
node	O
dissection	O
(	O
D1	O
including	O
the	O
nodes	O
surrounding	O
the	O
origin	O
of	O
left	O
gastric	O
artery	O
)	O
.	O

A	O
12	O
-	O
mm	O
trocar	O
for	O
the	O
laparoscope	O
was	O
placed	O
in	O
the	O
umbilicus	O
.	O

Pneumoperitoneum	O
was	O
then	O
established	O
with	O
carbon	O
dioxide	O
and	O
the	O
intraperitoneal	O
pressure	O
was	O
maintained	O
at	O
10	O
mm	O
Hg	O
.	O

Two	O
more	O
12	O
-	O
mm	O
trocars	O
were	O
inserted	O
in	O
the	O
midclavicular	O
line	O
below	O
the	O
costal	O
margin	O
and	O
2	O
cm	O
above	O
the	O
umbilicus	O
on	O
each	O
of	O
both	O
flanks	O
and	O
were	O
used	O
for	O
active	O
surgical	O
instruments	O
.	O

All	O
trocars	O
used	O
were	O
the	O
non	O
-	O
bladed	O
type	O
.	O

The	O
specimen	O
was	O
removed	O
through	O
a	O
small	O
medial	O
incision	O
which	O
was	O
55	O
mm	O
in	O
length	O
placed	O
after	O
resection	O
of	O
the	O
stomach	O
,	O
and	O
then	O
Roux	O
-	O
en	O
-	O
Y	O
reconstruction	O
(	O
RY	O
)	O
was	O
carried	O
out	O
(	O
Fig	O
.	O
1	O
)	O
.	O

A	O
tubular	O
shaped	O
drainage	O
tube	O
10	O
mm	O
in	O
diameter	O
was	O
inserted	O
and	O
placed	O
through	O
the	O
upper	O
trocar	O
site	O
made	O
on	O
the	O
right	O
flank	O
.	O

Wound	O
defect	O
at	O
the	O
umbilical	O
port	O
site	O
was	O
sutured	O
completely	O
including	O
the	O
peritoneum	O
with	O
0	O
absorbable	O
suture	O
and	O
fascial	O
incisions	O
at	O
all	O
other	O
trocar	O
insertion	O
sites	O
were	O
closed	O
with	O
2	O
-	O
0	O
absorbable	O
sutures	O
.	O

Surgical	O
duration	O
was	O
263	O
min	O
,	O
and	O
the	O
volume	O
of	O
blood	O
loss	O
was	O
less	O
than	O
50	O
mL	O
with	O
no	O
blood	O
transfusion	O
.	O

Postoperatively	O
,	O
the	O
patient	B-LIVB
complained	O
of	O
an	O
acidic	O
feeling	O
in	O
his	O
stomach	O
;	O
however	O
,	O
there	O
were	O
no	O
remarkable	O
abnormalities	O
on	O
biochemical	O
examination	O
of	O
serum	O
.	O

Radiological	O
findings	O
did	O
not	O
suggest	O
bowel	O
obstruction	O
until	O
3	O
days	O
postoperatively	O
,	O
although	O
mild	O
symptoms	O
such	O
as	O
general	O
malaise	O
and	O
vague	O
abdominal	O
pain	O
were	O
reported	O
on	O
day	O
three	O
.	O

However	O
,	O
on	O
day	O
4	O
,	O
the	O
patient	B-LIVB
started	O
to	O
complain	O
of	O
upper	O
abdominal	O
pain	O
and	O
developed	O
a	O
high	O
grade	O
fever	O
(	O
38	O
degrees	O
C	O
)	O
.	O

Complete	O
obstruction	O
of	O
the	O
small	O
bowel	O
and	O
leakage	O
of	O
contrast	O
media	O
were	O
demonstrated	O
by	O
Gastrografin	O
swallow	O
and	O
subsequent	O
abdominal	O
computed	O
tomography	O
(	O
CT	O
)	O
.	O

CT	O
also	O
showed	O
a	O
mass	O
lesion	O
at	O
the	O
trocar	O
insertion	O
site	O
on	O
the	O
upper	O
left	O
flank	O
,	O
suggesting	O
herniation	O
through	O
the	O
port	O
site	O
(	O
Fig	O
.	O
2	O
)	O
.	O

Marked	O
dilatation	O
of	O
the	O
duodenum	O
including	O
the	O
horizontal	O
part	O
and	O
second	O
portion	O
was	O
observed	O
.	O

A	O
diagnosis	O
of	O
staple	O
failure	O
of	O
the	O
stump	O
of	O
the	O
duodenum	O
and	O
port	O
-	O
site	O
herniation	O
of	O
the	O
small	O
bowel	O
was	O
made	O
,	O
and	O
exploratory	O
laparotomy	O
was	O
carried	O
out	O
.	O

A	O
small	O
medial	O
incision	O
that	O
had	O
been	O
made	O
at	O
the	O
initial	O
surgery	O
was	O
extended	O
downward	O
to	O
the	O
umbilicus	O
to	O
open	O
the	O
peritoneal	O
cavity	O
.	O

As	O
we	O
expected	O
,	O
the	O
small	O
bowel	O
was	O
incarcerated	O
into	O
the	O
peritoneal	O
defect	O
in	O
the	O
abdominal	O
wall	O
created	O
by	O
the	O
trocar	O
placed	O
in	O
the	O
left	O
upper	O
flank	O
leading	O
to	O
complete	O
obstruction	O
of	O
the	O
bowel	O
(	O
Fig	O
.	O
3	O
)	O
.	O

Part	O
of	O
the	O
jejunum	O
30	O
cm	O
distal	O
from	O
the	O
ligament	O
of	O
Treitz	O
herniated	O
around	O
the	O
fascial	O
stitch	O
,	O
which	O
still	O
existed	O
at	O
the	O
time	O
of	O
the	O
re	O
-	O
exploration	O
.	O

The	O
peritoneal	O
cavity	O
was	O
contaminated	O
with	O
intestinal	O
juice	O
.	O

Close	O
examination	O
after	O
reduction	O
of	O
the	O
incarcerated	O
bowel	O
did	O
not	O
demonstrate	O
necrosis	O
of	O
the	O
intestine	O
,	O
and	O
thus	O
,	O
we	O
decided	O
not	O
to	O
resect	O
this	O
lesion	O
.	O

Leakage	O
of	O
intestinal	O
juice	O
through	O
a	O
pinhole	O
fistula	O
at	O
the	O
duodenal	O
stump	O
was	O
also	O
observed	O
.	O

Tube	O
duodenostomy	O
was	O
performed	O
with	O
an	O
omental	O
patch	O
used	O
for	O
closure	O
of	O
the	O
fistula	O
.	O

The	O
peritoneal	O
defect	O
was	O
also	O
closed	O
.	O

The	O
postoperative	O
course	O
was	O
fairly	O
good	O
without	O
high	O
output	O
of	O
the	O
intestinal	O
juice	O
leakage	O
or	O
sepsis	O
.	O

The	O
patient	B-LIVB
remained	O
in	O
the	O
intensive	O
care	O
unit	O
for	O
5	O
days	O
after	O
re	O
-	O
operation	O
,	O
and	O
was	O
then	O
transferred	O
to	O
the	O
general	O
ward	O
.	O

Discussion	O

Port	O
-	O
site	O
herniation	O
,	O
which	O
is	O
one	O
of	O
the	O
major	O
complications	O
after	O
laparoscopic	O
procedures	O
[	O
1	O
]	O
,	O
sometimes	O
develops	O
into	O
serious	O
complications	O
,	O
such	O
as	O
bowel	O
obstruction	O
due	O
to	O
incarceration	O
into	O
the	O
fascial	O
defect	O
at	O
the	O
port	O
site	O
.	O

Boughey	O
et	O
al	O
.	O
have	O
reported	O
four	O
cases	O
of	O
Richter	O
'	O
s	O
hernia	O
that	O
occurred	O
at	O
a	O
port	O
site	O
after	O
laparoscopic	O
surgery	O
[	O
1	O
]	O
.	O

They	O
reviewed	O
previous	O
reports	O
and	O
found	O
the	O
incidence	O
to	O
be	O
0	O
.	O
2	O
to	O
3	O
%	O
.	O

A	O
report	O
describes	O
the	O
incidence	O
of	O
hernia	O
as	O
0	O
.	O
23	O
%	O
for	O
10	O
-	O
mm	O
trocar	O
use	O
,	O
rising	O
to	O
3	O
.	O
1	O
%	O
for	O
the	O
12	O
-	O
mm	O
trocar	O
[	O
2	O
]	O
suggesting	O
that	O
the	O
wound	O
created	O
by	O
a	O
larger	O
port	O
carries	O
a	O
greater	O
risk	O
of	O
herniation	O
.	O

Most	O
surgeons	O
now	O
routinely	O
close	O
the	O
fascia	O
of	O
port	O
sites	O
to	O
prevent	O
this	O
complication	O
[	O
2	O
]	O
.	O

According	O
to	O
previous	O
reports	O
,	O
port	O
site	O
herniation	O
apparently	O
happens	O
more	O
often	O
with	O
the	O
use	O
of	O
bladed	O
type	O
trocars	O
than	O
non	O
-	O
bladed	O
type	O
trocars	O
[	O
3	O
]	O
.	O

Indeed	O
,	O
Kolata	O
demonstrated	O
that	O
the	O
wounds	O
made	O
by	O
the	O
non	O
-	O
bladed	O
trocar	O
were	O
narrower	O
than	O
those	O
created	O
by	O
cutting	O
tip	O
trocars	O
in	O
a	O
pig	B-LIVB
experimental	O
model	O
[	O
4	O
]	O
.	O

Several	O
reports	O
even	O
concluded	O
that	O
port	O
sites	O
created	O
by	O
non	O
-	O
bladed	O
trocars	O
do	O
not	O
require	O
fascial	O
closure	O
[	O
3	O
]	O
.	O

However	O
,	O
the	O
current	O
case	O
suggests	O
that	O
thick	O
preperitoneum	O
is	O
a	O
potential	O
space	O
that	O
allows	O
for	O
the	O
development	O
of	O
bowel	O
herniation	O
even	O
with	O
the	O
use	O
of	O
non	O
-	O
bladed	O
type	O
trocars	O
.	O

A	O
previous	O
report	O
also	O
described	O
port	O
-	O
site	O
herniation	O
,	O
despite	O
the	O
closure	O
of	O
the	O
superficial	O
layer	O
of	O
the	O
fascial	O
defect	O
[	O
5	O
]	O
.	O

The	O
current	O
case	O
did	O
not	O
demonstrate	O
any	O
of	O
the	O
risk	O
factors	O
suggested	O
previously	O
[	O
6	O
]	O
;	O
1	O
)	O
enlargement	O
of	O
a	O
port	O
site	O
to	O
remove	O
specimen	O
;	O
2	O
)	O
glucose	O
intolerance	O
;	O
3	O
)	O
obesity	O
;	O
or	O
4	O
)	O
extensive	O
manipulation	O
of	O
the	O
trocar	O
during	O
relatively	O
prolonged	O
surgical	O
duration	O
,	O
which	O
might	O
have	O
enlarged	O
the	O
trocar	O
site	O
and	O
thus	O
induced	O
bowel	O
herniation	O
.	O

Therefore	O
,	O
we	O
recommend	O
closing	O
the	O
fascial	O
defect	O
,	O
including	O
the	O
peritoneum	O
,	O
especially	O
if	O
the	O
trocar	O
size	O
is	O
more	O
than	O
10	O
-	O
mm	O
and	O
in	O
the	O
presence	O
of	O
any	O
of	O
the	O
risk	O
factors	O
described	O
above	O
.	O

However	O
,	O
it	O
is	O
sometimes	O
difficult	O
to	O
completely	O
close	O
the	O
defect	O
,	O
including	O
the	O
peritoneum	O
,	O
especially	O
in	O
obese	O
patients	B-LIVB
.	O

Shaher	O
reviewed	O
different	O
wound	O
closure	O
techniques	O
by	O
a	O
literature	O
search	O
[	O
7	O
]	O
.	O

In	O
this	O
review	O
,	O
old	O
methods	O
using	O
classical	O
instruments	O
including	O
Deschamps	O
needle	O
are	O
also	O
useful	O
as	O
well	O
as	O
special	O
wound	O
devices	O
designed	O
for	O
port	O
site	O
closure	O
.	O

Elashry	O
et	O
al	O
.	O
described	O
a	O
prospective	O
randomized	O
study	O
demonstrating	O
that	O
the	O
Carter	O
-	O
Thomason	O
device	O
was	O
faster	O
and	O
resulted	O
in	O
fewer	O
port	O
-	O
closure	O
-	O
related	O
complications	O
among	O
eight	O
different	O
techniques	O
tested	O
[	O
8	O
]	O
.	O

Insertion	O
of	O
a	O
SURGICEL	O
plug	O
into	O
the	O
muscular	O
layer	O
of	O
trocar	O
wounds	O
has	O
also	O
been	O
proposed	O
by	O
Chiu	O
et	O
al	O
[	O
9	O
]	O
.	O

Alternatively	O
,	O
tangential	O
insertion	O
of	O
a	O
trocar	O
through	O
the	O
abdominal	O
wall	O
might	O
be	O
effective	O
in	O
reducing	O
the	O
size	O
of	O
fascial	O
defects	O
.	O

Moreover	O
,	O
recent	O
publications	O
have	O
demonstrated	O
that	O
radially	O
expanding	O
type	O
trocars	O
could	O
be	O
useful	O
to	O
avoid	O
the	O
necessity	O
of	O
closing	O
the	O
fascial	O
defect	O
[	O
10	O
]	O
.	O

Symptoms	O
of	O
trocar	O
-	O
site	O
herniation	O
vary	O
depending	O
on	O
the	O
severity	O
of	O
bowel	O
obstruction	O
.	O

Mild	O
symptoms	O
such	O
as	O
slight	O
nausea	O
and	O
vague	O
abdominal	O
pain	O
,	O
both	O
of	O
which	O
are	O
most	O
frequently	O
seen	O
in	O
the	O
early	O
normal	O
postoperative	O
course	O
after	O
abdominal	O
surgery	O
,	O
could	O
be	O
the	O
first	O
and	O
only	O
complaints	O
at	O
the	O
early	O
stage	O
of	O
this	O
complication	O
.	O

Thus	O
,	O
the	O
diagnosis	O
may	O
be	O
delayed	O
.	O

In	O
our	O
case	O
,	O
mild	O
abdominal	O
pain	O
with	O
general	O
malaise	O
might	O
have	O
been	O
symptoms	O
related	O
to	O
the	O
early	O
stage	O
of	O
the	O
onset	O
.	O

Abdominal	O
CT	O
showing	O
the	O
enlarged	O
duodenum	O
also	O
suggested	O
that	O
leakage	O
from	O
the	O
duodenal	O
stump	O
occurred	O
due	O
to	O
the	O
obstruction	O
of	O
the	O
distal	O
bowel	O
.	O

Thus	O
,	O
severe	O
complication	O
might	O
have	O
been	O
avoided	O
,	O
if	O
early	O
diagnosis	O
had	O
been	O
made	O
.	O

Although	O
the	O
benefit	O
of	O
Roux	O
-	O
en	O
-	O
Y	O
is	O
apparent	O
[	O
11	O
]	O
,	O
the	O
duodenal	O
stump	O
could	O
be	O
vulnerable	O
to	O
leakage	O
due	O
to	O
increased	O
intrabowel	O
pressure	O
.	O

Therefore	O
,	O
careful	O
management	O
of	O
the	O
postoperative	O
course	O
is	O
warranted	O
,	O
especially	O
after	O
procedures	O
involving	O
division	O
of	O
the	O
bowel	O
such	O
as	O
LADG	O
.	O

Moreover	O
,	O
special	O
attention	O
should	O
be	O
paid	O
in	O
patients	B-LIVB
with	O
risk	O
factors	O
for	O
port	O
site	O
hernia	O
such	O
as	O
obesity	O
,	O
aggressive	O
manipulation	O
through	O
the	O
port	O
sites	O
,	O
and	O
prolonged	O
surgery	O
.	O

Conclusion	O

Port	O
-	O
site	O
herniation	O
is	O
a	O
potentially	O
dangerous	O
complication	O
after	O
laparoscopic	O
procedures	O
.	O

Careful	O
management	O
of	O
the	O
postoperative	O
course	O
is	O
recommended	O
especially	O
for	O
patients	B-LIVB
with	O
risk	O
factors	O
such	O
as	O
obesity	O
and	O
extensive	O
manipulation	O
of	O
the	O
trocar	O
during	O
prolonged	O
surgical	O
duration	O
.	O

Competing	O
interests	O

The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O

TI	O
,	O
NF	O
,	O
HT	O
and	O
TK	O
performed	O
the	O
first	O
and	O
second	O
operation	O
.	O

TI	O
and	O
KK	O
were	O
responsible	O
for	O
the	O
postoperative	O
management	O
.	O

TI	O
,	O
HT	O
,	O
TW	O
,	O
and	O
KN	O
were	O
involved	O
in	O
editing	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Consent	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
the	O
patient	B-LIVB
for	O
publication	O
of	O
this	O
case	O
report	O
and	O
any	O
accompanying	O
images	O
.	O

A	O
copy	O
of	O
the	O
written	O
consent	O
is	O
available	O
for	O
review	O
by	O
the	O
Editor	O
-	O
in	O
-	O
Chief	O
of	O
this	O
journal	O
.	O

Comparison	O
of	O
strategies	O
for	O
identification	O
of	O
regulatory	O
quantitative	O
trait	O
loci	O
of	O
transcript	O
expression	O
traits	O

Abstract	O

In	O
order	O
to	O
identify	O
regulatory	O
genes	O
,	O
we	O
determined	O
the	O
heritability	O
of	O
gene	O
transcripts	O
,	O
performed	O
linkage	O
analysis	O
to	O
identify	O
quantitative	O
trait	O
loci	O
(	O
QTLs	O
)	O
,	O
and	O
evaluated	O
the	O
evidence	O
for	O
shared	O
genetic	O
effects	O
among	O
transcripts	O
with	O
co	O
-	O
localized	O
QTLs	O
in	O
non	O
-	O
diseased	O
participants	B-LIVB
from	O
14	O
CEPH	O
(	O
Centre	O
d	O
'	O
Etude	O
du	O
Polymorphisme	O
Humain	O
)	O
Utah	O
families	O
.	O

Seventy	O
-	O
six	O
percent	O
of	O
transcripts	O
had	O
a	O
significant	O
heritability	O
and	O
54	O
%	O
of	O
them	O
had	O
LOD	O
score	O
>=	O
1	O
.	O
8	O
.	O

Bivariate	O
genetic	O
analysis	O
of	O
15	O
transcripts	O
that	O
had	O
co	O
-	O
localized	O
QTLs	O
on	O
4q28	O
.	O
2	O
-	O
q31	O
.	O
1	O
identified	O
significant	O
genetic	O
correlation	O
among	O
some	O
transcripts	O
although	O
no	O
improvement	O
in	O
the	O
magnitude	O
of	O
LOD	O
scores	O
in	O
this	O
region	O
was	O
noted	O
.	O

Similar	O
results	O
were	O
found	O
in	O
analysis	O
of	O
12	O
transcripts	O
,	O
that	O
had	O
co	O
-	O
localized	O
QTLs	O
in	O
the	O
13q34	O
region	O
.	O

Principal	O
-	O
component	O
analyses	O
did	O
not	O
improve	O
the	O
ability	O
to	O
identify	O
chromosomal	O
regions	O
of	O
co	O
-	O
localized	O
gene	O
expressions	O
.	O

Background	O

There	O
is	O
a	O
breadth	O
of	O
information	O
being	O
generated	O
by	O
the	O
Human	B-LIVB
Genome	O
Project	O
and	O
the	O
interpretation	O
of	O
these	O
data	O
has	O
been	O
a	O
major	O
area	O
of	O
research	O
.	O

For	O
simple	O
Mendelian	O
disorders	O
,	O
the	O
identification	O
of	O
genetic	O
effects	O
is	O
fairly	O
straightforward	O
due	O
to	O
understanding	O
the	O
biology	O
that	O
drives	O
these	O
disorders	O
.	O

However	O
,	O
for	O
complex	O
oligogenic	O
or	O
polygenic	O
disorders	O
,	O
understanding	O
all	O
the	O
interconnections	O
between	O
genes	O
influencing	O
a	O
trait	O
is	O
a	O
difficult	O
task	O
because	O
the	O
understanding	O
of	O
the	O
biology	O
of	O
many	O
of	O
these	O
disorders	O
is	O
still	O
evolving	O
.	O

Multiple	O
gene	O
x	O
gene	O
and	O
gene	O
x	O
environment	O
interactions	O
can	O
influence	O
the	O
expression	O
of	O
phenotypes	O
.	O

Genes	O
can	O
interact	O
by	O
modifying	O
the	O
expression	O
of	O
other	O
genes	O
and	O
therefore	O
function	O
as	O
regulatory	O
genes	O
[	O
1	O
]	O
.	O

In	O
an	O
effort	O
to	O
dissect	O
some	O
of	O
these	O
complexities	O
,	O
we	O
performed	O
linkage	O
analysis	O
of	O
gene	O
expression	O
transcripts	O
of	O
members	O
of	O
Centre	O
d	O
'	O
Etude	O
du	O
Polymorphisme	O
Humain	O
(	O
CEPH	O
)	O
Utah	O
families	O
to	O
determine	O
the	O
heritability	O
of	O
transcripts	O
and	O
the	O
evidence	O
for	O
regulatory	O
quantitative	O
trait	O
loci	O
(	O
QTLs	O
)	O
and	O
we	O
performed	O
pairwise	O
bivariate	O
linkage	O
analysis	O
and	O
principal	O
-	O
component	O
analysis	O
(	O
PCA	O
)	O
for	O
data	O
-	O
reduction	O
to	O
evaluate	O
the	O
evidence	O
for	O
shared	O
genetic	O
effects	O
.	O

The	O
ability	O
to	O
assess	O
gene	O
expression	O
traits	O
simultaneously	O
and	O
to	O
link	O
them	O
to	O
QTLs	O
offers	O
the	O
possibility	O
of	O
identifying	O
previously	O
unknown	O
underlying	O
molecular	O
processes	O
for	O
future	O
investigation	O
.	O

Methods	O

Population	O
and	O
phenotypes	O

We	O
used	O
the	O
Genetic	O
Analysis	O
Workshop	O
15	O
(	O
GAW	O
15	O
)	O
Problem	O
1	O
microarray	O
gene	O
expression	O
profiles	O
for	O
the	O
analyses	O
.	O

Data	O
were	O
available	O
for	O
14	O
three	O
-	O
generation	O
CEPH	O
Utah	O
families	O
.	O

Expression	O
levels	O
of	O
genes	O
were	O
obtained	O
from	O
lymphoblastoid	O
cells	O
using	O
the	O
Affymetrix	O
Human	B-LIVB
Focus	O
Arrays	O
[	O
2	O
]	O
.	O

We	O
were	O
provided	O
with	O
data	O
on	O
3554	O
transcripts	O
that	O
showed	O
greater	O
variation	O
between	O
individuals	O
than	O
within	O
the	O
same	O
individual	O
.	O

Family	O
members	O
were	O
genotyped	O
for	O
2882	O
autosomal	O
and	O
X	O
-	O
linked	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNP	O
)	O
generated	O
by	O
the	O
SNP	O
Consortium	O
.	O

Genetic	O
map	O
positions	O
were	O
obtained	O
using	O
the	O
SNP	O
Mapping	O
web	O
application	O
developed	O
by	O
the	O
University	O
College	O
Dublin	O
Conway	O
Institute	O
of	O
Biomolecular	O
and	O
Biomedical	O
Research	O
,	O
which	O
uses	O
the	O
Rutgers	O
Combined	O
Linkage	O
-	O
Physical	O
Map	O
of	O
the	O
Human	B-LIVB
Genome	O
and	O
data	O
taken	O
from	O
the	O
NCBI	O
dbSNP	O
Build	O
123	O
(	O
in	O
Kosambi	O
centimorgans	O
)	O
.	O

This	O
information	O
was	O
used	O
to	O
calculate	O
multipoint	O
identity	O
by	O
descent	O
matrices	O
(	O
MIBDs	O
)	O
with	O
Merlin	O
and	O
Minx	O
[	O
3	O
]	O
,	O
after	O
removal	O
of	O
Mendelian	O
inconsistencies	O
and	O
double	O
recombinants	O
with	O
Preswalk	O
(	O
based	O
on	O
Simwalk	O
mistyping	O
probabilities	O
)	O
[	O
4	O
]	O
.	O

MIBDs	O
were	O
used	O
for	O
linkage	O
analyses	O
.	O

Transcript	O
distributions	O
were	O
normalized	O
using	O
an	O
inverse	O
normalization	O
transformation	O
of	O
z	O
-	O
scores	O
of	O
individual	O
transcripts	O
regressed	O
on	O
the	O
mean	O
individual	O
transcript	O
level	O
.	O

We	O
further	O
adjusted	O
for	O
the	O
effects	O
of	O
age	O
,	O
age2	O
,	O
sex	O
,	O
age	O
x	O
sex	O
and	O
age2	O
x	O
sex	O
interaction	O
using	O
predictive	O
linear	O
regression	O
models	O
in	O
SAS	O
9	O
.	O
1	O
(	O
Cary	O
,	O
NC	O
)	O
.	O

We	O
generated	O
these	O
residuals	O
as	O
part	O
of	O
our	O
processing	O
of	O
the	O
transcripts	O
for	O
linkage	O
analyses	O
.	O

Heritability	O
estimation	O
and	O
linkage	O
analysis	O

Heritability	O
was	O
estimated	O
using	O
maximum	O
likelihood	O
variance	O
decomposition	O
methods	O
in	O
SOLAR	O
[	O
5	O
,	O
6	O
]	O
.	O

Genome	O
scans	O
were	O
performed	O
using	O
multipoint	O
variance	O
-	O
components	O
models	O
that	O
test	O
for	O
linkage	O
between	O
traits	O
and	O
genetic	O
variants	O
by	O
partitioning	O
the	O
variance	O
of	O
the	O
expression	O
level	O
into	O
its	O
additive	O
genetic	O
and	O
environmental	O
variance	O
components	O
[	O
7	O
]	O
.	O

For	O
transcripts	O
with	O
co	O
-	O
localized	O
QTLs	O
,	O
we	O
performed	O
bivariate	O
linkage	O
analysis	O
to	O
identify	O
shared	O
genetic	O
effects	O
.	O

The	O
bivariate	O
polygenic	O
model	O
estimates	O
correlations	O
caused	O
by	O
residual	O
additive	O
genetic	O
effects	O
(	O
rho	O
G	O
)	O
and	O
correlations	O
caused	O
by	O
random	O
environmental	O
effects	O
(	O
rho	O
E	O
)	O
[	O
8	O
]	O
.	O

To	O
test	O
for	O
additive	O
genetic	O
correlation	O
among	O
pairs	O
of	O
traits	O
,	O
the	O
log	O
likelihood	O
of	O
a	O
model	O
in	O
which	O
rho	O
G	O
is	O
constrained	O
to	O
0	O
(	O
null	O
hypothesis	O
,	O
no	O
correlation	O
)	O
or	O
rho	O
G	O
=	O
1	O
(	O
null	O
hypothesis	O
,	O
complete	O
shared	O
genetic	O
effect	O
)	O
is	O
compared	O
to	O
that	O
of	O
a	O
model	O
in	O
which	O
rho	O
G	O
is	O
estimated	O
for	O
the	O
traits	O
.	O

Significant	O
differences	O
among	O
the	O
models	O
(	O
rho	O
G	O
!=	O
0	O
)	O
suggest	O
that	O
some	O
of	O
the	O
same	O
genes	O
influence	O
both	O
traits	O
.	O

We	O
also	O
performed	O
linkage	O
analysis	O
using	O
the	O
factors	O
obtained	O
from	O
the	O
PCA	O
in	O
a	O
sample	O
of	O
transcripts	O
with	O
co	O
-	O
localized	O
QTLs	O
.	O

Principal	O
-	O
component	O
analysis	O

PCA	O
was	O
used	O
to	O
reduce	O
the	O
number	O
of	O
expression	O
profiles	O
into	O
statistically	O
meaningful	O
groups	O
while	O
retaining	O
the	O
original	O
total	O
variance	O
using	O
all	O
the	O
expression	O
profiles	O
[	O
9	O
,	O
10	O
]	O
.	O

We	O
selected	O
two	O
different	O
chromosomal	O
regions	O
of	O
a	O
length	O
of	O
10	O
to	O
12	O
MB	O
in	O
which	O
the	O
QTLs	O
of	O
at	O
least	O
10	O
transcripts	O
were	O
co	O
-	O
localized	O
.	O

Only	O
transcripts	O
of	O
genes	O
that	O
were	O
not	O
located	O
in	O
these	O
selected	O
chromosomal	O
regions	O
were	O
included	O
in	O
the	O
analyses	O
(	O
trans	O
-	O
regulatory	O
genes	O
)	O
.	O

Because	O
of	O
the	O
small	O
number	O
of	O
individuals	O
in	O
the	O
study	O
and	O
concerns	O
of	O
overfitting	O
the	O
model	O
,	O
a	O
maximum	O
sample	O
of	O
50	O
transcript	O
values	O
were	O
considered	O
at	O
one	O
time	O
[	O
11	O
]	O
.	O

The	O
number	O
of	O
factors	O
was	O
determined	O
using	O
the	O
eigenvalue	O
-	O
one	O
requirement	O
[	O
11	O
]	O
.	O

Factors	O
are	O
interpreted	O
by	O
examining	O
the	O
varimax	O
-	O
rotated	O
factor	O
loadings	O
,	O
which	O
are	O
the	O
correlations	O
between	O
each	O
phenotype	O
and	O
the	O
factor	O
in	O
question	O
.	O

Factor	O
loadings	O
greater	O
than	O
or	O
equal	O
to	O
0	O
.	O
40	O
in	O
absolute	O
value	O
were	O
used	O
to	O
interpret	O
factors	O
and	O
to	O
characterize	O
the	O
factor	O
structures	O
;	O
this	O
criterion	O
ensures	O
that	O
the	O
individual	O
factor	O
variables	O
share	O
at	O
least	O
15	O
%	O
of	O
their	O
variance	O
with	O
the	O
given	O
factor	O
[	O
9	O
]	O
.	O

The	O
principle	O
components	O
were	O
obtained	O
by	O
calculating	O
the	O
eigenvalues	O
of	O
the	O
sample	O
covariance	O
matrix	O
,	O
which	O
represent	O
the	O
amount	O
of	O
variance	O
contributed	O
by	O
each	O
factor	O
.	O

Only	O
factors	O
with	O
eigenvalues	O
higher	O
than	O
1	O
were	O
considered	O
for	O
linkage	O
analysis	O
.	O

Integrating	O
data	O
from	O
linkage	O
analysis	O
for	O
gene	O
co	O
-	O
expression	O

Linkage	O
signals	O
of	O
individual	O
transcript	O
expressions	O
were	O
recorded	O
and	O
the	O
location	O
of	O
QTLs	O
was	O
compared	O
to	O
the	O
location	O
of	O
the	O
transcript	O
gene	O
in	O
order	O
to	O
identify	O
trans	O
-	O
regulatory	O
sites	O
.	O

In	O
addition	O
,	O
the	O
location	O
and	O
LOD	O
scores	O
of	O
QTLs	O
identified	O
in	O
single	O
individual	O
transcript	O
analysis	O
(	O
univariate	O
analysis	O
)	O
were	O
compared	O
with	O
the	O
location	O
of	O
the	O
QTLs	O
identified	O
using	O
bivariate	O
analysis	O
or	O
factors	O
of	O
the	O
PCA	O
.	O

This	O
allowed	O
a	O
determination	O
of	O
whether	O
the	O
bivariate	O
analysis	O
or	O
PCA	O
data	O
reduction	O
analysis	O
improved	O
our	O
evidence	O
for	O
linkage	O
,	O
and	O
if	O
so	O
,	O
a	O
more	O
in	O
-	O
depth	O
examination	O
of	O
the	O
transcripts	O
included	O
in	O
the	O
principal	O
components	O
needs	O
to	O
be	O
examined	O
for	O
biologic	O
interactions	O
on	O
complex	O
disorders	O
.	O

Results	O

Among	O
194	O
individuals	O
from	O
14	O
families	O
,	O
17	O
individuals	O
with	O
missing	O
information	O
on	O
age	O
were	O
excluded	O
.	O

Seventy	O
-	O
six	O
percent	O
(	O
n	O
=	O
2688	O
)	O
of	O
the	O
transcripts	O
had	O
significant	O
heritability	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
were	O
considered	O
for	O
the	O
linkage	O
analysis	O
.	O

Of	O
this	O
,	O
1448	O
(	O
54	O
%	O
)	O
transcripts	O
displayed	O
suggestive	O
evidence	O
of	O
linkage	O
(	O
had	O
a	O
maximum	O
LOD	O
score	O
>=	O
1	O
.	O
8	O
[	O
12	O
]	O
)	O
.	O

The	O
QTLs	O
of	O
1661	O
transcripts	O
(	O
759	O
of	O
which	O
with	O
LOD	O
>=	O
1	O
.	O
8	O
)	O
were	O
localized	O
in	O
a	O
different	O
region	O
than	O
the	O
gene	O
transcript	O
(	O
trans	O
-	O
regulatory	O
sites	O
)	O
.	O

We	O
used	O
two	O
different	O
chromosomal	O
regions	O
with	O
co	O
-	O
localized	O
transcript	O
QTLs	O
,	O
chromosomes	O
4q28	O
.	O
2	O
-	O
q31	O
.	O
1	O
and	O
13q34	O
,	O
for	O
more	O
in	O
-	O
depth	O
analyses	O
.	O

Chromosome	O
4q28	O
.	O
2	O
-	O
q31	O
.	O
1	O
region	O

Table	O
1	O
reports	O
the	O
results	O
for	O
the	O
chromosome	O
4q28	O
.	O
2	O
-	O
q31	O
.	O
1	O
region	O
.	O

Fifteen	O
transcripts	O
co	O
-	O
localized	O
in	O
this	O
region	O
in	O
the	O
univariate	O
linkage	O
analysis	O
,	O
and	O
the	O
LOD	O
scores	O
ranged	O
from	O
1	O
.	O
17	O
to	O
3	O
.	O
72	O
.	O

The	O
strongest	O
linkage	O
signals	O
were	O
observed	O
for	O
the	O
transcripts	O
of	O
the	O
MX2	O
,	O
NUCB2	O
,	O
and	O
SNX4	O
genes	O
.	O

Using	O
PCA	O
,	O
we	O
obtained	O
five	O
factors	O
from	O
the	O
15	O
transcripts	O
with	O
eigenvalues	O
greater	O
than	O
1	O
.	O

Only	O
one	O
factor	O
,	O
with	O
a	O
high	O
positive	O
loading	O
for	O
the	O
MX2	O
gene	O
transcript	O
,	O
had	O
a	O
significant	O
heritability	O
and	O
a	O
LOD	O
score	O
>=	O
1	O
.	O
8	O
.	O

The	O
linkage	O
analysis	O
using	O
this	O
factor	O
identified	O
the	O
chromosome	O
region	O
for	O
the	O
MX2	O
gene	O
,	O
but	O
the	O
LOD	O
score	O
was	O
lower	O
than	O
the	O
one	O
obtained	O
by	O
single	O
linkage	O
analysis	O
of	O
the	O
MX2	O
transcript	O
.	O

We	O
then	O
performed	O
bivariate	O
analysis	O
of	O
all	O
pairwise	O
co	O
-	O
localized	O
transcripts	O
on	O
4q28	O
.	O
2	O
-	O
q31	O
.	O
1	O
and	O
found	O
evidence	O
for	O
genetic	O
correlation	O
of	O
co	O
-	O
localized	O
genes	O
,	O
although	O
without	O
much	O
increase	O
in	O
the	O
magnitude	O
of	O
the	O
LOD	O
score	O
(	O
Figure	O
1	O
)	O
.	O

This	O
analysis	O
identified	O
two	O
networks	O
of	O
gene	O
expressions	O
(	O
Figure	O
1	O
)	O
.	O

We	O
obtained	O
two	O
factors	O
using	O
PCA	O
of	O
the	O
first	O
network	O
(	O
Group	O
1	O
,	O
SNX4	O
,	O
YWHAQ	O
,	O
ASS	O
,	O
MX2	O
,	O
and	O
ISGF3G	O
gene	O
transcripts	O
)	O
.	O

Both	O
factors	O
had	O
significant	O
heritability	O
;	O
however	O
,	O
only	O
Factor	O
1	O
,	O
loading	O
heavily	O
on	O
the	O
MX2	O
gene	O
,	O
localized	O
to	O
the	O
4q28	O
.	O
2	O
-	O
q31	O
.	O
1	O
region	O
(	O
Table	O
1	O
)	O
,	O
and	O
the	O
magnitude	O
of	O
the	O
LOD	O
score	O
was	O
lower	O
than	O
that	O
of	O
the	O
univariate	O
MX2	O
gene	O
transcript	O
analysis	O
(	O
LOD	O
=	O
2	O
.	O
28	O
)	O
.	O

The	O
heritability	O
of	O
one	O
factor	O
obtained	O
using	O
PCA	O
for	O
Group	O
2	O
transcripts	O
was	O
not	O
significant	O
and	O
further	O
analysis	O
was	O
not	O
performed	O
.	O

Chromosome	O
13q34	O
region	O

We	O
performed	O
analysis	O
in	O
an	O
additional	O
chromosome	O
region	O
of	O
co	O
-	O
localized	O
transcripts	O
,	O
13q34	O
region	O
,	O
and	O
noted	O
similar	O
results	O
.	O

Using	O
univariate	O
analysis	O
,	O
12	O
transcripts	O
co	O
-	O
localized	O
in	O
this	O
region	O
;	O
and	O
bivariate	O
analysis	O
revealed	O
an	O
intricate	O
network	O
of	O
correlated	O
traits	O
(	O
Table	O
2	O
and	O
Figure	O
2	O
)	O
.	O

Using	O
PCA	O
,	O
we	O
obtained	O
five	O
factors	O
,	O
three	O
of	O
them	O
with	O
significant	O
heritability	O
.	O

Similar	O
to	O
our	O
previous	O
findings	O
on	O
chomosome	O
4	O
,	O
PCA	O
factors	O
did	O
not	O
improve	O
the	O
magnitude	O
of	O
the	O
LOD	O
scores	O
when	O
compared	O
to	O
univariate	O
analysis	O
.	O

Discussion	O

In	O
this	O
study	O
,	O
we	O
identified	O
co	O
-	O
localized	O
QTLs	O
of	O
individual	O
transcripts	O
and	O
compared	O
the	O
univariate	O
and	O
bivariate	O
linkage	O
results	O
using	O
single	O
transcripts	O
to	O
those	O
using	O
factors	O
obtained	O
from	O
PCA	O
.	O

By	O
using	O
factors	O
that	O
accounted	O
for	O
the	O
variance	O
of	O
multiple	O
transcripts	O
with	O
co	O
-	O
localized	O
QTLs	O
,	O
we	O
attempted	O
to	O
reduce	O
the	O
number	O
of	O
linkage	O
analyses	O
performed	O
as	O
well	O
as	O
possibly	O
identifying	O
previously	O
unknown	O
patterns	O
of	O
associated	O
gene	O
expression	O
profiles	O
.	O

The	O
PCA	O
did	O
in	O
fact	O
reduce	O
the	O
number	O
of	O
linkage	O
analyses	O
performed	O
,	O
but	O
it	O
did	O
not	O
improve	O
the	O
magnitude	O
of	O
signals	O
in	O
the	O
target	O
QTLs	O
as	O
compared	O
with	O
univariate	O
or	O
bivariate	O
analyses	O
.	O

In	O
fact	O
,	O
in	O
at	O
least	O
one	O
case	O
,	O
PCA	O
was	O
unable	O
to	O
detect	O
a	O
linkage	O
signal	O
for	O
the	O
main	O
gene	O
transcript	O
loading	O
in	O
the	O
factor	O
(	O
Table	O
1	O
,	O
Group	O
1	O
,	O
Factor	O
2	O
)	O
.	O

We	O
also	O
performed	O
pairwise	O
bivariate	O
genetic	O
analysis	O
on	O
those	O
transcripts	O
that	O
co	O
-	O
localized	O
to	O
the	O
same	O
genomic	O
region	O
,	O
presumably	O
because	O
this	O
area	O
of	O
the	O
genome	O
harbored	O
genes	O
involved	O
in	O
the	O
regulation	O
of	O
these	O
transcripts	O
[	O
2	O
]	O
.	O

We	O
detected	O
significant	O
genetic	O
correlation	O
of	O
these	O
co	O
-	O
localized	O
transcripts	O
,	O
indicating	O
potential	O
gene	O
networks	O
operating	O
in	O
these	O
regions	O
.	O

However	O
,	O
in	O
most	O
cases	O
,	O
bivariate	O
linkage	O
analysis	O
did	O
not	O
improve	O
the	O
magnitude	O
of	O
the	O
LOD	O
score	O
compared	O
to	O
univariate	O
analysis	O
.	O

Most	O
traits	O
were	O
highly	O
correlated	O
(	O
rho	O
G	O
>	O
0	O
.	O
60	O
)	O
,	O
and	O
therefore	O
they	O
may	O
provide	O
redundant	O
information	O
that	O
may	O
reduce	O
the	O
power	O
for	O
detection	O
of	O
the	O
bivariate	O
signal	O
[	O
8	O
]	O
.	O

In	O
addition	O
,	O
because	O
rho	O
G	O
is	O
a	O
test	O
of	O
the	O
overall	O
additive	O
genetic	O
correlation	O
among	O
two	O
traits	O
and	O
not	O
the	O
QTL	O
-	O
specific	O
pleiotropy	O
,	O
it	O
is	O
possible	O
that	O
the	O
co	O
-	O
localized	O
linkage	O
signals	O
are	O
not	O
in	O
fact	O
genetically	O
correlated	O
.	O

Further	O
analysis	O
is	O
required	O
to	O
address	O
these	O
issues	O
.	O

The	O
chromosome	O
regions	O
selected	O
for	O
detailed	O
analyses	O
were	O
arbitrarily	O
chosen	O
as	O
we	O
identified	O
multiple	O
other	O
regions	O
with	O
co	O
-	O
localized	O
linkage	O
of	O
gene	O
expressions	O
.	O

The	O
results	O
from	O
our	O
univariate	O
genome	O
scan	O
differ	O
markedly	O
from	O
those	O
reported	O
by	O
Morley	O
et	O
al	O
.	O

[	O
2	O
]	O
because	O
we	O
included	O
a	O
smaller	O
sample	O
of	O
individuals	O
so	O
that	O
adjustment	O
for	O
covariate	O
effects	O
of	O
age	O
could	O
be	O
made	O
.	O

Our	O
analysis	O
strategy	O
also	O
adjusted	O
for	O
the	O
effects	O
of	O
age	O
and	O
sex	O
,	O
which	O
could	O
also	O
add	O
to	O
the	O
observed	O
differences	O
[	O
13	O
]	O
.	O

Finally	O
,	O
our	O
definition	O
of	O
genome	O
window	O
size	O
for	O
co	O
-	O
localized	O
gene	O
expressions	O
was	O
twice	O
larger	O
than	O
the	O
one	O
described	O
in	O
the	O
study	O
of	O
Morley	O
et	O
al	O
.	O

Conclusion	O

We	O
identified	O
several	O
chromosomal	O
regions	O
of	O
co	O
-	O
localized	O
trans	O
-	O
regulatory	O
genes	O
with	O
significant	O
heritability	O
.	O

Some	O
of	O
these	O
regulatory	O
genes	O
displayed	O
strong	O
additive	O
genetic	O
correlations	O
,	O
and	O
may	O
be	O
part	O
of	O
genetic	O
networks	O
.	O

However	O
,	O
when	O
compared	O
to	O
univariate	O
analysis	O
,	O
linkage	O
analysis	O
of	O
bivariate	O
phenotypes	O
and	O
factor	O
scores	O
obtained	O
from	O
PCA	O
did	O
not	O
improve	O
the	O
ability	O
to	O
identify	O
chromosomal	O
regions	O
of	O
co	O
-	O
localized	O
gene	O
expressions	O
.	O

List	O
of	O
Abbreviations	O

CEPH	O
:	O
Centre	O
d	O
'	O
Etude	O
du	O
Polymorphisme	O
Humain	O

GAW	O
:	O
Genetic	O
Analysis	O
Workshop	O

H2	O
:	O
heritability	O

LOD	O
:	O
logarithm	O
of	O
the	O
odds	O

MIBD	O
:	O
multipoint	O
identity	O
-	O
by	O
-	O
descent	O
matrices	O

N	O
/	O
A	O
:	O
not	O
apply	O

NCBI	O
:	O
National	O
Center	O
for	O
Biotechnology	O
Information	O

PCA	O
:	O
principal	O
-	O
component	O
analysis	O

QTL	O
:	O
quantitative	O
trait	O
loci	O

SE	O
:	O
standard	O
error	O
of	O
the	O
mean	O

SNP	O
:	O
single	O
-	O
nucleotide	O
polymorphism	O

SOLAR	O
:	O
Sequential	O
Oligogenic	O
Linkage	O
Analysis	O
Routines	O

Competing	O
interests	O

The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Potentiation	O
of	O
Nerve	O
Growth	O
Factor	O
-	O
Induced	O
Neurite	O
Outgrowth	O
by	O
Fluvoxamine	O
:	O
Role	O
of	O
Sigma	O
-	O
1	O
Receptors	O
,	O
IP3	O
Receptors	O
and	O
Cellular	O
Signaling	O
Pathways	O

Abstract	O

Background	O

Selective	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
have	O
been	O
widely	O
used	O
and	O
are	O
a	O
major	O
therapeutic	O
advance	O
in	O
psychopharmacology	O
.	O

However	O
,	O
their	O
pharmacology	O
is	O
quite	O
heterogeneous	O
.	O

The	O
SSRI	O
fluvoxamine	O
,	O
with	O
sigma	O
-	O
1	O
receptor	O
agonism	O
,	O
is	O
shown	O
to	O
potentiate	O
nerve	O
-	O
growth	O
factor	O
(	O
NGF	O
)	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC	O
12	O
cells	O
.	O

However	O
,	O
the	O
precise	O
cellular	O
and	O
molecular	O
mechanisms	O
underlying	O
potentiation	O
by	O
fluvoxamine	O
are	O
not	O
fully	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
roles	O
of	O
cellular	O
signaling	O
pathways	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
fluvoxamine	O
and	O
sigma	O
-	O
1	O
receptor	O
agonists	O
.	O

Methods	O
and	O
Findings	O

The	O
effects	O
of	O
three	O
SSRIs	O
(	O
fluvoxamine	O
,	O
sertraline	O
,	O
paroxetine	O
)	O
and	O
three	O
sigma	O
-	O
1	O
receptor	O
agonists	O
(	O
SA4503	O
,	O
4	O
-	O
phenyl	O
-	O
1	O
-	O
(	O
4	O
-	O
phenylbutyl	O
)	O
piperidine	O
(	O
PPBP	O
)	O
,	O
and	O
dehydroepiandrosterone	O
(	O
DHEA	O
)	O
-	O
sulfate	O
)	O
on	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
were	O
examined	O
.	O

Also	O
examined	O
were	O
the	O
effects	O
of	O
the	O
sigma	O
-	O
1	O
receptor	O
antagonist	O
NE	O
-	O
100	O
,	O
inositol	O
1	O
,	O
4	O
,	O
5	O
-	O
triphosphate	O
(	O
IP3	O
)	O
receptor	O
antagonist	O
,	O
and	O
specific	O
inhibitors	O
of	O
signaling	O
pathways	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
selective	O
sigma	O
-	O
1	O
receptor	O
agonist	O
SA4503	O
.	O

Fluvoxamine	O
(	O
but	O
not	O
sertraline	O
or	O
paroxetine	O
)	O
and	O
the	O
sigma	O
-	O
1	O
receptor	O
agonists	O
SA4503	O
,	O
PPBP	O
,	O
and	O
DHEA	O
-	O
sulfate	O
significantly	O
potentiated	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

The	O
potentiation	O
by	O
fluvoxamine	O
and	O
the	O
three	O
sigma	O
-	O
1	O
receptor	O
agonists	O
was	O
blocked	O
by	O
co	O
-	O
administration	O
of	O
the	O
selective	O
sigma	O
-	O
1	O
receptor	O
antagonist	O
NE	O
-	O
100	O
,	O
suggesting	O
that	O
sigma	O
-	O
1	O
receptors	O
play	O
a	O
role	O
in	O
blocking	O
the	O
enhancement	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O

Moreover	O
,	O
the	O
potentiation	O
by	O
SA4503	O
was	O
blocked	O
by	O
co	O
-	O
administration	O
of	O
the	O
IP3	O
receptor	O
antagonist	O
xestospongin	O
C	O
.	O

In	O
addition	O
,	O
the	O
specific	O
inhibitors	O
of	O
phospholipase	O
C	O
(	O
PLC	O
-	O
gamma	O
)	O
,	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
,	O
p38MAPK	O
,	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
,	O
and	O
the	O
Ras	O
/	O
Raf	O
/	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
signaling	O
pathways	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
.	O

Conclusion	O

These	O
findings	O
suggest	O
that	O
stimulation	O
of	O
sigma	O
-	O
1	O
receptors	O
and	O
subsequent	O
interaction	O
with	O
IP3	O
receptors	O
,	O
PLC	O
-	O
gamma	O
,	O
PI3K	O
,	O
p38MAPK	O
,	O
JNK	O
,	O
and	O
the	O
Ras	O
/	O
Raf	O
/	O
MAPK	O
signaling	O
pathways	O
are	O
involved	O
in	O
the	O
mechanisms	O
of	O
action	O
of	O
sigma	O
-	O
1	O
receptor	O
agonists	O
such	O
as	O
fluvoxamine	O
and	O
SA4503	O
.	O

Introduction	O

Selective	O
serotonin	O
(	O
5	O
-	O
HT	O
;	O
5	O
-	O
hydroxytryptamine	O
)	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
have	O
emerged	O
as	O
a	O
major	O
therapeutic	O
advance	O
in	O
psychopharmacology	O
.	O

SSRIs	O
are	O
the	O
treatment	O
of	O
choice	O
for	O
many	O
indications	O
,	O
including	O
major	O
depressive	O
disorder	O
,	O
dysthymia	O
,	O
panic	O
disorder	O
,	O
obsessive	O
-	O
compulsive	O
disorder	O
,	O
eating	O
disorders	O
,	O
and	O
premenstrual	O
dysphoric	O
disorder	O
.	O

In	O
contrast	O
,	O
it	O
is	O
well	O
known	O
that	O
their	O
pharmacology	O
is	O
quite	O
heterogeneous	O
,	O
although	O
all	O
of	O
them	O
block	O
5	O
-	O
HT	O
transporters	O
,	O
thus	O
increasing	O
5	O
-	O
HT	O
levels	O
throughout	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
[	O
1	O
]	O
-	O
[	O
9	O
]	O
.	O

Accumulating	O
evidence	O
suggests	O
that	O
sigma	O
-	O
1	O
receptors	O
,	O
which	O
are	O
intracellular	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
proteins	O
,	O
are	O
involved	O
in	O
both	O
the	O
neuroplasticity	O
and	O
pathophysiology	O
of	O
neuropsychiatric	O
diseases	O
such	O
as	O
major	O
depressive	O
disorder	O
,	O
anxiety	O
,	O
schizophrenia	O
,	O
and	O
Alzheimer	O
'	O
s	O
disease	O
[	O
10	O
]	O
-	O
[	O
18	O
]	O
.	O

Previously	O
,	O
we	O
reported	O
that	O
some	O
SSRIs	O
possess	O
high	O
to	O
moderate	O
affinities	O
for	O
sigma	O
-	O
1	O
receptors	O
in	O
the	O
rat	B-LIVB
brain	O
.	O

The	O
rank	O
order	O
of	O
SSRIs	O
affinities	O
for	O
sigma	O
-	O
1	O
receptors	O
is	O
fluvoxamine	O
(	O
Ki	O
=	O
36	O
nM	O
)	O
>	O
sertraline	O
(	O
Ki	O
=	O
57	O
nM	O
)	O
>	O
>	O
paroxetine	O
(	O
Ki	O
=	O
1893	O
nM	O
)	O
[	O
19	O
]	O
.	O

Recently	O
,	O
we	O
reported	O
that	O
fluvoxamine	O
,	O
but	O
not	O
paroxetine	O
,	O
significantly	O
ameliorated	O
cognitive	O
deficits	O
in	O
mice	B-LIVB
after	O
repeated	O
phencyclidine	O
administration	O
,	O
and	O
that	O
the	O
effects	O
of	O
fluvoxamine	O
were	O
antagonized	O
by	O
co	O
-	O
administration	O
of	O
the	O
selective	O
sigma	O
-	O
1	O
receptor	O
antagonist	O
NE	O
-	O
100	O
[	O
20	O
]	O
,	O
suggesting	O
that	O
sigma	O
-	O
1	O
receptors	O
are	O
involved	O
in	O
the	O
mechanism	O
of	O
action	O
of	O
fluvoxamine	O
[	O
9	O
]	O
.	O

Interestingly	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
sigma	O
-	O
1	O
receptor	O
agonists	O
including	O
fluvoxamine	O
could	O
potentiate	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
,	O
and	O
that	O
NE	O
-	O
100	O
blocked	O
the	O
potentiation	O
by	O
sigma	O
-	O
1	O
receptor	O
agonists	O
,	O
suggesting	O
sigma	O
-	O
1	O
receptors	O
are	O
involved	O
in	O
neuroplasticity	O
[	O
21	O
]	O
.	O

However	O
,	O
the	O
precise	O
cellular	O
mechanisms	O
underlying	O
the	O
potentiation	O
by	O
sigma	O
-	O
1	O
receptor	O
agonists	O
are	O
not	O
fully	O
understood	O
[	O
13	O
]	O
,	O
[	O
21	O
]	O
.	O

It	O
is	O
therefore	O
of	O
great	O
interest	O
to	O
study	O
the	O
precise	O
cellular	O
mechanisms	O
underlying	O
the	O
enhancement	O
by	O
fluvoxamine	O
on	O
NGF	O
-	O
induced	O
neurite	O
sprouting	O
in	O
PC12	O
cells	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
effects	O
of	O
three	O
SSRIs	O
(	O
fluvoxamine	O
,	O
sertraline	O
,	O
paroxetine	O
)	O
,	O
as	O
well	O
as	O
the	O
effects	O
of	O
a	O
sigma	O
-	O
1	O
receptor	O
agonist	O
(	O
4	O
-	O
phenyl	O
-	O
1	O
-	O
(	O
4	O
-	O
phenylbutyl	O
)	O
piperidine	O
(	O
PPBP	O
)	O
,	O
dehydroepiandrosterone	O
-	O
sulphate	O
(	O
DHEA	O
)	O
-	O
sulfate	O
)	O
[	O
9	O
]	O
,	O
[	O
22	O
]	O
-	O
[	O
28	O
]	O
and	O
the	O
selective	O
sigma	O
-	O
1	O
receptor	O
agonist	O
SA4503	O
[	O
29	O
]	O
,	O
[	O
30	O
]	O
,	O
on	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
.	O

Furthermore	O
,	O
it	O
is	O
also	O
known	O
that	O
sigma	O
-	O
1	O
receptors	O
have	O
been	O
shown	O
to	O
interact	O
with	O
IP3	O
receptors	O
(	O
17	O
,	O
18	O
)	O
.	O

Therefore	O
,	O
we	O
examined	O
the	O
effects	O
of	O
NE	O
-	O
100	O
and	O
xestospongin	O
C	O
(	O
a	O
selective	O
inositol	O
1	O
,	O
4	O
,	O
5	O
-	O
triphosphate	O
(	O
IP3	O
)	O
receptor	O
antagonist	O
)	O
[	O
31	O
]	O
in	O
order	O
to	O
investigate	O
the	O
roles	O
of	O
sigma	O
-	O
1	O
receptors	O
and	O
IP3	O
receptors	O
in	O
the	O
mechanisms	O
underlying	O
the	O
enhancement	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
.	O

Moreover	O
,	O
we	O
examined	O
the	O
effects	O
of	O
specific	O
inhibitors	O
of	O
several	O
cellular	O
signaling	O
targets	O
on	O
the	O
enhancement	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
,	O
since	O
several	O
signal	O
transduction	O
molecules	O
have	O
been	O
implicated	O
in	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
[	O
32	O
]	O
.	O

Materials	O
and	O
Methods	O

Drugs	O

The	O
drugs	O
were	O
obtained	O
from	O
the	O
following	O
sources	O
:	O
fluvoxamine	O
maleate	O
(	O
Solvay	O
Seiyaku	O
K	O
.	O
K	O
.	O
,	O
Tokyo	O
,	O
Japan	O
)	O
;	O
paroxetine	O
hydrochloride	O
,	O
dehydroepiandosterone	O
-	O
sulfate	O
(	O
DHEA	O
-	O
sulfate	O
)	O
,	O
LY294002	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
;	O
sertraline	O
(	O
Toronto	O
Research	O
Chemicals	O
Inc	O
.	O
,	O
North	O
York	O
,	O
ON	O
,	O
Canada	O
)	O
;	O
SA4503	O
(	O
M	O
'	O
s	O
Science	O
Corporation	O
,	O
Kobe	O
,	O
Japan	O
)	O
;	O
NGF	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
)	O
;	O
xestospongin	O
C	O
,	O
lovastatin	O
,	O
PD98059	O
,	O
GW5074	O
,	O
SB203580	O
,	O
MEK	O
1	O
/	O
2	O
inhibitor	O
(	O
SL327	O
)	O
,	O
and	O
SP600125	O
(	O
Calbiochem	O
-	O
Novabiochem	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

The	O
selective	O
sigma	O
-	O
1	O
receptor	O
antagonists	O
NE	O
-	O
100	O
and	O
4	O
-	O
phenyl	O
-	O
1	O
-	O
(	O
4	O
-	O
phenylbutyl	O
)	O
piperidine	O
(	O
PPBP	O
)	O
were	O
synthesized	O
in	O
our	O
laboratory	O
.	O

Other	O
drugs	O
were	O
purchased	O
from	O
commercial	O
sources	O
.	O

Cell	O
culture	O

PC12	O
sells	O
(	O
RIKEN	O
Cell	O
Bank	O
,	O
Tsukuba	O
,	O
Japan	O
)	O
were	O
cultured	O
at	O
37	O
degrees	O
C	O
,	O
5	O
%	O
CO2	O
with	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
'	O
s	O
medium	O
(	O
DMEM	O
)	O
supplemented	O
with	O
5	O
%	O
heat	O
-	O
inactivated	O
fetal	O
bovine	B-LIVB
serum	O
(	O
FBS	O
)	O
,	O
10	O
%	O
heat	O
-	O
inactivated	O
horse	B-LIVB
serum	O
,	O
and	O
1	O
%	O
penicillin	O
.	O

The	O
medium	O
was	O
changed	O
two	O
or	O
three	O
times	O
a	O
week	O
.	O

PC12	O
cells	O
were	O
plated	O
onto	O
24	O
-	O
well	O
tissue	O
culture	O
plates	O
coated	O
with	O
poly	O
-	O
D	O
-	O
lysine	O
/	O
laminin	O
.	O

Cells	O
were	O
plated	O
at	O
relatively	O
low	O
density	O
(	O
0	O
.	O
25	O
x	O
104	O
cells	O
/	O
cm2	O
)	O
in	O
DMEM	O
medium	O
containing	O
0	O
.	O
5	O
%	O
FBS	O
,	O
1	O
%	O
penicillin	O
streptomycin	O
.	O

Medium	O
containing	O
a	O
minimal	O
level	O
of	O
serum	O
(	O
0	O
.	O
5	O
%	O
FBS	O
)	O
was	O
used	O
,	O
since	O
serum	O
is	O
known	O
to	O
contain	O
steroid	O
hormones	O
that	O
bind	O
to	O
sigma	O
-	O
1	O
receptors	O
[	O
21	O
]	O
.	O

First	O
,	O
we	O
examined	O
the	O
optimal	O
concentration	O
of	O
NGF	O
for	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
.	O

NGF	O
(	O
2	O
.	O
5	O
,	O
5	O
,	O
10	O
,	O
20	O
,	O
40	O
ng	O
/	O
ml	O
)	O
increased	O
the	O
number	O
of	O
cells	O
with	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Figure	O
1	O
)	O
.	O

In	O
the	O
subsequent	O
studies	O
,	O
2	O
.	O
5	O
ng	O
/	O
ml	O
of	O
NGF	O
was	O
used	O
to	O
study	O
the	O
potentiating	O
effects	O
of	O
sigma	O
-	O
1	O
receptor	O
agonists	O
on	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O

Twenty	O
-	O
four	O
hours	O
after	O
plating	O
,	O
the	O
medium	O
was	O
replaced	O
with	O
DMEM	O
medium	O
containing	O
0	O
.	O
5	O
%	O
FBS	O
and	O
1	O
%	O
penicillin	O
streptomycin	O
with	O
NGF	O
(	O
2	O
.	O
5	O
ng	O
/	O
ml	O
)	O
with	O
or	O
without	O
several	O
drugs	O
.	O

Quantification	O
of	O
neurite	O
sprouting	O

Five	O
days	O
after	O
incubation	O
with	O
NGF	O
(	O
2	O
.	O
5	O
ng	O
/	O
ml	O
)	O
with	O
or	O
without	O
the	O
several	O
drugs	O
,	O
morphometric	O
analysis	O
was	O
performed	O
on	O
digitized	O
images	O
of	O
live	O
cells	O
taken	O
under	O
phase	O
-	O
contrast	O
illumination	O
with	O
an	O
inverted	O
microscope	O
linked	O
to	O
a	O
camera	O
.	O

Images	O
of	O
three	O
fields	O
per	O
well	O
were	O
taken	O
,	O
with	O
an	O
average	O
of	O
100	O
cells	O
per	O
field	O
.	O

Differentiated	O
cells	O
were	O
counted	O
by	O
visual	O
examination	O
of	O
the	O
field	O
;	O
only	O
cells	O
that	O
had	O
at	O
least	O
one	O
neurite	O
with	O
a	O
length	O
equal	O
to	O
the	O
cell	O
body	O
diameter	O
were	O
counted	O
,	O
and	O
were	O
then	O
expressed	O
as	O
a	O
percentage	O
of	O
the	O
total	O
cells	O
in	O
the	O
field	O
.	O

The	O
counting	O
was	O
performed	O
in	O
a	O
blinded	O
manner	O
.	O

Immunocytochemistry	O

Cells	O
were	O
fixed	O
for	O
30	O
min	O
at	O
room	O
temperature	O
with	O
4	O
%	O
paraformaldehyde	O
then	O
permeabilized	O
with	O
0	O
.	O
2	O
%	O
Triton	O
and	O
blocked	O
with	O
1	O
.	O
5	O
%	O
normal	O
goat	B-LIVB
serum	O
,	O
0	O
.	O
1	O
%	O
bovine	B-LIVB
serum	O
albumin	O
(	O
BSA	O
)	O
in	O
0	O
.	O
1	O
M	O
phosphate	O
-	O
buffer	O
saline	O
for	O
1	O
h	O
to	O
reduce	O
nonspecific	O
binding	O
.	O

Cells	O
were	O
incubated	O
overnight	O
at	O
4	O
degrees	O
C	O
with	O
anti	O
-	O
microtubule	O
-	O
associated	O
protein	O
2	O
(	O
MAP	O
-	O
2	O
)	O
antibodies	O
(	O
1	O
:	O
1000	O
dilution	O
in	O
blocking	O
solution	O
,	O
Chemicon	O
International	O
,	O
Temecula	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O
immunolabeling	O
was	O
visualized	O
with	O
secondary	O
antibodies	O
conjugated	O
to	O
Alexa	O
-	O
488	O
(	O
1	O
:	O
1000	O
;	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
.	O

MAP	O
-	O
2	O
immuncytochemistry	O
was	O
visualized	O
with	O
a	O
fluorescence	O
microscope	O
(	O
Axiovert	O
200	O
,	O
Carl	O
Zeiss	O
,	O
Oberkocken	O
,	O
Germany	O
)	O
.	O

Statistical	O
analysis	O

Data	O
are	O
expressed	O
as	O
means	O
+/-	O
S	O
.	O
E	O
.	O
M	O
.	O

Statistical	O
analysis	O
was	O
performed	O
by	O
using	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
and	O
the	O
post	O
hoc	O
Bonferroni	O
/	O
Dunn	O
test	O
.	O

P	O
values	O
less	O
than	O
0	O
.	O
05	O
were	O
considered	O
statistically	O
significant	O
.	O

Results	O

Effects	O
of	O
SSRIs	O
on	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O

Fluvoxamine	O
(	O
0	O
.	O
1	O
,	O
1	O
.	O
0	O
,	O
or	O
10	O
micro	O
M	O
)	O
significantly	O
increased	O
the	O
number	O
of	O
cells	O
with	O
neurite	O
outgrowth	O
by	O
NGF	O
(	O
2	O
.	O
5	O
ng	O
/	O
ml	O
)	O
in	O
PC12	O
cells	O
,	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Figure	O
2	O
and	O
4	O
)	O
.	O

In	O
contrast	O
,	O
sertraline	O
(	O
0	O
.	O
1	O
,	O
1	O
.	O
0	O
,	O
or	O
10	O
micro	O
M	O
)	O
and	O
paroxetine	O
(	O
0	O
.	O
1	O
,	O
1	O
.	O
0	O
,	O
or	O
10	O
micro	O
M	O
)	O
did	O
not	O
increase	O
the	O
number	O
of	O
cells	O
with	O
neurite	O
outgrowth	O
by	O
NGF	O
(	O
2	O
.	O
5	O
ng	O
/	O
ml	O
)	O
.	O

A	O
higher	O
concentration	O
(	O
10	O
micro	O
M	O
)	O
of	O
paroxetine	O
and	O
sertraline	O
significantly	O
decreased	O
the	O
number	O
of	O
cells	O
with	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
,	O
suggesting	O
the	O
cellular	O
toxicity	O
of	O
these	O
drugs	O
in	O
PC12	O
cells	O
(	O
Figure	O
2	O
)	O
.	O

Role	O
of	O
sigma	O
-	O
1	O
receptors	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
fluvoxamine	O
and	O
SA4503	O

The	O
selective	O
and	O
potent	O
sigma	O
-	O
1	O
receptor	O
agonist	O
SA4503	O
(	O
0	O
.	O
01	O
,	O
0	O
.	O
1	O
,	O
or	O
1	O
.	O
0	O
micro	O
M	O
)	O
significantly	O
increased	O
the	O
number	O
of	O
cells	O
with	O
neurite	O
outgrowth	O
by	O
NGF	O
(	O
2	O
.	O
5	O
ng	O
/	O
ml	O
)	O
in	O
PC12	O
cells	O
,	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Figure	O
3	O
and	O
4	O
)	O
.	O

In	O
addition	O
,	O
other	O
sigma	O
-	O
1	O
receptor	O
agonists	O
-	O
PPBP	O
(	O
0	O
.	O
1	O
,	O
1	O
.	O
0	O
,	O
or	O
10	O
micro	O
M	O
)	O
[	O
22	O
]	O
-	O
[	O
26	O
]	O
and	O
DHEA	O
-	O
sulphate	O
(	O
0	O
.	O
1	O
,	O
1	O
.	O
0	O
,	O
or	O
10	O
micro	O
M	O
)	O
[	O
9	O
]	O
,	O
[	O
27	O
]	O
,	O
[	O
28	O
]	O
-	O
significantly	O
increased	O
the	O
number	O
of	O
such	O
cells	O
,	O
also	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Figure	O
3	O
)	O
.	O

In	O
the	O
absence	O
of	O
NGF	O
,	O
sigma	O
-	O
1	O
receptor	O
agonists	O
did	O
not	O
produce	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

To	O
investigate	O
the	O
role	O
of	O
sigma	O
-	O
1	O
receptors	O
,	O
we	O
examined	O
the	O
effects	O
of	O
NE	O
-	O
100	O
(	O
a	O
selective	O
sigma	O
-	O
1	O
receptor	O
antagonist	O
)	O
on	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
fluvoxamine	O
,	O
SA4503	O
,	O
PPBP	O
,	O
and	O
DHEA	O
-	O
sulphate	O
.	O

Co	O
-	O
administration	O
of	O
NE	O
-	O
100	O
(	O
1	O
.	O
0	O
micro	O
M	O
)	O
significantly	O
blocked	O
such	O
potentiation	O
by	O
fluvoxamine	O
(	O
10	O
micro	O
M	O
)	O
,	O
SA4503	O
(	O
1	O
.	O
0	O
micro	O
M	O
)	O
,	O
PPBP	O
(	O
10	O
micro	O
M	O
)	O
,	O
or	O
DHEA	O
-	O
sulphate	O
(	O
10	O
micro	O
M	O
)	O
(	O
Figure	O
2	O
and	O
3	O
)	O
.	O

Furthermore	O
,	O
administration	O
of	O
NE	O
-	O
100	O
(	O
1	O
.	O
0	O
micro	O
M	O
)	O
alone	O
did	O
not	O
alter	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
(	O
Figure	O
2	O
)	O
.	O

Role	O
of	O
IP3	O
receptors	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O

Sigma	O
-	O
1	O
receptors	O
have	O
been	O
shown	O
to	O
interact	O
with	O
IP3	O
receptors	O
(	O
17	O
,	O
18	O
,	O
33	O
-	O
35	O
)	O
.	O

To	O
investigate	O
the	O
role	O
of	O
IP3	O
receptors	O
in	O
the	O
effects	O
of	O
SA4503	O
on	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
,	O
we	O
examined	O
the	O
effects	O
of	O
xestospongin	O
C	O
(	O
a	O
selective	O
,	O
reversible	O
,	O
and	O
membrane	O
-	O
permeable	O
inhibitor	O
of	O
IP3	O
receptors	O
)	O
[	O
31	O
]	O
on	O
the	O
effects	O
of	O
SA4503	O
on	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O

Co	O
-	O
administration	O
of	O
xestospongin	O
C	O
(	O
1	O
.	O
0	O
micro	O
M	O
)	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
(	O
1	O
.	O
0	O
micro	O
M	O
)	O
(	O
Figure	O
5	O
)	O
.	O

Furthermore	O
,	O
administration	O
of	O
xestospongin	O
C	O
(	O
1	O
.	O
0	O
micro	O
M	O
)	O
alone	O
did	O
not	O
alter	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
(	O
Figure	O
5	O
)	O
.	O

Role	O
of	O
signaling	O
molecules	O
proximal	O
to	O
TrkA	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O

Next	O
,	O
we	O
examined	O
the	O
effects	O
of	O
the	O
specific	O
inhibitors	O
of	O
PLC	O
-	O
gamma	O
,	O
PI3K	O
,	O
p38	O
MAPK	O
,	O
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
,	O
since	O
these	O
signaling	O
molecules	O
are	O
activated	O
upon	O
the	O
addition	O
of	O
NGF	O
[	O
36	O
]	O
.	O

The	O
PLC	O
-	O
gamma	O
inhibitor	O
(	O
U73122	O
;	O
1	O
.	O
0	O
micro	O
M	O
)	O
,	O
PI3K	O
inhibitor	O
(	O
LY294002	O
;	O
1	O
.	O
0	O
micro	O
M	O
)	O
,	O
p38	O
MAPK	O
inhibitor	O
(	O
SB203580	O
;	O
1	O
.	O
0	O
micro	O
M	O
)	O
,	O
and	O
JNK	O
inhibitor	O
(	O
SP600125	O
;	O
1	O
.	O
0	O
micro	O
M	O
)	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
(	O
1	O
.	O
0	O
micro	O
M	O
)	O
(	O
Figure	O
6	O
)	O
.	O

In	O
contrast	O
,	O
these	O
inhibitors	O
alone	O
did	O
not	O
alter	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
(	O
Figure	O
6	O
)	O
.	O

Role	O
of	O
Raf	O
/	O
Ras	O
/	O
ERK	O
/	O
MAPK	O
pathway	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O

The	O
Raf	O
/	O
Ras	O
/	O
ERK	O
/	O
MAPK	O
pathway	O
is	O
known	O
to	O
be	O
involved	O
in	O
NGF	O
-	O
induced	O
outgrowth	O
[	O
32	O
]	O
.	O

Therefore	O
,	O
we	O
examined	O
the	O
effects	O
of	O
this	O
pathway	O
'	O
s	O
specific	O
inhibitors	O
.	O

The	O
Ras	O
inhibitor	O
(	O
GW5074	O
;	O
1	O
.	O
0	O
micro	O
M	O
)	O
,	O
Raf	O
inhibitor	O
(	O
lovastatin	O
;	O
1	O
.	O
0	O
micro	O
M	O
)	O
,	O
MEK1	O
/	O
2	O
inhibitor	O
(	O
SL327	O
;	O
1	O
.	O
0	O
micro	O
M	O
)	O
,	O
and	O
MAPK	O
inhibitor	O
(	O
PD98059	O
;	O
1	O
.	O
0	O
micro	O
M	O
)	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
(	O
1	O
.	O
0	O
micro	O
M	O
)	O
(	O
Figure	O
7	O
)	O
.	O

In	O
contrast	O
,	O
these	O
inhibitors	O
alone	O
did	O
not	O
alter	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
(	O
Figure	O
7	O
)	O
.	O

Discussion	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
fluvoxamine	O
(	O
but	O
not	O
sertraline	O
or	O
paroxetine	O
)	O
and	O
the	O
sigma	O
-	O
1	O
receptor	O
agonists	O
(	O
SA4503	O
,	O
PPBP	O
,	O
DHEA	O
-	O
sulfate	O
)	O
could	O
potentiate	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
,	O
and	O
that	O
the	O
effects	O
of	O
these	O
drugs	O
were	O
blocked	O
by	O
co	O
-	O
incubation	O
with	O
the	O
selective	O
sigma	O
-	O
1	O
receptor	O
antagonist	O
NE	O
-	O
100	O
.	O

These	O
findings	O
suggest	O
that	O
agonism	O
at	O
sigma	O
-	O
1	O
receptors	O
for	O
these	O
drugs	O
is	O
involved	O
in	O
the	O
mechanisms	O
underlying	O
the	O
drugs	O
'	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O

As	O
shown	O
in	O
Figure	O
1	O
,	O
NGF	O
increased	O
the	O
number	O
of	O
cells	O
with	O
neurite	O
outgrowth	O
in	O
PC12	O
,	O
in	O
a	O
concentration	O
dependent	O
manner	O
.	O

To	O
examine	O
whether	O
or	O
not	O
the	O
NGF	O
levels	O
are	O
altered	O
by	O
incubation	O
with	O
sigma	O
-	O
1	O
receptor	O
agonists	O
,	O
we	O
measured	O
the	O
levels	O
of	O
NGF	O
in	O
PC12	O
cells	O
with	O
or	O
without	O
sigma	O
-	O
1	O
receptor	O
agonist	O
SA4503	O
.	O

No	O
differences	O
of	O
NGF	O
levels	O
were	O
shown	O
in	O
the	O
between	O
control	O
group	O
and	O
SA4503	O
-	O
treated	O
group	O
(	O
data	O
not	O
shown	O
)	O
.	O

It	O
is	O
,	O
therefore	O
,	O
unlikely	O
that	O
the	O
potentaition	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
sigma	O
-	O
1	O
receptor	O
agonists	O
might	O
be	O
due	O
to	O
increased	O
levels	O
of	O
NGF	O
.	O

Unlike	O
fluvoxamine	O
,	O
sertraline	O
,	O
which	O
has	O
a	O
moderate	O
affinity	O
for	O
sigma	O
-	O
1	O
receptors	O
,	O
did	O
not	O
alter	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O

The	O
reasons	O
underlying	O
this	O
discrepancy	O
between	O
these	O
two	O
SSRIs	O
are	O
currently	O
unclear	O
.	O

One	O
possibility	O
may	O
involve	O
the	O
difference	O
in	O
pharmacological	O
actions	O
(	O
agonist	O
vs	O
.	O
antagonist	O
)	O
between	O
these	O
SSRIs	O
at	O
sigma	O
-	O
1	O
receptors	O
.	O

Interestingly	O
,	O
we	O
recently	O
found	O
that	O
,	O
in	O
a	O
novel	O
object	O
recognition	O
test	O
,	O
phencyclidine	O
-	O
induced	O
cognitive	O
deficits	O
could	O
be	O
significantly	O
improved	O
by	O
subsequent	O
subchronic	O
(	O
14	O
days	O
)	O
administration	O
of	O
fluvoxamine	O
,	O
but	O
not	O
of	O
sertraline	O
,	O
suggesting	O
that	O
sigma	O
-	O
1	O
receptor	O
agonism	O
is	O
involved	O
in	O
fluvoxamine	O
'	O
s	O
mechanism	O
of	O
action	O
[	O
9	O
]	O
,	O
Ishima	O
et	O
al	O
.	O
,	O
submitted	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
fluvoxamine	O
and	O
sertraline	O
may	O
function	O
as	O
an	O
agonist	O
and	O
an	O
antagonist	O
at	O
sigma	O
-	O
1	O
receptors	O
,	O
respectively	O
,	O
although	O
further	O
study	O
is	O
necessary	O
.	O

Another	O
possibility	O
may	O
be	O
that	O
other	O
pharmacological	O
activities	O
of	O
sertraline	O
mask	O
the	O
effects	O
of	O
sigma	O
-	O
1	O
receptor	O
agonism	O
.	O

In	O
this	O
study	O
,	O
we	O
also	O
found	O
that	O
high	O
concentration	O
(	O
10	O
micro	O
M	O
)	O
of	O
paroxetine	O
and	O
sertraline	O
,	O
but	O
not	O
fluvoxamine	O
,	O
showed	O
cytotoxicity	O
in	O
PC12	O
cells	O
,	O
suggesting	O
that	O
fluvoxamine	O
may	O
be	O
a	O
safe	O
drug	O
than	O
paroxetine	O
and	O
sertraline	O
.	O

Sigma	O
-	O
1	O
receptors	O
have	O
been	O
shown	O
to	O
affect	O
intracellular	O
Ca2	O
+	O
signaling	O
,	O
although	O
the	O
precise	O
molecular	O
and	O
cellular	O
mechanisms	O
underlying	O
this	O
effect	O
are	O
unknown	O
.	O

Sigma	O
-	O
1	O
receptors	O
bind	O
to	O
IP3	O
receptors	O
in	O
ER	O
,	O
and	O
sigma	O
-	O
1	O
receptors	O
regulate	O
Ca2	O
+	O
release	O
from	O
intracellular	O
Ca2	O
+	O
storage	O
sites	O
[	O
12	O
]	O
.	O

Very	O
recently	O
,	O
Hayashi	O
and	O
Su	O
[	O
17	O
]	O
reported	O
that	O
sigma	O
-	O
1	O
receptors	O
function	O
as	O
novel	O
ligand	O
-	O
operated	O
chaperones	O
that	O
specifically	O
target	O
mitochondrion	O
-	O
associated	O
ER	O
membrane	O
.	O

Furthermore	O
,	O
sigma	O
-	O
1	O
receptors	O
form	O
Ca2	O
+	O
-	O
sensitive	O
chaperone	O
machinery	O
with	O
another	O
chaperone	O
,	O
BiP	O
,	O
and	O
prolong	O
Ca2	O
+	O
signaling	O
from	O
ER	O
into	O
mitochondria	O
by	O
stabilizing	O
IP3	O
receptors	O
at	O
mitochondrion	O
-	O
associated	O
ER	O
membrane	O
[	O
17	O
]	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
the	O
IP3	O
receptor	O
antagonist	O
xestospongin	O
C	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
,	O
suggesting	O
the	O
role	O
of	O
IP3	O
receptors	O
on	O
sigma	O
-	O
1	O
receptor	O
-	O
mediated	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O

Therefore	O
,	O
it	O
is	O
likely	O
that	O
stimulation	O
at	O
sigma	O
-	O
1	O
receptors	O
by	O
sigma	O
-	O
1	O
receptor	O
agonists	O
and	O
subsequent	O
interaction	O
with	O
IP3	O
receptors	O
are	O
involved	O
in	O
the	O
mechanism	O
underlying	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
sigma	O
-	O
1	O
receptor	O
agonists	O
.	O

NGF	O
binds	O
to	O
the	O
high	O
-	O
affinity	O
tyrosine	O
receptor	O
TrkA	O
,	O
initiating	O
several	O
signaling	O
pathways	O
affecting	O
both	O
morphological	O
and	O
transcriptional	O
targets	O
[	O
32	O
]	O
,	O
[	O
36	O
]	O
,	O
[	O
37	O
]	O
.	O

The	O
signaling	O
molecules	O
,	O
including	O
PLC	O
-	O
gamma	O
,	O
PI3K	O
,	O
p38	O
MAPK	O
,	O
and	O
JNK	O
,	O
are	O
activated	O
upon	O
the	O
addition	O
of	O
NGF	O
[	O
38	O
]	O
.	O

PLC	O
-	O
gamma	O
catalyzes	O
the	O
hydrolysis	O
of	O
phosphatidylinositol	O
-	O
4	O
,	O
5	O
-	O
bisphosphate	O
(	O
PIP2	O
)	O
to	O
diacylglycerol	O
(	O
DAG	O
)	O
and	O
inositol	O
triphosphate	O
(	O
IP3	O
)	O
.	O

DAG	O
activates	O
protein	O
kinase	O
C	O
,	O
and	O
IP3	O
promotes	O
transient	O
release	O
of	O
Ca2	O
+	O
from	O
the	O
ER	O
[	O
39	O
]	O
.	O

The	O
pathway	O
via	O
PLC	O
-	O
gamma	O
is	O
responsible	O
for	O
NGF	O
-	O
induced	O
cell	O
differentiation	O
[	O
40	O
]	O
and	O
neurite	O
outgrowth	O
[	O
41	O
]	O
.	O

Furthermore	O
,	O
stimulation	O
of	O
PI3K	O
is	O
reported	O
to	O
be	O
involved	O
in	O
the	O
promotion	O
of	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
[	O
42	O
]	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
the	O
PLC	O
-	O
gamma	O
inhibitor	O
U73122	O
and	O
the	O
PI3K	O
inhibitor	O
LY294002	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
both	O
the	O
p38MAPK	O
inhibitor	O
SB203580	O
and	O
the	O
JNK	O
inhibitor	O
SP600125	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
.	O

In	O
addition	O
,	O
it	O
is	O
also	O
interesting	O
that	O
neurite	O
outgrowth	O
induced	O
by	O
low	O
concentration	O
(	O
2	O
.	O
5	O
ng	O
/	O
ml	O
)	O
of	O
NGF	O
was	O
not	O
blocked	O
by	O
these	O
inihibitors	O
,	O
consistent	O
with	O
a	O
previous	O
report	O
[	O
43	O
]	O
,	O
[	O
44	O
]	O
,	O
suggesting	O
the	O
existence	O
of	O
novel	O
pathway	O
(	O
s	O
)	O
for	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
PLC	O
-	O
gamma	O
,	O
PI3K	O
,	O
p38MAPK	O
,	O
and	O
JNK	O
signaling	O
pathways	O
are	O
involved	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
sigma	O
-	O
1	O
receptor	O
agonists	O
(	O
Figure	O
8	O
)	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
the	O
specific	O
inhibitors	O
for	O
the	O
Raf	O
/	O
Ras	O
/	O
MEK	O
/	O
MAPK	O
pathways	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
,	O
suggesting	O
that	O
these	O
pathways	O
are	O
involved	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
sigma	O
-	O
1	O
receptor	O
agonists	O
(	O
Figure	O
8	O
)	O
.	O

Our	O
recent	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
study	O
demonstrated	O
that	O
,	O
after	O
a	O
single	O
oral	O
administration	O
,	O
fluvoxamine	O
bound	O
to	O
sigma	O
-	O
1	O
receptors	O
in	O
the	O
living	O
human	B-LIVB
brain	O
[	O
45	O
]	O
.	O

This	O
finding	O
suggests	O
that	O
sigma	O
-	O
1	O
receptors	O
are	O
involved	O
in	O
the	O
mechanism	O
of	O
action	O
of	O
fluvoxamine	O
in	O
the	O
human	B-LIVB
brain	O
[	O
45	O
]	O
.	O

Taken	O
together	O
,	O
the	O
past	O
and	O
present	O
findings	O
suggest	O
that	O
,	O
unlike	O
paroxetine	O
and	O
sertraline	O
,	O
the	O
SSRI	O
fluvoxamine	O
,	O
with	O
its	O
sigma	O
-	O
1	O
receptor	O
agonistic	O
activity	O
,	O
might	O
be	O
a	O
unique	O
therapeutic	O
drug	O
for	O
neuropsychiatric	O
diseases	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
results	O
suggest	O
that	O
,	O
as	O
a	O
sigma	O
-	O
1	O
receptor	O
agonist	O
,	O
fluvoxamine	O
could	O
potentiate	O
the	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
.	O

Furthermore	O
,	O
it	O
is	O
likely	O
that	O
interaction	O
with	O
IP3	O
receptors	O
and	O
several	O
subsequent	O
signaling	O
molecules	O
are	O
involved	O
in	O
the	O
mechanism	O
underlying	O
the	O
pharmacological	O
action	O
of	O
sigma	O
-	O
1	O
receptor	O
agonists	O
.	O

Therefore	O
,	O
it	O
is	O
likely	O
that	O
sigma	O
-	O
1	O
receptor	O
agonists	O
such	O
as	O
fluvoxamine	O
and	O
DHEA	O
-	O
sulfate	O
,	O
which	O
are	O
available	O
around	O
the	O
world	O
,	O
would	O
be	O
unique	O
therapeutic	O
drugs	O
for	O
neuropsychiatric	O
diseases	O
.	O

A	O
novel	O
,	O
non	O
-	O
invasive	O
,	O
online	O
-	O
monitoring	O
,	O
versatile	O
and	O
easy	O
plant	O
-	O
based	O
probe	O
for	O
measuring	O
leaf	O
water	O
status	O

Abstract	O

A	O
high	O
-	O
precision	O
pressure	O
probe	O
is	O
described	O
which	O
allows	O
non	O
-	O
invasive	O
online	O
-	O
monitoring	O
of	O
the	O
water	O
relations	O
of	O
intact	O
leaves	O
.	O

Real	O
-	O
time	O
recording	O
of	O
the	O
leaf	O
water	O
status	O
occurred	O
by	O
data	O
transfer	O
to	O
an	O
Internet	O
server	O
.	O

The	O
leaf	O
patch	O
clamp	O
pressure	O
probe	O
measures	O
the	O
attenuated	O
pressure	O
,	O
Pp	O
,	O
of	O
a	O
leaf	O
patch	O
in	O
response	O
to	O
a	O
constant	O
clamp	O
pressure	O
,	O
Pclamp	O
.	O

Pp	O
is	O
sensed	O
by	O
a	O
miniaturized	O
silicone	O
pressure	O
sensor	O
integrated	O
into	O
the	O
device	O
.	O

The	O
magnitude	O
of	O
Pp	O
is	O
dictated	O
by	O
the	O
transfer	O
function	O
of	O
the	O
leaf	O
,	O
Tf	O
,	O
which	O
is	O
a	O
function	O
of	O
leaf	O
patch	O
volume	O
and	O
ultimately	O
of	O
cell	O
turgor	O
pressure	O
,	O
Pc	O
,	O
as	O
shown	O
theoretically	O
.	O

The	O
power	O
function	O
Tf	O
=	O
f	O
(	O
Pc	O
)	O
theoretically	O
derived	O
was	O
experimentally	O
confirmed	O
by	O
concomitant	O
Pp	O
and	O
Pc	O
measurements	O
on	O
intact	O
leaflets	O
of	O
the	O
liana	O
Tetrastigma	B-LIVB
voinierianum	I-LIVB
under	O
greenhouse	O
conditions	O
.	O

Simultaneous	O
Pp	O
recordings	O
on	O
leaflets	O
up	O
to	O
10	O
m	O
height	O
above	O
ground	O
demonstrated	O
that	O
changes	O
in	O
Tf	O
induced	O
by	O
Pc	O
changes	O
due	O
to	O
changes	O
of	O
microclimate	O
and	O
/	O
or	O
of	O
the	O
irrigation	O
regime	O
were	O
sensitively	O
reflected	O
in	O
corresponding	O
changes	O
of	O
Pp	O
.	O

Analysis	O
of	O
the	O
data	O
show	O
that	O
transpirational	O
water	O
loss	O
during	O
the	O
morning	O
hours	O
was	O
associated	O
with	O
a	O
transient	O
rise	O
in	O
turgor	O
pressure	O
gradients	O
within	O
the	O
leaflets	O
.	O

Subsequent	O
recovery	O
of	O
turgescence	O
during	O
the	O
afternoon	O
was	O
much	O
faster	O
than	O
the	O
preceding	O
transpiration	O
-	O
induced	O
water	O
loss	O
if	O
the	O
plants	O
were	O
well	O
irrigated	O
.	O

Our	O
data	O
show	O
the	O
enormous	O
potential	O
of	O
the	O
leaf	O
patch	O
clamp	O
pressure	O
probe	O
for	O
leaf	O
water	O
studies	O
including	O
unravelling	O
of	O
the	O
hydraulic	O
communication	O
between	O
neighbouring	O
leaves	O
and	O
over	O
long	O
distances	O
within	O
tall	O
plants	O
(	O
trees	O
)	O
.	O

Introduction	O

Optimum	O
water	O
supply	O
,	O
particularly	O
at	O
peak	O
needs	O
of	O
the	O
plants	O
,	O
is	O
an	O
important	O
issue	O
for	O
greenhouse	O
and	O
field	O
vegetable	O
production	O
.	O

In	O
a	O
greenhouse	O
on	O
a	O
sunny	O
day	O
,	O
evaporation	O
and	O
transpiration	O
(	O
so	O
-	O
called	O
evapotranspiration	O
)	O
can	O
occur	O
so	O
rapidly	O
that	O
water	O
loss	O
can	O
cause	O
plant	O
damage	O
before	O
wilting	O
symptoms	O
are	O
visible	O
.	O

Even	O
at	O
lower	O
temperatures	O
the	O
restricted	O
rooting	O
in	O
greenhouses	O
leads	O
frequently	O
to	O
plant	O
water	O
deficiency	O
.	O

Thus	O
,	O
no	O
matter	O
how	O
slight	O
,	O
drought	O
stress	O
will	O
result	O
in	O
a	O
significant	O
reduction	O
in	O
growth	O
and	O
,	O
in	O
turn	O
,	O
of	O
harvest	O
yield	O
.	O

On	O
the	O
other	O
hand	O
,	O
over	O
-	O
irrigation	O
must	O
be	O
avoided	O
and	O
the	O
appropriate	O
method	O
of	O
watering	O
must	O
be	O
selected	O
because	O
wet	O
soils	O
and	O
permanent	O
moisture	O
on	O
plant	O
organs	O
promote	O
the	O
incidence	O
of	O
root	O
mould	O
,	O
grey	O
mould	O
(	O
Botrytis	O
blight	O
)	O
,	O
formation	O
of	O
leaf	O
oedema	O
,	O
and	O
other	O
plant	O
diseases	O
(	O
Sherf	O
and	O
MacNab	O
,	O
1986	O
)	O
.	O

Conservation	O
of	O
water	O
is	O
another	O
important	O
issue	O
in	O
semi	O
-	O
arid	O
and	O
arid	O
regions	O
where	O
water	O
is	O
scarce	O
.	O

The	O
advent	O
of	O
(	O
subsurface	O
)	O
drip	O
irrigation	O
has	O
considerably	O
reduced	O
water	O
consumption	O
of	O
agricultural	O
,	O
horticultural	O
,	O
and	O
greenhouse	O
crops	O
,	O
but	O
has	O
also	O
highlighted	O
the	O
need	O
for	O
sensors	O
monitoring	O
water	O
deficiency	O
of	O
plants	O
directly	O
and	O
online	O
(	O
Jones	O
,	O
2004	O
)	O
.	O

In	O
plant	O
physiology	O
and	O
agriculture	O
the	O
pressure	O
bomb	O
technique	O
pioneered	O
by	O
Scholander	O
et	O
al	O
.	O

(	O
1965	O
)	O
is	O
a	O
widely	O
accepted	O
reference	O
technique	O
for	O
measuring	O
leaf	O
water	O
status	O
.	O

However	O
,	O
the	O
method	O
is	O
massively	O
invasive	O
,	O
slow	O
,	O
labour	O
-	O
intensive	O
(	O
and	O
therefore	O
expensive	O
)	O
,	O
unsuitable	O
for	O
automation	O
,	O
and	O
gives	O
only	O
spot	O
measurements	O
.	O

Furthermore	O
,	O
interpretation	O
of	O
the	O
data	O
is	O
still	O
a	O
matter	O
of	O
debate	O
(	O
Zimmermann	O
U	O
et	O
al	O
.	O
,	O
2004	O
;	O
Zimmermann	O
D	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

Leaf	O
thickness	O
is	O
also	O
sometimes	O
used	O
as	O
an	O
indicator	O
for	O
water	O
stress	O
(	O
Burquez	O
,	O
1987	O
;	O
McBurney	O
,	O
1992	O
;	O
Malone	O
,	O
1993	O
)	O
.	O

Leaf	O
thickness	O
monitoring	O
devices	O
are	O
commercially	O
available	O
.	O

They	O
are	O
non	O
-	O
invasive	O
and	O
suitable	O
for	O
online	O
measurements	O
,	O
but	O
have	O
the	O
disadvantage	O
that	O
changes	O
in	O
water	O
status	O
are	O
frequently	O
not	O
reflected	O
sensitively	O
in	O
changes	O
of	O
leaf	O
thickness	O
.	O

The	O
pressure	O
probe	O
technique	O
pioneered	O
by	O
Zimmermann	O
,	O
Tomos	O
,	O
and	O
others	O
(	O
Zimmermann	O
et	O
al	O
.	O
,	O
1969	O
,	O
2004	O
;	O
Tomos	O
,	O
1988	O
;	O
Balling	O
and	O
Zimmermann	O
,	O
1990	O
)	O
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
a	O
well	O
established	O
technology	O
for	O
measuring	O
turgor	O
and	O
xylem	O
pressure	O
on	O
the	O
levels	O
of	O
individual	O
cells	O
and	O
xylem	O
vessels	O
,	O
respectively	O
.	O

This	O
technique	O
is	O
not	O
suitable	O
for	O
automation	O
.	O

Moreover	O
,	O
the	O
probe	O
technique	O
requires	O
rather	O
sophisticated	O
equipment	O
and	O
a	O
high	O
level	O
of	O
technical	O
skill	O
.	O

These	O
disadvantages	O
are	O
also	O
shared	O
by	O
the	O
ball	O
tonometry	O
,	O
a	O
method	O
which	O
allows	O
non	O
-	O
invasive	O
monitoring	O
of	O
cell	O
turgor	O
pressure	O
by	O
application	O
of	O
an	O
external	O
pressure	O
(	O
Lintilhac	O
et	O
al	O
.	O
,	O
2000	O
;	O
Geitmann	O
,	O
2006	O
)	O
.	O

Other	O
water	O
stress	O
monitoring	O
devices	O
are	O
described	O
in	O
the	O
literature	O
,	O
but	O
all	O
of	O
them	O
have	O
various	O
disadvantages	O
which	O
prevented	O
their	O
implementation	O
for	O
leaf	O
water	O
status	O
measurements	O
in	O
greenhouses	O
or	O
in	O
the	O
field	O
(	O
see	O
,	O
for	O
example	O
,	O
the	O
review	O
article	O
of	O
Jones	O
,	O
2004	O
,	O
and	O
also	O
Grant	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

In	O
this	O
communication	O
a	O
novel	O
,	O
non	O
-	O
invasive	O
,	O
online	O
-	O
monitoring	O
plant	O
-	O
based	O
probe	O
is	O
described	O
that	O
meets	O
the	O
demands	O
of	O
controlling	O
horticultural	O
and	O
agricultural	O
water	O
applications	O
.	O

The	O
probe	O
is	O
characterized	O
by	O
high	O
precision	O
,	O
operating	O
convenience	O
,	O
minimum	O
costs	O
,	O
and	O
by	O
automation	O
suitability	O
.	O

Data	O
can	O
be	O
transferred	O
wireless	O
to	O
a	O
personal	O
computer	O
or	O
to	O
an	O
Internet	O
server	O
via	O
a	O
mobile	O
phone	O
network	O
for	O
real	O
-	O
time	O
evaluation	O
and	O
for	O
the	O
automatic	O
regulation	O
of	O
irrigation	O
.	O

The	O
technology	O
includes	O
a	O
miniaturized	O
silicone	O
pressure	O
sensor	O
integrated	O
into	O
a	O
spring	O
clamp	O
that	O
is	O
clamped	O
to	O
a	O
patch	O
of	O
an	O
intact	O
plant	O
leaf	O
.	O

The	O
patch	O
clamp	O
pressure	O
probe	O
measures	O
the	O
attenuated	O
pressure	O
response	O
of	O
the	O
leaf	O
patch	O
upon	O
the	O
application	O
of	O
a	O
constant	O
,	O
clamped	O
pressure	O
.	O

The	O
attenuation	O
of	O
the	O
applied	O
pressure	O
depends	O
on	O
the	O
transfer	O
function	O
of	O
the	O
leaf	O
.	O

The	O
magnitude	O
of	O
the	O
transfer	O
function	O
depends	O
on	O
two	O
terms	O
,	O
a	O
turgor	O
pressure	O
-	O
independent	O
term	O
(	O
related	O
to	O
the	O
compression	O
of	O
the	O
cuticle	O
,	O
cell	O
walls	O
,	O
and	O
other	O
structural	O
elements	O
)	O
and	O
a	O
turgor	O
pressure	O
-	O
dependent	O
term	O
.	O

Theory	O
shows	O
that	O
the	O
turgor	O
pressure	O
-	O
dependent	O
part	O
of	O
the	O
transfer	O
function	O
Tf	O
is	O
a	O
power	O
function	O
of	O
the	O
cell	O
turgor	O
pressure	O
,	O
Pc	O
,	O
and	O
predicts	O
that	O
Tf	O
assumes	O
values	O
close	O
to	O
zero	O
if	O
Pc	O
is	O
high	O
and	O
,	O
vice	O
versa	O
,	O
values	O
close	O
to	O
unity	O
if	O
Pc	O
is	O
low	O
.	O

This	O
could	O
be	O
verified	O
by	O
combined	O
turgor	O
pressure	O
probe	O
and	O
leaf	O
patch	O
clamp	O
pressure	O
probe	O
measurements	O
on	O
leaflets	O
of	O
the	O
liana	O
Tetrastigma	B-LIVB
voinierianum	I-LIVB
.	O

The	O
10	O
-	O
m	O
tall	O
liana	O
growing	O
in	O
a	O
tropical	O
greenhouse	O
was	O
selected	O
for	O
the	O
first	O
studies	O
because	O
a	O
comprehensive	O
data	O
set	O
about	O
diurnal	O
changes	O
in	O
xylem	O
and	O
turgor	O
pressure	O
gradients	O
under	O
various	O
environmental	O
conditions	O
existed	O
for	O
this	O
greenhouse	O
plant	O
(	O
Benkert	O
et	O
al	O
.	O
,	O
1995	O
;	O
Th	O
u	O
rmer	O
et	O
al	O
.	O
,	O
1999	O
;	O
see	O
also	O
Zimmermann	O
et	O
al	O
.	O
,	O
2004	O
)	O
.	O

Measurements	O
of	O
diurnal	O
changes	O
of	O
the	O
patch	O
clamp	O
pressure	O
performed	O
here	O
yielded	O
results	O
which	O
were	O
consistent	O
with	O
the	O
previous	O
pressure	O
probe	O
work	O
on	O
the	O
liana	O
.	O

The	O
data	O
also	O
demonstrated	O
that	O
changes	O
in	O
the	O
irrigation	O
regime	O
and	O
in	O
microclimate	O
can	O
be	O
sensed	O
by	O
this	O
novel	O
probe	O
very	O
sensitively	O
and	O
that	O
use	O
of	O
several	O
probes	O
allowed	O
the	O
study	O
of	O
the	O
diurnal	O
water	O
transport	O
at	O
multiple	O
scales	O
from	O
single	O
leaves	O
to	O
the	O
whole	O
organism	O
(	O
Meinzer	O
et	O
al	O
.	O
,	O
2001	O
)	O
.	O

This	O
can	O
be	O
done	O
without	O
knowledge	O
of	O
the	O
turgor	O
pressure	O
because	O
the	O
transfer	O
function	O
is	O
a	O
direct	O
measure	O
of	O
leaf	O
water	O
status	O
.	O

Materials	O
and	O
methods	O

Plant	O
material	O

Experiments	O
were	O
performed	O
on	O
two	O
specimens	O
of	O
the	O
liana	O
Tetrastigma	B-LIVB
voinierianum	I-LIVB
,	O
growing	O
in	O
the	O
c	O
.	O

12	O
m	O
tall	O
tropical	O
greenhouse	O
of	O
the	O
University	O
of	O
Salzburg	O
,	O
Austria	O
.	O

The	O
ground	O
ascended	O
by	O
about	O
5	O
m	O
towards	O
the	O
backstage	O
of	O
the	O
greenhouse	O
.	O

The	O
height	O
of	O
the	O
plant	O
in	O
this	O
area	O
was	O
about	O
4	O
.	O
5	O
m	O
,	O
whereas	O
the	O
height	O
of	O
the	O
plant	O
in	O
the	O
front	O
area	O
reached	O
10	O
m	O
.	O

However	O
,	O
the	O
stem	O
and	O
the	O
branches	O
of	O
the	O
two	O
plants	O
were	O
considerably	O
longer	O
,	O
because	O
the	O
plants	O
had	O
grown	O
vertically	O
upwards	O
and	O
then	O
part	O
of	O
the	O
way	O
downwards	O
.	O

First	O
measurements	O
were	O
performed	O
during	O
the	O
last	O
week	O
of	O
May	O
,	O
2007	O
.	O

This	O
week	O
was	O
very	O
sunny	O
and	O
warm	O
.	O

Experiments	O
were	O
repeated	O
during	O
the	O
last	O
week	O
of	O
August	O
and	O
the	O
first	O
week	O
of	O
September	O
,	O
2007	O
.	O

At	O
this	O
time	O
of	O
the	O
year	O
the	O
weather	O
conditions	O
were	O
quite	O
poor	O
.	O

The	O
weeks	O
were	O
rainy	O
,	O
sunshine	O
occurred	O
only	O
occasionally	O
.	O

On	O
average	O
,	O
the	O
sky	O
was	O
very	O
cloudy	O
.	O

Due	O
to	O
the	O
variable	O
weather	O
conditions	O
the	O
ambient	O
temperature	O
,	O
T	O
,	O
in	O
the	O
greenhouse	O
usually	O
varied	O
between	O
19	O
degrees	O
C	O
and	O
27	O
degrees	O
C	O
.	O

By	O
contrast	O
,	O
during	O
the	O
hot	O
week	O
in	O
May	O
temperatures	O
at	O
the	O
top	O
of	O
the	O
plants	O
could	O
reach	O
up	O
to	O
44	O
degrees	O
C	O
.	O

The	O
greenhouse	O
was	O
illuminated	O
between	O
07	O
.	O
30	O
h	O
and	O
19	O
.	O
00	O
h	O
(	O
CET	O
=	O
Central	O
European	O
Time	O
)	O
.	O

During	O
the	O
day	O
-	O
time	O
,	O
the	O
artificial	O
illumination	O
was	O
switched	O
off	O
automatically	O
once	O
the	O
natural	O
irradiance	O
exceeded	O
about	O
45	O
mu	O
mol	O
photons	O
m	O
-	O
2	O
s	O
-	O
1	O
at	O
ground	O
level	O
.	O

At	O
full	O
sunshine	O
,	O
the	O
light	O
intensity	O
was	O
limited	O
by	O
automatically	O
operating	O
blinds	O
.	O

The	O
relative	O
humidity	O
(	O
r	O
.	O
h	O
.	O
)	O
of	O
the	O
air	O
was	O
regulated	O
by	O
overhead	O
misters	O
.	O

Despite	O
attempts	O
to	O
keep	O
the	O
r	O
.	O
h	O
.	O
above	O
60	O
-	O
70	O
%	O
large	O
axial	O
r	O
.	O
h	O
.	O
gradients	O
along	O
the	O
stem	O
of	O
the	O
liana	O
were	O
observed	O
during	O
sunny	O
days	O
(	O
see	O
below	O
)	O
.	O

The	O
ambient	O
temperature	O
and	O
relative	O
humidity	O
at	O
the	O
measuring	O
sites	O
were	O
determined	O
by	O
using	O
thermistors	O
(	O
Tinytag	O
;	O
RS	O
Components	O
GmbH	O
,	O
M	O
o	O
rfelden	O
-	O
Walldorf	O
,	O
Germany	O
)	O
.	O

Leaf	O
patch	O
clamp	O
pressure	O
probe	O
and	O
data	O
acquisition	O

The	O
pressure	O
sensor	O
chip	O
allows	O
pressure	O
measurements	O
up	O
to	O
100	O
kPa	O
.	O

The	O
sensor	O
consists	O
of	O
a	O
miniature	O
piezoresistive	O
Wheatstone	O
bridge	O
.	O

The	O
sensors	O
used	O
in	O
this	O
work	O
were	O
purchased	O
from	O
the	O
company	O
'	O
Raumedic	O
'	O
(	O
Helmbrechts	O
,	O
Germany	O
)	O
and	O
from	O
the	O
company	O
'	O
Keller	O
'	O
(	O
AG	O
,	O
Druckmesstechnik	O
;	O
Winterthur	O
,	O
Switzerland	O
)	O
.	O

However	O
,	O
it	O
has	O
to	O
be	O
pointed	O
out	O
that	O
any	O
other	O
miniaturized	O
pressure	O
or	O
force	O
sensor	O
could	O
be	O
used	O
.	O

The	O
sensor	O
chip	O
was	O
integrated	O
into	O
one	O
of	O
the	O
planar	O
circular	O
pads	O
of	O
a	O
spring	O
clamp	O
shown	O
schematically	O
in	O
Fig	O
.	O

1	O
.	O

The	O
spring	O
clamp	O
consisted	O
of	O
two	O
curved	O
arms	O
bridged	O
by	O
a	O
spring	O
in	O
the	O
middle	O
(	O
Wolfcraft	O
GmbH	O
;	O
microfix	O
S	O
(	O
B3630Fz60	O
)	O
,	O
Kempenich	O
,	O
Germany	O
)	O
.	O

The	O
clamp	O
pressure	O
exerted	O
by	O
the	O
spring	O
on	O
the	O
leaf	O
,	O
Pclamp	O
,	O
could	O
be	O
varied	O
by	O
a	O
stiff	O
strap	O
(	O
made	O
of	O
synthetic	O
material	O
)	O
spanned	O
between	O
the	O
arms	O
of	O
the	O
spring	O
clip	O
at	O
the	O
handhold	O
site	O
(	O
Fig	O
.	O
1	O
)	O
.	O

The	O
length	O
of	O
the	O
strap	O
and	O
thus	O
the	O
spring	O
load	O
acting	O
on	O
the	O
leaflet	O
between	O
the	O
two	O
pads	O
could	O
be	O
varied	O
by	O
regularly	O
punched	O
holes	O
(	O
as	O
in	O
a	O
belt	O
)	O
.	O

Calibration	O
of	O
the	O
sensor	O
chips	O
was	O
performed	O
by	O
pressurization	O
in	O
a	O
pressure	O
chamber	O
equipped	O
with	O
an	O
integrated	O
manometer	O
(	O
LEO	O
1	O
,	O
Keller	O
AG	O
,	O
Winterthur	O
,	O
Switzerland	O
)	O
.	O

The	O
readings	O
of	O
all	O
sensors	O
used	O
in	O
this	O
study	O
increased	O
linearly	O
with	O
pressure	O
in	O
the	O
range	O
between	O
0	O
kPa	O
and	O
100	O
kPa	O
.	O

The	O
pressure	O
sensitivity	O
of	O
the	O
various	O
sensors	O
was	O
found	O
to	O
be	O
almost	O
identical	O
for	O
all	O
probes	O
.	O

Before	O
use	O
the	O
probes	O
were	O
also	O
tested	O
for	O
temperature	O
-	O
sensitivity	O
in	O
an	O
accessible	O
climate	O
chamber	O
because	O
it	O
is	O
well	O
-	O
known	O
that	O
silicone	O
-	O
embedded	O
sensors	O
tend	O
to	O
become	O
temperature	O
-	O
sensitive	O
during	O
storage	O
.	O

Probes	O
were	O
subject	O
to	O
temperature	O
regimes	O
ranging	O
from	O
10	O
degrees	O
C	O
to	O
35	O
degrees	O
C	O
.	O

Probes	O
were	O
not	O
used	O
if	O
the	O
temperature	O
treatment	O
induced	O
a	O
pressure	O
change	O
larger	O
than	O
0	O
.	O
5	O
kPa	O
.	O

The	O
signals	O
of	O
the	O
leaf	O
patch	O
clamp	O
pressure	O
probe	O
were	O
transmitted	O
by	O
a	O
telemetry	O
system	O
(	O
teleBITcom	O
gmbh	O
,	O
Teltow	O
,	O
Germany	O
)	O
.	O

The	O
operating	O
distance	O
between	O
the	O
battery	O
-	O
powered	O
wireless	O
telemetric	O
transmitter	O
and	O
the	O
receiver	O
base	O
station	O
was	O
up	O
to	O
400	O
m	O
.	O

Each	O
transmitter	O
read	O
,	O
amplified	O
,	O
and	O
converted	O
the	O
analogue	O
signals	O
of	O
the	O
pressure	O
sensor	O
into	O
digitalized	O
signals	O
.	O

The	O
data	O
were	O
sent	O
together	O
with	O
the	O
transmitter	O
ID	O
-	O
code	O
every	O
90	O
s	O
via	O
the	O
ISM	O
band	O
of	O
433	O
MHz	O
to	O
the	O
receiver	O
base	O
station	O
which	O
logged	O
and	O
transferred	O
the	O
data	O
to	O
a	O
personal	O
computer	O
or	O
to	O
a	O
GPRS	O
modem	O
linked	O
to	O
an	O
Internet	O
server	O
(	O
NTBB	O
Systemtechnik	O
GmbH	O
,	O
Zeuthen	O
,	O
Germany	O
)	O
for	O
analysis	O
and	O
archival	O
storage	O
.	O

For	O
sensor	O
calibration	O
and	O
data	O
recording	O
the	O
SENBIT	O
software	O
(	O
teleBITcom	O
gmbh	O
,	O
Teltow	O
,	O
Germany	O
)	O
was	O
used	O
.	O

The	O
software	O
allowed	O
communication	O
with	O
up	O
to	O
32	O
sensors	O
at	O
regular	O
short	O
intervals	O
(	O
90	O
s	O
to	O
5	O
min	O
)	O
.	O

In	O
this	O
study	O
,	O
up	O
to	O
10	O
sensor	O
/	O
transmitter	O
units	O
were	O
installed	O
at	O
different	O
heights	O
on	O
the	O
two	O
lianas	O
.	O

Data	O
transfer	O
to	O
the	O
Internet	O
server	O
operated	O
without	O
any	O
problem	O
during	O
the	O
entire	O
experimental	O
period	O
.	O

However	O
,	O
for	O
safety	O
reasons	O
hard	O
-	O
wired	O
conventional	O
data	O
acquisition	O
was	O
also	O
performed	O
using	O
dataloggers	O
(	O
Raumedic	O
,	O
Helmbrechts	O
,	O
Germany	O
)	O
.	O

The	O
dataloggers	O
were	O
controlled	O
by	O
a	O
computer	O
program	O
that	O
provided	O
functions	O
for	O
data	O
storage	O
and	O
sensor	O
calibration	O
.	O

Data	O
were	O
transferred	O
regularly	O
from	O
the	O
dataloggers	O
to	O
a	O
personal	O
computer	O
.	O

Cell	O
turgor	O
pressure	O
probe	O

Turgor	O
pressure	O
measurements	O
were	O
performed	O
on	O
leaflets	O
of	O
the	O
10	O
-	O
m	O
tall	O
liana	O
at	O
c	O
.	O

0	O
.	O
2	O
m	O
height	O
above	O
the	O
roots	O
.	O

The	O
construction	O
and	O
function	O
of	O
the	O
cell	O
turgor	O
pressure	O
probe	O
has	O
been	O
described	O
elsewhere	O
(	O
Zimmermann	O
et	O
al	O
.	O
,	O
1969	O
,	O
2004	O
)	O
.	O

Briefly	O
,	O
the	O
microcapillary	O
was	O
filled	O
with	O
oil	O
up	O
to	O
the	O
very	O
tip	O
and	O
was	O
then	O
inserted	O
into	O
the	O
upper	O
leaflet	O
surface	O
between	O
the	O
main	O
vein	O
and	O
the	O
leaflet	O
edge	O
.	O

Insertion	O
was	O
made	O
under	O
a	O
small	O
overpressure	O
(	O
about	O
20	O
kPa	O
)	O
achieved	O
by	O
appropriate	O
displacement	O
of	O
the	O
metal	O
rod	O
in	O
the	O
probe	O
in	O
order	O
to	O
avoid	O
tip	O
clogging	O
.	O

Penetration	O
was	O
stopped	O
upon	O
reaching	O
the	O
mesophyll	O
cell	O
layer	O
and	O
formation	O
of	O
a	O
stable	O
oil	O
/	O
sap	O
meniscus	O
within	O
the	O
tip	O
region	O
of	O
the	O
microcapillary	O
of	O
the	O
probe	O
.	O

During	O
the	O
measurements	O
it	O
was	O
regularly	O
proved	O
whether	O
the	O
tip	O
was	O
clogged	O
or	O
not	O
by	O
appropriate	O
displacement	O
of	O
the	O
metal	O
rod	O
.	O

Theoretical	O
background	O

The	O
input	O
pressure	O
,	O
Pin	O
,	O
experienced	O
by	O
the	O
cells	O
in	O
a	O
leaf	O
patch	O
is	O
equal	O
to	O
the	O
clamp	O
pressure	O
,	O
Pclamp	O
,	O
only	O
if	O
the	O
pressure	O
signal	O
is	O
transferred	O
lossless	O
to	O
the	O
cells	O
in	O
the	O
leaves	O
.	O

However	O
,	O
losses	O
usually	O
occur	O
due	O
to	O
the	O
compressibility	O
and	O
the	O
deformability	O
of	O
the	O
silicone	O
of	O
the	O
pressure	O
sensor	O
as	O
well	O
as	O
of	O
the	O
compressibility	O
of	O
the	O
cuticle	O
and	O
other	O
structural	O
elements	O
of	O
the	O
leaf	O
.	O

Therefore	O
,	O
theory	O
shows	O
that	O
only	O
a	O
fraction	O
of	O
Pclamp	O
may	O
arrive	O
at	O
the	O
cells	O
,	O
i	O
.	O
e	O
.	O
that	O
the	O
attenuation	O
factor	O
,	O
Fa	O
=	O
Pin	O
/	O
Pclamp	O
,	O
is	O
smaller	O
than	O
unity	O
.	O

Fa	O
depends	O
on	O
the	O
individual	O
leaf	O
properties	O
.	O

Fa	O
can	O
be	O
assumed	O
to	O
be	O
constant	O
(	O
and	O
leaf	O
thickness	O
changes	O
are	O
negligible	O
)	O
if	O
the	O
structural	O
elements	O
are	O
completely	O
pre	O
-	O
compressed	O
by	O
application	O
of	O
an	O
appropriate	O
Pclamp	O
.	O

If	O
Pclamp	O
is	O
kept	O
constant	O
during	O
the	O
following	O
experimental	O
period	O
,	O
Pin	O
is	O
constant	O
and	O
the	O
output	O
pressure	O
,	O
Pp	O
,	O
is	O
only	O
determined	O
by	O
the	O
cell	O
transfer	O
function	O
,	O
Tf	O
(	O
V	O
)	O
,	O
where	O
V	O
is	O
the	O
leaf	O
patch	O
volume	O
.	O

In	O
other	O
words	O
,	O
Tf	O
(	O
V	O
)	O
determines	O
the	O
fraction	O
of	O
Pin	O
sensed	O
by	O
the	O
probe	O
.	O

It	O
is	O
dimensionless	O
and	O
assumes	O
values	O
between	O
zero	O
and	O
unity	O
:	O
(	O
1	O
)	O
Tf	O
depends	O
on	O
the	O
volume	O
of	O
the	O
leaf	O
patch	O
,	O
V	O
,	O
at	O
constant	O
ambient	O
temperature	O
,	O
T	O
:	O
(	O
2	O
)	O
delta	O
V	O
depends	O
on	O
changes	O
in	O
cell	O
turgor	O
pressure	O
,	O
delta	O
Pc	O
,	O
as	O
follows	O
:	O
(	O
3	O
)	O
where	O
op	O
is	O
the	O
average	O
volumetric	O
elastic	O
modulus	O
of	O
the	O
clamped	O
tissue	O
(	O
Philip	O
,	O
1958	O
)	O
.	O

op	O
is	O
a	O
very	O
complex	O
parameter	O
and	O
will	O
be	O
dictated	O
by	O
the	O
turgor	O
pressure	O
in	O
the	O
turgescent	O
state	O
.	O

For	O
a	O
first	O
approximation	O
it	O
is	O
assumed	O
that	O
op	O
increases	O
linearly	O
with	O
Pc	O
(	O
support	O
for	O
this	O
assumption	O
is	O
given	O
by	O
Zimmermann	O
and	O
Steudle	O
,	O
1978	O
;	O
Zimmermann	O
and	O
H	O
u	O
sken	O
,	O
1980	O
;	O
Wendler	O
et	O
al	O
.	O
,	O
1983	O
)	O
:	O
(	O
4	O
)	O
where	O
a	O
and	O
b	O
are	O
constants	O
for	O
individual	O
leaf	O
properties	O
.	O

Because	O
of	O
the	O
viscoelastic	O
properties	O
of	O
the	O
cell	O
wall	O
,	O
the	O
magnitude	O
of	O
the	O
constants	O
depends	O
on	O
the	O
duration	O
of	O
the	O
external	O
pressure	O
application	O
(	O
Zimmermann	O
and	O
H	O
u	O
sken	O
,	O
1980	O
)	O
.	O

The	O
constants	O
are	O
relatively	O
large	O
if	O
rapid	O
turgor	O
pressure	O
changes	O
are	O
induced	O
(	O
e	O
.	O
g	O
.	O
by	O
using	O
the	O
cell	O
turgor	O
pressure	O
probe	O
)	O
,	O
whereas	O
slow	O
turgor	O
pressure	O
changes	O
(	O
e	O
.	O
g	O
.	O
under	O
transpirational	O
conditions	O
)	O
result	O
in	O
small	O
values	O
.	O

Combining	O
equations	O
2	O
-	O
4	O
leads	O
to	O
equation	O
5	O
.	O
(	O
5	O
)	O

Equation	O
5	O
can	O
be	O
integrated	O
by	O
assuming	O
for	O
a	O
first	O
approximation	O
that	O
at	O
Pc	O
=	O
0	O
Tf	O
=	O
1	O
and	O
that	O
the	O
internal	O
osmotic	O
pressure	O
of	O
the	O
cells	O
remained	O
constant	O
.	O

After	O
appropriate	O
re	O
-	O
arrangements	O
equation	O
6	O
is	O
obtained	O
:	O
(	O
6	O
)	O
and	O
,	O
respectively	O
,	O
if	O
the	O
denominator	O
is	O
replaced	O
by	O
equation	O
4	O
:	O
(	O
7	O
)	O

Introducing	O
equation	O
6	O
into	O
equation	O
1	O
yields	O
the	O
wanted	O
relationship	O
between	O
the	O
parameters	O
Pp	O
and	O
Pin	O
:	O
(	O
8	O
)	O

Equation	O
8	O
can	O
be	O
verified	O
experimentally	O
.	O

Inspection	O
of	O
the	O
equation	O
shows	O
that	O
the	O
patch	O
clamp	O
pressure	O
,	O
Pp	O
,	O
is	O
a	O
power	O
function	O
of	O
the	O
turgor	O
pressure	O
,	O
Pc	O
.	O

The	O
exponent	O
of	O
the	O
function	O
is	O
equal	O
to	O
or	O
smaller	O
than	O
unity	O
.	O

If	O
a	O
=	O
1	O
and	O
b	O
<	O
<	O
Pc	O
,	O
equation	O
8	O
turns	O
into	O
Pp	O
=	O
b	O
/	O
Pc	O
,	O
i	O
.	O
e	O
.	O
both	O
parameters	O
are	O
directly	O
reciprocally	O
coupled	O
with	O
each	O
other	O
.	O

Thus	O
Tf	O
assumes	O
low	O
values	O
if	O
Pc	O
is	O
high	O
and	O
,	O
vice	O
versa	O
,	O
a	O
value	O
close	O
to	O
unity	O
if	O
Pc	O
is	O
close	O
to	O
zero	O
.	O

Using	O
appropriate	O
values	O
for	O
a	O
and	O
b	O
for	O
a	O
given	O
leaf	O
(	O
see	O
below	O
)	O
it	O
can	O
be	O
shown	O
that	O
below	O
Pc	O
=	O
100	O
kPa	O
,	O
Pp	O
increases	O
dramatically	O
.	O

This	O
means	O
that	O
the	O
transfer	O
function	O
responds	O
very	O
sensitively	O
upon	O
loss	O
of	O
complete	O
turgor	O
pressure	O
.	O

In	O
the	O
derivation	O
of	O
equation	O
8	O
it	O
was	O
assumed	O
that	O
op	O
is	O
temperature	O
-	O
independent	O
.	O

However	O
,	O
temperature	O
effects	O
on	O
cell	O
elasticity	O
are	O
well	O
-	O
known	O
,	O
although	O
they	O
are	O
not	O
very	O
large	O
in	O
the	O
temperature	O
range	O
investigated	O
here	O
(	O
see	O
,	O
for	O
example	O
,	O
Petersen	O
et	O
al	O
.	O
,	O
1982	O
;	O
Niklas	O
,	O
1992	O
;	O
Hogan	O
and	O
Niklas	O
,	O
2004	O
;	O
Edelmann	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O

Temperature	O
effects	O
on	O
op	O
cannot	O
be	O
excluded	O
if	O
different	O
values	O
for	O
the	O
Pclamp	O
,	O
and	O
,	O
in	O
turn	O
,	O
for	O
the	O
input	O
pressure	O
,	O
Pin	O
,	O
are	O
selected	O
,	O
as	O
well	O
as	O
if	O
significantly	O
different	O
values	O
for	O
the	O
constants	O
a	O
and	O
b	O
are	O
assumed	O
for	O
optimum	O
fitting	O
of	O
the	O
Pp	O
=	O
f	O
(	O
Pc	O
)	O
curves	O
.	O

Therefore	O
,	O
in	O
the	O
case	O
of	O
large	O
temperature	O
gradients	O
as	O
observed	O
here	O
(	O
see	O
Figs	O
2	O
and	O
3	O
)	O
only	O
the	O
relative	O
,	O
but	O
not	O
the	O
absolute	O
changes	O
in	O
Pp	O
measured	O
at	O
the	O
different	O
heights	O
can	O
be	O
compared	O
with	O
each	O
other	O
.	O

However	O
,	O
Pp	O
values	O
measured	O
at	O
the	O
same	O
height	O
are	O
still	O
comparable	O
and	O
give	O
information	O
about	O
the	O
turgescence	O
,	O
i	O
.	O
e	O
.	O
about	O
the	O
water	O
status	O
of	O
the	O
leaf	O
cells	O
.	O

Results	O

The	O
leaf	O
patch	O
clamp	O
pressure	O
probe	O
was	O
clamped	O
about	O
2	O
cm	O
away	O
from	O
the	O
edge	O
of	O
a	O
leaflet	O
of	O
the	O
compound	O
leaves	O
.	O

Leaflets	O
of	O
similar	O
size	O
(	O
176	O
+/-	O
58	O
cm2	O
,	O
n	O
=	O
12	O
)	O
were	O
used	O
.	O

Inspection	O
of	O
the	O
leaf	O
patches	O
after	O
removal	O
of	O
the	O
probes	O
under	O
the	O
microscope	O
revealed	O
no	O
changes	O
in	O
leaflet	O
appearance	O
beneath	O
the	O
pads	O
,	O
even	O
after	O
several	O
weeks	O
.	O

Lesions	O
on	O
the	O
leaves	O
were	O
never	O
found	O
.	O

Only	O
occasionally	O
were	O
very	O
slight	O
impressions	O
of	O
the	O
pads	O
on	O
the	O
leaflet	O
surface	O
observed	O
.	O

Clamping	O
of	O
the	O
leaves	O
could	O
be	O
performed	O
at	O
any	O
time	O
of	O
the	O
day	O
.	O

Clamp	O
pressures	O
,	O
Pclamp	O
,	O
applied	O
to	O
the	O
leaves	O
were	O
of	O
the	O
order	O
of	O
80	O
-	O
200	O
kPa	O
.	O

The	O
optimum	O
value	O
for	O
Pclamp	O
of	O
a	O
given	O
leaf	O
has	O
to	O
be	O
found	O
empirically	O
.	O

Experience	O
shows	O
that	O
Pclamp	O
values	O
could	O
be	O
considered	O
as	O
optimal	O
if	O
the	O
output	O
pressure	O
Pp	O
assumed	O
values	O
between	O
10	O
kPa	O
and	O
25	O
kPa	O
upon	O
clamping	O
in	O
the	O
early	O
morning	O
(	O
when	O
turgor	O
pressure	O
was	O
high	O
)	O
or	O
between	O
50	O
kPa	O
and	O
70	O
kPa	O
upon	O
clamping	O
around	O
noon	O
or	O
towards	O
early	O
afternoon	O
(	O
when	O
turgor	O
pressure	O
was	O
usually	O
low	O
)	O
.	O

The	O
magnitude	O
of	O
Pp	O
depended	O
on	O
the	O
compressibility	O
and	O
deformability	O
properties	O
of	O
the	O
individual	O
leaves	O
which	O
may	O
vary	O
considerably	O
due	O
to	O
age	O
,	O
morphology	O
,	O
leaf	O
thickness	O
,	O
abiotic	O
factors	O
etc	O
.	O

The	O
magnitude	O
of	O
Pclamp	O
had	O
no	O
effect	O
on	O
the	O
diurnal	O
profiles	O
of	O
Pp	O
,	O
in	O
response	O
to	O
changes	O
in	O
microclimate	O
and	O
/	O
or	O
changes	O
in	O
the	O
irrigation	O
regime	O
.	O

Probes	O
clamped	O
on	O
the	O
same	O
leaflet	O
or	O
nearby	O
leaflets	O
of	O
leaves	O
responded	O
almost	O
identically	O
upon	O
temporary	O
changes	O
in	O
transpiration	O
and	O
/	O
or	O
water	O
supply	O
even	O
if	O
the	O
Pclamp	O
values	O
were	O
different	O
due	O
to	O
different	O
leaf	O
thickness	O
as	O
well	O
as	O
local	O
compressibility	O
and	O
deformability	O
properties	O
(	O
data	O
not	O
shown	O
)	O
.	O

This	O
was	O
found	O
over	O
the	O
entire	O
height	O
of	O
the	O
plants	O
.	O

Screening	O
experiments	O
proved	O
further	O
that	O
a	O
high	O
surface	O
roughness	O
prevented	O
a	O
uniform	O
contact	O
between	O
the	O
pads	O
of	O
the	O
probe	O
and	O
the	O
leaf	O
.	O

Non	O
-	O
uniform	O
contact	O
resulted	O
in	O
a	O
reduced	O
pressure	O
response	O
of	O
the	O
probe	O
(	O
data	O
not	O
shown	O
)	O
.	O

Thus	O
,	O
in	O
order	O
to	O
obtain	O
maximum	O
resolution	O
of	O
microclimate	O
-	O
induced	O
and	O
/	O
or	O
plant	O
-	O
based	O
effects	O
on	O
the	O
Pp	O
values	O
,	O
it	O
was	O
crucial	O
that	O
the	O
probe	O
was	O
placed	O
on	O
relatively	O
smooth	O
areas	O
,	O
i	O
.	O
e	O
.	O
preferentially	O
between	O
the	O
veins	O
rather	O
than	O
on	O
the	O
veins	O
in	O
order	O
to	O
guarantee	O
a	O
uniform	O
pressure	O
transmission	O
.	O

It	O
also	O
turned	O
out	O
that	O
areas	O
with	O
lesions	O
or	O
covered	O
with	O
dust	O
should	O
be	O
avoided	O
.	O

Probably	O
due	O
to	O
the	O
absence	O
of	O
dust	O
,	O
high	O
resolution	O
results	O
were	O
obtained	O
when	O
the	O
sensor	O
-	O
containing	O
pad	O
faced	O
the	O
abaxial	O
side	O
,	O
but	O
not	O
the	O
adaxial	O
side	O
of	O
the	O
leaf	O
.	O

Diurnal	O
changes	O
in	O
the	O
patch	O
clamp	O
pressure	O

Figure	O
2A	O
represents	O
Pp	O
recordings	O
conducted	O
on	O
the	O
10	O
m	O
tall	O
liana	O
on	O
24	O
May	O
and	O
25	O
May	O
,	O
2007	O
.	O

The	O
plant	O
was	O
well	O
-	O
watered	O
before	O
the	O
beginning	O
of	O
the	O
measurements	O
(	O
22	O
May	O
)	O
and	O
was	O
also	O
watered	O
regularly	O
during	O
the	O
experimental	O
period	O
.	O

The	O
sufficient	O
supply	O
of	O
the	O
leaves	O
with	O
water	O
was	O
indicated	O
by	O
high	O
turgor	O
pressure	O
values	O
of	O
c	O
.	O

500	O
kPa	O
at	O
predawn	O
and	O
guttation	O
up	O
to	O
a	O
height	O
of	O
6	O
m	O
around	O
sunrise	O
(	O
see	O
also	O
Th	O
u	O
rmer	O
et	O
al	O
.	O
,	O
1999	O
)	O
.	O

Diurnal	O
changes	O
of	O
the	O
Pp	O
values	O
were	O
recorded	O
simultaneously	O
at	O
0	O
.	O
2	O
m	O
,	O
6	O
m	O
,	O
and	O
10	O
m	O
height	O
.	O

The	O
corresponding	O
diurnal	O
changes	O
in	O
the	O
ambient	O
temperature	O
,	O
T	O
,	O
and	O
relative	O
humidity	O
,	O
r	O
.	O
h	O
.	O
,	O
measured	O
close	O
to	O
the	O
sites	O
of	O
the	O
patch	O
clamp	O
pressure	O
probes	O
,	O
are	O
given	O
in	O
Fig	O
.	O

2B	O
and	O
C	O
.	O

It	O
was	O
very	O
sunny	O
on	O
24	O
May	O
resulting	O
in	O
a	O
rapid	O
heating	O
-	O
up	O
of	O
the	O
greenhouse	O
,	O
particularly	O
in	O
the	O
upper	O
part	O
.	O

This	O
led	O
to	O
the	O
development	O
of	O
large	O
vertical	O
gradients	O
in	O
T	O
and	O
r	O
.	O
h	O
.	O
along	O
the	O
stem	O
of	O
the	O
liana	O
(	O
Fig	O
.	O
2B	O
,	O
C	O
)	O
.	O

Because	O
sunlight	O
was	O
dimmed	O
by	O
operation	O
of	O
the	O
automatic	O
blinds	O
at	O
noon	O
(	O
see	O
Materials	O
and	O
methods	O
)	O
the	O
gradients	O
did	O
not	O
reach	O
maximum	O
values	O
before	O
the	O
afternoon	O
.	O

Between	O
15	O
.	O
30	O
h	O
and	O
16	O
.	O
30	O
h	O
an	O
ambient	O
temperature	O
of	O
44	O
degrees	O
C	O
and	O
a	O
relative	O
humidity	O
of	O
20	O
%	O
were	O
recorded	O
at	O
the	O
top	O
of	O
the	O
liana	O
,	O
whereas	O
at	O
0	O
.	O
2	O
m	O
height	O
T	O
and	O
r	O
.	O
h	O
.	O
were	O
27	O
degrees	O
C	O
and	O
70	O
%	O
,	O
respectively	O
.	O

The	O
gradients	O
in	O
T	O
and	O
r	O
.	O
h	O
.	O
disappeared	O
at	O
c	O
.	O

22	O
.	O
00	O
h	O
.	O

Due	O
to	O
the	O
dense	O
foliage	O
of	O
the	O
plant	O
above	O
c	O
.	O

7	O
m	O
and	O
due	O
to	O
light	O
dimming	O
by	O
the	O
blinds	O
,	O
leaves	O
closer	O
to	O
the	O
ground	O
only	O
became	O
exposed	O
to	O
direct	O
sunshine	O
towards	O
the	O
early	O
afternoon	O
.	O

In	O
contrast	O
to	O
24	O
May	O
,	O
the	O
following	O
day	O
was	O
cloudy	O
until	O
noon	O
.	O

Thus	O
,	O
leaves	O
in	O
the	O
upper	O
part	O
of	O
the	O
liana	O
became	O
fully	O
exposed	O
to	O
bright	O
sunshine	O
first	O
around	O
14	O
.	O
00	O
h	O
as	O
indicated	O
by	O
the	O
rapid	O
increase	O
in	O
T	O
and	O
the	O
corresponding	O
decrease	O
of	O
r	O
.	O
h	O
.	O
above	O
a	O
height	O
of	O
6	O
m	O
(	O
Fig	O
.	O
2B	O
,	O
C	O
)	O
.	O

Despite	O
the	O
strongly	O
delayed	O
exposure	O
of	O
the	O
leaves	O
to	O
sunshine	O
,	O
comparable	O
maximum	O
values	O
for	O
T	O
and	O
r	O
.	O
h	O
.	O
at	O
the	O
three	O
measuring	O
sites	O
,	O
as	O
well	O
as	O
vertical	O
gradients	O
in	O
T	O
and	O
r	O
.	O
h	O
.	O
of	O
comparable	O
size	O
,	O
were	O
measured	O
between	O
15	O
.	O
30	O
h	O
and	O
16	O
.	O
30	O
h	O
as	O
on	O
the	O
day	O
before	O
.	O

Inspection	O
of	O
Fig	O
.	O

2	O
shows	O
that	O
the	O
diurnal	O
changes	O
of	O
T	O
and	O
r	O
.	O
h	O
.	O
at	O
the	O
three	O
measuring	O
sites	O
are	O
reflected	O
in	O
corresponding	O
changes	O
of	O
Pp	O
.	O

During	O
the	O
nights	O
the	O
Pp	O
values	O
were	O
low	O
.	O

After	O
sunrise	O
at	O
04	O
.	O
24	O
h	O
the	O
Pp	O
values	O
remained	O
low	O
for	O
further	O
4	O
-	O
5	O
h	O
,	O
except	O
at	O
6	O
m	O
height	O
where	O
a	O
slight	O
and	O
continuous	O
increase	O
in	O
the	O
Pp	O
values	O
was	O
very	O
often	O
recorded	O
.	O

After	O
about	O
09	O
.	O
00	O
h	O
the	O
Pp	O
values	O
increased	O
over	O
the	O
entire	O
height	O
of	O
the	O
liana	O
.	O

Peaking	O
of	O
the	O
Pp	O
values	O
occurred	O
between	O
15	O
.	O
30	O
h	O
and	O
16	O
.	O
30	O
h	O
at	O
all	O
heights	O
when	O
the	O
T	O
and	O
r	O
.	O
h	O
.	O
gradients	O
reached	O
maximum	O
values	O
.	O

Towards	O
the	O
evening	O
the	O
Pp	O
values	O
decreased	O
again	O
in	O
order	O
to	O
reach	O
the	O
original	O
low	O
values	O
at	O
c	O
.	O

22	O
.	O
00	O
h	O
.	O

Until	O
peaking	O
in	O
the	O
afternoon	O
,	O
more	O
or	O
less	O
pronounced	O
fluctuations	O
of	O
the	O
Pp	O
values	O
were	O
seen	O
.	O

A	O
part	O
of	O
these	O
fluctuations	O
seemed	O
to	O
be	O
correlated	O
with	O
changes	O
in	O
the	O
local	O
ambient	O
temperature	O
,	O
relative	O
humidity	O
and	O
/	O
or	O
with	O
a	O
temporary	O
exposure	O
of	O
the	O
clamped	O
leaflet	O
to	O
sunshine	O
(	O
compare	O
Fig	O
.	O
2A	O
with	O
Fig	O
.	O
2B	O
,	O
C	O
)	O
.	O

However	O
,	O
there	O
was	O
also	O
a	O
considerable	O
number	O
of	O
fluctuations	O
which	O
could	O
not	O
be	O
traced	O
back	O
to	O
changes	O
in	O
the	O
microclimate	O
.	O

An	O
example	O
can	O
be	O
found	O
in	O
Fig	O
.	O

2A	O
(	O
arrow	O
)	O
.	O

The	O
peaking	O
of	O
the	O
Pp	O
value	O
measured	O
at	O
a	O
height	O
of	O
0	O
.	O
2	O
m	O
around	O
14	O
.	O
00	O
h	O
is	O
obviously	O
not	O
induced	O
by	O
changes	O
in	O
the	O
local	O
temperature	O
and	O
relative	O
humidity	O
or	O
by	O
exposure	O
to	O
sunshine	O
.	O

Similar	O
diurnal	O
changes	O
in	O
Pp	O
,	O
T	O
,	O
and	O
r	O
.	O
h	O
.	O
were	O
also	O
found	O
for	O
the	O
4	O
.	O
5	O
m	O
tall	O
liana	O
in	O
the	O
backstage	O
of	O
the	O
greenhouse	O
(	O
data	O
not	O
shown	O
)	O
.	O

Figure	O
3	O
shows	O
long	O
-	O
term	O
Pp	O
,	O
T	O
,	O
and	O
r	O
.	O
h	O
.	O
measurements	O
performed	O
at	O
0	O
.	O
2	O
m	O
,	O
6	O
m	O
,	O
and	O
10	O
m	O
height	O
in	O
late	O
summer	O
2007	O
.	O

In	O
contrast	O
to	O
the	O
experimental	O
conditions	O
in	O
late	O
spring	O
(	O
Fig	O
.	O
2	O
)	O
the	O
liana	O
had	O
been	O
watered	O
only	O
sporadically	O
during	O
the	O
weeks	O
before	O
the	O
measurements	O
.	O

The	O
soil	O
was	O
extremely	O
dry	O
and	O
no	O
guttation	O
was	O
observed	O
at	O
predawn	O
,	O
even	O
at	O
0	O
.	O
2	O
m	O
height	O
.	O

Turgor	O
pressure	O
measurements	O
performed	O
at	O
0	O
.	O
2	O
m	O
height	O
yielded	O
values	O
below	O
250	O
kPa	O
at	O
predawn	O
.	O

Continuous	O
irrigation	O
was	O
started	O
at	O
10	O
.	O
00	O
h	O
on	O
28	O
August	O
(	O
c	O
.	O
400	O
l	O
d	O
-	O
1	O
)	O
.	O

Guttation	O
occurred	O
at	O
0	O
.	O
2	O
m	O
height	O
,	O
but	O
not	O
at	O
6	O
m	O
height	O
on	O
1	O
September	O
.	O

At	O
sunrise	O
(	O
05	O
.	O
25	O
h	O
)	O
,	O
turgor	O
pressures	O
of	O
c	O
.	O

500	O
kPa	O
were	O
recorded	O
at	O
the	O
base	O
of	O
the	O
liana	O
.	O

Guttation	O
at	O
6	O
m	O
height	O
was	O
still	O
not	O
observed	O
on	O
3	O
September	O
indicating	O
that	O
the	O
hydration	O
state	O
of	O
the	O
plant	O
was	O
still	O
less	O
than	O
in	O
the	O
last	O
week	O
of	O
May	O
.	O

The	O
T	O
and	O
r	O
.	O
h	O
.	O
profiles	O
during	O
the	O
end	O
of	O
summer	O
were	O
also	O
different	O
to	O
those	O
in	O
late	O
spring	O
(	O
compare	O
Fig	O
.	O
2B	O
,	O
C	O
with	O
Fig	O
.	O
3B	O
,	O
C	O
)	O
.	O

On	O
28	O
August	O
when	O
irrigation	O
started	O
it	O
was	O
sunny	O
.	O

Similarly	O
to	O
May	O
,	O
peak	O
values	O
of	O
T	O
and	O
r	O
.	O
h	O
.	O
were	O
reached	O
at	O
c	O
.	O

15	O
.	O
30	O
h	O
.	O

However	O
,	O
temperatures	O
at	O
the	O
top	O
of	O
the	O
plant	O
did	O
not	O
exceed	O
35	O
degrees	O
C	O
and	O
r	O
.	O
h	O
.	O
did	O
not	O
drop	O
below	O
40	O
%	O
.	O

Accordingly	O
,	O
the	O
vertical	O
T	O
and	O
r	O
.	O
h	O
.	O
gradients	O
were	O
smaller	O
than	O
those	O
measured	O
at	O
the	O
end	O
of	O
May	O
.	O

On	O
29	O
August	O
,	O
when	O
it	O
became	O
very	O
rainy	O
and	O
light	O
irradiance	O
dropped	O
dramatically	O
,	O
gradients	O
in	O
T	O
and	O
r	O
.	O
h	O
.	O
of	O
slightly	O
decreased	O
size	O
were	O
still	O
recorded	O
.	O

Peaking	O
of	O
T	O
and	O
r	O
.	O
h	O
.	O
occurred	O
at	O
c	O
.	O

14	O
.	O
30	O
h	O
.	O

T	O
and	O
r	O
.	O
h	O
.	O
gradients	O
did	O
not	O
develop	O
in	O
the	O
following	O
three	O
days	O
which	O
were	O
very	O
cloudy	O
and	O
rainy	O
.	O

An	O
almost	O
constant	O
temperature	O
of	O
c	O
.	O

25	O
degrees	O
C	O
and	O
a	O
relative	O
humidity	O
of	O
80	O
%	O
were	O
measured	O
on	O
the	O
ground	O
and	O
at	O
the	O
top	O
of	O
the	O
greenhouse	O
throughout	O
the	O
day	O
;	O
light	O
irradiance	O
did	O
not	O
exceed	O
40	O
mu	O
mol	O
photons	O
m	O
-	O
2	O
s	O
-	O
1	O
.	O

Only	O
on	O
31	O
August	O
,	O
did	O
the	O
rain	O
stop	O
and	O
the	O
upper	O
part	O
of	O
the	O
liana	O
was	O
exposed	O
to	O
sunshine	O
for	O
1	O
-	O
2	O
h	O
and	O
thus	O
small	O
T	O
and	O
r	O
.	O
h	O
.	O
gradients	O
developed	O
.	O

The	O
following	O
days	O
of	O
2	O
and	O
3	O
September	O
were	O
partly	O
cloudy	O
and	O
sunny	O
and	O
the	O
peaking	O
of	O
T	O
and	O
r	O
.	O
h	O
.	O
occurred	O
at	O
c	O
.	O

13	O
.	O
00	O
h	O
.	O

The	O
upper	O
,	O
but	O
not	O
the	O
lower	O
part	O
of	O
the	O
liana	O
was	O
exposed	O
to	O
sunshine	O
for	O
several	O
hours	O
.	O

This	O
resulted	O
in	O
the	O
formation	O
of	O
T	O
and	O
r	O
.	O
h	O
.	O
gradients	O
.	O

The	O
size	O
of	O
the	O
gradients	O
was	O
similar	O
to	O
that	O
measured	O
on	O
29	O
August	O
.	O

Inspection	O
of	O
Fig	O
.	O

3A	O
indicates	O
that	O
peaking	O
of	O
the	O
Pp	O
values	O
coincided	O
with	O
peaking	O
of	O
r	O
.	O
h	O
.	O
and	O
T	O
in	O
Fig	O
.	O

3B	O
and	O
C	O
.	O

Figure	O
3A	O
shows	O
further	O
that	O
the	O
peak	O
amplitude	O
of	O
the	O
Pp	O
values	O
recorded	O
at	O
the	O
three	O
measuring	O
sites	O
decreased	O
continuously	O
from	O
28	O
August	O
whereas	O
the	O
low	O
Pp	O
values	O
at	O
the	O
nights	O
remained	O
unaltered	O
.	O

The	O
peak	O
amplitude	O
measured	O
on	O
29	O
August	O
was	O
only	O
slightly	O
lower	O
than	O
that	O
measured	O
on	O
the	O
day	O
before	O
,	O
the	O
peak	O
amplitude	O
was	O
rather	O
low	O
on	O
30	O
August	O
.	O

It	O
remained	O
at	O
this	O
low	O
level	O
until	O
2	O
September	O
,	O
except	O
that	O
on	O
31	O
August	O
the	O
peak	O
amplitude	O
at	O
the	O
three	O
measuring	O
sites	O
increased	O
slightly	O
,	O
presumably	O
because	O
of	O
the	O
short	O
-	O
time	O
exposure	O
of	O
the	O
upper	O
leaves	O
to	O
sun	O
(	O
see	O
above	O
)	O
.	O

Comparison	O
of	O
the	O
diurnal	O
changes	O
in	O
the	O
Pp	O
values	O
with	O
the	O
corresponding	O
T	O
and	O
r	O
.	O
h	O
.	O
changes	O
in	O
Fig	O
.	O

3B	O
and	O
C	O
indicates	O
that	O
part	O
of	O
the	O
changes	O
in	O
the	O
peak	O
amplitude	O
of	O
the	O
Pp	O
values	O
were	O
induced	O
by	O
changes	O
in	O
the	O
environmental	O
parameters	O
.	O

However	O
,	O
part	O
of	O
the	O
changes	O
must	O
obviously	O
be	O
attributed	O
to	O
irrigation	O
.	O

This	O
conclusion	O
can	O
be	O
drawn	O
if	O
,	O
for	O
example	O
,	O
the	O
peaking	O
of	O
Pp	O
on	O
2	O
and	O
3	O
September	O
is	O
compared	O
with	O
the	O
peaking	O
of	O
Pp	O
on	O
29	O
August	O
.	O

Despite	O
the	O
comparable	O
size	O
of	O
the	O
T	O
and	O
r	O
.	O
h	O
.	O
gradients	O
,	O
the	O
peak	O
Pp	O
values	O
were	O
much	O
smaller	O
,	O
particularly	O
at	O
0	O
.	O
2	O
m	O
height	O
,	O
on	O
2	O
and	O
3	O
September	O
compared	O
with	O
29	O
August	O
.	O

Plots	O
of	O
the	O
Pp	O
values	O
measured	O
at	O
6	O
m	O
and	O
10	O
m	O
height	O
on	O
24	O
May	O
,	O
28	O
August	O
,	O
and	O
2	O
September	O
against	O
r	O
.	O
h	O
.	O

(	O
or	O
against	O
T	O
since	O
both	O
parameters	O
were	O
usually	O
closely	O
related	O
)	O
also	O
support	O
the	O
view	O
that	O
the	O
local	O
microclimate	O
is	O
not	O
the	O
only	O
factor	O
which	O
determined	O
the	O
magnitude	O
of	O
the	O
Pp	O
values	O
at	O
the	O
three	O
measuring	O
sites	O
.	O

Figure	O
4	O
shows	O
that	O
the	O
Pp	O
values	O
recorded	O
at	O
6	O
m	O
and	O
10	O
m	O
height	O
increased	O
with	O
decreasing	O
r	O
.	O
h	O
.	O
from	O
c	O
.	O

09	O
.	O
00	O
h	O
until	O
r	O
.	O
h	O
.	O
reached	O
the	O
minimum	O
value	O
(	O
and	O
T	O
the	O
maximum	O
value	O
,	O
respectively	O
)	O
,	O
when	O
with	O
the	O
progression	O
of	O
the	O
day	O
r	O
.	O
h	O
.	O
increased	O
and	O
T	O
decreased	O
,	O
Pp	O
decreased	O
again	O
.	O

This	O
decrease	O
was	O
much	O
faster	O
than	O
expected	O
in	O
the	O
light	O
of	O
the	O
preceding	O
r	O
.	O
h	O
.	O
-	O
induced	O
increase	O
of	O
Pp	O
if	O
the	O
plant	O
was	O
well	O
-	O
watered	O
(	O
24	O
May	O
;	O
Fig	O
.	O
4A	O
,	O
B	O
)	O
.	O

Refilling	O
of	O
the	O
leaf	O
cells	O
was	O
apparently	O
enhanced	O
by	O
the	O
high	O
hydration	O
state	O
of	O
the	O
plant	O
.	O

By	O
contrast	O
,	O
when	O
the	O
liana	O
had	O
not	O
been	O
irrigated	O
well	O
(	O
28	O
August	O
,	O
Fig	O
.	O
4C	O
,	O
D	O
)	O
both	O
kinetics	O
of	O
the	O
changes	O
of	O
Pp	O
with	O
r	O
.	O
h	O
.	O
were	O
comparable	O
.	O

The	O
low	O
hydration	O
state	O
of	O
the	O
plant	O
apparently	O
delayed	O
cell	O
refilling	O
.	O

After	O
4	O
d	O
irrigation	O
(	O
2	O
September	O
)	O
,	O
the	O
low	O
value	O
of	O
Pp	O
recovered	O
at	O
relatively	O
low	O
r	O
.	O
h	O
.	O
as	O
in	O
May	O
at	O
10	O
m	O
height	O
(	O
Fig	O
.	O
4F	O
)	O
,	O
but	O
not	O
at	O
6	O
m	O
height	O
(	O
Fig	O
.	O
4E	O
)	O
.	O

Recovery	O
of	O
the	O
low	O
Pp	O
values	O
at	O
this	O
height	O
occurred	O
,	O
however	O
,	O
at	O
significantly	O
lower	O
r	O
.	O
h	O
.	O
than	O
on	O
28	O
August	O
,	O
indicating	O
that	O
rehydration	O
of	O
the	O
leaves	O
at	O
this	O
height	O
had	O
not	O
been	O
completed	O
.	O

Evaluation	O
of	O
other	O
data	O
sets	O
yielded	O
similar	O
results	O
(	O
not	O
shown	O
)	O
.	O

Patch	O
clamp	O
pressure	O
versus	O
cell	O
turgor	O
pressure	O
measurements	O

The	O
leaf	O
patch	O
clamp	O
pressure	O
probe	O
measures	O
the	O
pressure	O
transfer	O
function	O
of	O
a	O
defined	O
leaflet	O
area	O
.	O

The	O
above	O
theoretical	O
considerations	O
have	O
shown	O
that	O
the	O
transfer	O
function	O
is	O
mainly	O
determined	O
by	O
turgor	O
pressure	O
provided	O
that	O
the	O
structural	O
elements	O
do	O
not	O
contribute	O
or	O
constantly	O
contribute	O
to	O
the	O
pressure	O
signal	O
transfer	O
.	O

In	O
order	O
to	O
prove	O
the	O
theory	O
parallel	O
measurements	O
of	O
leaf	O
patch	O
clamp	O
pressure	O
(	O
Pp	O
)	O
and	O
cell	O
turgor	O
pressure	O
(	O
Pc	O
)	O
were	O
performed	O
on	O
a	O
leaflet	O
at	O
0	O
.	O
2	O
m	O
height	O
(	O
Fig	O
.	O
5A	O
)	O
.	O

Simultaneously	O
,	O
the	O
Pp	O
values	O
were	O
recorded	O
at	O
6	O
m	O
and	O
10	O
m	O
height	O
(	O
Fig	O
.	O
5B	O
,	O
C	O
)	O
.	O

Measurements	O
were	O
performed	O
after	O
several	O
days	O
of	O
irrigation	O
.	O

In	O
these	O
experiments	O
,	O
the	O
microcapillary	O
of	O
the	O
turgor	O
pressure	O
probe	O
was	O
inserted	O
into	O
parenchymal	O
cells	O
located	O
close	O
to	O
the	O
main	O
vein	O
on	O
the	O
abaxial	O
side	O
of	O
a	O
leaflet	O
,	O
i	O
.	O
e	O
.	O
c	O
.	O

10	O
cm	O
away	O
from	O
the	O
leaf	O
patch	O
clamp	O
pressure	O
probe	O
near	O
the	O
leaflet	O
periphery	O
.	O

Turgor	O
pressure	O
measurements	O
on	O
leaf	O
cells	O
of	O
T	B-LIVB
.	I-LIVB
voinierianum	I-LIVB
were	O
difficult	O
to	O
perform	O
because	O
of	O
the	O
presence	O
of	O
mucilage	O
.	O

Mucilage	O
resulted	O
in	O
clogging	O
of	O
the	O
tip	O
of	O
the	O
microcapillary	O
of	O
the	O
cell	O
turgor	O
pressure	O
probe	O
.	O

For	O
this	O
reason	O
,	O
measurements	O
with	O
the	O
Scholander	O
pressure	O
chamber	O
were	O
not	O
very	O
reliable	O
.	O

It	O
was	O
extremely	O
difficult	O
to	O
determine	O
exactly	O
the	O
balancing	O
pressure	O
at	O
which	O
water	O
appears	O
at	O
the	O
cut	O
end	O
of	O
the	O
petiole	O
of	O
the	O
leaf	O
.	O

In	O
Fig	O
.	O

5A	O
the	O
average	O
turgor	O
pressure	O
values	O
are	O
plotted	O
which	O
were	O
calculated	O
from	O
3	O
-	O
8	O
min	O
long	O
measurements	O
.	O

Inspection	O
of	O
Fig	O
.	O

5A	O
-	O
C	O
shows	O
that	O
Pc	O
exhibited	O
similar	O
diurnal	O
changes	O
as	O
the	O
Pp	O
values	O
at	O
0	O
.	O
2	O
m	O
,	O
6	O
m	O
,	O
and	O
10	O
m	O
height	O
.	O

Changes	O
in	O
Pc	O
after	O
sunrise	O
preceded	O
changes	O
in	O
Pp	O
,	O
most	O
likely	O
due	O
to	O
the	O
different	O
measuring	O
sites	O
on	O
the	O
leaflets	O
.	O

After	O
the	O
onset	O
of	O
transpiration	O
the	O
loss	O
of	O
turgor	O
pressure	O
of	O
cells	O
located	O
at	O
the	O
periphery	O
of	O
the	O
leaflets	O
(	O
where	O
Pp	O
is	O
recorded	O
)	O
is	O
apparently	O
immediately	O
compensated	O
by	O
water	O
shifting	O
from	O
the	O
xylem	O
and	O
the	O
cells	O
located	O
close	O
to	O
the	O
main	O
vein	O
(	O
where	O
Pc	O
is	O
measured	O
)	O
.	O

Consistent	O
with	O
this	O
explanation	O
,	O
towards	O
the	O
afternoon	O
when	O
all	O
cells	O
throughout	O
the	O
leaflets	O
exhibit	O
low	O
turgor	O
pressure	O
,	O
the	O
increase	O
in	O
Pc	O
and	O
the	O
decrease	O
in	O
Pp	O
occurred	O
nearly	O
concomitantly	O
.	O

Interestingly	O
,	O
the	O
delay	O
between	O
the	O
response	O
of	O
Pc	O
and	O
Pp	O
upon	O
changes	O
in	O
T	O
and	O
r	O
.	O
h	O
.	O
in	O
the	O
early	O
morning	O
hours	O
decreased	O
from	O
about	O
2	O
.	O
5	O
h	O
at	O
0	O
.	O
2	O
m	O
height	O
to	O
1	O
.	O
5	O
h	O
at	O
6	O
m	O
height	O
,	O
and	O
to	O
1	O
h	O
at	O
10	O
m	O
height	O
.	O

In	O
Fig	O
.	O

5D	O
the	O
Pp	O
values	O
measured	O
at	O
the	O
three	O
heights	O
are	O
plotted	O
against	O
the	O
corresponding	O
Pc	O
values	O
(	O
i	O
.	O
e	O
.	O
neglecting	O
the	O
delayed	O
response	O
of	O
Pp	O
)	O
.	O

The	O
curves	O
could	O
be	O
fitted	O
quite	O
well	O
by	O
equation	O
8	O
.	O

Fitting	O
of	O
the	O
curves	O
required	O
the	O
assumption	O
of	O
different	O
values	O
for	O
the	O
constants	O
a	O
and	O
b	O
in	O
equation	O
4	O
(	O
see	O
legend	O
to	O
Fig	O
.	O
5	O
)	O
indicating	O
that	O
the	O
elastic	O
properties	O
of	O
the	O
leaves	O
were	O
different	O
,	O
presumably	O
due	O
to	O
changes	O
of	O
the	O
ambient	O
temperature	O
with	O
height	O
(	O
see	O
above	O
)	O
.	O

Turgor	O
pressure	O
measurements	O
at	O
5	O
m	O
height	O
failed	O
because	O
of	O
abundant	O
mucilage	O
in	O
the	O
leaflet	O
tissue	O
at	O
this	O
time	O
of	O
the	O
year	O
.	O

Mucilage	O
in	O
the	O
cells	O
and	O
xylem	O
vessels	O
was	O
less	O
abundant	O
when	O
turgor	O
pressure	O
measurements	O
were	O
performed	O
during	O
the	O
summer	O
of	O
1999	O
.	O

Plot	O
of	O
the	O
Pc	O
data	O
measured	O
by	O
Th	O
u	O
rmer	O
et	O
al	O
.	O

(	O
1999	O
)	O
at	O
5	O
m	O
height	O
against	O
online	O
recordings	O
of	O
Pp	O
in	O
May	O
2007	O
revealed	O
very	O
good	O
agreement	O
between	O
both	O
parameters	O
,	O
even	O
though	O
the	O
microcapillary	O
was	O
inserted	O
into	O
cells	O
located	O
on	O
the	O
upper	O
leaflet	O
surface	O
between	O
the	O
main	O
vein	O
and	O
the	O
leaflet	O
edge	O
(	O
Fig	O
.	O
6	O
)	O
.	O

On	O
both	O
measuring	O
days	O
in	O
1999	O
and	O
2007	O
,	O
similar	O
environmental	O
conditions	O
existed	O
.	O

Inspection	O
of	O
Fig	O
.	O

6	O
shows	O
that	O
Pp	O
measured	O
at	O
6	O
m	O
height	O
was	O
delayed	O
by	O
c	O
.	O

1	O
.	O
5	O
h	O
.	O

A	O
plot	O
of	O
the	O
Pp	O
values	O
against	O
the	O
Pc	O
values	O
according	O
to	O
Fig	O
.	O

5D	O
could	O
also	O
be	O
fitted	O
very	O
well	O
by	O
equation	O
8	O
(	O
see	O
inset	O
of	O
Fig	O
.	O
6	O
)	O
indicating	O
the	O
validity	O
of	O
equation	O
8	O
to	O
describe	O
properly	O
the	O
relationship	O
between	O
Pp	O
and	O
Pc	O
.	O

Discussion	O

The	O
results	O
presented	O
here	O
demonstrate	O
that	O
the	O
novel	O
patch	O
clamp	O
pressure	O
probe	O
is	O
a	O
very	O
sensitive	O
,	O
versatile	O
,	O
and	O
easy	O
-	O
to	O
-	O
handle	O
plant	O
-	O
based	O
tool	O
for	O
online	O
monitoring	O
of	O
the	O
effects	O
of	O
evapotranspiration	O
and	O
/	O
or	O
of	O
irrigation	O
regimes	O
on	O
the	O
water	O
relations	O
of	O
leaves	O
(	O
Figs	O
2	O
,	O
3	O
)	O
.	O

The	O
probe	O
measures	O
the	O
output	O
signal	O
upon	O
application	O
of	O
a	O
constantly	O
clamped	O
pressure	O
,	O
i	O
.	O
e	O
.	O
the	O
pressure	O
transfer	O
function	O
of	O
leaf	O
patches	O
.	O

Since	O
the	O
application	O
of	O
the	O
probe	O
is	O
not	O
restricted	O
to	O
special	O
leaves	O
,	O
patch	O
clamp	O
pressure	O
measurements	O
will	O
readily	O
show	O
which	O
crop	O
varieties	O
can	O
be	O
grown	O
with	O
the	O
least	O
water	O
for	O
the	O
most	O
yield	O
.	O

It	O
has	O
also	O
been	O
demonstated	O
here	O
that	O
the	O
plant	O
-	O
based	O
data	O
can	O
be	O
sent	O
by	O
small	O
telemetric	O
units	O
connected	O
to	O
the	O
patch	O
clamp	O
pressure	O
probes	O
to	O
a	O
receiver	O
base	O
station	O
which	O
logs	O
and	O
stores	O
the	O
data	O
pending	O
transfer	O
to	O
a	O
GPRS	O
modem	O
linked	O
to	O
an	O
Internet	O
server	O
.	O

The	O
telemetric	O
systems	O
operated	O
faultlessly	O
.	O

This	O
is	O
a	O
very	O
important	O
result	O
because	O
there	O
is	O
agreement	O
between	O
scientists	O
and	O
growers	O
(	O
Jones	O
,	O
2004	O
)	O
that	O
control	O
of	O
irrigation	O
must	O
be	O
tied	O
to	O
remote	O
sensing	O
devices	O
in	O
order	O
to	O
reduce	O
manpower	O
and	O
to	O
conserve	O
water	O
.	O

The	O
patch	O
clamp	O
pressure	O
probe	O
technique	O
introduced	O
here	O
meets	O
these	O
demands	O
.	O

A	O
further	O
advantage	O
is	O
that	O
the	O
probe	O
is	O
cheap	O
and	O
easy	O
to	O
handle	O
.	O

Some	O
care	O
is	O
required	O
only	O
when	O
clamping	O
the	O
leaf	O
.	O

Leaves	O
must	O
be	O
clean	O
and	O
any	O
rough	O
surface	O
topography	O
must	O
be	O
avoided	O
.	O

This	O
implies	O
that	O
the	O
dimensions	O
of	O
the	O
pads	O
of	O
the	O
spring	O
clamp	O
must	O
be	O
adjusted	O
to	O
the	O
size	O
of	O
the	O
intercostal	O
area	O
since	O
non	O
-	O
uniform	O
contact	O
between	O
leaf	O
surface	O
and	O
pads	O
lowered	O
the	O
output	O
pressure	O
signal	O
.	O

Experience	O
collected	O
with	O
patch	O
clamp	O
pressure	O
measurements	O
on	O
T	B-LIVB
.	I-LIVB
voinierianum	I-LIVB
and	O
on	O
preliminary	O
results	O
of	O
other	O
plants	O
(	O
e	O
.	O
g	O
.	O
grapevines	O
,	O
bananas	B-LIVB
,	O
Eucalyptus	O
,	O
and	O
Arabidopsis	O
)	O
showed	O
that	O
a	O
smooth	O
intercostal	O
leaf	O
area	O
for	O
clamping	O
can	O
readily	O
be	O
found	O
.	O

Equally	O
,	O
optimum	O
values	O
for	O
the	O
clamp	O
pressure	O
can	O
also	O
be	O
relatively	O
quickly	O
selected	O
empirically	O
if	O
the	O
guidelines	O
mentioned	O
above	O
are	O
followed	O
.	O

For	O
many	O
purposes	O
calibration	O
of	O
the	O
leaf	O
patch	O
clamp	O
pressure	O
probe	O
against	O
the	O
cell	O
turgor	O
pressure	O
probe	O
is	O
not	O
stringent	O
.	O

It	O
may	O
be	O
sufficient	O
to	O
know	O
that	O
the	O
transfer	O
function	O
assumes	O
small	O
values	O
at	O
full	O
turgescence	O
and	O
is	O
nearly	O
unity	O
at	O
low	O
turgescence	O
.	O

However	O
,	O
for	O
scientific	O
reasons	O
and	O
for	O
the	O
application	O
of	O
the	O
probe	O
in	O
basic	O
research	O
,	O
the	O
dependency	O
of	O
the	O
transfer	O
function	O
on	O
cell	O
turgor	O
pressure	O
might	O
be	O
of	O
great	O
interest	O
.	O

The	O
theoretical	O
considerations	O
have	O
demonstrated	O
that	O
the	O
relationship	O
between	O
the	O
transfer	O
function	O
and	O
the	O
turgor	O
pressure	O
can	O
obviously	O
be	O
described	O
by	O
equation	O
8	O
,	O
i	O
.	O
e	O
.	O
by	O
a	O
power	O
function	O
.	O

Concomitant	O
measurements	O
of	O
turgor	O
pressure	O
and	O
patch	O
clamp	O
pressure	O
have	O
confirmed	O
the	O
theoretical	O
considerations	O
(	O
Fig	O
.	O
5	O
)	O
.	O

Analogous	O
recordings	O
of	O
turgor	O
pressure	O
and	O
patch	O
clamp	O
pressure	O
on	O
grapevines	O
,	O
bananas	B-LIVB
,	O
and	O
Eucalyptus	B-LIVB
trees	O
also	O
yielded	O
results	O
(	O
D	O
Zimmermann	O
,	O
unpublished	O
results	O
)	O
which	O
were	O
consistent	O
with	O
the	O
predictions	O
of	O
equation	O
8	O
.	O

Patch	O
clamp	O
pressure	O
measurements	O
allow	O
,	O
therefore	O
,	O
calculation	O
of	O
turgor	O
pressures	O
if	O
the	O
constants	O
a	O
and	O
b	O
defined	O
by	O
equation	O
4	O
are	O
known	O
.	O

These	O
parameters	O
can	O
be	O
obtained	O
by	O
numerical	O
fitting	O
of	O
Pp	O
versus	O
Pc	O
curves	O
.	O

Online	O
patch	O
clamp	O
pressure	O
measurements	O
open	O
up	O
new	O
possibilities	O
to	O
unravel	O
the	O
hydraulic	O
communication	O
among	O
leaves	O
,	O
including	O
tall	O
trees	O
.	O

It	O
is	O
shown	O
here	O
that	O
the	O
patch	O
clamp	O
pressure	O
can	O
simultaneously	O
be	O
monitored	O
in	O
shaded	O
or	O
sun	O
-	O
exposed	O
leaflets	O
at	O
different	O
heights	O
under	O
greenhouse	O
conditions	O
by	O
using	O
several	O
probes	O
.	O

It	O
was	O
even	O
possible	O
to	O
measure	O
the	O
turgor	O
pressure	O
at	O
different	O
sites	O
on	O
the	O
leaf	O
.	O

Therefore	O
,	O
water	O
shifting	O
between	O
leaf	O
cells	O
via	O
the	O
apoplastic	O
and	O
symplastic	O
pathways	O
can	O
be	O
studied	O
.	O

Physically	O
sound	O
theories	O
are	O
available	O
(	O
Molz	O
and	O
Ikenberry	O
,	O
1974	O
;	O
Molz	O
et	O
al	O
.	O
,	O
1979	O
)	O
,	O
but	O
experimental	O
facts	O
are	O
not	O
available	O
or	O
are	O
mainly	O
based	O
on	O
speculations	O
(	O
Steudle	O
and	O
French	O
,	O
1996	O
)	O
.	O

The	O
first	O
evidence	O
for	O
the	O
dynamics	O
of	O
the	O
hydraulic	O
communication	O
between	O
leaflets	O
at	O
different	O
height	O
and	O
within	O
leaflets	O
is	O
given	O
here	O
.	O

Th	O
u	O
rmer	O
et	O
al	O
.	O

(	O
1999	O
)	O
have	O
shown	O
by	O
using	O
the	O
xylem	O
and	O
turgor	O
pressure	O
probe	O
that	O
the	O
decrease	O
in	O
local	O
xylem	O
pressure	O
after	O
daybreak	O
from	O
positive	O
,	O
sub	O
-	O
atmospheric	O
or	O
slightly	O
above	O
-	O
atmospheric	O
values	O
to	O
negative	O
values	O
was	O
associated	O
with	O
an	O
almost	O
1	O
:	O
1	O
decrease	O
in	O
turgor	O
pressure	O
of	O
the	O
cells	O
located	O
close	O
to	O
the	O
main	O
vein	O
of	O
the	O
leaflets	O
(	O
see	O
also	O
Zimmermann	O
et	O
al	O
.	O
,	O
2004	O
)	O
.	O

Similarly	O
,	O
in	O
the	O
afternoon	O
,	O
the	O
increase	O
of	O
xylem	O
pressure	O
in	O
non	O
-	O
cavitated	O
vessels	O
towards	O
more	O
positive	O
values	O
correlated	O
with	O
a	O
1	O
:	O
1	O
increase	O
in	O
cell	O
turgor	O
pressure	O
.	O

Obviously	O
,	O
changes	O
in	O
transpiration	O
resulted	O
in	O
a	O
very	O
rapid	O
establishment	O
of	O
a	O
new	O
local	O
water	O
equilibrium	O
state	O
between	O
the	O
xylem	O
and	O
the	O
turgor	O
pressure	O
of	O
the	O
adjacent	O
cells	O
.	O

The	O
turgor	O
pressure	O
measurements	O
of	O
Th	O
u	O
rmer	O
et	O
al	O
.	O

(	O
1999	O
)	O
were	O
performed	O
at	O
1	O
m	O
and	O
5	O
m	O
height	O
.	O

No	O
significant	O
differences	O
in	O
the	O
turgor	O
pressure	O
values	O
were	O
found	O
over	O
the	O
day	O
.	O

The	O
turgor	O
pressure	O
measurements	O
at	O
0	O
.	O
2	O
m	O
height	O
reported	O
here	O
confirmed	O
the	O
finding	O
of	O
Th	O
u	O
rmer	O
et	O
al	O
.	O

(	O
1999	O
)	O
that	O
the	O
turgor	O
pressure	O
in	O
the	O
cells	O
located	O
near	O
the	O
main	O
vein	O
dropped	O
immediately	O
upon	O
daybreak	O
.	O

However	O
,	O
our	O
patch	O
clamp	O
pressure	O
measurements	O
at	O
the	O
periphery	O
of	O
the	O
leaflets	O
imply	O
that	O
the	O
turgor	O
pressure	O
of	O
these	O
cells	O
apparently	O
had	O
a	O
significantly	O
delayed	O
response	O
upon	O
the	O
onset	O
of	O
transpiration	O
.	O

This	O
finding	O
can	O
be	O
taken	O
as	O
evidence	O
that	O
turgor	O
pressure	O
gradients	O
are	O
temporarily	O
generated	O
within	O
the	O
leaf	O
during	O
the	O
early	O
morning	O
hours	O
.	O

This	O
delay	O
in	O
the	O
response	O
of	O
patch	O
clamp	O
pressure	O
after	O
daybreak	O
was	O
c	O
.	O

1	O
h	O
for	O
leaves	O
at	O
the	O
top	O
,	O
but	O
c	O
.	O

2	O
.	O
5	O
h	O
for	O
leaves	O
at	O
the	O
base	O
.	O

The	O
data	O
suggest	O
that	O
with	O
progression	O
of	O
the	O
day	O
the	O
gradients	O
collapsed	O
first	O
at	O
the	O
top	O
of	O
the	O
liana	O
,	O
where	O
transpiration	O
was	O
high	O
,	O
before	O
it	O
occurred	O
in	O
leaves	O
further	O
down	O
.	O

During	O
the	O
afternoon	O
hours	O
the	O
increase	O
in	O
the	O
turgor	O
pressure	O
values	O
measured	O
close	O
to	O
the	O
main	O
vein	O
coincided	O
with	O
the	O
values	O
measured	O
by	O
the	O
patch	O
clamp	O
pressure	O
probe	O
(	O
Fig	O
.	O
5	O
)	O
.	O

The	O
unbalanced	O
osmotic	O
pressure	O
throughout	O
the	O
leaflets	O
obviously	O
favoured	O
simultaneous	O
turgor	O
pressure	O
regeneration	O
in	O
all	O
leaflet	O
cells	O
.	O

The	O
process	O
seemed	O
to	O
be	O
very	O
similar	O
to	O
the	O
refilling	O
of	O
the	O
cells	O
of	O
the	O
resurrection	O
plant	O
Myrothamnus	B-LIVB
flabellifolia	I-LIVB
with	O
water	O
after	O
desiccation	O
(	O
Wagner	O
et	O
al	O
.	O
,	O
2000	O
)	O
.	O

Uniform	O
radial	O
refilling	O
of	O
cells	O
with	O
water	O
in	O
this	O
species	O
is	O
also	O
driven	O
by	O
the	O
unbalanced	O
osmotic	O
pressure	O
throughout	O
the	O
tissue	O
.	O

As	O
indicated	O
by	O
Fig	O
.	O

4A	O
and	O
B	O
,	O
restoration	O
of	O
full	O
turgescence	O
in	O
T	B-LIVB
.	I-LIVB
voinierianum	I-LIVB
was	O
faster	O
than	O
the	O
preceding	O
turgor	O
pressure	O
loss	O
if	O
the	O
lianas	O
were	O
well	O
-	O
watered	O
.	O

By	O
contrast	O
,	O
limitations	O
in	O
water	O
supply	O
resulted	O
in	O
the	O
coincidence	O
of	O
the	O
phases	O
of	O
turgor	O
pressure	O
loss	O
and	O
regeneration	O
.	O

Interestingly	O
,	O
watering	O
of	O
the	O
lianas	O
after	O
non	O
-	O
irrigation	O
seemed	O
to	O
lead	O
preferentially	O
to	O
water	O
shifting	O
to	O
the	O
top	O
of	O
the	O
plant	O
,	O
because	O
,	O
after	O
3	O
d	O
of	O
irrigation	O
,	O
turgor	O
pressure	O
regeneration	O
during	O
the	O
afternoon	O
was	O
very	O
fast	O
again	O
at	O
10	O
m	O
height	O
(	O
Fig	O
.	O
4F	O
)	O
,	O
but	O
not	O
at	O
5	O
m	O
height	O
(	O
Fig	O
.	O
4E	O
)	O
.	O

Rapid	O
water	O
movement	O
to	O
the	O
top	O
is	O
expected	O
if	O
hydrostatic	O
pressure	O
,	O
osmotic	O
pressure	O
,	O
and	O
/	O
or	O
gel	O
-	O
based	O
gradients	O
throughout	O
the	O
vessels	O
exist	O
or	O
are	O
generated	O
rapidly	O
in	O
the	O
afternoon	O
when	O
cavitation	O
has	O
occurred	O
.	O

This	O
was	O
demonstrated	O
by	O
Benkert	O
et	O
al	O
.	O

(	O
1995	O
)	O
and	O
Th	O
u	O
rmer	O
et	O
al	O
.	O

(	O
1999	O
)	O
by	O
using	O
the	O
xylem	O
pressure	O
probe	O
.	O

Continuous	O
xylem	O
pressure	O
gradients	O
during	O
the	O
morning	O
hours	O
can	O
also	O
explain	O
why	O
changes	O
in	O
Pp	O
at	O
lower	O
heights	O
were	O
frequently	O
found	O
which	O
could	O
not	O
be	O
correlated	O
with	O
changes	O
in	O
local	O
temperature	O
or	O
relative	O
humidity	O
.	O

Water	O
loss	O
at	O
the	O
top	O
of	O
the	O
plant	O
induces	O
a	O
drop	O
in	O
xylem	O
pressure	O
which	O
is	O
transferred	O
rapidly	O
to	O
the	O
basal	O
leaves	O
where	O
it	O
induces	O
a	O
temporary	O
turgor	O
pressure	O
loss	O
that	O
is	O
soon	O
compensated	O
by	O
water	O
uptake	O
from	O
the	O
roots	O
(	O
arrow	O
in	O
Fig	O
.	O
2	O
)	O
.	O

Even	O
though	O
more	O
work	O
is	O
required	O
,	O
the	O
present	O
study	O
shows	O
that	O
the	O
leaf	O
patch	O
clamp	O
pressure	O
probe	O
is	O
a	O
promising	O
tool	O
to	O
elucidate	O
short	O
-	O
and	O
long	O
-	O
distance	O
water	O
transport	O
in	O
T	B-LIVB
.	I-LIVB
voinierianum	I-LIVB
and	O
other	O
plants	O
.	O

CHEK2	O
Mutations	O
Affecting	O
Kinase	O
Activity	O
Together	O
With	O
Mutations	O
in	O
TP53	O
Indicate	O
a	O
Functional	O
Pathway	O
Associated	O
with	O
Resistance	O
to	O
Epirubicin	O
in	O
Primary	O
Breast	O
Cancer	O

Abstract	O

Background	O

Chemoresistance	O
is	O
the	O
main	O
obstacle	O
to	O
cure	O
in	O
most	O
malignant	O
diseases	O
.	O

Anthracyclines	O
are	O
among	O
the	O
main	O
drugs	O
used	O
for	O
breast	O
cancer	O
therapy	O
and	O
in	O
many	O
other	O
malignant	O
conditions	O
.	O

Single	O
parameter	O
analysis	O
or	O
global	O
gene	O
expression	O
profiles	O
have	O
failed	O
to	O
identify	O
mechanisms	O
causing	O
in	O
vivo	O
resistance	O
to	O
anthracyclines	O
.	O

While	O
we	O
previously	O
found	O
TP53	O
mutations	O
in	O
the	O
L2	O
/	O
L3	O
domains	O
to	O
be	O
associated	O
with	O
drug	O
resistance	O
,	O
some	O
tumors	O
harboring	O
wild	O
-	O
type	O
TP53	O
were	O
also	O
therapy	O
resistant	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
;	O
1	O
)	O
To	O
explore	O
alterations	O
in	O
the	O
TP53	O
gene	O
with	O
respect	O
to	O
resistance	O
to	O
a	O
regular	O
dose	O
epirubicin	O
regimen	O
(	O
90	O
mg	O
/	O
m2	O
every	O
3	O
week	O
)	O
in	O
patients	B-LIVB
with	O
primary	O
,	O
locally	O
advanced	O
breast	O
cancer	O
;	O
2	O
)	O
Identify	O
critical	O
mechanisms	O
activating	O
p53	O
in	O
response	O
to	O
DNA	O
damage	O
in	O
breast	O
cancer	O
;	O
3	O
)	O
Evaluate	O
in	O
vitro	O
function	O
of	O
Chk2	O
and	O
p14	O
proteins	O
corresponding	O
to	O
identified	O
mutations	O
in	O
the	O
CHEK2	O
and	O
p14	O
(	O
ARF	O
)	O
genes	O
;	O
and	O
4	O
)	O
Explore	O
potential	O
CHEK2	O
or	O
p14	O
(	O
ARF	O
)	O
germline	O
mutations	O
with	O
respect	O
to	O
family	O
cancer	O
incidence	O
.	O

Methods	O
and	O
Findings	O

Snap	O
-	O
frozen	O
biopsies	O
from	O
109	O
patients	B-LIVB
collected	O
prior	O
to	O
epirubicin	O
(	O
as	O
preoperative	O
therapy	O
were	O
investigated	O
for	O
TP53	O
,	O
CHEK2	O
and	O
p14	O
(	O
ARF	O
)	O
mutations	O
by	O
sequencing	O
the	O
coding	O
region	O
and	O
p14	O
(	O
ARF	O
)	O
promoter	O
methylations	O
.	O

TP53	O
mutastions	O
were	O
associated	O
with	O
chemoresistance	O
,	O
defined	O
as	O
progressive	O
disease	O
on	O
therapy	O
(	O
p	O
=	O
0	O
.	O
0358	O
;	O
p	O
=	O
0	O
.	O
0136	O
for	O
mutations	O
affecting	O
p53	O
loop	O
domains	O
L2	O
/	O
L3	O
)	O
.	O

Germline	O
CHEK2	O
mutations	O
(	O
n	O
=	O
3	O
)	O
were	O
associated	O
with	O
therapy	O
resistance	O
(	O
p	O
=	O
0	O
.	O
0226	O
)	O
.	O

Combined	O
,	O
mutations	O
affecting	O
either	O
CHEK2	O
or	O
TP53	O
strongly	O
predicted	O
therapy	O
resistance	O
(	O
p	O
=	O
0	O
.	O
0101	O
;	O
TP53	O
mutations	O
restricted	O
to	O
the	O
L2	O
/	O
L3	O
domains	O
:	O
p	O
=	O
0	O
.	O
0032	O
)	O
.	O

Two	O
patients	B-LIVB
progressing	O
on	O
therapy	O
harbored	O
the	O
CHEK2	O
mutation	O
,	O
Arg95Ter	O
,	O
completely	O
abrogating	O
Chk2	O
protein	O
dimerization	O
and	O
kinase	O
activity	O
.	O

One	O
patient	B-LIVB
(	O
Epi132	O
)	O
revealed	O
family	O
cancer	O
occurrence	O
resembling	O
families	O
harboring	O
CHEK2	O
mutations	O
in	O
general	O
,	O
the	O
other	O
patient	B-LIVB
(	O
epi203	O
)	O
was	O
non	O
-	O
conclusive	O
.	O

No	O
mutation	O
or	O
promoter	O
hypermethylation	O
in	O
p14	O
(	O
ARF	O
)	O
were	O
detected	O
.	O

Conclusion	O

This	O
study	O
is	O
the	O
first	O
reporting	O
an	O
association	O
between	O
CHEK2	O
mutations	O
and	O
therapy	O
resistance	O
in	O
human	B-LIVB
cancers	O
and	O
to	O
document	O
mutations	O
in	O
two	O
genes	O
acting	O
direct	O
up	O
/	O
down	O
-	O
stream	O
to	O
each	O
other	O
to	O
cause	O
therapy	O
failure	O
,	O
emphasizing	O
the	O
need	O
to	O
investigate	O
functional	O
cascades	O
in	O
future	O
studies	O
.	O

Introduction	O

Chemoresistance	O
is	O
the	O
main	O
obstacle	O
to	O
cure	O
in	O
most	O
malignancies	O
,	O
including	O
breast	O
cancer	O
.	O

While	O
adjuvant	O
chemotherapy	O
may	O
reduce	O
the	O
hazard	O
rate	O
of	O
relapse	O
by	O
about	O
one	O
third	O
in	O
breast	O
cancer	O
patients	B-LIVB
[	O
1	O
]	O
,	O
the	O
majority	O
among	O
patients	B-LIVB
harboring	O
micro	O
-	O
metastases	O
are	O
not	O
cured	O
by	O
today	O
'	O
s	O
standards	O
.	O

Considering	O
patients	B-LIVB
harboring	O
distant	O
metastases	O
,	O
resistance	O
and	O
therapy	O
failure	O
inevitably	O
occurs	O
,	O
in	O
general	O
over	O
a	O
time	O
period	O
of	O
less	O
than	O
one	O
year	O
for	O
each	O
individual	O
regimen	O
[	O
2	O
]	O
.	O

Despite	O
extensive	O
experimental	O
research	O
[	O
3	O
]	O
,	O
little	O
data	O
are	O
available	O
considering	O
chemoresistance	O
in	O
vivo	O
.	O

For	O
anthracycline	O
therapy	O
in	O
breast	O
cancer	O
,	O
topoisomerase	O
-	O
II	O
amplifications	O
have	O
been	O
associated	O
with	O
a	O
dose	O
-	O
responsiveness	O
different	O
from	O
what	O
is	O
observed	O
in	O
non	O
-	O
amplified	O
tumors	O
4	O
,	O
5	O
.	O

Several	O
studies	O
have	O
tried	O
to	O
generate	O
"	O
prediction	O
profiles	O
"	O
based	O
on	O
gene	O
expression	O
microarrays	O
[	O
6	O
]	O
,	O
[	O
7	O
]	O
,	O
[	O
8	O
]	O
,	O
however	O
,	O
none	O
of	O
the	O
different	O
profiles	O
generated	O
expressed	O
a	O
sensitivity	O
suitable	O
for	O
clinical	O
applications	O
,	O
or	O
have	O
been	O
successfully	O
reproduced	O
by	O
others	O
(	O
see	O
references	O
to	O
original	O
works	O
in	O
[	O
9	O
]	O
and	O
[	O
10	O
]	O
)	O
.	O

p53	O
(	O
the	O
protein	O
encoded	O
by	O
the	O
TP53	O
gene	O
)	O
plays	O
a	O
key	O
role	O
in	O
executing	O
DNA	O
-	O
damage	O
induced	O
apoptosis	O
and	O
growth	O
arrest	O
[	O
11	O
]	O
.	O

Previously	O
,	O
our	O
group	O
reported	O
mutations	O
in	O
the	O
zink	O
-	O
binding	O
domains	O
L2	O
(	O
codons	O
163	O
-	O
195	O
)	O
and	O
L3	O
(	O
codons	O
236	O
-	O
251	O
)	O
of	O
p53	O
critical	O
to	O
DNA	O
binding	O
[	O
12	O
]	O
to	O
be	O
associated	O
with	O
but	O
not	O
fully	O
predictive	O
for	O
resistance	O
to	O
chemotherapy	O
with	O
a	O
low	O
-	O
dose	O
weekly	O
anthracycline	O
[	O
13	O
]	O
or	O
a	O
mitomycin	O
plus	O
5	O
-	O
fluoro	O
-	O
uracil	O
containing	O
[	O
14	O
]	O
regimen	O
.	O

Similar	O
findings	O
were	O
reported	O
by	O
another	O
group	O
[	O
15	O
]	O
.	O

In	O
contrast	O
,	O
others	O
reported	O
TP53	O
mutations	O
to	O
predict	O
sensitivity	O
to	O
a	O
dose	O
-	O
dense	O
epirubicin	O
-	O
cyclophosphamide	O
regimen	O
[	O
16	O
]	O
.	O

The	O
finding	O
that	O
some	O
tumors	O
harboring	O
wild	O
-	O
type	O
TP53	O
may	O
be	O
resistant	O
to	O
anthracycline	O
therapy	O
lead	O
us	O
to	O
postulate	O
that	O
other	O
genes	O
involved	O
in	O
the	O
p53	O
pathway	O
could	O
be	O
mutated	O
in	O
these	O
tumors	O
[	O
3	O
]	O
.	O

p53	O
is	O
activated	O
by	O
post	O
-	O
translational	O
modifications	O
,	O
and	O
the	O
protein	O
is	O
phosphorylated	O
at	O
multiple	O
amino	O
acids	O
[	O
17	O
]	O
.	O

Phosphorylation	O
at	O
Ser	O
20	O
(	O
Ser	O
23	O
in	O
mice	B-LIVB
)	O
by	O
the	O
Chk2	O
protein	O
(	O
coded	O
by	O
the	O
CHEK2	O
gene	O
)	O
in	O
response	O
to	O
DNA	O
damage	O
activates	O
p53	O
by	O
inhibiting	O
binding	O
to	O
,	O
and	O
deactivation	O
by	O
,	O
the	O
MDM2	O
(	O
Mouse	B-LIVB
Minute	O
2	O
homolog	O
;	O
HDM2	O
)	O
protein	O
[	O
18	O
]	O
,	O
[	O
19	O
]	O
,	O
[	O
20	O
]	O
.	O

While	O
experimental	O
studies	O
have	O
suggested	O
a	O
critical	O
role	O
of	O
Chk2	O
in	O
activating	O
p53	O
apoptotic	O
response	O
to	O
genotoxic	O
stress	O
[	O
21	O
]	O
,	O
[	O
22	O
]	O
,	O
others	O
claim	O
Chk2	O
to	O
be	O
dispensable	O
for	O
p53	O
activation	O
with	O
respect	O
to	O
apoptosis	O
as	O
well	O
as	O
growth	O
arrest	O
[	O
23	O
]	O
.	O

Following	O
an	O
initial	O
report	O
of	O
a	O
CHEK2	O
germline	O
mutation	O
in	O
a	O
family	O
filling	O
the	O
characteristics	O
of	O
a	O
Li	O
-	O
Fraumeni	O
syndrome	O
(	O
LFS	O
)	O
[	O
24	O
]	O
,	O
recent	O
papers	O
have	O
suggested	O
germline	O
mutations	O
in	O
CHEK2	O
to	O
be	O
associated	O
with	O
a	O
moderately	O
increased	O
risk	O
of	O
breast	O
and	O
colon	O
cancers	O
(	O
see	O
references	O
in	O
[	O
25	O
]	O
)	O
.	O

Recently	O
,	O
we	O
discovered	O
a	O
somatic	O
,	O
nonsense	O
CHEK2	O
mutation	O
in	O
a	O
single	O
patient	B-LIVB
expressing	O
resistance	O
to	O
doxorubicin	O
low	O
dose	O
therapy	O
[	O
26	O
]	O
.	O

A	O
second	O
mechanism	O
of	O
p53	O
activation	O
is	O
through	O
p14	O
(	O
ARF	O
)	O
(	O
p19	O
in	O
mice	B-LIVB
)	O
function	O
.	O

p14	O
(	O
ARF	O
)	O
does	O
not	O
phosphorylate	O
p53	O
,	O
but	O
inhibits	O
MDM2	O
dependent	O
p53	O
degradation	O
through	O
direct	O
MDM2	O
binding	O
.	O

While	O
p14	O
(	O
ARF	O
)	O
-	O
mediated	O
p53	O
activation	O
has	O
been	O
linked	O
to	O
oncogene	O
-	O
induced	O
p53	O
activation	O
and	O
,	O
in	O
general	O
,	O
considered	O
not	O
involved	O
in	O
response	O
to	O
DNA	O
damage	O
(	O
see	O
references	O
in	O
[	O
27	O
]	O
)	O
,	O
p14	O
(	O
ARF	O
)	O
may	O
be	O
activated	O
through	O
the	O
E2F1	O
/	O
retinoblastoma	O
pathway	O
[	O
28	O
]	O
.	O

Importantly	O
,	O
two	O
recent	O
studies	O
revealed	O
lack	O
of	O
p19	O
(	O
mouse	B-LIVB
homologue	O
of	O
human	B-LIVB
p14	O
(	O
ARF	O
)	O
)	O
function	O
in	O
mice	B-LIVB
to	O
inhibit	O
p53	O
tumor	O
suppressor	O
function	O
in	O
response	O
to	O
ionizing	O
radiation	O
as	O
well	O
as	O
DNA	O
damaging	O
agents	O
[	O
29	O
]	O
,	O
[	O
30	O
]	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
1	O
)	O
to	O
explore	O
alterations	O
in	O
the	O
TP53	O
gene	O
with	O
respect	O
to	O
resistance	O
to	O
a	O
regular	O
dose	O
epirubicin	O
regimen	O
(	O
90	O
mg	O
/	O
m2	O
body	O
surface	O
every	O
3	O
week	O
)	O
in	O
patient	B-LIVB
with	O
primary	O
,	O
locally	O
advanced	O
,	O
breast	O
cancer	O
;	O
2	O
)	O
To	O
explore	O
defects	O
in	O
potential	O
mechanisms	O
activating	O
p53	O
in	O
response	O
to	O
DNA	O
damage	O
in	O
breast	O
cancer	O
as	O
a	O
cause	O
of	O
drug	O
resistance	O
in	O
wild	O
-	O
type	O
tumors	O
.	O

To	O
do	O
so	O
,	O
we	O
sequenced	O
the	O
complete	O
coding	O
regions	O
for	O
the	O
CHEK2	O
and	O
p14	O
(	O
ARF	O
)	O
genes	O
and	O
analyzed	O
for	O
p14	O
(	O
ARF	O
)	O
promoter	O
hypermetylations	O
;	O
3	O
)	O
Evaluate	O
in	O
vitro	O
function	O
of	O
potential	O
Chk2	O
and	O
p14	O
(	O
ARF	O
)	O
protein	O
translates	O
corresponding	O
to	O
identified	O
mutations	O
in	O
the	O
CHEK2	O
and	O
p14	O
(	O
ARF	O
)	O
genes	O
;	O
4	O
)	O
Identify	O
potential	O
TP53	O
,	O
CHEK2	O
and	O
p14	O
(	O
ARF	O
)	O
mutations	O
to	O
be	O
germline	O
,	O
explore	O
the	O
incidence	O
of	O
different	O
cancers	O
among	O
affected	O
relatives	O
with	O
respect	O
to	O
specific	O
mutations	O
.	O

By	O
comparing	O
in	O
vitro	O
characteristics	O
of	O
specific	O
mutations	O
to	O
drug	O
sensitivity	O
and	O
family	O
cancer	O
risk	O
syndromes	O
,	O
this	O
may	O
add	O
to	O
our	O
understanding	O
of	O
the	O
importance	O
of	O
these	O
gene	O
cascades	O
executing	O
response	O
to	O
DNA	O
damage	O
versus	O
tumor	O
suppression	O
activity	O
.	O

Analyzing	O
tumor	O
samples	O
from	O
a	O
total	O
of	O
109	O
primary	O
locally	O
advanced	O
breast	O
cancer	O
patients	B-LIVB
treated	O
with	O
epirubicin	O
90mg	O
/	O
3	O
weekly	O
,	O
we	O
found	O
TP53	O
mutations	O
affecting	O
the	O
L2	O
/	O
L3	O
domains	O
or	O
protein	O
dimerization	O
,	O
as	O
well	O
as	O
non	O
-	O
functional	O
CHEK2	O
mutations	O
abrogating	O
dimerization	O
and	O
phosphorylation	O
,	O
to	O
be	O
associated	O
with	O
therapy	O
resistance	O
;	O
no	O
mutation	O
or	O
promoter	O
hypermethylations	O
of	O
the	O
p14	O
(	O
ARF	O
)	O
gene	O
was	O
discovered	O
.	O

Our	O
findings	O
suggest	O
a	O
critical	O
role	O
for	O
Chk2	O
with	O
respect	O
to	O
DNA	O
-	O
damage	O
-	O
dependent	O
p53	O
activation	O
and	O
resistance	O
to	O
anthracycline	O
therapy	O
in	O
human	B-LIVB
breast	O
cancer	O
.	O

Materials	O
and	O
Methods	O

Patients	B-LIVB

A	O
total	O
of	O
223	O
patients	B-LIVB
with	O
locally	O
advanced	O
non	O
-	O
inflammatory	O
breast	O
cancer	O
(	O
T3	O
-	O
4	O
and	O
/	O
or	O
N2	O
)	O
were	O
randomly	O
allocated	O
to	O
primary	O
treatment	O
either	O
with	O
epirubicin	O
90	O
mg	O
/	O
m2	O
or	O
paclitaxel	O
200	O
mg	O
/	O
m2	O
.	O

The	O
primary	O
aim	O
of	O
the	O
study	O
was	O
identification	O
of	O
markers	O
predicting	O
drug	O
resistance	O
to	O
the	O
regimens	O
.	O

Thus	O
,	O
the	O
reason	O
for	O
randomizing	O
patients	B-LIVB
was	O
not	O
for	O
effect	O
comparison	O
,	O
but	O
to	O
achieve	O
similar	O
patient	B-LIVB
cohorts	O
in	O
the	O
two	O
arms	O
.	O

Based	O
on	O
the	O
findings	O
of	O
a	O
clinical	O
lack	O
of	O
cross	O
-	O
resistance	O
between	O
anthracyclines	O
and	O
taxane	O
therapies	O
in	O
breast	O
cancer	O
[	O
31	O
]	O
,	O
we	O
hypothesized	O
the	O
mechanisms	O
of	O
resistance	O
to	O
be	O
different	O
between	O
the	O
two	O
compounds	O
.	O

While	O
the	O
analysis	O
of	O
tumor	O
samples	O
from	O
the	O
paclitaxel	O
is	O
ongoing	O
,	O
we	O
here	O
report	O
our	O
findings	O
from	O
the	O
patients	B-LIVB
allocated	O
to	O
the	O
epirubicin	O
arm	O
.	O

The	O
epirubicin	O
arm	O
included	O
a	O
total	O
of	O
109	O
patients	B-LIVB
(	O
age	O
28	O
to	O
70	O
years	O
,	O
median	O
51	O
years	O
)	O
.	O

Two	O
patients	B-LIVB
were	O
analyzed	O
for	O
gene	O
mutations	O
but	O
omitted	O
from	O
statistical	O
analysis	O
as	O
protocol	O
violators	O
;	O
histopathological	O
examination	O
revealed	O
one	O
patient	B-LIVB
(	O
Epi089	O
)	O
to	O
harbor	O
a	O
sarcomatoid	O
tumor	O
,	O
while	O
one	O
patient	B-LIVB
Epi232	O
was	O
erroneously	O
enrolled	O
with	O
stage	O
II	O
disease	O
.	O

The	O
study	O
protocol	O
was	O
approved	O
by	O
the	O
Regional	O
Ethical	O
Committee	O
(	O
Norwegian	O
Health	O
Region	O
III	O
)	O
,	O
including	O
formal	O
Biobank	O
registration	O
in	O
accordance	O
to	O
Norwegian	O
law	O
.	O

The	O
study	O
and	O
protocol	O
is	O
registered	O
under	O
the	O
Norwegian	O
Social	O
Science	O
Data	O
services	O
(	O
(	O
www	O
.	O
nsd	O
/	O
uib	O
/	O
personvern	O
/	O
database	O
/	O
)	O
,	O
University	O
of	O
Bergen	O
project	O
no	O
16297	O
and	O
Helse	O
Bergen	O
project	O
no	O
13025	O
)	O
.	O

Each	O
patient	B-LIVB
gave	O
written	O
informed	O
consent	O
.	O

Tissue	O
Sampling	O

Before	O
commencing	O
chemotherapy	O
,	O
each	O
patient	B-LIVB
had	O
an	O
incisional	O
tumor	O
biopsy	O
as	O
described	O
previously	O
[	O
14	O
]	O
.	O

All	O
tissue	O
samples	O
were	O
snap	O
-	O
frozen	O
immediately	O
on	O
removal	O
in	O
the	O
theatre	O
.	O

Treatment	O
Regime	O
and	O
Staging	O

Primary	O
treatment	O
consisted	O
of	O
epirubicin	O
(	O
90	O
mg	O
/	O
m2	O
)	O
administered	O
as	O
a	O
3	O
-	O
weekly	O
schedule	O
.	O

Treatment	O
was	O
scheduled	O
for	O
four	O
cycles	O
unless	O
progression	O
occurred	O
at	O
an	O
earlier	O
stage	O
.	O

Clinical	O
response	O
was	O
assessed	O
before	O
each	O
treatment	O
cycle	O
,	O
and	O
the	O
final	O
response	O
evaluated	O
3	O
weeks	O
after	O
the	O
4th	O
cycle	O
for	O
overall	O
response	O
classification	O
.	O

Because	O
the	O
protocol	O
was	O
implemented	O
by	O
October	O
1997	O
with	O
patients	B-LIVB
enrolled	O
between	O
November	O
1997	O
and	O
December	O
2003	O
,	O
responses	O
were	O
consistently	O
graded	O
by	O
the	O
UICC	O
system	O
[	O
32	O
]	O
and	O
not	O
the	O
more	O
recently	O
implemented	O
"	O
RECIST	O
"	O
criteria	O
[	O
33	O
]	O
.	O

Thus	O
,	O
responses	O
were	O
classified	O
as	O
CR	O
(	O
Complete	O
Response	O
,	O
complete	O
disappearance	O
of	O
all	O
tumor	O
lesions	O
)	O
,	O
PR	O
(	O
Partial	O
Response	O
,	O
reduction	O
>=	O
50	O
%	O
in	O
the	O
sum	O
of	O
all	O
tumor	O
lesions	O
,	O
calculated	O
for	O
each	O
as	O
the	O
product	O
of	O
the	O
largest	O
diameter	O
and	O
the	O
one	O
perpendicular	O
to	O
it	O
)	O
,	O
PD	O
(	O
Progressive	O
Disease	O
,	O
increase	O
in	O
the	O
diameter	O
product	O
of	O
any	O
individual	O
tumor	O
lesion	O
by	O
>=	O
25	O
%	O
)	O
,	O
and	O
SD	O
(	O
Stable	O
Disease	O
,	O
anything	O
between	O
PR	O
and	O
PD	O
)	O
.	O

To	O
analyze	O
for	O
the	O
predictive	O
value	O
of	O
the	O
different	O
parameters	O
,	O
similar	O
to	O
our	O
previous	O
studies	O
[	O
13	O
]	O
,	O
[	O
14	O
]	O
we	O
compared	O
PD	O
tumors	O
(	O
non	O
responders	O
)	O
with	O
the	O
combined	O
group	O
of	O
tumors	O
classified	O
as	O
SD	O
/	O
PR	O
/	O
CR	O
(	O
responders	O
)	O
;	O
the	O
reason	O
for	O
this	O
approach	O
is	O
discussed	O
in	O
detail	O
elsewhere	O
[	O
34	O
]	O
.	O

Median	O
follow	O
-	O
up	O
time	O
was	O
defined	O
from	O
patient	B-LIVB
inclusion	O
in	O
the	O
study	O
up	O
to	O
October	O
31	O
,	O
2006	O
.	O

Deaths	O
attributable	O
to	O
causes	O
other	O
than	O
breast	O
cancer	O
were	O
treated	O
as	O
censored	O
observations	O
.	O

All	O
patient	B-LIVB
records	O
were	O
subject	O
to	O
central	O
audit	O
for	O
response	O
classification	O
(	O
by	O
E	O
.	O
L	O
.	O
,	O
B	O
.	O
O	O
.	O
and	O
P	O
.	O
E	O
.	O
L	O
.	O
)	O
.	O

Response	O
classifications	O
were	O
completed	O
and	O
approved	O
without	O
any	O
knowledge	O
about	O
result	O
from	O
laboratory	O
analysis	O
.	O

RNA	O
Purification	O

Total	O
RNA	O
was	O
purified	O
by	O
Trizol	O
(	O
Life	O
Technologies	O
,	O
Inc	O
.	O
)	O
extraction	O
from	O
snap	O
-	O
frozen	O
tissue	O
samples	O
according	O
to	O
manufacturer	O
'	O
s	O
instructions	O
.	O

After	O
extraction	O
,	O
the	O
RNA	O
was	O
dissolved	O
in	O
100	O
micro	O
l	O
of	O
DEPC	O
treated	O
ddH2O	O
.	O

cDNA	O
was	O
synthesized	O
by	O
reverse	O
transcription	O
using	O
Transcriptor	O
reverse	O
transcriptase	O
(	O
Roche	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

DNA	O
Purification	O

Genomic	O
DNA	O
from	O
tumor	O
biopsies	O
and	O
blood	O
lymphocytes	O
was	O
isolated	O
using	O
QIAamp	O
DNA	O
Mini	O
kit	O
(	O
Qiagen	O
,	O
Chatsworth	O
,	O
CA	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Mutation	O
Analysis	O

All	O
mutational	O
analysis	O
was	O
performed	O
blinded	O
to	O
clinical	O
data	O
.	O

Mutations	O
in	O
TP53	O
,	O
CHEK2	O
and	O
p14	O
(	O
ARF	O
)	O
genes	O
were	O
analyzed	O
by	O
PCR	O
(	O
or	O
nested	O
PCR	O
)	O
amplification	O
and	O
sequencing	O
of	O
PCR	O
product	O
,	O
or	O
by	O
cloning	O
of	O
PCR	O
products	O
and	O
sequencing	O
of	O
the	O
resulting	O
plasmids	O
(	O
all	O
primers	O
described	O
in	O
Table	O
1	O
)	O
.	O

Cloning	O
was	O
performed	O
using	O
the	O
TOPO	O
TA	O
Cloning	O
kit	O
(	O
Invitrogen	O
)	O
.	O

Sequencing	O
of	O
clones	O
was	O
performed	O
until	O
at	O
least	O
10	O
different	O
sequences	O
covered	O
all	O
parts	O
of	O
the	O
CHEK2	O
coding	O
sequence	O
.	O

DNA	O
sequencing	O
was	O
carried	O
out	O
directly	O
on	O
1	O
micro	O
l	O
PCR	O
product	O
or	O
plasmid	O
using	O
Big	O
Dye	O
terminator	O
mix	O
(	O
Applied	O
Biosystems	O
)	O
.	O

Capillary	O
gel	O
electrophoresis	O
,	O
data	O
collection	O
,	O
and	O
sequence	O
analysis	O
were	O
done	O
on	O
an	O
automated	O
DNA	O
sequencer	O
(	O
ABI	O
3700	O
)	O
.	O

When	O
a	O
mutation	O
was	O
detected	O
,	O
the	O
relevant	O
exon	O
was	O
amplified	O
by	O
PCR	O
from	O
genomic	O
tumor	O
DNA	O
and	O
DNA	O
from	O
blood	O
lymphocytes	O
and	O
sequenced	O
for	O
verification	O
and	O
germline	O
detection	O
.	O

(	O
Primers	O
described	O
in	O
Table	O
1	O
)	O
.	O

Loss	O
of	O
Heterozygosity	O
(	O
LOH	O
)	O

Loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
in	O
tumors	O
with	O
mutations	O
in	O
CHEK2	O
was	O
assessed	O
using	O
the	O
microsatellite	O
marker	O
,	O
D22S275	O
,	O
which	O
maps	O
to	O
intron	O
4	O
of	O
CHEK2	O
.	O

LOH	O
in	O
tumors	O
with	O
mutation	O
in	O
TP53	O
was	O
assessed	O
using	O
two	O
markers	O
,	O
one	O
variable	O
number	O
tandem	O
repeat	O
in	O
intron	O
1	O
[	O
35	O
]	O
and	O
a	O
CA	O
repeat	O
close	O
to	O
the	O
TP53	O
gene	O
[	O
36	O
]	O
.	O

Fluorescently	O
end	O
-	O
labeled	O
primers	O
were	O
used	O
in	O
the	O
PCR	O
,	O
and	O
the	O
PCR	O
products	O
were	O
analyzed	O
on	O
an	O
ABI	O
3700	O
.	O

LOH	O
was	O
evaluated	O
by	O
comparing	O
the	O
allele	O
peak	O
-	O
height	O
ratios	O
from	O
blood	O
DNA	O
and	O
tumor	O
DNA	O
.	O

A	O
sample	O
was	O
scored	O
as	O
having	O
AI	O
(	O
Allelic	O
Imbalance	O
)	O
when	O
a	O
reduction	O
in	O
peak	O
height	O
of	O
one	O
allele	O
in	O
tumor	O
sample	O
was	O
at	O
least	O
18	O
%	O
compared	O
with	O
that	O
of	O
blood	O
DNA	O
from	O
the	O
same	O
patient	B-LIVB
[	O
37	O
]	O
.	O

Analysis	O
of	O
p14	O
(	O
ARF	O
)	O
promoter	O
methylation	O

Genomic	O
DNA	O
was	O
subjected	O
to	O
bisulphate	O
conversion	O
using	O
the	O
CpGenome	O
DNA	O
Modification	O
Kit	O
(	O
Intergen	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Both	O
the	O
unmethylated	O
-	O
and	O
methylated	O
-	O
specific	O
PCRs	O
were	O
performed	O
in	O
50	O
micro	O
l	O
reaction	O
mixes	O
containing	O
2	O
.	O
5	O
U	O
AmpliTaq	O
Gold	O
DNA	O
Polymerase	O
(	O
Applied	O
Biosystems	O
)	O
,	O
1	O
x	O
PCR	O
buffer	O
,	O
1	O
.	O
5	O
mM	O
MgCl2	O
,	O
0	O
.	O
1	O
mM	O
of	O
each	O
deoxynucleotide	O
triphosphate	O
,	O
0	O
.	O
2	O
micro	O
M	O
of	O
each	O
primer	O
(	O
Table	O
1	O
)	O
and	O
2	O
micro	O
l	O
of	O
modified	O
genomic	O
DNA	O
.	O

Thermocycling	O
conditions	O
for	O
both	O
the	O
unmethylated	O
-	O
and	O
methylated	O
-	O
specific	O
PCRs	O
were	O
an	O
initial	O
step	O
of	O
5	O
minutes	O
at	O
95	O
degrees	O
C	O
followed	O
by	O
35	O
cycles	O
of	O
30	O
sec	O
.	O
at	O
94	O
degrees	O
C	O
,	O
30	O
sec	O
.	O
at	O
60	O
.	O
5	O
degrees	O
C	O
and	O
60	O
sec	O
.	O
at	O
72	O
degrees	O
C	O
before	O
a	O
final	O
elongation	O
step	O
at	O
72	O
degrees	O
C	O
for	O
7	O
min	O
.	O

Chk2	O
Dimerisation	O

Chk2	O
mutant	O
'	O
s	O
ability	O
to	O
form	O
dimers	O
with	O
the	O
wild	O
-	O
type	O
protein	O
was	O
investigated	O
by	O
immunoprecipitation	O
.	O

U	O
-	O
2	O
-	O
OS	O
cells	O
were	O
co	O
-	O
transfected	O
with	O
expression	O
vectors	O
expressing	O
wild	O
-	O
type	O
Chk2	O
with	O
N	O
-	O
terminal	O
Xpr	O
-	O
tag	O
(	O
pcDNA4	O
/	O
HisMax	O
,	O
Invitrogen	O
)	O
and	O
mutated	O
Chk2	O
forms	O
with	O
C	O
-	O
terminal	O
V5	O
-	O
tag	O
(	O
pcDNA3	O
.	O
1	O
/	O
V5	O
-	O
His	O
,	O
Invitrogen	O
)	O
.	O

Transfection	O
was	O
performed	O
using	O
FuGene	O
6	O
.	O
0	O
transfection	O
reagent	O
(	O
Roche	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Cells	O
were	O
harvested	O
in	O
lysisbuffer	O
(	O
50	O
mM	O
TrisHCl	O
pH	O
8	O
.	O
0	O
,	O
150	O
mM	O
NaCl	O
,	O
0	O
.	O
5	O
%	O
NP40	O
,	O
5	O
mM	O
EDTA	O
pH	O
8	O
.	O
0	O
)	O
48	O
hours	O
after	O
transfection	O
.	O

An	O
aliquote	O
of	O
the	O
cell	O
lysate	O
was	O
harvested	O
for	O
subsequent	O
Chk2	O
-	O
mutant	O
-	O
V5	O
transfection	O
verification	O
.	O

Samples	O
were	O
further	O
incubated	O
with	O
A	O
/	O
G	O
Pluss	O
Agarose	O
beads	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
at	O
4	O
degrees	O
C	O
for	O
25	O
minutes	O
before	O
the	O
beads	O
were	O
removed	O
by	O
centrifugation	O
at	O
5000g	O
for	O
4	O
minutes	O
and	O
the	O
samples	O
were	O
incubated	O
with	O
1	O
.	O
5	O
micro	O
g	O
anti	O
-	O
V5	O
(	O
Invitrogen	O
)	O
at	O
4	O
degrees	O
C	O
for	O
90	O
minutes	O
.	O

Fresh	O
A	O
/	O
G	O
Pluss	O
Agarose	O
beads	O
were	O
added	O
and	O
the	O
samples	O
were	O
incubated	O
for	O
another	O
90	O
minutes	O
at	O
4	O
degrees	O
C	O
.	O

The	O
beads	O
were	O
washed	O
three	O
times	O
with	O
1	O
x	O
PBS	O
,	O
before	O
being	O
separated	O
on	O
a	O
10	O
%	O
polyacrylamide	O
gel	O
and	O
blotted	O
on	O
to	O
a	O
nitrocellulose	O
membrane	O
.	O

Chk2	O
-	O
wild	O
-	O
type	O
-	O
Xpr	O
co	O
-	O
precipitated	O
with	O
Chk2	O
-	O
mutant	O
-	O
V5	O
was	O
detected	O
through	O
incubations	O
with	O
anti	O
-	O
Xpr	O
antibody	O
(	O
Invitrogen	O
)	O
,	O
HRP	O
-	O
conjugated	O
secondary	O
antibody	O
and	O
ECL	O
detection	O
reagent	O
(	O
GE	O
Healthcare	O
)	O
.	O

Kinase	O
Activity	O

Chk2	O
mutant	O
'	O
s	O
ability	O
to	O
function	O
as	O
kinases	O
was	O
investigated	O
through	O
an	O
in	O
vitro	O
kinase	O
assay	O
.	O

The	O
V5	O
expression	O
vectors	O
used	O
for	O
the	O
dimerisation	O
study	O
were	O
also	O
used	O
to	O
express	O
Chk2	O
mutants	O
in	O
the	O
kinase	O
assay	O
.	O

U	O
-	O
2	O
-	O
OS	O
cells	O
were	O
transfected	O
using	O
the	O
FuGene	O
6	O
.	O
0	O
transfection	O
reagent	O
(	O
Roche	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Cells	O
were	O
then	O
incubated	O
at	O
37	O
degrees	O
C	O
in	O
5	O
%	O
CO2	O
and	O
humidified	O
atmosphere	O
.	O

After	O
24	O
hours	O
doxorubicin	O
(	O
Nycomed	O
Pharma	O
)	O
was	O
added	O
to	O
the	O
media	O
to	O
a	O
final	O
concentration	O
of	O
50ng	O
/	O
ml	O
and	O
the	O
cells	O
were	O
further	O
incubated	O
for	O
24	O
hours	O
before	O
harvest	O
.	O

75	O
cm2	O
of	O
90	O
%	O
confluent	O
cells	O
were	O
harvested	O
in	O
500	O
micro	O
l	O
lysis	O
buffer	O
(	O
50	O
mM	O
HEPES	O
,	O
150	O
mM	O
NaCl	O
,	O
10	O
%	O
glycerol	O
,	O
0	O
.	O
5	O
%	O
Triton	O
X	O
-	O
100	O
,	O
2	O
mM	O
MgCl2	O
,	O
5	O
mM	O
EDTA	O
)	O
,	O
and	O
the	O
cytosol	O
was	O
incubated	O
for	O
90	O
minutes	O
at	O
4	O
degrees	O
C	O
with	O
50	O
micro	O
l	O
50	O
%	O
Glutathione	O
Sepharose	O
beads	O
(	O
Amersham	O
Biosciences	O
)	O
linked	O
to	O
anti	O
-	O
V5	O
antibody	O
(	O
Invitrogen	O
)	O
.	O

The	O
beads	O
were	O
then	O
washed	O
twice	O
with	O
lysisbuffer	O
containing	O
500	O
mM	O
NaCl	O
and	O
twice	O
with	O
kinase	O
assay	O
buffer	O
(	O
50	O
mM	O
HEPES	O
,	O
10	O
mM	O
MgCl2	O
,	O
5	O
mM	O
MnCl2	O
,	O
2	O
.	O
5	O
mM	O
EGTA	O
)	O
.	O

The	O
beads	O
received	O
30	O
micro	O
l	O
kinase	O
assay	O
buffer	O
with	O
7	O
.	O
5	O
micro	O
M	O
cold	O
ATP	O
,	O
10	O
micro	O
Ci	O
32P	O
-	O
gamma	O
-	O
ATP	O
(	O
GE	O
Healthcare	O
)	O
and	O
2	O
micro	O
g	O
isolated	O
Cdc25C	O
peptide	O
,	O
and	O
was	O
incubated	O
at	O
30	O
degrees	O
C	O
for	O
30	O
minutes	O
.	O

Samples	O
were	O
separated	O
on	O
a	O
12	O
.	O
5	O
%	O
polyacrylamide	O
gel	O
and	O
blotted	O
on	O
to	O
a	O
nitrocellulose	O
membrane	O
.	O

A	O
radiosensitive	O
imaging	O
plate	O
was	O
exposed	O
to	O
the	O
membrane	O
and	O
the	O
plate	O
was	O
read	O
in	O
a	O
FLA200	O
imager	O
(	O
Fuji	O
)	O
.	O

The	O
kinase	O
assay	O
described	O
above	O
was	O
also	O
used	O
to	O
determine	O
the	O
Chk2	O
mutants	O
'	O
kinase	O
activity	O
after	O
co	O
-	O
transfection	O
of	O
each	O
Chk2	O
mutant	O
and	O
wild	O
-	O
type	O
Chk2	O
in	O
equal	O
amounts	O
.	O

Statistical	O
Analysis	O

Statistical	O
analysis	O
was	O
performed	O
using	O
the	O
Primer	O
of	O
Biostatistics	O
system	O
,	O
version	O
5	O
.	O
0	O
[	O
38	O
]	O
.	O

The	O
differences	O
in	O
the	O
distribution	O
of	O
TP53	O
and	O
CHEK2	O
mutations	O
among	O
patients	B-LIVB
revealing	O
a	O
PD	O
and	O
the	O
responders	O
were	O
analyzed	O
with	O
use	O
of	O
Fisher	O
'	O
s	O
exact	O
test	O
.	O

P	O
-	O
values	O
are	O
reported	O
as	O
accumulated	O
two	O
-	O
sided	O
.	O

Because	O
of	O
the	O
limited	O
time	O
of	O
the	O
follow	O
-	O
up	O
,	O
no	O
formal	O
statistical	O
assessment	O
of	O
overall	O
survival	O
was	O
performed	O
.	O

Relapse	O
-	O
free	O
survival	O
was	O
analyzed	O
by	O
the	O
log	O
-	O
rank	O
test	O
.	O

Details	O
regarding	O
outcome	O
in	O
individual	O
patients	B-LIVB
with	O
mutations	O
are	O
shown	O
in	O
Table	O
2	O
and	O
3	O
to	O
make	O
them	O
available	O
to	O
the	O
reader	O
.	O

Results	O

TP53	O
Mutations	O
and	O
Response	O
to	O
Therapy	O

The	O
TP53	O
mutations	O
identified	O
in	O
the	O
tumors	O
of	O
the	O
patients	B-LIVB
treated	O
with	O
epirubicin	O
together	O
with	O
the	O
clinical	O
response	O
to	O
therapy	O
and	O
follow	O
-	O
up	O
data	O
are	O
presented	O
in	O
Table	O
2	O
.	O

Somatic	O
TP53	O
mutations	O
were	O
identified	O
in	O
23	O
(	O
21	O
.	O
5	O
%	O
)	O
of	O
the	O
patients	B-LIVB
.	O

Normal	O
tissue	O
(	O
WBC	O
)	O
was	O
available	O
from	O
18	O
of	O
these	O
for	O
germline	O
characterization	O
,	O
revealing	O
none	O
of	O
the	O
mutations	O
identified	O
to	O
be	O
germline	O
alterations	O
.	O

Of	O
the	O
23	O
mutations	O
detected	O
,	O
20	O
were	O
missense	O
and	O
3	O
were	O
nonsense	O
.	O

One	O
mutation	O
(	O
del483CAT	O
)	O
has	O
not	O
been	O
reported	O
previously	O
either	O
in	O
breast	O
cancer	O
or	O
in	O
any	O
other	O
tumor	O
type	O
(	O
IARC	O
database	O
:	O
http	O
:	O
/	O
/	O
www	O
.	O
iarc	O
.	O
fr	O
/	O
p53	O
/	O
)	O
.	O

Twelve	O
of	O
the	O
mutations	O
directly	O
or	O
indirectly	O
affected	O
the	O
L2	O
/	O
L3	O
domains	O
of	O
the	O
p53	O
protein	O
(	O
Table	O
2	O
)	O
previous	O
found	O
to	O
predict	O
a	O
poor	O
prognosis	O
[	O
39	O
]	O
and	O
drug	O
resistance	O
[	O
14	O
]	O
,	O
[	O
40	O
]	O
.	O

For	O
statistical	O
comparison	O
,	O
mutation	O
Gly325Ter	O
(	O
patient	B-LIVB
Epi215	O
)	O
located	O
to	O
the	O
tetramerization	O
domain	O
is	O
grouped	O
together	O
with	O
the	O
mutations	O
affecting	O
the	O
L2	O
/	O
L3	O
domain	O
,	O
since	O
this	O
mutation	O
leads	O
to	O
truncation	O
of	O
the	O
protein	O
and	O
with	O
loss	O
of	O
tetramerization	O
and	O
functional	O
defects	O
similar	O
to	O
L2	O
/	O
L3	O
mutations	O
[	O
41	O
]	O
.	O

There	O
was	O
a	O
statistical	O
significant	O
correlation	O
between	O
TP53	O
mutation	O
status	O
and	O
lack	O
of	O
treatment	O
response	O
(	O
PD	O
)	O
(	O
Table	O
4	O
;	O
p	O
=	O
0	O
.	O
0358	O
;	O
Fisher	O
exact	O
test	O
)	O
.	O

When	O
tumors	O
harboring	O
TP53	O
mutations	O
affecting	O
the	O
p53	O
L2	O
/	O
L3	O
DNA	O
-	O
binding	O
domains	O
were	O
compared	O
to	O
those	O
with	O
wild	O
-	O
type	O
TP53	O
or	O
TP53	O
mutations	O
outside	O
the	O
L2	O
/	O
L3	O
domains	O
,	O
this	O
correlation	O
was	O
further	O
strengthened	O
(	O
p	O
=	O
0	O
.	O
0136	O
)	O
.	O

The	O
previously	O
described	O
TP53	O
polymorphism	O
,	O
Arg72Pro	O
[	O
42	O
]	O
was	O
detected	O
in	O
31	O
(	O
29	O
%	O
)	O
of	O
our	O
patients	B-LIVB
.	O

No	O
correlation	O
was	O
found	O
between	O
this	O
polymorphism	O
and	O
lack	O
of	O
treatment	O
response	O
(	O
p	O
=	O
0	O
.	O
2750	O
;	O
Fisher	O
exact	O
test	O
)	O
or	O
TP53	O
mutational	O
status	O
(	O
p	O
=	O
0	O
.	O
2024	O
)	O
.	O

CHEK2	O
Mutations	O
and	O
Response	O
to	O
Therapy	O

Table	O
3	O
presents	O
the	O
patients	B-LIVB
with	O
detected	O
CHEK2	O
mutations	O
together	O
with	O
a	O
description	O
of	O
the	O
clinical	O
response	O
and	O
follow	O
up	O
-	O
data	O
.	O

CHEK2	O
mutations	O
were	O
identified	O
in	O
three	O
out	O
of	O
the	O
109	O
patients	B-LIVB
(	O
2	O
.	O
8	O
%	O
)	O
.	O

Notably	O
,	O
each	O
of	O
the	O
CHEK2	O
mutations	O
identified	O
was	O
also	O
present	O
in	O
patient	B-LIVB
lymphocyte	O
DNA	O
,	O
confirming	O
a	O
germline	O
origin	O
.	O

The	O
Arg95Ter	O
(	O
C283T	O
)	O
mutation	O
is	O
novel	O
.	O

This	O
mutation	O
was	O
present	O
in	O
two	O
patients	B-LIVB
(	O
Epi132	O
and	O
Epi203	O
)	O
living	O
in	O
different	O
parts	O
of	O
Norway	O
with	O
no	O
known	O
family	O
relationship	O
.	O

However	O
,	O
linkage	O
analysis	O
using	O
microsatellite	O
markers	O
(	O
D22S275	O
,	O
D22S272	O
,	O
D22S1172	O
and	O
D22S423	O
)	O
suggested	O
a	O
common	O
founder	O
mutation	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
C283T	O
transition	O
generates	O
a	O
novel	O
stop	O
codon	O
in	O
exon	O
1	O
of	O
CHEK2	O
,	O
leading	O
to	O
truncation	O
of	O
the	O
Chk2	O
protein	O
.	O

LOH	O
analysis	O
indicated	O
loss	O
of	O
the	O
wild	O
-	O
type	O
CHEK2	O
allele	O
in	O
the	O
both	O
tumors	O
from	O
the	O
two	O
patients	B-LIVB
harboring	O
this	O
mutation	O
(	O
Epi132	O
and	O
Epi203	O
)	O
.	O

Both	O
these	O
tumors	O
were	O
non	O
-	O
responsive	O
to	O
epirubicin	O
therapy	O
(	O
PD	O
)	O
.	O

In	O
contrast	O
,	O
the	O
third	O
patient	B-LIVB
with	O
a	O
germline	O
CHEK2	O
mutation	O
(	O
patient	B-LIVB
Epi151	O
;	O
point	O
mutation	O
at	O
T1091C	O
,	O
Ile364Thr	O
)	O
had	O
a	O
partial	O
response	O
to	O
epirubicin	O
therapy	O
.	O

This	O
tumor	O
was	O
non	O
-	O
informative	O
with	O
respect	O
to	O
LOH	O
.	O

Taking	O
all	O
CHEK2	O
mutations	O
together	O
,	O
they	O
predicted	O
resistance	O
to	O
epirubicin	O
(	O
p	O
=	O
0	O
.	O
0226	O
)	O
.	O

The	O
previously	O
described	O
silent	O
Glu84Glu	O
(	O
A252G	O
)	O
polymorphism	O
[	O
24	O
]	O
,	O
[	O
43	O
]	O
in	O
exon	O
1	O
was	O
detected	O
in	O
two	O
(	O
1	O
.	O
9	O
%	O
)	O
patients	B-LIVB
.	O

No	O
association	O
between	O
this	O
polymorphism	O
and	O
treatment	O
response	O
was	O
recorded	O
.	O

One	O
of	O
the	O
tumors	O
(	O
Epi203	O
)	O
harboring	O
the	O
C283T	O
substitution	O
(	O
Arg95Ter	O
)	O
also	O
harbored	O
a	O
somatic	O
TP53	O
mutation	O
in	O
codon	O
175	O
,	O
Arg175His	O
,	O
located	O
in	O
the	O
L2	O
domain	O
of	O
p53	O
(	O
Table	O
2	O
)	O
.	O

This	O
mutation	O
was	O
detected	O
in	O
another	O
four	O
of	O
our	O
patients	B-LIVB
treated	O
with	O
epirubicin	O
(	O
Table	O
2	O
)	O
.	O

In	O
addition	O
,	O
TP53	O
Arg175His	O
mutation	O
was	O
recorded	O
in	O
one	O
patient	B-LIVB
of	O
our	O
previous	O
study	O
evaluating	O
response	O
to	O
doxorubicin	O
[	O
13	O
]	O
.	O

The	O
fact	O
that	O
none	O
of	O
the	O
Arg175His	O
patients	B-LIVB
presented	O
here	O
or	O
in	O
our	O
previous	O
study	O
revealed	O
resistance	O
to	O
therapy	O
(	O
PD	O
)	O
suggests	O
this	O
mutation	O
may	O
not	O
cause	O
resistance	O
to	O
anthracyclines	O
in	O
breast	O
cancers	O
in	O
vivo	O
.	O

Omitting	O
the	O
tumor	O
harboring	O
both	O
a	O
CHEK2	O
and	O
a	O
TP53	O
mutation	O
(	O
patient	B-LIVB
Epi203	O
)	O
from	O
statistical	O
analysis	O
,	O
Chk2	O
mutations	O
(	O
n	O
=	O
2	O
)	O
were	O
non	O
-	O
significantly	O
associated	O
with	O
therapy	O
resistance	O
(	O
p	O
=	O
0	O
.	O
1633	O
)	O
.	O

In	O
a	O
previous	O
study	O
[	O
26	O
]	O
,	O
however	O
,	O
we	O
analyzed	O
for	O
CHEK2	O
mutation	O
status	O
in	O
relation	O
to	O
therapy	O
outcome	O
in	O
a	O
cohort	O
of	O
patients	B-LIVB
from	O
doxorubicin	O
study	O
[	O
13	O
]	O
.	O

In	O
that	O
study	O
[	O
26	O
]	O
,	O
we	O
detected	O
the	O
previously	O
identified	O
mutation	O
Ile157Thr	O
.	O

In	O
addition	O
,	O
we	O
detected	O
a	O
novel	O
nonsense	O
somatic	O
mutation	O
(	O
1368InsA	O
)	O
.	O

This	O
mutation	O
was	O
associated	O
with	O
lack	O
of	O
function	O
in	O
vitro	O
;	O
moreover	O
,	O
it	O
was	O
associated	O
with	O
drug	O
resistance	O
in	O
vivo	O
.	O

Analyzing	O
our	O
material	O
and	O
this	O
cohort	O
[	O
26	O
]	O
together	O
,	O
(	O
n	O
=	O
160	O
)	O
,	O
CHEK2	O
mutations	O
(	O
n	O
=	O
5	O
in	O
total	O
)	O
predicted	O
for	O
resistance	O
to	O
doxorubicin	O
and	O
epirubicin	O
therapy	O
(	O
p	O
=	O
0	O
.	O
0123	O
)	O
.	O

Even	O
though	O
,	O
excluding	O
patient	B-LIVB
Epi203	O
(	O
harboring	O
TP53	O
Arg175His	O
and	O
Arg95Ter	O
CHEK2	O
mutation	O
)	O
as	O
well	O
as	O
other	O
patients	B-LIVB
harboring	O
TP53	O
L2	O
/	O
L3	O
mutations	O
(	O
n	O
=	O
129	O
)	O
,	O
CHEK2	O
mutations	O
(	O
n	O
=	O
4	O
in	O
total	O
)	O
predicted	O
for	O
resistance	O
to	O
doxorubicin	O
and	O
epirubicin	O
therapy	O
(	O
p	O
=	O
0	O
.	O
030	O
)	O
.	O

TP53	O
and	O
CHEK2	O
Mutations	O
Combined	O
and	O
Response	O
to	O
Therapy	O

Assuming	O
that	O
TP53	O
and	O
CHEK2	O
mutations	O
may	O
substitute	O
for	O
each	O
other	O
,	O
we	O
analyzed	O
for	O
the	O
predictive	O
effect	O
of	O
mutations	O
in	O
both	O
genes	O
.	O

The	O
occurrence	O
of	O
a	O
mutation	O
affecting	O
either	O
CHEK2	O
or	O
TP53	O
strongly	O
predicted	O
therapy	O
resistance	O
(	O
p	O
=	O
0	O
.	O
0101	O
;	O
Fisher	O
exact	O
test	O
)	O
.	O

When	O
tumors	O
harboring	O
TP53	O
-	O
L2	O
/	O
L3	O
mutations	O
and	O
CHEK2	O
mutations	O
were	O
compared	O
with	O
those	O
wild	O
-	O
type	O
or	O
TP53	O
mutations	O
outside	O
the	O
L2	O
/	O
L3	O
domain	O
,	O
the	O
correlation	O
was	O
further	O
strengthened	O
(	O
p	O
=	O
0	O
.	O
0032	O
;	O
Fisher	O
exact	O
test	O
)	O
.	O

The	O
significance	O
was	O
preserved	O
when	O
comparing	O
patients	B-LIVB
with	O
a	O
PD	O
to	O
objective	O
responders	O
(	O
CR	O
and	O
PR	O
)	O
excluding	O
patients	B-LIVB
with	O
stable	O
disease	O
(	O
SD	O
)	O
from	O
the	O
statistical	O
analysis	O
(	O
Table	O
4	O
)	O
.	O

p14	O
(	O
ARF	O
)	O
Mutations	O
and	O
Promoter	O
Methylations	O

Neither	O
mutations	O
nor	O
polymorphisms	O
in	O
the	O
coding	O
region	O
of	O
p14	O
(	O
ARF	O
)	O
were	O
observed	O
among	O
the	O
107	O
patients	B-LIVB
analyzed	O
.	O

Likewise	O
,	O
no	O
promoter	O
methylations	O
were	O
detected	O
.	O

Influence	O
of	O
CHEK2	O
and	O
TP53	O
Mutation	O
Status	O
on	O
Relapse	O
-	O
Free	O
Survival	O

Because	O
of	O
the	O
limited	O
time	O
of	O
the	O
follow	O
-	O
up	O
,	O
no	O
formal	O
statistical	O
assessment	O
of	O
overall	O
survival	O
was	O
performed	O
.	O

Details	O
regarding	O
outcome	O
for	O
individual	O
patients	B-LIVB
with	O
mutations	O
are	O
described	O
in	O
Table	O
2	O
and	O
3	O
to	O
make	O
these	O
data	O
available	O
to	O
the	O
reader	O
.	O

Relapse	O
-	O
free	O
survival	O
is	O
depicted	O
in	O
(	O
Figure	O
1	O
)	O
.	O

Figure	O
1A	O
shows	O
relapse	O
-	O
free	O
survival	O
for	O
the	O
patients	B-LIVB
with	O
TP53	O
and	O
CHEK2	O
mutations	O
(	O
all	O
mutations	O
found	O
)	O
compared	O
to	O
patients	B-LIVB
without	O
any	O
TP53	O
or	O
CHEK2	O
mutations	O
,	O
no	O
difference	O
in	O
relapse	O
-	O
free	O
survival	O
was	O
observed	O
.	O

Similar	O
,	O
no	O
difference	O
was	O
seen	O
when	O
grouping	O
TP53	O
mutations	O
outside	O
L2	O
/	O
L3	O
and	O
CHEK2	O
mutation	O
not	O
affecting	O
kinase	O
function	O
(	O
Ile364Thr	O
)	O
as	O
wild	O
-	O
type	O
(	O
Figure	O
1B	O
)	O
.	O

Grouping	O
tumors	O
harboring	O
a	O
mutation	O
in	O
L2	O
/	O
L3	O
together	O
with	O
CHEK2	O
mutations	O
affecting	O
kinase	O
domain	O
(	O
Arg95Ter	O
)	O
in	O
one	O
group	O
,	O
mutations	O
outside	O
TP53	O
L2	O
/	O
L3	O
and	O
Ile364Thr	O
as	O
one	O
group	O
and	O
tumors	O
without	O
any	O
found	O
mutations	O
in	O
TP53	O
and	O
CHEK2	O
separately	O
,	O
again	O
no	O
noticeably	O
difference	O
in	O
relapse	O
-	O
free	O
survival	O
were	O
seen	O
(	O
Figure	O
1C	O
)	O
.	O

Notably	O
,	O
in	O
addition	O
to	O
a	O
short	O
median	O
follow	O
-	O
up	O
time	O
,	O
a	O
total	O
of	O
35	O
patients	B-LIVB
with	O
a	O
sub	O
-	O
optimal	O
response	O
to	O
epirubicin	O
received	O
subsequent	O
treatment	O
with	O
paclitaxel	O
,	O
which	O
may	O
have	O
influenced	O
the	O
outcome	O
.	O

CHEK2	O
Mutant	O
'	O
s	O
Capability	O
to	O
Form	O
Dimers	O

To	O
investigate	O
whether	O
the	O
identified	O
CHEK2	O
mutations	O
affect	O
the	O
ability	O
of	O
the	O
Chk2	O
protein	O
to	O
form	O
dimers	O
,	O
co	O
-	O
transfection	O
and	O
immunopresipitation	O
of	O
V5	O
-	O
tagged	O
mutants	O
and	O
Xpress	O
-	O
tagged	O
wild	O
-	O
type	O
Chk2	O
were	O
performed	O
using	O
CHEK2	O
low	O
-	O
expressing	O
U	O
-	O
2	O
-	O
OS	O
cells	O
.	O

As	O
we	O
identified	O
the	O
previously	O
characterized	O
CHEK2	O
germline	O
mutants	O
variants	O
Arg117His	O
(	O
n	O
=	O
2	O
and	O
Ile157Thr	O
(	O
n	O
=	O
1	O
)	O
among	O
patients	B-LIVB
allocated	O
to	O
primary	O
treatment	O
with	O
paclitaxel	O
in	O
our	O
ongoing	O
study	O
,	O
these	O
mutants	O
were	O
evaluated	O
together	O
with	O
Arg95Ter	O
and	O
Ile364Thr	O
.	O

The	O
results	O
presented	O
in	O
Figure	O
2	O
show	O
that	O
all	O
Chk2	O
variants	O
carrying	O
a	O
point	O
mutation	O
were	O
able	O
to	O
form	O
dimers	O
with	O
wild	O
-	O
type	O
Chk2	O
,	O
whereas	O
the	O
Arg95Ter	O
variant	O
was	O
not	O
.	O

Kinase	O
Activity	O
of	O
CHEK2	O
Mutants	O

To	O
investigate	O
whether	O
the	O
identified	O
CHEK2	O
mutants	O
retained	O
the	O
wild	O
-	O
type	O
kinase	O
activity	O
,	O
an	O
in	O
vitro	O
Chk2	O
kinase	O
assay	O
with	O
respect	O
to	O
Chk2	O
autophosphorylation	O
and	O
Cdc25	O
substrate	O
phosphorylation	O
was	O
performed	O
.	O

The	O
U	O
-	O
2	O
-	O
OS	O
cells	O
were	O
preferred	O
for	O
this	O
assay	O
because	O
they	O
were	O
previously	O
found	O
to	O
express	O
only	O
low	O
levels	O
of	O
endogenous	O
Chk2	O
[	O
44	O
]	O
.	O

This	O
was	O
confirmed	O
by	O
us	O
using	O
an	O
antibody	O
recognizing	O
endogenous	O
protein	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
cells	O
have	O
previously	O
been	O
used	O
by	O
other	O
investigators	O
to	O
study	O
Chk2	O
kinase	O
activity	O
[	O
44	O
]	O
,	O
[	O
45	O
]	O
,	O
[	O
46	O
]	O
.	O

The	O
two	O
mutants	O
Arg117Gly	O
and	O
Ile157Thr	O
were	O
previously	O
tested	O
for	O
in	O
vitro	O
kinase	O
activity	O
[	O
47	O
]	O
,	O
but	O
were	O
both	O
included	O
here	O
,	O
together	O
with	O
wild	O
-	O
type	O
CHEK2	O
as	O
controls	O
.	O

Compared	O
to	O
wild	O
-	O
type	O
Chk2	O
,	O
the	O
Ile157Thr	O
mutant	O
retained	O
wild	O
-	O
type	O
kinase	O
activity	O
.	O

The	O
mutant	O
Ile364Thr	O
showed	O
partially	O
reduced	O
kinase	O
activity	O
both	O
in	O
term	O
of	O
Cdc25	O
-	O
phosphorylation	O
and	O
autophosphorylation	O
(	O
Figure	O
3	O
)	O
.	O

In	O
contrast	O
,	O
the	O
mutant	O
Arg117Gly	O
showed	O
strongly	O
reduced	O
kinase	O
activity	O
while	O
the	O
Arg95Ter	O
mutant	O
was	O
totally	O
devoid	O
of	O
any	O
Chk2	O
kinase	O
activity	O
.	O

The	O
activity	O
recorded	O
for	O
Ile157Thr	O
and	O
Arg117Gly	O
was	O
consistent	O
with	O
previously	O
reported	O
results	O
for	O
these	O
two	O
mutants	O
[	O
47	O
]	O
.	O

Notably	O
,	O
there	O
was	O
an	O
internal	O
consistency	O
with	O
respect	O
to	O
percentage	O
activity	O
reduction	O
comparing	O
individual	O
mutants	O
with	O
respect	O
to	O
autophosphorylation	O
and	O
phosphorylation	O
of	O
Cdc25	O
(	O
Figure	O
3	O
)	O
.	O

Since	O
enzymatically	O
active	O
Chk2	O
exists	O
as	O
dimers	O
,	O
it	O
was	O
important	O
to	O
determine	O
the	O
effect	O
of	O
Chk2	O
mutants	O
on	O
wild	O
-	O
type	O
/	O
mutant	O
heterodimer	O
kinase	O
activity	O
.	O

The	O
effect	O
on	O
Chk2	O
kinase	O
activities	O
(	O
Chk2	O
autophosphorylation	O
and	O
Cdc25	O
substrate	O
phosphorylation	O
)	O
of	O
the	O
individual	O
mutants	O
were	O
therefore	O
determined	O
after	O
co	O
-	O
transfection	O
with	O
wild	O
-	O
type	O
Chk2	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O

The	O
results	O
from	O
this	O
co	O
-	O
transfection	O
-	O
kinase	O
assay	O
(	O
Figure	O
4	O
)	O
were	O
similar	O
to	O
those	O
of	O
the	O
single	O
-	O
transfection	O
assay	O
(	O
Figure	O
3	O
)	O
except	O
in	O
the	O
case	O
of	O
the	O
Arg117Gly	O
mutant	O
,	O
which	O
expressed	O
a	O
substantial	O
kinase	O
activity	O
when	O
complexed	O
with	O
wild	O
-	O
type	O
Chk2	O
.	O

This	O
is	O
consistent	O
with	O
previous	O
data	O
indicating	O
that	O
the	O
Arg117Gly	O
mutant	O
has	O
neglectable	O
kinase	O
activity	O
itself	O
but	O
dimerizes	O
efficiently	O
to	O
Chk2	O
wild	O
-	O
type	O
without	O
strongly	O
affecting	O
the	O
wild	O
-	O
type	O
Chk2	O
activity	O
.	O

Hence	O
,	O
the	O
activity	O
detected	O
is	O
probably	O
caused	O
by	O
the	O
co	O
-	O
transfected	O
and	O
co	O
-	O
precipitated	O
wild	O
-	O
type	O
protein	O
.	O

To	O
rule	O
out	O
the	O
possibility	O
that	O
endogenously	O
expressed	O
wild	O
-	O
type	O
Chk2	O
contributed	O
to	O
observed	O
Arg117Gly	O
kinase	O
activity	O
shown	O
in	O
Figure	O
4	O
,	O
we	O
compared	O
the	O
Arg117Gly	O
variant	O
activity	O
in	O
the	O
presence	O
or	O
absence	O
of	O
co	O
-	O
transfected	O
wild	O
-	O
type	O
Chk2	O
to	O
the	O
activities	O
of	O
Arg95Ter	O
under	O
the	O
same	O
conditions	O
.	O

The	O
Arg95Ter	O
variant	O
does	O
not	O
form	O
dimers	O
with	O
wild	O
-	O
type	O
Chk2	O
.	O

As	O
seen	O
in	O
Figure	O
5	O
,	O
Arg117Gly	O
,	O
which	O
forms	O
dimers	O
with	O
Chk2	O
wild	O
-	O
type	O
,	O
allows	O
increased	O
activity	O
when	O
co	O
-	O
transfected	O
with	O
wild	O
-	O
type	O
as	O
compared	O
to	O
the	O
corresponding	O
activity	O
for	O
the	O
Arg95Ter	O
mutant	O
.	O

The	O
fact	O
that	O
Arg117Gly	O
,	O
when	O
transfected	O
alone	O
,	O
displays	O
very	O
similar	O
activity	O
as	O
Arg95Ter	O
or	O
negative	O
control	O
(	O
background	O
levels	O
)	O
,	O
strongly	O
indicates	O
that	O
the	O
contribution	O
of	O
endogenous	O
Chk2	O
,	O
which	O
,	O
similarly	O
to	O
exogenously	O
expressed	O
wild	O
-	O
type	O
Chk2	O
co	O
-	O
precipitate	O
with	O
Arg117Gly	O
is	O
non	O
-	O
significant	O
.	O

Family	O
Cancer	O
Incidence	O
in	O
Relation	O
to	O
CHEK2	O
Germline	O
Mutations	O

Following	O
an	O
initial	O
report	O
of	O
a	O
family	O
with	O
a	O
CHEK2	O
germline	O
mutation	O
expressing	O
an	O
increased	O
cancer	O
incidence	O
resembling	O
the	O
Li	O
-	O
Fraumeni	O
syndrome	O
[	O
24	O
]	O
,	O
recent	O
studies	O
have	O
revealed	O
the	O
more	O
common	O
CHEK2	O
mutations	O
to	O
be	O
associated	O
with	O
a	O
moderately	O
increased	O
risk	O
of	O
breast	O
and	O
colorectal	O
cancers	O
.	O

We	O
hypothesized	O
that	O
CHEK2	O
mutations	O
having	O
a	O
detrimental	O
effect	O
on	O
drug	O
sensitivity	O
could	O
be	O
associated	O
with	O
a	O
more	O
aggressive	O
,	O
Li	O
-	O
Fraumeni	O
or	O
a	O
Li	O
-	O
Fraumeni	O
-	O
like	O
(	O
LFL	O
)	O
cancer	O
syndrome	O
[	O
48	O
]	O
.	O

Except	O
from	O
the	O
patient	B-LIVB
harboring	O
the	O
Ile364Thr	O
mutation	O
who	O
did	O
not	O
have	O
any	O
known	O
congestion	O
of	O
cancer	O
disease	O
in	O
the	O
family	O
,	O
a	O
detailed	O
assessment	O
of	O
family	O
cancer	O
history	O
was	O
performed	O
for	O
each	O
patient	B-LIVB
harboring	O
a	O
germline	O
CHEK2	O
mutation	O
.	O

The	O
family	O
cancer	O
pedigrees	O
are	O
depicted	O
in	O
Figure	O
6	O
.	O

While	O
patients	B-LIVB
harboring	O
CHEK2	O
germline	O
mutations	O
revealed	O
different	O
types	O
of	O
cancers	O
(	O
mainly	O
breast	O
and	O
tumors	O
of	O
the	O
gastrointestinal	O
area	O
)	O
in	O
their	O
family	O
,	O
surprisingly	O
,	O
no	O
distinct	O
pattern	O
discriminating	O
families	O
harboring	O
the	O
Arg95Ter	O
mutation	O
from	O
the	O
other	O
CHEK2	O
mutated	O
families	O
could	O
be	O
identified	O
.	O

One	O
of	O
them	O
(	O
Epi203	O
)	O
,	O
who	O
inherited	O
the	O
mutation	O
from	O
her	O
father	O
'	O
s	O
side	O
of	O
the	O
family	O
,	O
had	O
no	O
accumulation	O
of	O
either	O
breast	O
or	O
colorectal	O
cancer	O
on	O
that	O
side	O
.	O

It	O
should	O
be	O
noted	O
,	O
however	O
,	O
that	O
two	O
brothers	O
of	O
her	O
fathers	O
mother	O
had	O
prostate	O
cancer	O
,	O
and	O
two	O
siblings	O
of	O
his	O
father	O
having	O
hepatocellular	O
carcinoma	O
and	O
bladder	O
cancer	O
,	O
respectively	O
)	O
,	O
while	O
the	O
other	O
expressed	O
a	O
disease	O
pattern	O
resembling	O
what	O
has	O
been	O
seen	O
with	O
the	O
more	O
common	O
CHEK2	O
mutations	O
,	O
like	O
del1100C	O
[	O
25	O
]	O
.	O

Discussion	O

TP53	O
plays	O
a	O
key	O
role	O
as	O
a	O
tumor	O
suppressor	O
gene	O
.	O

Its	O
protein	O
product	O
activates	O
processes	O
such	O
as	O
growth	O
arrest	O
,	O
DNA	O
repair	O
,	O
apoptosis	O
and	O
/	O
or	O
senescence	O
in	O
response	O
to	O
genotoxic	O
damage	O
as	O
well	O
as	O
oncogene	O
activity	O
[	O
49	O
]	O
,	O
[	O
50	O
]	O
.	O

Despite	O
being	O
extensively	O
studied	O
,	O
critical	O
issues	O
regarding	O
regulation	O
of	O
the	O
p53	O
protein	O
remain	O
poorly	O
understood	O
,	O
and	O
conflicting	O
evidence	O
obtained	O
in	O
different	O
experimental	O
systems	O
make	O
the	O
clinical	O
relevance	O
of	O
experimental	O
data	O
questionable	O
.	O

Chemoresistance	O
is	O
the	O
main	O
obstacle	O
to	O
cancer	O
cure	O
in	O
most	O
malignancies	O
,	O
including	O
breast	O
cancer	O
.	O

Previously	O
,	O
we	O
found	O
TP53	O
mutations	O
affecting	O
the	O
L2	O
/	O
L3	O
DNA	O
binding	O
domain	O
to	O
be	O
associated	O
with	O
lack	O
of	O
responsiveness	O
to	O
doxorubicin	O
monotherapy	O
[	O
13	O
]	O
as	O
well	O
as	O
mitomycin	O
and	O
5	O
-	O
fluoro	O
-	O
uracil	O
in	O
concert	O
[	O
14	O
]	O
.	O

However	O
,	O
some	O
tumors	O
revealed	O
therapy	O
resistance	O
despite	O
harboring	O
wild	O
-	O
type	O
TP53	O
.	O

Postulating	O
that	O
these	O
tumors	O
may	O
harbor	O
genetic	O
disturbances	O
in	O
genes	O
playing	O
a	O
key	O
role	O
in	O
the	O
p53	O
pathway	O
,	O
we	O
here	O
sequenced	O
TP53	O
along	O
with	O
CHEK2	O
and	O
p14	O
(	O
ARF	O
)	O
,	O
the	O
latter	O
two	O
known	O
to	O
play	O
a	O
critical	O
role	O
as	O
p53	O
activators	O
,	O
in	O
tumors	O
from	O
109	O
patients	B-LIVB
treated	O
with	O
epirubicin	O
monotherapy	O
.	O

Our	O
results	O
confirm	O
TP53	O
mutations	O
,	O
in	O
particular	O
those	O
affecting	O
the	O
L2	O
/	O
L3	O
domains	O
,	O
to	O
be	O
associated	O
with	O
drug	O
resistance	O
.	O

Most	O
importantly	O
,	O
we	O
also	O
found	O
CHEK2	O
mutations	O
generating	O
a	O
non	O
-	O
functional	O
protein	O
in	O
our	O
in	O
vitro	O
assays	O
to	O
be	O
associated	O
with	O
drug	O
resistance	O
.	O

In	O
contrast	O
,	O
none	O
of	O
our	O
tumors	O
harbored	O
either	O
mutations	O
or	O
expressed	O
promoter	O
hypermethylations	O
affecting	O
the	O
p14	O
.	O

Based	O
on	O
in	O
vitro	O
assays	O
,	O
we	O
were	O
able	O
to	O
classify	O
the	O
different	O
Chk2	O
mutants	O
with	O
respect	O
to	O
dimerization	O
capability	O
as	O
well	O
as	O
kinase	O
activity	O
(	O
Chk2	O
autophosphorylation	O
and	O
Cdc25	O
substrate	O
phosphorylation	O
)	O
.	O

In	O
addition	O
,	O
the	O
kinase	O
activities	O
of	O
the	O
Chk2	O
wild	O
-	O
type	O
/	O
mutant	O
complexes	O
were	O
monitored	O
in	O
co	O
-	O
transfection	O
experiments	O
.	O

Notably	O
,	O
each	O
point	O
mutation	O
(	O
except	O
for	O
Arg117Gly	O
)	O
revealed	O
similar	O
relative	O
kinase	O
efficacy	O
whether	O
co	O
-	O
transfected	O
with	O
wild	O
-	O
type	O
Chk2	O
or	O
not	O
(	O
Figure	O
3	O
and	O
4	O
)	O
.	O

Cells	O
co	O
-	O
transfected	O
with	O
Arg117Gly	O
and	O
wild	O
-	O
type	O
Chk2	O
revealed	O
kinase	O
activity	O
,	O
probably	O
due	O
to	O
the	O
contribution	O
of	O
the	O
wild	O
type	O
protein	O
in	O
Chk2	O
mutant	O
-	O
wild	O
-	O
type	O
heterodimers	O
.	O

In	O
contrast	O
,	O
cells	O
transfected	O
with	O
Arg95Ter	O
revealed	O
no	O
kinase	O
activity	O
whether	O
co	O
-	O
transfected	O
with	O
wild	O
-	O
type	O
Chk2	O
or	O
not	O
,	O
clearly	O
distinguishing	O
this	O
mutation	O
from	O
the	O
others	O
(	O
Figure	O
3	O
and	O
5	O
)	O
.	O

All	O
in	O
vitro	O
assays	O
were	O
based	O
on	O
transfection	O
of	O
the	O
U	O
-	O
2	O
-	O
OS	O
cell	O
line	O
,	O
a	O
cell	O
line	O
known	O
to	O
express	O
wild	O
-	O
type	O
Chk2	O
at	O
low	O
levels	O
,	O
and	O
previously	O
used	O
by	O
other	O
investigators	O
to	O
study	O
Chk2	O
activity	O
[	O
44	O
]	O
,	O
[	O
45	O
]	O
,	O
[	O
46	O
]	O
.	O

Since	O
we	O
were	O
not	O
able	O
to	O
obtain	O
satisfactory	O
technical	O
quality	O
of	O
the	O
kinase	O
assay	O
in	O
cell	O
lines	O
negative	O
for	O
Chk2	O
(	O
HCT	O
15	O
and	O
HCT	O
116	O
)	O
,	O
we	O
assessed	O
potential	O
background	O
kinase	O
activity	O
due	O
to	O
endogenous	O
Chk2	O
by	O
performing	O
western	O
blot	O
analysis	O
revealing	O
the	O
endogenous	O
levels	O
of	O
Chk2	O
in	O
U	O
-	O
2	O
-	O
OS	O
cells	O
to	O
be	O
non	O
-	O
significant	O
compared	O
to	O
the	O
exogenously	O
expressed	O
Chk2	O
levels	O
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
also	O
performed	O
a	O
separate	O
kinase	O
assay	O
,	O
directly	O
comparing	O
the	O
effect	O
of	O
binding	O
partners	O
for	O
the	O
dimerizing	O
Arg117Gly	O
and	O
the	O
non	O
-	O
dimerizing	O
Arg95Ter	O
.	O

This	O
assay	O
also	O
revealed	O
the	O
contribution	O
of	O
endogenous	O
Chk2	O
to	O
be	O
non	O
-	O
significant	O
(	O
Figure	O
5	O
)	O
.	O

Taking	O
our	O
in	O
vitro	O
findings	O
together	O
with	O
in	O
vivo	O
observations	O
,	O
our	O
present	O
data	O
confirm	O
that	O
the	O
functionally	O
defective	O
CHEK2	O
Arg95Ter	O
mutation	O
,	O
together	O
with	O
LOH	O
,	O
is	O
associated	O
with	O
resistance	O
to	O
anthracycline	O
therapy	O
.	O

In	O
contrast	O
,	O
the	O
patient	B-LIVB
harboring	O
the	O
Ile364Thr	O
mutation	O
,	O
moderately	O
reducing	O
phosphorylation	O
activity	O
,	O
responded	O
well	O
to	O
therapy	O
.	O

The	O
other	O
missense	O
mutations	O
;	O
Arg117Gly	O
and	O
Ile157Thr	O
were	O
observed	O
among	O
patients	B-LIVB
receiving	O
paclitaxel	O
therapy	O
only	O
;	O
thus	O
,	O
their	O
influence	O
on	O
anthracycline	O
sensitivity	O
in	O
vivo	O
could	O
not	O
be	O
addressed	O
.	O

Yet	O
,	O
based	O
on	O
the	O
finding	O
that	O
the	O
Arg117Gly	O
mutant	O
expressed	O
no	O
intrinsic	O
activity	O
,	O
but	O
readily	O
dimerized	O
to	O
the	O
wild	O
-	O
type	O
protein	O
without	O
abolishing	O
its	O
activity	O
,	O
we	O
hypothesize	O
that	O
this	O
mutation	O
and	O
,	O
probably	O
,	O
other	O
yet	O
unidentified	O
CHEK2	O
mutations	O
with	O
a	O
similar	O
lack	O
of	O
intrinsic	O
kinase	O
activity	O
,	O
may	O
cause	O
resistance	O
to	O
anthracycline	O
therapy	O
if	O
combined	O
with	O
LOH	O
in	O
breast	O
cancer	O
.	O

Our	O
present	O
findings	O
have	O
two	O
major	O
implications	O
.	O

First	O
,	O
we	O
confirm	O
that	O
mutations	O
in	O
genes	O
encoding	O
proteins	O
located	O
within	O
the	O
same	O
functional	O
pathway	O
may	O
substitute	O
for	O
each	O
other	O
with	O
respect	O
to	O
drug	O
sensitivity	O
,	O
revealing	O
for	O
the	O
first	O
time	O
a	O
functional	O
pathway	O
critical	O
to	O
chemotherapy	O
response	O
in	O
vivo	O
.	O

Second	O
,	O
the	O
identification	O
of	O
mutations	O
in	O
the	O
CHEK2	O
but	O
not	O
in	O
the	O
p14	O
(	O
ARF	O
)	O
gene	O
in	O
resistant	O
tumors	O
suggests	O
that	O
Chk2	O
mediated	O
phosphorylation	O
of	O
p53	O
is	O
a	O
critical	O
event	O
in	O
executing	O
anti	O
-	O
tumor	O
effect	O
as	O
a	O
response	O
to	O
DNA	O
damaging	O
agents	O
in	O
breast	O
cancer	O
.	O

This	O
adds	O
to	O
our	O
understanding	O
not	O
only	O
of	O
the	O
function	O
of	O
p53	O
but	O
Chk2	O
as	O
well	O
.	O

p53	O
undergoes	O
phosphorylation	O
at	O
multiple	O
sites	O
by	O
different	O
kinases	O
,	O
including	O
Chk2	O
[	O
51	O
]	O
.	O

While	O
activation	O
of	O
the	O
ATM	O
leading	O
to	O
direct	O
(	O
Ser	O
15	O
)	O
and	O
Chk2	O
-	O
mediated	O
(	O
Ser	O
20	O
)	O
phosphorylation	O
of	O
p53	O
is	O
considered	O
an	O
important	O
mechanism	O
for	O
triggering	O
p53	O
activation	O
in	O
response	O
to	O
DNA	O
damage	O
[	O
52	O
]	O
,	O
some	O
reports	O
suggest	O
ATM	O
[	O
53	O
]	O
and	O
even	O
Chk2	O
[	O
23	O
]	O
to	O
be	O
redundant	O
to	O
this	O
function	O
.	O

Importantly	O
,	O
Chk2	O
has	O
been	O
shown	O
capable	O
of	O
inducing	O
ATM	O
-	O
independent	O
apoptosis	O
in	O
vitro	O
[	O
21	O
]	O
.	O

While	O
Chk2	O
phosphorylates	O
p53	O
at	O
Ser	O
20	O
,	O
thereby	O
stabilizing	O
p53	O
by	O
preventing	O
MDM2	O
binding	O
[	O
19	O
]	O
,	O
Chk2	O
also	O
phosphorylates	O
p53	O
at	O
six	O
additional	O
sites	O
,	O
including	O
Ser	O
313	O
and	O
Ser	O
314	O
located	O
in	O
the	O
nuclear	O
localization	O
signal	O
domain	O
of	O
p53	O
[	O
51	O
]	O
.	O

In	O
addition	O
,	O
Chk2	O
phosphorylates	O
other	O
important	O
targets	O
like	O
BRCA1	O
,	O
Cdc25A	O
and	O
Cdc25C	O
involved	O
in	O
DNA	O
repair	O
,	O
G1	O
and	O
G2	O
arrest	O
,	O
respectively	O
[	O
54	O
]	O
.	O

Despite	O
the	O
wide	O
range	O
of	O
known	O
Chk2	O
substrates	O
relevant	O
for	O
DNA	O
repair	O
and	O
cell	O
cycle	O
control	O
,	O
our	O
present	O
findings	O
that	O
CHEK2	O
mutations	O
leading	O
to	O
non	O
-	O
functional	O
Chk2	O
protein	O
may	O
substitute	O
for	O
p53	O
mutations	O
strongly	O
advocate	O
a	O
role	O
for	O
Chk2	O
with	O
respect	O
to	O
drug	O
sensitivity	O
executed	O
through	O
p53	O
activation	O
.	O

Notably	O
,	O
one	O
of	O
the	O
tumors	O
(	O
Epi203	O
)	O
with	O
the	O
Arg95Ter	O
CHEK2	O
mutation	O
in	O
addition	O
harbored	O
a	O
somatic	O
TP53	O
mutation	O
,	O
Arg175His	O
,	O
with	O
allelic	O
imbalance	O
for	O
the	O
TP53	O
gene	O
(	O
Table	O
2	O
)	O
.	O

Importantly	O
,	O
among	O
another	O
four	O
patients	B-LIVB
in	O
this	O
study	O
(	O
Epi063	O
,	O
Epi071	O
,	O
Epi087	O
,	O
Epi153	O
)	O
and	O
one	O
patient	B-LIVB
from	O
our	O
previous	O
doxorubicin	O
protocol	O
[	O
13	O
]	O
harboring	O
the	O
Arg175His	O
mutation	O
together	O
with	O
allelic	O
imbalance	O
for	O
TP53	O
,	O
all	O
five	O
of	O
these	O
patients	B-LIVB
responded	O
to	O
anthracycline	O
therapy	O
either	O
with	O
a	O
partial	O
response	O
or	O
stable	O
disease	O
.	O

In	O
contrast	O
,	O
Epi132	O
and	O
the	O
only	O
patient	B-LIVB
for	O
whom	O
we	O
previously	O
identified	O
a	O
non	O
-	O
functional	O
CHEK2	O
mutation	O
(	O
1368InsA	O
;	O
coding	O
for	O
a	O
non	O
-	O
functional	O
protein	O
translate	O
with	O
cytoplasmic	O
location	O
[	O
26	O
]	O
)	O
expressed	O
resistance	O
to	O
epirubicin	O
and	O
doxorubicin	O
,	O
respectively	O
.	O

Arg175His	O
is	O
a	O
p53	O
"	O
hot	O
-	O
spot	O
"	O
structural	O
mutation	O
reported	O
to	O
have	O
defects	O
with	O
respect	O
to	O
transcriptional	O
activation	O
and	O
also	O
to	O
negatively	O
interact	O
with	O
wild	O
-	O
type	O
p53	O
[	O
55	O
]	O
.	O

While	O
this	O
mutation	O
has	O
been	O
shown	O
to	O
enhance	O
chemoresistance	O
upon	O
transfection	O
into	O
p53	O
null	O
Saos	O
-	O
2	O
cells	O
[	O
56	O
]	O
,	O
these	O
osteosarcoma	O
-	O
derived	O
cells	O
may	O
not	O
necessarily	O
be	O
representative	O
for	O
breast	O
cancers	O
in	O
vivo	O
.	O

Recent	O
evidence	O
strongly	O
support	O
p53	O
to	O
be	O
involved	O
also	O
in	O
non	O
-	O
transcriptional	O
mediated	O
apoptosis	O
by	O
interacting	O
with	O
the	O
Bcl	O
-	O
2	O
/	O
Bax	O
system	O
[	O
57	O
]	O
,	O
and	O
transcription	O
-	O
defect	O
structural	O
p53	O
mutants	O
have	O
been	O
shown	O
to	O
execute	O
non	O
-	O
transcriptional	O
apoptosis	O
in	O
experimental	O
systems	O
[	O
58	O
]	O
.	O

Concomitant	O
inactivation	O
of	O
Chk2	O
and	O
p53	O
in	O
breast	O
cancer	O
has	O
been	O
recorded	O
by	O
others	O
[	O
59	O
]	O
,	O
and	O
the	O
finding	O
that	O
a	O
somatic	O
mutation	O
may	O
generate	O
a	O
"	O
growth	O
advantage	O
"	O
in	O
tumor	O
cells	O
already	O
harboring	O
a	O
germline	O
CHEK2	O
mutation	O
may	O
not	O
implicate	O
an	O
effect	O
on	O
drug	O
sensitivity	O
in	O
tumors	O
not	O
yet	O
exposed	O
to	O
cytotoxic	O
compounds	O
.	O

Rather	O
,	O
it	O
may	O
indicate	O
a	O
growth	O
advantage	O
,	O
probably	O
related	O
to	O
loss	O
of	O
p21	O
function	O
.	O

Notably	O
,	O
in	O
a	O
previous	O
study	O
we	O
found	O
the	O
p21	O
polymorphism	O
G251A	O
to	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
developing	O
large	O
breast	O
cancers	O
but	O
to	O
have	O
no	O
effect	O
on	O
drug	O
sensitivity	O
[	O
60	O
]	O
,	O
indicating	O
that	O
growth	O
rate	O
and	O
drug	O
resistance	O
may	O
be	O
regulated	O
independently	O
.	O

Taken	O
together	O
,	O
we	O
believe	O
our	O
findings	O
advocate	O
a	O
role	O
for	O
Chk2	O
in	O
executing	O
cellular	O
response	O
to	O
anthracycline	O
-	O
induced	O
DNA	O
damage	O
.	O

As	O
mentioned	O
above	O
,	O
removing	O
TP53	O
mutated	O
tumors	O
including	O
the	O
double	O
-	O
mutated	O
Epi203	O
from	O
statistical	O
analysis	O
,	O
CHEK2	O
mutation	O
status	O
still	O
predicted	O
for	O
resistance	O
to	O
anthracycline	O
therapy	O
.	O

In	O
addition	O
,	O
removing	O
the	O
tumors	O
harboring	O
the	O
Arg175His	O
mutation	O
from	O
the	O
p53	O
"	O
L2	O
/	O
L3	O
"	O
group	O
strengthened	O
the	O
correlation	O
to	O
lack	O
of	O
treatment	O
response	O
to	O
epirubicin	O
(	O
p	O
=	O
0	O
.	O
0005	O
)	O
.	O

Comparing	O
the	O
effects	O
of	O
mutations	O
in	O
the	O
CHEK2	O
gene	O
to	O
TP53	O
mutations	O
indirectly	O
underlines	O
the	O
importance	O
of	O
the	O
role	O
of	O
Chk2	O
to	O
chemoresistance	O
.	O

Our	O
present	O
findings	O
as	O
well	O
as	O
results	O
from	O
our	O
previous	O
studies	O
[	O
13	O
]	O
,	O
[	O
14	O
]	O
revealed	O
that	O
about	O
50	O
%	O
of	O
the	O
patients	B-LIVB
with	O
tumors	O
harboring	O
TP53	O
L2	O
/	O
L3	O
mutations	O
to	O
be	O
non	O
-	O
responders	O
to	O
primary	O
therapy	O
.	O

In	O
contrast	O
,	O
all	O
our	O
three	O
patients	B-LIVB
harboring	O
a	O
non	O
-	O
functional	O
CHEK2	O
mutation	O
(	O
the	O
two	O
Arg95Ter	O
mutated	O
patients	B-LIVB
here	O
and	O
our	O
previous	O
patient	B-LIVB
harboring	O
the	O
1368InsA	O
)	O
expressed	O
primary	O
resistance	O
to	O
therapy	O
.	O

We	O
previously	O
hypothesized	O
that	O
therapy	O
response	O
in	O
tumors	O
harboring	O
TP53	O
L2	O
/	O
L3	O
mutations	O
could	O
be	O
due	O
to	O
redundant	O
pathways	O
acting	O
in	O
concert	O
[	O
3	O
]	O
.	O

Although	O
no	O
definite	O
conclusion	O
should	O
be	O
drawn	O
from	O
a	O
limited	O
number	O
of	O
observation	O
,	O
the	O
fact	O
that	O
Chk2	O
not	O
only	O
phosphorylates	O
p53	O
but	O
also	O
phosphorylates	O
other	O
substrates	O
such	O
as	O
Cdc25A	O
and	O
Cdc25C	O
[	O
54	O
]	O
and	O
E2F1	O
in	O
response	O
to	O
etoposide	O
-	O
induced	O
DNA	O
damage	O
[	O
61	O
]	O
may	O
indicate	O
that	O
inactivation	O
of	O
redundant	O
pathways	O
could	O
take	O
place	O
in	O
parallel	O
.	O

The	O
literature	O
remains	O
inconsistent	O
with	O
respect	O
to	O
whether	O
the	O
border	O
amino	O
acids	O
163	O
,	O
195	O
,	O
236	O
and	O
251	O
should	O
be	O
included	O
in	O
the	O
p53	O
L2	O
and	O
L3	O
domains	O
[	O
12	O
]	O
.	O

Taking	O
a	O
conservative	O
approach	O
,	O
we	O
classified	O
patient	B-LIVB
Epi56	O
,	O
harboring	O
a	O
mutation	O
in	O
codon	O
163	O
,	O
as	O
a	O
L2	O
/	O
L3	O
mutant	O
.	O

The	O
patient	B-LIVB
harboring	O
this	O
mutation	O
responded	O
to	O
therapy	O
(	O
PR	O
)	O
.	O

If	O
this	O
mutation	O
was	O
classified	O
as	O
outside	O
the	O
L2	O
domain	O
,	O
our	O
p	O
-	O
value	O
had	O
been	O
strengthened	O
from	O
p	O
=	O
0	O
.	O
0136	O
to	O
p	O
=	O
0	O
.	O
0096	O
.	O

Germline	O
mutations	O
in	O
TP53	O
cause	O
the	O
Li	O
-	O
Fraumeni	O
and	O
Li	O
-	O
Fraumeni	O
-	O
like	O
cancer	O
disposition	O
syndromes	O
.	O

However	O
,	O
while	O
the	O
germline	O
and	O
somatic	O
mutations	O
associated	O
with	O
these	O
syndromes	O
reveal	O
a	O
preference	O
for	O
the	O
same	O
codons	O
[	O
48	O
]	O
,	O
TP53	O
mutations	O
affecting	O
the	O
DNA	O
-	O
binding	O
domains	O
seem	O
associated	O
with	O
a	O
poor	O
prognosis	O
[	O
62	O
]	O
,	O
[	O
63	O
]	O
,	O
[	O
64	O
]	O
and	O
,	O
in	O
particular	O
,	O
drug	O
resistance	O
[	O
14	O
]	O
,	O
[	O
40	O
]	O
in	O
breast	O
cancer	O
.	O

Thus	O
,	O
tumor	O
suppression	O
and	O
tumor	O
cell	O
response	O
to	O
chemotherapeutics	O
may	O
involve	O
different	O
parts	O
of	O
p53	O
protein	O
function	O
.	O

Following	O
an	O
initial	O
report	O
identifying	O
a	O
CHEK2	O
mutation	O
in	O
a	O
family	O
expressing	O
characteristics	O
of	O
the	O
Li	O
-	O
Fraumeni	O
syndrome	O
[	O
65	O
]	O
,	O
recent	O
evidence	O
has	O
linked	O
CHEK2	O
founder	O
mutations	O
to	O
a	O
moderately	O
increased	O
risk	O
of	O
breast	O
-	O
and	O
colorectal	O
cancers	O
with	O
some	O
additional	O
disposition	O
for	O
other	O
malignancies	O
as	O
well	O
[	O
66	O
]	O
.	O

However	O
,	O
cancer	O
incidence	O
and	O
phenotypes	O
did	O
not	O
reveal	O
an	O
aggressive	O
Li	O
-	O
Fraumeni	O
or	O
Li	O
-	O
Fraumeni	O
-	O
like	O
tumor	O
pattern	O
.	O

Similar	O
to	O
the	O
two	O
patients	B-LIVB
in	O
our	O
paclitaxel	O
treatment	O
arm	O
harboring	O
the	O
rare	O
but	O
previously	O
characterized	O
mutation	O
Arg117Gly	O
and	O
the	O
patient	B-LIVB
with	O
the	O
Ile157Thr	O
mutation	O
,	O
they	O
expressed	O
a	O
moderately	O
increased	O
risk	O
of	O
breast	O
and	O
gastrointestinal	O
cancers	O
(	O
Fig	O
.	O
6	O
)	O
.	O

Thus	O
,	O
CHEK2	O
resembles	O
TP53	O
in	O
as	O
much	O
as	O
there	O
seems	O
to	O
be	O
no	O
direct	O
correlation	O
between	O
effects	O
of	O
individual	O
mutations	O
with	O
respect	O
to	O
tumor	O
suppression	O
and	O
drug	O
resistance	O
.	O

Our	O
finding	O
that	O
TP53	O
mutations	O
located	O
to	O
the	O
DNA	O
-	O
binding	O
domains	O
predicts	O
drug	O
resistance	O
may	O
indicate	O
transcriptional	O
mechanisms	O
to	O
be	O
involved	O
in	O
drug	O
-	O
induced	O
cell	O
death	O
.	O

p53	O
induced	O
apoptosis	O
has	O
been	O
associated	O
with	O
transcriptional	O
induction	O
of	O
genes	O
including	O
Puma	O
and	O
Noxa	O
as	O
well	O
as	O
Bax	O
in	O
experimental	O
systems	O
[	O
55	O
]	O
,	O
[	O
67	O
]	O
,	O
[	O
68	O
]	O
.	O

Yet	O
,	O
recent	O
evidence	O
has	O
revealed	O
p53	O
to	O
induce	O
apoptosis	O
through	O
non	O
-	O
transcriptional	O
mechanisms	O
by	O
direct	O
protein	O
interactions	O
with	O
members	O
of	O
the	O
Bcl	O
-	O
2	O
/	O
Bax	O
system	O
and	O
mitochondrial	O
release	O
of	O
cytochrom	O
c	O
[	O
57	O
]	O
,	O
[	O
69	O
]	O
.	O

In	O
deed	O
,	O
there	O
is	O
evidence	O
that	O
the	O
DNA	O
-	O
binding	O
domains	O
,	O
in	O
particular	O
the	O
L3	O
part	O
of	O
the	O
protein	O
,	O
may	O
be	O
critical	O
also	O
to	O
transcriptional	O
-	O
independent	O
apoptosis	O
[	O
70	O
]	O
.	O

Of	O
particular	O
note	O
is	O
the	O
finding	O
that	O
Chk2	O
may	O
regulate	O
transcriptional	O
-	O
independent	O
p53	O
-	O
mediated	O
apoptosis	O
in	O
response	O
to	O
DNA	O
-	O
damage	O
created	O
through	O
ionizing	O
irradiation	O
[	O
71	O
]	O
.	O

Interestingly	O
,	O
Krajewski	O
et	O
al	O
[	O
72	O
]	O
reported	O
low	O
expression	O
of	O
Bax	O
assessed	O
by	O
immunostaining	O
to	O
be	O
associated	O
with	O
a	O
low	O
response	O
to	O
chemotherapy	O
in	O
metastatic	O
breast	O
cancer	O
.	O

Although	O
no	O
conclusion	O
should	O
be	O
drawn	O
at	O
this	O
stage	O
,	O
together	O
these	O
findings	O
are	O
consistent	O
with	O
the	O
challenging	O
hypothesis	O
that	O
transcription	O
-	O
independent	O
activation	O
of	O
Bax	O
following	O
Chk2	O
-	O
phosphorylation	O
may	O
represent	O
a	O
key	O
pathway	O
in	O
p53	O
dependent	O
cell	O
death	O
in	O
breast	O
cancer	O
in	O
vivo	O
.	O

p14	O
acts	O
by	O
releasing	O
p53	O
from	O
MDM2	O
binding	O
,	O
and	O
has	O
been	O
related	O
to	O
oncogene	O
-	O
induced	O
p53	O
activation	O
[	O
73	O
]	O
.	O

Recently	O
,	O
p14	O
was	O
shown	O
to	O
affect	O
p53	O
by	O
additional	O
mechanisms	O
,	O
including	O
acetylations	O
[	O
74	O
]	O
,	O
response	O
to	O
ionizing	O
radiation	O
in	O
human	B-LIVB
fibroblasts	O
[	O
75	O
]	O
,	O
and	O
tumor	O
-	O
suppression	O
following	O
ionizing	O
radiation	O
in	O
mice	B-LIVB
[	O
76	O
]	O
,	O
[	O
77	O
]	O
.	O

These	O
findings	O
further	O
links	O
the	O
retinoblastoma	O
and	O
p53	O
pathways	O
[	O
28	O
]	O
.	O

As	O
such	O
,	O
we	O
believe	O
the	O
negative	O
finding	O
with	O
respect	O
to	O
its	O
role	O
in	O
chemoresistance	O
adds	O
important	O
information	O
.	O

Contrasting	O
earlier	O
findings	O
by	O
us	O
and	O
others	O
[	O
15	O
]	O
,	O
a	O
recent	O
study	O
revealed	O
TP53	O
mutations	O
to	O
be	O
associated	O
with	O
increased	O
likelihood	O
of	O
having	O
a	O
complete	O
response	O
to	O
chemotherapy	O
[	O
16	O
]	O
.	O

These	O
results	O
may	O
not	O
necessarily	O
be	O
at	O
conflict	O
.	O

In	O
the	O
latter	O
study	O
,	O
patients	B-LIVB
received	O
treatment	O
with	O
a	O
"	O
dose	O
-	O
dense	O
"	O
chemotherapy	O
regimen	O
;	O
if	O
confirmed	O
,	O
the	O
combined	O
data	O
may	O
outline	O
a	O
therapeutic	O
indication	O
for	O
aggressive	O
dose	O
-	O
dense	O
therapy	O
based	O
on	O
tumor	O
TP53	O
/	O
CHEK2	O
status	O
.	O

So	O
far	O
attempts	O
to	O
identify	O
single	O
markers	O
and	O
,	O
more	O
recently	O
,	O
gene	O
expression	O
arrays	O
predicting	O
chemoresistance	O
have	O
not	O
proved	O
successful	O
(	O
see	O
refs	O
in	O
[	O
9	O
]	O
,	O
[	O
10	O
]	O
)	O
.	O

The	O
findings	O
presented	O
here	O
reveal	O
for	O
the	O
first	O
time	O
defects	O
in	O
a	O
functional	O
gene	O
cascade	O
to	O
be	O
associated	O
with	O
drug	O
resistance	O
in	O
a	O
human	B-LIVB
cancer	O
in	O
vivo	O
.	O

Moreover	O
,	O
the	O
findings	O
are	O
made	O
in	O
breast	O
cancer	O
,	O
the	O
most	O
frequent	O
malignant	O
disease	O
among	O
women	O
in	O
the	O
industrialized	O
world	O
,	O
and	O
relate	O
to	O
resistance	O
to	O
anthracyclines	O
,	O
the	O
type	O
of	O
cytotoxic	O
compounds	O
most	O
frequently	O
employed	O
for	O
this	O
malignancy	O
.	O

While	O
the	O
only	O
study	O
we	O
are	O
aware	O
of	O
comparing	O
TP53	O
mutation	O
status	O
in	O
primaries	O
and	O
their	O
distant	O
metastases	O
suggested	O
an	O
increasing	O
fraction	O
of	O
tumors	O
to	O
express	O
mutated	O
TP53	O
during	O
progression	O
[	O
78	O
]	O
,	O
we	O
do	O
not	O
know	O
the	O
potential	O
contribution	O
of	O
either	O
TP53	O
or	O
CHEK2	O
mutations	O
to	O
drug	O
resistance	O
in	O
micrometastases	O
or	O
in	O
metastatic	O
disease	O
.	O

Yet	O
the	O
finding	O
that	O
one	O
of	O
our	O
non	O
-	O
functional	O
CHEK2	O
mutations	O
associated	O
with	O
chemoresistance	O
(	O
1368InsA	O
)	O
occurred	O
as	O
a	O
somatic	O
,	O
not	O
germline	O
mutation	O
,	O
suggest	O
such	O
mutations	O
may	O
be	O
selected	O
for	O
during	O
tumor	O
progression	O
.	O

We	O
propose	O
the	O
findings	O
presented	O
here	O
provide	O
important	O
beacons	O
identifying	O
a	O
functional	O
pathway	O
[	O
3	O
]	O
likely	O
to	O
be	O
disturbed	O
through	O
different	O
mechanisms	O
in	O
relation	O
to	O
therapy	O
resistance	O
in	O
advanced	O
disease	O
.	O

In	O
conclusion	O
,	O
we	O
believe	O
our	O
findings	O
here	O
that	O
mutations	O
in	O
the	O
TP53	O
and	O
CHEK2	O
genes	O
each	O
may	O
cause	O
resistance	O
to	O
anthracycline	O
therapy	O
in	O
primary	O
tumors	O
to	O
have	O
wide	O
implications	O
to	O
future	O
research	O
in	O
this	O
area	O
.	O

While	O
results	O
from	O
experimental	O
systems	O
are	O
mandatory	O
generating	O
hypotheses	O
,	O
conflicting	O
data	O
from	O
in	O
vitro	O
studies	O
underlines	O
the	O
pivotal	O
role	O
of	O
identifying	O
defects	O
associated	O
with	O
therapy	O
resistance	O
in	O
vivo	O
.	O

Either	O
through	O
mutations	O
of	O
the	O
genes	O
themselves	O
,	O
or	O
inactivation	O
of	O
this	O
functional	O
cascade	O
through	O
co	O
-	O
factors	O
,	O
we	O
believe	O
identification	O
of	O
the	O
Chk2	O
-	O
p53	O
axis	O
as	O
critical	O
to	O
anthracycline	O
therapy	O
response	O
provides	O
a	O
functional	O
clue	O
for	O
further	O
investigations	O
in	O
this	O
area	O
.	O

Host	O
immunity	O
in	O
the	O
protective	O
response	O
to	O
vaccination	O
with	O
heat	O
-	O
killed	O
Burkholderia	B-LIVB
mallei	I-LIVB

Abstract	O

Background	O

We	O
performed	O
initial	O
cell	O
,	O
cytokine	O
and	O
complement	O
depletion	O
studies	O
to	O
investigate	O
the	O
possible	O
role	O
of	O
these	O
effectors	O
in	O
response	O
to	O
vaccination	O
with	O
heat	O
-	O
killed	O
Burkholderia	B-LIVB
mallei	I-LIVB
in	O
a	O
susceptible	O
BALB	O
/	O
c	O
mouse	B-LIVB
model	O
of	O
infection	O
.	O

Results	O

While	O
protection	O
with	O
heat	O
-	O
killed	O
bacilli	O
did	O
not	O
result	O
in	O
sterilizing	O
immunity	O
,	O
limited	O
protection	O
was	O
afforded	O
against	O
an	O
otherwise	O
lethal	O
infection	O
and	O
provided	O
insight	O
into	O
potential	O
host	O
protective	O
mechanisms	O
.	O

Our	O
results	O
demonstrated	O
that	O
mice	B-LIVB
depleted	O
of	O
either	O
B	O
cells	O
,	O
TNF	O
-	O
alpha	O
or	O
IFN	O
-	O
gamma	O
exhibited	O
decreased	O
survival	O
rates	O
,	O
indicating	O
a	O
role	O
for	O
these	O
effectors	O
in	O
obtaining	O
partial	O
protection	O
from	O
a	O
lethal	O
challenge	O
by	O
the	O
intraperitoneal	O
route	O
.	O

Additionally	O
,	O
complement	O
depletion	O
had	O
no	O
effect	O
on	O
immunoglobulin	O
production	O
when	O
compared	O
to	O
non	O
-	O
complement	O
depleted	O
controls	O
infected	O
intranasally	O
.	O

Conclusion	O

The	O
data	O
provide	O
a	O
basis	O
for	O
future	O
studies	O
of	O
protection	O
via	O
vaccination	O
using	O
either	O
subunit	O
or	O
whole	O
-	O
organism	O
vaccine	O
preparations	O
from	O
lethal	O
infection	O
in	O
the	O
experimental	O
BALB	O
/	O
c	O
mouse	B-LIVB
model	O
.	O

The	O
results	O
of	O
this	O
study	O
demonstrate	O
participation	O
of	O
B220	O
+	O
cells	O
and	O
pro	O
-	O
inflammatory	O
cytokines	O
IFN	O
-	O
gamma	O
and	O
TNF	O
-	O
alpha	O
in	O
protection	O
following	O
HK	O
vaccination	O
.	O

Background	O

Burkholderia	B-LIVB
mallei	I-LIVB
,	O
the	O
etiologic	O
agent	O
of	O
glanders	O
,	O
is	O
a	O
gram	O
-	O
negative	O
,	O
capsulated	O
,	O
non	O
-	O
motile	O
,	O
facultative	O
intracelluar	O
bacterium	O
.	O

Most	O
known	O
members	O
of	O
the	O
Burkholderiaceae	O
are	O
resident	O
in	O
the	O
soil	O
;	O
however	O
,	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
is	O
thought	O
to	O
be	O
an	O
obligate	O
mammalian	O
pathogen	O
.	O

Horses	B-LIVB
are	O
highly	O
susceptible	O
to	O
infection	O
and	O
considered	O
the	O
natural	O
reservoir	O
for	O
infection	O
,	O
although	O
mules	B-LIVB
and	O
donkeys	B-LIVB
are	O
also	O
susceptible	O
[	O
1	O
]	O
.	O

Clinically	O
,	O
glanders	O
in	O
solipeds	O
can	O
present	O
as	O
either	O
a	O
chronic	O
(	O
horses	B-LIVB
)	O
or	O
acute	O
(	O
mules	B-LIVB
and	O
donkeys	B-LIVB
)	O
form	O
.	O

Naturally	O
acquired	O
human	B-LIVB
infection	O
with	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
,	O
although	O
not	O
seen	O
in	O
the	O
United	O
States	O
since	O
1945	O
,	O
has	O
occurred	O
rarely	O
and	O
sporadically	O
among	O
laboratory	O
workers	O
and	O
those	O
in	O
direct	O
contact	O
with	O
infected	O
animals	O
[	O
2	O
]	O
.	O

However	O
,	O
glanders	O
is	O
endemic	O
among	O
domestic	O
animals	O
in	O
Africa	O
,	O
Asia	O
,	O
the	O
Middle	O
East	O
,	O
and	O
Central	O
and	O
South	O
America	O
.	O

The	O
course	O
of	O
infection	O
is	O
dependent	O
on	O
the	O
route	O
of	O
exposure	O
.	O

Direct	O
contact	O
with	O
the	O
skin	O
can	O
lead	O
to	O
a	O
systemic	O
infection	O
.	O

Inhalation	O
of	O
aerosol	O
or	O
dust	O
containing	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
can	O
lead	O
to	O
septicemic	O
,	O
pulmonary	O
,	O
or	O
chronic	O
infections	O
of	O
the	O
muscle	O
,	O
liver	O
and	O
spleen	O
.	O

The	O
disease	O
has	O
a	O
95	O
%	O
case	O
fatality	O
rate	O
for	O
untreated	O
septicemic	O
infections	O
and	O
a	O
50	O
%	O
case	O
fatality	O
rate	O
in	O
antibiotic	O
-	O
treated	O
individuals	O
[	O
3	O
]	O
.	O

There	O
is	O
no	O
human	B-LIVB
or	O
animal	O
vaccine	O
available	O
for	O
glanders	O
,	O
and	O
development	O
of	O
a	O
partial	O
or	O
fully	O
protective	O
adaptive	O
host	O
response	O
to	O
the	O
organism	O
has	O
not	O
been	O
well	O
-	O
defined	O
.	O

Previous	O
studies	O
with	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
and	O
the	O
host	O
response	O
have	O
shown	O
that	O
a	O
mixed	O
immune	O
response	O
consisting	O
of	O
both	O
Th1	O
and	O
Th2	O
-	O
associated	O
cytokines	O
with	O
a	O
predominant	O
IgG1	O
subclass	O
does	O
not	O
correlate	O
with	O
protection	O
[	O
4	O
]	O
.	O

Additional	O
studies	O
with	O
passive	O
transfer	O
of	O
monoclonal	O
antibodies	O
specific	O
for	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
have	O
correlated	O
with	O
early	O
protection	O
from	O
infection	O
[	O
5	O
]	O
.	O

Recent	O
studies	O
have	O
also	O
shown	O
the	O
Th1	O
cytokine	O
IL	O
-	O
12	O
to	O
mediate	O
partial	O
protection	O
to	O
non	O
-	O
viable	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
-	O
vaccinated	O
mice	B-LIVB
[	O
6	O
]	O
.	O

Thus	O
,	O
full	O
correlates	O
of	O
protection	O
mediated	O
by	O
the	O
adaptive	O
immune	O
system	O
against	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
remain	O
to	O
be	O
fully	O
elucidated	O
.	O

In	O
this	O
series	O
of	O
studies	O
,	O
we	O
sought	O
to	O
address	O
the	O
impact	O
of	O
depletion	O
of	O
the	O
major	O
effector	O
lymphoid	O
cell	O
populations	O
(	O
B220	O
+	O
B	O
cells	O
,	O
CD4	O
+	O
or	O
CD8	O
+	O
T	O
cells	O
)	O
and	O
key	O
pro	O
-	O
inflammatory	O
/	O
Type	O
1	O
cytokines	O
(	O
IFN	O
-	O
gamma	O
or	O
TNF	O
-	O
alpha	O
)	O
on	O
survival	O
in	O
BALB	O
/	O
c	O
mice	B-LIVB
vaccinated	O
with	O
heat	O
killed	O
(	O
HK	O
)	O
bacilli	O
followed	O
by	O
an	O
intraperitoneal	O
(	O
i	O
.	O
p	O
.	O
)	O
challenge	O
with	O
live	O
organism	O
.	O

In	O
addition	O
,	O
studies	O
investigating	O
the	O
effect	O
of	O
complement	O
on	O
opsonization	O
of	O
organism	O
and	O
antibody	O
production	O
were	O
assessed	O
.	O

Heat	O
killed	O
bacteria	O
were	O
used	O
as	O
a	O
model	O
of	O
vaccination	O
to	O
allow	O
evaluation	O
of	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
specific	O
immune	O
responses	O
.	O

The	O
results	O
of	O
this	O
study	O
demonstrate	O
participation	O
of	O
B220	O
+	O
cells	O
and	O
pro	O
-	O
inflammatory	O
cytokines	O
IFN	O
-	O
gamma	O
and	O
TNF	O
-	O
alpha	O
in	O
protection	O
following	O
HK	O
vaccination	O
.	O

Results	O

Heat	O
-	O
killed	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
vaccination	O
mediates	O
partial	O
protection	O
from	O
lethal	O
challenge	O

To	O
begin	O
to	O
address	O
this	O
issue	O
in	O
an	O
animal	O
model	O
of	O
acute	O
infection	O
,	O
we	O
established	O
that	O
immunologically	O
naive	O
BALB	O
/	O
c	O
mice	B-LIVB
challenged	O
i	O
.	O
p	O
.	O
with	O
2	O
x	O
107	O
CFU	O
resulted	O
in	O
death	O
by	O
day	O
4	O
-	O
6	O
,	O
while	O
i	O
.	O
p	O
.	O
immunization	O
with	O
1	O
x	O
105	O
heat	O
killed	O
(	O
HK	O
)	O
bacteria	O
provided	O
partial	O
protection	O
against	O
a	O
subsequent	O
challenge	O
.	O

Two	O
independent	O
experiments	O
resulted	O
in	O
similar	O
findings	O
of	O
40	O
%	O
survival	O
for	O
HK	O
-	O
vaccinated	O
mice	B-LIVB
with	O
a	O
mean	O
survival	O
time	O
(	O
MST	O
)	O
of	O
8	O
days	O
versus	O
4	O
days	O
in	O
na	O
i	O
ve	O
mice	B-LIVB
(	O
Fig	O
.	O
1	O
)	O
.	O

The	O
administration	O
of	O
vaccines	O
for	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
during	O
an	O
outbreak	O
would	O
mandate	O
relatively	O
rapid	O
onset	O
of	O
protection	O
for	O
human	B-LIVB
or	O
veterinary	O
use	O
.	O

Based	O
on	O
non	O
-	O
routine	O
use	O
and	O
vaccine	O
implementation	O
in	O
the	O
course	O
of	O
an	O
outbreak	O
,	O
a	O
14	O
day	O
window	O
was	O
chosen	O
for	O
assessment	O
of	O
protection	O
.	O

Our	O
results	O
indicate	O
that	O
HK	O
vaccination	O
can	O
afford	O
partial	O
protection	O
to	O
an	O
otherwise	O
lethal	O
challenge	O
of	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
by	O
the	O
i	O
.	O
p	O
.	O
route	O
.	O

Effects	O
of	O
cell	O
depletion	O
on	O
HK	O
-	O
vaccinated	O
survival	O

To	O
dissect	O
the	O
cellular	O
basis	O
for	O
protection	O
mediated	O
by	O
HK	O
vaccination	O
,	O
13	O
days	O
after	O
immunization	O
with	O
HK	O
bacteria	O
(	O
day	O
-	O
1	O
)	O
,	O
and	O
at	O
day	O
of	O
challenge	O
,	O
mice	B-LIVB
were	O
dosed	O
with	O
antibodies	O
to	O
deplete	O
CD4	O
+	O
,	O
CD8	O
+	O
or	O
B220	O
+	O
cells	O
.	O

Antibody	O
depletion	O
of	O
CD4	O
+	O
,	O
CD8	O
+	O
,	O
or	O
B220	O
+	O
cells	O
in	O
these	O
mice	B-LIVB
was	O
confirmed	O
by	O
flow	O
cytometric	O
analysis	O
with	O
depletion	O
efficiencies	O
for	O
CD4	O
,	O
CD8	O
,	O
and	O
B220	O
populations	O
at	O
99	O
.	O
7	O
%	O
,	O
96	O
%	O
,	O
and	O
95	O
%	O
,	O
respectively	O
,	O
relative	O
to	O
mice	B-LIVB
treated	O
with	O
isotype	O
control	O
monoclonal	O
antibodies	O
(	O
data	O
not	O
shown	O
)	O
.	O

Our	O
results	O
demonstrated	O
decreased	O
survival	O
rates	O
in	O
B220	O
(	O
p	O
=	O
0	O
.	O
3418	O
)	O
,	O
CD4	O
+	O
(	O
p	O
=	O
0	O
.	O
5417	O
)	O
and	O
CD8	O
+	O
(	O
p	O
=	O
0	O
.	O
4684	O
)	O
antibody	O
depleted	O
mice	B-LIVB
,	O
compared	O
to	O
isotype	O
control	O
antibody	O
,	O
a	O
finding	O
that	O
indicated	O
a	O
possible	O
role	O
for	O
vaccine	O
induced	O
antibody	O
production	O
.	O

When	O
challenged	O
with	O
2	O
x	O
107	O
CFU	O
/	O
mouse	B-LIVB
by	O
the	O
i	O
.	O
p	O
.	O
route	O
,	O
loss	O
of	O
T	O
cells	O
resulted	O
in	O
reduced	O
survival	O
(	O
50	O
%	O
)	O
relative	O
to	O
the	O
non	O
-	O
specific	O
isotype	O
control	O
(	O
Fig	O
.	O
2	O
)	O
.	O

In	O
contrast	O
to	O
the	O
loss	O
of	O
T	O
cells	O
,	O
depletion	O
of	O
B220	O
+	O
cells	O
resulted	O
in	O
100	O
%	O
mortality	O
relative	O
to	O
the	O
non	O
-	O
specific	O
isotype	O
control	O
(	O
Fig	O
.	O
2	O
)	O
.	O

To	O
further	O
evaluate	O
the	O
necessity	O
of	O
these	O
effector	O
cells	O
in	O
providing	O
protection	O
following	O
HK	O
vaccination	O
,	O
relatively	O
resistant	O
C57BL	O
/	O
6	O
mice	B-LIVB
,	O
deficient	O
in	O
mature	O
B	O
-	O
cells	O
(	O
mu	O
MT	O
)	O
,	O
CD4	O
T	O
-	O
cells	O
(	O
CD4	O
-	O
/	O
-	O
)	O
or	O
CD8	O
T	O
-	O
cells	O
(	O
CD8	O
-	O
/	O
-	O
)	O
were	O
subjected	O
to	O
an	O
identical	O
HK	O
vaccination	O
and	O
challenge	O
regimen	O
.	O

Mature	O
,	O
B	O
-	O
cell	O
-	O
deficient	O
mice	B-LIVB
demonstrated	O
a	O
50	O
%	O
decreased	O
survival	O
(	O
p	O
=	O
0	O
.	O
0888	O
)	O
compared	O
to	O
the	O
wild	O
-	O
type	O
mice	B-LIVB
with	O
an	O
MST	O
of	O
35	O
.	O
5	O
days	O
(	O
Fig	O
.	O
3	O
)	O
.	O

CD4	O
-	O
/	O
-	O
and	O
CD8	O
-	O
/	O
-	O
mice	B-LIVB
exhibited	O
a	O
60	O
%	O
(	O
p	O
=	O
0	O
.	O
1343	O
)	O
and	O
0	O
%	O
reduced	O
survival	O
,	O
respectively	O
(	O
Fig	O
.	O
3	O
)	O
.	O

Effects	O
of	O
cytokine	O
depletion	O
on	O
HK	O
vaccination	O

Similar	O
studies	O
were	O
performed	O
to	O
determine	O
the	O
role	O
of	O
IFN	O
-	O
gamma	O
or	O
TNF	O
-	O
alpha	O
in	O
acute	O
infection	O
in	O
BALB	O
/	O
c	O
mice	B-LIVB
immunized	O
with	O
HK	O
bacteria	O
.	O

Six	O
hours	O
before	O
challenge	O
,	O
mice	B-LIVB
were	O
dosed	O
with	O
antibodies	O
that	O
neutralize	O
IFN	O
-	O
gamma	O
or	O
TNF	O
-	O
alpha	O
.	O

Individual	O
depletion	O
of	O
either	O
TNF	O
-	O
alpha	O
(	O
p	O
=	O
0	O
.	O
0145	O
)	O
or	O
IFN	O
-	O
gamma	O
(	O
p	O
=	O
0	O
.	O
0446	O
)	O
resulted	O
in	O
100	O
%	O
mortality	O
with	O
an	O
MST	O
of	O
3	O
and	O
2	O
days	O
,	O
respectively	O
,	O
compared	O
to	O
the	O
HK	O
-	O
vaccinated	O
isotype	O
control	O
mice	B-LIVB
(	O
Fig	O
.	O
4	O
)	O
.	O

In	O
contrast	O
,	O
40	O
%	O
of	O
HK	O
-	O
vaccinated	O
,	O
isotype	O
control	O
mice	B-LIVB
survived	O
to	O
at	O
least	O
12	O
days	O
post	O
-	O
challenge	O
(	O
Fig	O
4	O
)	O
.	O

To	O
further	O
evaluate	O
the	O
host	O
TNF	O
-	O
alpha	O
response	O
during	O
an	O
established	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
chronic	O
infection	O
,	O
we	O
infected	O
12	O
BALB	O
/	O
c	O
mice	B-LIVB
by	O
the	O
i	O
.	O
p	O
.	O
route	O
with	O
1	O
x	O
106	O
CFU	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
.	O

One	O
animal	O
was	O
terminally	O
ill	O
on	O
day	O
37	O
post	O
-	O
infection	O
.	O

On	O
day	O
42	O
post	O
-	O
infection	O
,	O
the	O
remaining	O
11	O
mice	B-LIVB
were	O
dosed	O
with	O
either	O
anti	O
-	O
TNF	O
-	O
alpha	O
(	O
n	O
=	O
6	O
)	O
,	O
or	O
control	O
mAb	O
(	O
AFRC	O
Mac	O
49	O
)	O
(	O
n	O
=	O
5	O
)	O
.	O

No	O
further	O
deaths	O
were	O
observed	O
in	O
the	O
control	O
mAb	O
-	O
treated	O
mice	B-LIVB
.	O

Rapid	O
mortality	O
was	O
observed	O
in	O
the	O
anti	O
-	O
TNF	O
-	O
alpha	O
-	O
treated	O
group	O
,	O
with	O
all	O
mice	B-LIVB
dying	O
within	O
7	O
days	O
of	O
treatment	O
(	O
p	O
=	O
0	O
.	O
0023	O
)	O
relative	O
to	O
the	O
isotype	O
-	O
treated	O
controls	O
(	O
Fig	O
.	O
5	O
)	O
.	O

J774A	O
.	O
1	O
uptake	O
of	O
serum	O
treated	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB

Complement	O
mediated	O
uptake	O
assays	O
were	O
performed	O
to	O
evaluate	O
opsonization	O
.	O

Results	O
indicated	O
enhanced	O
bacterial	O
uptake	O
in	O
J774A	O
.	O
1	O
phagocytes	O
inoculated	O
with	O
serum	O
treated	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
(	O
p	O
=	O
.	O
0082	O
)	O
,	O
compared	O
to	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
alone	O
,	O
while	O
heat	O
-	O
inactivated	O
serum	O
produced	O
uptake	O
percentages	O
similar	O
to	O
those	O
prior	O
to	O
serum	O
addition	O
(	O
Fig	O
.	O
6	O
)	O
.	O

Taken	O
together	O
,	O
these	O
results	O
imply	O
an	O
active	O
role	O
for	O
complement	O
components	O
in	O
the	O
uptake	O
of	O
organism	O
by	O
macrophages	O
.	O

Immunoglobulin	O
production	O
in	O
HK	O
vaccinated	O
BALB	O
/	O
c	O
mice	B-LIVB

We	O
further	O
characterized	O
the	O
ability	O
of	O
HK	O
vaccination	O
to	O
induce	O
a	O
predominant	O
IgG	O
isotype	O
by	O
determining	O
IgG2a	O
/	O
IgG1	O
ratios	O
in	O
i	O
.	O
p	O
.	O
and	O
i	O
.	O
n	O
.	O
vaccinated	O
BALB	O
/	O
c	O
mice	B-LIVB
.	O

Pre	O
(	O
day	O
14	O
post	O
vaccination	O
)	O
and	O
post	O
(	O
day	O
2	O
post	O
infection	O
)	O
exposure	O
serum	O
samples	O
were	O
obtained	O
and	O
evaluated	O
for	O
IgG	O
isotype	O
concentrations	O
(	O
Table	O
1	O
)	O
.	O

No	O
appreciable	O
differences	O
in	O
IgG	O
pre	O
-	O
exposure	O
levels	O
were	O
seen	O
when	O
comparing	O
i	O
.	O
n	O
.	O
to	O
i	O
.	O
p	O
.	O
vaccination	O
.	O

In	O
addition	O
,	O
cobra	O
venom	O
factor	O
-	O
treated	O
animals	O
showed	O
no	O
significant	O
differences	O
to	O
non	O
-	O
cobra	O
venom	O
factor	O
-	O
treated	O
animals	O
in	O
IgG	O
pre	O
-	O
exposure	O
(	O
challenge	O
)	O
levels	O
.	O

Conversely	O
,	O
isotype	O
switching	O
in	O
the	O
cobra	O
venom	O
factor	O
treated	O
animals	O
was	O
enhanced	O
in	O
post	O
-	O
exposure	O
serum	O
IgG2a	O
(	O
Table	O
1	O
)	O
.	O

Discussion	O

Recent	O
studies	O
have	O
shown	O
a	O
key	O
role	O
in	O
protection	O
from	O
lethal	O
challenge	O
for	O
IFN	O
-	O
gamma	O
in	O
non	O
-	O
vaccinated	O
mice	B-LIVB
from	O
either	O
NK	O
and	O
/	O
or	O
NKT	O
cells	O
following	O
experimental	O
exposure	O
to	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
and	O
B	B-LIVB
.	I-LIVB
pseudomallei	I-LIVB
[	O
7	O
,	O
8	O
]	O
.	O

A	O
similar	O
protective	O
role	O
in	O
the	O
innate	O
response	O
to	O
infection	O
has	O
been	O
demonstrated	O
for	O
TNF	O
-	O
alpha	O
in	O
B	B-LIVB
.	I-LIVB
pseudomallei	I-LIVB
infection	O
[	O
8	O
]	O
.	O

The	O
studies	O
presented	O
here	O
are	O
consistent	O
with	O
the	O
essential	O
role	O
of	O
these	O
factors	O
in	O
the	O
relative	O
levels	O
of	O
protection	O
conferred	O
by	O
vaccination	O
with	O
heat	O
-	O
killed	O
B	B-LIVB
.	I-LIVB
pseudomallei	I-LIVB
and	O
would	O
appear	O
to	O
be	O
viable	O
early	O
markers	O
for	O
protection	O
from	O
lethal	O
acute	O
infection	O
[	O
9	O
]	O
.	O

Currently	O
,	O
there	O
are	O
no	O
fully	O
protective	O
vaccines	O
against	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
or	O
B	B-LIVB
.	I-LIVB
pseudomallei	I-LIVB
in	O
a	O
murine	B-LIVB
model	O
,	O
particularly	O
for	O
the	O
sensitive	O
BALB	O
/	O
c	O
versus	O
C57BL6	O
models	O
.	O

Previous	O
studies	O
have	O
also	O
demonstrated	O
that	O
both	O
the	O
humoral	O
and	O
cell	O
-	O
mediated	O
arms	O
are	O
essential	O
for	O
protection	O
from	O
B	B-LIVB
.	I-LIVB
pseudomallei	I-LIVB
infection	O
[	O
10	O
]	O
.	O

Thus	O
,	O
loss	O
or	O
reduction	O
of	O
TNF	O
-	O
alpha	O
and	O
IFN	O
-	O
gamma	O
levels	O
result	O
in	O
significantly	O
reduced	O
survival	O
rates	O
,	O
substantiating	O
previous	O
reports	O
of	O
the	O
role	O
of	O
these	O
factors	O
in	O
protection	O
against	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
[	O
7	O
]	O
.	O

Moreover	O
,	O
we	O
demonstrate	O
a	O
role	O
for	O
sustained	O
TNF	O
-	O
alpha	O
production	O
in	O
the	O
maintenance	O
of	O
host	O
survival	O
throughout	O
the	O
course	O
of	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
infection	O
.	O

Mice	B-LIVB
with	O
an	O
established	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
chronic	O
infection	O
rapidly	O
lost	O
the	O
ability	O
to	O
control	O
the	O
growth	O
of	O
the	O
bacillus	O
upon	O
neutralization	O
of	O
TNF	O
-	O
alpha	O
.	O

This	O
would	O
suggest	O
a	O
potential	O
role	O
for	O
TNF	O
-	O
alpha	O
in	O
the	O
maintenance	O
of	O
productive	O
granulomas	O
which	O
may	O
limit	O
the	O
spread	O
of	O
bacteria	O
in	O
chronically	O
infected	O
hosts	O
,	O
or	O
,	O
alternatively	O
,	O
in	O
direct	O
or	O
indirect	O
microbicidal	O
or	O
bacteriostatic	O
activities	O
at	O
the	O
sites	O
of	O
infection	O
.	O

Additional	O
studies	O
are	O
underway	O
to	O
determine	O
more	O
precisely	O
the	O
role	O
of	O
TNF	O
-	O
alpha	O
in	O
host	O
protection	O
to	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
.	O

Multiple	O
innate	O
and	O
adaptive	O
cell	O
types	O
may	O
contribute	O
to	O
the	O
production	O
of	O
IFN	O
-	O
gamma	O
in	O
response	O
to	O
infection	O
with	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
following	O
vaccination	O
.	O

Our	O
results	O
with	O
individual	O
depletion	O
of	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	O
suggests	O
that	O
both	O
cell	O
types	O
may	O
compensate	O
for	O
the	O
functional	O
loss	O
of	O
the	O
other	O
effector	O
cell	O
type	O
in	O
the	O
production	O
of	O
this	O
key	O
cytokine	O
.	O

The	O
effector	O
role	O
for	O
IFN	O
-	O
gamma	O
in	O
mediating	O
protection	O
against	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
may	O
include	O
both	O
immunoregulatory	O
and	O
non	O
-	O
regulatory	O
functions	O
.	O

Regardless	O
,	O
the	O
requirement	O
of	O
IFN	O
-	O
gamma	O
,	O
as	O
demonstrated	O
by	O
administration	O
of	O
neutralizing	O
antibody	O
prior	O
to	O
infection	O
,	O
indicates	O
that	O
stimulation	O
of	O
IFN	O
-	O
gamma	O
response	O
is	O
a	O
desirable	O
goal	O
for	O
a	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
vaccine	O
.	O

Similarly	O
,	O
B220	O
-	O
positive	O
cells	O
appear	O
to	O
play	O
a	O
role	O
in	O
protection	O
following	O
vaccination	O
with	O
heat	O
-	O
killed	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
.	O

Interestingly	O
,	O
this	O
protective	O
immunity	O
,	O
occurring	O
in	O
other	O
intracellular	O
pathogens	O
,	O
is	O
not	O
exclusively	O
dependent	O
on	O
B	O
cells	O
[	O
11	O
]	O
.	O

Passive	O
protection	O
has	O
been	O
demonstrated	O
against	O
acute	O
Burkholderia	O
infection	O
by	O
monoclonal	O
antibodies	O
[	O
5	O
,	O
12	O
]	O
.	O

Protection	O
against	O
B	B-LIVB
.	I-LIVB
pseudomallei	I-LIVB
infection	O
by	O
anti	O
-	O
LPS	O
,	O
capsular	O
polysaccharide	O
and	O
proteins	O
has	O
been	O
short	O
-	O
lived	O
,	O
suggesting	O
that	O
antibody	O
production	O
offers	O
limited	O
protection	O
in	O
the	O
initial	O
stages	O
of	O
infection	O
by	O
an	O
as	O
-	O
yet	O
-	O
undefined	O
mechanism	O
[	O
12	O
]	O
.	O

We	O
have	O
shown	O
that	O
following	O
depletion	O
of	O
B220	O
+	O
cells	O
,	O
survival	O
rates	O
decreased	O
as	O
much	O
as	O
100	O
%	O
relative	O
to	O
non	O
-	O
depleted	O
controls	O
and	O
individual	O
CD4	O
/	O
CD8	O
-	O
depleted	O
mice	B-LIVB
via	O
the	O
intraperitoneal	O
route	O
.	O

Results	O
from	O
C57BL	O
/	O
6	O
mice	B-LIVB
deficient	O
in	O
mature	O
B	O
-	O
cells	O
(	O
mu	O
MT	O
)	O
,	O
CD4	O
T	O
-	O
cells	O
(	O
CD4	O
-	O
/	O
-	O
)	O
or	O
CD8	O
T	O
-	O
cells	O
(	O
CD8	O
-	O
/	O
-	O
)	O
substantiate	O
the	O
requirement	O
for	O
B	O
-	O
cell	O
involvement	O
by	O
evidence	O
of	O
mu	O
MT	O
and	O
CD4	O
-	O
/	O
-	O
decreased	O
survival	O
.	O

The	O
lack	O
of	O
an	O
effective	O
CTL	O
response	O
to	O
vaccination	O
did	O
not	O
appear	O
to	O
alter	O
survival	O
in	O
what	O
would	O
appear	O
to	O
be	O
a	O
CD4	O
/	O
B	O
-	O
cell	O
(	O
humoral	O
)	O
-	O
driven	O
response	O
.	O

In	O
CD4	O
-	O
deficient	O
mice	B-LIVB
,	O
we	O
have	O
the	O
additional	O
potential	O
variable	O
that	O
a	O
CD4	O
-	O
dependent	O
antibody	O
response	O
might	O
also	O
be	O
inhibited	O
during	O
the	O
vaccination	O
phase	O
relative	O
to	O
mice	B-LIVB
treated	O
with	O
antibody	O
immediately	O
prior	O
to	O
and	O
during	O
the	O
early	O
phases	O
of	O
infection	O
.	O

Although	O
not	O
statistically	O
significant	O
,	O
we	O
did	O
observe	O
a	O
decrease	O
in	O
survival	O
in	O
mu	O
MT	O
(	O
mature	O
B	O
cell	O
)	O
deficient	O
mice	B-LIVB
as	O
early	O
as	O
day	O
9	O
post	O
challenge	O
,	O
whereas	O
CD4	O
-	O
deficient	O
mice	B-LIVB
produced	O
similar	O
results	O
at	O
day	O
32	O
post	O
challenge	O
,	O
indicating	O
a	O
role	O
for	O
B	O
cells	O
independent	O
of	O
CD4	O
T	O
cell	O
help	O
,	O
perhaps	O
through	O
a	O
T	O
-	O
independent	O
mechanism	O
of	O
antibody	O
production	O
.	O

Although	O
CD8	O
-	O
/	O
-	O
C57BL	O
/	O
6	O
demonstrated	O
no	O
decreased	O
survival	O
in	O
our	O
HK	O
-	O
vaccinated	O
model	O
,	O
a	O
lack	O
of	O
potential	O
endogenous	O
protein	O
production	O
by	O
HK	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
may	O
have	O
contributed	O
to	O
limited	O
MHC	O
-	O
I	O
presentation	O
.	O

Complement	O
associated	O
studies	O
revealed	O
increased	O
J774A	O
.	O
1	O
uptake	O
of	O
serum	O
-	O
treated	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
.	O

Complement	O
-	O
mediated	O
uptake	O
studies	O
of	O
B	B-LIVB
.	I-LIVB
pseudomallei	I-LIVB
by	O
polymorphonuclear	O
leukocytes	O
(	O
PMNs	O
)	O
suggest	O
that	O
capsule	O
production	O
contributes	O
to	O
resistance	O
of	O
phagocytosis	O
by	O
reducing	O
C3b	O
bacterial	O
deposition	O
[	O
13	O
]	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
a	O
polysaccharide	O
capsule	O
is	O
present	O
in	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
,	O
[	O
14	O
,	O
15	O
]	O
although	O
in	O
the	O
present	O
study	O
enhanced	O
uptake	O
with	O
serum	O
-	O
treated	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
was	O
observed	O
.	O

Intracellular	O
survival	O
assays	O
of	O
complement	O
mediated	O
uptake	O
of	O
organisms	O
were	O
not	O
performed	O
in	O
the	O
present	O
study	O
,	O
thus	O
,	O
the	O
role	O
of	O
complement	O
opsonization	O
on	O
intracellular	O
survival	O
is	O
not	O
fully	O
resolved	O
.	O

Previous	O
reports	O
have	O
demonstrated	O
the	O
ability	O
of	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
to	O
survive	O
within	O
macrophage	O
without	O
the	O
aid	O
of	O
serum	O
coating	O
organisms	O
[	O
16	O
]	O
.	O

Conversely	O
,	O
the	O
idea	O
of	O
antibody	O
mediated	O
opsonization	O
to	O
facilitate	O
macrophage	O
activation	O
and	O
clearance	O
of	O
intracellular	O
organisms	O
may	O
offer	O
support	O
to	O
the	O
role	O
of	O
B	O
cells	O
in	O
an	O
effective	O
immune	O
response	O
.	O

A	O
possible	O
protective	O
mechanism	O
may	O
include	O
HK	O
vaccination	O
induced	O
production	O
of	O
opsonizing	O
antibodies	O
which	O
may	O
aid	O
in	O
complement	O
mediated	O
uptake	O
,	O
thereby	O
limiting	O
the	O
initial	O
bacterial	O
threshold	O
below	O
a	O
lethal	O
level	O
.	O

Immunoglobulin	O
responses	O
to	O
HK	O
vaccination	O
resulted	O
in	O
modest	O
levels	O
of	O
IgG1	O
following	O
2	O
weeks	O
post	O
vaccination	O
,	O
while	O
post	O
-	O
exposure	O
levels	O
were	O
indicative	O
of	O
efficient	O
class	O
switching	O
to	O
a	O
favorable	O
IgG2a	O
isotype	O
.	O

Importantly	O
,	O
cobra	O
venom	O
factor	O
treatment	O
of	O
animals	O
at	O
time	O
of	O
vaccination	O
did	O
not	O
alter	O
their	O
ability	O
to	O
produce	O
immunoglobulin	O
.	O

In	O
fact	O
,	O
cobra	O
venom	O
factor	O
treated	O
animals	O
resulted	O
in	O
higher	O
IgG2a	O
levels	O
when	O
compared	O
to	O
non	O
-	O
treated	O
.	O

Complement	O
activation	O
can	O
modulate	O
both	O
the	O
primary	O
and	O
secondary	O
immune	O
responses	O
and	O
has	O
been	O
shown	O
to	O
enhance	O
secondary	O
immune	O
responses	O
to	O
vaccination	O
[	O
17	O
]	O
.	O

The	O
current	O
results	O
suggest	O
that	O
cobra	O
venom	O
factor	O
treatment	O
may	O
affect	O
the	O
modulation	O
of	O
the	O
immune	O
response	O
to	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
infection	O
through	O
B	O
cell	O
activation	O
and	O
/	O
or	O
memory	O
B	O
cell	O
generation	O
.	O

Conclusion	O

In	O
summary	O
,	O
our	O
results	O
provide	O
a	O
basis	O
for	O
future	O
studies	O
of	O
protection	O
via	O
vaccination	O
using	O
either	O
subunit	O
or	O
whole	O
-	O
organism	O
vaccine	O
preparations	O
from	O
lethal	O
infection	O
in	O
the	O
experimental	O
BALB	O
/	O
c	O
mouse	B-LIVB
model	O
.	O

Understanding	O
and	O
defining	O
the	O
role	O
of	O
B	O
cells	O
in	O
adaptive	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
immunity	O
will	O
likely	O
be	O
fundamental	O
to	O
the	O
design	O
of	O
an	O
efficacious	O
vaccine	O
and	O
important	O
goals	O
of	O
future	O
research	O
.	O

Methods	O

Bacterial	O
strain	O
and	O
mice	B-LIVB

B	B-LIVB
.	I-LIVB
mallei	I-LIVB
strain	O
ATCC	O
23344	O
(	O
China	O
7	O
)	O
was	O
cultured	O
on	O
Luria	O
-	O
Bertani	O
agar	O
supplemented	O
with	O
4	O
%	O
glycerol	O
(	O
LB	O
+	O
4	O
%	O
G	O
)	O
agar	O
plates	O
for	O
48	O
h	O
at	O
37	O
degrees	O
C	O
.	O

Isolated	O
colonies	O
were	O
sub	O
-	O
cultured	O
to	O
LB	O
+	O
4	O
%	O
G	O
broth	O
,	O
and	O
cultures	O
were	O
incubated	O
at	O
37	O
degrees	O
C	O
until	O
optical	O
density	O
readings	O
at	O
600	O
nm	O
(	O
OD600	O
)	O
reached	O
an	O
exponential	O
phase	O
of	O
growth	O
.	O

Bacteria	O
were	O
pelleted	O
by	O
centrifugation	O
,	O
washed	O
and	O
re	O
-	O
suspended	O
in	O
sterile	O
1	O
x	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
,	O
pH	O
7	O
.	O
4	O
)	O
to	O
obtain	O
the	O
desired	O
CFU	O
/	O
ml	O
.	O

To	O
obtain	O
HK	O
inoculums	O
,	O
bacterial	O
suspensions	O
were	O
incubated	O
at	O
85	O
degrees	O
C	O
for	O
3	O
h	O
and	O
stored	O
at	O
4	O
degrees	O
C	O
until	O
use	O
.	O

The	O
absence	O
of	O
live	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
organisms	O
in	O
the	O
HK	O
preparations	O
was	O
confirmed	O
after	O
plating	O
10	O
%	O
of	O
the	O
total	O
inoculums	O
(	O
v	O
/	O
v	O
)	O
and	O
incubating	O
these	O
at	O
37	O
degrees	O
C	O
for	O
48	O
h	O
.	O

All	O
procedures	O
were	O
performed	O
under	O
a	O
class	O
II	O
biosafety	O
cabinet	O
in	O
a	O
biosafety	O
level	O
3	O
laboratory	O
.	O

Female	O
,	O
6	O
-	O
to	O
8	O
-	O
week	O
-	O
old	O
,	O
BALB	O
/	O
c	O
mice	B-LIVB
(	O
n	O
=	O
5	O
-	O
7	O
)	O
were	O
obtained	O
from	O
Harlan	O
Sprague	O
Dawley	O
,	O
Inc	O
.	O

(	O
Indianapolis	O
,	O
Indiana	O
)	O
.	O

Female	O
,	O
6	O
-	O
to	O
8	O
-	O
week	O
-	O
old	O
,	O
C57BL	O
/	O
6	O
mice	B-LIVB
deficient	O
in	O
mature	O
B	O
-	O
cells	O
(	O
mu	O
MT	O
)	O
,	O
CD4	O
T	O
-	O
cells	O
(	O
CD4	O
-	O
/	O
-	O
)	O
and	O
CD8	O
T	O
-	O
cells	O
(	O
CD8	O
-	O
/	O
-	O
)	O
and	O
wild	O
-	O
type	O
mice	B-LIVB
were	O
obtained	O
from	O
The	O
Jackson	O
Laboratory	O
(	O
Bar	O
Harbor	O
,	O
Maine	O
)	O
.	O

Vaccination	O
and	O
challenge	O

BALB	O
/	O
c	O
and	O
C57BL	O
/	O
6	O
mice	B-LIVB
were	O
grouped	O
and	O
vaccinated	O
with	O
0	O
.	O
5	O
mu	O
g	O
of	O
HK	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
(	O
without	O
adjuvant	O
)	O
by	O
i	O
.	O
p	O
.	O
injection	O
using	O
a	O
25	O
-	O
gauge	O
syringe	O
.	O

Two	O
weeks	O
post	O
HK	O
vaccination	O
mice	B-LIVB
were	O
injected	O
i	O
.	O
p	O
.	O
with	O
2	O
x	O
107	O
CFU	O
/	O
100	O
mu	O
l	O
of	O
live	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
(	O
~	O
20	O
LD50	O
)	O
[	O
18	O
]	O
.	O

Complement	O
depleted	O
animals	O
were	O
challenged	O
with	O
2	O
.	O
5	O
x	O
104	O
CFU	O
/	O
50	O
mu	O
l	O
(	O
~	O
0	O
.	O
25	O
LD50	O
)	O
by	O
intranasal	O
(	O
i	O
.	O
n	O
.	O
)	O
route	O
.	O

Aliquots	O
from	O
the	O
inoculums	O
were	O
plated	O
to	O
confirm	O
the	O
infecting	O
dose	O
.	O

All	O
procedures	O
and	O
animal	O
protocols	O
used	O
in	O
this	O
study	O
were	O
approved	O
by	O
the	O
Biosafety	O
and	O
IACUC	O
committees	O
at	O
UTMB	O
and	O
conducted	O
in	O
either	O
BSL	O
-	O
3	O
or	O
ABSL	O
-	O
3	O
laboratories	O
.	O

Cell	O
and	O
cytokine	O
depletions	O

Acute	O
in	O
vivo	O
cell	O
/	O
cytokine	O
depletion	O
was	O
performed	O
with	O
monoclonal	O
rat	B-LIVB
anti	O
-	O
mouse	B-LIVB
CD4	O
(	O
GK1	O
.	O
5	O
)	O
,	O
CD8	O
alpha	O
(	O
53	O
-	O
6	O
.	O
7	O
)	O
or	O
B220	O
(	O
RA3	O
-	O
6B2	O
)	O
obtained	O
from	O
R	O
&	O
D	O
Systems	O
,	O
Inc	O
.	O

(	O
Minneapolis	O
,	O
MN	O
)	O
by	O
methods	O
similar	O
to	O
those	O
we	O
have	O
previously	O
described	O
[	O
19	O
]	O
.	O

Functional	O
grade	O
purified	O
rat	B-LIVB
anti	O
-	O
mouse	B-LIVB
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
,	O
AN	O
-	O
18	O
)	O
was	O
obtained	O
from	O
eBioscience	O
(	O
San	O
Diego	O
,	O
CA	O
)	O
and	O
purified	O
anti	O
-	O
mouse	B-LIVB
tumor	O
necrosis	O
factor	O
(	O
TNF	O
-	O
alpha	O
,	O
MP6	O
-	O
XT3	O
)	O
from	O
BD	O
Pharmingen	O
(	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

IFN	O
-	O
gamma	O
and	O
TNF	O
-	O
alpha	O
antibodies	O
were	O
injected	O
i	O
.	O
p	O
.	O

6	O
h	O
prior	O
to	O
challenge	O
,	O
200	O
mu	O
g	O
per	O
mouse	B-LIVB
in	O
200	O
mu	O
l	O
PBS	O
or	O
at	O
later	O
time	O
points	O
as	O
indicated	O
.	O

Rat	B-LIVB
IgG	O
isotype	O
control	O
was	O
obtained	O
from	O
Southern	O
Biotech	O
(	O
Birmingham	O
,	O
AL	O
)	O
and	O
administered	O
i	O
.	O
p	O
.	O
on	O
day	O
of	O
challenge	O
,	O
200	O
mu	O
g	O
/	O
mouse	B-LIVB
.	O

Rat	B-LIVB
anti	O
-	O
mouse	B-LIVB
CD4	O
,	O
CD8	O
alpha	O
and	O
B220	O
were	O
injected	O
i	O
.	O
p	O
.	O
twice	O
,	O
1	O
day	O
prior	O
to	O
challenge	O
and	O
on	O
day	O
of	O
challenge	O
,	O
with	O
an	O
equivalent	O
dosage	O
sufficient	O
to	O
deplete	O
T	O
or	O
B	O
cells	O
from	O
6	O
x	O
108	O
bone	O
marrow	O
cells	O
per	O
injection	O
.	O

The	O
efficiency	O
of	O
depletion	O
at	O
time	O
of	O
infection	O
for	O
CD4	O
+	O
,	O
CD8	O
+	O
,	O
and	O
B220	O
+	O
cells	O
was	O
confirmed	O
by	O
flow	O
cytometry	O
analysis	O
immediately	O
prior	O
to	O
infection	O
.	O

Complement	O
depletion	O
with	O
cobra	O
venom	O
factor	O

Mice	B-LIVB
,	O
six	O
to	O
seven	O
per	O
group	O
,	O
were	O
vaccinated	O
i	O
.	O
p	O
.	O
with	O
1	O
x	O
105	O
CFU	O
of	O
nonviable	O
B	B-LIVB
.	I-LIVB
mallei	I-LIVB
cell	O
preparation	O
in	O
a	O
total	O
volume	O
of	O
0	O
.	O
1	O
ml	O
.	O

Two	O
weeks	O
later	O
,	O
24	O
h	O
and	O
1	O
h	O
before	O
challenge	O
,	O
complement	O
depleted	O
mice	B-LIVB
were	O
treated	O
i	O
.	O
p	O
.	O
with	O
12	O
.	O
5	O
units	O
total	O
cobra	O
venom	O
factor	O
(	O
Quidel	O
Corporation	O
Speciality	O
Products	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
in	O
0	O
.	O
1	O
ml	O
of	O
PBS	O
.	O

Complement	O
depletion	O
was	O
confirmed	O
prior	O
to	O
challenge	O
by	O
micro	O
-	O
titer	O
hemolytic	O
complement	O
activity	O
(	O
CH50	O
)	O
assay	O
as	O
previously	O
described	O
[	O
20	O
]	O
.	O

B	B-LIVB
.	I-LIVB
mallei	I-LIVB
J774A	O
.	O
1	O
uptake	O
assays	O

J774A	O
.	O
1	O
cells	O
were	O
seeded	O
(	O
5	O
x	O
105	O
)	O
onto	O
Corning	O
costar	O
24	O
well	O
plates	O
(	O
Corning	O
,	O
NY	O
)	O
with	O
DMEM	O
and	O
incubated	O
overnight	O
at	O
37	O
degrees	O
C	O
with	O
5	O
%	O
CO2	O
.	O

Bacterial	O
suspensions	O
were	O
incubated	O
at	O
37	O
degrees	O
C	O
for	O
45	O
minutes	O
supplemented	O
with	O
2	O
%	O
mouse	B-LIVB
serum	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
St	O
.	O
Louis	O
,	O
MO	O
.	O
)	O
,	O
heat	O
inactivated	O
mouse	B-LIVB
serum	O
(	O
56	O
degrees	O
C	O
30	O
minutes	O
)	O
,	O
or	O
bacteria	O
alone	O
and	O
then	O
added	O
at	O
an	O
MOI	O
of	O
10	O
:	O
1	O
to	O
J774A	O
.	O
1	O
cells	O
in	O
triplicate	O
.	O

Inoculated	O
wells	O
were	O
centrifuged	O
at	O
800	O
g	O
for	O
2	O
minutes	O
and	O
incubated	O
for	O
2	O
hours	O
at	O
37	O
degrees	O
C	O
with	O
5	O
%	O
CO2	O
followed	O
by	O
a	O
PBS	O
wash	O
(	O
x	O
2	O
)	O
and	O
2	O
hour	O
incubation	O
with	O
250	O
mu	O
g	O
/	O
ml	O
kanamycin	O
.	O

Wells	O
were	O
washed	O
twice	O
with	O
PBS	O
and	O
lysed	O
with	O
0	O
.	O
1	O
%	O
Triton	O
X	O
-	O
100	O
,	O
followed	O
by	O
serial	O
10	O
-	O
fold	O
dilutions	O
plated	O
on	O
LBG	O
plates	O
and	O
incubated	O
at	O
37	O
degrees	O
C	O
for	O
2	O
days	O
.	O

Colony	O
forming	O
units	O
were	O
enumerated	O
and	O
uptake	O
expressed	O
as	O
a	O
percentage	O
of	O
initial	O
inoculating	O
dose	O
+/-	O
SEM	O
.	O

Antibodies	O
and	O
flow	O
cytometry	O

Flow	O
cytometric	O
analysis	O
was	O
performed	O
on	O
0	O
.	O
1	O
-	O
ml	O
blood	O
samples	O
transferred	O
to	O
micro	O
centrifuge	O
tubes	O
containing	O
90	O
mu	O
l	O
of	O
acid	O
citrate	O
dextrose	O
(	O
ACD	O
)	O
solution	O
.	O

Red	O
blood	O
cells	O
were	O
lysed	O
using	O
ACK	O
-	O
lysing	O
buffer	O
(	O
Biosource	O
International	O
,	O
Inc	O
.	O
,	O
Camarillo	O
,	O
CA	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instruction	O
.	O

Antibodies	O
used	O
for	O
analysis	O
of	O
surface	O
markers	O
included	O
:	O
FITC	O
-	O
conjugated	O
rat	B-LIVB
anti	O
-	O
mouse	B-LIVB
CD45R	O
/	O
B220	O
(	O
RA3	O
-	O
6B2	O
,	O
BD	O
Pharmingen	O
San	O
Diego	O
,	O
CA	O
)	O
for	O
B	O
cells	O
;	O
FITC	O
-	O
conjugated	O
rat	B-LIVB
anti	O
-	O
mouse	B-LIVB
CD8	O
alpha	O
(	O
53	O
-	O
6	O
.	O
7	O
)	O
and	O
CD4	O
(	O
GK1	O
.	O
5	O
,	O
BD	O
Pharmingen	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
for	O
CD8	O
+	O
or	O
CD4	O
+	O
cells	O
,	O
respectively	O
.	O

Samples	O
evaluated	O
for	O
CD4	O
+	O
and	O
CD8	O
alpha	O
+	O
cells	O
were	O
also	O
incubated	O
with	O
biotin	O
-	O
conjugated	O
hamster	O
anti	O
-	O
mouse	B-LIVB
CD3e	O
(	O
145	O
-	O
2C11	O
)	O
monoclonal	O
antibody	O
(	O
BD	O
Pharmingen	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
and	O
subsequently	O
with	O
streptavidin	O
APC	O
Cy7	O
.	O

Isotype	O
-	O
matched	O
,	O
non	O
-	O
specific	O
controls	O
were	O
assayed	O
in	O
parallel	O
(	O
BD	O
Pharmingen	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

Surface	O
staining	O
was	O
performed	O
according	O
to	O
previously	O
published	O
protocols	O
[	O
21	O
]	O
.	O

Following	O
cell	O
staining	O
,	O
the	O
samples	O
were	O
fixed	O
with	O
2	O
%	O
buffered	O
paraformaldehyde	O
overnight	O
prior	O
to	O
analysis	O
by	O
flow	O
cytometry	O
.	O

Samples	O
were	O
analyzed	O
using	O
a	O
FACSCalibur	O
flow	O
cytometer	O
with	O
BD	O
CellQuest	O
Pro	O
software	O
.	O

Antibody	O
assays	O

Immunoglobulin	O
subclass	O
IgG1	O
and	O
IgG2a	O
titers	O
in	O
mice	B-LIVB
were	O
determined	O
by	O
a	O
whole	O
bacterial	O
cell	O
ELISA	O
performed	O
in	O
96	O
-	O
well	O
,	O
Immulon	O
2	O
HB	O
,	O
round	O
-	O
bottom	O
plates	O
(	O
Dynex	O
Technologies	O
)	O
.	O

B	B-LIVB
.	I-LIVB
mallei	I-LIVB
antigen	O
was	O
diluted	O
in	O
0	O
.	O
1	O
M	O
carbonate	O
buffer	O
(	O
pH	O
9	O
.	O
5	O
)	O
and	O
50	O
mu	O
l	O
of	O
diluted	O
cells	O
placed	O
into	O
wells	O
.	O

Plates	O
were	O
stored	O
overnight	O
at	O
4	O
degrees	O
C	O
.	O

The	O
plates	O
were	O
washed	O
with	O
washing	O
solution	O
(	O
1	O
x	O
PBS	O
,	O
0	O
.	O
05	O
%	O
Tween	O
20	O
)	O
,	O
and	O
incubated	O
with	O
100	O
mu	O
l	O
of	O
blocking	O
solution	O
(	O
1	O
x	O
PBS	O
,	O
1	O
%	O
bovine	B-LIVB
serum	O
albumin	O
,	O
0	O
.	O
05	O
%	O
Tween	O
20	O
)	O
for	O
1	O
h	O
at	O
37	O
degrees	O
C	O
.	O

Dilutions	O
of	O
mouse	B-LIVB
sera	O
were	O
made	O
with	O
blocking	O
solution	O
in	O
duplicate	O
and	O
plates	O
were	O
incubated	O
for	O
1	O
h	O
at	O
37	O
degrees	O
C	O
.	O

Following	O
incubation	O
,	O
plates	O
were	O
washed	O
and	O
50	O
mu	O
l	O
of	O
anti	O
-	O
Ig	O
-	O
horseradish	B-LIVB
peroxidase	O
subclass	O
conjugate	O
,	O
diluted	O
accordingly	O
to	O
manufacturer	O
'	O
s	O
instructions	O
(	O
Southern	O
Biotechnology	O
Associates	O
,	O
Inc	O
.	O
Birmingham	O
,	O
Ala	O
.	O
)	O
,	O
was	O
added	O
to	O
each	O
well	O
and	O
incubated	O
for	O
1	O
h	O
at	O
37	O
degrees	O
C	O
.	O

After	O
washing	O
,	O
50	O
mu	O
l	O
of	O
2	O
,	O
2	O
'	O
-	O
azino	O
-	O
di	O
-	O
(	O
3	O
-	O
ethylbenzthizoline	O
)	O
-	O
6	O
-	O
sulfonate	O
(	O
ABTS	O
)	O
peroxidase	O
substrate	O
(	O
KPL	O
,	O
Inc	O
.	O
,	O
Gaithersburg	O
,	O
Maryland	O
)	O
was	O
added	O
to	O
each	O
well	O
and	O
plates	O
incubated	O
for	O
25	O
min	O
at	O
room	O
temperature	O
.	O

The	O
amount	O
of	O
bound	O
antibody	O
was	O
determined	O
colorimetrically	O
by	O
absorbance	O
at	O
405	O
nm	O
.	O

Statistical	O
analysis	O

Survival	O
curves	O
were	O
calculated	O
by	O
Kaplan	O
Meier	O
survival	O
analysis	O
with	O
log	O
-	O
rank	O
tests	O
between	O
groups	O
using	O
GraphPad	O
Prism	O
(	O
V	O
.	O
4	O
.	O
03	O
for	O
windows	O
)	O
.	O

Statistical	O
analysis	O
was	O
generally	O
performed	O
with	O
the	O
paired	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

P	O
value	O
<=	O
0	O
.	O
05	O
was	O
considered	O
significant	O
.	O

Abbreviations	O

HK	O
:	O
Heat	O
-	O
killed	O
;	O
i	O
.	O
p	O
.	O
:	O
intraperitoneal	O
;	O
i	O
.	O
n	O
.	O
:	O
intranasal	O
.	O

Authors	O
'	O
contributions	O

GCW	O
designed	O
and	O
conducted	O
experiments	O
and	O
drafted	O
the	O
manuscript	O
.	O

BMJ	O
carried	O
out	O
the	O
immunoassays	O
and	O
animal	O
work	O
.	O

SP	O
provided	O
analysis	O
of	O
data	O
and	O
contributed	O
to	O
design	O
and	O
animal	O
work	O
.	O

RAL	O
participated	O
in	O
the	O
generation	O
and	O
analysis	O
of	O
chronic	O
TNF	O
-	O
alpha	O
data	O
.	O

DME	O
conceived	O
the	O
study	O
,	O
and	O
participated	O
in	O
its	O
design	O
and	O
coordination	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
.	O

AGT	O
participated	O
in	O
the	O
bacterial	O
work	O
and	O
drafting	O
of	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

The	O
ineffectiveness	O
of	O
tobramycin	O
combination	O
therapy	O
in	O
Streptococcus	B-LIVB
faecium	I-LIVB
endocarditis	O
.	O

Abstract	O

A	O
patient	B-LIVB
required	O
mitral	O
valve	O
replacement	O
following	O
ineffective	O
antibiotic	O
treatment	O
of	O
enterococcal	O
endocarditis	O
caused	O
by	O
Streptococcus	B-LIVB
faecium	I-LIVB
.	O

Endocarditis	O
had	O
relapsed	O
despite	O
therapy	O
with	O
ampicillin	O
and	O
tobramycin	O
for	O
six	O
weeks	O
.	O

A	O
second	O
relapse	O
had	O
occurred	O
following	O
treatment	O
with	O
penicillin	O
and	O
gentamicin	O
.	O

Initial	O
failure	O
of	O
antibiotic	O
therapy	O
may	O
be	O
related	O
to	O
the	O
known	O
lack	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
synergy	O
between	O
penicillin	O
and	O
tobramycin	O
against	O
S	B-LIVB
.	I-LIVB
faecium	I-LIVB
.	O

Effective	O
therapy	O
of	O
enterococcal	O
endocarditis	O
requires	O
considerations	O
of	O
bacterial	O
speciation	O
,	O
determination	O
of	O
high	O
-	O
level	O
aminoglycoside	O
resistance	O
,	O
and	O
preferably	O
adequate	O
antibiotic	O
synergy	O
studies	O
to	O
assure	O
effective	O
therapy	O
.	O

THE	O
YALE	O
JOURNAL	O
OF	O
BIOLOGY	O
AND	O
MEDICINE	O
56	O
(	O
1983	O
)	O
,	O
243	O
-	O
249	O

The	O
Ineffectiveness	O
of	O
Tobramycin	O
Combination	O
Therapy	O

in	O
Streptococcus	B-LIVB
Faecium	I-LIVB
Endocarditis	O

JUDITH	O
A	O
.	O

GOLDSTEIN	O
,	O
M	O
.	O
D	O
.	O
,	O
a	O
HOWARD	O
COHEN	O
,	O
M	O
.	O
D	O
.	O
,	O
a	O
AND	O

FRANK	O
J	O
.	O

BIA	O
,	O
M	O
.	O
D	O
.	O
,	O
M	O
.	O
P	O
.	O
H	O
.	O
a	O
,	O
b	O

aInfectious	O
Disease	O
Section	O
of	O
the	O
Department	O
of	O
Medicine	O
,	O
and	O
bThe	O
Department	O
of	O

Laboratory	O
Medicine	O
,	O
Veterans	O
Administration	O
Medical	O
Center	O
,	O

West	O
Haven	O
,	O
and	O
Yale	O
University	O
School	O
of	O
Medicine	O
,	O

New	O
Haven	O
,	O
Connecticut	O

Received	O
July	O
11	O
,	O
1983	O

A	O
patient	B-LIVB
required	O
mitral	O
valve	O
replacement	O
following	O
ineffective	O
antibiotic	O
treatment	O
of	O
enterococcal	O
endocarditis	O
caused	O
by	O
Streptococcusfaecium	B-LIVB
.	O

Endocarditis	O
had	O
relapsed	O
despite	O
therapy	O
with	O
ampicillin	O
and	O
tobramycin	O
for	O
six	O
weeks	O
.	O

A	O
second	O
relapse	O
had	O
occurred	O
following	O
treatment	O
with	O
penicillin	O
and	O
gentamicin	O
.	O

Initial	O
failure	O
of	O
antibiotic	O
therapy	O
may	O
be	O
related	O
to	O
the	O
known	O
lack	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
synergy	O
between	O
penicillin	O
and	O
tobramycin	O
against	O
S	B-LIVB
.	I-LIVB
faecium	I-LIVB
.	O

Effective	O
therapy	O
of	O
enterococcal	O
endocarditis	O
requires	O
considerations	O
of	O
bacterial	O
speciation	O
,	O
determination	O
of	O
high	O
-	O
level	O
aminoglycoside	O
resistance	O
,	O
and	O
preferably	O
adequate	O
antibiotic	O
synergy	O
studies	O
to	O
assure	O
effective	O
therapy	O
.	O

INTRODUCTION	O

Enterococcal	O
endocarditis	O
requires	O
special	O
therapeutic	O
considerations	O
because	O
the	O
responsible	O
organisms	O
are	O
relatively	O
penicillin	O
-	O
resistant	O
streptococci	O
which	O
require	O
synergistic	O
combinations	O
of	O
antibiotics	O
to	O
achieve	O
acceptable	O
cure	O
rates	O
[	O
1	O
,	O
2	O
]	O
.	O

The	O
group	O
D	O
enterococci	O
include	O
three	O
main	O
species	O
S	B-LIVB
.	I-LIVB
faecalis	I-LIVB
,	O
S	B-LIVB
.	I-LIVB
faecium	I-LIVB
,	O
and	O
S	B-LIVB
.	I-LIVB
durans	I-LIVB
.	O

S	B-LIVB
.	I-LIVB
faecium	I-LIVB
cause	O
a	O
minority	O
of	O
all	O
cases	O
of	O
enterococcal	O
endocarditis	O
,	O
in	O
those	O
instances	O
in	O
which	O
enterococci	O
have	O
been	O
speciated	O
[	O
3	O
]	O
,	O
but	O
they	O
have	O
been	O
more	O
resistant	O
both	O
to	O
penicillin	O
and	O
penicillin	O
-	O
aminoglycoside	O
combinations	O
than	O
S	B-LIVB
.	I-LIVB
faecalis	I-LIVB
[	O
4	O
,	O
5	O
,	O
6	O
]	O
.	O

We	O
describe	O
a	O
64	O
-	O
year	O
-	O
old	O
man	B-LIVB
with	O
S	B-LIVB
.	I-LIVB
faecium	I-LIVB
endocarditis	O
in	O
whom	O
a	O
six	O
-	O
week	O
course	O
of	O
ampicillin	O
and	O
tobramycin	O
,	O
followed	O
by	O
additional	O
courses	O
of	O
penicillin	O
and	O
other	O
aminoglycosides	O
,	O
failed	O
to	O
eradicate	O
the	O
organism	O
from	O
the	O
patient	B-LIVB
'	O
s	O
mitral	O
valve	O
.	O

This	O
case	O
is	O
of	O
interest	O
because	O
therapeutic	O
failure	O
of	O
ampicillin	O
and	O
tobramycin	O
in	O
S	B-LIVB
.	I-LIVB
faecium	I-LIVB
endocarditis	O
has	O
not	O
been	O
reported	O
previously	O
,	O
but	O
might	O
have	O
been	O
predicted	O
on	O
the	O
basis	O
of	O
previous	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
[	O
6	O
]	O
.	O

Although	O
the	O
need	O
for	O
both	O
a	O
penicillin	O
derivative	O
and	O
an	O
aminoglycoside	O
in	O
the	O
therapy	O
of	O
enterococcal	O
endocarditis	O
is	O
widely	O
known	O
,	O
it	O
is	O
important	O
to	O
distinguish	O
between	O
the	O
differing	O
efficacies	O
of	O
penicillin	O
-	O
aminoglycoside	O
combinations	O
for	O
treating	O
various	O
species	O
of	O
enterococci	O
such	O
as	O
S	B-LIVB
.	I-LIVB
faecium	I-LIVB
.	O

243	O

Address	O
reprint	O
requests	O
to	O
:	O
Judith	O
A	O
.	O
Goldstein	O
,	O
M	O
.	O
D	O
.	O
,	O
Section	O
of	O
Infectious	O
Diseases	O
,	O
Department	O
of	O
Medicine	O
,	O
Long	O
Island	O
Jewish	O
-	O
Hillside	O
Medical	O
Center	O
,	O
Queen	O
'	O
s	O
Hosp	O
.	O

Center	O
Affiliate	O
,	O
82	O
-	O
68	O
164th	O
Street	O
,	O
Jamaica	O
,	O
NY	O
11432	O

Copyright	O
c	O
1983	O
by	O
The	O
Yale	O
Journal	O
of	O
Biology	O
and	O
Medicine	O
,	O
Inc	O
.	O

All	O
rights	O
of	O
reproduction	O
in	O
any	O
form	O
reserved	O
.	O

GOLDSTEIN	O
ET	O
AL	O
.	O

CASE	O
REPORT	O

A	O
64	O
-	O
year	O
-	O
old	O
male	O
was	O
in	O
good	O
health	O
until	O
December	O
1980	O
,	O
when	O
he	O
noted	O
intermittent	O
night	O
sweats	O
,	O
malaise	O
,	O
fever	O
,	O
and	O
fatigue	O
.	O

He	O
received	O
oral	O
erythromycin	O
for	O
14	O
days	O
with	O
transient	O
improvement	O
of	O
symptoms	O
.	O

However	O
,	O
after	O
completing	O
therapy	O
,	O
symptoms	O
reappeared	O
and	O
he	O
noted	O
a	O
15	O
-	O
pound	O
weight	O
loss	O
with	O
low	O
-	O
grade	O
fever	O
(	O
99	O
-	O
100	O
.	O
5	O
?	O
F	O
)	O
during	O
the	O
two	O
months	O
preceding	O
admission	O
.	O

There	O
was	O
no	O
previous	O
history	O
of	O
rheumatic	O
or	O
congenital	O
heart	O
disease	O
.	O

In	O
March	O
1981	O
,	O
the	O
patient	B-LIVB
was	O
admitted	O
to	O
his	O
community	O
hospital	O
where	O
evaluation	O
revealed	O
a	O
new	O
apical	O
systolic	O
murmur	O
radiating	O
to	O
the	O
axilla	O
.	O

There	O
were	O
no	O
petechiae	O
,	O
Janeway	O
lesions	O
,	O
Osler	O
'	O
s	O
nodes	O
,	O
Roth	O
spots	O
,	O
or	O
splenomegaly	O
.	O

The	O
hematocrit	O
was	O
34	O
.	O
8	O
percent	O
,	O
WBC	O
count	O
9	O
,	O
300	O
cells	O
per	O
cu	O
mm	O
with	O
a	O
differential	O
count	O
of	O
67	O
segmented	O
forms	O
,	O
9	O
bands	O
,	O
15	O
lymphocytes	O
,	O
7	O
monocytes	O
,	O
1	O
eosinophil	O
,	O
and	O
1	O
basophil	O
.	O

The	O
erythrocyte	O
sedimentation	O
rate	O
(	O
ESR	O
)	O
was	O
62	O
mm	O
per	O
hour	O
(	O
nl	O
<	O
10	O
mm	O
per	O
hour	O
)	O
and	O
the	O
serum	O
rheumatoid	O
factor	O
titer	O
was	O
1	O
:	O
320	O
.	O

Chest	O
films	O
and	O
electrocardiogram	O
were	O
reportedly	O
normal	O
.	O

Group	O
D	O
streptococci	O
grew	O
from	O
three	O
sets	O
of	O
blood	O
cultures	O
.	O

Enterococcal	O
endocarditis	O
was	O
diagnosed	O
and	O
he	O
was	O
treated	O
with	O
six	O
weeks	O
of	O
parenteral	O
ampicillin	O
(	O
12	O
grams	O
per	O
day	O
)	O
and	O
tobramycin	O
(	O
3	O
mg	O
per	O
kg	O
per	O
day	O
)	O
.	O

Resolution	O
of	O
symptoms	O
occurred	O
within	O
several	O
days	O
after	O
antibiotics	O
were	O
begun	O
.	O

Serum	O
bactericidal	O
titers	O
against	O
the	O
organism	O
,	O
obtained	O
during	O
peak	O
antibiotic	O
levels	O
,	O
were	O
1	O
:	O
8	O
or	O
greater	O
on	O
several	O
occasions	O
,	O
and	O
blood	O
cultures	O
were	O
negative	O
while	O
the	O
patient	B-LIVB
was	O
receiving	O
antibiotics	O
.	O

M	O
-	O
mode	O
echocardiography	O
demonstrated	O
left	O
atrial	O
enlargement	O
but	O
no	O
definable	O
abnormalities	O
of	O
the	O
mitral	O
or	O
aortic	O
valves	O
.	O

Intravenous	O
pyelogram	O
,	O
oral	O
cholecystogram	O
,	O
cystoscopy	O
,	O
liver	O
-	O
spleen	O
scan	O
,	O
and	O
upper	O
and	O
lower	O
gastrointestinal	O
series	O
were	O
normal	O
except	O
for	O
a	O
few	O
sigmoid	O
diverticuli	O
.	O

Flexible	O
signoidoscopy	O
demonstrated	O
both	O
a	O
small	O
perianal	O
fissure	O
and	O
hemorrhoids	O
.	O

Blood	O
cultures	O
two	O
weeks	O
after	O
therapy	O
were	O
negative	O
.	O

Second	O
Admission	O
(	O
June	O
19	O
-	O
August	O
4	O
,	O
1981	O
)	O

In	O
June	O
1981	O
,	O
he	O
again	O
noted	O
intermittent	O
fever	O
,	O
night	O
sweats	O
,	O
and	O
fatigue	O
.	O

Group	O
D	O
streptococci	O
grew	O
from	O
three	O
sets	O
of	O
blood	O
cultures	O
and	O
he	O
was	O
admitted	O
to	O
the	O
West	O
Haven	O
VA	O
Medical	O
Center	O
for	O
recurrent	O
endocarditis	O
.	O

On	O
examination	O
a	O
somewhat	O
louder	O
apical	O
systolic	O
murmur	O
was	O
noted	O
.	O

The	O
ESR	O
was	O
50	O
mm	O
/	O
hour	O
and	O
rheumatoid	O
factor	O
titer	O
was	O
1	O
:	O
320	O
.	O

Serum	O
complement	O
levels	O
were	O
normal	O
and	O
cryoglobulins	O
were	O
not	O
detectable	O
.	O

Chest	O
films	O
,	O
EKG	O
,	O
and	O
urinalysis	O
were	O
normal	O
.	O

Cardiac	O
M	O
-	O
mode	O
echocardiogram	O
revealed	O
a	O
globular	O
mass	O
attached	O
to	O
the	O
posterior	O
mitral	O
valve	O
leaflet	O
with	O
prolapse	O
into	O
a	O
slightly	O
enlarged	O
left	O
atrium	O
.	O

A	O
twodimensional	O
echocardiogram	O
confirmed	O
mitral	O
valve	O
prolapse	O
and	O
suggested	O
a	O
posterior	O
leaflet	O
vegetation	O
.	O

Gallium	O
citrate	O
scan	O
was	O
negative	O
.	O

Three	O
separate	O
morphologic	O
colony	O
variants	O
were	O
isolated	O
from	O
blood	O
,	O
each	O
identified	O
as	O
S	B-LIVB
.	I-LIVB
faecium	I-LIVB
by	O
Dr	O
.	O
R	O
.	O
R	O
.	O

Facklam	O
(	O
Center	O
for	O
Disease	O
Control	O
,	O
Atlanta	O
,	O
Georgia	O
)	O
.	O

The	O
patient	B-LIVB
received	O
intravenous	O
penicillin	O
(	O
20	O
million	O
units	O
per	O
day	O
)	O
and	O
gentamicin	O
(	O
3	O
mg	O
per	O
kg	O
per	O
day	O
)	O
for	O
six	O
weeks	O
with	O
improvement	O
.	O

Peak	O
serum	O
bactericidal	O
titers	O
of	O
1	O
:	O
8	O
or	O
greater	O
were	O
achieved	O
against	O
two	O
of	O
the	O
colony	O
variants	O
;	O
however	O
,	O
against	O
the	O
large	O
colony	O
morphotype	O
,	O
a	O
titer	O
of	O
only	O
1	O
:	O
2	O
was	O
obtained	O
.	O

An	O
enlarged	O
left	O
atrium	O
with	O
intermittent	O
fluttering	O
and	O
prolapse	O
of	O
the	O
mitral	O
valve	O
was	O
noted	O
on	O
echocardiography	O
three	O
weeks	O
into	O
therapy	O
.	O

Multiple	O
blood	O
cultures	O
taken	O
while	O
the	O
patient	B-LIVB
was	O
receiving	O
antibiotics	O
were	O
negative	O
,	O
as	O
were	O
those	O
obtained	O
48	O
and	O
72	O
hours	O
after	O
discontinuation	O
of	O
antibiotics	O
.	O

244	O

S	B-LIVB
.	I-LIVB

FAECIUM	B-LIVB
ENDOCARDITIS	O

Third	O
Admission	O
(	O
August	O
12	O
-	O
October	O
4	O
,	O
1981	O
)	O

Withing	O
a	O
week	O
following	O
discharge	O
,	O
the	O
patient	B-LIVB
again	O
developed	O
fever	O
,	O
nocturnal	O
sweats	O
,	O
and	O
malaise	O
.	O

S	B-LIVB
.	I-LIVB
faecium	I-LIVB
(	O
large	O
colony	O
morphotype	O
,	O
and	O
poorly	O
growing	O
small	O
colony	O
morphotype	O
)	O
grew	O
from	O
six	O
sets	O
of	O
blood	O
cultures	O
obtained	O
on	O
admission	O
.	O

Penicillin	O
(	O
30	O
million	O
units	O
/	O
day	O
)	O
and	O
gentamicin	O
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
)	O
were	O
again	O
administered	O
,	O
initially	O
achieving	O
peak	O
serum	O
inhibitory	O
and	O
bactericidal	O
dilutions	O
of	O
1	O
:	O
16	O
and	O
1	O
:	O
8	O
against	O
the	O
organism	O
,	O
respectively	O
.	O

However	O
,	O
the	O
organism	O
had	O
a	O
lowlevel	O
resistance	O
to	O
streptomycin	O
(	O
MIC	O
<	O
125	O
/	O
Ag	O
/	O
ml	O
)	O
,	O
and	O
streptomycin	O
(	O
2	O
grams	O
per	O
day	O
)	O
was	O
substituted	O
for	O
gentamicin	O
two	O
weeks	O
into	O
antibiotic	O
therapy	O
.	O

Repeat	O
echocardiograms	O
showed	O
irregular	O
and	O
shaggy	O
densities	O
of	O
both	O
mitral	O
valve	O
leaflets	O
with	O
partial	O
prolapse	O
.	O

Cardiac	O
catheterization	O
demonstrated	O
marked	O
mitral	O
valve	O
prolapse	O
with	O
mitral	O
regurgitation	O
.	O

A	O
radiolucent	O
filling	O
defect	O
was	O
noted	O
,	O
suggesting	O
a	O
coronary	O
artery	O
embolus	O
at	O
the	O
origin	O
of	O
the	O
left	O
anterior	O
descending	O
(	O
LAD	O
)	O
artery	O
,	O
causing	O
75	O
percent	O
occlusion	O
of	O
the	O
lumen	O
.	O

The	O
patient	B-LIVB
underwent	O
mitral	O
valve	O
replacement	O
,	O
receiving	O
a	O
number	O
31	O
porcine	O
Hancock	O
bioprosthesis	O
and	O
bypass	O
graft	O
to	O
the	O
midportion	O
of	O
the	O
LAD	O
.	O

The	O
mitral	O
valve	O
was	O
thickened	O
with	O
several	O
ruptured	O
chordae	O
of	O
the	O
posterior	O
leaflet	O
noted	O
,	O
but	O
no	O
vegetations	O
.	O

The	O
aortic	O
valve	O
appeared	O
normal	O
,	O
with	O
no	O
visible	O
septal	O
or	O
ring	O
abscesses	O
.	O

The	O
occlusion	O
in	O
the	O
LAD	O
was	O
not	O
approached	O
to	O
avoid	O
embolizing	O
distal	O
fragments	O
.	O

Histopathologically	O
the	O
mitral	O
valve	O
showed	O
mild	O
fibrosis	O
and	O
myxoid	O
degeneration	O
without	O
inflammatory	O
changes	O
.	O

Bacterial	O
and	O
fungal	O
stains	O
were	O
negative	O
but	O
S	B-LIVB
.	I-LIVB
faecium	I-LIVB
grew	O
from	O
fragments	O
of	O
the	O
resected	O
valve	O
.	O

Following	O
surgery	O
the	O
patient	B-LIVB
received	O
six	O
additional	O
weeks	O
parenteral	O
penicillin	O
and	O
streptomycin	O
.	O

Repeat	O
blood	O
cultures	O
on	O
this	O
regimen	O
and	O
following	O
therapy	O
were	O
negative	O
.	O

Evaluation	O
six	O
months	O
following	O
discontinuation	O
of	O
antibiotics	O
showed	O
no	O
evidence	O
of	O
recurrent	O
endocarditis	O
.	O

LABORATORY	O
EVALUATION	O

The	O
minimum	O
inhibitory	O
and	O
bactericidal	O
concentrations	O
of	O
penicillin	O
,	O
ampicillin	O
,	O
and	O
tobramycin	O
against	O
the	O
S	B-LIVB
.	I-LIVB
faecium	I-LIVB
isolated	O
from	O
the	O
patient	B-LIVB
'	O
s	O
blood	O
cultures	O

TABLE	O
1	O

Minimum	O
Inhibitory	O
and	O
Bactericidal	O
Concentrations	O
of	O
Antibiotics	O
,	O

Against	O
Streptococcus	B-LIVB
faecium	I-LIVB
Isolates	O
from	O
Blood	O
Cultures	O

Date	O
Penicillin	O
Ampicillin	O
Tobramycin	O

Organism	O
Isolated	O
MIC	O
MIC	O
MBC	O
MIC	O
MBC	O
S	B-LIVB
.	I-LIVB
faecium	I-LIVB
,	O
prior	O
to	O
ampicillin	O
/	O

tobramycin	O
therapy	O
3	O
/	O
17	O
/	O
81	O
2	O
1	O
2	O
>	O
32	O
>	O
32	O
S	B-LIVB
.	I-LIVB
faecium	I-LIVB
,	O
after	O
ampicillin	O
/	O

tobramycin	O
therapy	O

a	O
.	O

Large	O
colony	O

variant	O
6	O
/	O
16	O
/	O
81	O
2	O
1	O
1	O
>	O
32	O
>	O
32	O
b	O
.	O

Medium	O
colony	O

variant	O
6	O
/	O
16	O
/	O
81	O
2	O
1	O
2	O
32	O
32	O
c	O
.	O

Small	O
colony	O

variant	O
6	O
/	O
16	O
/	O
81	O
4	O
2	O
4	O
>	O
32	O
>	O
32	O
aMIC	O
and	O
MBC	O
are	O
minimum	O
inhibitory	O
and	O
bactericidal	O
concentrations	O
of	O
antibiotics	O
,	O
respectively	O
,	O
in	O
tig	O
/	O
ml	O
.	O

245	O

GOLDSTEIN	O
ET	O
AL	O
.	O

FIG	O
.	O

1	O
.	O

Time	O
-	O
kill	O
curve	O
demonstrat8	O
3	O
-	O
\	O
"	O
'	O
'	O
ing	O
the	O
effects	O
of	O
various	O
penicillinO	O
aminoglycoside	O
combinations	O
on	O
S	O
.	O

{	O
73	O
2	O
-	O
\	O
>	O
,	O
faecium	O
obtained	O
from	O
the	O
patient	B-LIVB
'	O
s	O

blood	O
cultures	O
immediately	O
prior	O
to	O
mitral	O
valve	O
excision	O
.	O

Note	O
the	O
lack	O
of	O
4u	O
,	O
synergy	O
between	O
penicillin	O
and	O
tobra25kg	O
/	O
rm	O
Streporrrychn	O
t	O
mycin	O
against	O
this	O
organism	O
when	O

/	O
0	O
units	O
/	O
mI	O
Penicillin	O
_	O
compared	O
to	O
synergistic	O
combinations	O
0	O
4	O
8	O
12	O
6	O
20	O
24	O
of	O
penicillin	O
-	O
gentamicin	O
and	O
penicillin	O

HOURS	O
streptomycin	O
.	O

after	O
initial	O
oral	O
erythromycin	O
therapy	O
,	O
and	O
prior	O
to	O
therapy	O
for	O
endocarditis	O
,	O
are	O
shown	O
in	O
Table	O
1	O
.	O

Following	O
combined	O
therapy	O
with	O
ampicillin	O
and	O
tobramycin	O
and	O
relapse	O
of	O
endocarditis	O
,	O
three	O
morphological	O
variants	O
were	O
isolated	O
from	O
blood	O
cultures	O
and	O
also	O
evaluated	O
.	O

Twenty	O
-	O
four	O
hour	O
time	O
-	O
kill	O
curves	O
for	O
penicillin	O
in	O
combination	O
with	O
various	O
aminoglycosides	O
were	O
performed	O
by	O
Dr	O
.	O
Robert	O
Moellering	O
on	O
the	O
S	B-LIVB
.	I-LIVB
faecium	I-LIVB
isolated	O
from	O
the	O
patient	B-LIVB
'	O
s	O
blood	O
immediately	O
prior	O
to	O
mitral	O
valve	O
excision	O
and	O
replacement	O
(	O
Fig	O
.	O
1	O
)	O
.	O

Synergy	O
was	O
readily	O
demonstrable	O
against	O
this	O
organism	O
by	O
penicillin	O
-	O
streptomycin	O
and	O
penicillin	O
-	O
gentamicin	O
combinations	O
in	O
vitro	O
,	O
but	O
not	O
by	O
penicillin	O
-	O
tobramycin	O
.	O

DISCUSSION	O

Among	O
streptococci	O
,	O
the	O
enterococci	O
are	O
unusual	O
in	O
their	O
relative	O
resistance	O
to	O
a	O
broad	O
spectrum	O
of	O
antimicrobial	O
agents	O
,	O
and	O
single	O
-	O
agent	O
therapy	O
is	O
rarely	O
bactericidal	O
against	O
them	O
[	O
2	O
]	O
.	O

Since	O
Hunter	O
'	O
s	O
original	O
observations	O
in	O
1947	O
,	O
it	O
has	O
become	O
increasingly	O
clear	O
that	O
effective	O
synergistic	O
combinations	O
of	O
antibiotics	O
are	O
necessary	O
to	O
successfully	O
treat	O
enterococcal	O
endocarditis	O
[	O
1	O
]	O
.	O

Although	O
S	B-LIVB
.	I-LIVB
faecalis	I-LIVB
represents	O
the	O
majority	O
of	O
clinical	O
enterococcal	O
isolates	O
,	O
S	B-LIVB
.	I-LIVB
faecium	I-LIVB
nonetheless	O
comprises	O
5	O
-	O
10	O
percent	O
of	O
these	O
isolates	O
in	O
some	O
series	O
[	O
3	O
,	O
4	O
]	O
.	O

Moreover	O
,	O
major	O
differences	O
exist	O
in	O
antimicrobial	O
susceptibility	O
and	O
resistance	O
to	O
penicillin	O
-	O
aminoglycoside	O
synergism	O
between	O
these	O
two	O
enterococcal	O
species	O
.	O

The	O
MIC	O
of	O
penicillin	O
against	O
S	B-LIVB
.	I-LIVB
faecium	I-LIVB
is	O
higher	O
and	O
this	O
organism	O
is	O
more	O
resistant	O
to	O
a	O
number	O
of	O
different	O
combinations	O
of	O
penicillin	O
and	O
various	O
aminoglycosides	O
than	O
is	O
S	B-LIVB
.	I-LIVB
faecalis	I-LIVB
[	O
6	O
]	O
.	O

The	O
mechanisms	O
of	O
resistance	O
exhibited	O
by	O
enterococci	O
to	O
penicillin	O
-	O
aminoglycoside	O
synergy	O
have	O
been	O
investigated	O
.	O

Clinically	O
achievable	O
levels	O
of	O
amino	O

246	O

S	B-LIVB
.	I-LIVB

FAECIUM	B-LIVB
ENDOCARDITIS	O

glycosides	O
are	O
generally	O
ineffective	O
against	O
enterococci	O
.	O

This	O
intrinsic	O
low	O
-	O
level	O
resistance	O
(	O
MIC	O
c	O
250	O
isg	O
/	O
ml	O
)	O
is	O
thought	O
to	O
be	O
the	O
result	O
of	O
poor	O
antibiotic	O
penetration	O
of	O
the	O
bacterial	O
cell	O
wall	O
.	O

However	O
,	O
in	O
the	O
presence	O
of	O
antibiotics	O
that	O
interfere	O
with	O
cell	O
wall	O
synthesis	O
,	O
there	O
is	O
enhanced	O
aminoglycoside	O
uptake	O
[	O
7	O
]	O
.	O

In	O
concert	O
,	O
these	O
events	O
are	O
the	O
basis	O
for	O
penicillin	O
-	O
aminoglycoside	O
synergism	O
.	O

Ribosomal	O
resistance	O
of	O
the	O
30S	O
subunit	O
to	O
streptomycin	O
and	O
defective	O
uptake	O
of	O
gentamicin	O
in	O
the	O
presence	O
of	O
penicillin	O
have	O
been	O
reported	O
mechanisms	O
of	O
resistance	O
among	O
enterococcal	O
isolates	O
[	O
8	O
,	O
9	O
]	O
.	O

However	O
,	O
in	O
the	O
majority	O
of	O
instances	O
,	O
failure	O
of	O
synergy	O
involves	O
plasmid	O
-	O
mediated	O
production	O
of	O
aminoglycoside	O
-	O
modifying	O
enzymes	O
.	O

For	O
streptomycin	O
and	O
kanamycin	O
,	O
plasmid	O
-	O
mediated	O
enzymatic	O
inactivation	O
confers	O
high	O
-	O
level	O
resistance	O
(	O
MIC	O
>	O
2	O
,	O
000	O
Ag	O
/	O
ml	O
)	O
and	O
correlates	O
with	O
failure	O
of	O
these	O
aminoglycosides	O
to	O
exert	O
a	O
synergistic	O
effect	O
when	O
combined	O
with	O
penicillin	O
[	O
10	O
,	O
11	O
]	O
.	O

Plasmid	O
-	O
mediated	O
modifying	O
enzymes	O
have	O
been	O
found	O
in	O
both	O
S	B-LIVB
.	I-LIVB
faecalis	I-LIVB
and	O
S	B-LIVB
.	I-LIVB
faecium	I-LIVB
'	O
[	O
12	O
]	O
.	O

Currently	O
,	O
approximately	O
one	O
-	O
half	O
of	O
clinical	O
enterococcal	O
isolates	O
demonstrate	O
high	O
-	O
level	O
resistance	O
to	O
streptomycin	O
and	O
kanamycin	O
[	O
13	O
]	O
.	O

Combinations	O
of	O
penicillin	O
with	O
kanamycin	O
,	O
tobramycin	O
,	O
sisomicin	O
,	O
and	O
netilmicin	O
have	O
consistently	O
failed	O
to	O
demonstrate	O
synergistic	O
killing	O
of	O
S	B-LIVB
.	I-LIVB
faecium	I-LIVB
in	O
vitro	O
[	O
6	O
]	O
.	O

This	O
failure	O
of	O
synergy	O
occurs	O
even	O
when	O
high	O
-	O
level	O
resistance	O
to	O
these	O
aminoglycosides	O
is	O
not	O
present	O
.	O

The	O
mechanism	O
of	O
resistance	O
appears	O
to	O
be	O
related	O
to	O
the	O
production	O
of	O
an	O
inactivating	O
enzyme	O
that	O
acetylates	O
the	O
aminoglycoside	O
substrate	O
at	O
the	O
6	O
'	O
position1	O
[	O
14	O
]	O
.	O

The	O
genetic	O
basis	O
for	O
production	O
of	O
this	O
enzyme	O
has	O
not	O
been	O
well	O
-	O
defined	O
and	O
plasmid	O
transfer	O
experiments	O
have	O
thus	O
far	O
been	O
unsucessful	O
in	O
demonstrating	O
the	O
encodement	O
of	O
this	O
enzyme	O
by	O
extrachromosomal	O
DNA	O
[	O
14	O
]	O
.	O

Moellering	O
et	O
al	O
.	O
demonstrated	O
in	O
vivo	O
,	O
utilizing	O
the	O
rabbit	B-LIVB
model	O
of	O
endocarditis	O
,	O
that	O
penicillin	O
and	O
netilmicin	O
were	O
not	O
efficacious	O
in	O
the	O
treatment	O
of	O
endocarditis	O
caused	O
by	O
a	O
low	O
-	O
level	O
aminoglycoside	O
-	O
resistant	O
strain	O
of	O
S	B-LIVB
.	I-LIVB
faecium	I-LIVB
[	O
6	O
]	O
.	O

Although	O
combinations	O
of	O
penicillin	O
with	O
tobramycin	O
,	O
kanamycin	O
,	O
or	O
sisomicin	O
were	O
not	O
evaluated	O
,	O
the	O
authors	O
postulated	O
that	O
the	O
same	O
ineffectual	O
result	O
would	O
have	O
occurred	O
.	O

In	O
the	O
present	O
case	O
,	O
the	O
recurrence	O
of	O
S	B-LIVB
.	I-LIVB
faecium	I-LIVB
endocarditis	O
after	O
six	O
weeks	O
of	O
therapy	O
with	O
ampicillin	O
and	O
tobramycin	O
confirms	O
the	O
therapeutic	O
and	O
clinical	O
significance	O
of	O
their	O
data	O
,	O
and	O
emphasizes	O
that	O
tobramycin	O
is	O
not	O
an	O
aminoglycoside	O
to	O
be	O
used	O
for	O
treatment	O
of	O
serious	O
S	B-LIVB
.	I-LIVB
faecium	I-LIVB
infections	O
.	O

Bacterial	O
tolerance	O
has	O
been	O
suggested	O
as	O
a	O
possible	O
basis	O
for	O
therapeutic	O
failures	O
,	O
particularly	O
in	O
the	O
treatment	O
of	O
infections	O
caused	O
by	O
Staphylococcus	B-LIVB
aureus	I-LIVB
with	O
defects	O
in	O
the	O
production	O
of	O
autolysins	O
.	O

MBCs	O
are	O
generally	O
several	O
-	O
fold	O
higher	O
than	O
MICs	O
and	O
this	O
phenomenon	O
appears	O
to	O
be	O
associated	O
with	O
the	O
autolysin	O
defect	O
[	O
5	O
]	O
.	O

Lorian	O
has	O
also	O
described	O
the	O
formation	O
of	O
numerous	O
aberrant	O
cross	O
-	O
walls	O
by	O
S	B-LIVB
.	I-LIVB
faecalis	I-LIVB
grown	O
in	O
the	O
presence	O
of	O
subinhibitory	O
concentrations	O
of	O
penicillin	O
[	O
15	O
]	O
.	O

MBCs	O
were	O
only	O
slightly	O
higher	O
than	O
MICs	O
for	O
the	O
three	O
S	B-LIVB
.	I-LIVB
faecium	I-LIVB
variants	O
obtained	O
from	O
our	O
patient	B-LIVB
,	O
and	O
they	O
did	O
not	O
appear	O
to	O
be	O
tolerant	O
strains	O
of	O
S	B-LIVB
.	I-LIVB
faecium	I-LIVB
.	O

There	O
was	O
no	O
evidence	O
that	O
any	O
of	O
the	O
morphological	O
variants	O
isolated	O
were	O
unusually	O
resistant	O
to	O
antibiotics	O
.	O

Therefore	O
,	O
subsequent	O
failure	O
of	O
therapy	O
could	O
not	O
be	O
explained	O
on	O
the	O
basis	O
of	O
antibiotic	O
resistance	O
patterns	O
.	O

The	O
initial	O
failure	O
of	O
ampicillin	O
and	O
tobramycin	O
therapy	O
may	O
have	O
allowed	O
the	O
infecting	O
organism	O
to	O
become	O
better	O
established	O
and	O
more	O
difficult	O
to	O
eradicate	O
from	O
the	O
valve	O
.	O

Alternatively	O
,	O
a	O

'	O
Wennersten	O
C	O
,	O
Moellering	O
RC	O
Jr	O
:	O
Mechanism	O
of	O
resistance	O
to	O
penicillin	O
-	O
aminoglycoside	O
synergism	O
in	O
Streptococcus	B-LIVB
faecium	I-LIVB
.	O

Proceedings	O
of	O
the	O
1th	O
International	O
Congress	O
of	O
Chemotherapy	O
and	O
19th	O
Interscience	O
Conference	O
on	O
Antimicrobial	O
Agents	O
and	O
Chemotherapy	O
1	O
:	O
710	O
-	O
711	O
,	O
1979	O

247	O

248	O
GOLDSTEIN	O
ET	O
AL	O
.	O

persistent	O
focus	O
of	O
infection	O
causing	O
the	O
LAD	O
lesion	O
seen	O
by	O
arteriography	O
may	O
have	O
slowly	O
resolved	O
and	O
accounted	O
for	O
the	O
apparent	O
failure	O
to	O
respond	O
to	O
synergistic	O
combinations	O
of	O
antibiotics	O
.	O

In	O
summary	O
,	O
our	O
patient	B-LIVB
was	O
treated	O
for	O
Streptococcusfaecium	B-LIVB
endocarditis	O
with	O
both	O
ampicillin	O
and	O
the	O
aminoglycoside	O
antibiotic	O
,	O
tobramycin	O
.	O

Relapse	O
of	O
endocarditis	O
might	O
have	O
been	O
anticipated	O
on	O
the	O
basis	O
of	O
previous	O
experimental	O
data	O
showing	O
lack	O
of	O
synergy	O
when	O
tobramycin	O
is	O
used	O
against	O
this	O
organism	O
.	O

This	O
case	O
graphically	O
illustrates	O
the	O
relevance	O
of	O
synergy	O
studies	O
to	O
therapeutic	O
considerations	O
in	O
the	O
treatment	O
of	O
endocarditis	O
.	O

However	O
,	O
subsequent	O
therapy	O
with	O
synergistic	O
combinations	O
of	O
antibiotics	O
did	O
not	O
result	O
in	O
cure	O
.	O

The	O
data	O
do	O
not	O
implicate	O
tolerant	O
organisms	O
as	O
a	O
cause	O
for	O
relapses	O
.	O

Failure	O
of	O
therapy	O
may	O
have	O
been	O
related	O
to	O
the	O
presence	O
of	O
protected	O
organisms	O
in	O
vegetations	O
which	O
were	O
seen	O
on	O
echocardiograms	O
,	O
and	O
also	O
suggested	O
by	O
the	O
presence	O
of	O
a	O
possible	O
coronary	O
artery	O
embolus	O
seen	O
on	O
coronary	O
arteriograms	O
.	O

In	O
conclusion	O
,	O
speciation	O
of	O
isolates	O
suspected	O
of	O
causing	O
endocarditis	O
and	O
adequate	O
synergy	O
studies	O
of	O
antibiotic	O
combinations	O
are	O
indicated	O
before	O
a	O
long	O
and	O
expensive	O
course	O
of	O
therapy	O
with	O
antimicrobial	O
agents	O
is	O
undertaken	O
for	O
this	O
disease	O
.	O

However	O
,	O
as	O
this	O
case	O
also	O
illustrates	O
,	O
demonstration	O
of	O
synergism	O
in	O
vitro	O
does	O
not	O
assure	O
clinical	O
cure	O
.	O

ACKNOWLEDGEMENTS	O

Dr	O
.	O
Goldstein	O
was	O
supported	O
by	O
training	O
grant	O
Al	O
07033	O
-	O
05	O
from	O
the	O
National	O
Institute	O
of	O
Allergy	O
and	O
Infectious	O
Diseases	O
.	O

The	O
authors	O
gratefully	O
acknowledge	O
the	O
advice	O
,	O
laboratory	O
assistance	O
,	O
and	O
careful	O
review	O
of	O
this	O
manuscript	O
by	O
Dr	O
.	O
Robert	O
C	O
.	O
Moellering	O
,	O
Jr	O
.	O

The	O
authors	O
also	O
wish	O
to	O
thank	O
Dr	O
.	O
Howard	O
S	O
.	O
Forster	O
for	O
referring	O
this	O
patient	B-LIVB
to	O
us	O
,	O
Ms	O
.	O
Mary	O
Murray	O
and	O
Deborah	O
Beauvais	O
for	O
manuscript	O
preparation	O
,	O
and	O
Ms	O
.	O
Gertrude	O
Barden	O
,	O
MT	O
(	O
ASCP	O
)	O
,	O
MHS	O
,	O
for	O
technical	O
assistance	O
and	O
advice	O
in	O
evaluation	O
of	O
this	O
patient	B-LIVB
.	O

REFERENCES	O

1	O
.	O

Hunter	O
TH	O
:	O
Use	O
of	O
streptomycin	O
in	O
the	O
treatment	O
of	O
bacterial	O
endocarditis	O
.	O

Am	O
J	O
Med	O
2	O
:	O
436	O
-	O
442	O
,	O

1947	O

2	O
.	O

Moellering	O
RC	O
Jr	O
,	O
Krogstad	O
DJ	O
:	O
Antibiotic	O
resistance	O
in	O
enterococci	O
.	O

Microbiology	O
293	O
-	O
298	O
,	O
1979	O
3	O
.	O

Facklam	O
RR	O
:	O
Recognition	O
of	O
group	O
D	O
streptococcal	O
species	O
of	O
human	B-LIVB
origin	O
by	O
biochemical	O
and	O

physiological	O
tests	O
.	O

Appl	O
Microbiol	O
23	O
:	O
1131	O
-	O
1139	O
,	O
1972	O

4	O
.	O

Toala	O
P	O
,	O
McDonald	O
A	O
,	O
Wilcox	O
C	O
,	O
et	O
al	O
:	O
Susceptibility	O
of	O
group	O
D	O
streptococcus	O
(	O
enterococcus	O
)	O
to	O
21	O

antibiotics	O
in	O
vitro	O
,	O
with	O
special	O
reference	O
to	O
species	O
differences	O
.	O

Am	O
J	O
Med	O
Sci	O
258	O
:	O
416	O
-	O
430	O
,	O
1969	O
5	O
.	O

Shungu	O
DL	O
,	O
Cornett	O
JB	O
,	O
Shockman	O
GD	O
:	O
Morphological	O
and	O
physiological	O
study	O
of	O
autolytic	O

defective	O
Streptococcus	B-LIVB
faecium	I-LIVB
strains	O
.	O

J	O
Bacteriol	O
138	O
:	O
598	O
-	O
608	O
,	O
1979	O

6	O
.	O

Moellering	O
RC	O
Jr	O
,	O
Korzeniowski	O
OM	O
,	O
Sande	O
MA	O
,	O
et	O
al	O
:	O
Species	O
-	O
specific	O
resistance	O
to	O
antimicrobial	O

synergism	O
in	O
Streptococcusfaecium	B-LIVB
and	O
Streptococcusfaecalis	B-LIVB
.	O

J	O
Infect	O
Dis	O
140	O
:	O
203	O
-	O
208	O
,	O
1979	O

7	O
.	O

Moellering	O
RC	O
Jr	O
,	O
Weinberg	O
AN	O
:	O
Studies	O
on	O
antibiotic	O
synergism	O
against	O
enterococci	O
.	O

11	O
.	O

Effect	O
of	O

various	O
antibiotics	O
on	O
the	O
uptake	O
of	O
'	O
4C	O
-	O
labelled	O
streptomycin	O
by	O
enterococci	O
.	O

J	O
Clin	O
Invest	O
50	O
:	O
2580	O
-	O
2584	O
,	O
1971	O

8	O
.	O

Zimmermann	O
RA	O
,	O
Moellering	O
RC	O
Jr	O
,	O
Weinberg	O
AN	O
:	O
Mechanisms	O
of	O
resistance	O
to	O
antibiotic	O

synergism	O
in	O
enterococci	O
.	O

J	O
Bacteriol	O
105	O
:	O
873	O
-	O
879	O
,	O
1971	O

9	O
.	O

Moellering	O
RC	O
Jr	O
,	O
Murray	O
BE	O
,	O
Schoenbaum	O
SC	O
,	O
et	O
al	O
:	O
A	O
novel	O
mechanism	O
of	O
resistance	O
to	O
penicillin	O

gentamicin	O
synergism	O
in	O
S	B-LIVB
.	I-LIVB
faecalis	I-LIVB
.	O

J	O
Infect	O
Dis	O
141	O
:	O
81	O
-	O
86	O
,	O
1980	O

10	O
.	O

Krogstad	O
DJ	O
,	O
Korfhagen	O
TR	O
,	O
Moellering	O
RC	O
Jr	O
,	O
et	O
al	O
:	O
Plasmid	O
-	O
mediated	O
resistance	O
to	O
antibiotic	O

synergism	O
in	O
enterococci	O
.	O

J	O
Clin	O
Invest	O
61	O
:	O
1645	O
-	O
1653	O
,	O
1978	O

11	O
.	O

Krogstad	O
DJ	O
,	O
Korfhagen	O
TR	O
,	O
Moellering	O
RC	O
Jr	O
,	O
et	O
al	O
:	O
Aminoglycoside	O
-	O
inactivating	O
enzymes	O
in	O

clinical	O
isolates	O
of	O
Streptococcusfaecalis	B-LIVB
:	O
An	O
explanation	O
for	O
resistance	O
to	O
antibiotic	O
synergism	O
.	O

J	O
Clin	O
Invest	O
62	O
:	O
480	O
-	O
486	O
,	O
1978	O

S	B-LIVB
.	I-LIVB

FAECIUM	B-LIVB
ENDOCARDITIS	O
249	O

12	O
.	O

Courvalin	O
PM	O
,	O
Shaw	O
WV	O
,	O
Jacob	O
AE	O
:	O
Plasmid	O
-	O
mediated	O
mechanisms	O
of	O
resistance	O
to	O

aminoglycoside	O
-	O
aminocyclitol	O
antibiotics	O
and	O
to	O
chloramphenicol	O
in	O
group	O
D	O
streptococci	O
.	O

Antimicrob	O
Agents	O
Chemother	O
13	O
:	O
716	O
-	O
725	O
,	O
1978	O

13	O
.	O

Calderwood	O
SA	O
,	O
Wennersten	O
C	O
,	O
Moellering	O
RC	O
Jr	O
,	O
et	O
al	O
:	O
Resistance	O
to	O
six	O
aminoglycosidic	O

aminocyclitol	O
antibiotics	O
among	O
enterococci	O
:	O
Prevalence	O
,	O
evolution	O
,	O
and	O
relationship	O
to	O
synergism	O
with	O
penicillin	O
.	O

Antimicrob	O
Agents	O
Chemother	O
12	O
:	O
401	O
-	O
405	O
,	O
1977	O

14	O
.	O

Bisno	O
AL	O
:	O
Treatment	O
of	O
infective	O
endocarditis	O
.	O

New	O
York	O
,	O
Grune	O
and	O
Stratton	O
,	O
1981	O
,	O
p	O
90	O

15	O
.	O

Lorian	O
V	O
:	O
Effects	O
of	O
subminimum	O
inhibitory	O
concentrations	O
of	O
antibiotics	O
on	O
bacteria	O
.	O

In	O
Antibiotics	O

in	O
Laboratory	O
Medicine	O
.	O

Edited	O
by	O
V	O
Lorian	O
.	O

Baltimore	O
,	O
Williams	O
and	O
Wilkins	O
,	O
1980	O
,	O
p	O
342	O

Structural	O
organization	O
of	O
a	O
17	O
KB	O
segment	O
of	O
the	O
alpha	O
2	O
collagen	O
gene	O
:	O
evaluation	O
by	O
R	O
loop	O
mapping	O
.	O

Abstract	O

A	O
recombinant	O
phage	O
,	O
SpC3	O
,	O
containing	O
a	O
17	O
kb	O
genomic	O
DNA	O
insert	O
representing	O
approximately	O
60	O
%	O
of	O
the	O
3	O
'	O
portion	O
of	O
the	O
sheep	B-LIVB
collagen	O
alpha	O
2	O
gene	O
,	O
was	O
evaluated	O
by	O
electron	O
microscopic	O
R	O
loop	O
analysis	O
.	O

A	O
minimum	O
of	O
17	O
intervening	O
sequences	O
(	O
introns	O
)	O
and	O
18	O
alpha	O
2	O
coding	O
sequences	O
(	O
exons	O
)	O
were	O
mapped	O
.	O

With	O
the	O
exception	O
of	O
the	O
850	O
base	O
pair	O
exon	O
located	O
at	O
the	O
extreme	O
3	O
'	O
end	O
of	O
the	O
insert	O
,	O
all	O
exons	O
contained	O
250	O
base	O
pairs	O
or	O
less	O
.	O

The	O
total	O
length	O
of	O
all	O
the	O
exons	O
in	O
SpC3	O
was	O
3	O
,	O
014	O
base	O
pairs	O
.	O

The	O
length	O
distribution	O
of	O
the	O
17	O
introns	O
ranged	O
from	O
300	O
to	O
1600	O
base	O
pairs	O
;	O
together	O
,	O
all	O
of	O
the	O
introns	O
comprised	O
14	O
,	O
070	O
base	O
pairs	O
of	O
SpC3	O
DNA	O
.	O

Thus	O
,	O
the	O
DNA	O
region	O
required	O
for	O
coding	O
the	O
interspersed	O
3	O
kb	O
of	O
alpha	O
2	O
collagen	O
genetic	O
information	O
was	O
5	O
.	O
6	O
fold	O
longer	O
than	O
the	O
corresponding	O
alpha	O
2	O
mRNA	O
coding	O
sequences	O
.	O
Images	O

Nucleic	O
Acids	O
Research	O

Structural	O
organization	O
of	O
a	O
17	O
KB	O
segment	O
of	O
the	O
a2	O
collagen	O
gene	O
:	O
evaluation	O
by	O
R	O
loop	O
mapping	O
Millie	O
P	O
.	O
Schafer	O
,	O
Charles	O
D	O
.	O
Boyd	O
,	O
Paul	O
Tolstoshev	O
and	O
Ronald	O
G	O
.	O
Crystal	O

Pulmonary	O
Branch	O
,	O
National	O
Heart	O
,	O
Lung	O
and	O
Blood	O
Institute	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
Bethesda	O
,	O
MD	O
20205	O
,	O
USA	O

Received	O
13	O
February	O
1980	O

ABSTRACT	O

A	O
recombinant	O
phage	O
,	O
SpC3	O
,	O
containing	O
a	O
17	O
kb	O
genomic	O
DNA	O
insert	O
rep	O

resenting	O
approximately	O
60	O
%	O
of	O
the	O
3	O
'	O
portion	O
of	O
the	O
sheep	B-LIVB
collagen	O
a2	O
gene	O
,	O
was	O
evaluated	O
by	O
electron	O
microscopic	O
R	O
loop	O
analysis	O
.	O

A	O
minimum	O
of	O
17	O
intervening	O
sequences	O
(	O
introns	O
)	O
and	O
18	O
a2	O
coding	O
sequences	O
(	O
exons	O
)	O
were	O

mapped	O
.	O

With	O
the	O
exception	O
of	O
the	O
850	O
base	O
pair	O
exon	O
located	O
at	O
the	O
extreme	O
3	O
'	O
end	O
of	O
the	O
insert	O
,	O
all	O
exons	O
contained	O
250	O
base	O
pairs	O
or	O
less	O
.	O

The	O
total	O
length	O
of	O
all	O
the	O
exons	O
in	O
SpC3	O
was	O
3	O
,	O
014	O
base	O
pairs	O
.	O

The	O
length	O
distribution	O
of	O
the	O
17	O
introns	O
ranged	O
from	O
300	O
to	O
1600	O
base	O
pairs	O
;	O
together	O
,	O
all	O
of	O
the	O
introns	O
comprised	O
14	O
,	O
070	O
base	O
pairs	O
of	O
SpC3	O
DNA	O
.	O

Thus	O
,	O
the	O
DNA	O
region	O

required	O
for	O
coding	O
the	O
interspersed	O
3	O
kb	O
of	O
a2	O
collagen	O
genetic	O
information	O
was	O
5	O
.	O
6	O
fold	O
longer	O
than	O
the	O
corresponding	O
a2	O
mRNA	O
coding	O
sequences	O
.	O

INTRODUCTION	O

Type	O
I	O
collagen	O
,	O
composed	O
of	O
two	O
al	O
(	O
I	O
)	O
and	O
one	O
a2	O
polypeptide	O
chains	O
,	O
is	O
the	O
most	O
abundant	O
of	O
the	O
five	O
known	O
mammalian	O
collagen	O
types	O
.	O

It	O
is	O
a	O
major	O
extracellular	O
constituent	O
of	O
tissues	O
such	O
as	O
bone	O
,	O
tendon	O
,	O
skin	O
and	O
lung	O
where	O
,	O
because	O
of	O
its	O
great	O
tensile	O
strength	O
,	O
it	O
plays	O
an	O
important	O

role	O
in	O
tissue	O
structure	O
and	O
function	O
.	O

The	O
polypeptides	O
comprising	O
type	O
I	O

collagen	O
are	O
synthesized	O
in	O
long	O
,	O
precursor	O
forms	O
,	O
referred	O
to	O
as	O
pro	O
al	O
(	O
I	O
)	O
and	O
pro	O
a2	O
chains	O
,	O
1	O
each	O
containing	O
approximately	O
1500	O
amino	O
acid	O
residues	O
(	O
1	O
)	O
.	O

1	O
The	O
terminology	O
for	O
the	O
primary	O
translation	O
products	O
of	O
the	O
various	O

collagen	O
messenger	O
RNAs	O
is	O
still	O
in	O
a	O
state	O
of	O
flux	O
.	O

It	O
is	O
known	O
that	O
al	O
(	O
I	O
)	O
and	O
a2	O
chains	O
are	O
synthesized	O
in	O
precursor	O
forms	O
;	O
these	O
are	O
currently	O
termed	O
pro	O
al	O
(	O
I	O
)	O
and	O
pro	O
a2	O
chains	O
(	O
1	O
)	O
.	O

However	O
,	O
recent	O
studies	O
(	O
43	O
,	O
44	O
)	O
have	O
shown	O
that	O
the	O
actual	O
primary	O
translation	O
product	O
of	O
al	O
(	O
I	O
)	O
mRNA	O
is	O
somewhat	O
larger	O

than	O
the	O
pro	O
al	O
(	O
I	O
)	O
chain	O
;	O
this	O
translation	O
product	O
has	O
been	O
termed	O
a	O
"	O
pre	O
-	O
pro	O
al	O
(	O
I	O
)	O
chain	O
.	O
"	O
Although	O
the	O
corresponding	O
"	O
pre	O
-	O
pro	O
a2	O
chain	O
"	O
likely	O
exists	O
,	O
it	O
has	O
not	O
yet	O
been	O
characterized	O
.	O

For	O
simplicity	O
,	O
therefore	O
,	O
until	O
the	O

proper	O
terminology	O
for	O
the	O
primary	O
translation	O
product	O
is	O
clarified	O
,	O
we	O
have	O

chosen	O
to	O
use	O
the	O
terms	O
"	O
al	O
(	O
I	O
)	O
"	O
and	O
"	O
a2	O
"	O
to	O
refer	O
to	O
the	O
type	O
I	O
collagen	O
mRNAs	O
and	O
collagen	O
structural	O
gene	O
sequences	O
.	O

?	O
)	O
IRL	O
Press	O
Umited	O
,	O
1	O
Falconberg	O
Court	O
,	O
London	O
W1V	O
5FG	O
,	O
U	O
.	O
K	O
.	O

Volurne	O
8	O
Number	O
10	O
1980	O

2241	O

Nucleic	O
Acids	O
Research	O

There	O
is	O
increasing	O
evidence	O
that	O
the	O
quantities	O
of	O
al	O
(	O
I	O
)	O
and	O
a2	O

chains	O
produced	O
by	O
cells	O
may	O
be	O
regulated	O
,	O
in	O
part	O
,	O
at	O
the	O
genomic	O
level	O

(	O
1	O
)	O
.	O

However	O
,	O
to	O
understand	O
the	O
processes	O
which	O
mediate	O
their	O
expression	O
,	O

it	O
is	O
necessary	O
to	O
understand	O
the	O
structural	O
organization	O
of	O
these	O
collagen	O
genes	O
and	O
the	O
various	O
enzymes	O
that	O
modify	O
the	O
collagen	O
chains	O
after	O
its	O

synthesis	O
(	O
1	O
)	O
.	O

As	O
an	O
initial	O
approach	O
to	O
this	O
problem	O
,	O
we	O
have	O
recently	O

isolated	O
a	O
recombinant	O
bacteriophage	O
,	O
termed	O
SpC3	O
,	O
containing	O
approximately	O
60	O
%	O
of	O
the	O
a2	O
gene	O
for	O
type	O
I	O
collagen	O
.	O

Partial	O
characterization	O
of	O
this	O

a2	O
gene	O
demonstrated	O
that	O
,	O
like	O
most	O
other	O
structurally	O
evaluated	O
eukaryotic	O
genes	O
,	O
the	O
coding	O
sequences	O
are	O
interspersed	O
with	O
intervening	O
sequences	O
(	O
2	O
)	O
.	O

The	O
present	O
study	O
further	O
characterizes	O
this	O
portion	O
of	O
the	O
a2	O

gene	O
by	O
utilizing	O
electron	O
microscopic	O
R	O
loop	O
analysis	O
to	O
map	O
the	O
coding	O
regions	O
(	O
exons	O
)	O
and	O
intervening	O
sequences	O
(	O
introns	O
)	O
contained	O
within	O
the	O
sheep	B-LIVB
genomic	O
insert	O
of	O
SpC3	O
.	O

The	O
data	O
suggests	O
that	O
the	O
structural	O

organization	O
of	O
this	O
portion	O
of	O
the	O
a2	O
collagen	O
gene	O
represents	O
3	O
kb	O
of	O
coding	O
information	O
that	O
is	O
interspersed	O
in	O
a	O
complex	O
fashion	O
with	O
17	O
introns	O
over	O
17	O
kb	O
of	O
genome	O
.	O

MATERIALS	O
AND	O
METHODS	O

Isolation	O
and	O
characterization	O
of	O
a2	O
collagen	O
recombinant	O
clone	O
,	O
SpC3	O
.	O

The	O
sheep	B-LIVB
a2	O
collagen	O
recombinant	O
clone	O
,	O
SpC3	O
,	O
containing	O
a	O
portion	O
of	O
the	O
sheep	B-LIVB
a2	O
gene	O
,	O
was	O
isolated	O
as	O
previously	O
described	O
(	O
2	O
)	O
.	O

Briefly	O
,	O

high	O
molecular	O
weight	O
fetal	O
sheep	B-LIVB
liver	O
DNA	O
was	O
extracted	O
by	O
the	O
method	O
of	O
Blin	O
and	O
Stafford	O
(	O
3	O
)	O
,	O
and	O
15	O
-	O
20	O
kb	O
DNA	O
fragments	O
,	O
resulting	O
from	O
partial	O
Eco	O
RI	O
digestion	O
,	O
were	O
isolated	O
and	O
ligated	O
to	O
the	O
left	O
and	O
right	O
arms	O
of	O
Charon	O
4A	O
.	O

The	O
recombinant	O
DNA	O
was	O
then	O
packaged	O
in	O
vitro	O
and	O
the	O
sheep	B-LIVB

genomic	O
library	O
amplified	O
(	O
4	O
-	O
6	O
)	O
.	O

Screening	O
of	O
the	O
sheep	B-LIVB
genomic	O
library	O
was	O

conducted	O
utilizing	O
[	O
32	O
P	O
]	O
-	O
labeled	O
fetal	O
sheep	B-LIVB
tendon	O
type	O
I	O
collagen	O
cDNA	O
and	O

several	O
positive	O
recombinant	O
phages	O
were	O
isolated	O
.	O

One	O
recombinant	O
,	O
containing	O
a	O
17	O
kb	O
sheep	B-LIVB
genomic	O
insert	O
,	O
was	O
demonstrated	O
to	O
have	O
coding	O
sequences	O
corresponding	O
to	O
60	O
%	O
of	O
the	O
3	O
'	O
end	O
of	O
a2	O
mRNA	O
.	O

Prior	O
studies	O
showed	O
that	O
the	O
insert	O
in	O
SpC3	O
was	O
not	O
due	O
to	O
ligation	O
of	O
noncontiguous	O
restriction	O
fragments	O
and	O
/	O
or	O
genetic	O
rearrangement	O
during	O
the	O
cloning	O
process	O
(	O
2	O
)	O
.	O

Electron	O
mi	O
croscopy	O
.	O

To	O
visualize	O
the	O
recombinant	O
bacteriophage	O
DNA	O
structure	O
complementary	O
to	O
a2	O
collagen	O
mRNA	O
,	O
1	O
iig	O
of	O
SpC3	O
DNA	O
was	O
lyophilized	O
with	O
1	O
ig	O
or	O
100	O
ng	O
of	O
mRNA	O

to	O
give	O
DNA	O
:	O
mRNA	O
ratios	O
of	O
1	O
:	O
1	O
and	O
10	O
:	O
1	O
,	O
respectively	O
.	O

These	O
were	O
then	O
dissolved	O
in	O
10	O
i1	O
of	O
R	O
loop	O
buffer	O
[	O
70	O
%	O
(	O
v	O
/	O
v	O
)	O
deionized	O
formamide	O
,	O
0	O
.	O
1	O
N	O
-	O
[	O
tris	O
(	O
hydroxy	O

2242	O

Nucleic	O
Acids	O
Research	O

methyl	O
)	O
methyl	O
]	O
glycine	O
(	O
tricine	O
)	O
-	O
NaOH	O
,	O
pH	O
8	O
.	O
0	O
,	O
0	O
.	O
5	O
M	O
NaCl	O
,	O
and	O
0	O
.	O
01	O
M	O
ethyl	O

enediaminetetraacetate	O
(	O
EDTA	O
)	O
]	O
,	O
incubated	O
in	O
sealed	O
capillary	O
tubes	O
at	O
520	O
for	O
14	O
hr	O
(	O
7	O
)	O
,	O
and	O
then	O
diluted	O
1	O
:	O
10	O
with	O
R	O
loop	O
buffer	O
.	O

Two	O
spreading	O
methods	O
were	O
used	O
to	O
subsequently	O
prepare	O
the	O
hybrids	O
for	O
visualization	O
in	O
the	O
electron	O
microscope	O
.	O

70	O
%	O
formamide	O
method	O
.	O

Immediately	O
before	O
spreading	O
onto	O
a	O
deionized	O

water	O
hypophase	O
,	O
the	O
nucleic	O
acid	O
mixtures	O
were	O
diluted	O
an	O
additional	O
10	O
-	O
fold	O
in	O
R	O
loop	O
buffer	O
and	O
cytochrome	O
c	O
,	O
100	O
vg	O
/	O
ml	O
,	O
was	O
added	O
.	O

Urea	O
-	O
formamide	O
method	O
.	O

The	O
nucleic	O
acid	O
solutions	O
were	O
spread	O
using	O
a	O
modification	O
of	O
the	O
method	O
of	O
Westphal	O
and	O
Lai	O
(	O
8	O
,	O
9	O
)	O
.	O

The	O
hyperphase	O
contained	O
55	O
%	O
formamide	O
,	O
2	O
.	O
6	O
M	O
urea	O
,	O
0	O
.	O
009	O
M	O
EDTA	O
,	O
0	O
.	O
09	O
M	O
tricine	O
-	O
NaOH	O
,	O
pH	O
8	O
.	O
0	O
,	O
and	O
the	O
nucleic	O
acid	O
mixture	O
(	O
approximately	O
0	O
.	O
1	O
to	O
1	O
.	O
0	O
ig	O
/	O
ml	O
)	O
.	O

The	O
mixture	O
was	O
heated	O
at	O
40	O
?	O
for	O
30	O
sec	O
,	O
placed	O
in	O
ice	O
water	O
,	O
and	O
then	O
allowed	O
to	O
reach	O
room	O
temperature	O
.	O

Cytochrome	O
c	O
,	O
100	O
pg	O
/	O
ml	O
,	O
was	O
added	O
immediately	O
before	O
spreading	O
onto	O
a	O
deionized	O
water	O
hypophase	O
.	O

The	O
nucleic	O
acid	O
-	O
protein	O
films	O
from	O
both	O
methods	O
were	O
absorbed	O
onto	O

parlodion	O
-	O
coated	O
grids	O
,	O
stained	O
with	O
uranyl	O
acetate	O
(	O
10	O
)	O
,	O
dehydrated	O
in	O
90	O
%	O
ethanol	O
and	O
rotary	O
-	O
shadowed	O
with	O
platinum	O
-	O
palladium	O
(	O
80	O
:	O
20	O
)	O
at	O
an	O
angle	O
of	O
50	O
.	O

Micrographs	O
were	O
taken	O
with	O
a	O
Siemens	O
Elmiskop	O
101	O
electron	O
microscope	O
at	O
an	O
original	O
magnification	O
of	O
10	O
,	O
000	O
and	O
an	O
accelerating	O
voltage	O
of	O
60	O
kv	O
.	O

Nucleic	O
acid	O
lengths	O
were	O
measured	O
at	O
a	O
final	O
magnification	O
of	O
43	O
,	O
000	O
with	O
a	O

Hewlett	O
-	O
Packard	O
9810A	O
calculator	O
equipped	O
with	O
a	O
9864A	O
digitizer	O
using	O
pBR322	O
and	O
fX	O
-	O
174	O
double	O
and	O
single	O
stranded	O
DNA	O
,	O
respectively	O
,	O
as	O
internal	O
length	O
standards	O
.	O

Approximately	O
10	O
,	O
000	O
hybrid	O
molecules	O
were	O
screened	O
for	O
these	O
studies	O
;	O
approximately	O
200	O
represented	O
molecules	O
containing	O
unambiguous	O
regions	O

appropriate	O
for	O
quantitative	O
analysis	O
.	O

The	O
mean	O
lengths	O
of	O
each	O
intron	O
and	O
exon	O
were	O
determined	O
for	O
each	O
method	O
and	O
the	O
data	O
expressed	O
as	O
mean	O
?	O

standard	O
deviation	O
.	O

Nucleic	O
acid	O
lengths	O
of	O
<	O
50	O
base	O
pairs	O
could	O
not	O
be	O

accurately	O
determined	O
using	O
the	O
methods	O
outlined	O
above	O
.	O

Thus	O
,	O
in	O
the	O
cases	O

where	O
introns	O
or	O
exons	O
were	O
of	O
this	O
length	O
or	O
less	O
,	O
accurate	O
error	O
estimates	O
could	O
not	O
be	O
made	O
.	O

Bi	O
ohazard	O
precauti	O
ons	O
.	O

The	O
construction	O
and	O
screening	O
of	O
the	O
sheep	B-LIVB
genomic	O
library	O
together	O
with	O
amplification	O
of	O
pCg45	O
and	O
preparation	O
of	O
high	O
titre	O
lysates	O
of	O
chimaeric	O

Charon	O
4A	O
were	O
performed	O
under	O
the	O
physical	O
and	O
biological	O
containment	O
levels	O
specified	O
by	O
the	O
NIH	O
guidelines	O
for	O
recombinant	O
DNA	O
research	O
(	O
11	O
)	O
.	O

2243	O

Nucleic	O
Acids	O
Research	O

RESULTS	O

Location	O
and	O
orientation	O
of	O
the	O
intervening	O
and	O
a2	O
mRNA	O
coding	O
sequences	O
in	O
the	O
SpC3	O
recombinant	O
DNA	O
.	O

Hybridization	O
of	O
fetal	O
sheep	B-LIVB
tendon	O
type	O
I	O
collagen	O
mRNA	O
to	O
SpC3	O
DNA	O

yielded	O
a	O
complex	O
R	O
loop	O
pattern	O
in	O
the	O
region	O
where	O
the	O
sheep	B-LIVB
genomic	O
insert	O
was	O
expected	O
to	O
be	O
ligated	O
to	O
the	O
arms	O
of	O
the	O
lambda	O
vector	O
,	O
Charon	O
4A	O
.	O

To	O

confirm	O
that	O
these	O
hybridization	O
events	O
were	O
restricted	O
to	O
the	O
inserted	O
sheep	B-LIVB
DNA	O
fragment	O
,	O
duplex	O
DNA	O
strands	O
on	O
both	O
sides	O
of	O
this	O
hybridization	O
area	O
were	O
measured	O
.	O

Using	O
pBR322	O
as	O
an	O
internal	O
length	O
standard	O
,	O
the	O
left	O
arm	O
of	O
the	O
phage	O
was	O
found	O
to	O
contain	O
21	O
,	O
780	O
?	O

1500	O
bp	O
,	O
and	O
the	O
right	O
arm	O
,	O
11	O
,	O
950	O
?	O

1030	O
bp	O
,	O
corresponding	O
to	O
the	O
report	O
values	O
for	O
the	O
left	O
and	O
right	O
arms	O
,	O
respectively	O
,	O
of	O
Charon	O
4A	O
DNA	O
(	O
5	O
,	O
6	O
)	O
.	O

The	O
hybridization	O
of	O
SpC3	O
to	O
a2	O
mRNA	O
resulted	O
in	O
the	O
destabilization	O
of	O

the	O
inserted	O
helical	O
duplex	O
DNA	O
fragment	O
such	O
that	O
one	O
DNA	O
strand	O
was	O
displaced	O
(	O
Figure	O
1	O
)	O
.	O

Occasionally	O
,	O
the	O
displaced	O
DNA	O
strand	O
was	O
mostly	O
absent	O
,	O
probably	O
due	O
to	O
fragmentation	O
induced	O
by	O
accidental	O
mechanical	O
shearing	O
.	O

This	O
event	O
considerably	O
enhanced	O
the	O
visualization	O
and	O
ordering	O
of	O
the	O
introns	O
.	O

As	O
the	O
a2	O
mRNA	O
annealed	O
to	O
complementary	O
DNA	O
regions	O
present	O
in	O
one	O

DNA	O
strand	O
,	O
numerous	O
single	O
-	O
stranded	O
loops	O
resulted	O
.	O

These	O
loops	O
,	O
referred	O
to	O
as	O
introns	O
,	O
represented	O
DNA	O
sequences	O
not	O
complementary	O
to	O
the	O
mRNA	O
.	O

Although	O
,	O
by	O
convention	O
,	O
introns	O
are	O
usually	O
sequentially	O
labeled	O
5	O
'	O
to	O
3	O
'	O
,	O
an	O
opposite	O
order	O
had	O
to	O
be	O
employed	O
in	O
this	O
case	O
as	O
SpC3	O
does	O
not	O
contain	O
the	O
sequences	O
coding	O
for	O
the	O
5	O
'	O
end	O
of	O
sheep	B-LIVB
a2	O
mRNA	O
.	O

Infrequently	O
,	O
all	O
introns	O

were	O
clearly	O
observed	O
within	O
the	O
same	O
hybrid	O
molecule	O
(	O
Figure	O
1	O
)	O
.	O

The	O
largest	O
introns	O
were	O
towards	O
the	O
left	O
arm	O
of	O
Charon	O
4A	O
and	O
were	O
more	O
clustered	O
than	O
the	O
introns	O
at	O
the	O
opposite	O
end	O
of	O
the	O
hybrid	O
.	O

Thus	O
,	O
much	O
of	O
the	O
genetic	O

information	O
coding	O
for	O
the	O
a2	O
mRNA	O
was	O
contained	O
in	O
that	O
half	O
of	O
the	O
hybrid	O
attached	O
to	O
the	O
right	O
arm	O
.	O

A	O
small	O
non	O
-	O
hybridized	O
tail	O
was	O
consistently	O
found	O
in	O
the	O
region	O
where	O

the	O
right	O
arm	O
of	O
the	O
phage	O
was	O
ligated	O
to	O
the	O
sheep	B-LIVB
genomic	O
insert	O
(	O
Figure	O
1	O
)	O
.	O

This	O
tail	O
likely	O
corresponded	O
to	O
the	O
3	O
'	O
poly	O
A	O
sequence	O
of	O
the	O
a2	O
mRNA	O
.	O

At	O

the	O
extreme	O
5	O
'	O
end	O
of	O
the	O
insert	O
,	O
a	O
variable	O
length	O
was	O
often	O
observed	O
for	O
the	O
remaining	O
unhybridized	O
mRNA	O
strand	O
.	O

This	O
was	O
most	O
likely	O
due	O
to	O
the	O
size	O
heterogeneity	O
of	O
the	O
a2	O
mRNA	O
used	O
in	O
these	O
studies	O
.	O

Size	O
determination	O
and	O
comparative	O
analysis	O
of	O
SpC3	O
introns	O
.	O

Although	O
localization	O
of	O
exon	O
and	O
intron	O
sequences	O
was	O
possible	O
with	O
both	O
the	O
70	O
%	O
formamide	O
and	O
urea	O
-	O
formamide	O
spreading	O
methods	O
,	O
the	O
probability	O
of	O

detecting	O
unambiguous	O
regions	O
in	O
a	O
hybrid	O
molecule	O
was	O
far	O
greater	O
with	O
the	O

2244	O

Nucleic	O
Acids	O
Research	O

A	O
B	O
'	O
,	O
:	O
'	O
14	O
.	O
0	O
.	O

13	O

7	O
1	O

-	O
5	O
13	O

.	O
.	O

.	O
.	O

,	O
4	O
x2	O
%	O
.	O

N1	O

9	O

>	O
10	O
R	O
4	O

Figure	O
1	O
.	O

Electron	O
microscopic	O
visualization	O
of	O
all	O
17	O
introns	O
and	O
18	O
exons	O

from	O
hybrid	O
molecules	O
formed	O
between	O
recombinant	O
clone	O
SpC3	O
DNA	O
and	O
fetal	O
sheep	B-LIVB

tendon	O
a2	O
mRNA	O
.	O

(	O
A	O
,	O
B	O
)	O
Shown	O
are	O
the	O
double	O
-	O
stranded	O
segment	O
of	O
the	O
right	O
arm	O
CR	O
)	O
of	O
Charon	O
4A	O
;	O
double	O
-	O
stranded	O
segment	O
of	O
the	O
left	O
arm	O
CL	O
)	O
of	O
Charon	O
4A	O
;	O
the	O

displaced	O
single	O
-	O
stranded	O
DNA	O
segment	O
of	O
the	O
insert	O
(	O
5	O
)	O
;	O
single	O
-	O
stranded	O
DNA	O
loops	O
representing	O
introns	O
sequentially	O
labeled	O
1	O
through	O
17	O
in	O
the	O
3	O
'	O
to	O
5	O
'	O
direction	O
;	O
and	O
18	O
regions	O
of	O
insert	O
DNA	O
sequences	O
hybridized	O
to	O
ct2	O
mRNA	O

-	O
-	O
-	O
-	O
)	O
.	O

(	O
C	O
,	O
D	O
)	O
Similar	O
to	O
(	O
A	O
,	O
B	O
)	O
but	O
the	O
single	O
-	O
stranded	O
DNA	O
segment	O
(	O
5	O
)	O
of	O
the	O
insert	O
is	O
mostly	O
absent	O
.	O

The	O
urea	O
-	O
formamide	O
spreading	O
method	O
,	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
,	O
was	O
employed	O
.	O

2245	O

Nucleic	O
Acids	O
Research	O

urea	O
-	O
formamide	O
method	O
than	O
with	O
the	O
70	O
%	O
formamide	O
procedure	O
.	O

For	O
this	O
reason	O
,	O
most	O
measurements	O
were	O
made	O
with	O
the	O
urea	O
-	O
formamide	O
method	O
(	O
Tables	O
1	O
,	O
2	O
)	O
.	O

For	O

example	O
,	O
the	O
lowest	O
probability	O
event	O
,	O
the	O
detection	O
of	O
intron	O
17	O
and	O
the	O
surrounding	O
small	O
exons	O
,	O
"	O
q	O
"	O
and	O
"	O
r	O
"	O
,	O
was	O
only	O
observed	O
by	O
way	O
of	O
the	O
ureaformamide	O
spreading	O
procedure	O
.	O

The	O
smallest	O
introns	O
,	O
7	O
and	O
12	O
,	O
were	O
found	O
to	O
contain	O
approximately	O

the	O
same	O
number	O
of	O
bases	O
.	O

Introns	O
1	O
through	O
8	O
,	O
representing	O
the	O
DNA	O
sequences	O
which	O
split	O
the	O
a2	O
coding	O
sequence	O
corresponding	O
to	O
the	O
3	O
'	O
end	O
of	O
the	O
a2	O
mRNA	O
,	O
varied	O
in	O
length	O
over	O
approximately	O
a	O
2	O
.	O
4	O
-	O
fold	O
range	O
.	O

With	O
the	O
exception	O
of	O

Table	O
1	O
.	O

Electron	O
microscopic	O
R	O
loop	O
analysis	O

present	O
in	O
SpC3	O
DNA1	O
.	O

of	O
the	O
sheep	B-LIVB
a2	O
introns	O

SpC3	O
was	O
hybridized	O
to	O
sheep	B-LIVB
a2	O
mRNA	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
;	O
intron	O
lengths	O
were	O
determined	O
by	O
comparison	O
with	O
*	O
X	O
-	O
174	O
DNA	O
lengths	O
.	O

2	O
Introns	O
are	O
designated	O
sequentially	O
3	O
'	O
to	O
5	O
'	O
.	O

3	O
All	O
data	O
is	O
presented	O
as	O
mean	O
?	O

standard	O
deviation	O
.	O

4	O
Intron	O
17	O
was	O
visualized	O
only	O
by	O
the	O
urea	O
-	O
formamide	O
method	O
.	O

2246	O

70	O
%	O
Formamide	O
Method	O
Urea	O
-	O
Formamide	O
Method	O

Intron2	O
Number	O
of	O
Intron	O
length	O
Number	O
of	O
Intron	O
length	O

introns	O
analyzed	O
(	O
bases	O
)	O
introns	O
analyzed	O
(	O
bases	O
)	O

1	O
10	O
819	O
t	O
063	O
35	O
806	O
t	O
76	O
2	O
12	O
771	O
?	O

89	O
46	O
757	O
t	O
78	O
3	O
11	O
458	O
?	O

58	O
47	O
464	O
?	O

66	O
4	O
6	O
627	O
?	O

53	O
41	O
611	O
?	O

73	O
5	O
5	O
554	O
?	O

51	O
34	O
562	O
?	O

76	O
6	O
6	O
675	O
?	O

19	O
40	O
684	O
?	O

76	O
7	O
5	O
386	O
?	O

48	O
50	O
342	O
?	O

54	O
8	O
7	O
771	O
?	O

84	O
49	O
757	O
?	O

82	O
9	O
8	O
1	O
,	O
181	O
?	O

94	O
52	O
1	O
,	O
124	O
?	O
122	O
10	O
8	O
1	O
,	O
133	O
?	O
106	O
53	O
1	O
,	O
124	O
?	O
137	O
11	O
10	O
964	O
t	O
?	O
79	O
61	O
952	O
?	O
105	O
12	O
9	O
362	O
?	O

77	O
62	O
342	O
?	O

71	O
13	O
4	O
723	O
?	O
222	O
53	O
806	O
?	O
105	O
14	O
4	O
1	O
,	O
085	O
?	O
142	O
53	O
1	O
,	O
075	O
?	O
105	O
15	O
3	O
795	O
?	O

60	O
47	O
806	O
?	O
100	O
16	O
2	O
1	O
,	O
229	O
?	O

48	O
43	O
1	O
,	O
319	O
?	O
146	O
174	O
-	O
-	O
12	O
1	O
,	O
539	O
?	O
166	O

1	O

Nucleic	O
Acids	O
Research	O

Table	O
2	O
.	O

Electron	O
microscopic	O
R	O
loop	O
analysis	O
of	O
the	O
sheep	B-LIVB
a2	O
exons	O

present	O
in	O
SpC3	O
DNA1	O
.	O

70	O
%	O
Formamide	O
Method	O
Urea	O
-	O
Formamide	O
Method	O

Exon2	O
Number	O
of	O
Exon	O
length	O
Number	O
of	O
Exon	O
length	O

exons	O
analyzed	O
(	O
base	O
pairs	O
)	O
exons	O
analyzed	O
(	O
base	O
pairs	O
)	O

a	O
7	O
807	O
?	O

883	O
26	O
883	O
?	O
132	O
b	O
10	O
252	O
?	O

35	O
41	O
234	O
?	O

49	O
c	O
11	O
151	O
?	O

25	O
48	O
182	O
?	O

42	O
d	O
6	O
252	O
?	O

60	O
44	O
234	O
?	O

62	O
e	O
5	O
126	O
?	O

45	O
37	O
129	O
?	O

47	O
f	O
5	O
126	O
?	O

38	O
35	O
104	O
?	O

41	O
9	O
5	O
176	O
?	O

48	O
40	O
182	O
?	O

54	O
h	O
5	O
100	O
?	O

43	O
47	O
104	O
?	O

31	O

7	O
100	O
?	O

35	O
50	O
104	O
?	O

28	O
j	O
7	O
126	O
?	O

48	O
45	O
130	O
?	O

47	O
k	O
8	O
50	O
?	O

48	O
51	O
52	O
?	O

39	O
1	O
9	O
75	O
?	O

10	O
60	O
52	O
?	O

44	O
m	O
6	O
126	O
?	O

43	O
51	O
182	O
?	O

54	O
n	O
4	O
100	O
?	O

45	O
53	O
52	O
?	O

42	O
o	O
3	O
<	O
504	O
50	O
78	O
?	O

36	O
p	O
2	O
126	O
?	O

71	O
47	O
104	O
?	O

36	O
q5	O
-	O
_	O
33	O
130	O
?	O
47	O
r5	O
r	O
6	O
78	O
?	O
36	O

SpC3	O
was	O
hybridized	O
to	O
sheep	B-LIVB
a2	O
mRNA	O
as	O
described	O
in	O
M4aterials	O
and	O

Methods	O
;	O
exon	O
lengths	O
were	O
determined	O
by	O
comparison	O
with	O
pBR322	O
DNA	O
lengths	O
.	O

2	O
Exons	O
are	O
designated	O
sequentially	O
3	O
'	O
to	O
5	O
'	O
.	O

3	O
All	O
data	O
is	O
presented	O
as	O
mean	O
?	O

standard	O
deviation	O
.	O

4	O
5	O

No	O
statistical	O
evaluation	O
was	O
possible	O
because	O
of	O
the	O
size	O
of	O
the	O
exon	O
(	O
see	O
(	O
Materials	O
and	O
Methods	O
)	O
.	O

Exons	O
q	O
and	O
r	O
were	O
only	O
analyzed	O
by	O
the	O
urea	O
-	O
formamide	O
method	O
.	O

intron	O
1	O
,	O
the	O
nucleotide	O
size	O
of	O
these	O
introns	O
was	O
less	O
than	O
800	O
bases	O
.	O

In	O
contrast	O
,	O
introns	O
9	O
through	O
17	O
varied	O
over	O
a	O
4	O
.	O
5	O
-	O
fold	O
range	O
.	O

Except	O
for	O
intron	O
12	O
,	O
all	O
of	O
the	O
introns	O
9	O
through	O
17	O
contained	O
800	O
bases	O
or	O
more	O
.	O

Summation	O
of	O
introns	O
1	O
through	O
16	O
for	O
the	O
70	O
%	O
formamide	O
and	O
urea	O

formamide	O
spreading	O
methods	O
yielded	O
12	O
,	O
533	O
and	O
12	O
,	O
531	O
bases	O
,	O
respectively	O
.	O

However	O
,	O
detection	O
of	O
intron	O
17	O
by	O
the	O
urea	O
-	O
formamide	O
method	O
indicates	O
that	O

the	O
actual	O
summed	O
value	O
for	O
the	O
intervening	O
sequences	O
of	O
SpC3	O
is	O
14	O
,	O
070	O
bases	O
.	O

2247	O

1	O

Nucleic	O
Acids	O
Research	O

Size	O
determination	O
and	O
the	O
comparative	O
analysis	O
of	O
SpC3	O
exons	O
.	O

Eighteen	O
exons	O
,	O
"	O
a	O
"	O
through	O
"	O
r	O
"	O
,	O
were	O
mapped	O
(	O
Table	O
2	O
)	O
.	O

The	O
largest	O
exon	O
,	O
"	O
a	O
"	O
,	O
located	O
on	O
the	O
extreme	O
3	O
'	O
end	O
of	O
the	O
sheep	B-LIVB
genomic	O
insert	O
,	O
contained	O

approximately	O
800	O
bp	O
.	O

With	O
the	O
exception	O
of	O
exon	O
"	O
m	O
"	O
,	O
exons	O
larger	O
than	O
150	O

base	O
pairs	O
were	O
confined	O
to	O
the	O
genetic	O
region	O
corresponding	O
to	O
the	O
far	O
3	O
'	O
end	O
of	O
the	O
a2	O
mRNA	O
.	O

Exon	O
"	O
a	O
"	O
and	O
exon	O
"	O
b	O
"	O
,	O
the	O
two	O
exons	O
situated	O
on	O
either	O
side	O
of	O
intron	O
1	O
,	O
coded	O
for	O
around	O
1000	O
bases	O
of	O
a2	O
collagen	O
information	O
;	O
these	O
two	O

exons	O
contained	O
one	O
-	O
third	O
of	O
the	O
mapped	O
3	O
,	O
014	O
DNA	O
bases	O
complementary	O
to	O
a2	O
mRNA	O
Length	O
distribution	O
and	O
organization	O
of	O
the	O
introns	O
and	O
exons	O
in	O
the	O
sheep	B-LIVB
genomi	O
c	O
i	O
nsert	O
.	O

There	O
was	O
a	O
sharp	O
contrast	O
in	O
the	O
size	O
distribution	O
of	O
the	O
exons	O
and	O
introns	O
contained	O
within	O
SpC3	O
(	O
Figure	O
2	O
)	O
.	O

While	O
the	O
intron	O
sizes	O
varied	O

considerably	O
,	O
the	O
exons	O
,	O
in	O
general	O
,	O
showed	O
a	O
very	O
narrow	O
distribution	O
of	O

lengths	O
,	O
and	O
thus	O
tended	O
to	O
cluster	O
at	O
the	O
lowest	O
end	O
of	O
the	O
length	O
distri	O

A	O
.	O

(	O
I	O
)	O

z	O
6	O
0	O

z	O

ZL4	O
0	O

021	O

z	O

10	O

B	O
.	O

8	O

z	O
0	O

16	O
0	O
z	O

2	O

20	O
400	O
600	O
800	O
1000	O
1200	O
1400	O
1600	O

LENGTH	O
IN	O
NUCLEOTIDES	O

Figure	O
2	O
.	O

Length	O
distribution	O
of	O
the	O
intron	O
and	O
exon	O
mean	O
lengths	O
measured	O
from	O
micrographs	O
prepared	O
by	O
the	O
urea	O
-	O
formamide	O
method	O
.	O

(	O
A	O
)	O
Introns	O
;	O
(	O
b	O
)	O
Exons	O
.	O

See	O
Tables	O
1	O
and	O
2	O
for	O
details	O
.	O

2248	O

Nucleic	O
Acids	O
Research	O
bution	O
graph	O
.	O

The	O
exon	O
in	O
the	O
800	O
-	O
900	O
bp	O
region	O
was	O
unique	O
and	O
was	O
the	O
only	O
exon	O
which	O
exhibited	O
length	O
overlap	O
with	O
introns	O
.	O

The	O
maps	O
of	O
the	O
a2	O
collagen	O
gene	O
obtained	O
with	O
both	O
electron	O
micro	O

scopic	O
spreading	O
methods	O
were	O
almost	O
identical	O
(	O
Figure	O
3	O
)	O
,	O
except	O
that	O
the	O

region	O
at	O
the	O
extreme	O
5	O
'	O
end	O
of	O
the	O
insert	O
could	O
only	O
be	O
mapped	O
with	O
the	O
ureaformamide	O
method	O
.	O

From	O
these	O
measurements	O
we	O
concluded	O
that	O
the	O
length	O
of	O
the	O
a2	O
collagen	O
genetic	O
regi	O
?	O
on	O
in	O
SpC3	O
was	O
17	O
,	O
084	O
bases	O
long	O
with	O
only	O
3	O
,	O
014	O
bases	O
actually	O
coding	O
for	O
a2	O
mRNA	O
.	O

Therefore	O
,	O
only	O
18	O
%	O
of	O
the	O
mapped	O
17	O
kb	O
sheep	B-LIVB
genetic	O
insert	O
actually	O
contained	O
a2	O
structural	O
information	O
.	O

DISCUSSION	O

The	O
organizational	O
structure	O
of	O
the	O
a2	O
collagen	O
gene	O
is	O
complex	O
.	O

A	O
minimum	O
of	O
17	O
introns	O
interrupt	O
the	O
3	O
kb	O
of	O
ca2	O
genetic	O
information	O
interspersed	O
as	O
18	O
exons	O
over	O
17	O
kb	O
of	O
sheep	B-LIVB
DNA	O
.	O

With	O
the	O
exception	O
of	O
exon	O
"	O
a	O
"	O
located	O
at	O
the	O
extreme	O
3	O
'	O
end	O
of	O
the	O
inserted	O
a2	O
gene	O
,	O
all	O
other	O
mapped	O
exons	O
are	O
rather	O
small	O
,	O
exhibiting	O
a	O
size	O
distribution	O
range	O
of	O
50	O
to	O
250	O
bp	O
.	O

In	O

contrast	O
,	O
the	O
intron	O
sizes	O
range	O
from	O
340	O
to	O
1540	O
bases	O
occupying	O
a	O
total	O

of	O
14	O
kb	O
.	O

Thus	O
,	O
the	O
DNA	O
region	O
containing	O
the	O
3	O
kb	O
of	O
a2	O
collagen	O
genetic	O
information	O
is	O
5	O
.	O
6	O
fold	O
longer	O
than	O
the	O
corresponding	O
co2	O
mRNA	O
sequences	O
.	O

Although	O
the	O
total	O
number	O
of	O
introns	O
present	O
within	O
the	O
60	O
%	O
3	O
'	O
portion	O

of	O
the	O
a2	O
sheep	B-LIVB
gene	O
was	O
determined	O
to	O
be	O
17	O
,	O
variation	O
in	O
the	O
precise	O
number	O

TRANSRIPTlO	O

A	O
5w	O
r	O

1	O
"	O
2a4	O
133	O
112s	O
11	O
.	O
17	O
0	O
.	O

3O	O
2	O
715	O
6	O
.	O
2	O
313	O
04	O
4	O
.	O
2B	O
3	O
.	O
51	O
2	O
.	O
2	O
12	O

EXON0	O
p	O
o	O
n	O
5	O
Ik	O
h	O
f	O
d	O
4	O
.	O

b	O

WPM300	O
16	O
16	O
14	O
13	O
12	O
11	O
10	O
9	O
6	O
7	O
6	O
5	O
4	O
3	O
2	O
1	O

B	O

110	O
16	O
4	O
.	O
2	O
13111	O
112n	O
1113104	O
3	O
.	O
6	O
gm74	O
2	O
6	O
.	O

4	O
4	O
2	O
3	O
.	O
2	O
22	O
in	O

1	O
a1m03	O
133	O
1	O
.	O
2	O
11	O
10	O
01	O
341	O
6	O
.	O

1	O
117	O
6	O
.	O
2	O
4	O
12	O
417	O
3I5	O
'	O
m	O
2	O

DM00	O
1	O
q5	O
p	O
0	O
n	O
m	O
I	O
k	O
.	O

j	O
i	O
h	O
g	O
f	O
d	O
c	O
b	O
a	O
147306	O
17	O
16	O
15	O
14	O
13	O
12	O
11	O
10	O
9	O
a	O
7	O
6	O
5	O
4	O
3	O
2	O
1	O

175	O
17	O
.	O
0	O
16	O
.	O
6	O
&	O
16	O
'	O
5	O
.	O
5	O
15	O
.	O
0	O
14	O
.	O
5	O
14	O
.	O

13	O
.	O
5	O
13	O
.	O
0	O
12	O
.	O
5	O
12	O
.	O
0	O
11	O
.	O
5	O
11	O
10	O
.	O
5M	O
10	O
.	O
0	O
9	O
.	O
5	O
9	O
.	O
0	O
8	O
.	O

5	O
.	O
0	O
71	O
7	O
.	O
0	O
6	O
.	O
5	O
6	O
.	O

5	O
.	O
5	O
50	O
4	O
.	O
5	O
4	O
.	O
0	O
3	O
.	O
5	O
3	O
.	O
0	O
2	O
.	O
5	O
2	O
.	O
0	O
1	O
.	O
5	O
1	O
.	O
0	O

KILOBASE	O

Fiue3	O
Organization	O
of	O
60	O
%	O
of	O
the	O
3	O
'	O
end	O
of	O
the	O
sheep	B-LIVB
a2	O
collagen	O
gene	O
.	O

(	O
A	O
)	O
}	O
The	O
exon	O
(	O
)	O
and	O
intron	O
(	O
CDJ	O
)	O
order	O
within	O
the	O
a2	O
gene	O
as	O
determined	O
by	O
R	O
loop	O
analysis	O
of	O
SpC3	O
DNA	O
-	O
a2	O
mRNA	O
hybrid	O
molecules	O
visualized	O
by	O
the	O
electron	O
microscopic	O
70	O
%	O
formamide	O
spreading	O
method	O
.	O

(	O
B	O
)	O
The	O
exon	O
Um	O
)	O

and	O
intron	O
(	O
Efl	O
)	O
order	O
within	O
the	O
a2	O
gene	O
as	O
determined	O
by	O
R	O
loop	O
analysis	O
of	O
SpC3	O
DNA	O
-	O
a2	O
mRNA	O
hybrid	O
molecules	O
evaluated	O
by	O
the	O
electron	O
microscopic	O

urea	O
-	O
formamide	O
spreading	O
method	O
.	O

Arrows	O
represent	O
the	O
approximate	O
location	O
of	O
intron	O
-	O
exon	O
junctions	O
.	O

All	O
values	O
are	O
presented	O
as	O
kilobase	O
pairs	O
.	O

2249	O

Nucleic	O
Acids	O
Research	O

of	O
introns	O
present	O
in	O
individual	O
hybrid	O
molecules	O
was	O
observed	O
.	O

The	O
reason	O

for	O
this	O
may	O
be	O
due	O
to	O
size	O
heterogeneity	O
of	O
the	O
a2	O
mRNA	O
used	O
as	O
a	O
complementary	O
probe	O
.	O

Although	O
the	O
a2	O
mRNA	O
was	O
extensively	O
purified	O
(	O
2	O
)	O
,	O
some	O
degradation	O
was	O
likely	O
present	O
.	O

It	O
is	O
also	O
possible	O
that	O
additional	O
introns	O
exist	O
that	O
are	O
too	O
small	O
to	O
be	O
detected	O
by	O
electron	O
microscopic	O
R	O
loop	O
analysis	O
.	O

The	O
most	O
likely	O
a2	O
genetic	O
regions	O
containing	O
such	O
introns	O
are	O
exons	O
"	O
g	O
"	O
and	O
"	O
m	O
"	O
.	O

Small	O

"	O
protrusions	O
"	O
were	O
sometimes	O
observed	O
within	O
these	O
exons	O
that	O
could	O
represent	O
small	O
introns	O
.	O

Very	O
small	O
introns	O
have	O
been	O
reported	O
for	O
tRNA	O
genes	O
(	O
12	O
,	O
13	O
)	O
,	O

and	O
it	O
will	O
be	O
necessary	O
to	O
sequence	O
these	O
regions	O
of	O
SpC3	O
to	O
determine	O
if	O
such	O
introns	O
are	O
present	O
within	O
the	O
a2	O
sheep	B-LIVB
genome	O
.	O

The	O
existence	O
of	O
mRNAs	O
comprised	O
of	O
sequences	O
complementary	O
to	O
noncontiguous	O
regions	O
in	O
a	O
DNA	O
genome	O
was	O
first	O
described	O
for	O
adenovirus	B-LIVB
(	O
14	O
,	O
15	O
)	O
and	O

simian	O
virus	O
(	O
16	O
,	O
17	O
)	O
genes	O
.	O

Similar	O
observations	O
were	O
soon	O
reported	O
for	O
eukaryotic	O
genes	O
,	O
including	O
serum	O
albumin	O
(	O
18	O
)	O
,	O
conalbumin	O
(	O
19	O
)	O
,	O
fibroin	O
(	O
20	O
)	O
,	O
s	O

globin	O
(	O
21	O
,	O
22	O
)	O
,	O
growth	O
hormones	O
(	O
23	O
,	O
24	O
)	O
,	O
immunoglobulin	O
(	O
25	O
)	O
,	O
lysozyme	O
(	O
26	O
)	O
,	O

ovalbumin	O
(	O
27	O
-	O
29	O
)	O
,	O
ovomucoid	O
(	O
30	O
)	O
,	O
rRNA	O
(	O
31	O
-	O
34	O
)	O
,	O
tRNA	O
(	O
12	O
,	O
13	O
)	O
,	O
and	O
vitellogenin	O
(	O
35	O
)	O
.	O

The	O
precise	O
number	O
or	O
occurrence	O
of	O
introns	O
within	O
these	O
genes	O
does	O
not	O
seem	O
to	O
follow	O
any	O
clear	O
pattern	O
.	O

However	O
,	O
the	O
genes	O
for	O
albumin	O
,	O
conalbumin	O
,	O

lysozyme	O
,	O
ovalbumin	O
,	O
and	O
ovomucoid	O
exhibit	O
a	O
structural	O
organization	O
comparable	O
to	O
the	O
a2	O
collagen	O
gene	O
.	O

All	O
of	O
these	O
genes	O
are	O
composed	O
of	O
numerous	O
small	O

exons	O
,	O
usually	O
less	O
than	O
250	O
base	O
pairs	O
,	O
and	O
introns	O
which	O
show	O
a	O
large	O
size	O
variation	O
within	O
an	O
individual	O
gene	O
.	O

Within	O
all	O
of	O
these	O
genomes	O
,	O
the	O
DNA	O

regions	O
required	O
for	O
coding	O
structural	O
formation	O
are	O
4	O
to	O
7	O
times	O
longer	O
than	O
the	O
corresponding	O
mRNA	O
coding	O
sequences	O
.	O

As	O
with	O
the	O
a2	O
collagen	O
gene	O
,	O
a	O
large	O
unique	O
exon	O
at	O
the	O
extreme	O
3	O
'	O
end	O

is	O
also	O
present	O
in	O
the	O
ovalbumin	O
gene	O
(	O
36	O
,	O
37	O
)	O
.	O

In	O
the	O
a2	O
gene	O
,	O
this	O
exon	O
was	O
800	O
to	O
900	O
nucleotides	O
in	O
length	O
,	O
while	O
in	O
the	O
ovalbumin	O
gene	O
the	O
exon	O
contained	O
1	O
,	O
030	O
base	O
pairs	O
.	O

Interestingly	O
,	O
this	O
ovalbumin	O
exon	O
contained	O
634	O
-	O
650	O
base	O
pairs	O
ot	O
DNA	O
sequence	O
to	O
the	O
3	O
'	O
side	O
of	O
the	O
terminator	O

triplet	O
,	O
suggesting	O
the	O
ovalbumin	O
mRNA	O
has	O
a	O
large	O
untranslated	O
region	O
at	O
the	O
3	O
'	O
end	O
.	O

The	O
consistent	O
appearance	O
of	O
a	O
small	O
non	O
-	O
hybridized	O
tail	O
,	O
approximately	O
100	O
nucleotides	O
in	O
length	O
,	O
in	O
the	O
region	O
where	O
the	O
right	O
arm	O
of	O
the	O
phage	O
was	O
ligated	O
to	O
the	O
sheep	B-LIVB
genomic	O
insert	O
of	O
SpC3	O
very	O
likely	O
corresponded	O
to	O
the	O

3	O
'	O
poly	O
A	O
sequence	O
of	O
the	O
a2	O
mRNA	O
.	O

This	O
would	O
suggest	O
that	O
the	O
a2	O
mRNA	O
coding	O
sequence	O
terminates	O
very	O
near	O
or	O
at	O
this	O
point	O
in	O
the	O
genome	O
.	O

Previously	O
published	O
biochemical	O
evidence	O
(	O
2	O
)	O
obtained	O
from	O
restriction	O
mapping	O
and	O
Southern	O
blot	O
analysis	O
using	O
[	O
32P	O
]	O
-	O
labeled	O
chick	O
a2	O
cDNA	O
probe	O
supports	O

2250	O

Nucleic	O
Acids	O
Research	O

this	O
observation	O
.	O

It	O
is	O
unclear	O
what	O
role	O
introns	O
play	O
in	O
genetic	O
expression	O
.	O

However	O
,	O

it	O
is	O
known	O
that	O
these	O
sequences	O
are	O
tranncribed	O
as	O
part	O
of	O
larger	O
precursor	O
mRNAs	O
and	O
the	O
introns	O
are	O
then	O
excised	O
and	O
the	O
fragmented	O
mRNA	O
chains	O

covalently	O
rejoined	O
(	O
38	O
)	O
.	O

Some	O
evidence	O
has	O
recently	O
accumulated	O
demonstrating	O
the	O
existence	O
of	O
precursor	O
a2	O
mRNAs	O
(	O
39	O
,	O
40	O
)	O
.	O

However	O
,	O
if	O
the	O
introns	O
in	O
the	O
a2	O
gene	O
are	O
transcribed	O
in	O
their	O
entirety	O
,	O
as	O
has	O
been	O

demonstrated	O
for	O
the	O
introns	O
in	O
ovalbumin	O
and	O
globin	O
(	O
41	O
,	O
42	O
)	O
,	O
much	O
larger	O
precursor	O
a2	O
mRNAs	O
may	O
exist	O
than	O
those	O
reported	O
to	O
date	O
.	O

For	O
if	O
the	O
re	O

mainder	O
of	O
the	O
a2	O
collagen	O
gene	O
has	O
a	O
structural	O
organization	O
comparable	O
to	O
the	O
60	O
%	O
3	O
'	O
portion	O
that	O
has	O
been	O
analyzed	O
,	O
it	O
is	O
probable	O
that	O
the	O
a2	O

collagen	O
gene	O
in	O
its	O
entirety	O
is	O
dispersed	O
throughout	O
a	O
30	O
kb	O
DNA	O
segment	O
.	O

ACKNOWLEDGMENTS	O

We	O
thank	O
Dr	O
.	O
John	O
Dahlberg	O
and	O
Frances	O
Loebenstein	O
,	O
Laboratory	O
of	O
Cellular	O
and	O
Molecular	O
Biology	O
,	O
National	O
Cancer	O
Institute	O
,	O
for	O
the	O
generous	O
use	O
of	O
a	O

Siemens	O
Elmiskop	O
101	O
electron	O
microscope	O
;	O
Dr	O
.	O
Ursula	O
Heine	O
and	O
Benjamin	O
Elliott	O
,	O
Laboratory	O
of	O
Viral	O
Carcinogenesis	O
,	O
National	O
Cancer	O
Institute	O
,	O
for	O
the	O
use	O
of	O
a	O
Hewlett	O
-	O
Packard	O
calculator	O
equipped	O
with	O
a	O
digitizer	O
and	O
a	O
Denton	O
vacuum	O

evaporator	O
,	O
and	O
Drs	O
.	O

Victor	O
Ferrans	O
and	O
Oichi	O
Kawanami	O
,	O
Laboratory	O
of	O
Pathology	O
,	O

National	O
Heart	O
,	O
Lung	O
,	O
and	O
Blood	O
Institute	O
,	O
for	O
expert	O
assistance	O
with	O
photography	O
.	O

We	O
are	O
also	O
grateful	O
to	O
Margery	O
Sullivan	O
,	O
Laboratory	O
of	O
Molecular	O
Genetics	O
,	O

National	O
Institute	O
of	O
Child	B-LIVB
Health	O
and	O
Human	B-LIVB
Development	O
,	O
for	O
helpful	O
discussions	O
and	O
to	O
Dr	O
.	O
Helga	O
Boedtker	O
,	O
Department	O
of	O
Chemistry	O
,	O
Harvard	O
University	O
,	O
for	O
making	O
available	O
the	O
recombinant	O
plasmid	O
pCg45	O
.	O

References	O

1	O
.	O

Prockop	O
,	O
D	O
.	O

J	O
.	O
,	O
Kivirikko	O
,	O
k	O
.	O

I	O
.	O
,	O
Tuderman	O
,	O
L	O
.	O
,	O
and	O
Guzman	O
,	O
N	O
.	O

A	O
.	O

(	O
1979	O
)	O
New	O
Engl	O
.	O

J	O
.	O

Med	O
.	O

301	O
,	O
13	O
-	O
23	O
and	O
77	O
-	O
85	O
.	O

2	O
.	O

Boyd	O
,	O
C	O
.	O

D	O
.	O
,	O
Tolstoshev	O
,	O
P	O
.	O
,	O
Schafer	O
,	O
M	O
.	O

P	O
.	O
,	O
Trapnell	O
,	O
B	O
.	O

C	O
.	O
,	O
Coon	O
,	O

H	O
.	O

C	O
.	O
,	O
Kretschmer	O
,	O
P	O
.	O

J	O
.	O
,	O
Nienhuis	O
,	O
A	O
.	O

W	O
.	O
,	O
and	O
Crystal	O
,	O
R	O
.	O

G	O
.	O

(	O
1980	O
)	O
J	O
.	O

Biol	O
.	O

Chem	O
.	O
,	O
in	O
press	O
.	O

3	O
.	O

Blin	O
,	O
N	O
.	O
,	O
and	O
Stafford	O
,	O
D	O
.	O

W	O
.	O

(	O
1976	O
)	O
Nucl	O
.	O

Acids	O
Res	O
.	O

3	O
,	O
2303	O
-	O
2308	O
.	O

4	O
.	O

Kretschmer	O
,	O
P	O
.	O

J	O
.	O
,	O
Kaufman	O
,	O
R	O
.	O

E	O
.	O
,	O
Coon	O
,	O
H	O
.	O

C	O
.	O
,	O
Chen	O
,	O
M	O
.	O

JY	O
.	O
,	O
Geist	O

C	O
.	O

E	O
.	O
,	O
and	O
Nienhuis	O
,	O
A	O
.	O

W	O
.	O

(	O
1980	O
)	O
J	O
.	O

Biol	O
.	O

Chem	O
.	O
,	O
in	O
press	O
.	O

5	O
.	O

Maniatis	O
,	O
T	O
.	O
,	O
Hardison	O
,	O
R	O
.	O

C	O
.	O
,	O
Lacey	O
,	O
E	O
.	O
,	O
Laver	O
,	O
H	O
.	O
,	O
O	O
'	O
Connell	O
,	O
C	O
.	O
,	O

Quon	O
,	O
D	O
.	O
,	O
Sim	O
,	O
G	O
.	O

K	O
.	O
,	O
and	O
Efstratiadis	O
,	O
A	O
.	O

(	O
1975	O
)	O
Cell	O
15	O
,	O
687	O
-	O
701	O
.	O

6	O
.	O

Blattner	O
,	O
F	O
.	O

R	O
.	O
,	O
Blechl	O
,	O
A	O
.	O

E	O
.	O
,	O
Denniston	O
-	O
Thompson	O
,	O
K	O
.	O
,	O
Faber	O
,	O
H	O
.	O

E	O
.	O
,	O

Richards	O
,	O
J	O
.	O

E	O
.	O
,	O
Slightom	O
,	O
H	O
.	O

L	O
.	O
,	O
Tucker	O
,	O
P	O
.	O

W	O
.	O
,	O
and	O
Smithies	O
,	O
0	O
.	O

(	O
1978	O
)	O
Science	O
202	O
,	O
1279	O
-	O
1284	O
.	O

7	O
.	O

Meyer	O
,	O
J	O
.	O
,	O
Neuwald	O
,	O
P	O
.	O

D	O
.	O
,	O
Lai	O
,	O
S	O
.	O
,	O
Maizel	O
,	O
J	O
.	O

V	O
.	O
,	O
Jr	O
.	O
,	O
and	O
Westphal	O
,	O

H	O
.	O

(	O
1977	O
)	O
J	O
.	O

Virol	O
.	O

21	O
,	O
1010	O
-	O
1014	O
.	O

2251	O

Nucleic	O
Acids	O
Research	O

8	O
.	O

Westphal	O
,	O
H	O
.	O
,	O
and	O
Lai	O
,	O
S	O
.	O

P	O
.	O

(	O
1977	O
)	O
J	O
.	O

Mol	O
.	O

Biol	O
.	O

116	O
,	O
525	O
-	O
548	O
.	O

9	O
.	O

Schafer	O
,	O
M	O
.	O

P	O
.	O
,	O
Rohrmann	O
,	O
G	O
.	O
,	O
Heine	O
,	O
U	O
.	O
,	O
and	O
Beaudreau	O
,	O
G	O
.	O

S	O
.	O

(	O
1979	O
)	O
Virol	O
.	O

95	O
,	O
176	O
-	O
184	O
.	O

10	O
.	O

Davis	O
,	O
R	O
.	O

W	O
.	O
,	O
Simon	O
,	O
M	O
.	O

M	O
.	O
,	O
and	O
Davison	O
,	O
N	O
.	O

(	O
1971	O
)	O
in	O
Methods	O
in	O

Enzymology	O
(	O
Grossman	O
,	O
L	O
.	O
and	O
Moldave	O
,	O
K	O
.	O
,	O
eds	O
)	O
Vol	O
.	O

21	O
,	O
pp	O
.	O

413428	O
,	O
Academic	O
Press	O
,	O
New	O
York	O
.	O

11	O
.	O

Federal	O
Register	O
(	O
1978	O
)	O
43	O
,	O
60108	O
-	O
60131	O
.	O

12	O
.	O

Goodman	O
,	O
H	O
.	O

M	O
.	O
,	O
Olson	O
,	O
M	O
.	O

V	O
.	O
,	O
Hall	O
,	O
B	O
.	O

D	O
.	O

(	O
1977	O
)	O
Pro	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U	O
.	O
S	O
.	O
A	O
.	O

74	O
,	O
5453	O
-	O
5457	O
.	O

13	O
.	O

Valenzuela	O
,	O
P	O
.	O
,	O
Venegas	O
,	O
A	O
.	O
,	O
Weinberg	O
,	O
F	O
.	O
,	O
Bishop	O
,	O
R	O
.	O
,	O
Rutter	O
,	O

W	O
.	O

J	O
.	O

(	O
1978	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U	O
.	O
S	O
.	O
A	O
.	O

75	O
,	O
190	O
-	O
194	O
.	O

14	O
.	O

Berget	O
,	O
S	O
.	O

M	O
.	O
,	O
Moore	O
,	O
C	O
.	O
,	O
and	O
Sharp	O
,	O
P	O
.	O

A	O
.	O

(	O
1977	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U	O
.	O
S	O
.	O
A	O
.	O

74	O
,	O
3171	O
-	O
3175	O
.	O

15	O
.	O

Chow	O
,	O
L	O
.	O

T	O
.	O
,	O
Gelinas	O
,	O
R	O
.	O

E	O
.	O
,	O
Broker	O
,	O
T	O
.	O
,	O
and	O
Roberts	O
,	O
R	O
.	O

J	O
.	O

(	O
1977	O
)	O

Cell	O
12	O
,	O
1	O
-	O
8	O
.	O

16	O
.	O

Berk	O
,	O
A	O
.	O

J	O
.	O
,	O
and	O
Sharp	O
,	O
P	O
.	O

A	O
.	O

(	O
1978	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U	O
.	O
S	O
.	O
A	O
.	O

75	O
,	O
1274	O
-	O
1278	O
.	O

17	O
.	O

Bratosin	O
,	O
S	O
.	O
,	O
Horowitz	O
,	O
M	O
.	O
,	O
Laub	O
,	O
0	O
.	O
,	O
and	O
Aloni	O
,	O
Y	O
.	O

(	O
1978	O
)	O

Cell	O
13	O
,	O
783	O
-	O
790	O
.	O

18	O
.	O

Sargent	O
,	O
T	O
.	O

D	O
.	O
,	O
Wu	O
,	O
J	O
.	O

R	O
.	O
,	O
Sala	O
-	O
Trepat	O
,	O
J	O
.	O

M	O
.	O
,	O
Wallace	O
,	O
R	O
.	O

B	O
.	O
,	O

Reyes	O
,	O
A	O
.	O

A	O
.	O
,	O
and	O
Bonner	O
,	O
J	O
.	O

(	O
1979	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U	O
.	O
S	O
.	O
A	O
.	O

76	O
,	O
3256	O
-	O
3260	O
.	O

19	O
.	O

Perrin	O
,	O
F	O
.	O
,	O
Cochet	O
,	O
M	O
.	O
,	O
Gerlinger	O
,	O
P	O
.	O
,	O
Cami	O
,	O
B	O
.	O
,	O
LePennec	O
,	O
J	O
.	O

P	O
.	O
,	O

and	O
Chambon	O
,	O
P	O
.	O

(	O
1979	O
)	O
Nucl	O
.	O

Acids	O
Res	O
.	O

6	O
2731	O
-	O
2748	O
.	O

20	O
.	O

Tsujimoto	O
,	O
Y	O
.	O
,	O
and	O
Suzuki	O
,	O
Y	O
.	O

(	O
1979	O
)	O
Cell	O
16	O
425	O
-	O
436	O
.	O

21	O
.	O

Jeffreys	O
,	O
A	O
.	O

J	O
.	O
,	O
and	O
Flavell	O
,	O
R	O
.	O

A	O
.	O

(	O
1977	O
)	O
Cell	O
12	O
,	O
1097	O
-	O
1108	O
.	O

22	O
.	O

Tilghman	O
,	O
S	O
.	O

M	O
.	O
,	O
Tiemeier	O
,	O
D	O
.	O

C	O
.	O
,	O
Seidman	O
,	O
J	O
.	O

C	O
.	O
,	O
Matija	O
Peterlin	O
,	O
B	O
.	O
,	O

Sullivan	O
,	O
M	O
.	O
,	O
Maizel	O
,	O
J	O
.	O

V	O
.	O
,	O
and	O
Leder	O
,	O
P	O
.	O

(	O
1978	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U	O
.	O
S	O
.	O
A	O
.	O

75	O
,	O
725	O
-	O
729	O
.	O

23	O
.	O

Fiddes	O
,	O
J	O
.	O

C	O
.	O
,	O
Seeburg	O
,	O
P	O
.	O

H	O
.	O
,	O
DeNoto	O
,	O
F	O
.	O

M	O
.	O
,	O
Hallewell	O
,	O
R	O
.	O

A	O
.	O
,	O

Baxter	O
,	O
J	O
.	O

D	O
.	O
,	O
and	O
Goodman	O
,	O
H	O
.	O

M	O
.	O

(	O
1979	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U	O
.	O
S	O
.	O
A	O
.	O

76	O
,	O
4294	O
-	O
4298	O
.	O

24	O
.	O

Soreq	O
,	O
H	O
.	O
,	O
Harpold	O
,	O
M	O
.	O
,	O
Evans	O
,	O
R	O
.	O
,	O
Darnell	O
,	O
Jr	O
.	O
,	O
J	O
.	O

E	O
.	O
,	O
and	O

Bancroft	O
,	O
F	O
.	O

C	O
.	O

(	O
1979	O
)	O
Nucl	O
.	O

Acids	O
Res	O
.	O

6	O
,	O
2471	O
-	O
2482	O
.	O

25	O
.	O

Tonegawa	O
,	O
S	O
.	O
,	O
Maxam	O
,	O
A	O
.	O

M	O
.	O
,	O
Tizard	O
,	O
R	O
.	O
,	O
Bernard	O
,	O
0	O
.	O
,	O
and	O
Gilbert	O
,	O
W	O
.	O

(	O
1978	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U	O
.	O
S	O
.	O
A	O
.	O

75	O
,	O
1485	O
-	O
1489	O
.	O

26	O
.	O

Nguyen	O
-	O
Huu	O
,	O
M	O
.	O

C	O
.	O
,	O
Stratmann	O
,	O
M	O
.	O
,	O
Groner	O
,	O
B	O
.	O
,	O
Wurtz	O
,	O
T	O
.	O
,	O
Land	O
,	O
M	O
.	O
,	O

Glesecke	O
,	O
K	O
.	O
,	O
Sippel	O
,	O
A	O
.	O

F	O
.	O
,	O
and	O
Schutz	O
,	O
G	O
.	O

(	O
1979	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U	O
.	O
S	O
.	O
A	O
.	O

76	O
,	O
76	O
-	O
80	O
.	O

27	O
.	O

Breathnach	O
,	O
R	O
.	O
,	O
Mandel	O
,	O
J	O
.	O

L	O
.	O
,	O
and	O
Chambon	O
,	O
P	O
.	O

(	O
1977	O
)	O
Nature	O
270	O
,	O

314	O
-	O
319	O
.	O

28	O
.	O

Dugaiczyk	O
,	O
A	O
.	O
,	O
Woo	O
,	O
S	O
.	O

L	O
.	O

C	O
.	O
,	O
Lai	O
,	O
E	O
.	O

C	O
.	O
,	O
Mace	O
,	O
M	O
.	O

L	O
.	O
,	O
Jr	O
.	O
,	O

McReynolds	O
,	O
L	O
.	O
,	O
and	O
O	O
'	O
Malley	O
,	O
B	O
.	O

W	O
.	O

(	O
1978	O
)	O
Nature	O
274	O
,	O
328	O
-	O
333	O
.	O

29	O
.	O

Weinstock	O
,	O
R	O
.	O
,	O
Sweet	O
,	O
R	O
.	O
,	O
Weiss	O
,	O
M	O
.	O
,	O
Cedar	O
,	O
M	O
.	O
,	O
and	O
Axel	O
,	O
R	O
.	O

(	O
1978	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U	O
.	O
S	O
.	O
A	O
.	O

75	O
,	O
1299	O
-	O
1303	O
.	O

30	O
.	O

Catterall	O
,	O
J	O
.	O

F	O
.	O
,	O
Stein	O
,	O
J	O
.	O

P	O
.	O
,	O
Lai	O
,	O
E	O
.	O

C	O
.	O
,	O
Woo	O
,	O
S	O
.	O

L	O
.	O

C	O
.	O
,	O

Dugaiczyk	O
,	O
Mace	O
,	O
M	O
.	O

L	O
.	O
,	O
Means	O
,	O
A	O
.	O

R	O
.	O
,	O
and	O
O	O
'	O
Malley	O
,	O
B	O
.	O

W	O
.	O

(	O
1979	O
)	O
Nature	O
278	O
,	O
323	O
-	O
327	O
.	O

31	O
.	O

White	O
,	O
R	O
.	O

L	O
.	O
,	O
and	O
Hogness	O
,	O
D	O
.	O

S	O
.	O

(	O
1977	O
)	O
Cell	O
10	O
,	O
177	O
-	O
192	O
.	O

32	O
.	O

Glover	O
,	O
D	O
.	O

M	O
.	O
,	O
and	O
Hogness	O
,	O
D	O
.	O

S	O
.	O

(	O
1977	O
)	O
Cell	O
16	O
,	O
167	O
-	O
176	O
.	O

33	O
.	O

Wellauer	O
,	O
P	O
.	O

K	O
.	O
,	O
and	O
David	O
,	O
I	O
.	O

B	O
.	O

(	O
1977	O
)	O
Cell	O
10	O
,	O
193	O
-	O
212	O
.	O

34	O
.	O

Pellegrini	O
,	O
M	O
.	O
,	O
Manning	O
,	O
J	O
.	O
,	O
and	O
Davidson	O
,	O
N	O
.	O

(	O
1977	O
)	O
Cell	O
10	O
,	O

213	O
-	O
214	O
.	O

35	O
.	O

Wahli	O
,	O
W	O
.	O
,	O
David	O
,	O
I	O
.	O

B	O
.	O
,	O
Wyler	O
,	O
T	O
.	O
,	O
Jaggi	O
,	O
R	O
.	O

B	O
.	O
,	O
Weber	O
,	O
R	O
.	O
,	O
and	O

Ryffel	O
,	O
G	O
.	O

V	O
.	O

(	O
1979	O
)	O
Cell	O
16	O
,	O
535	O
-	O
549	O
.	O

36	O
.	O

McReynolds	O
,	O
L	O
.	O
,	O
O	O
'	O
Malley	O
,	O
B	O
.	O

W	O
.	O
,	O
Nisbet	O
,	O
A	O
.	O

D	O
.	O
,	O
Fothergill	O
,	O
J	O
.	O

E	O
.	O
,	O

2252	O

Nucleic	O
Acids	O
Research	O

Givol	O
,	O
D	O
.	O
,	O
Fields	O
,	O
S	O
.	O
,	O
Robertson	O
,	O
M	O
.	O
,	O
Brownlee	O
,	O
G	O
.	O

G	O
.	O

(	O
1978	O
)	O
Nature	O
273	O
,	O
723	O
-	O
728	O
.	O

37	O
.	O

O	O
'	O
Hare	O
,	O
K	O
.	O
,	O
Breathnach	O
,	O
R	O
.	O
,	O
Benoist	O
,	O
C	O
.	O
,	O
Chambon	O
,	O
P	O
.	O

(	O
1979	O
)	O

Nucl	O
.	O

Acids	O
Res	O
.	O

7	O
,	O
321	O
-	O
334	O
.	O

38	O
.	O

Abelson	O
,	O
J	O
.	O

(	O
1979	O
)	O
Ann	O
.	O

Rev	O
.	O

Biochem	O
.	O

48	O
,	O
1035	O
-	O
1069	O
.	O

39	O
.	O

Adams	O
,	O
S	O
.	O

L	O
.	O
,	O
Alwine	O
,	O
J	O
.	O

C	O
.	O
,	O
de	O
Chrombrugghe	O
,	O
B	O
.	O
,	O
and	O
Pastan	O
,	O
I	O
.	O

(	O
1979	O
)	O
J	O
.	O

Biol	O
.	O

Chem	O
.	O

254	O
,	O
4935	O
-	O
4938	O
,	O

40	O
.	O

Rave	O
,	O
N	O
.	O
,	O
Crkvenjakow	O
,	O
R	O
.	O
,	O
and	O
Boedtker	O
,	O
H	O
.	O

(	O
1979	O
)	O
Nucl	O
.	O

Acids	O
Res	O
.	O

6	O
,	O
3559	O
-	O
3567	O
.	O

41	O
.	O

Roop	O
,	O
D	O
.	O

R	O
.	O
,	O
Nordstrom	O
,	O
J	O
.	O

L	O
.	O
,	O
Tsai	O
,	O
S	O
.	O

Y	O
.	O
,	O
Tsai	O
,	O
M	O
.	O

J	O
.	O
,	O
and	O

O	O
'	O
Malley	O
,	O
B	O
.	O

W	O
.	O

(	O
1978	O
)	O
Cell	O
15	O
,	O
671	O
-	O
685	O
.	O

42	O
.	O

Tilghman	O
,	O
S	O
.	O

M	O
.	O
,	O
Curtis	O
,	O
P	O
.	O

J	O
.	O
,	O
Tiemeier	O
,	O
D	O
.	O

C	O
.	O
,	O
Leder	O
,	O
P	O
.	O
,	O
and	O

Weissmann	O
,	O
C	O
.	O

(	O
1978	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U	O
.	O
S	O
.	O
A	O
.	O

75	O
,	O
1309	O
-	O
1313	O
.	O

43	O
.	O

Palmiter	O
,	O
R	O
.	O

D	O
.	O
,	O
Davidson	O
,	O
J	O
.	O

M	O
.	O
,	O
Gagnon	O
,	O
H	O
.	O
,	O
Rowe	O
,	O
D	O
.	O

W	O
.	O
,	O
and	O

Bornstein	O
,	O
P	O
.	O

(	O
1979	O
)	O
J	O
.	O

Biol	O
.	O

Chem	O
.	O

254	O
,	O
1433	O
-	O
1436	O
.	O

44	O
.	O

Graves	O
,	O
P	O
.	O

N	O
.	O
,	O
Olsen	O
,	O
B	O
.	O

R	O
.	O
,	O
Feitzig	O
,	O
P	O
.	O

P	O
.	O
,	O
Monson	O
,	O
J	O
.	O

M	O
.	O
and	O

Prockop	O
,	O
D	O
.	O

J	O
.	O

(	O
1979	O
)	O
Fed	O
.	O

Proc	O
.	O

38	O
,	O
620	O
.	O

2253	O

Thumb	O
force	O
deficit	O
after	O
lower	O
median	O
nerve	O
block	O

Abstract	O

Purpose	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
characterize	O
thumb	O
motor	O
dysfunction	O
resulting	O
from	O
simulated	O
lower	O
median	O
nerve	O
lesions	O
at	O
the	O
wrist	O
.	O

Methods	O

Bupivacaine	O
hydrochloride	O
was	O
injected	O
into	O
the	O
carpal	O
tunnel	O
of	O
six	O
healthy	O
subjects	O
to	O
locally	O
anesthetize	O
the	O
median	O
nerve	O
.	O

Motor	O
function	O
was	O
subsequently	O
evaluated	O
by	O
measuring	O
maximal	O
force	O
production	O
in	O
all	O
directions	O
within	O
the	O
transverse	O
plane	O
perpendicular	O
to	O
the	O
longitudinal	O
axis	O
of	O
the	O
thumb	O
.	O

Force	O
envelopes	O
were	O
constructed	O
using	O
these	O
measured	O
multidirectional	O
forces	O
.	O

Results	O

Blockage	O
of	O
the	O
median	O
nerve	O
resulted	O
in	O
decreased	O
force	O
magnitudes	O
and	O
thus	O
smaller	O
force	O
envelopes	O
.	O

The	O
average	O
force	O
decrease	O
around	O
the	O
force	O
envelope	O
was	O
27	O
.	O
9	O
%	O
.	O

A	O
maximum	O
decrease	O
of	O
42	O
.	O
4	O
%	O
occurred	O
in	O
a	O
direction	O
combining	O
abduction	O
and	O
slight	O
flexion	O
,	O
while	O
a	O
minimum	O
decrease	O
of	O
10	O
.	O
5	O
%	O
occurred	O
in	O
a	O
direction	O
combining	O
adduction	O
and	O
slight	O
flexion	O
.	O

Relative	O
decreases	O
in	O
adduction	O
,	O
extension	O
,	O
abduction	O
,	O
and	O
flexion	O
were	O
17	O
.	O
3	O
%	O
,	O
21	O
.	O
2	O
%	O
,	O
41	O
.	O
2	O
%	O
and	O
33	O
.	O
5	O
%	O
,	O
respectively	O
.	O

Areas	O
enclosed	O
by	O
pre	O
-	O
and	O
post	O
-	O
block	O
force	O
envelopes	O
were	O
20628	O
+/-	O
7747	O
N	O
.	O
N	O
,	O
and	O
10700	O
+/-	O
4474	O
N	O
.	O
N	O
,	O
respectively	O
,	O
representing	O
an	O
average	O
decrease	O
of	O
48	O
.	O
1	O
%	O
.	O

Relative	O
decreases	O
in	O
the	O
adduction	O
,	O
extension	O
,	O
abduction	O
,	O
and	O
flexion	O
quadrant	O
areas	O
were	O
31	O
.	O
5	O
%	O
,	O
42	O
.	O
3	O
%	O
,	O
60	O
.	O
9	O
%	O
,	O
and	O
52	O
.	O
3	O
%	O
,	O
respectively	O
.	O

Conclusion	O

Lower	O
median	O
nerve	O
lesion	O
,	O
simulated	O
by	O
a	O
nerve	O
block	O
at	O
the	O
wrist	O
,	O
compromise	O
normal	O
motor	O
function	O
of	O
the	O
thumb	O
.	O

A	O
median	O
nerve	O
block	O
results	O
in	O
force	O
deficits	O
in	O
all	O
directions	O
,	O
with	O
the	O
most	O
severe	O
impairment	O
in	O
abduction	O
and	O
flexion	O
.	O

From	O
our	O
results	O
,	O
such	O
a	O
means	O
of	O
motor	O
function	O
assessment	O
can	O
potentially	O
be	O
applied	O
to	O
functionally	O
evaluate	O
peripheral	O
neuropathies	O
.	O

Introduction	O

The	O
thumb	O
has	O
unique	O
anatomical	O
and	O
biomechanical	O
characteristics	O
that	O
are	O
required	O
to	O
perform	O
many	O
manipulative	O
tasks	O
.	O

Thumb	O
motor	O
dysfunction	O
resulting	O
from	O
neuromuscular	O
and	O
musculoskeletal	O
pathologies	O
severely	O
hinders	O
the	O
performance	O
of	O
these	O
daily	O
tasks	O
.	O

Clinical	O
treatment	O
,	O
prevention	O
protocols	O
,	O
and	O
rehabilitation	O
efficacy	O
requires	O
a	O
thorough	O
understanding	O
of	O
thumb	O
motor	O
capabilities	O
,	O
as	O
well	O
as	O
its	O
associated	O
functional	O
deficit	O
.	O

Investigations	O
of	O
underlying	O
pathological	O
mechanism	O
of	O
the	O
thumb	O
help	O
advance	O
clinical	O
treatments	O
such	O
as	O
tendon	O
transfers	O
[	O
1	O
]	O
,	O
functional	O
electrical	O
stimulation	O
[	O
2	O
]	O
and	O
plasticity	O
suppression	O
[	O
3	O
]	O
.	O

Measurement	O
of	O
strength	O
during	O
maximum	O
voluntary	O
contraction	O
is	O
a	O
simple	O
and	O
direct	O
means	O
of	O
assessing	O
neuromuscular	O
function	O
.	O

Popular	O
instruments	O
used	O
for	O
quantitative	O
assessment	O
of	O
thumb	O
strength	O
are	O
pinch	O
dynamometers	O
.	O

The	O
pinch	O
output	O
,	O
however	O
,	O
provides	O
limited	O
information	O
about	O
thumb	O
motor	O
function	O
in	O
that	O
it	O
offers	O
a	O
single	O
generic	O
force	O
in	O
one	O
specific	O
direction	O
.	O

Each	O
muscle	O
/	O
tendon	O
within	O
the	O
thumb	O
has	O
a	O
distinct	O
anatomical	O
origin	O
and	O
insertion	O
,	O
suggesting	O
its	O
external	O
force	O
potential	O
in	O
a	O
particular	O
direction	O
[	O
4	O
-	O
6	O
]	O
.	O

Hence	O
,	O
evaluation	O
of	O
strengths	O
in	O
multiple	O
directions	O
offers	O
insight	O
concerning	O
the	O
motor	O
capacity	O
of	O
individual	O
muscles	O
.	O

Force	O
production	O
of	O
a	O
digit	O
has	O
been	O
measured	O
in	O
various	O
directions	O
such	O
as	O
flexion	O
/	O
extension	O
[	O
7	O
,	O
8	O
]	O
,	O
abduction	O
/	O
adduction	O
[	O
9	O
-	O
14	O
]	O
,	O
or	O
in	O
combined	O
directions	O
[	O
15	O
,	O
16	O
]	O
.	O

Bourbonnais	O
et	O
al	O
.	O
developed	O
an	O
apparatus	O
to	O
measure	O
thumb	O
force	O
production	O
in	O
eight	O
directions	O
in	O
the	O
transverse	O
plane	O
of	O
the	O
thumb	O
and	O
investigated	O
force	O
dependence	O
on	O
the	O
direction	O
of	O
effort	O
[	O
15	O
]	O
.	O

Yokogawa	O
and	O
Hara	O
measured	O
index	O
fingertip	O
forces	O
in	O
various	O
directions	O
within	O
the	O
flexion	O
/	O
extension	O
plane	O
[	O
8	O
]	O
.	O

Recently	O
,	O
we	O
developed	O
experimental	O
apparatuses	O
to	O
measure	O
multi	O
-	O
directional	O
forces	O
of	O
a	O
digit	O
in	O
its	O
transverse	O
plane	O
[	O
17	O
-	O
19	O
]	O
.	O

From	O
these	O
multi	O
-	O
directional	O
forces	O
we	O
constructed	O
force	O
envelopes	O
representative	O
of	O
the	O
characteristic	O
force	O
output	O
pattern	O
of	O
a	O
digit	O
[	O
17	O
-	O
19	O
]	O
.	O

Disorders	O
resulting	O
from	O
traumatic	O
injuries	O
to	O
and	O
various	O
diseases	O
of	O
these	O
nerves	O
are	O
common	O
in	O
clinical	O
practice	O
.	O

Clinical	O
manifestations	O
of	O
hand	O
dysfunction	O
are	O
distinctive	O
depending	O
on	O
the	O
nerve	O
involved	O
.	O

For	O
example	O
,	O
thenar	O
atrophy	O
is	O
a	O
major	O
clinical	O
observation	O
affecting	O
thumb	O
function	O
at	O
the	O
later	O
stages	O
of	O
compression	O
neuropathy	O
of	O
the	O
median	O
nerve	O
.	O

Several	O
studies	O
have	O
been	O
conducted	O
to	O
investigate	O
the	O
effects	O
of	O
simulated	O
peripheral	O
neuropathies	O
using	O
local	O
anesthetization	O
[	O
5	O
,	O
16	O
,	O
20	O
,	O
21	O
]	O
.	O

Kozin	O
et	O
al	O
.	O

[	O
21	O
]	O
studied	O
the	O
effects	O
of	O
median	O
and	O
ulnar	O
nerve	O
blocks	O
on	O
grip	O
and	O
pinch	O
strength	O
and	O
showed	O
significant	O
decreases	O
following	O
nerve	O
blockage	O
[	O
21	O
]	O
.	O

Boatright	O
and	O
Kiebzak	O
[	O
20	O
]	O
investigated	O
the	O
effects	O
of	O
median	O
nerve	O
block	O
on	O
thumb	O
abduction	O
strength	O
.	O

Kaufman	O
et	O
al	O
.	O

[	O
5	O
]	O
measured	O
isometric	O
thumb	O
forces	O
in	O
eight	O
directions	O
together	O
with	O
electromyographic	O
signals	O
of	O
thumb	O
muscles	O
after	O
block	O
of	O
the	O
median	O
nerve	O
.	O

Labosky	O
and	O
Waggy	O
[	O
22	O
]	O
studied	O
the	O
strength	O
related	O
to	O
grip	O
,	O
pinch	O
,	O
thumb	O
adduction	O
,	O
thumb	O
abduction	O
,	O
and	O
finger	O
flexion	O
after	O
radial	O
nerve	O
block	O
[	O
22	O
]	O
.	O

Kuxhaus	O
studied	O
the	O
three	O
dimensional	O
feasible	O
force	O
set	O
at	O
the	O
thumb	O
-	O
tip	O
before	O
and	O
after	O
ulnar	O
nerve	O
block	O
and	O
reported	O
this	O
to	O
be	O
a	O
reproducible	O
and	O
sensitive	O
means	O
to	O
detect	O
impairment	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
utilize	O
our	O
developed	O
apparatus	O
and	O
protocols	O
to	O
investigate	O
the	O
effects	O
of	O
lower	O
median	O
nerve	O
lesion	O
on	O
thumb	O
motor	O
function	O
.	O

The	O
lesion	O
was	O
simulated	O
by	O
blocking	O
the	O
median	O
nerve	O
at	O
the	O
wrist	O
using	O
an	O
anesthetic	O
.	O

We	O
hypothesized	O
that	O
a	O
median	O
nerve	O
block	O
would	O
cause	O
(	O
1	O
)	O
a	O
decrease	O
in	O
force	O
production	O
,	O
which	O
would	O
be	O
direction	O
-	O
dependent	O
with	O
the	O
most	O
severe	O
reduction	O
in	O
the	O
abduction	O
direction	O
,	O
and	O
(	O
2	O
)	O
a	O
decrease	O
in	O
the	O
force	O
envelope	O
area	O
and	O
force	O
quadrant	O
area	O
,	O
with	O
the	O
greatest	O
decrease	O
in	O
the	O
abduction	O
quadrant	O
.	O

Methods	O

Subjects	O

Six	O
healthy	O
male	O
subjects	O
(	O
mean	O
age	O
:	O
26	O
.	O
9	O
+/-	O
5	O
.	O
1	O
years	O
)	O
participated	O
in	O
this	O
study	O
.	O

The	O
subjects	O
had	O
no	O
previous	O
history	O
of	O
neuromuscular	O
or	O
musculoskeletal	O
disorders	O
of	O
the	O
upper	O
extremities	O
.	O

Each	O
subject	O
signed	O
an	O
informed	O
consent	O
form	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
prior	O
to	O
participating	O
in	O
the	O
experiment	O
.	O

Median	O
nerve	O
block	O

Injections	O
were	O
performed	O
under	O
aseptic	O
conditions	O
while	O
the	O
subjects	O
sat	O
with	O
the	O
forearm	O
supinated	O
and	O
the	O
wrist	O
slightly	O
extended	O
.	O

After	O
the	O
skin	O
at	O
the	O
palmer	O
area	O
of	O
the	O
wrist	O
was	O
cleaned	O
with	O
alcohol	O
,	O
4	O
mL	O
of	O
0	O
.	O
5	O
%	O
bupivacaine	O
hydrochloride	O
(	O
Astra	O
Pharmaceuticals	O
,	O
Westborough	O
,	O
MA	O
,	O
USA	O
)	O
was	O
injected	O
into	O
the	O
carpal	O
tunnel	O
with	O
a	O
sterile	O
25	O
-	O
gauge	O
short	O
-	O
bevel	O
needle	O
.	O

The	O
needle	O
was	O
inserted	O
through	O
the	O
transverse	O
carpal	O
ligament	O
in	O
line	O
with	O
the	O
radial	O
border	O
of	O
the	O
fourth	O
digit	O
slightly	O
ulnar	O
to	O
the	O
palmaris	O
longus	O
tendon	O
at	O
the	O
level	O
of	O
the	O
distal	O
wrist	O
crease	O
.	O

Forty	O
minutes	O
was	O
allowed	O
for	O
the	O
median	O
nerve	O
block	O
to	O
reach	O
complete	O
effectiveness	O
[	O
23	O
]	O
and	O
was	O
verified	O
using	O
the	O
Semmes	O
-	O
Weinstein	O
monofilament	O
test	O
.	O

The	O
average	O
monofilament	O
score	O
was	O
2	O
.	O
85	O
across	O
the	O
five	O
digits	O
before	O
nerve	O
block	O
.	O

About	O
40	O
minutes	O
after	O
nerve	O
injection	O
,	O
little	O
sensory	O
impairment	O
occurred	O
in	O
the	O
ulnar	O
distribution	O
(	O
score	O
=	O
3	O
.	O
22	O
)	O
,	O
while	O
the	O
sensory	O
score	O
in	O
the	O
median	O
distribution	O
was	O
greater	O
than	O
6	O
.	O
15	O
.	O

The	O
effects	O
of	O
nerve	O
block	O
lasted	O
more	O
than	O
6	O
hours	O
with	O
all	O
subjects	O
regaining	O
normal	O
hand	O
function	O
within	O
12	O
hours	O
.	O

Testing	O
apparatus	O

The	O
experimental	O
apparatus	O
was	O
designed	O
and	O
constructed	O
to	O
measure	O
maximum	O
voluntary	O
contraction	O
forces	O
of	O
any	O
digit	O
at	O
any	O
point	O
along	O
the	O
digit	O
.	O

Force	O
application	O
was	O
possible	O
in	O
any	O
direction	O
within	O
the	O
transverse	O
plane	O
of	O
the	O
longitudinal	O
axis	O
of	O
the	O
digit	O
.	O

The	O
apparatus	O
consisted	O
of	O
position	O
control	O
accessories	O
,	O
a	O
force	O
transducer	O
,	O
and	O
a	O
custom	O
fitted	O
aluminum	O
ring	O
attached	O
to	O
the	O
transducer	O
(	O
Figure	O
1A	O
,	O
1B	O
)	O
.	O

The	O
transducer	O
(	O
Mini40	O
,	O
ATI	O
Industrial	O
Automation	O
,	O
NC	O
,	O
USA	O
)	O
,	O
capable	O
of	O
measuring	O
6	O
degrees	O
of	O
freedom	O
forces	O
and	O
moments	O
,	O
was	O
attached	O
to	O
a	O
mounting	O
clamp	O
via	O
an	O
aluminum	O
adapter	O
plate	O
while	O
the	O
aluminum	O
ring	O
was	O
secured	O
to	O
the	O
tool	O
side	O
of	O
the	O
transducer	O
using	O
a	O
custom	O
adapter	O
.	O

The	O
ring	O
served	O
as	O
a	O
connection	O
anchor	O
for	O
the	O
transducer	O
and	O
the	O
digit	O
.	O

The	O
force	O
transducer	O
and	O
ring	O
attachment	O
were	O
positioned	O
in	O
a	O
desired	O
orientation	O
using	O
an	O
aluminum	O
slide	O
rail	O
,	O
tubing	O
,	O
and	O
lockable	O
mounting	O
clamps	O
(	O
80	O
/	O
20	O
Inc	O
.	O
,	O
Columbia	O
City	O
,	O
IN	O
,	O
USA	O
)	O
.	O

The	O
slide	O
rail	O
was	O
secured	O
to	O
an	O
aluminum	O
base	O
plate	O
.	O

Foam	O
padded	O
wooden	O
blocks	O
with	O
two	O
locking	O
straps	O
secured	O
the	O
arm	O
to	O
the	O
base	O
plate	O
.	O

The	O
analog	O
outputs	O
from	O
the	O
transducer	O
were	O
digitized	O
using	O
a	O
16	O
-	O
bit	O
analog	O
-	O
to	O
-	O
digital	O
converter	O
(	O
PCI	O
-	O
6031	O
,	O
National	O
Instruments	O
,	O
TX	O
,	O
USA	O
)	O
.	O

The	O
X	O
(	O
abduction	O
/	O
adduction	O
)	O
and	O
Y	O
(	O
flexion	O
/	O
extension	O
)	O
force	O
components	O
in	O
the	O
transverse	O
plane	O
were	O
displayed	O
on	O
the	O
screen	O
while	O
the	O
subject	O
performed	O
a	O
force	O
production	O
task	O
.	O

The	O
resolutions	O
of	O
the	O
force	O
transducer	O
in	O
its	O
axial	O
(	O
flexion	O
/	O
extension	O
)	O
and	O
horizontal	O
(	O
abduction	O
/	O
adduction	O
)	O
directions	O
were	O
0	O
.	O
16	O
N	O
and	O
0	O
.	O
08	O
N	O
,	O
respectively	O
.	O

A	O
personal	O
computer	O
equipped	O
with	O
LabVIEW	O
(	O
National	O
Instrument	O
,	O
TX	O
,	O
USA	O
)	O
was	O
used	O
for	O
force	O
data	O
acquisition	O
,	O
display	O
,	O
and	O
processing	O
.	O

Experimental	O
procedures	O

Each	O
subject	O
was	O
tested	O
before	O
and	O
after	O
median	O
nerve	O
block	O
.	O

The	O
nerve	O
block	O
procedures	O
were	O
performed	O
immediately	O
after	O
the	O
completion	O
of	O
the	O
first	O
testing	O
session	O
.	O

Post	O
-	O
block	O
testing	O
started	O
after	O
the	O
verification	O
of	O
complete	O
median	O
nerve	O
block	O
,	O
approximately	O
40	O
minutes	O
after	O
the	O
injection	O
.	O

During	O
each	O
test	O
,	O
the	O
subject	O
was	O
seated	O
in	O
a	O
chair	O
adjacent	O
to	O
the	O
testing	O
station	O
modified	O
with	O
a	O
wooden	O
board	O
to	O
align	O
their	O
back	O
vertically	O
throughout	O
the	O
trials	O
.	O

The	O
subjects	O
rested	O
their	O
forearm	O
on	O
padded	O
wooden	O
blocks	O
positioning	O
their	O
shoulder	O
in	O
approximately	O
60	O
degrees	O
of	O
frontal	O
plane	O
abduction	O
.	O

Nylon	O
straps	O
fitted	O
with	O
plastic	O
snap	O
locking	O
mechanisms	O
secured	O
the	O
forearm	O
and	O
minimized	O
the	O
intervention	O
of	O
the	O
elbow	O
and	O
shoulder	O
during	O
thumb	O
force	O
application	O
.	O

Subjects	O
grasped	O
a	O
vertical	O
dowel	O
secured	O
to	O
the	O
distal	O
end	O
of	O
the	O
wooden	O
blocks	O
in	O
a	O
midprone	O
position	O
.	O

Formable	O
thermoplastic	O
braces	O
were	O
used	O
to	O
fix	O
the	O
elbow	O
in	O
90	O
degrees	O
of	O
flexion	O
,	O
and	O
the	O
wrist	O
in	O
20	O
degrees	O
of	O
extension	O
and	O
0	O
degrees	O
of	O
ulnar	O
deviation	O
.	O

A	O
metallic	O
brace	O
was	O
used	O
to	O
fix	O
the	O
interphalangeal	O
joint	O
of	O
the	O
thumb	O
in	O
full	O
extension	O
.	O

The	O
aluminum	O
ring	O
was	O
placed	O
around	O
the	O
middle	O
of	O
the	O
proximal	O
phalanx	O
and	O
oriented	O
to	O
accommodate	O
comfortable	O
thumb	O
position	O
with	O
the	O
metacarpophalangeal	O
joint	O
flexed	O
approximately	O
15	O
degrees	O
.	O

Prior	O
to	O
testing	O
,	O
a	O
line	O
was	O
drawn	O
on	O
the	O
proximal	O
phalange	O
at	O
the	O
midpoint	O
between	O
the	O
interphalangeal	O
and	O
metacarpophalangeal	O
joints	O
.	O

The	O
alignment	O
of	O
the	O
ring	O
with	O
the	O
circumferential	O
line	O
standardized	O
the	O
location	O
of	O
force	O
application	O
within	O
and	O
between	O
subjects	O
.	O

As	O
force	O
application	O
was	O
at	O
the	O
middle	O
of	O
the	O
proximal	O
phalanx	O
,	O
mechanical	O
action	O
pertains	O
to	O
both	O
the	O
metacarpophalangeal	O
and	O
carpometacarpal	O
joints	O
.	O

We	O
chose	O
the	O
terminology	O
of	O
flexion	O
/	O
extension	O
and	O
adduction	O
/	O
adduction	O
based	O
on	O
the	O
mechanical	O
action	O
with	O
respect	O
to	O
the	O
metacarpophalangeal	O
joint	O
.	O

With	O
the	O
thumb	O
in	O
the	O
ring	O
(	O
Figure	O
1B	O
)	O
,	O
extension	O
and	O
flexion	O
occurred	O
in	O
parallel	O
with	O
the	O
palm	O
,	O
and	O
abduction	O
and	O
adduction	O
occurred	O
in	O
a	O
plane	O
perpendicular	O
to	O
the	O
palm	O
.	O

Each	O
subject	O
performed	O
15	O
circumferential	O
MVC	O
trials	O
with	O
randomized	O
starting	O
directions	O
(	O
Figure	O
1C	O
)	O
.	O

The	O
subject	O
was	O
allotted	O
15	O
seconds	O
to	O
complete	O
each	O
circumferential	O
trial	O
,	O
and	O
was	O
instructed	O
to	O
use	O
the	O
entire	O
time	O
allotted	O
to	O
traverse	O
the	O
perimeter	O
of	O
the	O
ring	O
once	O
.	O

A	O
dot	O
generated	O
on	O
the	O
computer	O
screen	O
was	O
programmed	O
to	O
traverse	O
a	O
circle	O
within	O
15	O
seconds	O
to	O
provide	O
the	O
subject	O
with	O
directional	O
feedback	O
of	O
their	O
force	O
application	O
.	O

Subjects	O
were	O
given	O
60	O
seconds	O
of	O
rest	O
between	O
each	O
circumferential	O
trial	O
.	O

Each	O
subject	O
was	O
familiarized	O
with	O
the	O
task	O
with	O
a	O
few	O
practice	O
trials	O
.	O

Data	O
were	O
collected	O
from	O
each	O
subject	O
at	O
100	O
samples	O
per	O
second	O
producing	O
a	O
total	O
of	O
22	O
,	O
500	O
pairs	O
of	O
force	O
components	O
from	O
the	O
15	O
circumferential	O
trials	O
.	O

Our	O
previous	O
study	O
[	O
19	O
]	O
indicated	O
that	O
the	O
testing	O
protocol	O
did	O
not	O
cause	O
noticeable	O
fatigue	O
.	O

Force	O
envelope	O
and	O
quadrants	O

Data	O
from	O
multiple	O
circumferential	O
trials	O
were	O
accumulated	O
to	O
construct	O
a	O
force	O
envelope	O
.	O

The	O
procedures	O
to	O
generate	O
a	O
force	O
envelope	O
were	O
as	O
follows	O
:	O

Cartesian	O
force	O
coordinates	O
(	O
Xi	O
,	O
Yi	O
)	O
were	O
transformed	O
into	O
polar	O
coordinates	O
(	O
R	O
alpha	O
,	O
alpha	O
)	O
,	O
where	O
R	O
alpha	O
was	O
the	O
force	O
magnitude	O
at	O
an	O
angular	O
position	O
alpha	O
.	O

Each	O
alpha	O
was	O
rounded	O
to	O
the	O
nearest	O
integer	O
ranging	O
from	O
0	O
to	O
359	O
degrees	O
.	O

The	O
maximum	O
,	O
F	O
alpha	O
,	O
was	O
determined	O
from	O
a	O
string	O
of	O
N	O
data	O
points	O
along	O
each	O
radial	O
line	O
defined	O
by	O
alpha	O
.	O

At	O
the	O
completion	O
of	O
the	O
15	O
trials	O
,	O
there	O
were	O
,	O
on	O
average	O
,	O
N	O
=	O
63	O
data	O
points	O
on	O
each	O
radial	O
line	O
of	O
alpha	O
based	O
on	O
the	O
distribution	O
off	O
the	O
22	O
,	O
500	O
data	O
points	O
around	O
360	O
degrees	O
.	O

A	O
moving	O
average	O
with	O
an	O
interval	O
of	O
10	O
degrees	O
was	O
applied	O
to	O
the	O
maximal	O
series	O
data	O
F	O
alpha	O
(	O
alpha	O
=	O
0	O
,	O
1	O
,	O
2	O
,	O
.	O
.	O
.	O
,	O
359	O
)	O
to	O
obtain	O
filtered	O
maximal	O
forces	O
.	O

These	O
forces	O
formed	O
a	O
force	O
envelope	O
.	O

The	O
area	O
formed	O
by	O
a	O
force	O
envelope	O
was	O
divided	O
into	O
adduction	O
-	O
extension	O
,	O
extension	O
-	O
abduction	O
,	O
abduction	O
-	O
flexion	O
,	O
and	O
flexion	O
-	O
adduction	O
quadrants	O
by	O
radial	O
lines	O
oriented	O
at	O
0	O
degrees	O
,	O
90	O
degrees	O
,	O
180	O
degrees	O
,	O
and	O
270	O
degrees	O
A	O
quadrant	O
force	O
was	O
represented	O
using	O
the	O
mean	O
magnitude	O
of	O
the	O
forces	O
in	O
that	O
quadrant	O
.	O

The	O
areas	O
of	O
the	O
entire	O
envelope	O
and	O
each	O
quadrant	O
were	O
calculated	O
by	O
summing	O
the	O
areas	O
of	O
individual	O
arc	O
sections	O
formed	O
by	O
the	O
polar	O
coordinates	O
of	O
the	O
force	O
envelope	O
.	O

(	O
Figure	O
2	O
)	O
.	O

Statistical	O
Analyses	O

One	O
-	O
and	O
two	O
-	O
factor	O
repeated	O
measures	O
analyses	O
of	O
variance	O
(	O
ANOVA	O
)	O
were	O
used	O
to	O
analyze	O
outcome	O
measures	O
.	O

The	O
independent	O
variables	O
were	O
testing	O
SESSION	O
(	O
n	O
=	O
2	O
,	O
i	O
.	O
e	O
.	O
,	O
pre	O
-	O
and	O
post	O
-	O
block	O
)	O
,	O
force	O
DIRECTION	O
(	O
n	O
=	O
16	O
)	O
,	O
and	O
force	O
QUADRANT	O
(	O
n	O
=	O
4	O
)	O
,	O
with	O
SESSION	O
as	O
a	O
repeated	O
variable	O
.	O

Dependent	O
variables	O
were	O
directional	O
force	O
,	O
individual	O
quadrant	O
area	O
and	O
force	O
envelope	O
area	O
.	O

Statistical	O
analyses	O
were	O
performed	O
using	O
SPSS	O
11	O
(	O
SPSS	O
Inc	O
.	O
,	O
Illinois	O
)	O
with	O
statistical	O
significance	O
set	O
at	O
alpha	O
=	O
0	O
.	O
05	O
.	O

Results	O

Force	O
envelope	O
and	O
directional	O
forces	O

Figure	O
3	O
shows	O
the	O
force	O
envelopes	O
produced	O
by	O
each	O
subject	O
(	O
A	O
to	O
F	O
)	O
before	O
and	O
after	O
median	O
nerve	O
block	O
.	O

The	O
post	O
-	O
block	O
force	O
envelope	O
was	O
inside	O
the	O
pre	O
-	O
block	O
envelope	O
for	O
each	O
subject	O
,	O
indicating	O
a	O
decrease	O
in	O
force	O
magnitude	O
in	O
all	O
directions	O
after	O
nerve	O
block	O
.	O

Figure	O
4	O
shows	O
the	O
average	O
pre	O
-	O
and	O
post	O
-	O
block	O
force	O
envelope	O
across	O
all	O
subjects	O
.	O

Force	O
magnitudes	O
were	O
significantly	O
reduced	O
after	O
nerve	O
block	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
resulting	O
in	O
significantly	O
smaller	O
force	O
envelopes	O
.	O

The	O
average	O
decrease	O
across	O
all	O
directions	O
was	O
27	O
.	O
9	O
%	O
.	O

A	O
maximum	O
decrease	O
of	O
42	O
.	O
4	O
%	O
occurred	O
at	O
199	O
degrees	O
,	O
corresponding	O
to	O
a	O
combined	O
direction	O
of	O
abduction	O
and	O
slight	O
flexion	O
,	O
while	O
a	O
minimum	O
decrease	O
of	O
10	O
.	O
5	O
%	O
occurred	O
at	O
328	O
degrees	O
corresponding	O
to	O
a	O
combined	O
direction	O
of	O
adduction	O
and	O
slight	O
flexion	O
.	O

Relative	O
decreases	O
at	O
0	O
degrees	O
(	O
adduction	O
)	O
,	O
90	O
degrees	O
(	O
extension	O
)	O
,	O
180	O
degrees	O
(	O
abduction	O
)	O
,	O
and	O
270	O
degrees	O
(	O
flexion	O
)	O
directions	O
were	O
17	O
.	O
3	O
%	O
,	O
21	O
.	O
2	O
%	O
,	O
41	O
.	O
2	O
%	O
and	O
33	O
.	O
5	O
%	O
,	O
respectively	O
.	O

A	O
single	O
force	O
in	O
each	O
quadrant	O
was	O
represented	O
using	O
the	O
mean	O
magnitude	O
of	O
the	O
forces	O
in	O
that	O
quadrant	O
(	O
see	O
description	O
in	O
the	O
Methods	O
)	O
.	O

The	O
average	O
quadrant	O
forces	O
were	O
significantly	O
decreased	O
after	O
nerve	O
block	O
(	O
p	O
<	O
0	O
.	O
001	O
;	O
Figure	O
5	O
)	O
.	O

The	O
amount	O
of	O
decrease	O
was	O
also	O
different	O
between	O
quadrants	O
(	O
p	O
<	O
0	O
.	O
005	O
)	O
.	O

Relative	O
decreases	O
in	O
mean	O
quadrant	O
forces	O
were	O
24	O
.	O
5	O
%	O
,	O
38	O
.	O
7	O
%	O
,	O
32	O
.	O
1	O
%	O
,	O
and	O
18	O
.	O
1	O
%	O
for	O
extension	O
,	O
abduction	O
,	O
flexion	O
,	O
and	O
adduction	O
,	O
respectively	O
.	O

The	O
maximal	O
decreases	O
in	O
mean	O
quadrant	O
force	O
,	O
38	O
.	O
7	O
%	O
,	O
occurred	O
in	O
the	O
abduction	O
quadrant	O
.	O

Force	O
envelope	O
areas	O
and	O
quadrant	O
areas	O

Areas	O
enclosed	O
by	O
the	O
post	O
-	O
block	O
envelopes	O
were	O
significantly	O
smaller	O
than	O
the	O
pre	O
-	O
block	O
envelopes	O
(	O
p	O
<	O
0	O
.	O
001	O
;	O
Figure	O
4	O
)	O
.	O

Post	O
-	O
block	O
force	O
envelope	O
area	O
,	O
10700	O
+/-	O
4474	O
N	O
.	O
N	O
,	O
was	O
51	O
.	O
9	O
%	O
of	O
pre	O
-	O
block	O
force	O
envelope	O
area	O
,	O
20628	O
+/-	O
7747	O
N	O
.	O
N	O
.	O

Quadrant	O
area	O
decreased	O
significantly	O
(	O
p	O
<	O
0	O
.	O
001	O
;	O
Figure	O
6	O
)	O
.	O

The	O
maximal	O
percentage	O
decrease	O
in	O
area	O
after	O
nerve	O
block	O
was	O
60	O
.	O
9	O
%	O
in	O
the	O
abduction	O
quadrant	O
,	O
followed	O
by	O
a	O
52	O
.	O
3	O
%	O
area	O
decrease	O
in	O
the	O
flexion	O
quadrant	O
.	O

Discussion	O

In	O
this	O
study	O
we	O
simulated	O
a	O
lower	O
median	O
nerve	O
lesion	O
and	O
evaluated	O
the	O
resultant	O
thumb	O
motor	O
function	O
deficit	O
.	O

Our	O
internal	O
control	O
via	O
pre	O
-	O
and	O
post	O
-	O
block	O
design	O
offered	O
a	O
particular	O
advantage	O
of	O
investigating	O
the	O
mechanical	O
role	O
of	O
muscles	O
innervated	O
by	O
a	O
targeted	O
nerve	O
.	O

The	O
testing	O
and	O
analytical	O
methods	O
employed	O
have	O
provided	O
advanced	O
quantification	O
of	O
thumb	O
motor	O
function	O
.	O

The	O
results	O
have	O
confirmed	O
our	O
initial	O
hypotheses	O
that	O
greatest	O
force	O
decreases	O
occurred	O
in	O
directions	O
related	O
to	O
abduction	O
,	O
and	O
that	O
the	O
post	O
-	O
block	O
thumb	O
force	O
envelope	O
area	O
was	O
smaller	O
than	O
the	O
pre	O
-	O
block	O
force	O
envelope	O
area	O
.	O

Preferential	O
force	O
attenuation	O
in	O
the	O
quadrants	O
of	O
abduction	O
and	O
flexion	O
after	O
median	O
nerve	O
block	O
are	O
in	O
agreement	O
with	O
anatomical	O
and	O
neuromuscular	O
features	O
of	O
the	O
thumb	O
.	O

The	O
median	O
nerve	O
innervates	O
the	O
abductor	O
pollicis	O
brevis	O
,	O
the	O
opponens	O
pollicis	O
and	O
superficial	O
head	O
of	O
the	O
flexor	O
pollicis	O
brevis	O
,	O
all	O
of	O
which	O
contribute	O
to	O
the	O
abduction	O
and	O
flexion	O
of	O
the	O
thumb	O
[	O
4	O
]	O
;	O
therefore	O
,	O
denervation	O
of	O
these	O
muscles	O
after	O
median	O
nerve	O
block	O
would	O
cause	O
the	O
greatest	O
force	O
deficit	O
related	O
to	O
median	O
nerve	O
function	O
[	O
5	O
]	O
.	O

Additionally	O
,	O
as	O
force	O
application	O
moved	O
towards	O
adduction	O
,	O
the	O
force	O
deficit	O
decreased	O
as	O
neuromuscular	O
control	O
shifted	O
from	O
the	O
median	O
nerve	O
to	O
the	O
ulnar	O
nerve	O
via	O
the	O
first	O
dorsal	O
interosseous	O
and	O
adductor	O
pollicis	O
brevis	O
.	O

Force	O
deficit	O
in	O
extension	O
was	O
also	O
comparably	O
small	O
as	O
extension	O
forces	O
are	O
mainly	O
produced	O
by	O
the	O
extensors	O
pollicis	O
brevis	O
and	O
longus	O
originating	O
in	O
the	O
forearm	O
.	O

Our	O
reported	O
force	O
decreases	O
following	O
a	O
median	O
nerve	O
block	O
(	O
40	O
.	O
9	O
%	O
in	O
abduction	O
,	O
34	O
.	O
1	O
%	O
in	O
flexion	O
)	O
were	O
smaller	O
than	O
those	O
reported	O
in	O
the	O
literature	O
.	O

Kozin	O
et	O
al	O
.	O

[	O
21	O
]	O
reported	O
a	O
60	O
%	O
decrease	O
in	O
pinch	O
strength	O
after	O
a	O
median	O
nerve	O
block	O
using	O
mepivicaine	O
hydrochloride	O
[	O
21	O
]	O
.	O

Boatright	O
and	O
Kiebzak	O
[	O
20	O
]	O
reported	O
an	O
approximate	O
70	O
%	O
decrease	O
in	O
thumb	O
abduction	O
strength	O
after	O
median	O
nerve	O
block	O
using	O
Lidocaine	O
[	O
20	O
]	O
.	O

Kaufman	O
et	O
al	O
.	O

[	O
5	O
]	O
stated	O
that	O
a	O
median	O
nerve	O
block	O
with	O
Lidocaine	O
almost	O
completely	O
diminished	O
force	O
production	O
in	O
the	O
abduction	O
direction	O
[	O
5	O
]	O
.	O

The	O
discrepancy	O
may	O
be	O
due	O
to	O
the	O
anesthetic	O
used	O
and	O
strength	O
testing	O
method	O
.	O

Although	O
the	O
sensory	O
block	O
appeared	O
to	O
be	O
complete	O
for	O
each	O
method	O
,	O
the	O
motor	O
capabilities	O
of	O
the	O
muscles	O
associated	O
with	O
the	O
median	O
nerve	O
might	O
or	O
might	O
not	O
be	O
completely	O
eliminated	O
.	O

Such	O
a	O
result	O
is	O
largely	O
dependent	O
on	O
a	O
particular	O
anesthetic	O
,	O
its	O
concentration	O
and	O
dosage	O
,	O
as	O
well	O
as	O
the	O
efficacy	O
of	O
the	O
injection	O
technique	O
at	O
immersing	O
the	O
nerve	O
.	O

The	O
methods	O
of	O
strength	O
testing	O
may	O
also	O
help	O
explain	O
the	O
different	O
magnitudes	O
of	O
strength	O
deficit	O
after	O
the	O
nerve	O
block	O
.	O

All	O
previous	O
results	O
were	O
based	O
on	O
forces	O
obtained	O
in	O
discrete	O
direction	O
(	O
s	O
)	O
,	O
and	O
focused	O
exertions	O
,	O
while	O
the	O
current	O
study	O
utilized	O
a	O
method	O
of	O
force	O
production	O
in	O
a	O
continuous	O
,	O
circumferential	O
and	O
dynamic	O
manner	O
.	O

Furthermore	O
,	O
thumb	O
motor	O
performance	O
can	O
be	O
maintained	O
despite	O
the	O
absence	O
of	O
certain	O
individual	O
muscles	O
.	O

For	O
example	O
,	O
Britto	O
and	O
Elliot	O
reported	O
that	O
the	O
loss	O
of	O
abductor	O
pollicis	O
longus	O
and	O
extensor	O
pollicis	O
brevis	O
in	O
their	O
two	O
patients	B-LIVB
did	O
not	O
show	O
functional	O
compromise	O
of	O
strength	O
and	O
grip	O
strength	O
[	O
24	O
]	O
.	O

In	O
a	O
broader	O
sense	O
,	O
the	O
neuromuscular	O
system	O
has	O
remarkable	O
capabilities	O
to	O
accomplish	O
the	O
same	O
motor	O
function	O
goal	O
using	O
different	O
effectors	O
and	O
different	O
goals	O
using	O
the	O
same	O
effectors	O
,	O
a	O
phenomenon	O
so	O
called	O
"	O
motor	O
equivalence	O
"	O
[	O
25	O
]	O
.	O

An	O
unexpected	O
finding	O
from	O
this	O
study	O
was	O
that	O
the	O
force	O
deficit	O
occurred	O
in	O
all	O
directions	O
(	O
Figure	O
4	O
)	O
.	O

In	O
other	O
words	O
,	O
the	O
median	O
nerve	O
block	O
caused	O
reduced	O
force	O
production	O
by	O
those	O
muscles	O
not	O
associated	O
with	O
the	O
median	O
nerve	O
.	O

Several	O
potential	O
explanations	O
exist	O
to	O
describe	O
such	O
a	O
phenomenon	O
.	O

First	O
,	O
the	O
injection	O
into	O
the	O
carpal	O
tunnel	O
at	O
the	O
wrist	O
,	O
although	O
localized	O
,	O
potentially	O
diffused	O
into	O
the	O
intrinsic	O
fascia	O
of	O
the	O
hand	O
partially	O
compromising	O
function	O
of	O
the	O
ulnar	O
nerve	O
,	O
which	O
innervates	O
the	O
adductor	O
pollicis	O
.	O

Although	O
Semmes	O
-	O
Weinstein	O
monofilament	O
testing	O
confirmed	O
the	O
continued	O
sensation	O
of	O
the	O
digits	O
within	O
the	O
ulnar	O
nerve	O
distribution	O
,	O
it	O
is	O
not	O
inconceivable	O
that	O
the	O
injection	O
could	O
have	O
contaminated	O
the	O
ulnar	O
innervated	O
muscles	O
,	O
the	O
first	O
dorsal	O
interosseous	O
and	O
deep	O
head	O
of	O
the	O
flexor	O
pollicis	O
brevis	O
[	O
20	O
]	O
.	O

Secondly	O
,	O
thumb	O
force	O
in	O
any	O
direction	O
is	O
produced	O
by	O
synergistic	O
activation	O
of	O
the	O
many	O
intrinsic	O
muscles	O
,	O
and	O
as	O
a	O
result	O
,	O
the	O
muscular	O
deficiency	O
associated	O
with	O
one	O
direction	O
may	O
hinder	O
the	O
force	O
production	O
in	O
other	O
directions	O
by	O
other	O
muscles	O
[	O
5	O
,	O
22	O
]	O
.	O

For	O
example	O
,	O
Kaufman	O
et	O
al	O
.	O
demonstrated	O
that	O
thumb	O
muscles	O
not	O
innervated	O
by	O
the	O
median	O
nerve	O
displayed	O
lower	O
electromyographical	O
activation	O
and	O
shifted	O
the	O
direction	O
of	O
maximum	O
activation	O
after	O
a	O
median	O
nerve	O
block	O
[	O
5	O
]	O
.	O

Labosky	O
and	O
Waggy	O
showed	O
that	O
a	O
radial	O
nerve	O
block	O
caused	O
a	O
53	O
%	O
decrease	O
in	O
thumb	O
abduction	O
strength	O
because	O
of	O
the	O
lack	O
of	O
stabilization	O
of	O
the	O
radial	O
innervated	O
extensor	O
muscles	O
[	O
22	O
]	O
.	O

Consequently	O
,	O
deficiency	O
of	O
median	O
innervated	O
muscles	O
inherently	O
limits	O
force	O
production	O
in	O
other	O
directions	O
as	O
neuromuscular	O
switching	O
is	O
necessary	O
to	O
produce	O
force	O
in	O
changing	O
directions	O
.	O

The	O
median	O
innervated	O
muscles	O
are	O
the	O
dominant	O
abductors	O
of	O
the	O
thumb	O
metacarpophalangeal	O
and	O
carpometacarpal	O
joint	O
.	O

The	O
more	O
than	O
50	O
%	O
residual	O
abduction	O
force	O
found	O
in	O
this	O
study	O
suggests	O
that	O
the	O
injection	O
did	O
not	O
totally	O
block	O
the	O
motor	O
function	O
of	O
these	O
muscles	O
,	O
even	O
though	O
a	O
complete	O
sensory	O
loss	O
was	O
verified	O
.	O

This	O
concurs	O
with	O
clinical	O
observations	O
of	O
median	O
compression	O
neuropathy	O
.	O

Individuals	O
with	O
carpal	O
tunnel	O
syndrome	O
complain	O
of	O
sensory	O
dysfunction	O
early	O
in	O
the	O
disease	O
process	O
(	O
at	O
the	O
beginning	O
)	O
,	O
while	O
motor	O
signs	O
of	O
thenar	O
wasting	O
and	O
thumb	O
weakness	O
occur	O
as	O
the	O
disease	O
advances	O
.	O

The	O
concept	O
that	O
the	O
motor	O
deficit	O
is	O
more	O
resistant	O
to	O
peripheral	O
median	O
neuropathy	O
than	O
sensory	O
loss	O
has	O
been	O
well	O
documented	O
[	O
23	O
,	O
26	O
,	O
27	O
]	O
.	O

Butterworth	O
et	O
al	O
.	O
studied	O
the	O
temporal	O
effects	O
on	O
sensory	O
and	O
motor	O
blockade	O
after	O
injection	O
of	O
bupivacaine	O
or	O
mepivacaine	O
,	O
and	O
found	O
that	O
sensory	O
loss	O
was	O
complete	O
but	O
about	O
a	O
20	O
%	O
compound	O
motor	O
action	O
potential	O
remained	O
after	O
40	O
minutes	O
[	O
23	O
]	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
incorporated	O
a	O
method	O
for	O
assessing	O
thumb	O
motor	O
deficit	O
based	O
on	O
strength	O
measurement	O
with	O
a	O
standard	O
local	O
anesthetic	O
to	O
investigate	O
the	O
effects	O
of	O
a	O
simulated	O
median	O
neuropathy	O
on	O
thumb	O
motor	O
function	O
.	O

Median	O
nerve	O
block	O
results	O
in	O
force	O
deficits	O
in	O
all	O
directions	O
,	O
with	O
the	O
most	O
severe	O
impairment	O
in	O
abduction	O
and	O
flexion	O
.	O

Future	O
endeavors	O
using	O
this	O
methodology	O
can	O
potentially	O
further	O
elucidate	O
underlying	O
pathomechanisms	O
of	O
peripheral	O
neuropathies	O
in	O
all	O
digits	O
of	O
the	O
hand	O
.	O

